PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ASHWORTH, A; NAKIELNY, S; COHEN, P; MARSHALL, C				ASHWORTH, A; NAKIELNY, S; COHEN, P; MARSHALL, C			THE AMINO-ACID-SEQUENCE OF A MAMMALIAN MAP KINASE KINASE	ONCOGENE			English	Article							PROTEIN-KINASE; CONSERVED FEATURES; PHOSPHORYLATION; IDENTIFICATION; FAMILY	The amino acid sequence of the dual specificity mitogen-activated protein kinase kinase (MAPKK) has been determined by cDNA cloning and amino acid sequencing. MAPKK (393 residues, Mr 43,330) is a new member of the protein kinase subclass that comprises byr1 and STE7 that are involved in pheromone dependent signal transduction in yeast, wis1 a mitotic regulator in S. pombe and PBS2, which confers antibiotic resistance in S. cerevisiae.	UNIV DUNDEE, DEPT BIOCHEM, MRC, PROT PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND	University of Dundee	ASHWORTH, A (corresponding author), INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND.							ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; TRAVERSE S, 1992, IN PRESS BIOCH J, V288	16	69	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2555	2556						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461659				2022-12-28	WOS:A1992KA85600025
J	KOSAKA, M; IWAI, SA; NISHINA, Y; SUMI, T; NISHIMUNE, Y				KOSAKA, M; IWAI, SA; NISHINA, Y; SUMI, T; NISHIMUNE, Y			C-MYC AND P53 GENE-EXPRESSION IN THE DIFFERENTIATION OF TEMPERATURE-SENSITIVE MUTANTS OF TERATOCARCINOMA F9 CELLS	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; INCUBATION TEMPERATURES; RETINOIC ACID; DNA-SYNTHESIS; STEM-CELLS; TRANSFORMATION; INDUCTION; GROWTH; SUPPRESSOR; INHIBITORS	We have previously reported the isolation of several temperature-sensitive (ts) mutants of F9 cells. Further investigations showed that some mutants were induced to differentiate at non-permissive temperature of cell growth, accompanied by changes in the expression of various genes, whereas others were not. During the differentiation induced by shifting up to the nonpermissive temperature, a rapid and transient decrease in both c-myc and p53 mRNA levels and rapid induction of c-jun mRNA were observed. These changes were specific in differentiation-inducible mutants and were not observed in a non-inducible mutant. In both types of mutants, the level of c-myc mRNA decreased in association with growth retardation at the non-permissive temperature. The p53 mRNA, however, showed specific increase in the differentiation-inducible ts mutants. These observations suggest distinct roles for p53 and c-myc from proliferation to differentiation in teratocarcinoma stem cells.	OSAKA UNIV,FAC DENT,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC DENT,DEPT ORAL SURG 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			KOSAKA, Mitsuko/B-1603-2011; Nishina, Yuta/AHB-6194-2022	KOSAKA, Mitsuko/0000-0001-6146-5184; Nishina, Yuta/0000-0002-4958-1753				CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHANDRASEKARAN K, 1982, J CELL PHYSIOL, V113, P134, DOI 10.1002/jcp.1041130122; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUPREY P, 1985, P NATL ACAD SCI USA, V82, P8535, DOI 10.1073/pnas.82.24.8535; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KOSAKA M, 1991, EXP CELL RES, V192, P46, DOI 10.1016/0014-4827(91)90155-N; KURKINEN M, 1983, NUCLEIC ACIDS RES, V11, P6199, DOI 10.1093/nar/11.18.6199; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAMB AJ, 1986, MOL CELL BIOL, V6, P1385; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Maniatis T., 1982, MOL CLONING; MORITA T, 1988, GENE, V68, P109; NISHIMUNE Y, 1989, BIOCHEM BIOPH RES CO, V163, P1290; NISHIMUNE Y, 1983, EXP CELL RES, V146, P439, DOI 10.1016/0014-4827(83)90147-7; NISHIMUNE Y, 1989, BIOCHEM BIOPH RES CO, V165, P65, DOI 10.1016/0006-291X(89)91034-6; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SABBAG KR, 1989, DEVELOPMENT, V106, P195; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SEJERSEN T, 1985, EXP CELL RES, V160, P19, DOI 10.1016/0014-4827(85)90232-0; SHERMAN MI, 1985, CIBA F SYMP, V113, P42; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YANG-YEN H-F, 1990, New Biologist, V2, P351	31	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2455	2460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461650				2022-12-28	WOS:A1992KA85600010
J	PORTIER, M; MOLES, JP; MAZARS, GR; JEANTEUR, P; BATAILLE, R; KLEIN, B; THEILLET, C				PORTIER, M; MOLES, JP; MAZARS, GR; JEANTEUR, P; BATAILLE, R; KLEIN, B; THEILLET, C			P53 AND RAS GENE-MUTATIONS IN MULTIPLE-MYELOMA	ONCOGENE			English	Note							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN LYMPHOID MALIGNANCIES; TUMOR SUPPRESSOR GENE; C-MYC; N-RAS; ONCOGENE MUTATIONS; POINT MUTATION; CELL-LINES; EXPRESSION	We analysed genomic DNA from 30 patients with multiple myeloma (MM), searching for alterations in the p53 and RAS genes by a combination of polymerase chain reaction and single-strand conformation polymorphism techniques. Mutations in the p53 gene were observed in 20% (6 out of 30) of the patients, and were located in conserved sequence blocks within exons 5 and 7. These were single-nucleotide substitutions and consisted predominantly (4/6) of G:C to A:T transitions. Of the six patients with a mutated p53 gene, four were in the terminal phase of the disease. RAS gene mutations were found more frequently since they occurred in 47% (14 out of 30) of the patients. Mutations consisted of single-nucleotide substitutions, located in codons 12, 13 and 61 of either K- or N-RAS, to the exclusion of H-RAS. Moreover, one patient bore two simultaneous mutations, affecting simultaneously the K- and the N-RAS genes. RAS gene mutations were more frequently observed in patients with fulminating disease (10/15, 67%) than in patients with less aggressive forms of the disease (4/15, 26%). We also analysed genomic DNAs from 10 human myeloma cell lines, of which two bore mutations affecting codon 12 of the K-RAS gene, and one codon 12 of the N-RAS gene. The first two cell lines were obtained from freshly explanted tumor cells in which we observed identical mutations. Results presented here show that activating mutations in the RAS genes are, in MM, more frequent than those affecting the p53 gene and suggest that both events are related to terminal phases of the disease.	UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,URA 1191,PL EUGENE BATAILLON,F-34095 MONTPELLIER,FRANCE; INSERM,U IMMUNOPATHOL MALADIES TUMORALES & AUTOIMMUNES 291,F-34090 MONTPELLIER,FRANCE; HOP ST ELOI,CTR GUI DE CHAULIAC,F-34059 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier			Molès, Jean-Pierre/M-2286-2017; Theillet, Charles/O-7634-2018	Molès, Jean-Pierre/0000-0002-6863-6350; Theillet, Charles/0000-0001-5555-2759				BAKKUS MHC, 1990, ONCOGENE, V5, P1359; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; ERNST TJ, 1988, BLOOD, V72, P1163; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GREIL R, 1991, BLOOD, V78, P180; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KLEIN B, 1989, BLOOD, V73, P517; LEMAISTRE A, 1989, BLOOD, V73, P889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T, 1989, DECONTAMINATION DILU; MAZARS GR, 1992, ONCOGENE, V7, P1015; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; PALUMBO AP, 1989, CANCER RES, V49, P4701; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PETTERSSON M, 1992, BLOOD, V79, P495; RADICH JP, 1990, BLOOD, V76, P801; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAWADA M, 1989, NUCLEIC ACIDS RES, V17, P8867, DOI 10.1093/nar/17.21.8867; SELVANAYAGAM P, 1988, BLOOD, V71, P30; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SLINGERLAND JM, 1991, BLOOD, V77, P1500; WRIGHT PA, 1991, ONCOGENE, V6, P1693	28	151	154	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2539	2543						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461658				2022-12-28	WOS:A1992KA85600022
J	KITAGAWA, M; SAITOH, S; OGINO, H; OKABE, T; MATSUMOTO, H; OKUYAMA, A; TAMAI, K; OHBA, Y; YASUDA, H; NISHIMURA, S; TAYA, Y				KITAGAWA, M; SAITOH, S; OGINO, H; OKABE, T; MATSUMOTO, H; OKUYAMA, A; TAMAI, K; OHBA, Y; YASUDA, H; NISHIMURA, S; TAYA, Y			CDC2-LIKE KINASE IS ASSOCIATED WITH THE RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; CELL-CYCLE; GENE-PRODUCT; SUSCEPTIBILITY GENE; RB GENE; TERMINAL REGION; OSTEO-SARCOMA; PHOSPHORYLATION	The growth-suppressive activity of the retinoblastoma (RB) protein is suggested to be regulated by phosphorylation. In studies on the kinase that phosphorylates the RB proteins, we have previously found that RB proteins can be phosphorylated by purified cdc2 kinase. In this study, we noted that RB proteins immunoprecipitated from human cell lysates are weakly phosphorylated in the absence of purified cdc2 kinase. Immunoblot analysis showed the presence of p34cdc2 in the immunoprecipitates with anti-RB monoclonal antibody. In addition, the coprecipitated kinase was found to have the same substrate specificity as cdc2 kinase. The associated kinase activity was particularly high in cells arrested in G1/S and S phase by aphidicolin. Furthermore, RB proteins were shown to be phosphorylated in nuclear extracts by some endogenous cdc2-like kinase(s). These results suggest that cdc2-like kinase is the main kinase for phosphorylation of RB proteins in vivo.	NATL CANC CTR, RES INST, DIV BIOL, TOKYO 104, JAPAN; MBL CO LTD, INA LABS, INA, NAGANO 396, JAPAN; KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN	National Cancer Center - Japan; Kanazawa University	KITAGAWA, M (corresponding author), BANYU PHARMACEUT CO LTD, TSUKUBA RES INST, OKUBO 3, TSUKUBA 30033, JAPAN.		Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; IOANNIDES CG, 1987, P NATL ACAD SCI USA, V84, P4244, DOI 10.1073/pnas.84.12.4244; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; YASUDA H, 1990, BIOCHEM BIOPH RES CO, V172, P371, DOI 10.1016/0006-291X(90)90682-D; YOKOTA J, 1988, ONCOGENE, V3, P471; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	69	47	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1067	1074						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594240				2022-12-28	WOS:A1992HU64200003
J	WERGE, TM; BRADBURY, A; DILUZIO, A; CATTANEO, A				WERGE, TM; BRADBURY, A; DILUZIO, A; CATTANEO, A			A RECOMBINANT CELL-LINE EXPRESSING A FORM OF THE Y13-259 ANTI-P21RAS ANTIBODY WHICH BINDS PROTEIN-A AND MAY BE PRODUCED AS ASCITES	ONCOGENE			English	Note							ENCODED P21; RAS P21; MICROINJECTION; CLONING; GENE	We have recently reported the molecular cloning of the immunoglobulin genes encoding the variable regions of the rat anti-p21ras antibody, Y13-259. These genes were reassembled into expression vectors supplying DNA sequences encoding human gamma 1 and kappa constant domains, as well as the leader sequence for antibody secretion, thus yielding Hu-Y13-259, a secretory anti-p21ras antibody containing human constant regions. We now report the creation of a recombinant cell line, NSO/Hu-Y13-259/B6, secreting high levels of the Hu-Y13-259 Ig. The antigen specificity of this recombinant antibody was demonstrated to be identical to that of the parental Y13-259, i.e. the amino acid sequence 60-76 of the p21ras protein. Unlike the parental cell line, the recombinant cells could be grown as ascites in mice, allowing the production of large quantities of the protein A-binding Hu-Y13-259 antibody.	CNR,INST NEUROBIOL,VIALE KARL MARX 15,I-00156 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR)			Cattaneo, Antonino/AAA-7252-2019; CATTANEO, ANTONINO/K-4471-2016	CATTANEO, ANTONINO/0000-0002-6975-8923				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIOCCA S, 1990, EMBO J, V9, P101, DOI 10.1002/j.1460-2075.1990.tb08085.x; BOULAIN JC, 1986, MOL GEN GENET, V205, P339, DOI 10.1007/BF00430448; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; WERGE TM, 1990, FEBS LETT, V274, P193, DOI 10.1016/0014-5793(90)81362-R	13	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1033	1035						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570149				2022-12-28	WOS:A1992HP64200027
J	DAVIDOFF, AM; PENCE, JC; SHORTER, NA; IGLEHART, JD; MARKS, JR				DAVIDOFF, AM; PENCE, JC; SHORTER, NA; IGLEHART, JD; MARKS, JR			EXPRESSION OF P53 IN HUMAN NEUROBLASTOMA-DERIVED AND NEUROEPITHELIOMA-DERIVED CELL-LINES	ONCOGENE			English	Article							NEURO-BLASTOMA CELLS; TUMOR-ANTIGEN; TRANSFORMED-CELLS; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; HOST PROTEIN; T-ANTIGEN; GENE	Overexpression of the nuclear phosphoprotein p53 has been detected in many different transformed human cell lines and primary adult tumors. Elevated steady-state levels of p53 appear to be the result of an increase in the stability of the protein and, in adult cancers, high levels of the protein are associated with mutation of the p53 gene. In this study, overexpression of p53 was detected in 4 out of 5 human neuroblastoma-derived cell lines. The protein expressed by each of these four lines had a significantly prolonged half-life relative to the p53 protein in immortalized rodent fibroblasts and normal bovine adrenal medullary cells. However, no mutations were detected in the highly conserved regions of the p53 gene in these four neuroblastoma lines and the protein being expressed was not recognized by the mutant-specific anti-p53 monoclonal antibody, PAb 240. Upon retinoic acid-induced differentiation of the LA-N-5 neuroblastoma cell line, the level of p53 protein declined, as did the level of p53 mRNA, but the half-life of the protein remained unchanged. The high level of protein observed in the undifferentiated cell lines appears to result from expression of a stable wild-type p53 protein and increased transcription. In contrast, p53 protein was undetectable in two neuroepithelioma-derived cell lines; the p53 gene in one of these lines contained a nonsense mutation, while the other transcribed truncated p53 mRNA.	DUKE UNIV,MED CTR,DEPT SURG,BOX 3873,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710	Duke University; Duke University					NATIONAL CANCER INSTITUTE [F32CA008899] Funding Source: NIH RePORTER; NCI NIH HHS [1 F32 CA08899-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BRODEUR GM, 1981, CANCER RES, V41, P4678; CHANDRASEKARAN K, 1981, P NATL ACAD SCI-BIOL, V78, P6953, DOI 10.1073/pnas.78.11.6953; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawford L V, 1984, Mol Biol Med, V2, P261; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P569; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVITSKY K, 1983, INT J CANCER, V32, P597, DOI 10.1002/ijc.2910320513; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MARKS JR, 1989, J VIROL, V63, P790, DOI 10.1128/JVI.63.2.790-797.1989; MARKS JR, 1991, CANCER RES, V51, P2979; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PENCE JC, 1990, CANCER RES, V50, P5177; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHOHAT O, 1987, ONCOGENE, V1, P277; SIDELL N, 1988, CANCER RES, V48, P2226; SIDELL N, 1985, ADV NEUROBLASTOMA RE, P39; SOUSSI T, 1987, ONCOGENE, V1, P71; WILSON SP, 1983, METHOD ENZYMOL, V103, P305	39	133	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					127	133						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741160				2022-12-28	WOS:A1992HC22700017
J	LEPRINCE, D; CREPIEUX, P; STEHELIN, D				LEPRINCE, D; CREPIEUX, P; STEHELIN, D			C-ETS-1 DNA-BINDING TO THE PEA3 MOTIF IS DIFFERENTIALLY INHIBITED BY ALL THE MUTATIONS FOUND IN V-ETS	ONCOGENE			English	Article							LONG TERMINAL REPEAT; C-ETS; LEUKEMIA-VIRUS; PROTO-ONCOGENE; LYMPHOID-CELLS; E26 RETROVIRUS; SEQUENCE; PROTEINS; GENE; EXPRESSION	The proto-oncogene c-ets-1, one of the two cellular sequences transduced by the avian retrovirus E26, encodes for two transcription factors that activate through a purine-rich motif. The v-ets oncogene differs from its cellular progenitor p68c-ets-1 (i) by its fusion to gag- and myb-derived sequences in the E26 P135gag-myb-ets fusion protein, (ii) by two point mutations, and (iii) by the replacement of the 13 C-terminal amino acids present in c-ets-1 by 16 unrelated residues in v-ets. A 35 kDa protein which binds to the purine-rich PEA3 motif in a sequence-specific manner has been obtained by expression in Escherichia coli of the 311 carboxy-terminal amino acids of c-ets-1. Using various v-/c-ets-1 chimeric 35 kDa proteins expressed in bacteria, we have shown that all the mutations found in v-ets, when introduced into this c-ets-1 protein, diminish or even abolish its sequence-specific DNA binding. These results demonstrate that, in addition to the previously defined 85 amino acids located near the carboxy terminus of the c-ets-1 protein (the ETS domain), other sequences are required for sequence-specific DNA binding. In addition, the c-ets-1 35 kDa polypeptide carrying the two point mutations and the viral-specific carboxy terminus, and thus similar to the v-ets-encoded domain of the E26 P135gag-myb-ets, does not bind to the PEA3 motif.			LEPRINCE, D (corresponding author), INST PASTEUR,INSERM,U186,CNRS,URA 1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		Crepieux, Pascale/X-3217-2019	Leprince, Dominique/0000-0002-1999-0775				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Ivanov X, 1962, B I PATHOL COMP ANIM, V9, P5; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; POGNONEC P, 1989, ONCOGENE, V4, P691; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REDDY ESP, 1990, CANCER RES, V50, P5013; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TREISMAN J, 1989, CELL, V59, P553; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	38	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					9	17						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741168				2022-12-28	WOS:A1992HC22700002
J	HORAK, E; SMITH, K; BROMLEY, L; LEJEUNE, S; GREENALL, M; LANE, D; HARRIS, AL				HORAK, E; SMITH, K; BROMLEY, L; LEJEUNE, S; GREENALL, M; LANE, D; HARRIS, AL			MUTANT P53, EGF-RECEPTOR AND C-ERBB-2 EXPRESSION IN HUMAN BREAST-CANCER	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; CELLULAR PROTEIN P53; TRANSFORMED-CELLS; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; COLORECTAL CARCINOMAS; MONOCLONAL-ANTIBODIES; ALLELE LOSS; GENE; ONCOGENE	p53 expression was studied in 111 primary breast cancers with a monoclonal antibody (PAb240) that reacts with an epitope in mutant p53. Epidermal growth factor receptors (EGFr) and oestrogen receptors (ER) measured by ligand binding, c-erhB-2 expression assessed by immunochemistry and lymph node status were compared with p53 staining. Fifty-nine tumours (53%) were positive for p53, and this correlated with EGFr expression (P < 0.02), which is a known poor prognostic factor. Eighteen out of 59 p53+ tumours expressed c-erbB-2 versus 4 out of 52 p53- tumours assessed on paraffin sections. However, assessing c-erhB-2 by Southern blotting and immunochemistry on frozen sections showed that 20 out of 59 p53+ tumours overexpressed or had amplified c-erbB-2 compared with 15 out of 52 p53- tumours (not significant). Mean EGFr concentration in p53+ tumours was 31 fmol per mg of membrane protein versus 14 fmol mg-1 in p53- tumours. Cytoplasmic staining was the most frequent pattern found for p53, but some cases showed cytoplasmic plus nuclear staining, or focal cells with predominantly nuclear staining. Thus, abnormal p53 is the commonest oncogene abnormality described in breast cancer. The association with EGFr expression suggests that these oncogenes interact in the pathogenesis of breast cancer.	JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,CLIN ONCOL UNIT,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT SURG,OXFORD OX3 9DU,ENGLAND; IMPERIAL CANC RES FUND,S MIMMS EN6 3LD,HERTS,ENGLAND	University of Oxford; University of Oxford; University of Oxford			Harris, Adrian L/ABA-3343-2020; Lane, David P/C-4920-2008	Harris, Adrian L/0000-0003-1376-8409; Lane, David/0000-0003-0551-3545				ALI IU, 1989, ONCOGENE, V4, P89; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARNES DM, 1988, BRIT J CANCER, V58, P448, DOI 10.1038/bjc.1988.238; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BOS JL, 1989, CANCER RES, V49, P4682; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CATTORETTI G, 1988, BRIT J CANCER, V57, P353, DOI 10.1038/bjc.1988.81; CHIMCO WJ, 1988, NATURE, V332, P805; CHUMAKOV P, 1990, CELL BIOCH S14C, V106, P269; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; Crawford L V, 1984, Mol Biol Med, V2, P261; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P3927; GREEN AR, 1988, BRIT J CANCER, V58, P115, DOI 10.1038/bjc.1988.176; GRIMAUX M, 1990, INT J CANCER, V45, P255, DOI 10.1002/ijc.2910450209; GUERIN M, 1989, INT J CANCER, V43, P201, DOI 10.1002/ijc.2910430205; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1988, ONCOGENE HDB, P403; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; NICHOLSON S, 1989, LANCET, V1, P182; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PATERSON MC, 1991, CANCER RES, V51, P556; PEREZ R, 1984, BREAST CANCER RES TR, V4, P189, DOI 10.1007/BF01806484; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PROSSER J, 1990, ONCOGENE, V5, P1563; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SAINSBURY JRC, 1987, LANCET, V1, P1398; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHOHAT O, 1987, ONCOGENE, V1, P277; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1991, ONCOGENE, V6, P413; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1989, CANCER RES, V49, P3713; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WRIGHT C, 1989, CANCER RES, V49, P2087; WYSS R, 1987, ANTICANCER RES, V7, P721; YEE LD, 1989, SEMIN DIAGN PATHOL, V6, P110; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	65	106	106	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2277	2284						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1685017				2022-12-28	WOS:A1991GX73500015
J	INOUE, J; ITOH, M; AKIZAWA, T; TOYOSHIMA, H; YOSHIDA, M				INOUE, J; ITOH, M; AKIZAWA, T; TOYOSHIMA, H; YOSHIDA, M			HTLV-1 REX PROTEIN ACCUMULATES UNSPLICED RNA IN THE NUCLEUS AS WELL AS IN CYTOPLASM	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; VIRAL MESSENGER-RNA; TRANS-ACTIVATOR GENE; LONG TERMINAL REPEAT; RESPONSIVE ELEMENT; TARGET SEQUENCE; TYPE-1 AFFECTS; EXPRESSION; HIV-1	The Rex protein of human T-cell leukemia viruses (HTLV) is a trans-acting regulator inducing the expression of gag and env mRNA containing the introns. The rex gene can also induce expression of unspliced RNA of human immunodeficiency viruses (HIV). We have analyzed the level of spliced and unspliced RNAs in nucleus and cytoplasm to understand the mechanism by which the Rex protein modulates RNA processing. With the gag gene of HTLV-1, the unspliced RNA was accumulated by Rex protein in both nucleus and cytoplasm. However, the apparent effects on nuclear unspliced RNA depended on the reporter genes: with the env gene of HTLV-1 as well as that of HIV-1, Rex did not accumulate the unspliced RNA in nucleus, but did so only in cytoplasm. These results clearly indicate that Rex protein not only activates the nuclear export of unspliced RNA, but also modulates some steps of RNA processing before the splicing, probably through stabilization of the precursor RNA.	UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1988, JPN J CANCER RES, V79, P800, DOI 10.1111/j.1349-7006.1988.tb00038.x; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3635; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; ITOH M, 1989, ONCOGENE, V4, P1275; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; SADAIE MR, 1988, P NATL ACAD SCI USA, V85, P9224, DOI 10.1073/pnas.85.23.9224; SADAIE RM, 1988, SCIENCE, V239, P2910; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; TRONO D, 1990, EMBO J, V9, P4155, DOI 10.1002/j.1460-2075.1990.tb07638.x; YOSHIDA M, 1984, HUMAN T CELL LEUKEMI, P141; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; ZIMM K, 1983, CELL, V34, P865	34	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1753	1757						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923501				2022-12-28	WOS:A1991GX11800005
J	SCHNEIDER, R; SCHWEIGER, M				SCHNEIDER, R; SCHWEIGER, M			A NOVEL MODULAR MOSAIC OF CELL-ADHESION MOTIFS IN THE EXTRACELLULAR DOMAINS OF THE NEUROGENIC TRK AND TRKB TYROSINE KINASE RECEPTORS	ONCOGENE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; PROTEIN; GENE; EXPRESSION; SEQUENCES; ONCOGENE; PROTOONCOGENE; ACTIVATION; CONTAINS; FAMILY	The extracellular domains of the human trk proto-oncogene and the closely homologous murine trkB share two highly conserved regions as well as several invariant cysteines which are supposed to be important for ligand recognition. Detailed comparative sequence analyses have now revealed the presence of a novel combination of distinct cell adhesion motifs corresponding precisely with these conserved regions. The N-terminal part consists of an array of three tandem leucine-rich motifs of 24 amino acids which is flanked by two distinct cysteine clusters. Significantly homologous structural features are found in the toll gene product of Drosophila, a transmembrane protein mediating specific cell adhesion events involved in the dorsoventral embryonic pattern formation. Directly adjacent to these structures we additionally identified two repeats of the immunoglobulin-like C2 type, which are significantly similar to repeats found in the neural cell adhesion molecules (N-CAMs) and in the platelet-derived growth factor receptor (PDGFR)-like tyrosine kinase receptor family. Our findings indicate that the trk/trkB protein tyrosine kinase receptors are involved in the transmembrane signalling of growth factor binding as well as of specific cell adhesion events during neuronal development. Additionally, we propose that the specifically expressed truncated forms of the trkB receptor, lacking the tyrosine kinase domain, are functioning as neural cell adhesion molecules. The knowledge of this domain structure will facilitate the elucidation of the molecular reasons why alterations in the extracellular region lead to oncogenic activation of the human trk proto-oncogene, which is a major cause of papillary thyroid carcinoma.			SCHNEIDER, R (corresponding author), UNIV INNSBRUCK,INST BIOCHEM,PETER MAYR STR 1A,A-6020 INNSBRUCK,AUSTRIA.							Barton D E, 1988, Oncogene Res, V3, P323; BONGARZONE I, 1989, ONCOGENE, V4, P1457; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HERZOG H, 1989, P NATL ACAD SCI USA, V86, P3514, DOI 10.1073/pnas.86.10.3514; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HUNDKAPILLER T, 1988, ADV IMMUNOL, V44, P1; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MIOZZO M, 1990, ONCOGENE, V5, P1411; REBSTOCK S, 1990, J BIOL CHEM, V265, P7872; REYES AA, 1991, MOL CELL BIOL, V11, P1654, DOI 10.1128/MCB.11.3.1654; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	33	180	188	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1807	1811						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656363				2022-12-28	WOS:A1991GX11800013
J	MASHIYAMA, S; MURAKAMI, Y; YOSHIMOTO, T; SEKIYA, T; HAYASHI, K				MASHIYAMA, S; MURAKAMI, Y; YOSHIMOTO, T; SEKIYA, T; HAYASHI, K			DETECTION OF P53 GENE-MUTATIONS IN HUMAN BRAIN-TUMORS BY SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS OF POLYMERASE CHAIN-REACTION PRODUCTS	ONCOGENE			English	Article							POINT MUTATIONS; HUMAN GLIOMA; LUNG-CANCER; TRANSFORMATION; DNA; ONCOGENE; NEUROFIBROMATOSIS; RAS; ABNORMALITIES; AMPLIFICATION	Single-strand conformation polymorphism analysis of polymerase chain reaction products (PCR-SSCP analysis) was used for detection of mutations of the p53 gene in surgical specimens of human brain tumors. Six of 45 brain tumors showed mobility shifts in the analyses. These six tumors also showed loss of a normal allele. The samples were examined further by direct sequencing. Results showed that four of them had single-base substitutions and the other two had deletions of one and eight base pairs. Five of the six mutations detected were clustered in highly conserved regions of the p53 gene. The frequency of p53 gene mutations in primary brain tumors examined was 9.8%. We also found two new polymorphic markers in the p53 gene, one in intron 7 and the other in an Alu repeat in exon 11. Both markers could be detected by SSCP analysis. Using these two markers, we found two cases of loss of heterozygosity in other brain tumor specimens. Results suggested that aberrations of the p53 gene were not correlated with the malignancy of some types of brain tumors such as anaplastic astrocytoma and glioblastoma, contrary to previous observations on colorectal cancers.	NATL CANC CTR,RES INST,DIV ONCOGENE,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN; TOHOKU UNIV,SCH MED,INST BRAIN DIS,DIV NEUROSURG,AOBA KU,SENDAI,MIYAGI 980,JAPAN	National Cancer Center - Japan; Tohoku University								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIGNER SH, 1988, CANCER RES, V48, P405; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HENN W, 1986, HUM GENET, V74, P104; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUMPHREY PA, 1988, CANCER RES, V48, P2231; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; MACKAY J, 1988, LANCET, V2, P1384; MASHIYAMA S, 1990, Technique (Philadelphia), V2, P304; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MUNROE DG, 1988, ONCOGENE, V2, P621; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROHRINGER M, 1989, J NEUROSURG, V71, P665, DOI 10.3171/jns.1989.71.5.0665; RUSSELL DS, 1977, PATHOLOGY TUMORS NER; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SOUSSI T, 1990, ONCOGENE, V5, P945; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	41	217	219	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1313	1318						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886708				2022-12-28	WOS:A1991GX27200003
J	HENSEL, CH; XIANG, RH; SAKAGUCHI, AY; NAYLOR, SL				HENSEL, CH; XIANG, RH; SAKAGUCHI, AY; NAYLOR, SL			USE OF THE SINGLE-STRAND CONFORMATION POLYMORPHISM TECHNIQUE AND PCR TO DETECT P53 GENE-MUTATIONS IN SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; THERMOSTABLE DNA-POLYMERASE; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; POINT MUTATIONS; OSTEO-SARCOMA; T-ANTIGEN; EXPRESSION; CARCINOMA; TRANSFORMATION	Recent studies have suggested that the p53 oncoprotein might function normally as a tumor suppressor. Mutations in highly conserved regions of the p53 gene have been observed in numerous types of tumors and tumor cell lines. To detect in a more sensitive manner p53 gene mutations in small cell lung cancer (SCLC) we utilized the single strand conformation polymorphism (SSCP) technique of Orita et al., (1989). Using PCR primers for the most highly conserved regions of the p53 gene, including exons 4-9, we have identified p53 mutations in 5 of 9 small cell lung cancer (SCLC) tumor DNA samples and in 1 SCLC cell line. None of the mutations seen in tumor DNA samples were present in normal DNA from the same patients, indicating that mutation of the p53 gene in these tumors was a somatic event. Of the six mutations observed, two were found in exon 7, three were found in the region encompassing exons 8 and 9, and one was found in the region encompassing exons 5 and 6. Nucleotide sequencing of one of the exon 7 mutations and one of the exon 8-9 mutations indicated that each was a C to T transition. In SCLC-6 the mutation resulted in substitution of serine for proline at amino acid 278 and in SCLC-4 substitution of tryptophan for arginine at amino acid 248, both nonconservative amino acid substitutions. Both of these changes are in regions of the p53 gene where mutations have been observed in other tumors. Two additional mutations were observed in SCLC cell lines using conventional PCR techniques. One of these is a mutation which results in altered splicing of the p53 pre-mRNA.			HENSEL, CH (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284, USA.				NATIONAL CANCER INSTITUTE [R29CA044764, F32CA008711] Funding Source: NIH RePORTER; NCI NIH HHS [CA44764, CA08711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; CHENG J, 1990, BLOOD, V75, P730; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1988, NEW ENGL J MED, V318, P618; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GRIPPO P, 1968, J MOL BIOL, V36, P195, DOI 10.1016/0022-2836(68)90375-6; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P641; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRICKER MC, 1989, GENE, V85, P199, DOI 10.1016/0378-1119(89)90481-2; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEDUC F, 1989, AM J HUM GENET, V44, P282; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG LM, 1988, BIOTECHNIQUES, V6, P839; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; XU HJ, 1989, ONCOGENE, V4, P807; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471	54	83	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1067	1071						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648702				2022-12-28	WOS:A1991GU62200025
J	KIM, H; STRONG, TV; ANDERSON, SJ				KIM, H; STRONG, TV; ANDERSON, SJ			EVIDENCE FOR TAU-EXPRESSION IN CELLS OF MONOCYTE LINEAGE AND ITS INVITRO PHOSPHORYLATION BY V-FMS KINASE	ONCOGENE			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; PROTO-ONCOGENE; LOCALIZATION; CYTOSKELETAL; PATHOLOGY; FILAMENTS; CSF-1; LONG	The v-fms encoded kinase, which is known to associate with cytoskeletal elements, was shown to phosphorylate histiocytic proteins that had physical and immunological attributes in common with tau. Tau is a microtubule associated protein that is aberrantly phosphorylated in Alzheimer's disease of the brain. Since c-fms expression is normally exclusive to cells of monocyte lineage, these cells were examined for expression of tau. Heat stable tau was identified in cultured peripheral blood monocytes. This represents the first molecular characterization of tau in cells of non-neural origin.	UNIV ALABAMA,DEPT PATHOL,VOLKER HALL G-023,UAB STN,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	ANDERSON, SJ (corresponding author), UNIV ALABAMA,DEPT PATHOL,VOLKER HALL G-023,UAB STN,BIRMINGHAM,AL 35294, USA.		Strong, Theresa/GSM-6652-2022	Strong, Theresa/0000-0001-6783-8703	NIA NIH HHS [R0I-AG 06969] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006969] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; ANDERSON SJ, 1982, J VIROL, V44, P696, DOI 10.1128/JVI.44.2.696-702.1982; BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; BINDER LI, 1985, J CELL BIOL, V96, P1523; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HORWITZ DA, 1977, CLIN EXP IMMUNOL, V30, P289; JAMESON L, 1981, P NATL ACAD SCI-BIOL, V78, P3413, DOI 10.1073/pnas.78.6.3413; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; LEHTO VP, 1982, LAB INVEST, V47, P391; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528; RETTENMIER CW, 1985, CELL, V40, P971, DOI 10.1016/0092-8674(85)90357-5; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STRONG TV, 1990, SOMAT CELL MOLEC GEN, V16, P341, DOI 10.1007/BF01232462; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	27	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1085	1087						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829806				2022-12-28	WOS:A1991GU62200028
J	CHIAO, PJ; KANNAN, P; YIM, SO; KRIZMAN, DB; WU, TA; GALLICK, GE; TAINSKY, MA				CHIAO, PJ; KANNAN, P; YIM, SO; KRIZMAN, DB; WU, TA; GALLICK, GE; TAINSKY, MA			SUSCEPTIBILITY TO RAS ONCOGENE TRANSFORMATION IS COREGULATED WITH SIGNAL TRANSDUCTION THROUGH GROWTH-FACTOR RECEPTORS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; SARCOMA-VIRUS; MOLECULAR-CLONING; CELL-LINE; ORNITHINE DECARBOXYLASE; NUCLEOTIDE-SEQUENCE; RIBONUCLEIC-ACID; CHINESE-HAMSTER; EGF RECEPTOR; GENE	The human teratocarcinoma cell line PA-1 was derived from culturing ascites fluid cells from a patient with an ovarian germ line tumor. We previously described a nonneoplastic variant cloned from the PA-1 human teratocarcinoma cell line, clone 6, which at passage 40 was resistant to transformation by activated ras oncogenes. However, these cells could be transformed by a plasmid containing both myc and ras. Another PA-1 cell variant, clone 1, isolated at passage 63 and used 50 passages later becomes tumorigenic in nude mice after transfection with an activated ras oncogene (Tainsky et al, Anticancer Res., 8, 899-914, 1988). We report here that the progression from ras resistance to ras susceptibility occurs in both clone 1 and clone 6 cells during 25 passages in culture. In the presence of epidermal growth factor, transforming growth factor-alpha, and basic fibroblast growth factor, the ras-transformable cells exhibit anchorage independent growth, whereas the ras-resistant cells can not be growth stimulated by these growth factors. Similarly, ornithine decarboxylase (ODC) activity was inducible in ras susceptible and ras transformed cells by these growth factors, but not in the ras resistant cells. These differences are not due to the level and activity of epidermal growth factor receptor or to the level of expression of 25 proto-oncogenes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	TAINSKY, MA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [R01CA042810] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42810] Funding Source: Medline; PHS HHS [09299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BOS JL, 1989, CANCER RES, V49, P4682; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLBURN NH, 1985, MOL CELL BIOL, V5, P890, DOI 10.1128/MCB.5.4.890; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FEDELE LA, 1982, J VIROL, V41, P489; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; FRIEND SH, 1986, NATURE, V323, P5643; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HIGHFIELD PE, 1980, J VIROL, V36, P271, DOI 10.1128/JVI.36.1.271-279.1980; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; KRIZMAN DB, 1990, SOMAT CELL MOLEC GEN, V16, P115; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Maniatis T., 1982, MOL CLONING; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MILLER AD, 1984, CELL, V36, P51; MORIARITY DM, 1981, P NATL ACAD SCI-BIOL, V78, P2752, DOI 10.1073/pnas.78.5.2752; MORLA AO, 1986, P NATL ACAD SCI USA, V83, P8191, DOI 10.1073/pnas.83.21.8191; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAGER R, 1984, CANCER CELL, V2, P487; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; TAINSKY MA, 1988, ANTICANCER RES, V8, P899; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TREVILLYAN JM, 1983, BIOCHIM BIOPHYS ACTA, V762, P187, DOI 10.1016/0167-4889(83)90070-8; WATSON DK, 1983, P NATL ACAD SCI USA, V80, P4036; Williams-Ashman H G, 1972, Adv Enzyme Regul, V10, P225, DOI 10.1016/0065-2571(72)90016-7; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	55	14	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					713	720						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646984				2022-12-28	WOS:A1991GT82500005
J	STORK, P; LODA, M; BOSARI, S; WILEY, B; POPPENHUSEN, K; WOLFE, H				STORK, P; LODA, M; BOSARI, S; WILEY, B; POPPENHUSEN, K; WOLFE, H			DETECTION OF K-RAS MUTATIONS IN PANCREATIC AND HEPATIC NEOPLASMS BY NONISOTOPIC MISMATCHED POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article							HUMAN-COLON; ENZYMATIC AMPLIFICATION; POINT MUTATIONS; TRANSGENIC MICE; GENE-MUTATIONS; ONCOGENES; DNA; ACTIVATION; TUMORIGENESIS; CARCINOMAS	Mutations within codon 12 leading to activation of Kirsten-ras (K-ras) genes occur in a wide variety of human tumors, but have been reported most frequently in pancreatic carcinomas. We studied twenty-four paraffin-embedded pancreatic and hepatic tumors and two colon carcinoma cell lines with a rapid and simple approach that exploits allele-specific amplification of genomic DNA in a polymerase chain reaction (PCR). We extend the utility of this technique, which is dependent on an exact match at the 3' nucleotide between synthetic oligonucleotides and template DNA, to analyse paraffin-embedded tumor samples for the presence of point mutations at the first and second base of codon 12 of the K-ras gene. The PCR mismatch amplification technique demonstrated a 66% incidence of K-ras mutations at codon 12 in the group of pancreatic neoplasms as a whole. The percentage of mutations varied only slightly in the pancreatic cancer subcategories: 75% in ampullary, 66% in bile duct and 57% in the ductal adenocarcinomas. One islet cell carcinoma and normal tissues adjacent to the tumors revealed wild-type alleles only. One hepatoblastoma and one of six hepatocellular carcinomas also had codon 12 mutations. The PCR mismatch is a sensitive and rapid method that may be useful in screening neoplasms for K-ras point mutation and can be applied to archival material. This application allows a retrospective analyses of a wide range of pathological specimens to determine the role of K-ras mutations in human tumorigenesis.	NEW ENGLAND MED CTR HOSP, DEPT PATHOL, 171 HARRISON AVE, BOSTON, MA 02111 USA	Tufts Medical Center	WOLFE, H (corresponding author), NEW ENGLAND MED CTR HOSP, DEPT PATHOL, 171 HARRISON AVE, BOSTON, MA 02111 USA.		Bosari, Silvano/K-7744-2016	Bosari, Silvano/0000-0002-9744-6951				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHEHAB FF, 1989, P NATL ACAD SCI USA, V86, P9178, DOI 10.1073/pnas.86.23.9178; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GRUNEWALD K, 1989, INT J CANCER, V43, P1037, DOI 10.1002/ijc.2910430614; GU JR, 1986, J CELL PHYSIOL, P13; JIANG W, 1989, ONCOGENE, V4, P923; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OKAYAMA H, 1989, J LAB CLIN MED, V114, P105; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; TADA M, 1990, CANCER RES, V50, P1121; WATATANI M, 1989, CANCER RES, V49, P1103; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	28	96	103	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1991	6	5					857	862						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646989				2022-12-28	WOS:A1991GT82500023
J	GARCIA, IS; KANEKO, Y; GONZALEZSARMIENTO, R; CAMPBELL, K; WHITE, L; BOEHM, T; RABBITTS, TH				GARCIA, IS; KANEKO, Y; GONZALEZSARMIENTO, R; CAMPBELL, K; WHITE, L; BOEHM, T; RABBITTS, TH			A STUDY OF CHROMOSOME-11P13 TRANSLOCATIONS INVOLVING TCR-BETA AND TCR-DELTA IN HUMAN T-CELL LEUKEMIA	ONCOGENE			English	Article							BREAKPOINT CLUSTER REGION; CHAIN; LEUKEMIA; 11P13; LYMPHOMA; SEQUENCE; ORGANIZATION; INVERSION; DIVERSITY; TUMORS	A frequent site of translocation damage in human T-ALL has been localized to a specific region of chromosome band 11p13. Five new T-ALL cases are described which break in the major T-ALL(bcr) region of 11p13, two involving a novel translocation t(7;11)(q35;p13), with breakage at the T cell receptor (TCR) beta-gene from 7q35, and three involving TCR-delta from 14q11 in the more common t(11;14)(p13;q11). Analysis of the mechanism of one T-ALL(bcr)/TCR-beta translocation and a previously described t(11;14)(p13;q11) was conducted by genomic cloning of translocation breakpoints, using the polymerase chain reaction (PCR). Both seem to have occurred by recombinase error, but only the t(7;11) showed sequence-specific joining. Nonetheless recombinase mediation of the t(11;14) is implied by the presence of N-region addition (a hallmark of recombinase joins) on both derivative chromosomes. These observations reinforce the view that translocations in the T-ALL(bcr) region of chromosome 11p13 are a major lesion in human T-ALL. In addition, these can occur by mimicry of VDJ joining, but sequence specificity is not obligatory.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; SAITAMA CANC CTR,INA,SAITAMA 362,JAPAN; PRINCE WALES CHILDRENS HOSP,DIV HAEMATOL ONCOL,SYDNEY,NSW 2031,AUSTRALIA	MRC Laboratory Molecular Biology			Gonzalez-Sarmiento, Rogelio/V-5526-2019; Rabbitts, Terence/D-6262-2016	Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Rabbitts, Terence/0000-0002-4982-2609				BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BARKER PE, 1987, AM J HUM GENET, V39, P661; BOEHM T, 1990, NUCLEIC ACIDS RES, V18, P4298, DOI 10.1093/nar/18.14.4298; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; KANEKO Y, 1989, LEUKEMIA, V3, P886; KANEKO Y, 1988, BLOOD, V72, P534; LOH EY, 1988, P NATL ACAD SCI USA, V85, P9714, DOI 10.1073/pnas.85.24.9714; RABBITTS TH, 1991, IN PRESS ADV IMMUNOL, V50; ROYERPOKORA B, 1989, HUM GENET, V82, P264, DOI 10.1007/BF00291167; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STADEN R, 1990, COMPUT APPL BIOSCI, V6, P387; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TUNNACLIFFE A, 1985, NUCLEIC ACIDS RES, V13, P6651, DOI 10.1093/nar/13.18.6651; TUNNACLIFFE A, 1985, P NATL ACAD SCI USA, V82, P5068, DOI 10.1073/pnas.82.15.5068; YOFFE G, 1989, BLOOD, V74, P374	21	33	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					577	582						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827667				2022-12-28	WOS:A1991FR93900011
J	MAEKAWA, T; MATSUDA, S; FUJISAWA, J; YOSHIDA, M; ISHII, S				MAEKAWA, T; MATSUDA, S; FUJISAWA, J; YOSHIDA, M; ISHII, S			CYCLIC-AMP RESPONSE ELEMENT-BINDING PROTEIN, CRE-BP1, MEDIATES THE E1A-INDUCED BUT NOT THE TAX-INDUCED TRANSACTIVATION	ONCOGENE			English	Article							TRANSCRIPTION FACTOR ATF; LEUCINE ZIPPER STRUCTURE; LONG TERMINAL REPEAT; V-MYB ONCOGENE; VIRUS TYPE-I; C-MYB; FUNCTIONAL DOMAINS; INFECTED-CELLS; RECEPTOR GENE; CDNA CLONES	The adenovirus E1A protein and tax protein (Tax) of human T-cell leukemia virus-1 (HTLV-1) are transcriptional regulators that do not bind to DNA directly. The ATF sites/CRE (cyclic AMP response element) of the adenovirus E4 promoter and the long terminal repeat of HTLV-1 have been shown to be required for E1A and Tax inducibility, respectively. Using the c-Myb-CRE-BP1 fusion protein, it was shown that CRE-BP1, which could bind to the ATF sites/CRE, mediated the E1A-induced trans-activation. For this activation, the N-terminal portion of CRE-BP1, which contained the putative metal finger structure, was essential but not sufficient. In contrast, the trans-activation induced by HTLV-1 Tax was not mediated by CRE-BP1. These results strongly suggested that E1A activates transcription through interaction with CRE-BP1, but another CRE-binding protein participates in the Tax-induced trans-activation.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	RIKEN; University of Tokyo			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI SI, 1990, ONCOGENE, V5, P39; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEONG K, 1988, MOL CELL BIOL, V8, P1765, DOI 10.1128/MCB.8.4.1765; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SEILERTUYNS A, 1984, P NATL ACAD SCI-BIOL, V81, P2980, DOI 10.1073/pnas.81.10.2980; SHI P, 1988, J CELL BIOCHEM     S, V12, P381; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	43	68	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					627	632						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827668				2022-12-28	WOS:A1991FR93900018
J	HOSONO, S; LEE, CS; CHOU, MJ; YANG, CS; SHIH, C				HOSONO, S; LEE, CS; CHOU, MJ; YANG, CS; SHIH, C			MOLECULAR ANALYSIS OF THE P53 ALLELES IN PRIMARY HEPATOCELLULAR CARCINOMAS AND CELL-LINES	ONCOGENE			English	Article							HEPATITIS-B VIRUS; TUMOR SUPPRESSOR GENES; SV40-TRANSFORMED CELLS; INTEGRATION SITES; ANTI-ONCOGENE; DNA; EXPRESSION; PROTEIN; PRODUCT; CANCER	We have examined p53 oncogene/anti-oncogene alleles in 10 different human heptoma cell lines and 18 primary hepatocellular carcinomas. The p53 allele in these hepatoma cell lines appears to be a frequent target of mutation as demonstrated by Southern and Northern blotting, immunoprecipitation and Western blot analysis. In general, the steady state level of p53 specific RNA or protein in these hepatoma cell lines is higher than in normal liver. However, in three out of ten cell lines, normal-sized p53 mRNA cannot be detected. In contrast, the involvement of the p53 allele in primary hepatocellular carcinoma appears to be an exceedingly rare event. Steady state levels of p53 specific RNA in primary hepatomas are practically indistinguishable from those in normal adult liver. Using the polymerase chain reaction technique, we have amplified and subcloned exons 5, 6, 7 and 8 of p53 from 10 different hepatoma samples. DNA sequence analysis of these exon subclones reveals no apparent structural alterations. Finally, synthesis of p53 specific mRNA or protein in a HepG2 human hepatoblastoma cell line does not appear to be affected by gene expression and replication of human hepatitus B virus. Surprisingly, unlike many other kinds of human solid tumors, point mutations in p53 do not appear to be important in primary tumors of hepatocellular carcinomas.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; NATL TAIWAN UNIV,COLL MED,TAIPEI,TAIWAN	University of Pennsylvania; National Taiwan University			Shih, Chiaho/S-7017-2018		NCI NIH HHS [R01 CA 48198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BEASLEY RP, 1981, LANCET, V2, P1129; BLUMBERG BS, 1981, NEW ENGL J MED, V304, P782, DOI 10.1056/NEJM198103263041312; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CANNIZARO LA, 1989, AM J HUM GENET, V38, P812; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEJEAN A, 1984, P NATL ACAD SCI-BIOL, V81, P5350, DOI 10.1073/pnas.81.17.5350; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRIMM J, 1976, INT J BIOCHEM, V64, P249; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HINO O, 1989, J VIROL, V63, P2638, DOI 10.1128/JVI.63.6.2638-2643.1989; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; KORNBLUTH J, 1985, J IMMUNOL, V134, P728; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACNAB GM, 1976, BRIT J CANCER, V34, P509, DOI 10.1038/bjc.1976.205; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PAYNE GS, 1981, CELL, V23, P311, DOI 10.1016/0092-8674(81)90127-6; Robinson W.S., 1990, VIROLOGY, P2137; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIH CH, 1987, J VIROL, V61, P3491, DOI 10.1128/JVI.61.11.3491-3498.1987; SLAGLE BL, 1990, J CELL BIOCHEM, V14, P276; SOUSSI T, 1987, ONCOGENE, V1, P71; STANBRIDGE EJ, 1990, SCIENCE, V247, P12, DOI 10.1126/science.2403692; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	56	86	87	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					237	243						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1847999				2022-12-28	WOS:A1991FZ13400009
J	ADAM, D; MAUELER, W; SCHARTL, M				ADAM, D; MAUELER, W; SCHARTL, M			TRANSCRIPTIONAL ACTIVATION OF THE MELANOMA INDUCING XMRK ONCOGENE IN XIPHOPHORUS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; EGF-RECEPTOR; AUTOPHOSPHORYLATION SITES; CELL-LINE; CANCER; GENE; SEQUENCES; LOCUS	The melanoma inducing locus of Xiphophorus encodes a tumorigenic version of a novel putative receptor tyrosine kinase (Xmrk). To elucidate the mechanism of oncogenic activation of Xmrk, we compared the structure and expression of two oncogenic loci with the corresponding proto-oncogene. Only minor structural alterations were found to be specific for the oncogenic Xmrk genes. Marked overexpression of the oncogene transcripts in melanoma, which are approximately 1 kb shorter than the proto-oncogene transcript, correlates with the malignancy of the tumors. The tumor transcripts are derived from an alternative transcription start site that is used only in the oncogenic loci. Thus, oncogenic activation of the melanoma inducing Xmrk gene appears primarily to be due to novel transcriptional control and overexpression.	MAX PLANCK INST BIOCHEM, GENZENTRUM, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY	Max Planck Society			Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1988, NUCLEIC ACIDS RES, V16, P7212, DOI 10.1093/nar/16.14.7212; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; ANDERS A, 1978, BIOCHIM BIOPHYS ACTA, V516, P61, DOI 10.1016/0304-419X(78)90004-5; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; ATZ JAMES W., 1962, ZOOLOGICA [NEW YORK], V47, P153; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CARPENTER CD, 1990, BIOTECHNIQUES, V8, P26; Chaconas G, 1980, Methods Enzymol, V65, P75; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GORDON M, 1958, ANN NY ACAD SCI, V71, P1213, DOI 10.1111/j.1749-6632.1958.tb54683.x; Gordon M, 1927, GENETICS, V12, P253; HAUSSLER G, 1928, KLINWOCHENSCHR, V33, P1561; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JEFFREYS AJ, 1982, NATURE, V296, P9, DOI 10.1038/296009a0; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KOSSWIG C, 1965, Zoologischer Anzeiger, V175, P21; Kosswig C., 1928, Zeitschrift fuer Induktive Abstammungs- und Vererbungslehre, V47, P150; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MAUELER W, 1988, ONCOGENE, V2, P421; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nei M., 1987, MOL EVOLUTIONARY GEN; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; SCHARTL M, 1988, GENETICS, V119, P679; SCHARTL M, 1990, IN PRESS GENETICS; SCHWAB M, 1987, TRENDS GENET, V3, P38, DOI 10.1016/0168-9525(87)90164-8; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SINKOVICS JG, 1988, CRC CR REV IMMUNOL, V8, P217; TRONICK SR, 1988, ADV SEC MESS PHOSPH, V21, P201; Vielkind J. R., 1989, Journal of Aquatic Animal Health, V1, P69, DOI 10.1577/1548-8667(1989)001&lt;0069:GOMIXF&gt;2.3.CO;2; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINBERG RA, 1989, CANCER RES, V49, P3713; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZANDER C D, 1969, Mitteilungen aus dem Hamburgischen Zoologischen Museum und Institut, V66, P241; ZECHEL C, 1988, ONCOGENE, V3, P605	46	64	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1991	6	1					73	80						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846957				2022-12-28	WOS:A1991EY03900010
J	PETERS, DJ; MCGREW, BR; PERRON, DC; LIPTAK, LM; LAUDANO, AP				PETERS, DJ; MCGREW, BR; PERRON, DC; LIPTAK, LM; LAUDANO, AP			INVIVO PHOSPHORYLATION AND MEMBRANE ASSOCIATION OF THE FYN PROTOONCOGENE PRODUCT IN IM-9 HUMAN LYMPHOBLASTS	ONCOGENE			English	Article									UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03824	University System Of New Hampshire; University of New Hampshire								AMES GFL, 1974, J BIOL CHEM, V249, P634; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1988, PEPTIDES PROTEIN PHO; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; INOUE K, 1987, ONCOGENE, V1, P301; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KAWAKAMI Y, 1989, ONCOGENE, V4, P389; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; LINDER ME, 1988, J VIROL, V62, P2665, DOI 10.1128/JVI.62.8.2665-2673.1988; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MACAULEY A, 1988, MOL CELL BIOL, V8, P3560, DOI 10.1128/MCB.8.8.3560; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STEWARTJM, 1984, SOLID PHASE PEPTIDE; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	49	17	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1313	1319						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699196				2022-12-28	WOS:A1990EC24100006
J	WILDENHAIN, Y; PAWSON, T; BLACKSTEIN, ME; ANDRULIS, IL				WILDENHAIN, Y; PAWSON, T; BLACKSTEIN, ME; ANDRULIS, IL			P185NEU IS PHOSPHORYLATED ON TYROSINE IN HUMAN PRIMARY BREAST-TUMORS WHICH OVEREXPRESS NEU/ERBB-2	ONCOGENE			English	Article									MT SINAI HOSP, RES INST, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; MT SINAI HOSP, DEPT MED, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MED GENET, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT ANAT, TORONTO M5G 1X5, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Andrulis, Irene L./E-7267-2013					ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; KAMPS MP, 1988, ONCOGENE, V2, P305; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LETWIN K, 1988, ONCOGENE, V3, P621; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	20	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					879	883						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	1694290				2022-12-28	WOS:A1990DP55300014
J	CASES, S; DAUTRY, F				CASES, S; DAUTRY, F			INACTIVATION OF THE MURINE N-RAS GENE BY GENE TARGETING	ONCOGENE			English	Note							EMBRYONIC STEM-CELLS; HOMOLOGOUS RECOMBINATION; SIGNAL TRANSDUCTION; MUTATION; MICE; ORGANIZATION; EXPRESSION; PROTEIN; GROWTH; LOCUS	The mammalian ras genes have been implicated in the genesis of a wide variety of tumors. Although it is likely that they play an essential role in signal transduction, their specific function is still unknown. To initiate a genetic analysis of the ras genes in mammals we inactivated the N-ras gene in murine embryonic stem cells by gene targeting. The frequency of integration at the N-ras locus of our targeting vector being low (of the order of 1/5000 transfectants), we used a positive/negative selection followed by an analysis of individual colonies in order to minimize the in vitro manipulation of the embryonic stem cells. Using this approach, we isolated two clones of ES cells with one inactivated N-ras allele. These cells have no distinctive phenotype either in vitro or in vivo in chimeric mice.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOS JL, 1989, CANCER RES, V49, P4682; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHANG HY, 1987, ONCOGENE RES, V1, P129; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOULD B, 1988, CELL, V53, P753; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NICOLAIEW N, 1991, ONCOGENE, V6, P721; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	30	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2525	2528						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461656				2022-12-28	WOS:A1992KA85600019
J	PAULES, RS; RESNICK, J; KASENALLY, AB; ERNST, MK; DONOVAN, P; VANDEWOUDE, GF				PAULES, RS; RESNICK, J; KASENALLY, AB; ERNST, MK; DONOVAN, P; VANDEWOUDE, GF			CHARACTERIZATION OF ACTIVATED AND NORMAL MOUSE MOS GENE IN MURINE 3T3 CELLS	ONCOGENE			English	Article							PROTO-ONCOGENE PRODUCT; MEIOTIC MATURATION; SARCOMA-VIRUS; M-PHASE; DEVELOPMENTAL REGULATION; OOCYTE MATURATION; XENOPUS OOCYTES; CDC2 PROTEIN; GERM-CELLS; MEIOSIS-II	We have characterized the mouse Mos proto-oncogene product, pp39Mos in murine fibroblasts. When expressed in NIH3T3 cells under the influence of the long terminal repeat regulatory element from Moloney murine sarcoma virus [NIH(pTS-1) cells], the Mos protein was present in low levels and had a half-life of about 30 min. In extracts from NIH(pTS-1) cells, we detected additional forms of Mos protein that apparently arose from internal initiation codons (p24Mos and p29Mos) or from upstream non-AUG initiation codons (p42Mos and p44Mos). The Mos protein was found to exist in these cells as a phosphoprotein, pp39Mos, and, when immunoprecipitated with an antiserum specific for the Mos N-terminus [anti-Mos(6-24)], had autophosphorylating kinase activity. We found that anti-Mos(6-24) also detected non-Mos protein kinase activity and non-Mos phosphoproteins in addition to p39Mos. We present evidence, on both the RNA and protein levels, that non-transformed mouse 3T3 cells do not express endogenous Mos.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ABL,FREDERICK,MD 21702	Imperial College London; Ludwig Institute for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	PAULES, RS (corresponding author), NIEHS,MAMMALIAN MOLEC GENET GRP,POB 12233,RES TRIANGLE PK,NC 27709, USA.			Paules, Richard S/0000-0001-9106-7486	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FRANKEL AE, 1976, P NATL ACAD SCI USA, V73, P3705, DOI 10.1073/pnas.73.10.3705; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KESHET E, 1988, ONCOGENE, V2, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, J VIROL, V55, P874, DOI 10.1128/JVI.55.3.874-876.1985; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MELCHERS F, 1985, P NATL ACAD SCI USA, V82, P7681, DOI 10.1073/pnas.82.22.7681; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAPKOFF J, 1981, CELL, V27, P109, DOI 10.1016/0092-8674(81)90365-2; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PLATT EJ, 1986, ANAL BIOCHEM, V156, P126, DOI 10.1016/0003-2697(86)90163-6; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SCHULZ N, 1992, CANCER RES, V52, P450; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; Stein Gary S., 1989, P133; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; VANDEWOUDE GF, 1980, COLD SPRING HARB SYM, V44, P735, DOI 10.1101/SQB.1980.044.01.079; WASSERMAN WJ, 1978, J CELL BIOL, V78, P15; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142; ZINN K, 1983, CELL, V34, P856	51	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2489	2498						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461652				2022-12-28	WOS:A1992KA85600014
J	CHISHOLM, O; STAPLETON, P; SYMONDS, G				CHISHOLM, O; STAPLETON, P; SYMONDS, G			CONSTITUTIVE EXPRESSION OF EXOGENOUS MYC IN MYELOMONOCYTIC CELLS - ACQUISITION OF A MORE TRANSFORMED PHENOTYPE AND INHIBITION OF DIFFERENTIATION INDUCTION	ONCOGENE			English	Article							INDUCED TERMINAL DIFFERENTIATION; HUMAN MONOCYTIC DIFFERENTIATION; PROMYELOCYTIC LEUKEMIA-CELLS; MURINE ERYTHROLEUKEMIA-CELLS; COLONY-STIMULATING FACTORS; ONCOGENE-C-MYC; V-MYC; PROTO-ONCOGENE; MYELOID-LEUKEMIA; MULTISTEP CARCINOGENESIS	The effects of deregulated expression of the human c-myc and MC29 v-myc oncogenes have been examined in a murine myelomonocytic cell line J774 (c-myc) and in a variety of myelomonocytic cell lines of different degrees of maturity generated from primary hematopoietic tissue (v-myc). Introduction of a Moloney murine leukemia virus long terminal repeat (LTR) c-myc construct into J774 cells resulted in constitutive expression of the exogenous myc gene and a concomitant increase in the degree of transformation and tumorigenicity of the cells. In addition, constitutive expression of exogenous inhibited induced differentiation of these cells by a variety of treatments including addition to the medium of lipopolysaccharide (LPS) or the phorbol ester 12-O-tetradecanoyl phorbol 13-acetate (TPA) as well as complete withdrawal of serum from the medium. The degree, of increased transformation, tumorigenicity and inhibition of terminal differentiation was dependent upon the level of exogenous myc expression. For the v-myc-generated myelomonocytic cell lines, introduction of v-myc resulted in a high degree of transformation and, irrespective of the differentiation status of the cells, a block of induced differentiation. These results indicate that the level of constitutive myc expression can affect the transformed phenotype, tumorigenicity and differentiation inducibility of myelomonocytic cells.	CHILDRENS MED RES FDN, LEUKEMIA RES & VIRAL PATHOL UNIT, CAMPERDOWN, NSW 2050, AUSTRALIA; RW JOHNSON PHARMACEUT RES INST SYDNEY, EDGECLIFF, NSW 2027, AUSTRALIA	Children's Medical Research Institute - Australia			Chisholm, Orin/L-4206-2016	Chisholm, Orin/0000-0002-9749-4160				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BACON TA, 1991, ONCOGENE RES, V6, P21; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BLOOM BR, 1978, FED PROC, V37, P2765; BONHAM L, 1991, ONCOGENE, V6, P1073; BONHAM L, 1992, IN PRESS ONCOGENE; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHISHOLM O, 1988, NUCLEIC ACIDS RES, V16, P2352, DOI 10.1093/nar/16.5.2352; CHISHOLM O, 1992, INT J CANCER, V51, P149, DOI 10.1002/ijc.2910510126; Clark G., 1981, STAINING PROCEDURES; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; CORY S, 1987, ONCOGENE RES, V1, P61; DEXTER TM, 1979, NATURE, V277, P471, DOI 10.1038/277471a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ERBA HP, 1988, MOL CELL BIOL, V8, P1775, DOI 10.1128/MCB.8.4.1775; FALCONE G, 1987, EXP CELL RES, V168, P273, DOI 10.1016/0014-4827(87)90435-6; FILMUS J, 1985, CANCER RES, V45, P822; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREEN SM, 1989, ONCOGENE, V4, P737; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488; JAFFE BD, 1988, ONCOGENE, V2, P167; JUNGI TW, 1986, IMMUNOLOGY, V58, P131; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KOEFFLER HP, 1983, BLOOD, V62, P709; KOREN HS, 1975, J IMMUNOL, V114, P894; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOTEM J, 1977, J CELL PHYSIOL, V92, P97, DOI 10.1002/jcp.1040920112; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MARTINSSON T, 1988, ONCOGENE, V3, P437; MATSUHASHI C, 1981, MEN EKI GAKU JIKKEN; MCCAIRNS E, 1983, MOL CELL BIOCHEM, V56, P165; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1986, BLOOD, V67, P257; Metcalf D, 1984, CLONAL CULTURE HEMOP; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; OHNO H, 1988, CANCER RES, V48, P4959; PFEIFER S, 1980, INT J CANCER, V25, P235, DOI 10.1002/ijc.2910250211; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBITTS TH, 1985, TRENDS GENET, V1, P327, DOI 10.1016/0168-9525(85)90127-1; RALPH P, 1975, J IMMUNOL, V114, P898; RALPH P, 1977, CANCER RES, V37, P546; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SEGAL S, 1988, MOL IMMUNOL, V25, P1129, DOI 10.1016/0161-5890(88)90147-2; SHIROKI K, 1986, MOL CELL BIOL, V6, P4379, DOI 10.1128/MCB.6.12.4379; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAPLETON P, 1991, ONCOGENE, V6, P807; STEWART CC, 1984, MONONUCLEAR PHAGOCYT; SYMONDS G, 1982, EMBO J, V1, P1343, DOI 10.1002/j.1460-2075.1982.tb01320.x; SYMONDS G, 1989, ONCOGENE, V4, P285; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; VENTURA MA, 1987, EXP CELL RES, V170, P290, DOI 10.1016/0014-4827(87)90307-7; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEINBERG RA, 1989, CANCER RES, V49, P3713; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; ZERLIN M, 1987, ONCOGENE, V1, P19	83	20	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1827	1836						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501891				2022-12-28	WOS:A1992JJ37600019
J	ALMOUSTAFA, AE; QUATANNENS, B; DIETERLENLIEVRE, F; SAULE, S				ALMOUSTAFA, AE; QUATANNENS, B; DIETERLENLIEVRE, F; SAULE, S			TUMORIGENIC EFFECTS MEDIATED IN THE AVIAN EMBRYO BY ONE OR MORE ONCOGENES ASSOCIATED WITH V-MYC	ONCOGENE			English	Note							C-MYC; CELLS; TRANSFORMATION; E26; EXPRESSION; RETROVIRUS; DOMAINS; INVIVO; QUAIL; ERBA	We have previously shown that introduction of the v-myc oncogene in chick or quail embryos at E3 induces rapidly growing heart rhabdomyomas. We now report that a retrovirus containing one or two other oncogenes induces additional pathologies specified by the v-myc-associated oncogene. The v-mil/myc combination introduced at E3 induces, in addition to heart rhabdomyomas, tumors of proliferating celts aggregated onto the luminal aspect of vessels in both chick and quail embryos. In the quail these cells react positively with the quail-specific mAb QH1, which recognizes endothelial and most hemopoietic cells, while chick intravascular cells do not react with the chick-specific mAb VIA2 that recognizes hemopoietic cells. Thus the v-mil/myc tumors appear to be of endothelial origin. The v-myb-ets/myc combination injected at E3 induces cardiorhabdomyomas and aggressive VIA2-positive hemopoietic tumors in chick embryos, but only the v-myc-induced cardiorhabdomyomas in quail embryos. When injected into hatched animals, v-myc alone transforms hemopoietic and perhaps endothelial cells, but not cardiac cells. Thus the developmental stage at which a cell type can be transformed by v-myc and another associated oncogene depends on as yet undefined species-specific factors. More importantly, several examples of oncogene cooperation in vivo are adduced by these experiments. The type of cell transformed is specified by the viral oncogene combination.	CNRS,INST EMBRYOL CELLULAIRE & MOLEC,49BIS AV BELLE GABRIELLE,F-94130 NOGENT SUR MARNE,FRANCE; COLL FRANCE,F-75231 PARIS 05,FRANCE; INST PASTEUR,CNRS,URA 1160,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ALEXANDER RW, 1979, J NATL CANCER I, V62, P359; ALMOUSTAFA AE, 1988, CELL DIFFER DEV, V25, P119, DOI 10.1016/0922-3371(88)90005-6; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BACHNOU N, 1991, ONCOGENE, V6, P1041; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BECHADE C, 1988, J VIROL, V62, P1211; Begg AM, 1927, LANCET, V1, P912; BIEGALKE BJ, 1987, J VIROL, V61, P2139; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; FERRE F, 1986, CR ACAD SCI III-VIE, V303, P633; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; JAFFREDO T, 1989, DEVELOPMENT, V105, P679; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MARTIN P, 1986, J VIROL, V57, P1191, DOI 10.1128/JVI.57.3.1191-1194.1986; MARTIN P, 1986, VIROLOGY, V153, P272, DOI 10.1016/0042-6822(86)90030-9; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MURRAY JA, 1930, SCI REP CANCER RES F, V9, P1; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RONG PM, 1987, DEV BIOL, V122, P338, DOI 10.1016/0012-1606(87)90299-5; SAULE S, 1987, P NATL ACAD SCI USA, V84, P7982, DOI 10.1073/pnas.84.22.7982; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917	27	16	16	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1667	1670						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630827				2022-12-28	WOS:A1992JE81300027
J	ULLRICH, SJ; MERCER, WE; APPELLA, E				ULLRICH, SJ; MERCER, WE; APPELLA, E			HUMAN WILD-TYPE P53 ADOPTS A UNIQUE CONFORMATIONAL AND PHOSPHORYLATION STATE INVIVO DURING GROWTH ARREST OF GLIOBLASTOMA CELLS	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; LARGE-T-ANTIGEN; MUTANT P53; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; SUPPRESSOR PROTEIN; TRANSFORMED-CELLS; CYCLE CONTROL; EXPRESSION; GENE	The wild-type (wt) human tumor-suppressor gene product, p53, and its mutant form have been analysed in an in vivo system in which the inducible expression of wt p53 results in growth arrest in the G1 phase of the cell cycle. Two major pools of p53 are detected after wt p53 expression by their differential reactivity with the p53 monoclonal antibodies PAb 421 and 1801 as well as the mutant and wt-specific monoclonal antibodies PAb 240 and 1620; one pool contains wt and mutant p53 and is characterized as having a mutant conformation, whereas the other pool contains only wt p53 with a wt conformation. As G1 arrest is entered, the amount of wt p53 associated with the mutant pool decreases, such that by 12 h free wt and mutant p53 are the - major pools. Two-dimensional gel analysis of the p53 pools revealed that free wt p53 is phosphorylated to a greater degree than mutant p53, which correlated with the loss of the PAb 421 epitope on wt p53. In summary, the ability of wt p53 to exert an antiproliferative effect correlates with the presence of a unique conformational state of wt p53 characterized by increased phosphorylation and the loss of both the PAb 421 epitope and association with mutant p53 pool, whereas mutant p53 is unable to assume this conformational state.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University	ULLRICH, SJ (corresponding author), NCI,CELL BIOL LAB,BLDG 37,RM 1B03,BETHESDA,MD 20892, USA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINDLAY CA, 1989, CELL, V57, P1083; GANNON JV, 1990, EMBO J, V9, P1591; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1991, ONCOGENE, V6, P131; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1989, ONCOGENE, V4, P643; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHOHAT O, 1987, ONCOGENE, V1, P277; VANROY F, 1990, ONCOGENE, V5, P207; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	52	148	153	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1635	1643						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630823				2022-12-28	WOS:A1992JE81300021
J	WICK, M; LUCIBELLO, FC; MULLER, R				WICK, M; LUCIBELLO, FC; MULLER, R			INHIBITION OF FOS-INDUCED AND RAS-INDUCED TRANSFORMATION BY MUTANT FOS PROTEINS WITH STRUCTURAL ALTERATIONS IN FUNCTIONALLY DIFFERENT DOMAINS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING DOMAINS; PROTO-ONCOGENE FOS; C-FOS; GENE-EXPRESSION; LEUCINE ZIPPER; AUTO-REGULATION; JUN PROTEINS; ACTIVATION; COMPLEXES	We show that transformation-defective Fos proteins lacking either a functional leucine zipper (mutants L345 and J/R510s) or the 110 amino-terminal amino acids (mutant BR800) inhibit the induction of morphological transformation by v-Fos. Both types of mutants specifically repress transformation without any significant effect on cell proliferation. In contrast, several transformation-defective Fos mutants with structural alterations in the acidic region or the right half of the adjacent basic DNA contact site do not show any inhibition of transformation. This result, taken together with the repression of transformation by the leucine zipper-deficient mutants L345 and J/R510s, indicates that the interaction of Fos with proteins other than Jun is necessary for transformation. The leucine zipper-deficient mutants also inhibit Fos-mediated activation of AP-1-dependent transcription. This suggests that their inhibitory effect on transformation may at least in part be the result of the squelching of proteins other than Jun family members that are required for Fos-mediated transactivation. All three mutants were also found to inhibit transformation by the point-mutated H-ras oncogene from EJ carcinoma cells and to trigger a partial reversion of the transformed phenotype of Ras-transformed fibroblasts. These findings support the conclusion that Ras-induced transformation involves signal transduction pathways inducing the c-fos gene.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, W-3550 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1991, ONCOGENE, V6, P1325; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	49	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					859	867						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570155				2022-12-28	WOS:A1992HP64200004
J	MUROYA, K; HATTORI, S; NAKAMURA, S				MUROYA, K; HATTORI, S; NAKAMURA, S			NERVE GROWTH-FACTOR INDUCES RAPID ACCUMULATION OF THE GTP-BOUND FORM OF P21RAS IN RAT PHEOCHROMOCYTOMA PC12 CELLS	ONCOGENE			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; NEURONAL DIFFERENTIATION; ACTIVATING PROTEIN; MOLECULAR-CLONING; GAP; INDUCTION; KINASE; PHOSPHORYLATION; MICROINJECTION; STIMULATION	The ras gene product (p21) is thought to transduce signals from various growth and differentiation factors. p21 is a GTP-binding protein, and its activity is regulated by the bound GDP/GTP ratio. We analysed p21-bound nucleotides in cell lysates of rat pheochromocytoma cell line PC12 cells stimulated with various factors. Nerve growth factors (NGF) rapidly increased the relative amount of active p21-GTP complex to as much as 20% of the total amount of p21 within 2 min. The amount of p21-GTP then declined to 8% after 10 min, and this level was sustained for at least 2h. Epidermal growth factor (EGF) also stimulated a rapid accumulation of p21-GTP to the same extent as seen with NGF, but the amount of p21-GTP declined to 5% after 10 min and gradually returned to the basal level within 60 min. In contrast basic fibroblast growth factor, interleukin 6 and dibutyryl cAMP, which induce neuronal differentiation of PC12 cells, did not stimulate the accumulation of p21-GTP at any time point examined. Phorbol 12-myristate 13-acetate also had no effect. Interestingly, the protein kinase inhibitor K-252a specifically suppressed the NGF-induced accumulation of p21-GTP, but did not suppress the EGF-induced response. These results strongly suggest that an active p21-GTP complex transduces the differentiation signal from NGF. It may also be suggested that the process of activating p21 is mediated by a K-252a-sensitive protein kinase(s).	NATL INST NEUROSCI,NATL CTR NEUROL & PSYCHIAT,DIV BIOCHEM & CELLULAR BIOL,4-1-1 OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN	National Center for Neurology & Psychiatry - Japan								BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DOHERTY P, 1988, NEUROSCI LETT, V92, P222, DOI 10.1016/0304-3940(88)90065-1; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUNG YK, 1990, P NATL ACAD SCI USA, V87, P8008; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KASE H, 1986, J ANTIBIOT, V39, P1059, DOI 10.7164/antibiotics.39.1059; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LEVIMONTALCINI R, 1982, ANNU REV NEUROSCI, V5, P341, DOI 10.1146/annurev.ne.05.030182.002013; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	38	117	117	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					277	281						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549349				2022-12-28	WOS:A1992HG98200011
J	ABATE, C; MARSHAK, DR; CURRAN, T				ABATE, C; MARSHAK, DR; CURRAN, T			FOS IS PHOSPHORYLATED BY P34CDC2, CAMP-DEPENDENT PROTEIN-KINASE AND PROTEIN-KINASE-C AT MULTIPLE SITES CLUSTERED WITHIN REGULATORY REGIONS	ONCOGENE			English	Article							DNA-BINDING DOMAINS; OSTEO-SARCOMA VIRUS; LEUCINE ZIPPER; JUN; TRANSCRIPTION; IDENTIFICATION; ACTIVATION; ONCOGENE; INVITRO; SERUM	The proto-oncogene c-fos encodes a nuclear protein (Fos) that functions in transcriptional regulation in response to extracellular signals. Fos is extensively modified in the nucleus by serine and threonine phosphorylation. It has been suggested that phosphorylation may play an important role in regulating Fos function in normal and transformed cells. As a first step in addressing this issue, we have used purified Fos as a substrate for several serine-threonine protein kinases, including cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and p34cdc2. Each of these kinases phosphorylated Fos at several unique sites. These sites were located within two regions that were previously shown to reduce the transcriptional activity of Fos in vitro. Several of the sites modified in vitro were also shown to be phosphorylated in serum-stimulated fibroblasts. These findings demonstrate that Fos is a target for several protein kinases involved in signal transduction and suggest that phosphorylation could regulate the transcriptional properties of Fos.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT MOLEC ONCOL & VIROL, NUTLEY, NJ 07110 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Roche Holding; Cold Spring Harbor Laboratory			Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Abate-Shen, Cory/O-2520-2014; Curran, Thomas/AAE-7631-2019; Curran, Tom/F-5234-2018	Curran, Tom/0000-0003-1444-7551; Abate-Shen, Cory/0000-0002-5021-0570; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABATE C, 1991, MOL CELL BIOL, V11, P3629; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; CURRAN T, 1991, TRANSCRIPTION REGULA; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HIRAI SI, 1990, ONCOGENE, V5, P39; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUO K, 1990, ONCOGENE, V5, P921; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDY EPA, 1988, ONCOGENE HDB; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TURNER RS, 1985, J BIOL CHEM, V260, P1503	37	83	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2179	2185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766667				2022-12-28	WOS:A1991GX73500002
J	MORRIS, JF; MADDEN, SL; TOURNAY, OE; COOK, DM; SUKHATME, VP; RAUSCHER, FJ				MORRIS, JF; MADDEN, SL; TOURNAY, OE; COOK, DM; SUKHATME, VP; RAUSCHER, FJ			CHARACTERIZATION OF THE ZINC FINGER PROTEIN ENCODED BY THE WT1 WILMS-TUMOR LOCUS	ONCOGENE			English	Article							HUMAN CHROMOSOME-11; MAMMALIAN-CELLS; BINDING; GENE; FOS; DELETION; GROWTH; JUN; DIFFERENTIATION; PURIFICATION	We analysed the biochemical properties of the transcription factor encoded by the putative tumor-suppressor gene present at the WT1 Wilms' tumor locus. A gene containing the full-length amino acid coding sequence of human wt1 was reconstructed from synthetic oligonucleotides and cloned into expression vectors for in vitro and in vivo protein synthesis. Polyclonal rabbit antibodies specific for the WT1 protein were raised to an Escherichia coli-produced 91 amino acid N-terminal segment and to a 136 amino acid C-terminal segment, which contains the zinc finger domain. WT1 produced by in vitro translation migrated as a 52 kDa protein on sodium dodecylsulfate-polyacrylamide gels and bound to the EGR consensus sequence in gel-retardation assays. Expression of the wt1 gene via transient transfection in COS-1 cells revealed a 52 kDa protein which was immunoprecipitated by both the N-terminal- and C-terminal-specific antisera. Immunofluorescence studies of wt1-transfected COS-1 cells revealed that the WT1 protein was localized to the nucleus. Metabolic labeling with [P-32]orthophosphate failed to reveal significant phosphorylation of the WT1 protein in COS-1 cells. Two immunoreactive WT polypeptides of 52 and 54kDa were observed in murine embryonic stem cells and COS-1 kidney cells and may represent previously identified splicing variants of WT1. These antisera should be useful in characterizing the structure and function of the WT1 protein in human Wilms' tumor specimens.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	The Wistar Institute; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009, R01CA023413] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52009, CA-47983-04, CA-23413] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1701; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DILLON PJ, 1990, BIOTECHNIQUES, V9, P298; DILLON PJ, 1990, J VIROL, V64, P4428, DOI 10.1128/JVI.64.9.4428-4437.1990; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P184; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; MADDEN SL, 1991, IN PRESS SCIENCE; MATSUNAGA E, 1981, HUM GENET, V57, P231; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0	33	125	133	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2339	2348						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662794				2022-12-28	WOS:A1991GX73500024
J	KUHAR, SG; LEHMAN, JM				KUHAR, SG; LEHMAN, JM			T-ANTIGEN AND P53 IN PRECRISIS AND POSTCRISIS SIMIAN VIRUS-40-TRANSFORMED HUMAN CELL-LINES	ONCOGENE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; TRANSFORMED-CELLS; HUMAN-FIBROBLASTS; VIRUS-40; PROTEIN; SV40; GROWTH; FORMS	Infection of normal human diploid fibroblasts (HF) with the DNA tumor virus simian virus 40 (SV) leads to an extension of lifespan and concomitant increase in' the levels of the viral large tumor antigen (T antigen) and the cellular protein p53. The intracellular localization of T antigen and p53 was mostly nuclear in both SVpre-crisis and SVpost-crisis cells, however certain population doubling (PD) of the SVpre-crisis cells exhibited some cytoplasmic staining. The DNA content of SVpre-crisis cells shifted to tetraploidy and the SVpost-crisis cells were near-tetraploid. Quantitation of T antigen and p53 in single cells by flow cytometry demonstrated that for all antibodies tested the levels of T antigen were higher in the SVpre-crisis HF than in the SVpost-crisis. The quantity of p53 increased with increasing age of SVpre-crisis HF, and the levels of p53 were higher in the SVpost-crisis HF populations. Immunoprecipitation of p53, T antigen and complexes demonstrated that all p53 was bound to T antigen in SVpre-crisis HF and SVpost-crisis HF. The SVpre-crisis HF cells showed that 33% of all T antigen was bound to p53, while 67% was free, and the SVpost-crisis HF exhibited 50% free T antigen and 50% bound to p53. The half-life of p53 was similar in all SVpre-crisis HF; however, the half-life was 2-3 times greater in SVpost-crisis HF than in SVpre-crisis HF. These results suggest that the interaction of DNA (ploidy), T antigen, p53 and complexes may be involved in formation of a stable SV40-transformed human cell line.	UNION UNIV,DEPT MICROBIOL & IMMUNOL,A-68,ALBANY,NY 12208	Union College			Lehman, John M./AAU-4849-2020		NCI NIH HHS [CA41608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA041608, R01CA041608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1989, ONCOGENE, V4, P1103; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARA H, 1987, EXP CELL RES, V168, P531, DOI 10.1016/0014-4827(87)90025-5; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; JACOBBERGER JW, 1986, CYTOMETRY, V7, P356, DOI 10.1002/cyto.990070410; JENKINS JR, 1988, ONCOGENE HDB; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN JM, 1979, J SUPRAMOLEC STRUCT, V10, P25; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; SACK GH, 1981, EXP CELL RES, V134, P425, DOI 10.1016/0014-4827(81)90442-0; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHEIN HM, 1962, P SOC EXP BIOL MED, V109, P495, DOI 10.3181/00379727-109-27246; TACK LC, 1989, J VIROL, V63, P2352, DOI 10.1128/JVI.63.5.2352-2356.1989; TACK LC, 1988, J VIROL, V62, P1028, DOI 10.1128/JVI.62.3.1028-1037.1988; Tooze J, 1981, MOL BIOL TUMOR VIRUS; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	32	23	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1499	1506						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1656367				2022-12-28	WOS:A1991GX27400002
J	SOPCHAK, L; THRUSH, GR; LERMAN, SP; KING, SR				SOPCHAK, L; THRUSH, GR; LERMAN, SP; KING, SR			LOSS OF MYB EXPRESSION IN AN AGGRESSIVE SJL/J B-CELL LYMPHOMA	ONCOGENE			English	Article							C-MYB; NUCLEOTIDE-SEQUENCE; ONCOGENE ACTIVATION; V-MYB; DNA; SARCOMAS; TUMORS; GENES; MICE; AMPLIFICATION	SJL mice spontaneously develop B-cell lymphomas that can be propagated by transplantation into syngeneic mice. These tumors usually have an indolent phenotype and require at least several weeks to produce morbidity following transplantation. However an aggressive lymphoma (RCS5) has been found that produces morbidity within days of transplantation. RCS5 cells fail to express the H-2D(s) class I major histocompatibility complex antigen, whereas indolent tumors express H-2D(s). To identify genetic factors that may contribute to the tumorigenicity of B-cell lymphomas in SJL mice, tumor genomes were analyzed for mutations in cellular oncogenes. No rearrangements were detected by Southern hybridization analysis in tumors at the abl, myc, mhcl-2, Ha-ras, Ki-ras and raf loci. Indolent tumors were not rearranged at the myb oncogene, however alterations were detected in both myb alleles in RCS5. Northern hybridization analysis on RNA from in vivo-derived tumor preparations failed to detect any myb transcripts in RCS5. The loss of normal myb expression could directly contribute to the aggressive phenotype of RCS5. Alternatively, expression of the RCS5 myb allele may have contributed to early stages of tumor development. The possibilities that the observed myb mutations affect tumor aggressiveness and H-2D(s) expression are discussed.	WAYNE STATE UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,DETROIT,MI 48201	Wayne State University			King, Steven/AAE-2526-2019		NCI NIH HHS [CA22453, CA52603] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052603, P30CA022453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, J IMMUNOL, V139, P3822; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BONAVIDA B, 1985, SURV IMMUNOL RES, V4, P271; BUTCH AW, 1986, 6TH INT C IMM, P397; CAVENEE W, 1989, RECESSIVE ONCOGENES; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GRUNWALD DJ, 1982, J VIROL, V43, P92, DOI 10.1128/JVI.43.1.92-103.1982; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MURPHY ED, 1969, J NATL CANCER I, V42, P797; NAKAUCHI H, 1987, J IMMUNOL, V139, P2803; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Ponzio N M, 1986, Int Rev Immunol, V1, P273, DOI 10.3109/08830188609056610; PONZIO NM, 1977, CELL IMMUNOL, V32, P10, DOI 10.1016/0008-8749(77)90178-2; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROSLONIEC EF, 1984, J IMMUNOL, V132, P945; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; Sambrook J, 1989, MOL CLONING LABORATO; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SOPCHAK L, 1989, CANCER RES, V49, P665; STAVNEZER J, 1989, EUR J IMMUNOL, V19, P1063, DOI 10.1002/eji.1830190616; WIRSCHUBSKY Z, 1984, INT J CANCER, V33, P477, DOI 10.1002/ijc.2910330410; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	34	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1335	1338						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886709				2022-12-28	WOS:A1991GX27200006
J	CROOK, T; WREDE, D; TIDY, J; SCHOLEFIELD, J; CRAWFORD, L; VOUSDEN, KH				CROOK, T; WREDE, D; TIDY, J; SCHOLEFIELD, J; CRAWFORD, L; VOUSDEN, KH			STATUS OF C-MYC, P53 AND RETINOBLASTOMA GENES IN HUMAN PAPILLOMAVIRUS POSITIVE AND NEGATIVE SQUAMOUS-CELL CARCINOMAS OF THE ANUS	ONCOGENE			English	Article								We have examined a series of squamous cell carcinomas (SCC) of the anus, anal intraepithelial neoplasia grade III (AINIII) lesions and haemorrhoids for the presence of sequences from transforming human papillomavirus (HPV) types by polymerase chain reaction (PCR)/Southern blotting. In addition, the same DNAs have been analysed for abnormalities in the c-myc, p53 and retinoblastoma (Rb-1) gene loci by Southern blotting. HPV16 sequences were detected in a total of 38 of 50 (76%) and HPV18 sequences in 4 of the 50 cancers (8%). Of 12 haemorrhoids examined, none contained HPV16 or HPV18 sequences. Amplification of c-myc was demonstrated in 15 of the 50 cancers (30%), of which 13 were HPV16 positive, and one also positive for HPV18. Amplification of c-myc was not observed in the 5 AINIII or any of the 41 haemorrhoid DNAs analysed. Rearrangement of c-myc was not seen in any of the DNAs. Gross rearrangement, or loss of p53 or Rb-1 loci was not observed in any normal or tumour tissue. However, in preliminary analysis of p53 sequence, three tumours negative for HPV were heterozygous for p53 point mutation whereas six HPV positive tumours and two haemorrhoids were wild-type sequence throughout exons four to ten.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON WC2, ENGLAND; SAMARITAN HOSP WOMEN, DEPT GYNAECOL, LONDON NW1, ENGLAND; UNIV CAMBRIDGE, DEPT PATHOL, IMPERIAL CANCER RES FUND, TUMOUR VIRUS GRP, CAMBRIDGE CB2 1QP, ENGLAND; UNIV SHEFFIELD, NO GEN HOSP, CTR CLIN SCI, SURG UNIT, SHEFFIELD S5 7AU, ENGLAND	Ludwig Institute for Cancer Research; University of Cambridge; Northern General Hospital; University of Sheffield	VOUSDEN, KH (corresponding author), ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON WC2, ENGLAND.							Austin D F, 1982, Natl Cancer Inst Monogr, V62, P89; BARTEK J, 1990, ONCOGENE, V5, P893; BECKMANN AM, 1989, INT J CANCER, V43, P1042, DOI 10.1002/ijc.2910430615; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1990, ONCOGENE, V5, P619; CROOK T, 1989, MOL CARCINOGEN, V2, P308, DOI 10.1002/mc.2940020605; CROOK T, 1991, IN PRESS J VIROL; CROOK T, 1991, IN PRESS ONCOGENE; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; DARLING SM, 1986, P NATL ACAD SCI USA, V83, P135, DOI 10.1073/pnas.83.1.135; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; MORI N, 1990, ONCOGENE, V5, P1713; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCADIZ R, 1987, CANCER RES, V47, P4173; PALMER JG, 1987, LANCET, V2, P42; PALMER JG, 1989, DIS COLON RECTUM, V32, P1016, DOI 10.1007/BF02553872; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; REISSMANN PT, 1989, ONCOGENE, V4, P839; RIOU G, 1987, LANCET, V1, P761; RIOU G, 1990, LANCET, V335, P1171; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHEURLEN W, 1986, INT J CANCER, V38, P671, DOI 10.1002/ijc.2910380509; SCHOLEFIELD JH, 1989, LANCET, V2, P765; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TUCK SP, 1989, ONCOGENE RES, V4, P81; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOUNG LS, 1989, BRIT MED J, V298, P14, DOI 10.1136/bmj.298.6665.14	37	97	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1251	1257						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650445				2022-12-28	WOS:A1991GV26000022
J	ADNANE, J; GAUDRAY, P; DIONNE, CA; CRUMLEY, G; JAYE, M; SCHLESSINGER, J; JEANTEUR, P; BIRNBAUM, D; THEILLET, C				ADNANE, J; GAUDRAY, P; DIONNE, CA; CRUMLEY, G; JAYE, M; SCHLESSINGER, J; JEANTEUR, P; BIRNBAUM, D; THEILLET, C			BEK AND FLG, 2 RECEPTORS TO MEMBERS OF THE FGF FAMILY, ARE AMPLIFIED IN SUBSETS OF HUMAN BREAST CANCERS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; HER-2 NEU ONCOGENE; PROTO-ONCOGENE; AMPLIFICATION; GENE; CARCINOMAS; TUMORS; DNA; EXPRESSION; PHENOTYPE	Tumor DNA samples from 387 breast carcinomas have been investigated for amplification of BEK and FLG genes, both of which have been shown to code for cell surface receptors to FGFs. BEK and FLG were found amplified in 11.5 and 12.7% of breast tumors respectively. Statistical analysis, performed on the subset of 297 primary cancers without presurgical therapy, showed for BEK a trend of preferential amplification in patients above 50 years (P = 0.055), whereas amplification of FLG could significantly be correlated with nodal involvement (P = 0.032) and seemed prevalent in steroid hormones receptor positive tumors. Since the same tumors were previously analysed for the amplification of MYC, ERBB2 and HST/INT2/BCL1 possible associations with BEK and FLG amplifications were looked for. BEK was found significantly correlated with MYC and FLG with HST/INT2/BCL1. The amplification of these two FGF receptor genes may therefore represent additional steps in the molecular phenotyping of breast cancer.	FAC MED NICE,LGMCH,AV VALOMBROSE,F-06034 NICE,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE; RHONE POULENC RORER CENT RES,KING OF PRUSSIA,PA 19406; UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,UA 1191,F-34095 MONTPELLIER 2,FRANCE; CTR PAUL LAMARQUE,BIOCHIM LAB,F-34094 MONTPELLIER 2,FRANCE; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; New York University			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Birnbaum, Daniel/0000-0001-7920-9883				ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1988, BREAST CANCER CELLUL, P25; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; GOMPEL C, 1983, PRINCIPLES PRACTICES, V1, P245; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINTRUF C, 1990, GENE CHROMOSOME CANC, V2, P18, DOI 10.1002/gcc.2870020105; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THEILLET C, 1989, ONCOGENE, V4, P915; VARLEY JM, 1988, ONCOGENE, V3, P87; WILLIAMS BP, 1988, ONCOGENE, V3, P345; ZEILLINGER R, 1989, ONCOGENE, V4, P109; 1982, TUMORI, V68, P181	24	246	267	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					659	663						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851551				2022-12-28	WOS:A1991FR93900023
J	FUKUI, Y; SALTIEL, AR; HANAFUSA, H				FUKUI, Y; SALTIEL, AR; HANAFUSA, H			PHOSPHATIDYLINOSITOL-3 KINASE IS ACTIVATED IN V-SRC, V-YES, AND V-FPS TRANSFORMED CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							MIDDLE T-ANTIGEN; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; TYROSINE KINASE; SARCOMA-VIRUS; BOVINE BRAIN; ASSOCIATION; PP60C-SRC; 3-KINASE; PROTEIN	PI-3 kinase activity has been shown to associate with p60v-src. We found that immunoprecipitates of p60v-src exhibit an activity that catalyzes the formation of PI-3-P, PI-3,4-P2 and PIP3 from PI, PI-4-P, and PI-4,5-P2, respectively. Transformation of chicken embryo fibroblasts (CEF) by p60v-src of Rous sarcoma virus (RSV) caused elevation of PI-3-P, PI-3,4-P2, and PIP3, suggesting that the PI-3 kinase may be activated in these cells. Similar elevations were seen in cells transformed with the v-yes or v-fps oncogenes, but not with v-ros or v-ras. We have established also a system that allows the binding of PI-3 kinase to purified p60v-src in vitro, reproducing the binding seen in vivo. This assay indicated that more PI-3 kinase activity binds to purified p60v-src in cell lysates from CEF transformed with v-yes or v-fps, suggesting that some modification or overexpression of PI-3 kinase takes place in these cells.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University			Saltiel, Alan/L-3632-2019; Fukui, Yasuhisa/E-8806-2010	Saltiel, Alan/0000-0002-9726-9828	NCI NIH HHS [CA44356] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK033804, R01DK033804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CHAN TO, 1990, MOL CELL BIOL, V10, P3280, DOI 10.1128/MCB.10.6.3280; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FELDMAN RA, 1985, J VIROL, V42, P228; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SALTIEL AR, 1987, BIOCHEM J, V241, P759, DOI 10.1042/bj2410759; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SUMMERS MD, 1985, BANBURY REPORT, V22, P319; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	29	70	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					407	411						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849246				2022-12-28	WOS:A1991FT34400009
J	LUO, K; HURLEY, TR; SEFTON, BM				LUO, K; HURLEY, TR; SEFTON, BM			TRANSFER OF PROTEINS TO MEMBRANES FACILITATES BOTH CYANOGEN-BROMIDE CLEAVAGE AND 2-DIMENSIONAL PROTEOLYTIC MAPPING	ONCOGENE			English	Article											LUO, K (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92138, USA.				NATIONAL CANCER INSTITUTE [R01CA042350, P30CA014195, R01CA017289] Funding Source: NIH RePORTER; NCI NIH HHS [CA 17289, CA 42350, CA 14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOLEN JB, 1987, ONCOGENE RES, V1, P149; GIBSON W, 1974, VIROLOGY, V62, P319, DOI 10.1016/0042-6822(74)90395-X; GLYNN JP, 1964, CANCER RES, V24, P502; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LUO K, 1990, ONCOGENE, V5, P803; NIKODEM V, 1979, ANAL BIOCHEM, V97, P382, DOI 10.1016/0003-2697(79)90089-7; VEILLETTE A, 1988, ONCOGENE RES, V2, P385	12	118	120	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					921	923						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	1688326				2022-12-28	WOS:A1990DP55300020
J	RADER, JS; GOLUB, TR; HUDSON, JB; PATEL, D; BEDELL, MA; LAIMINS, LA				RADER, JS; GOLUB, TR; HUDSON, JB; PATEL, D; BEDELL, MA; LAIMINS, LA			INVITRO DIFFERENTIATION OF EPITHELIAL-CELLS FROM CERVICAL NEOPLASIAS RESEMBLES INVIVO LESIONS	ONCOGENE			English	Article									UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; MICHAEL REESE HOSP & MED CTR, DEPT OBSTET & GYNECOL, CHICAGO, IL 60616 USA	Howard Hughes Medical Institute; University of Chicago; Michael Reese Hospital & Medical Center								ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CAMPION MJ, 1986, LANCET, V2, P237; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1987, ONCOGENE, V1, P251; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P141; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GRUNEBAUM AN, 1983, OBSTET GYNECOL, V62, P448; HAUSEN HZ, 1985, PROG MED VIROL, V32, P15; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KOSS LG, 1956, ANN NY ACAD SCI, V63, P1245, DOI 10.1111/j.1749-6632.1956.tb32134.x; LORINCZ AT, 1986, J VIROL, V58, P225, DOI 10.1128/JVI.58.1.225-229.1986; MACNAB JCM, 1986, NEW ENGL J MED, V315, P1052, DOI 10.1056/NEJM198610233151703; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MCCANCE DJ, 1985, BRIT J OBSTET GYNAEC, V92, P1101, DOI 10.1111/j.1471-0528.1985.tb03019.x; MOORE KL, 1977, DEV HUMAN, P240; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3; WAGNER D, 1984, OBSTET GYNECOL, V64, P767; WOODRUFF JD, 1980, OBSTET GYNECOL, V56, P727; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989	26	56	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1990	5	4					571	576						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1691480				2022-12-28	WOS:A1990DB85300017
J	KELLY, K; DAVIS, P; MITSUYA, H; IRVING, S; WRIGHT, J; GRASSMANN, R; FLECKENSTEIN, B; WANO, Y; GREENE, W; SIEBENLIST, U				KELLY, K; DAVIS, P; MITSUYA, H; IRVING, S; WRIGHT, J; GRASSMANN, R; FLECKENSTEIN, B; WANO, Y; GREENE, W; SIEBENLIST, U			A HIGH PROPORTION OF EARLY RESPONSE GENES ARE CONSTITUTIVELY ACTIVATED IN T-CELLS BY HTLV-I	ONCOGENE			English	Article							VIRUS TYPE-I; COLONY-STIMULATING FACTOR; LEUKEMIA-LYMPHOMA VIRUS; GROWTH-FACTORS ENCODES; DNA-BINDING PROTEINS; LONG TERMINAL REPEAT; ZINC FINGER PROTEIN; INTERLEUKIN-2 RECEPTOR; TRANS-ACTIVATION; TAX GENE	Immortalization of T cells by HTLV-I is mediated by the X region of the virus and probably involves transactivation of cellular genes. We show that T cells transformed by HTLV-I constitutively express a high proportion of early response genes that are normally transiently induced following antigenic or mitogenic activation of T cells. Thus, HTLV-I-infected T cells display an `early activation' phenotype that is distinct from the gene expression pattern of continuously dividing T cells. Ten early response genes representing a diverse array of functional categories were assayed. Four DNA-binding proteins/transcription factors including the p50 subunit of NF-kappa-B were evaluated. A protein(s) encoded by the X region of HTLV-I appeared to contribute to up-regulated expression of most, if not all, of the early response genes. For those genes that could be assayed, increased transcriptional rates, but not substantial changes in mRNA half-life, were demonstrated in the presence of pX-encoded proteins, suggesting that the transcriptional transactivator, Tax, affects the induction or maintenance of transcription for these mitogen-inducible genes. Therefore, Tax may mimic or interact with a component(s) of the signal transduction pathway activated by antigen or mitogen treatment. These data demonstrate that early response genes, some of which probably play roles in initiating or maintaining cellular proliferation, are frequent targets of HTLV-I activation.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; NCI,CLIN ONCOL PROGRAM,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; UNIV ERLANGEN NURNBERG,INST KLIN & MOLEK VIROL,W-8520 ERLANGEN,GERMANY; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Erlangen Nuremberg; Duke University; Duke University	KELLY, K (corresponding author), NCI,PATHOL LAB,BETHESDA,MD 20892, USA.							BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BOHNLEIN E, 1989, J VIROL, V63, P1578; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HATTORI T, 1981, BLOOD, V58, P645; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KELLY K, 1988, J BIOL CHEM, V263, P4828; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITSUYA H, 1984, SCIENCE, V225, P1484, DOI 10.1126/science.6206569; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYOSHI I, 1981, NATURE, V299, P640; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5489; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1034	61	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1463	1470						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630809				2022-12-28	WOS:A1992JE81300001
J	ALBAGLI, O; FLOURENS, A; CREPIEUX, P; BEGUE, A; STEHELIN, D; LEPRINCE, D				ALBAGLI, O; FLOURENS, A; CREPIEUX, P; BEGUE, A; STEHELIN, D; LEPRINCE, D			PHYLOGENY OF THE P68C-ETS-1 AMINO-TERMINAL TRANSACTIVATING DOMAIN REVEALS SOME HIGHLY CONSERVED STRUCTURAL FEATURES	ONCOGENE			English	Note								The chicken c-ets-1 locus gives rise to two distinct transcription factors differing only in their structurally and functionally unrelated N-termini. One of these transcription factors, p54c-ets-1, contains a specific, short (27 amino acids), hydrophilic N-terminus encoded by a single exon, I54, that is widely conserved among vertebrates. The other one, p68c-ets-1, the cellular counterpart of the viral ets oncogene product, differs in the replacement of the I54 by two exons, termed alpha and beta encoding a larger (71 amino acids), hydrophobic N-terminus which, in contrast to I54, exhibits properties of a transactivating domain. To date the alpha and beta exons have only been found in chicken. Here, we demonstrate the existence of the alpha and beta-exons in other avian species (quail and duck) and the existence of the alpha exon in reptiles (turtle). However, none of them could be detected in mammals. Our results strongly suggest that, in contrast to the phylogenetically well-conserved I54 exon, the alpha-exon is restricted to reptilian species (birds and 'true' reptiles), whereas the beta-exon is detectable so far only in birds. Comparison of their amino acid sequences reveals that the alpha-exon and to a much greater extent the beta-exon have diverged faster than the I54 exon. In addition, we show that the N- and C-terminal thirds of the alpha-exon and the highly hydrophobic nature of the alpha-beta-encoded sequence are heavily conserved features and thus likely to be required for function as a transactivating domain in p68c-ets-1 and possibly in the viral P135gag-myb-ets transforming protein.	INST PASTEUR, CNRS, URA 1160, 1 RUE CALMETTE, F-59019 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Crepieux, Pascale/X-3217-2019	Leprince, Dominique/0000-0002-1999-0775				BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHEN JH, 1990, ONCOGENE RES, V5, P277; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRASER N, 1991, NATURE, V349, P278, DOI 10.1038/349278a0; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; REISZ RR, 1991, NATURE, V349, P324, DOI 10.1038/349324a0; SCHNEIKERT J, 1992, IN PRESS ONCOGENE; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOOD WM, 1991, MOL ENDOCRINOL, V5, P1049, DOI 10.1210/mend-5-8-1049	27	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1435	1439						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620554				2022-12-28	WOS:A1992HZ97100024
J	BURKE, LC; BYBEE, A; THOMAS, NSB				BURKE, LC; BYBEE, A; THOMAS, NSB			THE RETINOBLASTOMA PROTEIN IS PARTIALLY PHOSPHORYLATED DURING EARLY G1 IN CYCLING CELLS BUT NOT IN G1 CELLS ARRESTED WITH ALPHA-INTERFERON	ONCOGENE			English	Note							SUSCEPTIBILITY GENE-PRODUCT; EXPRESSION; MITOSIS; KINASE; RB	The retinoblastoma protein (pRB) is thought to act as a tumour suppressor which is inactivated by phosphorylation. In quiescent (G0) cells pRB exists in a hypophosphorylated form (pRB110), but proliferating cells in G1 contain a significant proportion of phosphorylated pRB (pRB112-114). Studies of synchronized or elutriated cells have suggested that the phosphorylated forms of pRB disappear as cells pass from G2/M to G0/G1 and that pRB is phosphorylated again to pRB114 at the G1/S border. In this study we used two-parameter flow cytometry and cell sorting to isolate cycling cells in early and late G1 (G1A and G1B), and we show that partially phosphorylated pRB is present in cycling human lymphoid cells even in G1A. These G1A cells contain intermediate forms of pRB which become further phosphorylated to pRB112-114 as cells pass into G1B. Therefore pRB is at least partially phosphorylated from early G1 onwards. Cell cycle arrest by alpha-interferon (alpha-IFN) results in an accumulation of cells in both G1A and G1B, and these cells contain mainly pRB110. Since pRB110 is thought to prevent cell proliferation, the cytostatic effect of alpha-IFN may therefore occur by preventing the initial phosphorylation of pRB during or prior to G1A.	UNIV COLL & MIDDLESEX SCH MED,DEPT HAEMATOL,MOLEC BIOL LAB,98 CHENIES MEWS,LONDON WC1E 6HX,ENGLAND	University of London; University College London								BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DARZYNKIEWICZ Z, 1982, J CELL PHYSIOL, V113, P465, DOI 10.1002/jcp.1041130316; DARZYNKIEWICZ Z, 1980, CYTOMETRY, V1, P98, DOI 10.1002/cyto.990010203; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V64, P521; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; PARDEE AB, 1987, CANCER RES, V47, P1488; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SILVERMAN RH, 1982, EUR J BIOCHEM, V126, P333; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THOMAS NSB, 1991, ONCOGENE, V6, P317; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; XU HJ, 1989, ONCOGENE, V4, P807; Zetterberg A, 1990, CURR OPIN CELL BIOL, V2, P296, DOI 10.1016/0955-0674(90)90022-7	30	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					783	788						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565475				2022-12-28	WOS:A1992HQ68200024
J	STRAUSS, M; HERING, S; LIEBER, A; HERRMANN, G; GRIFFIN, BE; ARNOLD, W				STRAUSS, M; HERING, S; LIEBER, A; HERRMANN, G; GRIFFIN, BE; ARNOLD, W			STIMULATION OF CELL-DIVISION AND FIBROBLAST FOCUS FORMATION BY ANTISENSE REPRESSION OF RETINOBLASTOMA PROTEIN-SYNTHESIS	ONCOGENE			English	Article							LARGE T-ANTIGENS; GENE-PRODUCT; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; HUMAN CANCER; EXPRESSION; VIRUS; CYCLE; SV40; PHOSPHORYLATION	Circumstantial evidence supports a role for the retinoblastoma susceptibility gene, Rb-1, in the maintenance of normal cell growth, in that loss of its function results in abnormal growth and malignancy. Here we report that a high rate of mitosis and efficient dense focus formation in human embryonic lung fibroblasts (HEL cells) is induced by antisense oligonucleotide-directed inhibition of synthesis of p105-Rb, the product of the Rb-1 gene. mRNA specific for p105-Rb is truncated at the site of base pairing with the antisense oligonucleotide, and no synthesis of p105-Rb is observed. The rate of mitosis is considerably increased and the frequency of dense focus formation is extremely high in treated cells. However, although phosphothioate oligodeoxyribonucleotides taken up by the cells remain stable for at least 4 weeks, the recipient cells do not become immortal; nor are they able to induce tumor formation in nude mice. Thus, loss of Rb-1 function is not sufficient per se to allow malignant transformation.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; INST CANC RES,W-1115 BERLIN,GERMANY	Imperial College London	STRAUSS, M (corresponding author), INST MOLEC BIOL,MOLEK ZELLGENET ABT,ROBERT ROSSLE STR 10,W-1115 BERLIN,GERMANY.							AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREIGEL S, 1990, INT J CANCER, V46, P125; HANSEN MF, 1988, CELL, V53, P172, DOI 10.1016/0092-8674(88)90376-5; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STRAUSS M, 1990, ONCOGENE, V5, P1223; STRAUSS M, 1990, CANCER CELL-MON REV, V2, P360; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471	37	28	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					769	773						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565472				2022-12-28	WOS:A1992HQ68200021
J	GRECO, A; PIEROTTI, MA; BONGARZONE, I; PAGLIARDINI, S; LANZI, C; DELLAPORTA, G				GRECO, A; PIEROTTI, MA; BONGARZONE, I; PAGLIARDINI, S; LANZI, C; DELLAPORTA, G			TRK-T1 IS A NOVEL ONCOGENE FORMED BY THE FUSION OF TPR AND TRK GENES IN HUMAN PAPILLARY THYROID CARCINOMAS	ONCOGENE			English	Article							TYROSINE KINASE DOMAIN; PROTO-ONCOGENE; BIOCHEMICAL-CHARACTERIZATION; ACTIVATION; PROTOONCOGENE; SEQUENCES; RECOMBINATION; PROTEINS; MECHANISM; DNA	We have recently reported the frequent activation of the TRK oncogene in human papillary thyroid carcinoma. In this paper we describe the isolation and characterization of one of the thyroid TRK oncogenes, designated TRK-T1. A 1746-bp-long cDNA was isolated from a library derived from a primary transformant. The cDNA was able to induce foci in NIH3T3 cells. Sequence analysis revealed that TRK-T1 is created by an intrachromosomal rearrangement that juxtaposes the 5' end of the TPR gene to the TRK tyrosine kinase domain. The resulting hybrid mRNA contains 598 nucleotides of the TPR gene and 1148 nucleotides of the TRK proto-oncogene. TRK-T1 mRNA encodes a protein of 55 kDa reacting with antibodies against the carboxy terminus of the proto-TRK protein. We show also the involvement of TPR in the generation of another TRK-T oncogene.	IST NAZL TUMORI,DIV EXPTL ONCOL B,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	GRECO, A (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY.		Pierotti, Marco Alessandro/AAC-4728-2022; Lanzi, Cinzia/J-6539-2016; Bongarzone, Italia/B-9544-2017; Greco, Angela/C-1953-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Lanzi, Cinzia/0000-0002-4480-9413; Bongarzone, Italia/0000-0003-2530-9170; Greco, Angela/0000-0003-2994-0349				BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; CHAN AML, 1987, ONCOGENE, V1, P229; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KING WSH, 1988, ONCOGENE, V2, P617; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MIOZZO M, 1990, ONCOGENE, V5, P1411; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MORRIS CM, 1991, ONCOGENE, V6, P1093; NALDINI L, 1991, ONCOGENE, V6, P501; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	31	205	227	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					237	242						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532241				2022-12-28	WOS:A1992HG98200005
J	BERANGER, F; TAVITIAN, A; DEGUNZBURG, J				BERANGER, F; TAVITIAN, A; DEGUNZBURG, J			POSTTRANSLATIONAL PROCESSING AND SUBCELLULAR-LOCALIZATION OF THE RAS-RELATED RAP2 PROTEIN	ONCOGENE			English	Article							GTP-BINDING PROTEIN; GAMMA SUBUNITS CONTAIN; NUCLEAR-ENVELOPE; ENDOPLASMIC-RETICULUM; CATALYTIC DOMAIN; PLASMA-MEMBRANE; MEVALONIC ACID; GENE-PRODUCT; LAMIN B; P21	The ras-related rap2 gene encodes a 21 kDa GTP-binding protein that exhibits many structural similarities with Ras proteins. In particular, it contains a C-terminal CAAX sequence (C, cysteine; A, aliphatic residue; X, any amino acid) which has been shown to direct the post-translational modifications responsible for membrane binding of Ras proteins and nuclear lamins. We have generated cell lines overexpressing the Rap2 protein as well as specific anti-Rap2 antibodies and show that the protein is tightly associated with cellular membranes. Similarly to Ras proteins, the Rap2 protein is synthesized as a soluble and hydrophilic precursor that is processed to the mature hydrophobic membrane-bound form. During its maturation, the Rap2 protein is modified by the attachment of both palmitate and polyisoprenoid groups, as is also the case for H- and N-Ras proteins. Subcellular fractionation by sucrose density centrifugation as well as indirect immunofluorescence experiments show that the Rap2 protein is localized in a low-density compartment that morphologically overlaps with the endoplasmic reticulum, whereas Ras proteins are associated with the plasma membrane. In spite of similar post-translational modifications by palmitoylation and polyisoprenylation, Ras and Rap2 proteins are thus located on distinct subcellular structures.			BERANGER, F (corresponding author), FAC MED LARIBOISIERE,INSERM,U248,10 AVE VERDUN,F-75010 PARIS,FRANCE.		Beranger, Florence/R-7581-2019					ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERGER M, 1984, J BIOL CHEM, V259, P7245; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HORI Y, 1991, ONCOGENE, V6, P515; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JIMENEZ B, 1991, IN PRESS INT J CANCE; JOHN J, 1988, J BIOL CHEM, V263, P11792; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, IN PRESS P NATL ACAD; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANDERSLUIJS P, 1991, IN PRESS P NATL ACAD; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VONMOLLARD F, 1990, P NATL ACAD SCI USA, V87, P5692; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	61	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1835	1842						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923507				2022-12-28	WOS:A1991GX11800016
J	DELSENNO, L; MAESTRI, I; PIVA, R; BIANCHINI, E; ROSSI, R; UBERTI, ED				DELSENNO, L; MAESTRI, I; PIVA, R; BIANCHINI, E; ROSSI, R; UBERTI, ED			A C-MYC GENE VARIANT WITHOUT EXON 1 AND WITH AN ABNORMAL METHYLATION PATTERN INHERITED IN A WOMAN WITH NO EVIDENCE OF MALIGNANCY	ONCOGENE			English	Note							TRANSLOCATION; ONCOGENES; LYMPHOMAS; CELLS; HYPOMETHYLATION; CHROMOSOME-8; ACTIVATION; CANCER	A c-myc DNA with a deletion which includes 5' flanking, exon 1 and intron I sequences has been found in normal white blood cells of a mother and one daughter in a Northern Italian family. In addition, the degree of methylation of specific CCGG sites in the truncated DNA is lower in both mother and daughter than that found in normal DNA. It is of interest that deletions of the first exon and hypomethylation of the c-myc gene have usually been observed only in some neoplasias. However, our results demonstrate that the c-myc truncated DNA with the abnormal methylation pattern here reported is a genomic variant which by itself is not related to neoplastic transformation.	UNIV FERRARA,CTR STUDI BIOCHIM PATHOL GENOMA UMANO,I-44100 FERRARA,ITALY; UNIV FERRARA,IST MED INTERNA,SEZ ENDOCRINOL,I-44100 FERRARA,ITALY	University of Ferrara; University of Ferrara	DELSENNO, L (corresponding author), UNIV FERRARA,IST CHIM BIOL,VL BORSARI 46,I-44100 FERRARA,ITALY.			degli Uberti, Ettore/0000-0002-9441-7223; Piva, Roberta/0000-0003-2663-6210; maestri, iva/0000-0002-3485-4640				ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ALT FW, 1986, COLD SPRING HARB SYM, V1, P931; AVVEDIMENTO VE, 1985, HUM GENET, V71, P163, DOI 10.1007/BF00283375; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CHEAH MSC, 1984, JNCI-J NATL CANCER I, V73, P1057; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DELSENNO L, 1986, FEBS LETT, V196, P296, DOI 10.1016/0014-5793(86)80266-6; DELSENNO L, 1989, J UROLOGY, V142, P146; DELSENNO L, 1984, NEW TRENDS EXPT HEMA, P230; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; HALL JM, 1989, AM J HUM GENET, V44, P577; HALUSKA FG, 1989, NUCLEIC ACIDS RES, V15, P865; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; MIDDLETON PG, 1988, NUCLEIC ACIDS RES, V13, P5723; OCONNELL P, 1987, CYTOGENET CELL GENET, V46, P673; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RANZANI GN, 1989, ATTI ASS GENET ITA Y, V30, P295; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SILVA AJ, 1988, CELL, V54, P145, DOI 10.1016/0092-8674(88)90546-6	20	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1895	1898						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923512				2022-12-28	WOS:A1991GX11800024
J	DEPPERT, W; KURTH, M; GRAESSMANN, M; GRAESSMANN, A; KNIPPSCHILD, U				DEPPERT, W; KURTH, M; GRAESSMANN, M; GRAESSMANN, A; KNIPPSCHILD, U			ALTERED PHOSPHORYLATION AT SPECIFIC SITES CONFERS A MUTANT PHENOTYPE TO SV40 WILD-TYPE LARGE T-ANTIGEN IN A FLAT REVERTANT OF SV40-TRANSFORMED CELLS	ONCOGENE			English	Article							SIMIAN VIRUS-40; TUMOR-ANTIGEN; PROTEIN PHOSPHATASE-2A; TRANSFORMED-CELLS; DNA-REPLICATION; BINDING; P53; POLYOMAVIRUS; ASSOCIATION; SUPPRESSOR	The Rev2 cell line is a cellular revertant of the SV40 wild-type transformed rat cell line SV-52 [Bauer, M., Guhl, E., Graessmann, M. & Graessmann, A. (1987). J. Virol., 61, 1821-1827]. To characterize the level of cellular interference with the SV40 large T antigen (large T)-induced transformation pathway in Rev2 cells, we analysed the biological and biochemical properties of large T expressed in Rev2 cells. We found that Rev2 cells encoded an authentic wild-type large T, with regard to its sequence and its transforming functions. No differences were found in the metabolic stability of large T, or in complex formation with the cellular p53 protein, or in p53 metabolic stabilization. In contrast to SV-52 cells, Rev2 cells showed no association of large T with the chromatin fraction of isolated nuclei. This difference correlated with a reduced affinity of the Rev2 large T to SV40 DNA in vitro. The T proteins from both cell lines were phosphorylated at the same multiple sites. However, in Rev2 cells the phosphorylation of large T at specific serine -residues was significantly reduced. Thus the revertant phenotype of Rev2 cells may be due to an altered phosphorylation state of its large T protein, leading to altered nuclear localization and reduced transforming activity. The alterations of Rev2 large T properties and phosphorylation were very similar to the changes observed with mutant large T in FR(tsA58)A cells, an SV40 tsA58 N-type transformant, when the cells had reverted to the normal phenotype at the non-permissive growth temperature. Thus altered phosphorylation might provide a common structural basis for the biological inactivation of the large T proteins in these cells.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,W-1000 BERLIN 33,GERMANY	Free University of Berlin	DEPPERT, W (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.							BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOURRE F, 1983, NATURE, V305, P68, DOI 10.1038/305068a0; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; DEPPERT W, 1989, CURR TOP MICROBIOL, V144, P77; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; FANNING E, 1982, EMBO J, V1, P1023, DOI 10.1002/j.1460-2075.1982.tb01290.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HINZPETER M, 1987, ONCOGENE, V1, P119; HOESS A, 1990, J VIROL, V64, P4799; KNIPPSCHILD U, 1991, J VIROL, V65, P4414, DOI 10.1128/JVI.65.8.4414-4423.1991; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; Martin R G, 1981, Adv Cancer Res, V34, P1, DOI 10.1016/S0065-230X(08)60238-9; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PINTEL D, 1981, J VIROL, V38, P518, DOI 10.1128/JVI.38.2.518-528.1981; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RICHTER W, 1990, VIROLOGY, V174, P543, DOI 10.1016/0042-6822(90)90108-4; ROBB JA, 1973, EXP CELL RES, V81, P120, DOI 10.1016/0014-4827(73)90118-3; RYAN KW, 1985, MOL CELL BIOL, V5, P3577, DOI 10.1128/MCB.5.12.3577; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SCHEIDTMANN KH, 1984, J VIROL, V50, P636, DOI 10.1128/JVI.50.2.636-640.1984; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHIRMBECK R, 1988, VIROLOGY, V165, P527, DOI 10.1016/0042-6822(88)90597-1; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; STAUFENBIEL M, 1983, EUR J CELL BIOL, V31, P341; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; VANROY F, 1990, ONCOGENE, V5, P207; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	41	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1931	1938						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923516				2022-12-28	WOS:A1991GX11800030
J	NISHI, T; LEE, PSY; OKA, K; LEVIN, VA; TANASE, S; MORINO, Y; SAYA, H				NISHI, T; LEE, PSY; OKA, K; LEVIN, VA; TANASE, S; MORINO, Y; SAYA, H			DIFFERENTIAL EXPRESSION OF 2 TYPES OF THE NEUROFIBROMATOSIS TYPE-1 (NF1) GENE TRANSCRIPTS RELATED TO NEURONAL DIFFERENTIATION	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; BLASTOMA CELLS; PC12 CELLS; RAS P21; ENCODES; GAP; DOMAIN; LOCUS; IRA1	A 360 residue region encoded by the neurofibromatosis type 1 (NF1) gene shows significant homology to the catalytic domains of both mammalian GTPase-activating proteins (GAP) and yeast IRA proteins. This GAP-related domain of the NF1 gene (NF1-GRD), like the GAP and IRA protein, has been reported to mediate hydrolysis of Ras-bound GTP to GDP, resulting in inactivation of Ras protein. In the present study, we identified two different types of NF1-GRD cDNA. One (type 1) is identical to the previously reported sequence, and the other (type II) contained an additional 63 bp insertion that encodes for a region of 21 amino acids in the center of the NF1-GRD molecule. Alternative splicing is the most likely mechanism by which these two types of transcripts arise. Our observations reveal that the type I transcript is predominantly expressed in undifferentiated cells, whereas the type 11 transcript predominates in differentiated cells. Furthermore, the expression pattern of type I and type II NF1-GRD mRNA immediately changed in SH-SY5Y neuroblastoma cells when neuronal differentiation programs were induced by retinoic acid treatment. We propose that the differential expression of type I and type 11 NF1-GRD transcripts might be an 'on/off' switch that regulates the catalytic activity of the NF1 gene product, which plays an important role in the regulation of neuronal differentiation.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROONCOL, HOUSTON, TX 77030 USA; KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, KUMAMOTO 860, JAPAN	University of Texas System; UTMD Anderson Cancer Center; Kumamoto University			Saya, Hideyuki/J-4325-2013		NCRR NIH HHS [RR5511-27] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADEM A, 1987, DEV BRAIN RES, V33, P235, DOI 10.1016/0165-3806(87)90156-8; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Crowe FW, 1956, CLIN PATHOLOGICAL GE; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; PREIS PN, 1988, CANCER RES, V48, P6530; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; ROSS RA, 1985, CANCER RES, V45, P1628; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	24	135	139	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1555	1559						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923522				2022-12-28	WOS:A1991GX27400009
J	JAHNER, D; HUNTER, T				JAHNER, D; HUNTER, T			THE STIMULATION OF QUIESCENT RAT FIBROBLASTS BY V-SRC AND V-FPS ONCOGENIC PROTEIN-TYROSINE KINASES LEADS TO THE INDUCTION OF A SUBSET OF IMMEDIATE EARLY GENES	ONCOGENE			English	Article								The stimulation of quiescent murine fibroblasts by growth factors and by phorbol esters results in a rapid and transient transcriptional activation of a large group of so-called immediate early genes. Several such genes were found to be induced in chicken embryo fibroblasts following activation of a temperature sensitive (ts) Rous sarcoma virus v-src mutant following temperature shift (Simmons et al., 1989). In contrast, the classical immediate early genes c-myc, c-fos and c-jun were essentially uninducible upon activation of a ts v-src mutant in rat-1 fibroblasts (Welham et al., 1990). We have cloned 9 cDNAs of genes that are rapidly and transiently inducible in rat fibroblasts by ts v-src mutants, and by a ts Fujinami sarcoma virus v-fps mutant. Six of these cDNAs are derived from the known immediate early genes NGFI-A, KC, c-fos, tissue factor, PC4 and ornithine decarboxylase; the other three cDNAs have not been described before. These 9 genes showed individual profiles of inducibility by fetal calf serum, epidermal growth factor (EGF) and by phorbol esters. Their response to the retroviral oncogenic protein-tyrosine kinases correlated best with the one to EGF, suggesting a common pathway of signal transduction. c-fos did not respond strongly to this pathway but was well induced by fetal calf serum. NGFI-A, however, was induced to a similar extent by all activators tested. Furthermore, we demonstrated that the induction of several of these genes by the retroviral oncogenic protein-tyrosine kinases is rapid, direct and occurs at the transcriptional level.	SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA	Salk Institute	HUNTER, T (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.				NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14195, CA-39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; Bogenberger J, 1988, Oncogene Res, V3, P301; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHEN YC, 1977, CELL, V11, P513, DOI 10.1016/0092-8674(77)90069-1; CHIARUGI V, 1987, ONCOGENE, V2, P37; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; DURKIN JP, 1984, J CELL PHYSIOL, V120, P135, DOI 10.1002/jcp.1041200205; DURKIN JP, 1991, IN PRESS CELL SIGNAL; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GILMAN MZ, 1988, COLD SPRING HARB SYM, V53, P761, DOI 10.1101/SQB.1988.053.01.086; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; JAHNER D, 1991, IN PRESS MOL CELL BI; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINS TJ, 1989, J CELL BIOL, V108, P683, DOI 10.1083/jcb.108.2.683; MARTINSGREEN M, 1990, J CELL BIOL, V110, P581, DOI 10.1083/jcb.110.3.581; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOSS P, 1984, J VIROL, V52, P557, DOI 10.1128/JVI.52.2.557-565.1984; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; ROLLINS BJ, 1987, SCIENCE, V238, P1269, DOI 10.1126/science.3685976; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STOECKLE M Y, 1990, New Biologist, V2, P313; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; VARNUM BC, 1989, ONCOGENE, V4, P1263; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WEINMASTER GA, 1988, J VIROL, V62, P3849, DOI 10.1128/JVI.62.10.3849-3854.1988; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1	85	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1259	1268						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861868				2022-12-28	WOS:A1991GV26000023
J	MARCELLUS, R; WHITFIELD, JF; RAPTIS, L				MARCELLUS, R; WHITFIELD, JF; RAPTIS, L			POLYOMA-VIRUS MIDDLE TUMOR-ANTIGEN STIMULATES MEMBRANE-ASSOCIATED PROTEIN-KINASE-C AT LOWER LEVELS THAN REQUIRED FOR PHOSPHATIDYLINOSITOL KINASE ACTIVATION AND NEOPLASTIC TRANSFORMATION	ONCOGENE			English	Article							T-ANTIGEN; TYROSINE KINASE; RAT-CELLS; PP60C-SRC; GENE; SRC; PRODUCT; DEPHOSPHORYLATION; PHOSPHORYLATION; FIBROBLASTS	Twelve independent rat F111 cell lines expressing the polyoma virus middle tumor antigen (mT) under control of the dexamethasone-regulatable MMTV-LTR promoter were assayed for levels of membrane-associated protein kinase C (PKC) activity. Low background levels of mT antigen expression (approximately 2%), although insufficient for transformation, triggered a dramatic increase in PKC activity. Under the same conditions, levels of the mT-associated phosphatidylinositol kinase activity were low, indicating that this kinase might be a factor limiting transformation in this cell system.	QUEENS UNIV, DEPT MICROBIOL & IMMUNOL, KINGSTON K7L 3N6, ONTARIO, CANADA; NATL RES COUNCIL CANADA, INST BIOL SCI, CELL SYST SECT, OTTAWA K1A 0R6, ONTARIO, CANADA	Queens University - Canada; National Research Council Canada	RAPTIS, L (corresponding author), QUEENS UNIV, DEPT MICROBIOL & IMMUNOL, KINGSTON K7L 3N6, ONTARIO, CANADA.							BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CHAKRAVARTHY BR, 1990, BIOCHEM BIOPH RES CO, V171, P1105, DOI 10.1016/0006-291X(90)90798-R; CHAKRAVARTHY BR, 1989, BIOCHEM BIOPH RES CO, V160, P340, DOI 10.1016/0006-291X(89)91661-6; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DOBROVOLNY MA, 1990, 6TH ANN M ONC FRED, P80; DOTTO GP, 1985, NATURE, V318, P472; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; DURKIN JP, 1990, CELL SIGNAL, V2, P285, DOI 10.1016/0898-6568(90)90056-G; DURKIN JP, 1990, IN PRESS CELLULAR SI; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MARSHALL CJ, 1989, INT J CANCER, P29; MATTHEWS JT, 1986, J VIROL, V58, P239, DOI 10.1128/JVI.58.2.239-246.1986; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; RAPTIS L, 1986, BIOCHEM BIOPH RES CO, V136, P995, DOI 10.1016/0006-291X(86)90431-6; RAPTIS L, 1986, BIOCHEM BIOPH RES CO, V140, P1106, DOI 10.1016/0006-291X(86)90749-7; RAPTIS L, 1988, BIOCHEM BIOPH RES CO, V154, P306, DOI 10.1016/0006-291X(88)90685-7; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RAPTIS L, 1989, J VIROL, V63, P753, DOI 10.1128/JVI.63.2.753-758.1989; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; WHITFIELD JF, 1990, CALCIUM CELL CYCLES; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	37	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1037	1040						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648699				2022-12-28	WOS:A1991GU62200020
J	MEIJER, I; VANDAM, H; BOOT, AJM; BOS, JL; ZANTEMA, A; VANDEREB, AJ				MEIJER, I; VANDAM, H; BOOT, AJM; BOS, JL; ZANTEMA, A; VANDEREB, AJ			CO-REGULATED EXPRESSION OF JUNB AND MHC CLASS-I GENES IN ADENOVIRUS-TRANSFORMED CELLS	ONCOGENE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR FAMILY; DNA-BINDING; RAT-CELLS; E1A GENE; FUNCTIONAL DOMAINS; PROTEIN; PROMOTER; AP-1; FOS	The expression of the junB gene parallels the expression of the MHC class I genes in Adenovirus (Ad) transformed cells. In Ad12E1-transformed primary BRK cells both genes are transcriptionally repressed only when the 13S product of Ad12E1A is present. This indicates that repression of MHC class I and junB genes is a function of conserved region 3 (CR3) of the Ad12E1A protein. In Ad5-transformed BRK cells expression of these genes is unchanged. In established NRK cells, however, introduction of Ad12E1A does not cause repression of the MHC class I and junB genes, but in these cells Ad5E1A increases the expression of both MHC class I and junB. Using mutant Ad5E1A genes, it is shown that this activation is mediated by CR1. Introduction of a functional junB gene under the control of a heterologous promoter in Ad12E1-transformed BRK cells causes no increase in MHC class I expression. This demonstrates that the down-regulation of junB is not directly responsible for class I repression, but rather that both genes are coregulated by the Ad12E1 region.	LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	VANDEREB, AJ (corresponding author), LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS.			van Dam, Hans/0000-0002-8307-4325				ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERNARDS R, 1987, TRENDS GENET, V3, P298, DOI 10.1016/0168-9525(87)90272-1; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLARK L, 1988, GENE DEV, V2, P991, DOI 10.1101/gad.2.8.991; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JOCHEMSEN AG, 1984, EMBO J, V3, P2923, DOI 10.1002/j.1460-2075.1984.tb02233.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MEIJER I, 1989, J VIROL, V63, P4039, DOI 10.1128/JVI.63.9.4039-4042.1989; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TIMMERS HTM, 1990, THESIS U LEIDEN; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1989, ONCOGENE, V4, P1207; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VOGT PK, 1990, IN PRESS ADV CANCER; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	40	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					911	916						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906158				2022-12-28	WOS:A1991GU62200004
J	JONES, RE; DEFEOJONES, D; MCAVOY, EM; VUOCOLO, GA; WEGRZYN, RJ; HASKELL, KM; OLIFF, A				JONES, RE; DEFEOJONES, D; MCAVOY, EM; VUOCOLO, GA; WEGRZYN, RJ; HASKELL, KM; OLIFF, A			MAMMALIAN-CELL LINES ENGINEERED TO IDENTIFY INHIBITORS OF SPECIFIC SIGNAL TRANSDUCTION PATHWAYS	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; SERUM-RESPONSE ELEMENT; PROTEIN KINASE-C; SWISS 3T3 CELLS; TRANSCRIPTION FACTOR; BIOLOGICAL-ACTIVITY; ENHANCER ELEMENTS; PHORBOL ESTERS; TUMOR-PROMOTER; RAS ONCOGENE	A variety of signal transduction pathways contribute to the regulation of transcription in mammalian cells. Several of these pathways ultimately rely upon the interaction of transcription factors with genetic sequences termed response elements in the promoter regions of some genes. The biochemical mechanisms that control the levels and state of activation of transcription factors are poorly understood. However, specific phosphorylation events mediated by protein kinase C, growth factor receptor-linked tyrosine kinases, and protein kinase A clearly participate in the regulation of these signal transduction pathways. To understand the relationship between activation and/or inhibition of these pathways and regulation of gene expression controlled by specific response elements, cell lines were prepared containing the TPA response element (TRE), serum response element (SRE), or cyclic AMP response element (CRE) fused to a gene encoding a secretable form of alkaline phosphatase (SEAP). These TRE-SEAP, SRE-SEAP, and CRE-SEAP cells exhibit dramatic increases in alkaline phosphatase (AP) activity following exposure to TPA, PDGF, or forskolin. Down regulation of protein kinase C or inhibition of tyrosine kinase activity blocked the stimulation of AP activity caused by TPA or PDGF. These cell lines can be used to characterize existing inhibitors, and to identify new agents that affect specific signal transduction pathways in mammalian cells.	MERCK SHARP & DOHME LTD,DEPT CANC RES,BLDG 16-101,W POINT,PA 19486	Merck & Company	OLIFF, A (corresponding author), MERCK SHARP & DOHME LTD,DEPT CANC RES,BLDG 16-101,W POINT,PA 19486, USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NISHIZUKA Y, 1984, NATURE, V308, P6893; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLIFF A, 1983, J VIROL, V48, P542, DOI 10.1128/JVI.48.2.542-546.1983; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; SAINSBURY JRC, 1987, LANCET, V1, P1398; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STRAATEN F, 1983, P NATL ACAD SCI USA, V80, P3183; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; TJIAN R, 1987, SCIENCE, V238, P1386; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WHANG Y, 1987, J VIROL, V61, P1796, DOI 10.1128/JVI.61.6.1796-1807.1987; XIAO H, 1986, MOL CELL BIOL, V6, P3200, DOI 10.1128/MCB.6.9.3200	50	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					745	751						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1711189				2022-12-28	WOS:A1991GT82500009
J	KERN, SE; KINZLER, KW; BAKER, SJ; NIGRO, JM; ROTTER, V; LEVINE, AJ; FRIEDMAN, P; PRIVES, C; VOGELSTEIN, B				KERN, SE; KINZLER, KW; BAKER, SJ; NIGRO, JM; ROTTER, V; LEVINE, AJ; FRIEDMAN, P; PRIVES, C; VOGELSTEIN, B			MUTANT P53 PROTEINS BIND DNA ABNORMALLY INVITRO	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; TRANSFORMATION-RELATED PROTEIN; RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODY; LAC REPRESSOR; HOST PROTEIN; 3T3 CELLS; COS CELLS	The p53 gene encodes a phosphoprotein which binds DNA. Many types of tumors contain mutant p53 genes, but the effects of these mutations on the intrinsic properties of p53 are largely unknown. In the present study, we tested the effect of p53 mutations on DNA-binding. Each of 15 different mutant p53 gene products derived from human tumors or mouse transformants bound calf thymus DNA more weakly than did wild-type products. A significant subset of mutant proteins were also found to be underphosphorylated compared to the wild-type protein when produced in a reticulocyte lysate system, but this did not appear to explain the pattern of alterations of DNA-binding. The tested mutations were dispersed over several regions of the p53 gene and included representatives of all four of the evolutionarily conserved domains that are the known 'hot spots' for p53 mutation. The results suggest common pathways by which these various mutations affect the normal function of p53.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,424 N BOND ST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231; PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Princeton University; Columbia University			Baker, Suzanne J/N-8167-2018		NCI NIH HHS [CA43460, CA35494, CA09243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035494, R01CA035494, T32CA009243, R37CA043460, R01CA043460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MCCORMICK F, 1981, NATURE, V292, P62; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	51	189	201	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					131	136						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846954				2022-12-28	WOS:A1991EY03900018
J	MARRIOTT, SJ; TRINH, D; BRADY, JN				MARRIOTT, SJ; TRINH, D; BRADY, JN			ACTIVATION OF INTERLEUKIN-2 RECEPTOR-ALPHA EXPRESSION BY EXTRACELLULAR HTLV-I TAX1 PROTEIN - A POTENTIAL ROLE IN HTLV-I PATHOGENESIS	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; PERIPHERAL-BLOOD LYMPHOCYTES; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; IL-2 RECEPTOR; TAT GENE; TRANSFORMATION	The Tax1 protein of human T cell leukemia/lymphoma virus type I (HTLV-1) has been shown to stimulate the proliferation of human lymphocytes. Here we report that lymphocyte proliferation can be induced at extracellular Tax1 concentrations as low as 25 pM. The proliferative response induced by extracellular Tax1 is accompanied by an activation of endogenous interleukin-2 receptor alpha-chain (IL-2R-alpha) expression in human lymphocytes. Functional activation of IL-2R-alpha expression in peripheral blood lymphocytes treated with Tax1 was demonstrated using an [I-125]IL-2-binding assay. In addition, an enzyme-linked immunosorbent assay demonstrated that soluble IL-2R-alpha in the medium of IL-2- and Tax1-treated cells was over 13-fold greater than in the medium of control treated cells. Overexpression of IL-2R-alpha is a common clinical feature of some patients with adult T-cell leukemia (ATL) and tropical spastic paraparesis/HTLV-I-associated myopathy (TSP/HAM). The ability of extracellular Tax1 protein to activate expression of IL-2R-alpha in both infected and uninfected lymphocytes may contribute to the abnormal lymphocyte proliferation observed in both ATL and TSP/HAM.	NIH,MOLEC VIROL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	MARRIOTT, SJ (corresponding author), BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030, USA.							ARYA SK, 1984, SCIENCE, V225, P1086; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; CANN AJ, 1988, ONCOGENE, V3, P123; COATES SR, 1990, J CLIN MICROBIOL, V28, P1139, DOI 10.1128/JCM.28.6.1139-1142.1990; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GESSAIN A, 1985, LANCET, V2, P407; GIAM CZ, 1988, P NATL ACAD SCI USA, V83, P7192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HATTORI T, 1981, BLOOD, V58, P645; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOYAMA Y, 1988, NEUROLOGY, V38, P816, DOI 10.1212/WNL.38.5.816; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KASHIWAGI S, 1990, J INFECT DIS, V161, P426, DOI 10.1093/infdis/161.3.426; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P F, 1990, New Biologist, V2, P1034; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MARRIOTT SJ, 1991, NEW BIOL, V3, P678; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RUBIN LA, 1985, J IMMUNOL, V135, P3172; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; YODOI J, 1983, BLOOD, V62, P509; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534	45	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1749	1755						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501887				2022-12-28	WOS:A1992JJ37600011
J	MORRISON, LE; BOEHMELT, G; ENRIETTO, PJ				MORRISON, LE; BOEHMELT, G; ENRIETTO, PJ			MUTATIONS IN THE REL-HOMOLOGY DOMAIN ALTER THE BIOCHEMICAL-PROPERTIES OF V-REL AND RENDER IT TRANSFORMATION DEFECTIVE IN CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; LYMPHOID-CELLS; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; SPLEEN-CELLS; C-REL; ACTIVATION	Sequential deletions of approximately 100 base pairs were made in the rel-homology domain of the viral rel protein. Each deletion mutant was cloned into a replication-competent viral vector and assayed in chicken embryo fibroblasts (CEFs). The deleted v-rel proteins were analysed for localization, complex formation and ability to induce transformation. In vitro-translated mutant proteins were assayed for binding to a NF-kappa-B consensus sequence. All the deletion mutants between nucleotides 37 and 798 in v-rel were transformation defective. Each of the mutants localized predominantly in the cytoplasm, whereas wild-type v-rel localizes predominantly in the nucleus of CEFs. Any disruption of the rel-homology domain reduced binding of the mutant v-rel proteins to the cellular protein, p36, while the requirements for binding to p68c-rel, p115 and p124 appeared to be more complicated. The binding of these three proteins to v-rel appeared to be linked and mediated through c-rel, suggesting that v-rel disrupts normal c-rel function. None of the deletion mutants in this region were able to bind to the NF-kappa-B site. However, mutants which lie outside the rel-homology domain retained the ability to transform CEFs, localize to the nucleus, complex with p36, p115, p124 and p68c-rel and bind to the NK-kappa-B site. These results suggest that transformation by v-rel requires an intact rel-homology domain and that the biochemical properties of v-rel are linked and dependent upon higher order protein structure for full function.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NCI NIH HHS [2T32CA09176, R0I CA51792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176, R01CA051792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BHAT GV, 1990, ONCOGENE, V5, P625; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; COHEN RS, 1981, VIROLOGY, V113, P672, DOI 10.1016/0042-6822(81)90196-3; DAVEY J, 1985, CELL, V40, P667, DOI 10.1016/0092-8674(85)90215-6; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HOELZER JD, 1979, VIROLOGY, V93, P20, DOI 10.1016/0042-6822(79)90272-1; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IP YT, 1991, CELL, V64, P439; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P667; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PURCHASE HG, 1975, RETICULOENDOTHELIOSI; RICE NR, 1982, J VIROL, V42, P237, DOI 10.1128/JVI.42.1.237-252.1982; RICHARDSON PM, 1991, IN PRESS J VIROL, V65; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK S, 1988, ONCOGENE RES, V2, P102; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	44	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1137	1147						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594245				2022-12-28	WOS:A1992HU64200011
J	AMLER, LC; SCHWAB, M				AMLER, LC; SCHWAB, M			MULTIPLE AMPLICONS OF DISCRETE SIZES ENCOMPASSING N-MYC IN NEUROBLASTOMA-CELLS EVOLVE THROUGH DIFFERENTIAL RECOMBINATION FROM A LARGE PRECURSOR DNA	ONCOGENE			English	Note							NEURO-BLASTOMA; AMPLIFICATION; GENE; ONCOGENE	Human neuroblastoma cells often carry cytogenetic abnormalities signaling amplification of the gene N-myc. In most cell lines amplified N-myc is localized in homogeneously staining regions (HSRs). Varying proportions of the amplified DNA consist of multiple tandem arrays of DNA segments encompassing N-myc. Here we report the cloning and sequencing of a DNA breakpoint which represents the joint of the tandem repeats of a 280-kb amplicon of neuroblastoma line NMB. The breakpoint is located in the first intron of the N-myc gene and leads to the deletion of the 5' region of N-myc in this 20-copy amplicon. The representation of DNA derived from the non-N-myc part of the novel joint in the different amplicons suggests that an increase in N-myc copy numbers involves a multistep process proceeding from large 'precursors' to smaller multicopy amplicons.			AMLER, LC (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST EXPTL PATHOL,W-6900 HEIDELBERG,GERMANY.							AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; HILLER S, 1991, ONCOGENE, V6, P969; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; Maniatis T., 1982, MOL CLONING; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160	13	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					807	809						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565478				2022-12-28	WOS:A1992HQ68200028
J	LINDER, S; POPOWICZ, P; SVENSSON, C; MARSHALL, H; BONDESSON, M; AKUSJARVI, G				LINDER, S; POPOWICZ, P; SVENSSON, C; MARSHALL, H; BONDESSON, M; AKUSJARVI, G			ENHANCED INVASIVE PROPERTIES OF RAT EMBRYO FIBROBLASTS TRANSFORMED BY ADENOVIRUS E1A MUTANTS WITH DELETIONS IN THE CARBOXY-TERMINAL EXON	ONCOGENE			English	Article							TOXIC LYMPHOCYTES-T; REGULATORY FUNCTIONS; CELL-TRANSFORMATION; TUMOR-CELLS; EXPRESSION; ONCOGENE; GENE; REGION; METASTASIS; PROTEIN	E1A genes deficient in the carboxy-terminal exon can cooperate with activated ras oncogenes to induce transformation of rat embryo fibroblasts. However, the resulting transformed foci show a distinct appearance characterized by a decreased adhesion of the cells to the substrate. Here, we demonstrate that cell lines derived from foci showing the variant morphology are defective in down-regulation of stromelysin 1 metalloprotease expression and show an increased invasive propensity compared with cells transformed by wild-type E1A. The altered focus morphology, the high invasive propensity and the elevated stromelysin 1 expression were abrogated by glucocorticoid treatment. Our results show that E1A functions necessary for transformation and inhibition of invasive properties may be separated, and indicate that a 23 amino acid serine/threonine-rich region within the E1A carboxy-terminal exon is required for efficient repression of metalloprotease expression in transformed cells.	KAROLINSKA INST & HOSP, RADIUMHEMMET, DEPT ONCOL, DIV EXPTL ONCOL, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MICROBIAL GENET, S-10401 STOCKHOLM 60, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet			Bondesson, Maria/H-3027-2012	Bondesson, Maria/0000-0001-6358-5788				ALBINI A, 1987, CANCER RES, V47, P3239; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; FRISCH SM, 1990, ONCOGENE, V5, P75; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GOPAS J, 1989, ADV CANCER RES, V53, P89; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MARTENS I, 1990, EXP CELL RES, V187, P143, DOI 10.1016/0014-4827(90)90128-W; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; URBANELLI D, 1989, VIROLOGY, V173, P607, DOI 10.1016/0042-6822(89)90572-2; VANDAM H, 1989, ONCOGENE, V4, P1207; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	37	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					439	443						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1532246				2022-12-28	WOS:A1992HK00500006
J	REDDY, ESP; RAO, VN				REDDY, ESP; RAO, VN			ERG, AN ETS-RELATED GENE, CODES FOR SEQUENCE-SPECIFIC TRANSCRIPTIONAL ACTIVATORS	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; LONG TERMINAL REPEAT; AVIAN LEUKEMIA-VIRUS; PROTO-ONCOGENE; DNA-BINDING; C-ETS; V-ETS; CHROMOSOME-21; PROTEINS; CELLS	E26 is a replication-defective avian acute leukemia virus which causes erythroblastosis and myeloblastosis in chickens. It carries two distinct oncogenes, v-myb and v-ets, both of which contribute to its transforming properties. Several genes related to the ets oncogene (c-ets-1, ets-2, erg, elk-1, elk-2, PU.1/Spi-1, E74 and Fli-1) have been described. Previously we have shown that the erg gene (ets-related gene) codes for at least two proteins (erg-1 and erg-2) because of alternative splicing and alternative usage of the initiation codon. We have expressed erg-1 and erg-2 proteins in Escherichia coli and have used these recombinant proteins to show that they bind to DNA in a sequence-specific manner. erg proteins exhibited different sequence specificity and affinity for the oligonucleotides recognized by c-ets-1, ets-2, some of PU.1/Spi-1 and elk-1, suggesting that the DNA-binding specificities of erg and other members may overlap but are not necessarily identical. The erg gene was found to transactivate a reporter gene that was linked to erg target sequences. These results suggest that erg-1 and erg-2 are sequence-specific transcriptional activators like the other members of the ets oncogene superfamily which represent a distinct class of transcriptional activators.	TEMPLE UNIV,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1991, IN PRESS ONCOGENE; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1986, GENE ANAL TECH, V3, P41; REDDY ESP, 1991, ERG ELK 1 ELK 2 GUID; REDDY ESP, 1990, CANCER RES, V50, P5013; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; [No title captured]	36	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2285	2289						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766675				2022-12-28	WOS:A1991GX73500016
J	SU, HY; BOS, TJ; MONTECLARO, FS; VOGT, PK				SU, HY; BOS, TJ; MONTECLARO, FS; VOGT, PK			JUN INHIBITS MYOGENIC DIFFERENTIATION	ONCOGENE			English	Article							C-JUN; V-JUN; REGULATORY GENE; CELLS; ONCOGENES; MYOD1; EXPRESSION; TRANSFORMATION; TRANSCRIPTION; PROGRAM	Myoblasts from skeletal muscle of chicken or Japanese quail embryos were infected with avian sarcoma virus 17 (ASV-17), a retrovirus carrying the jun oncogene. At high multiplicities of infection ASV-17-induced morphologic transformation inhibited fusion of myoblasts into myotubes and stimulated extended replication. The expression of the muscle-specific proteins desmin, myosin and creatine phosphokinase was inhibited in ASV-17-infected cultures. Immunofluorescent staining detected strong expression of the ASV-17 Gag-Jun fusion protein in the nuclei of infected mononuclear myoblasts, but Gag-Jun was not detectable in multinucleated myotubes that occurred in clonal populations of ASV-17-infected quail myoblasts. This result suggests that the nuclear expression of viral jun and myogenic differentiation are mutually exclusive events. A mutant of ASV-17, ts jun-1, is partly temperature-sensitive in its ability to transform chicken embryo fibroblasts. At the non-permissive temperature of 41.5-degrees-C, multinucleated myotubes readily formed in ts jun-1-infected myoblast cultures and expressed muscle-specific proteins detectable by immunofluorescent staining. These myotubes also showed strong immunofluorescent staining for Gag-Jun in the cell nuclei. The nuclear expression of a Jun protein that is defective in its transforming function appears therefore to be compatible with myogenesis. Several retroviral constructs carrying various viral and cellular jun inserts, as well as jun deletion mutants and recombinants between c-jun and v-jun, were tested for their effect on myogenic differentiation. There was an approximate correlation between the ability of a construct to transform chicken embryo fibroblasts and its effectiveness in interfering with myogenic differentiation. We conclude that the expression of an oncogenic jun gene in myoblasts strongly inhibits myogenic differentiation, and that a highly transforming Jun protein cannot be expressed in the nuclei of differentiating myotubes, while the presence of transformation-defective variants of Jun is compatible with differentiation.	UNIV SO CALIF, SCH MED, NORRIS CANC CTR, LOS ANGELES, CA 90033 USA	University of Southern California	SU, HY (corresponding author), UNIV SO CALIF, SCH MED, DEPT MICROBIOL, 2011 ZONAL AVE, LOS ANGELES, CA 90033 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate C, 1990, Semin Cancer Biol, V1, P19; ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BISCHOFF R, 1969, J CELL BIOL, V41, P188, DOI 10.1083/jcb.41.1.188; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CAPLAN AI, 1976, J EMBRYOL EXP MORPH, V36, P175; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; CURRAN M, 1991, TRANSCRIPTIONAL REGU; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GROSSI M, 1991, ONCOGENE, V6, P1767; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LILLIE RD, 1969, BIOL STAINS, P74; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LOUGH J, 1977, DEV BIOL, V57, P330, DOI 10.1016/0012-1606(77)90219-6; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; TOYOSHIMA K, 1969, VIROLOGY, V39, P930, DOI 10.1016/0042-6822(69)90030-0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VOGT PK, 1969, FUNDAMENTAL TECHNIQU, P316; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Yaffe D, 1969, Curr Top Dev Biol, V4, P37, DOI 10.1016/S0070-2153(08)60480-9	32	60	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1759	1766						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656361				2022-12-28	WOS:A1991GX11800006
J	BHATIA, K; HUPPI, K; MCKEITHAN, T; SIWARSKI, D; MUSHINSKI, JF; MAGRATH, I				BHATIA, K; HUPPI, K; MCKEITHAN, T; SIWARSKI, D; MUSHINSKI, JF; MAGRATH, I			MOUSE BCL-3 - CDNA STRUCTURE, MAPPING AND STAGE-DEPENDENT EXPRESSION IN LYMPHOCYTES-B	ONCOGENE			English	Note							LIGHT CHAIN GENE; CELL-CYCLE CONTROL; CHROMOSOME-TRANSLOCATION; LEUKEMIA; DIFFERENTIATION; BREAKPOINT; LYMPHOMAS; SEQUENCE; CLONING; ACTIVATION	Human B-cell chronic lymphocytic leukemias (CLLs) are malignancies of mature B lymphocytes. A subset of these tumors is associated with a non-random t(14; 19) translocation (Ueshima et al., 1985). Recently a gene (bcl-3) has been identified in the region adjacent to the chromosome 19 breakpoint in this translocation (McKeithan et al., 1987; Ohno et al., 1990). We now report the isolation of cDNA clones of mouse bcl-3. The mouse bcl-3-coding region is 1746 bp long and exhibits 80% identity with human bcl-3 at both the nucleotide and amino acid level. The bcl-3 locus maps to the proximal end of mouse chromosome 7, which is syntenic to human chromosome 19. The bcl-3 probe readily detects particularly abundant amounts of a 1.8 kb mRNA in mouse tumors consisting of follicular center mature B cells and large pre-B cells, but not in small pre-B cells. The bcl-3 pattern of expression is distinctive in the spectrum of B-cell maturation in that bcl-3 transcripts are particularly abundant in B-cell lines immortalized just prior to Ig switch. The bcl-3 pattern of expression also bears close resemblance to that of bcl-2 (Gurfinkel et al., 1987), which is frequently associated with human B follicular lymphomas {t(14;18)} and some chronic lymphocytic leukemias (Adachi et al., 1989; 1990; Adachi & Tsujimoto, 1989).	UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; NCI,GENET LAB,BETHESDA,MD 20892	University of Chicago; University of Chicago; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BHATIA, K (corresponding author), NCI,PEDIAT BRANCH,LYMPHOMA BIOL SECT,BETHESDA,MD 20892, USA.			McKeithan, Timothy/0000-0003-2242-3074	NATIONAL CANCER INSTITUTE [R29CA049207] Funding Source: NIH RePORTER; NCI NIH HHS [CA49207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1989, ONCOGENE, V4, P1073; CAVANNA JS, 1990, GENOMICS, V7, P12, DOI 10.1016/0888-7543(90)90513-T; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; Green EL, 1981, GENETICS PROBABILITY, P77; GURFINKEL N, 1987, EUR J IMMUNOL, V17, P567, DOI 10.1002/eji.1830170421; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; MUSHINSKI JF, 1987, CANCER INVEST, V5, P345; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; SAUNDERS AM, 1990, GENOMICS, V8, P525, DOI 10.1016/0888-7543(90)90040-2; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263	20	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1569	1573						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923524				2022-12-28	WOS:A1991GX27400011
J	ZOBEL, A; KALKBRENNER, F; GUEHMANN, S; NAWRATH, M; VORBRUEGGEN, G; MOELLING, K				ZOBEL, A; KALKBRENNER, F; GUEHMANN, S; NAWRATH, M; VORBRUEGGEN, G; MOELLING, K			INTERACTION OF THE V-MYB AND C-MYB PROTEINS WITH REGULATORY SEQUENCES OF THE HUMAN C-MYC GENE	ONCOGENE			English	Article							COLI RNA-POLYMERASE; MOUSE ERYTHROLEUKEMIA-CELLS; HUMAN HEMATOPOIETIC-CELLS; AVIAN-LEUKOSIS VIRUS; DNA-BINDING DOMAIN; BURKITT-LYMPHOMA; PROTO-ONCOGENE; NUCLEOTIDE-SEQUENCE; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODY	Eight c-Myb-binding sites have been identified in the regulatory region of the human c-myc gene using gel retardation and DNAase I footprint assays with purified bacterially expressed full-length and carboxy-terminally truncated c-Myb proteins. These binding sites exhibit different affinities whereby strong binding correlates better with conservation of the palindromic sequences, AACXGTT or AACGTT, than the previously described consensus sequence. Flanking AT-rich sequences further increase the binding affinity. The c-Myb-binding sites are arranged in pairs consisting of one high- and one low-affinity binding site. Binding of the Myb proteins to these sites is non-cooperative. The v-Myb protein protects two nucleotides fewer than the c-Myb protein. Co-transfection of reporter CAT genes, containing upstream human c-myc sequences including exon 1, with c-Myb-expressing constructs resulted in positive transactivation, which was eightfold with full-length Myb and 14-fold with the truncated Myb. This result suggests that the Myb protein could participate in regulation of human c-myc gene expression.	MAX PLANCK INST MOLEC GENET,SCHUSTER ABT,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								BADING H, 1987, ONCOGENE, V1, P395; BADING H, 1988, ONCOGENE, V3, P257; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6348; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KELLY K, 1988, J BIOL CHEM, V263, P4828; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCMAHON J, 1988, ONCOGENE, V3, P717; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	73	68	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1397	1407						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679531				2022-12-28	WOS:A1991GX27200016
J	CHAN, J; WATT, VM				CHAN, J; WATT, VM			EEK AND ERK, NEW MEMBERS OF THE EPH SUBCLASS OF RECEPTOR PROTEIN-TYROSINE KINASES	ONCOGENE			English	Article							PHOSPHOTYROSINE ANTIBODY; GEL-ELECTROPHORESIS; DNA FRAGMENTS; GENE; PDGF; FAMILY; BRAIN; PHOSPHORYLATION; LOCALIZATION; EXPRESSION	We have identified human and rat DNAs encoding two novel members of the eph subclass of putative receptor protein-tyrosine kinases. Rat cDNA clones encoding eek (eph- and elk-related kinase) were isolated from a brain cDNA library probed with DNA encoding the kinase region of the insulin receptor-related receptor. The predicted eek protein contains all the amino acid residues conserved in the catalytic domains of protein-tyrosine kinases and is most similar to two putative receptor protein-tyrosine kinases of the eph subclass, elk (69%) and eph (57%). Human genomic DNAs encoding part of eek (EEK) as well as another putative protein-tyrosine kinase most similar to elk (90%), ERK (elk-related kinase), were isolated and partially characterized. The novel identity of these two eph-family genes was further supported by Southern blot analyses and localization to human chromosome 1. In Northern blot analysis of rat RNA, DNAs encoding rat eek and human ERK hybridized to transcripts most abundant in brain and lung, respectively. These two new members of the eph subclass of receptor protein-tyrosine kinases, eek and erk, may therefore have tissue-specific functions distinct from those of other eph family members.	UNIV TORONTO,DEPT PHYSIOL,MED SCI BLDG,ROOM 3360,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	WATT, VM (corresponding author), UNIV TORONTO,DEPT PHYSIOL,MED SCI BLDG,ROOM 3360,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA.							ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHBERG AM, 1989, GENETICS, V122, P153; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIER P, 1990, CYTOGENET CELL GENET, V54, P80, DOI 10.1159/000132963; SHIER P, 1989, J BIOL CHEM, V264, P14605; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WATT VM, 1990, HUM GENET, V85, P651; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	39	58	130	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1057	1061						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648701				2022-12-28	WOS:A1991GU62200023
J	SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; PARMENTIER, C; MONIER, R				SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; PARMENTIER, C; MONIER, R			GSP MUTATIONS IN HUMAN THYROID-TUMORS	ONCOGENE			English	Note							HUMAN PITUITARY-TUMORS; RAS GENE-MUTATIONS; ADENYLATE-CYCLASE; ONCOGENE; PROLIFERATION; STIMULATION; LEUKEMIAS; CANCER	The presence of gsp mutations at codons 201 and 227 in the gene coding for the alpha-subunit of the GTP-binding G(s) protein which stimulates adenylyl cyclase (AC) has been investigated in 31 samples of differentiated thyroid tumours, which had been previously characterized with respect to their adenylyl cyclase activity (ACA) before and after stimulation by thryoid-stimulating hormone (TSH). Polymerase chain reaction (PCR) amplification of DNA extracted from these tumours, followed by high stringency oligonucleotide probing, enabled the detection of mutations in three samples originating from tumours with high constitutive ACA, which was not significantly further stimulated by TSH. Two mutations were at codon 227 and replaced Gln227 by His or Lys, and one was at codon 201, with the substitution of Arg201 by Ser. Because thyrocytes belong to the subset of differentiated cells which are programmed to proliferate in response to elevated cAMP levels, the gsp mutations observed in some differentiated thyroid carcinomas probably contributed to their tumorigenic phenotype.	CNRS,INST RECH SCI CANC,F-94802 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CARAYON P, 1980, J CLIN ENDOCR METAB, V51, P915, DOI 10.1210/jcem-51-4-915; CLEMENTI E, 1990, ONCOGENE, V5, P1059; DEVRIES MV, 1986, GENE, V50, P313; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KOSAZA T, 1988, P NATL ACAD SCI USA, V85, P2081; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MULDER MP, 1989, ONCOGENE, V4, P1345; SPADA A, 1984, ENDOCRINOLOGY, V115, P1203, DOI 10.1210/endo-115-3-1203; SUAREZ HG, 1990, ONCOGENE, V5, P565; THOMASMORVAN C, 1982, ACTA ENDOCRINOL-COP, V101, P25, DOI 10.1530/acta.0.1010025; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; YUNIS JJ, 1989, ONCOGENE, V4, P609	21	227	230	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					677	679						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903197				2022-12-28	WOS:A1991FR93900027
J	SAINTRUF, C; MALFOY, B; SCHOLL, S; ZAFRANI, B; DUTRILLAUX, B				SAINTRUF, C; MALFOY, B; SCHOLL, S; ZAFRANI, B; DUTRILLAUX, B			GST-PI-GENE IS FREQUENTLY COAMPLIFIED WITH INT2 AND HSTF1 PROTOONCOGENES IN HUMAN BREAST CANCERS	ONCOGENE			English	Article							GLUTATHIONE-S-TRANSFERASE; HUMAN DESMIN GENE; TUMOR-CELL-LINES; SV40 DNA; AMPLIFICATION; EXPRESSION; ASSIGNMENT; MARKER; BCL-1	The glutathione S-transferase gene (GST-pi) is located on the same chromosome band (11q13) as proto-oncogenes INT2 and HSTF1 which are frequently amplified in breast cancer. Using the Southern blot technique, we looked for the amplification of the GST-pi gene in 17 fresh tumors from human mammary carcinoma. The tumors were preselected because either they had an amplification of the INT2 proto-oncogene detected by dot blot, or their karyotypes exhibited or did not exhibit homogeneously staining regions, a cytogenetic character indicating amplification. Coamplification of GST-pi, HSTF1 and INT2 was observed in five tumors, and coamplification of GST-pi and HSTF1 without amplification of INT2 in another tumor. We also observed coamplification of GST-pi, INT2, HSTF1 in the mammary carcinoma cell line MDA/MB134, whereas GST-pi alone was amplified in the mammary epithelial cell line HBL100. These results indicate that INT2, HSTF1 and GST-pi belong to the same large amplicon. Since GST-pi is involved in intracellular detoxication and since chemotherapeutic drugs are among its substrates, it will be of interest to study GST-pi gene expression as well as the response to chemotherapy in patients presenting this amplicon.	INST CURIE,BIOL SECT,CNRS,URA 620,26 RUE ULM,F-75231 PARIS 05,FRANCE; INST CURIE,MED SECT,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								ADELAIDE J, 1988, ONCOGENE, V2, P413; ALI IU, 1989, ONCOGENE, V4, P89; BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; DIILIO C, 1988, CARCINOGENESIS, V9, P335; DULIK DM, 1986, BIOCHEM PHARMACOL, V35, P3405, DOI 10.1016/0006-2952(86)90444-2; DUTRILLAUX B, IN PRESS CANCER GENE; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GERBAULTSEUREAU M, 1987, ANN GENET-PARIS, V30, P146; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HILL DL, 1976, P AM ASSOC CANC RES, V17, P52; HOWIE AF, 1990, CARCINOGENESIS, V11, P295, DOI 10.1093/carcin/11.2.295; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JOLLY DJ, 1982, P NATL ACAD SCI-BIOL, V79, P5038, DOI 10.1073/pnas.79.16.5038; KANO T, 1987, CANCER RES, V47, P5626; LI YC, 1988, P NATL ACAD SCI USA, V85, P344, DOI 10.1073/pnas.85.2.344; LILIENBAUM A, 1988, CELL MOL BIOL, V34, P663; MARLHENS F, 1988, ANN GENET-PARIS, V31, P81; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; MOSCOW JA, 1989, CANCER RES, V49, P1422; NGUYEN C, 1988, ONCOGENE, V3, P703; SAINTRUF C, 1989, INT J CANCER, V44, P367, DOI 10.1002/ijc.2910440230; SAINTRUF C, IN PRESS CANCER GENE; SAINTRUF C, 1990, GENES CHROMOSOMES CA, V2, P63; SHEA TC, 1988, CANCER RES, V48, P527; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; THEILLET C, 1990, ONCOGENE, V5, P147; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3; 1981, CLASSIFICATION HISTO; 1982, TNM VICC TNM ATLAS; 1989, CYTOGENET CELL GENET, V51, P1	36	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					403	406						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1826346				2022-12-28	WOS:A1991FT34400008
J	SCHONTHAL, A; TSUKITANI, Y; FERAMISCO, JR				SCHONTHAL, A; TSUKITANI, Y; FERAMISCO, JR			TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF C-FOS EXPRESSION BY THE TUMOR PROMOTER OKADAIC ACID	ONCOGENE			English	Article							PROTEIN-KINASE-C; RABBIT SKELETAL-MUSCLE; SERUM-RESPONSE ELEMENT; SWISS MOUSE 3T3-CELLS; MESSENGER-RNA; GROWTH-FACTOR; CELL-CYCLE; PHOSPHOPROTEIN PHOSPHATASE; SIGNAL TRANSDUCTION; GENE-EXPRESSION	Phosphorylation events are major regulatory mechanisms of signal transduction pathways that control cell growth and differentiation. We analyzed the potential contribution of serine/threonine specific protein phosphatases to the regulation of the c-fos gene, a proto-oncogene that is involved in the regulation of cell growth and differentiation. By use of okadaic acid, an inhibitor of protein phosphatases 1 and 2A, we present evidence that expression of the c-fos gene is regulated by serine/threonine specific protein phosphatases. This control is exerted on the transcriptional as well as the post-transcriptional level. The results suggest that dephosphorylation of regulatory phosphoproteins is an important mechanism for the down-regulation of c-fos promoter activity and the rapid degradation of c-fos mRNA. Examination of two protein kinase pathways that are known to regulate c-fos expression indicated that okadaic acid acted synergistically with protein kinase C, but not with protein kinase A. Since inhibition of serine/threonine specific phosphatases increases proto-oncogene expression, these experiments further strengthen the view that certain protein phosphatases may act as negative regulators of cell growth.	FUJISAWA PHARMACEUT CO LTD, OSAKA 532, JAPAN	Astellas Pharmaceuticals	SCHONTHAL, A (corresponding author), UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653				BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; Curran T, 1988, ONCOGENE HDB, P307; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FUJIKI H, 1987, P JPN ACAD B-PHYS, V63, P51, DOI 10.2183/pjab.63.51; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HARLOW E, 1988, ANTIBODIES; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOLMES CFB, 1986, BIOCH BIOPHYS ACTA, V870; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KLEE CB, 1988, MOL ASPECTS CELLULAR, P225; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHONTHAL A, 1990, CELL SIGNAL, V2, P215, DOI 10.1016/0898-6568(90)90049-G; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEWART AA, 1980, FEBS LETT, V119, P16, DOI 10.1016/0014-5793(80)80988-4; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	70	81	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					423	430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1901402				2022-12-28	WOS:A1991FT34400011
J	ZWILLER, J; SASSONECORSI, P; KAKAZU, K; BOYNTON, AL				ZWILLER, J; SASSONECORSI, P; KAKAZU, K; BOYNTON, AL			INHIBITION OF PDGF-INDUCED C-JUN AND C-FOS EXPRESSION BY A TYROSINE PROTEIN-KINASE INHIBITOR	ONCOGENE			English	Article							GROWTH-FACTORS; SIGNAL TRANSDUCTION; LEUCINE ZIPPER; 3T3 CELLS; MOUSE FIBROBLASTS; ONCOGENE; INDUCTION; FAMILY; TRANSCRIPTION; STIMULATION	The expression of the proto-oncogenes c-fos, c-jun, jun B and jun D was monitored in quiescent C3H10T1/2 fibroblasts after stimulation with PDGF. The mRNA level of c-fos, c-jun and jun B, but not of jun D, was stimulated by PDGF. The inductions were abolished when genistein, a specific tyrosine protein kinase inhibitor, was added concomitantly with PDGF, a condition in which DNA synthesis is known to be inhibited. As already shown previously, treatment with PDGF and genistein for 4 h followed by the replacement with fresh medium induces the progression of the cells through the G1 phase of their growth-division cycle, without phospholipase C activation. The removal of PDGF and genistein was accompanied by an important increase in c-fos, c-jun and jun B mRNA expression, which correlated with the entrance of cells into G1 phase. Thus, the proto-oncogene expressions induced by PDGF are also obtained in the absence of phospholipase C activation. This result also suggests that the mRNA levels of c-jun, jun B and to a lesser degree c-fos are positively regulated by tyrosine protein kinase activity, whereas jun D is negatively regulated.	CNRS,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE; UNIV HAWAII,CANC RES CTR HAWAII,HONOLULU,HI 96813	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Cancer Research Center of Hawaii; University of Hawaii System	ZWILLER, J (corresponding author), CNRS,CTR NEUROCHIM,5 RUE PASCAL,F-67084 STRASBOURG,FRANCE.		Sassone-Corsi, Paolo/H-6182-2011		NCI NIH HHS [CA42942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OLAH Z, 1990, CANCER RES, V31, pA76; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; STILES CD, 1985, CANCER RES, V45, P5215; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	30	56	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					219	221						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900355				2022-12-28	WOS:A1991FZ13400006
J	LEIBOVITCH, SA; LENORMAND, JL; LEIBOVITCH, MP; GUILLER, M; MALLARD, L; HAREL, J				LEIBOVITCH, SA; LENORMAND, JL; LEIBOVITCH, MP; GUILLER, M; MALLARD, L; HAREL, J			RAT MYOGENIC C-MOS CDNA - CLONING SEQUENCE-ANALYSIS AND REGULATION DURING MUSCLE DEVELOPMENT	ONCOGENE			English	Article											LEIBOVITCH, SA (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 126,UA 1158,39 RUE CAMILLE DESMOULINS,F-94800 VILLEJUIF,FRANCE.		Lenormand, Jean-Luc/M-6644-2014; Lenormand, Jean-Luc/ABF-3850-2021	Lenormand, Jean-Luc/0000-0002-2766-9180				BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BARTON PJR, 1985, J BIOL CHEM, V260, P8578; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERCK AJ, 1978, P NATL ACAD SCI USA, V75, P1274; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; FRANKEL AE, 1976, P NATL ACAD SCI USA, V73, P3705, DOI 10.1073/pnas.73.10.3705; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4500; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; HILLION J, 1984, CANCER RES, V44, P2959; HUNTER T, 1986, ENZYMES, V17, P191; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; KURUTA N, 1989, EMBO J, V8, P457; LEIBOVITCH MP, 1987, EXP CELL RES, V170, P80, DOI 10.1016/0014-4827(87)90118-2; LEIBOVITCH SA, 1986, CANCER RES, V46, P4097; LEIBOVITCH SA, 1986, EXP CELL RES, V166, P526, DOI 10.1016/0014-4827(86)90497-0; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; SWAN D, 1982, J VIROL, V44, P753; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1982, EMBO J, V1, P1313, DOI 10.1002/j.1460-2075.1982.tb01316.x; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	46	30	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1149	1157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	1697408				2022-12-28	WOS:A1990DX36100006
J	STRAUSS, M; HERING, S; LUBBE, L; GRIFFIN, BE				STRAUSS, M; HERING, S; LUBBE, L; GRIFFIN, BE			IMMORTALIZATION AND TRANSFORMATION OF HUMAN FIBROBLASTS BY REGULATED EXPRESSION OF POLYOMA-VIRUS T-ANTIGENS	ONCOGENE			English	Article									ROYAL POSTGRAD MED SCH,DEPT VIROL,DU CANE RD,LONDON W12 0NN,ENGLAND; ACAD SCI GDR,CENT INST MOLEC BIOL,O-1086 BERLIN,GERMANY; CENT INST CANC RES,BERLIN,GERMANY	Imperial College London; German Academy of Sciences at Berlin								BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BRAVO R, 1985, FEBS LETT, V182, P435, DOI 10.1016/0014-5793(85)80349-5; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLERTANT P, 1984, NATURE, V311, P276, DOI 10.1038/311276a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GOTOH S, 1979, J GEN VIROL, V42, P409, DOI 10.1099/0022-1317-42-2-409; GRIFFIN BE, 1979, J VIROL, V39, P653; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LINZER DIH, 1988, TRENDS GENET, V4, P245, DOI 10.1016/0168-9525(88)90029-7; LOMAX CA, 1978, INTERVIROLOGY, V9, P28, DOI 10.1159/000148918; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; POMERANTZ BJ, 1984, J VIROL, V49, P925, DOI 10.1128/JVI.49.3.925-937.1984; PONTEN J, 1985, IARC SCI PUBL, V58, P171; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RASSOULZADEGAN M, 1983, P NATL ACAD SCI USA, V80, P4345; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1984, CANCER CELL, V2, P487; SMALL MB, 1982, NATURE, V296, P671, DOI 10.1038/296671a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; STRAUSS M, 1986, GENE, V49, P331, DOI 10.1016/0378-1119(86)90369-0; STRAUSS M, 1989, CURR TOP MICROBIOL, V44, P129; TANG A, 1989, ONCOGENE, V4, P401; TEVETHIA MJ, 1984, VIROLOGY, V137, P414, DOI 10.1016/0042-6822(84)90234-4; Tooze J., 1980, MOL BIOL TUMOR VIR 2; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	45	35	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1223	1229						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	1697410				2022-12-28	WOS:A1990DX36100016
J	REDDY, MVR; DESAI, M; JEYAPAUL, J; PRASAD, DDK; SESHAMMA, T; PALMERI, D; KHAN, SA				REDDY, MVR; DESAI, M; JEYAPAUL, J; PRASAD, DDK; SESHAMMA, T; PALMERI, D; KHAN, SA			FUNCTIONAL-ANALYSIS OF THE N-TERMINAL DOMAIN OF TAT PROTEIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	ONCOGENE			English	Article							ACTIVATION-RESPONSIVE REGION; RNA-BINDING PROTEIN; CELL-FREE SYSTEM; HIV-1 TAT; TRANS-ACTIVATION; MUTATIONAL ANALYSIS; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; NUCLEAR-PROTEIN; BASIC DOMAIN	The Tat protein of human immunodeficiency virus type 1 (HIV-1) is a potent trans-activator of the viral long terminal repeat (LTR). The N-terminal region of Tat is rich in proline and acidic residues analogous to the activation domains of other transcription factors such as GAL4 and CTF/NF-1. Several basic residues are also present in this region. To investigate the role of these structural features in the Tat-mediated trans-activation, we have chemically synthesized and evaluated Tat analogs with alanine or glutamine replacing one or more of these amino acid residues. Our data show that substitution of Glu-2, His-13, or all the proline in the Pro-Xaa3-Pro triad drastically reduced activity. In contrast, changes at Arg-7, Lys-12 and any one proline residue in the triad moderately reduced, and substitution of Lys-19 showed tittle effect on, activity. These results show that the native structure of the N-terminal 19 amino acid sequence is essential for Tat function. and that the overall topology of this domain and not the acidic residues alone appears necessary for trans-activation.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NIAID NIH HHS [AI27422, AI25380] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027422, P01AI025380] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BRAKE DA, 1990, J VIROL, V64, P962, DOI 10.1128/JVI.64.2.962-965.1990; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; JEYAPAUL J, 1991, ONCOGENE, V6, P1507; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LATCHMAN DS, 1990, BIOCHEM J, V270, P281, DOI 10.1042/bj2700281; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYERS G, 1989, HUMAN RETROVIRUS AID, P11; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAPPAPORT J, 1989, New Biologist, V1, P101; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; ROBSON B, 1986, INTRO PROTEIN PROTEI; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUBEN S, 1989, J VIROL, V63, P1; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SUBRAMANIAN T, 1991, EMBO J, V10, P2311, DOI 10.1002/j.1460-2075.1991.tb07768.x; TILEY LS, 1990, VIROLOGY, V178, P560, DOI 10.1016/0042-6822(90)90354-T; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055	46	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1743	1748						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501886				2022-12-28	WOS:A1992JJ37600010
J	MICHALSKI, AJ; COTTER, FE; COWELL, JK				MICHALSKI, AJ; COTTER, FE; COWELL, JK			ISOLATION OF CHROMOSOME-SPECIFIC DNA-SEQUENCES FROM AN ALU POLYMERASE CHAIN-REACTION LIBRARY TO DEFINE THE BREAKPOINT IN A PATIENT WITH A CONSTITUTIONAL TRANSLOCATION T(1,13) (Q22,Q12) AND GANGLIONEUROBLASTOMA	ONCOGENE			English	Article							SOMATIC-CELL HYBRID; NEURO-BLASTOMA; HUMAN NEUROBLASTOMAS; WILMS-TUMOR; RAPID ISOLATION; HUMAN GENOME; SHORT ARM; GENE; RETINOBLASTOMA; HETEROZYGOSITY	We describe the cytogenetic and molecular characterization of a t(1;13)(q22;q12) constitutional rearrangement occurring in a patient with a relatively benign form of neuroblastoma, called gangtioneuroblastoma. Somatic cell hybrids were generated between mouse 3T3 cells and a lymphoblastoid cell line from this patient, D.G. One isolated subclone, DGF27C11, contained the derivative chromosome, 1pter-q22 = 13q12-qter, but no other material from either chromosome 1 or 13. Using available DNA probes the 13 breakpoint was assigned proximal to all reported markers. In order to generate flanking markers to define this translocation further, an Alu polymerase chain reaction library was constructed from a somatic cell hybrid containing only the proximal, 13pter-13q14, region of chromosome 13. Seven unique sequences have been isolated from the library, three of which lie below and four of which lie above the 13q12 breakpoint. More precise mapping of the distal markers was achieved using a panel of somatic cell hybrids with overlapping deletions of chromosome 13. The paucity of probes in the 1q22 region has made a precise assignment of this breakpoint difficult, however it has been shown to lie distal to c-SKI and proximal to APOA2. This refined characterization of the breakpoint is a prerequisite for its cloning, which may yield genes important in the pathogenesis of ganglioneuroblastoma.	INST CHILD HLTH,IMPERIAL CANC RES FDN,MOLEC ONCOL GRP,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND	University of London; University College London				Cowell, John/0000-0002-2079-5950				BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BROOKSWILSON AR, 1990, GENOMICS, V7, P614, DOI 10.1016/0888-7543(90)90207-B; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; COLE CG, 1991, GENOMICS, V10, P816, DOI 10.1016/0888-7543(91)90468-T; COTTER FE, 1991, GENOMICS, V9, P473, DOI 10.1016/0888-7543(91)90413-9; COTTER FE, 1990, GENOMICS, V7, P257, DOI 10.1016/0888-7543(90)90548-9; COWELL JK, 1980, J NATL CANCER I, V65, P955; COWELL JK, 1989, CYTOGENET CELL GENET, V52, P1, DOI 10.1159/000132827; COWELL JK, 1986, HUMAN CYTOGENETICS P, P202; DRYJA TP, 1984, HUM GENET, V65, P320, DOI 10.1007/BF00291555; FLOYDSMITH G, 1986, IMMUNOGENETICS, V24, P171; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GILBERT F, 1984, CANCER RES, V44, P5444; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GRUNDY P, 1988, NATURE, V336, P375; GUZZETTA V, 1991, GENOMICS, V9, P31, DOI 10.1016/0888-7543(91)90217-3; HIGGINS MJ, 1989, MOL CELL BIOL, V9, P1; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; HUNT JD, 1990, GENE CHROMOSOME CANC, V2, P137, DOI 10.1002/gcc.2870020210; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KUSHNER BH, 1986, CANCER-AM CANCER SOC, V57, P1887, DOI 10.1002/1097-0142(19860501)57:9<1887::AID-CNCR2820570931>3.0.CO;2-7; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MIDDLETONPRICE HR, 1988, HUM GENET, V79, P283, DOI 10.1007/BF00366253; MITCHELL CD, 1991, ONCOGENE, V6, P89; MITCHELL CD, 1989, ONCOGENE, V4, P253; MOORE JW, 1986, HUM GENET, V72, P297, DOI 10.1007/BF00290952; MOORHEAD PS, 1980, ADV NEUROBLASTOMA RE, P109; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; NAGANO H, 1980, JPN J HUM GENET, V25, P39, DOI 10.1007/BF01876544; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; OCONNELL P, 1989, SCIENCE, V244, P1087, DOI 10.1126/science.2543077; RAY PN, 1985, NATURE, V318, P672, DOI 10.1038/318672a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SANGER WG, 1984, CANCER GENET CYTOGEN, V11, P153, DOI 10.1016/0165-4608(84)90109-2; SCHEFFER H, 1986, CYTOGENET CELL GENET, V52, P971; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SUZUKI T, 1989, CANCER RES, V49, P1095; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADEY RB, 1990, ONCOGENE, V5, P901; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	55	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1595	1602						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630820				2022-12-28	WOS:A1992JE81300016
J	ISHIZAKA, Y; SHIMA, H; SUGIMURA, T; NAGAO, M				ISHIZAKA, Y; SHIMA, H; SUGIMURA, T; NAGAO, M			DETECTION OF PHOSPHORYLATED RETTPC ONCOGENE PRODUCT IN CYTOPLASM	ONCOGENE			English	Note							THYROID PAPILLARY CARCINOMAS; HUMAN TRK ONCOGENE; PROTO-ONCOGENE; CELL-LINE; TYROSINE KINASE; EXPRESSION; TRANSFORMATION; CLEAVAGE; ANTIGENS; CLONING	The product of the ret(TPC) oncogene, an activated form of the ret proto-oncogene found in human papillary thyroid carcinomas, was identified as a 57-kDa protein (p57retTPC) by Western blotting with a polyclonal antibody raised by an oligopeptide corresponding to the carboxy-terminal region of the ret proto-oncogene product. Subcellular fractionation experiments using NIH3T3 cell transformants induced by the ret(TPC) cDNA showed that p57retTPC was localized in a soluble cytoplasmic fraction, whereas the ret proto-oncogene products expressed in a neuroblastoma cell line were present in a membrane fraction. Immunostaining also demonstrated that p57retTPC is localized in the cytoplasm. Immunoprecipitation with antiphosphotyrosine antibody followed by Western blotting revealed that p57retTPC is constitutively phosphorylated, whereas the ret proto-oncogene products are not. These findings suggest that p57retTPC has an abererant tyrosine kinase activity resulting in autophosphorylation associated with change in its location.	NATL CANC CTR,RES INST,DIV CARCINOGENESIS,TSUKIJI 5,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DEGRAAF FK, 1978, BIOCHEMISTRY-US, V17, P1137, DOI 10.1021/bi00599a031; DONGHI R, 1989, ONCOGENE, V4, P521; EMORI Y, 1986, J BIOL CHEM, V261, P9472; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARLOW E, 1988, ANTIBODIES LABORATOR; IKEDA I, 1990, ONCOGENE, V5, P1291; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; ISHIZAKA Y, 1987, CARCINOGENESIS, V8, P1575, DOI 10.1093/carcin/8.11.1575; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ISHIZAKA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1331, DOI 10.1016/0006-291X(91)91719-S; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ITOH F, 1989, Tumor Research, V24, P1; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASAKI H, 1985, J MOL BIOL, V182, P217, DOI 10.1016/0022-2836(85)90340-7; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NODA T, 1987, J VIROL, V61, P2253, DOI 10.1128/JVI.61.7.2253-2263.1987; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SOZZI G, 1991, ONCOGENE, V6, P339; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4	32	50	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1441	1444						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620555				2022-12-28	WOS:A1992HZ97100025
J	DANISH, R; ELAWAR, O; WEBER, BL; LANGMORE, J; TURKA, LA; RYAN, JJ; CLARKE, MF				DANISH, R; ELAWAR, O; WEBER, BL; LANGMORE, J; TURKA, LA; RYAN, JJ; CLARKE, MF			C-MYB EFFECTS ON KINETIC EVENTS DURING MEL CELL-DIFFERENTIATION	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; FRIEND-ERYTHROLEUKEMIA CELLS; HUMAN LYMPHOCYTES-T; ERYTHROID-DIFFERENTIATION; GENE-EXPRESSION; GLOBIN GENES; V-MYB; TRANSFORMING GENE; DNA-POLYMERASE; MESSENGER-RNA	During dimethylsulfoxide (DSMO)-induced differentation of Friend mouse erythroleukemia (MEL) cells there is a biphasic fall in c-myb mRNA levels. We have previously shown that constitutive expression of c-myb blocks differentiation. To delineate more accurately the point at which Myb blocks differentiation, MEL cells were transfected with a human c-myb construct under the control of the beta-globin promoter and enhancers. In concert with endogenous DMSO-induced globin transcription during MEL cell differentiation, the beta-globin c-myb transcription unit of the transfected plasmid is activated after 3-5 days of culture in media containing DMSO. Here we describe c-myb-transformed MEL clones which undergo delayed expression of the exogenous c-myb following 3-5 days of culture in DMSO. In contrast to wild-type MEL cells, both clones failed to display phenotypic markers of differentiation and continued to proliferate for up to 10 days of culture. These data suggest that the late fall in c-myb levels may be required in order for differentiation to occur. Additionally, we suggest that constitutive expression of c-myb does not block early commitment events such as activation of histone Hl', subsequent chromatin condensation, and alteration of proliferation-related gene expression. Taken together, these results show that c-myb acts very late in the process of differentiation.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,C570 MSRB II,1150 W MED CTR DR,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NCI NIH HHS [CA46657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFFOLTER M, 1987, MOL CELL BIOL, V7, P3663, DOI 10.1128/MCB.7.10.3663; ALONSO A, 1988, EMBO J, V7, P3003, DOI 10.1002/j.1460-2075.1988.tb03163.x; APPELS R, 1972, J MOL BIOL, V70, P425, DOI 10.1016/0022-2836(72)90550-5; BALCAREK JM, 1983, J BIOL CHEM, V258, P622; BANCHEV T, 1988, EXP CELL RES, V17, P1; BEHRINGER RR, 1987, P NATL ACAD SCI USA, V84, P7056, DOI 10.1073/pnas.84.20.7056; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BERGMANN DG, 1981, J VIROL, V40, P450, DOI 10.1128/JVI.40.2.450-455.1981; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BOETTIGER D, 1984, J VIROL, V49, P841, DOI 10.1128/JVI.49.3.841-847.1984; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DOENECKE D, 1986, J MOL BIOL, V187, P461, DOI 10.1016/0022-2836(86)90446-8; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GJERSET R, 1982, P NATL ACAD SCI-BIOL, V79, P2333, DOI 10.1073/pnas.79.7.2333; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; GUSELLA JF, 1980, BLOOD, V56, P481; GUSELLA JF, 1982, J CELL PHYSIOL, V113, P179, DOI 10.1002/jcp.1041130127; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUBER HE, 1987, J BIOL CHEM, V262, P16224; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KEPPEL F, 1977, P NATL ACAD SCI USA, V74, P653, DOI 10.1073/pnas.74.2.653; KEUHL WM, 1988, CURR TOP MICROBIOL I, V141, P318; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LENNOX RW, 1984, HISTONE GENES STRUCT, P373; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PRAGNELL IB, 1977, EXP CELL RES, V108, P269, DOI 10.1016/S0014-4827(77)80034-7; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROCHE J, 1985, NATURE, V314, P197, DOI 10.1038/314197a0; ROSS J, 1972, P NATL ACAD SCI USA, V69, P3620, DOI 10.1073/pnas.69.12.3620; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; RUIZCARRILLO A, 1976, ARCH BIOCHEM BIOPHYS, V174, P273, DOI 10.1016/0003-9861(76)90346-5; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; SMITH BJ, 1984, EUR J BIOCHEM, V138, P309, DOI 10.1111/j.1432-1033.1984.tb07916.x; SOUZA LM, 1980, J VIROL, V36, P325, DOI 10.1128/JVI.36.2.325-336.1980; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON ML, 1958, J BIOPHYS BIOCHEM CY, V4, P475, DOI 10.1083/jcb.4.4.475; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	66	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					901	907						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1533276				2022-12-28	WOS:A1992HP64200009
J	DEGROOT, RP; MEIJER, I; VANDENBRINK, S; MUMMERY, C; KRUIJER, W				DEGROOT, RP; MEIJER, I; VANDENBRINK, S; MUMMERY, C; KRUIJER, W			DIFFERENTIAL REGULATION OF JUNB AND JUND BY ADENOVIRUS TYPE-5 AND TYPE-12 E1A-PROTEINS	ONCOGENE			English	Note							EMBRYONAL CARCINOMA-CELLS; CELLULAR TRANSCRIPTION FACTOR; C-HA-RAS; PROTO-ONCOGENE; RESPONSE ELEMENT; TRANS-ACTIVATION; MESSENGER-RNAS; FACTOR FAMILY; E1A PRODUCTS; GENE FAMILY	The genes of the Jun family encode components of the TPA-inducible transcription factor AP-1. These genes are induced by a wide variety of extracellular stimuli, such as growth factors, phorbol esters and activators of protein kinase A. We have previously shown that the adenovirus type 5 E1A protein (E1A5) induces c-jun and junB expression in a number of different cell types. In this paper we show that the third member of the Jun family junD, is also strongly induced by E1A5. Multiple sequences in the junB and junD promoters are responsible for the effects of E1A5. By contrast, adenovirus type 12 E1A (E1A12), like retinoic acid (RA), strongly induces c-jun expression, while expression of junB and junD is not altered. Interestingly, E1A12 expression leads to complete differentiation of P19 EC cells, comparable to the effect of RA on these cells, while E1A5-expressing cells are only partially differentiated.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS; LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Leiden University; Leiden University - Excl LUMC				Mummery, Christine/0000-0002-4549-6535				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BUCKBINDER L, 1989, EMBO J, V8, P4239, DOI 10.1002/j.1460-2075.1989.tb08609.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; FRISCH SM, 1990, ONCOGENE, V5, P75; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; Imler J L, 1989, Prog Growth Factor Res, V1, P69, DOI 10.1016/0955-2235(89)90001-X; JALINOT P, 1988, P NATL ACAD SCI USA, V85, P2484, DOI 10.1073/pnas.85.8.2484; JONES N, 1979, P NATL ACAD SCI USA, V79, P3655; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P592; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEZA MA, 1988, J VIROL, V62, P3003, DOI 10.1128/JVI.62.8.3003-3013.1988; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MEIJER I, 1991, ONCOGENE, V6, P911; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; REES AR, 1979, NATURE, V281, P309, DOI 10.1038/281309a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1989, ONCOGENE, V4, P707; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; YANG-YEN H-F, 1990, New Biologist, V2, P351; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	55	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2357	2361						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1837351				2022-12-28	WOS:A1991GX73500027
J	SCHAFER, R; NIRKKO, AC; AMBUHL, PM; GRZESCHIK, KH; SCHWARTEWALDHOFF, I				SCHAFER, R; NIRKKO, AC; AMBUHL, PM; GRZESCHIK, KH; SCHWARTEWALDHOFF, I			EVIDENCE FOR HUMAN DNA-MEDIATED TRANSFER OF THE SUPPRESSED PHENOTYPE INTO MALIGNANT CHINESE-HAMSTER CELLS	ONCOGENE			English	Article							DIPLOID MOUSE FIBROBLASTS; HA-RAS ONCOGENE; TRANSFORMED PHENOTYPE; GENETIC-ANALYSIS; RB GENE; TUMOR SUPPRESSION; PARTIAL REVERSION; CARCINOMA-CELLS; TRANSGENIC MICE; SRC GENE	Genetic suppression of the neoplastic phenotype has been demonstrated in somatic cell hybrids between tumor and normal cells. Suppression in whole-cell and microcell hybrids cannot, as yet, be attributed to specific elements defined at the molecular level. To identify a gene capable of suppressing the neoplastic phenotype, we have introduced DNA of normal human cells into tumorigenic Chinese hamster Wg3-h-o cells. Primary and secondary transfectants which exhibit the suppressed phenotype similar to Wg3-h-o x embryonic fibroblast hybrids were selected. The cells require serum growth factors and anchorage for proliferation in vitro and show a reduced tumorigenicity in nude mice. Transferred human DNA segments were molecularly cloned from a secondary transfectant. Indirect evidence suggests that the cloned human DNA is associated with the expression of the suppressed phenotype.	UNIV MARBURG,INST HUMAN GENET,W-3550 MARBURG,GERMANY	Philipps University Marburg	SCHAFER, R (corresponding author), UNIV ZURICH,INST PATHOL,DIV CANC RES,SCHMELZBERGSTR 12,CH-8091 ZURICH,SWITZERLAND.							BAKER RF, 1983, P NATL ACAD SCI-BIOL, V80, P1174, DOI 10.1073/pnas.80.5.1174; BARDWELL L, 1989, MUTAGENESIS, V4, P245, DOI 10.1093/mutage/4.4.245; BECHER R, 1983, CANCER GENET CYTOGEN, V9, P173, DOI 10.1016/0165-4608(83)90038-9; BENEDICT WF, 1984, CANCER RES, V44, P3471; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; CULINE S, 1989, INT J CANCER, V44, P990; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DYSON PJ, 1982, CELL, V30, P491, DOI 10.1016/0092-8674(82)90246-X; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HOWELL N, 1981, CYTOGENET CELL GENET, V31, P214, DOI 10.1159/000131651; HSU TC, 1964, J NATL CANCER I, V32, P857; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Iten E, 1989, Recent Results Cancer Res, V113, P78; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KOZAK CA, 1977, EXP CELL RES, V105, P109, DOI 10.1016/0014-4827(77)90156-2; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MARSHALL CJ, 1980, EXP CELL RES, V127, P373, DOI 10.1016/0014-4827(80)90442-5; MIKKELSEN T, 1990, CELL GROWTH DIFFER, V1, P201; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OSHIMURA M, 1989, P AM ASSOC CANC RES, V30, P786; PADMANABHAN R, 1987, MOL CELL BIOL, V7, P1894, DOI 10.1128/MCB.7.5.1894; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; PIZON V, 1988, ONCOGENE, V3, P201; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1981, CANCER RES, V41, P1214; SCHAFER R, 1983, CANCER RES, V43, P2240; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P9099, DOI 10.1073/pnas.84.24.9099; STOLER A, 1985, P NATL ACAD SCI USA, V82, P570, DOI 10.1073/pnas.82.2.570; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TRENT JM, 1981, CANCER GENET CYTOGEN, V3, P279, DOI 10.1016/0165-4608(81)90037-6; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	56	5	5	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2221	2228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766670				2022-12-28	WOS:A1991GX73500007
J	ASHTONRICKARDT, PG; WYLLIE, AH; BIRD, CC; DUNLOP, MG; STEEL, CM; MORRIS, RG; PIRIS, J; ROMANOWSKI, P; WOOD, R; WHITE, R; NAKAMURA, Y				ASHTONRICKARDT, PG; WYLLIE, AH; BIRD, CC; DUNLOP, MG; STEEL, CM; MORRIS, RG; PIRIS, J; ROMANOWSKI, P; WOOD, R; WHITE, R; NAKAMURA, Y			MCC, A CANDIDATE FAMILIAL POLYPOSIS GENE IN 5Q.21, SHOWS FREQUENT ALLELE LOSS IN COLORECTAL AND LUNG-CANCER	ONCOGENE			English	Article							ADENOMATOUS POLYPOSIS; CHROMOSOME-5; CARCINOMAS; MUTATIONS; TUMORIGENESIS; DELETIONS; TUMORS; RFLP; COLI	MCC is a gene located within human chromosome band 5q.21 that shows somatically acquired mutations in colorectal cancer, and may be identical to the gene responsible for inheritance of familial adenomatous polyposis. Here we demonstrate that alleles contiguous with or within MCC are deleted in a high proportion of sporadic colorectal carcinomas. Of 106 carcinomas that were informative concurrently at close-flanking sites both centromeric and telomeric to MCC, 41.5% showed acquired allele loss contiguous with MCC. Evidence is presented to show that the true frequency of loss of MCC alleles is higher still. In contrast, allele losses in chromosome 5 that were incompatible with involvement of MCC were very rare (2% of a total series of 201 informative tumours). Interstitial deletion was the commonest mechanism of allele loss, and L5.71-3, a probe known to include coding sequences of MCC, marks the most consistently deleted site. Moreover mapping of chromosome break-points with six probes within 5q.21 sited the common critical deletion in a 2.5 Mb region which included L5.71-3. However use of L5.71-3 itself suggested that critical deleted regions may lie on either side of the probed sequence. The simplest explanation for this unexpected finding is that MCC itself is the essential deleted gene, the lost exons lying sometimes centromeric to, sometimes telomeric to and occasionally within the region detected by L5.71-3. Tumours in which MCC-related alleles were lost by interstitial deletion were in general larger than those with other mechanisms of acquired homozygosity (e.g. mitotic recombination), but there were no other obvious associations with clinicopathological features. Between 20% and 25% of lung cancers also showed acquired allele losses contiguous with MCC. The significance of this observation is still to be determined, as lung tumours show allele losses at many other sites, but the specificity of the probes used in this study does establish that the 5q.21 losses in these tumours are compatible with involvement of MCC.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; MED RES COUNCIL HUMAN GENET UNIT,EDINBURGH,SCOTLAND; UNIV UTAH,MED CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,TOKYO 170,JAPAN	University of Edinburgh; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Japanese Foundation for Cancer Research			Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851; Wood, Rachael/0000-0003-4453-623X				ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; CAREY FA, 1990, CANCER, V65, P2266, DOI 10.1002/1097-0142(19900515)65:10<2266::AID-CNCR2820651018>3.0.CO;2-R; CASTAGNOLI A, 1987, NUCLEIC ACIDS RES, V15, P866, DOI 10.1093/nar/15.2.866; DEVILEE P, 1991, ONCOGENE, V6, P1705; DOZIER C, 1986, NUCLEIC ACIDS RES, V14, P1928, DOI 10.1093/nar/14.4.1928; DUNLOP MG, 1990, AM J HUM GENET, V47, P982; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HAMILTON SR, 1990, HEREDITARY COLORECTA, P315; HOSHINO Y, 1991, BIOCHEM BIOPH RES CO, V174, P298, DOI 10.1016/0006-291X(91)90520-H; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MIYAKI M, 1990, CANCER RES, V50, P7166; OKAMOTO M, 1990, HUM GENET, V85, P595; PURDIE CA, 1991, AM J PATHOL, V138, P807; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TOPS CM, 1989, LANCET, V2, P12361; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; XIANG K, 1987, NUCLEIC ACIDS RES, V15, P7654, DOI 10.1093/nar/15.18.7654	26	75	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1881	1886						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656365				2022-12-28	WOS:A1991GX11800022
J	HAMANN, U; WENZEL, A; FRANK, R; SCHWAB, M				HAMANN, U; WENZEL, A; FRANK, R; SCHWAB, M			THE MYCN PROTEIN OF HUMAN NEUROBLASTOMA-CELLS IS PHOSPHORYLATED BY CASEIN KINASE-II IN THE CENTRAL REGION AND AT SERINE 367	ONCOGENE			English	Article							SV40 LARGE-T; RETINOBLASTOMA SUSCEPTIBILITY GENE; EPIDERMAL GROWTH-FACTOR; BALB/C 3T3 FIBROBLASTS; AMINO-ACID-SEQUENCE; HUMAN C-MYC; N-MYC; DNA-BINDING; ADENOVIRUS E1A; NUCLEAR-LOCALIZATION	The MYCN gene has been implicated in certain neuronal tumours, such as neuroblastomas and retinoblastomas. These tumours express high levels of mRNA and protein of MYCN as a result of amplification. MYCN encodes a short-lived nuclear phosphoprotein whose function has not yet been elucidated. This study was undertaken to determine the pattern of MYCN protein (pMYCN) phosphorylation in human neuroblastoma cells. We report that pMYCN is phosphorylated in vitro by purified casein kinase II (CK-II). Two-dimensional phosphopeptide maps showed that most of the phosphopeptides of pMYCN phosphorylated in vitro by CK-II correspond to those phosphorylated in vivo. Fine mapping of the phosphorylation sites was performed using two synthetic MYCN peptides corresponding to pMYCN CK-II consensus sequences. Both peptides were found to be phosphorylated by CK-II and competitively inhibited CK-II phosphorylation of pMYCN in vitro. Thus, we have localized two major CK-II phosphorylation sites in pMYCN, one to the highly acidic central region and the second to serine 367 proximal to the C-terminus. Our data demonstrate that pMYCN is a physiological substrate for CK-II and, since CK-II activity is stimulated in response to mitogens, CK-II phosphorylation of pMYCN may, therefore, represent one signal transduction pathway used by neuroblastoma cells.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	HAMANN, U (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST EXPTL PATHOL,W-6900 HEIDELBERG,GERMANY.							ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BISTER K, 1987, ONCOGENE, V1, P97; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CAVALIERI F, 1988, ONCOGENE, V2, P289; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; FIGGE J, 1988, NATURE, V334, P109, DOI 10.1038/334109a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FIRZLAFF J M, 1989, New Biologist, V1, P44; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1987, ANN REV BIOCH, V56, P567; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MA A, 1989, GROWTH REGULATION CA, V2, P17; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINNA LA, 1979, BIOCHEM BIOPH RES CO, V87, P114, DOI 10.1016/0006-291X(79)91654-1; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SPECTOR DL, 1987, ONCOGENE, V1, P5; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; WALTON GM, 1983, J BIOL CHEM, V258, P4440; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	66	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1745	1751						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923500				2022-12-28	WOS:A1991GX11800004
J	LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP				LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP			ACCUMULATION OF THE C-MOS PROTEIN IS CORRELATED WITH POSTNATAL-DEVELOPMENT OF SKELETAL-MUSCLE	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; PROTOONCOGENE PRODUCT; ONCOGENE PRODUCT; MOUSE-TISSUES; GENE-PRODUCT; EXPRESSION; SEQUENCE; CELLS; TRANSCRIPTS; HOMOLOG	Previously we reported that c-mos proto-oncogene RNA was developmentally up-regulated during post-natal maturation of the rat skeletal muscle. Using two different site-directed affinity-purified antipeptide antibodies we can observe that c-mos product (p43 c-mos) accumulates increasingly during post-natal development of the skeletal muscle and exhibits protein kinase activity. We find that in adult rat p43 c-mos is 10-fold higher in skeletal muscle than in ovaries, and 20- to 40-fold higher than in heart, lung, testis and liver, and may represent about 0.005% of the total soluble proteins. In addition adult skeletal muscle from Xenopus, mouse and man was found to contain p43 c-mos. These data argue in favour of a novel muscle-specific function of c-mos.			LEIBOVITCH, SA (corresponding author), INST GUSTAVE ROUSSY,CNRS,URA 126,UA1158,ONCOL MOLEC LAB,39 RUE C DESMOULINS,F-94800 VILLEJUIF,FRANCE.		Lenormand, Jean-Luc/ABF-3850-2021; Lenormand, Jean-Luc/M-6644-2014	Lenormand, Jean-Luc/0000-0002-2766-9180				BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARRINGTON JC, 1987, NUCLEIC ACIDS RES, V15, P10066, DOI 10.1093/nar/15.23.10066; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4510; HERZOG NK, 1989, ONCOGENE, V4, P1307; HUNTER T, 1986, ENZYMES, V7, P181; KURUTA N, 1989, EMBO J, V8, P457; LEIBOVITCH MP, 1987, EXP CELL RES, V170, P80, DOI 10.1016/0014-4827(87)90118-2; LEIBOVITCH SA, 1986, EXP CELL RES, V166, P526, DOI 10.1016/0014-4827(86)90497-0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0	35	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1617	1622						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1833718				2022-12-28	WOS:A1991GX27400017
J	CHAMPIONARNAUD, P; GESNEL, MC; FOULKES, N; RONSIN, C; SASSONECORSI, P; BREATHNACH, R				CHAMPIONARNAUD, P; GESNEL, MC; FOULKES, N; RONSIN, C; SASSONECORSI, P; BREATHNACH, R			ACTIVATION OF TRANSCRIPTION VIA AP-1 OR CREB REGULATORY SITES IS BLOCKED BY PROTEIN TYROSINE PHOSPHATASES	ONCOGENE			English	Article							HUMAN ESTROGEN-RECEPTOR; EPIDERMAL GROWTH-FACTOR; ROUS-SARCOMA VIRUS; HUMAN-PLACENTA; CYCLIC-AMP; RAT FIBROBLASTS; MESSENGER-RNA; C-JUN; GENE; KINASE	Transcriptional activation endowed by AP-1 or CREB binding sites can be significantly reduced in transient transfection tests by expression from the corresponding cloned cDNAs of protein tyrosine phosphatases. Both the protein tyrosine phosphatase 1B and the T-cell protein tyrosine phosphatase, as well as a novel form of this latter protein generated by an alternative splicing event show this activity. The effect is specific, as none of the protein tyrosine phosphatases alters transcriptional activation by either the estrogen receptor, GAL4, or a GAL4-VP16 fusion protein. Furthermore, the activities of the SV40 early gene promoter and a Moloney murine leukemia virus long terminal repeat promoter are not reduced by these phosphatases. We conclude that a yet to be identified protein phosphorylated on tyrosine is necessary for a full transcriptional response via AP-1 or CREB binding sites.	UNIV NANTES,FAC SCI & TECH,F-44035 NANTES,FRANCE; CHR NANTES,INSERM,U211,F-44035 NANTES,FRANCE; FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67085 STRASBOURG,FRANCE	Nantes Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	BREATHNACH, R (corresponding author), UNIV NANTES,FAC SCI & TECH,F-44035 NANTES,FRANCE.		Breathnach, Richard/K-7599-2015					ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P9035; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1990, ONCOGENE, V5, P423; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	50	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1203	1209						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650442				2022-12-28	WOS:A1991GV26000016
J	FUTREAL, PA; BARRETT, JC				FUTREAL, PA; BARRETT, JC			FAILURE OF SENESCENT CELLS TO PHOSPHORYLATE THE RB PROTEIN	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN-DIPLOID FIBROBLASTS; SYRIAN-HAMSTER TUMORS; CELLULAR SENESCENCE; PRODUCT; EXPRESSION; CYCLE; IDENTIFICATION; SUPPRESSION; CARCINOMA	The product of the RB susceptibility gene has been shown to be differentially phosphorylated during the cell cycle, suggesting a role in the regulation of cell cycle progression. We examined the expression and phosphorylation status of the RB protein in senescent Syrian hamster embryo cells. Both phosphorylated and unphosphorylated forms of the RB protein were observed in cells at early passages; however, only unphosphorylated RB protein was found in senescent cells. When nonsenescent cells at low population doubling levels were made quiescent by reducing the serum concentration of the media, the RB protein in these cells was mostly in the unphosphorylated protein in these cells was mostly in the unphosphorylated form. When stimulated with serum, phosphorylation of the RB protein occurred between 10-20 h after stimulation, which corresponded with the induction of DNA synthesis. Senescent cells, in contrast, did not show any phosphorylation of the RB protein in response to serum. In addition, cell lines that had escaped cellular senescence at various stages of neoplastic progression were examined; all 25 cell lines examined expressed RB protein, which was phosphorylated normally. These results suggest that the RB protein plays a role in cellular senescence with phosphorylation status determining this role. Factors controlling this phosphorylation are potential key factors in controlling cellular life span in culture.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill	FUTREAL, PA (corresponding author), NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709, USA.							BARRETT JC, 1987, MECHANISMS ENV CARCI, P73; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6464; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRISTOFALO VJ, 1985, TESTING THEORIES AGI, P201; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIORDANO T, 1989, EXP CELL RES, V185, P399, DOI 10.1016/0014-4827(89)90310-8; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1980, ANN REV GERONTOLOGY, V1, P26; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; OSHIMURA M, 1988, CANCER RES, V48, P1623; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; Smith J R, 1990, Adv Cancer Res, V54, P63, DOI 10.1016/S0065-230X(08)60808-8; SMITH JR, 1989, GENOME, V31, P386, DOI 10.1139/g89-058; SMITH JR, 1989, EXP GERONTOL, V24, P377, DOI 10.1016/0531-5565(89)90045-4; STEIN GH, 1986, P NATL ACAD SCI USA, V83, P9030, DOI 10.1073/pnas.83.23.9030; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; XU HJ, 1989, ONCOGENE, V4, P807; [No title captured]	45	74	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1109	1113						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861860				2022-12-28	WOS:A1991GV26000003
J	CHAMPIONARNAUD, P; RONSIN, C; GILBERT, E; GESNEL, MC; HOUSSAINT, E; BREATHNACH, R				CHAMPIONARNAUD, P; RONSIN, C; GILBERT, E; GESNEL, MC; HOUSSAINT, E; BREATHNACH, R			MULTIPLE MESSENGER-RNAS CODE FOR PROTEINS RELATED TO THE BEK FIBROBLAST GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							TYROSINE KINASE; CELL-GROWTH; NUCLEOTIDE-SEQUENCE; GENE FAMILY; FACTOR CDNA; EXPRESSION; CLONING; DIFFERENTIATION; MEMBER; FORMS	The BEK transmembrane protein tyrosine kinase is a receptor for both acidic and basic fibroblast growth factors. We identify several different transcripts which code for BEK-related proteins. These proteins differ from BEK in regions expected to control receptor activity. Thus, some of the proteins have altered extracellular, ligand-binding domains, and others an altered carboxyterminal tail. Still other forms of BEK differ only in their juxtamembrane domains. Sequencing of parts of the BEK gene shows that alternative splicing of the premessenger can account for at least some of this diversity. In particular, an apparently tissue specific, mutually exclusive splicing of two internal exons permits both the previously described K-SAM mRNA and the BEK mRNA to be derived from the same premessenger.	CHR NANTES, INSERM, U211, PLATEAU TECH, QUAI MONCOUSU, F-44035 NANTES 01, FRANCE; UNIV NANTES, FAC SCI, F-44035 NANTES, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite	BREATHNACH, R (corresponding author), CHR NANTES, INSERM, U211, PLATEAU TECH, QUAI MONCOUSU, F-44035 NANTES 01, FRANCE.		Breathnach, Richard/K-7599-2015					ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JEANNY JC, 1987, EXP CELL RES, V171, P63, DOI 10.1016/0014-4827(87)90251-5; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; Sambrook J, 1989, MOL CLONING LABORATO; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					979	987						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648704				2022-12-28	WOS:A1991GU62200012
J	LIN, YZJ; CLINTON, GM				LIN, YZJ; CLINTON, GM			A SOLUBLE-PROTEIN RELATED TO THE HER-2 PROTOONCOGENE PRODUCT IS RELEASED FROM HUMAN BREAST-CARCINOMA CELLS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; FACTOR STIMULATE PHOSPHORYLATION; NEU ONCOGENE; EGF RECEPTOR; AMPLIFICATION; EXPRESSION; ADENOCARCINOMA; OVEREXPRESSION; MECHANISMS	Amplified expression of p185HER-2, the protein product of the HER-2/neu proto-oncogene, appears to be involved in carcinogenesis of human mammary epithelial cells. Our data suggest that an extracellular 130 Kda glycoprotein released from breast carcinoma cells may be related to the ectodomain of p185HER-2: (1) Both cellular p185HER-2 and extracellular p130, when reduced and alkylated, reacted with antipeptide antibody against the N-terminus of the HER-2 protein [alpha-N(HER-21)] and reactivity was blocked by cognate peptide; (2) Neither p130 nor other extracellular proteins reacted with antiserum against the C-terminus of p185HER-2 [alpha-C(HER-2)]; (3) Partial proteolysis of p185HER-2 generated an immunoreactive fragment of 130 kDa that was similar to extracellular p130; (4) Both p130 and p185HER-2 contained carbohydrate that bound to Con-A Sepharose; (50 The amount of p130 released from breast cells corresponded to the levels of expression of cellular p185HER-2. Release of the ectodomain of p185HER-2 from breast carcinoma cells may be involved in their malignant growth and may be a useful marker for assessing the expression of p185HER-2 in human tumors.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL CANCER INSTITUTE [R01CA039641] Funding Source: NIH RePORTER; NCI NIH HHS [CA39641] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BERGER MS, 1988, CANCER RES, V48, P1238; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DRYLAND A, 1986, J CHEM SOC PERK T 1, P125, DOI 10.1039/p19860000125; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN YHJ, 1990, MOL CELL ENDOCRINOL, V69, P111, DOI 10.1016/0303-7207(90)90004-R; LOUGHNAN MS, 1988, P NATL ACAD SCI USA, V85, P3115, DOI 10.1073/pnas.85.9.3115; MCDONALD RG, 1989, J BIOL CHEM, V264, P3256; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; ZHOU DJ, 1987, CANCER RES, V47, P6123	25	91	97	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					639	643						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1674366				2022-12-28	WOS:A1991FR93900020
J	TOURAY, M; RYAN, F; SAURER, S; MARTIN, F; JAGGI, R				TOURAY, M; RYAN, F; SAURER, S; MARTIN, F; JAGGI, R			MOS-INDUCED INHIBITION OF GLUCOCORTICOID RECEPTOR FUNCTION IS MEDIATED BY FOS	ONCOGENE			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; DNA-BINDING DOMAIN; GENE-EXPRESSION; C-FOS; PHORBOL ESTER; RAS ONCOGENE; DEPENDENT TRANSCRIPTION; STEROID-HORMONES; V-MOS	Activation of glucocorticoid hormone-dependent transcription involves the binding of the glucocorticoid hormone to its receptor followed by a specific interaction of the hormone/receptor complex with glucocorticoid responsive elements in the promoter region of hormone-inducible genes. In stably transfected NIH3T3 cells expressing the oncogene product of v-mos or fos, the expression from two glucocorticoid responsive promoters, MMTV LTR and metallothionein IIA (Mt(IIA)), was shown to be impaired and was only transient. Cadmium-dependent Mt(IIA) gene expression was not affected by the expression of v-mos in the cells. In transiently transfected NIH3T3 cells constitutive fos expression also inhibited glucocorticoid hormone-induced expression from the MMTV LTR. However, co-expression of antisense fos (here referred to as sof) inhibited the down-regulatory effect of Fos on glucocorticoid induced gene expression. v-mos expression in NIH3T3 cells induces fos mRNA and functional fos product (Fos) as reflected by its ability to induce expression of a transiently transfected AP-1 dependent reporter plasmid. We show that sof expression inhibits the down-regulatory effect of mos on expression of a transiently transfected pMMTV LTR-CAT. Our findings, thus, strongly suggest that the inhibition of glucocorticoid receptor function in cells expressing the v-mos oncogene is mediated by Fos.	UNIV BERN, DEPT CLIN & EXPTL CANC RES, TIEFENAUSTR 120, CH-3004 BERN, SWITZERLAND; NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND	University of Bern; University College Dublin			Ryan, Fergus/B-8407-2012					ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BUETTI E, 1983, EMBO J, V2, P1423, DOI 10.1002/j.1460-2075.1983.tb01601.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HAMILTON BJ, 1989, P NATL ACAD SCI USA, V86, P597, DOI 10.1073/pnas.86.2.597; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAGGI R, 1989, CANCER RES, V49, pS2266; JAGGI R, 1988, J STEROID BIOCHEM, V29, P457, DOI 10.1016/0022-4731(88)90179-3; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; PRATT WB, 1988, J BIOL CHEM, V263, P267; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SALMONS B, 1986, GENE, V45, P215, DOI 10.1016/0378-1119(86)90257-X; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHUSTER WA, 1988, EMBO J, V7, P1721, DOI 10.1002/j.1460-2075.1988.tb03001.x; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; VASSALLI JD, 1976, CELL, V8, P271, DOI 10.1016/0092-8674(76)90011-8; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	59	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1991	6	2					211	217						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1847998				2022-12-28	WOS:A1991FZ13400005
J	STORM, SM; CLEVELAND, JL; RAPP, UR				STORM, SM; CLEVELAND, JL; RAPP, UR			EXPRESSION OF RAF FAMILY PROTOONCOGENES IN NORMAL MOUSE-TISSUES	ONCOGENE			English	Article									NCI,VIRAL PATHOL SECT,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CLAYCOMB WC, 1987, BIOCHEM J, V247, P701, DOI 10.1042/bj2470701; CLEVELAND JL, 1987, J IMMUNOL, V138, P3495; FREDRICKSON TN, 1988, AM J PATHOL, V131, P444; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KESHET E, 1988, ONCOGENE, V2, P235; LEGUELLEC R, 1988, NUCLEIC ACIDS RES, V16, P10357; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PERRIMON N, 1984, GENETICS, V108, P559; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, 1988, HDB ONCOGENES, P213; REDDY EPA, 1988, ONCOGENE HDB; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; Robaire B., 1988, P999; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	34	197	202	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					345	351						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690378				2022-12-28	WOS:A1990CW41500012
J	PARK, JG; REDDY, EP				PARK, JG; REDDY, EP			LARGE-SCALE MOLECULAR MAPPING OF HUMAN C-MYB LOCUS - C-MYB PROTOONCOGENE IS NOT INVOLVED IN 6Q- ABNORMALITIES OF LYMPHOID TUMORS	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; CELL-LINES ML-1; HUMAN CANCER; CYTOGENETIC CHARACTERIZATION; MYELOGENOUS LEUKEMIA; BURKITT-LYMPHOMA; TRANSLOCATION; GENE; DNA; RETINOBLASTOMA	Chromosomal abnormalities in the 6q region have been observed frequently in several T-cell and myeloid leukemias. Interestingly, this region was found to contain three cellular oncogenes, c-myb, c-fyn and c-ros. Several of the tumors that exhibit 6q- abnormalities have also been found to express high levels of c-myb and, in some cases, amplification of the c-myb gene, leading to the suggestion that this gene could tie in proximity to the deletions observed in these tumors. To determine if c-myb gene activation is associated with 6q- abnormalities, we developed a megabase map of the human c-myb locus using pulsed-field gel electrophoresis. We then examined the occurrence of abnormalities near the c-myb gene in several hematopoietic tumor cell lines containing well-characterized 6q- abnormalities. Our results show that no rearrangements or deletions occur within a region of 1.0 Mbp of the c-myb locus in these cell lines. However, several of the cell lines exhibited differential and partial methylation patterns which seem to be prevalent amongst different cell lines.	WISTAR INST, PHILADELPHIA, PA 19104 USA	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA21124, CAS52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009, P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLETTA C, 1987, SCIENCE, V235, P1064, DOI 10.1126/science.3469751; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; BROWN WRA, 1986, NATURE, V322, P477, DOI 10.1038/322477a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DASGUPTA P, 1989, ONCOGENE, V4, P1201; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GEMMILL RM, 1989, GENOMICS, V4, P28, DOI 10.1016/0888-7543(89)90310-8; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HAYATA I, 1975, IN VITRO CELL DEV B, V11, P361; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KATHELEEN G, 1986, SOM CELL MOL GEN, V12, P185; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MEESE E, 1989, GENE CHROMOSOME CANC, V1, P88, DOI 10.1002/gcc.2870010114; MITELMAN F, 1984, NATURE, V310, P325, DOI 10.1038/310325a0; MITELMAN F, 1983, CYTOGENET CELL GENET, V36, P1, DOI 10.1159/000131930; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; OHYASHIKI K, 1988, CANCER GENET CYTOGEN, V33, P83, DOI 10.1016/0165-4608(88)90053-2; OHYASHIKI K, 1986, CANCER RES, V46, P3642; OKADA M, 1990, CANCER GENET CYTOGEN, V48, P229, DOI 10.1016/0165-4608(90)90125-T; OSHIMURA HM, 1975, IN VITRO, V11, P361; OSHIMURA M, 1977, CANCER, V40, P1161, DOI 10.1002/1097-0142(197709)40:3<1161::AID-CNCR2820400327>3.0.CO;2-2; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; RABBITTS TH, 1988, TRENDS GENET, V4, P300, DOI 10.1016/0168-9525(88)90106-0; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SMITH SD, 1986, BLOOD, V67, P650; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TRENT JM, 1983, CANCER GENET CYTOGEN, V9, P177, DOI 10.1016/0165-4608(83)90039-0	40	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1603	1609						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630821				2022-12-28	WOS:A1992JE81300017
J	SLADEK, TL; JACOBBERGER, JW				SLADEK, TL; JACOBBERGER, JW			DEPENDENCE OF SV40 LARGE T-ANTIGEN CELL-CYCLE REGULATION ON T-ANTIGEN EXPRESSION LEVELS	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; SIMIAN VIRUS-40; FLOW-CYTOMETRY; RECOMBINANT RETROVIRUSES; INTRACELLULAR ANTIGENS; MOUSE FIBROBLASTS; TUMOR-ANTIGEN; P53; TRANSFORMATION; GENE	Simian virus 40 (SV40) large T antigen (Tag) expression results in reduced percentages of G1-phase cells and increased percentages of S- and G2 + M-phase cells in exponentially growing fibroblast populations as compared with identical cell populations not expressing Tag. This effect is the result of reduced G1 and increased G2 + M cell cycle phase durations caused by Tag [Sladek, T.L. & Jacobberger, J.W. (1992). J. Virol., 66, 1059-1065]. Using recombinant retroviruses to manipulate Tag expression over a 25-fold range, it is shown here that the magnitude of this cell cycle phenotype increases as a function of increasing intracellular Tag concentration. This effect of Tag on the cell cycle is not independent of negative regulation by cellular mechanisms since exponentially growing cell populations producing high and increasing levels of Tag, increase the fraction of cells residing in G1 and decrease the fraction in S and G2 + M as a function of cell density. Therefore, the data in this paper show, first, that Tag is a concentration-dependent, positive cell cycle regulator in exponentially proliferating cells and, second, that endogenous cellular mechanisms negatively regulating the cell cycle in response to cell density override the effect of Tag.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,2109 ADELBERT RD,CLEVELAND,OH 44106	Case Western Reserve University			Jacobberger, James/P-9183-2014	Jacobberger, James/0000-0002-3092-5157	NCI NIH HHS [CA43703] Funding Source: Medline; NHLBI NIH HHS [HL41945] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041945] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAISCH H, 1988, CYTOMETRY, V9, P325, DOI 10.1002/cyto.990090409; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CHANG SMW, 1987, MOL CELL BIOL, V7, P854, DOI 10.1128/MCB.7.2.854; COSENZA SC, 1991, J CELL PHYSIOL, V147, P231, DOI 10.1002/jcp.1041470207; CRAWFORD L, 1982, J VIROL, V41, P709, DOI 10.1128/JVI.41.2.709-709.1982; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEAN PN, 1987, CYCLE ANAL, P207; DEAN PN, 1990, FLOW CYTOMETRY SORTI, P415; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYLES J, 1986, J CELL SCI S, V4, P155; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JACOBBERGER JW, 1986, CYTOMETRY, V7, P356, DOI 10.1002/cyto.990070410; JACOBBERGER JW, 1989, FLOW CYTOMETRY ADV R, P305; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEHMAN JM, 1988, CYTOMETRY, V9, P52, DOI 10.1002/cyto.990090109; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LINNEY E, 1987, J VIROL, V61, P3248, DOI 10.1128/JVI.61.10.3248-3253.1987; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1986, VIROLOGY, V147, P206; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; SCHIMENTI KJ, 1992, CYTOMETRY, V13, P48, DOI 10.1002/cyto.990130109; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SLADEK TL, 1990, J VIROL, V64, P3135, DOI 10.1128/JVI.64.6.3135-3138.1990; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	38	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1305	1313						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620545				2022-12-28	WOS:A1992HZ97100008
J	KRAFT, AS; WANG, SS; XIANG, JL; POUNCEY, L; KIDD, VJ				KRAFT, AS; WANG, SS; XIANG, JL; POUNCEY, L; KIDD, VJ			REGULATION OF THE P58GTA CELL-DIVISION CONTROL-RELATED PROTEIN-KINASE DURING PHORBOL 12-MYRISTATE 13-ACETATE-INDUCED TERMINAL DIFFERENTIATION OF U937 CELLS	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; EXPRESSION; PHOSPHORYLATION; ONCOGENE; HL-60; INCREASE; CYCLE; AP-1	We describe the regulation of expression, activity and subcellular localization of a cell cycle control-related kinase, p58GTA, during the withdrawal from the cell cycle of U937 human leukemic cells induced by phorbol esters. Our studies indicate that steady-state mRNA, protein levels, transcription and subcellular localization of this kinase are affected in distinctly different manners by phorbol esters (phorbol 12-myristate 13-acetate, PMA). Steady-state mRNA levels increase dramatically within 1 h of PMA treatment, while steady-state protein levels increase only slightly. However, within 24 h of PMA treatment both steady-state p58GTA mRNA and protein levels decrease markedly. Assays of p58GTA protein kinase activity show that, even though steady-state protein levels are relatively constant, protein kinase activity increases within 30 min of PMA treatment, and then peaks at 2 h and 12 h after PMA treatment. Once again, p58GTA protein kinase activity decreases by 48 h to levels similar to unstimulated cells. These results suggest that the expression of the p58GTA protein kinase gene and, quite possibly, its post-translational modification are affected by phorbol esters in a complex manner.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA42533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; BUNNELL BA, 1990, SOMAT CELL MOLEC GEN, V16, P151, DOI 10.1007/BF01233045; BUNNELL BA, 1990, BIOCHEM BIOPH RES CO, V171, P196, DOI 10.1016/0006-291X(90)91376-4; EIPERS PG, 1991, GENOMICS, V11, P621, DOI 10.1016/0888-7543(91)90069-Q; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; KIDD VJ, 1991, CELL GROWTH DIFFER, V2, P85; KRAFT AS, 1987, ONCOGENE, V1, P111; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; POUNCEY L, 1991, SOMAT CELL MOLEC GEN, V17, P435, DOI 10.1007/BF01233167; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WILLIAM F, 1988, J CELL PHYSIOL, V137, P402, DOI 10.1002/jcp.1041370303; YEN A, 1987, CANCER RES, V47, P129	22	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					501	506						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549364				2022-12-28	WOS:A1992HK00500015
J	BEIMLING, P; MOELLING, K				BEIMLING, P; MOELLING, K			DIRECT INTERACTION OF CREB PROTEIN WITH 21 BP TAX-RESPONSE ELEMENTS OF HTLV-I LTR	ONCOGENE			English	Note							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANS-ACTIVATOR PROTEIN; DNA-BINDING PROTEINS; NUCLEAR FACTOR CREB; GENE-EXPRESSION; CYCLIC-AMP; TRANSCRIPTIONAL ACTIVATION; KINASE-A	The three 21-bp repeats (Tax-responsive elements) of the long terminal repeat (LTR) of the human T-cell leukemia virus (HTLV-I) mediates the response of the Tax protein. Ail three Tax-responsive elements (TREs) contain a TGACG motif, reminiscent of the CREB/ATF-binding site TGACGTCA. DNA-affinity chromatography with the 5'-TRE resulted in a previous study in proteins of about 32, 36 to 42, 50 and 110 kDa. Here we demonstrate that the 42 kDa protein is the cAMP-response element-binding (CREB) protein. This is shown by phosphorylation of the proteins eluted from the DNA-affinity column with protein kinase A (PKA) in vitro and subsequent indirect immunoprecipitation with a CREB-specific antiserum raised against an internal CREB-specific peptide. This method allows detection of phosphorylated proteins by autoradiography with high sensitivity and is superior to metabolic labeling. One of the phosphorylated proteins co-migrates with immuno-affinity-purified CREB protein-also phosphorylated in vitro-and competes with the peptide antigen, which proves the specificity of the reaction. The purified CREB protein leads to specific DNA-protein complexes in DNA mobility-shift analyses with all three TREs. Comparison of these TRE-CREB complexes with those formed by nuclear extracts from the HTLV-I-transformed T-cell line C81-66-45 indicates that additional cellular factors contribute to the complexes, especially to the middle TRE. This is also shown by using CREB-depleted instead of complete nuclear extracts for DNA mobility-shift assays. Antibodies against CREB but not Tax affect the mobility of the DNA-protein complex.	MAX PLANCK INST MOLEC GENET,SCHUSTER ABT,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; BEIMLING P, 1990, ONCOGENE, V5, P361; BEIMLING P, 1989, ONCOGENE, V4, P511; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOHNLEIN E, 1989, J VIROL, V63, P1578; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KADISON P, 1990, J VIROL, V64, P2141, DOI 10.1128/JVI.64.5.2141-2148.1990; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	50	67	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					257	262						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532242				2022-12-28	WOS:A1992HG98200008
J	GARCIA, R; PARIKH, NU; SAYA, H; GALLICK, GE				GARCIA, R; PARIKH, NU; SAYA, H; GALLICK, GE			EFFECT OF HERBIMYCIN-A ON GROWTH AND PP60C-SRC ACTIVITY IN HUMAN COLON-TUMOR CELL-LINES	ONCOGENE			English	Article							TYROSINE PROTEIN-KINASES; ROUS-SARCOMA VIRUS; SRC GENE-PRODUCT; RAT-KIDNEY CELLS; C-SRC; MITOGENIC RESPONSIVENESS; SIGNAL TRANSDUCTION; MUCOSAL CELLS; PHOSPHORYLATION; CARCINOMA	The effect of herbimycin A, an ansamycin antibiotic which inhibits cellular transformation by retroviral tyrosine kinases, on the monolayer growth of seven colon tumor cell lines and one cell line established from normal colonic mucosa, CCL239, was examined. Each colon tumor cell line tested showed dose-dependent growth inhibition in response to herbimycin A. A 125 ng ml-1 dose of the antibiotic caused > 40% growth inhibition in all colon tumor cell lines after two cell doublings. In contrast, at similar herbimycin A concentrations only 12% inhibition was observed in 'normal' CCL239 cells. No major morphologic changes were observed at the light microscopic level in any of the tumor cell lines or CCL239 cells in response to treatment with herbimycin A. Studies using the HT29 colon adenocarcinoma cell line showed dose-dependent inactivation of pp60c-src by herbimycin A, resulting in decreased autophosphorylation, enolase phosphorylation and steady-state levels, which correlated with cellular growth inhibition. Herbimycin A-induced reductions in pp60c-src kinase activity preceded changes in pp60c-src steady-state levels. Growth and pp60c-src inhibition were reversible following removal of herbimycin A from cell culture media. Our results suggest that regulation of pp60c-src tyrosine kinase activity may be important in growth control of colon tumor cells.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROONCOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Saya, Hideyuki/J-4325-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM013005] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13005-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SM, 1990, ONCOGENE, V5, P317; BARNEKOW A, 1987, CANCER RES, V47, P235; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DESEAU V, 1987, J CELL BIOCHEM, V35, P113, DOI 10.1002/jcb.240350205; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FOSS FM, 1989, ONCOGENE RES, V5, P13; GALLICK GE, 1984, VIROLOGY, V139, P366, DOI 10.1016/0042-6822(84)90382-9; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HONMA Y, 1989, CANCER RES, V49, P331; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1984, ADV CYCLIC NUCL PROT, V17, P443; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOH SWM, 1991, BIOCHEM BIOPH RES CO, V174, P452, DOI 10.1016/0006-291X(91)91437-H; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LUTTRELL LM, 1989, ONCOGENE, V4, P317; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MAXWELL SA, 1987, CANCER RES, V47, P1731; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MURAKAMI Y, 1988, CANCER RES, V48, P1587; MUSER J, 1989, ONCOGENE, V4, P1433; OMURA S, 1979, TETRAHEDRON LETT, P4323; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PREIS PN, 1988, CANCER RES, V48, P6530; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; ROSEN N, 1986, J BIOL CHEM, V261, P3754; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAYA H, 1989, J CELL BIOCH UCL B S, V13, P111; SEFTON BM, 1986, CURR TOP MICROBIOL, V123, P39; SEFTON BM, 1984, ADV CYCLIC NUCL PROT, V18, P195; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUZUKAKETSUCHIYA K, 1989, J ANTIBIOT, V42, P1831, DOI 10.7164/antibiotics.42.1831; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UEHARA Y, 1988, J ANTIBIOT, V41, P831, DOI 10.7164/antibiotics.41.831; UMEZAWA K, 1987, EXPERIENTIA, V43, P614, DOI 10.1007/BF02126351; WASILENKO WJ, 1987, J CELL PHYSIOL, V131, P450, DOI 10.1002/jcp.1041310318; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU KT, 1985, J BIOL CHEM, V260, P5838	64	65	67	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					1983	1989						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719464				2022-12-28	WOS:A1991GX11900007
J	LEVESQUE, KS; MATTEI, MG; LEVY, LS				LEVESQUE, KS; MATTEI, MG; LEVY, LS			EVOLUTIONARY CONSERVATION AND CHROMOSOMAL LOCALIZATION OF FLVI-1	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; TRANSCRIPTION FACTOR; ERYTHROLEUKEMIAS; INTEGRATION; VIRUS; PU.1	A locus in feline DNA, termed flvi-1, has been identified as harboring retroviral integrations commonly found in natural feline lymphomas induced by infection with feline leukemia virus (FeLV). Southern blot analysis of human and murine DNA using restriction fragments representing flvi-1 demonstrates its phylogenetic conservation among mammals. flvi-1 is localized to murine chromosome 2, proximal portion of band E, by in situ hybridization to metaphase chromosomes. This position is adjacent to that of another putative proto-oncogene, sfpi-1, although probes representing flvi-1 and sfpi-1 do not cross-hybridize. The repeated implication of flvi-1 in natural feline leukemogenesis, its evolutionary conservation and its chromosomal position support the hypothesis that flvi-1 may represent a previously unidentified proto-oncogene.	TULANE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,1430 TULANE AVE,NEW ORLEANS,LA 70112; HOP ENFANTS LA TIMONE,INSERM,U-242,F-13385 MARSEILLE,FRANCE	Tulane University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille					NATIONAL CANCER INSTITUTE [R01CA048801] Funding Source: NIH RePORTER; NCI NIH HHS [CA48801] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUNG HJ, 1991, IN PRESS CURR TOP MI, V171; LEVESQUE KS, 1990, J VIROL, V64, P3455, DOI 10.1128/JVI.64.7.3455-3462.1990; Maniatis T., 1982, MOL CLONING; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1990, ONCOGENE, V5, P941; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Mullins J.I., 1990, RETROVIRUS BIOL HUMA, P87; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; SPIRO C, 1988, J VIROL, V62, P4129, DOI 10.1128/JVI.62.11.4129-4135.1988	13	11	11	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1377	1379						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679530				2022-12-28	WOS:A1991GX27200013
J	BALENTIEN, E; MUFSON, BE; SHATTUCK, RL; DERYNCK, R; RICHMOND, A				BALENTIEN, E; MUFSON, BE; SHATTUCK, RL; DERYNCK, R; RICHMOND, A			EFFECTS OF MGSA GRO-ALPHA ON MELANOCYTE TRANSFORMATION	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; STIMULATORY ACTIVITY; CELL-LINES; MONOCLONAL-ANTIBODY; MURINE MELANOCYTES; MALIGNANT-MELANOMA; TUMOR PROGRESSION; AUTOCRINE GROWTH; TRANSGENIC MICE; FACTOR CDNA	In the work described here we demonstrate that the clonal cell line Mel-a-6, produced by transfection of mouse Melan-a cells with human MGSA, had an increased ability to form large colonies in soft agar and increased ability to form tumors when injected into nude mice as compared to cells transfected with the neomycin resistance gene alone. This effect appeared to be dependent on the levels of MGSA produced since another transfected clone, Mel-a-l, produced only a low level of MGSA transgene mRNA, formed only minimal large colonies in soft agar and had a tumorigenic rate equal to that of neomycin resistant controls. The histology of the Mel-a-6 tumors is compatible with features normally exhibited by melanoma tumors. The cells do not stain for melanin, and they are positive for the neural crest marker protein S-100 as well as the HMB 45 melanoma specific antigen. Immunohistochemical studies revealed expression of the human MGSA in tumor cells from tissues, excised from animals injected with cells from clone Mel-a-6. Whereas DNA ploidy analysis suggests that in vitro the Mel-a parent cell line, control Mel-a-neo, Mel-a-1 and Mel-a-6 cells show no evidence of aneuploidy, the nuclei isolated from the tumors from animals injected with Mel-a-6 do exhibit aneuploidy. These data suggest that over-expression of MGSA in immortalized melanocytes contributes to transformation.	VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37240; DEPT VET AFFAIRS,NASHVILLE,TN; GENENTECH INC,DEPT DEV BIOL,S SAN FRANCISCO,CA; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,DEPT MED,ATLANTA,GA 30322; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37240	Vanderbilt University; Roche Holding; Genentech; Emory University; Emory University; Vanderbilt University	RICHMOND, A (corresponding author), VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37240, USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X				ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; BAKER N, 1990, NUCLEIC ACIDS RES, V18, P21; BALENTIEN F, 1990, BIOCHEM, V29, P10225; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BORDONI R, 1990, J CELL BIOCHEM, V44, P207, DOI 10.1002/jcb.240440403; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; CHENEVIXTRENCH G, 1990, ONCOGENE, V5, P1187; DERYNCK R, 1987, CANCER RES, V47, P707; DICKER P, 1981, EXP CELL RES, V135, P221, DOI 10.1016/0014-4827(81)90314-1; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ERISMAN MD, 1982, P NATL ACAD SCI-BIOL, V79, P2379, DOI 10.1073/pnas.79.7.2379; FINZI E, 1990, J INVEST DERMATOL, V95, P382, DOI 10.1111/1523-1747.ep12555464; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GATTUSO P, 1990, SURGERY, V108, P702; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GIANGASPERO F, 1987, CANCER, V60, P59, DOI 10.1002/1097-0142(19870701)60:1<59::AID-CNCR2820600111>3.0.CO;2-4; GOWN AM, 1986, AM J PATHOL, V123, P195; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HERLYN M, 1987, LAB INVEST, V56, P461; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KHEIR S M, 1988, Annals of Surgery, V207, P455, DOI 10.1097/00000658-198804000-00014; LAWSON DH, 1987, J CELL BIOCHEM, V34, P169, DOI 10.1002/jcb.240340304; LINDGREN V, 1989, P NATL ACAD SCI USA, V86, P5025, DOI 10.1073/pnas.86.13.5025; MANIATIS T, 1987, MOL CLONING; Masson P, 1928, AM J PATHOL, V4, P181; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; NAKAJIMA T, 1982, CANCER, V50, P912, DOI 10.1002/1097-0142(19820901)50:5<912::AID-CNCR2820500519>3.0.CO;2-U; NAKANISHI Y, 1988, EXP CELL BIOL, V56, P74; ORDONEZ NG, 1988, AM J CLIN PATHOL, V90, P385, DOI 10.1093/ajcp/90.4.385; RICHMOND A, 1988, J CELL BIOCHEM, V36, P185, DOI 10.1002/jcb.240360209; RICHMOND A, 1986, J INVEST DERMATOL, V86, P295, DOI 10.1111/1523-1747.ep12285452; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RICHMOND A, 1985, CANCER RES, V45, P6390; RICHMOND A, 1982, COLD SPRING HARBOR C, V9, P885; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIPPOLATHIELE M, 1989, MOL CELL BIOL, V9, P925, DOI 10.1128/MCB.9.3.925; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TODARO GJ, 1977, NATURE, V267, P526, DOI 10.1038/267526a0; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WILSON RE, 1989, CANCER RES, V49, P711	47	96	100	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1115	1124						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861861				2022-12-28	WOS:A1991GV26000004
J	BANNISTER, AJ; COOK, A; KOUZARIDES, T				BANNISTER, AJ; COOK, A; KOUZARIDES, T			INVITRO DNA-BINDING ACTIVITY OF FOS/JUN AND BZLF1 BUT NOT C/EBP IS AFFECTED BY REDOX CHANGES	ONCOGENE			English	Article								The leucine zipper family of proteins have a DNA binding domain composed of a leucine zipper dimerisation interface and a basic DNA binding structure. We show here that redox changes affect the in vitro DNA binding ability of a select subset of leucine zipper proteins. The bacterially expressed DNA binding domains of Fos/Jun and BZLF1 are unable to bind DNA under non-reducing conditions whereas binding of the C/EBP DNA binding domain is unaffected. Sensitivity to redox state is due to the presence of a conserved cysteine residue in the basic DNA binding motif of Fos, Jun and BZLF1 but not C/EBP. Under non-reducing conditions an intermolecular disulphide bridge is formed between the cysteine residues of each basic motif within a dimer, which prevents DNA binding. We show that oxidation of these C residues can be achieved enzymatically, using glutathione peroxidase, and that DNA binding protects them from oxidation. These data raise the possibility that intracellular changes in the redox state may differentially regulate the activity of leucine zipper family members. In addition the loss of DNA binding activity under non-reducing conditions has implications for the purification methods used to isolate proteins of the leucine zipper family for structural analysis.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT PATHOL, DIV VIROL, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	KOUZARIDES, T (corresponding author), UNIV CAMBRIDGE, WELLCOME INST, CTR CANC RES, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.			Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1989, New Biologist, V1, P35; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V57, P209; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KOUZARIDES T, 1991, ONCOGENE, V6, P195; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATSUI M, 1990, ONCOGENE, V5, P249; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTERS DW, 1986, J BIOL CHEM, V261, P5372; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	47	160	163	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1243	1250						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1907361				2022-12-28	WOS:A1991GV26000021
J	TOURAY, M; RYAN, F; JAGGI, R; MARTIN, F				TOURAY, M; RYAN, F; JAGGI, R; MARTIN, F			CHARACTERIZATION OF FUNCTIONAL INHIBITION OF THE GLUCOCORTICOID RECEPTOR BY FOS/JUN	ONCOGENE			English	Article								We have studied the effects of Fos and Fos/Jun on glucocorticoid induction of hormone-sensitive gene expression. In NIH3T3 cells overexpression of Fos or Fos/Jun by transfection of pSV2-fos and pSV2-jun inhibited glucocorticoid-dependent expression of MMTV LTR-CAT. Expression of p39v-mos had a similar effect on glucocorticoid-dependent reporter gene expression which is most likely mediated by simulation of endogenous Fos. In both cases, this inhibition could be overcome by overexpression of the glucocorticoid receptor (GR) from a transiently transfected expression vector. In receptor deficient CV-1 cells glucocorticoid-dependent reporter gene expression was induced by a range of functional GR truncation mutants. It was established that the C/D domain of the receptor was a sufficient target for inhibition by Fos and Fos/Jun. The C/D domain encompasses the DNA-binding domain, a dimerisation domain and a weak transactivational domain of the GR. When present simultaneously in the cell nucleus Fos and Jun were shown to form a specific and stable protein/protein complex with the glucocorticoid receptor. Finally, it was demonstrated that the GR interacts physically with both Fos and Jun when cotranslated simultaneously in vitro. We propose that this interaction may be the mechanism by which Fos of Fos/Jun bring about inhibition of GR function.	NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND; UNIV BERN, DEPT CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND	University College Dublin; University of Bern	MARTIN, F (corresponding author), NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND.		Ryan, Fergus/B-8407-2012					ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HAMILTON BJ, 1989, P NATL ACAD SCI USA, V86, P597, DOI 10.1073/pnas.86.2.597; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAGGI R, 1989, CANCER RES, V49, pS2266; JAGGI R, 1988, J STEROID BIOCHEM, V29, P457, DOI 10.1016/0022-4731(88)90179-3; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PRATT WB, 1988, J BIOL CHEM, V263, P267; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; TOURAY M, 1991, ONCOGENE, V6, P211; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VASSALLI JD, 1976, CELL, V8, P271, DOI 10.1016/0092-8674(76)90011-8; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	50	81	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1227	1234						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650443				2022-12-28	WOS:A1991GV26000019
J	CAO, HN; DECKER, S; STERN, DF				CAO, HN; DECKER, S; STERN, DF			TPA INHIBITS THE TYROSINE KINASE-ACTIVITY OF THE NEU PROTEIN INVIVO AND INVITRO	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-RECEPTOR; EGF RECEPTOR; HUMAN-BREAST; INDEPENDENT MECHANISMS; ONCOGENE; PHOSPHORYLATION; GENE; AMPLIFICATION; C-ERBB-2	P185 is a receptor-like protein encoded by the neu/erbB-2 proto-oncogene. A point mutation in the transmembrane domain renders this protein oncogenic. We report here that incubation of cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) stimulates the phosphorylation of the normal neu protein (p185) and the oncogenic neu protein (p185*). The increased phosphorylation occurs mainly on serine and threonine residues. Phosphate labeling experiments showed that TPA causes a reduction of basal phosphotyrosine in p185 but not p185*. Immunoblotting with antiphosphotyrosine antibody yielded similar results. TPA also inhibited tyrosine phosphorylation of p185* in an in vitro immune complex kinase assay. These data suggest that protein kinase C, the receptor for TPA, regulates p185 function through serine or threonine phosphorylation.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University	CAO, HN (corresponding author), YALE UNIV,SCH MED,DEPT PATHOL,310 CEDAR ST,NEW HAVEN,CT 06510, USA.				NATIONAL CANCER INSTITUTE [R01CA037754, R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [CA45708, CA37754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BROWN KD, 1979, BIOCHEM BIOPH RES CO, V86, P1037, DOI 10.1016/0006-291X(79)90221-3; COCHET C, 1984, J BIOL CHEM, V259, P2553; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; KAMPS MP, 1988, ONCOGENE, V2, P305; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CS, 1986, J BIOL CHEM, V261, P10078; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LIVNEH E, 1988, MOL CELL BIOL, V103, P1355; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3400; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	38	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					705	711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1675782				2022-12-28	WOS:A1991GT82500004
J	LEROY, X; ESCOT, C; BROUILLET, JP; THEILLET, C; MAUDELONDE, T; SIMONYLAFONTAINE, J; PUJOL, H; ROCHEFORT, H				LEROY, X; ESCOT, C; BROUILLET, JP; THEILLET, C; MAUDELONDE, T; SIMONYLAFONTAINE, J; PUJOL, H; ROCHEFORT, H			DECREASE OF C-ERBB-2 AND C-MYC RNA LEVELS IN TAMOXIFEN-TREATED BREAST-CANCER	ONCOGENE			English	Article							FATTY-ACID SYNTHETASE; ONCOGENE EXPRESSION; ESTROGEN-RECEPTOR; PROTO-ONCOGENE; GENE AMPLIFICATION; MAMMARY-CARCINOMA; HUMAN-TUMORS; CELLS; OVEREXPRESSION; ONCOPROTEIN	The c-myc, c-erbB-2, hst and int-2 oncogenes are frequently amplified and/or overexpressed in human breast carcinomas. We studied the effect of tamoxifen on RNA levels of these oncogenes in 19 breast cancer patients treated for 3 weeks prior to surgery as compared with 22 control patients. RNA levels were measured by in situ hybridization coupled with computer-aided quantification. c-myc and c-erbB-2 expression was high in the control population (mean values: 23.4 and 29.1 grains/cell respectively) and significantly decreased in the tamoxifen-treated population (mean values: 14.6 and 7.4 grains/cell respectively) (P = 0.018, P = 0.003 respectively); hst and int-2 RNA levels were low (2-6 grains/cell) and not significantly altered by the treatment. There was a correlation between gene amplification and expression for c-erbB-2 (P = 0.0005) and hst (P = 0.02) in the control population. Elevated c-erbB-2 RNA level was correlated with the absence of estrogen (P = 0.02) or progesterone (P = 0.05) receptors. In the ER+ population, the tamoxifen-treated group had significantly lower c-myc expression levels than the control group (P = 0.04) which is in agreement with the estrogen induction of c-myc in ER+ T47D cell line and its inhibition by antiestrogens. Surprisingly, c-erbB-2 expression in the tamoxifen-treated group was significantly diminished in the ER- (P = 0.02) and PR- (P = 0.01) populations. This effect was not observed in the ER- BT474 cell line. These results suggest that in vivo tamoxifen decreases c-myc and c-erbB-2 RNA levels in breast cancer cells via two different mechanisms. To our knowledge this is the first evidence of in vivo down regulation of a gene by tamoxifen in ER- breast cancer cells.	INSERM,U148,UNITE HORMONES & CANC,60 RUE NAVACELLES,F-34090 MONTPELLIER,FRANCE; CTR PAUL LAMARQUE,BIOCHIM LAB,CNRS,UA 1191,F-34033 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS)			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				ADNANE J, 1989, ONCOGENE, V4, P1389; BARDON S, 1984, MOL CELL ENDOCRINOL, V35, P89, DOI 10.1016/0303-7207(84)90004-2; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER MS, 1988, CANCER RES, V48, P1238; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHALBOS D, 1990, JNCI-J NATL CANCER I, V82, P602, DOI 10.1093/jnci/82.7.602; DATI C, 1990, ONCOGENE, V5, P1001; DUBIK D, 1988, J BIOL CHEM, V263, P12705; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; ESCOT C, 1990, J CLIN ENDOCR METAB, V70, P1319, DOI 10.1210/jcem-70-5-1319; ESCOT C, 1991, IN PRESS ANAL CELL P; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FAYE JC, 1980, BIOCHEM BIOPH RES CO, V93, P1225, DOI 10.1016/0006-291X(80)90620-8; GUERIN M, 1988, ONCOGENE RES, V3, P21; JORDAN VC, 1986, ESTROEN ANTIESTROGEN; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LACROIX H, 1989, ONCOGENE, V4, P145; LISCIA DS, 1989, ONCOGENE, V4, P1219; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MAUDELONDE T, 1989, CANCER, V63, P1265, DOI 10.1002/1097-0142(19890401)63:7<1265::AID-CNCR2820630706>3.0.CO;2-Z; MAUDELONDE T, 1988, CANCER RES, V48, P462; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; PIKE MC, 1981, BANBURY REPORT, V8; READ LD, 1990, CANCER RES, V50, P3947; ROCHEFORT H, 1991, IN PRESS AM J ONCOL; RUSHDI AA, 1983, SCIENCE, V22, P390; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; SUTHERLAND RL, 1980, NATURE, V288, P273, DOI 10.1038/288273a0; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THEILLET C, 1989, ONCOGENE, V4, P915; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WALKER RA, 1989, J PATHOL, V158, P977; WRIGHT C, 1989, CANCER RES, V49, P2087; ZEILLINGER R, 1989, ONCOGENE, V4, P109; 1981, HISTOLOGICAL CLASSIF	39	67	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					431	437						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1707153				2022-12-28	WOS:A1991FT34400012
J	KOUZARIDES, T; PACKHAM, G; COOK, A; FARRELL, PJ				KOUZARIDES, T; PACKHAM, G; COOK, A; FARRELL, PJ			THE BZLF1 PROTEIN OF EBV HAS A COILED COIL DIMERIZATION DOMAIN WITHOUT A HEPTAD LEUCINE REPEAT BUT WITH HOMOLOGY TO THE C/EBP LEUCINE ZIPPER	ONCOGENE			English	Article							DNA-BINDING SPECIFICITY; LIVER NUCLEAR-PROTEIN; EPSTEIN-BARR VIRUSES; FOS-JUN INTERACTION; SWITCH GENE BZLF1; DIMERIZATION SPECIFICITY; ZTA TRANSACTIVATOR; MESSENGER-RNAS; EARLY PROMOTER; C-FOS	The EBV transactivator protein BZLF1 can bind many sites in EBV genome, most of which have homology to a consensus AP-1 site, the binding site for the fos/jun family of transcription factors. Here we present evidence that BZLF1 can also recognise the binding site for the CCAAT/enhancer binding protein C/EBP and that a BZLF1 binding site within the BZLF1 promoter is recognised by the C/EBP protein. Analysis of the BZLF1 DNA binding domain suggests that the BZLF1 protein binds to DNA as a dimer using sequences adjacent to a basic DNA binding motif. The BZLF1 dimerisation domain does not have a hepatad repeat of leucine residues common to leucine zipper proteins but does not have characteristics of a coiled coil structure, as judged by site directed mutagenesis. We therefore propose that the dimerisation domain of BZLF1 is structurally related to the coiled coil structure of leucine zippers but lacks the highly conserved leucine repeat. We show that the PZLF1 dimerisation domain has residues in common with the C/EBP leucine zipper and discuss the possible implications of this relationship.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research	KOUZARIDES, T (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PATHOL,DIV VIROL,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND.			Kouzarides, Tony/0000-0002-8918-4162; Farrell, Paul/0000-0002-6754-9351				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHAVRIER P, 1989, J VIROL, V63, P607, DOI 10.1128/JVI.63.2.607-614.1989; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COHEN DR, 1990, ONCOGENE, V5, P929; COUNTRYMAN J, 1987, J VIROL, V61, P3672, DOI 10.1128/JVI.61.12.3672-3679.1987; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; COX MA, 1990, J VIROL, V64, P313, DOI 10.1128/JVI.64.1.313-321.1990; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FLEMINGTON E, 1990, J VIROL, V64, P1217, DOI 10.1128/JVI.64.3.1217-1226.1990; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KENNEY S, 1989, J VIROL, V63, P1729, DOI 10.1128/JVI.63.4.1729-1736.1989; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; LIEBERMAN PM, 1989, J VIROL, V63, P3040, DOI 10.1128/JVI.63.7.3040-3050.1989; LIEBERMAN PM, 1990, J VIROL, V64, P2560, DOI 10.1128/JVI.64.6.2560-2568.1990; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MANET E, 1989, EMBO J, V8, P1819, DOI 10.1002/j.1460-2075.1989.tb03576.x; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; PACKHAM G, 1990, J VIROL, V64, P2110, DOI 10.1128/JVI.64.5.2110-2116.1990; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; TAYLOR N, 1989, J VIROL, V63, P1721, DOI 10.1128/JVI.63.4.1721-1728.1989; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	47	96	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					195	204						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1847997				2022-12-28	WOS:A1991FZ13400003
J	SHIGEOKA, H; YANG, HC				SHIGEOKA, H; YANG, HC			C-FOS REGULATION IN UNTRANSFORMED AS COMPARED TO TRANSFORMED BALB/C 3T3 FIBROBLASTS	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DIV MED ONCOL,TORRANCE,CA 90509; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT MED,TORRANCE,CA 90509	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; Berridge M J, 1986, J Cell Sci Suppl, V4, P137; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1984, CELL, V36, P259; DUBROW R, 1979, CANCER RES, V39, P2718; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1986, SCIENCE, V234, P160; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TABAK HF, 1978, NUCLEIC ACIDS RES, V5, P2321, DOI 10.1093/nar/5.7.2321; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANG HC, 1989, EXP CELL RES, V183, P36, DOI 10.1016/0014-4827(89)90416-3; YANG HC, 1987, J CELL PHYSIOL, V133, P377, DOI 10.1002/jcp.1041330224	40	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					741	745						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	1693185				2022-12-28	WOS:A1990DG37400015
J	ESPINO, PC; HARVEY, R; SCHWEICKHARDT, RL; WHITE, GA; SMITH, AE; CHENG, SH				ESPINO, PC; HARVEY, R; SCHWEICKHARDT, RL; WHITE, GA; SMITH, AE; CHENG, SH			THE AMINO-TERMINAL REGION OF PP60C-SRC HAS A MODULATORY ROLE AND CONTAINS MULTIPLE SITES OF TYROSINE PHOSPHORYLATION	ONCOGENE			English	Article									GENZYME CORP,CELLULAR REGULAT LAB,1 MT RD,FRAMINGHAM,MA 01701; GENZYME CORP,DNA CHEM LAB,FRAMINGHAM,MA 01701	Sanofi-Aventis; Genzyme Corporation; Sanofi-Aventis; Genzyme Corporation			Cheng, Seng H/AAC-6564-2022		NATIONAL CANCER INSTITUTE [R01CA043186] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 43186-03, N44 CP 85655] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROWN DJ, 1984, J BIOL CHEM, V259, P9580; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHAKALAPARAMPIL I, 1988, CELL, V52, P801; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1984, MOL CELL BIOL, V4, P1213, DOI 10.1128/MCB.4.7.1213; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HIROTA Y, 1988, MOL CELL BIOL, V8, P1826, DOI 10.1128/MCB.8.4.1826; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; Patchinsky T., 1986, J VIROL, V59, P73; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Potts W M, 1988, Oncogene Res, V3, P343; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RYDER JW, 1987, MOL CELL BIOL, V7, P1139, DOI 10.1128/MCB.7.3.1139; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SATO M, 1989, J VIROL, V63, P638; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	56	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					283	293						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690377				2022-12-28	WOS:A1990CW41500005
J	LONGSTREET, M; MILLER, B; HOWE, PH				LONGSTREET, M; MILLER, B; HOWE, PH			LOSS OF TRANSFORMING GROWTH FACTOR-BETA-1 (TGF-BETA-1)-INDUCED GROWTH ARREST AND P34(CDC2) REGULATION IN RAS-TRANSFECTED EPITHELIAL-CELLS	ONCOGENE			English	Article							CDC2 PROTEIN-KINASE; FACTOR-BETA; TGF-BETA; C-MYC; RETINOBLASTOMA PROTEIN; HISTONE-H1 KINASE; INHIBITION; PHOSPHORYLATION; PROLIFERATION; EXPRESSION	Transforming growth factor beta-1 (TGF-beta-1) is a potent inhibitor of mink lung epithelial (CCL64) cell growth in culture. The fact that many transformed epithelial cells have escaped from negative growth control by TGF-beta-1 suggests that transfected epithelial cells may be an appropriate model for investigating the growth-inhibitory mechanism of TGF-beta-1. We transfected CCL64 cells with a mouse c-myc oncogene (pSVc-myc1), a mutated Harvey-ras (Ha-ras) oncogene, or a combination of both. The results indicate that cells transfected with c-myc alone exhibit normal morphology and maintain sensitivity to TGF-beta-1 growth arrest, but are unable to form colonies in soft agar in the presence or absence of FGF-beta-1. Cells transfected with Ha-ras, or co-transfected with c-myc, display a transformed morphology, grow spontaneously under anchorage-independent conditions and acquire a complete resistance to growth inhibition by TGF-beta-1. Affinity cross-linking of [I-125]TGF-beta-1 to cell-surface receptors from these transfectants revealed that all three TGF-beta receptor types were present and no significant differences in [I-125]TGF-beta-1 labeling of these receptors was observed. Since we have previously demonstrated that modulation of p34cdc2 kinase is a marker for TGF-beta-1 growth inhibition, we investigated p34cdc2 activity in the CCL64 transfected clones. The results show that in the control CCL64 cells and in the myc-transfected clones TGF-beta-1 regulation of p34cdc2 activity is maintained. In the ras- and ras + myc-transfected cells p34cdc2 phosphorylation and histone HI kinase activity is significantly increased and regulation by TGF-beta-1 is lost.	CLEVELAND CLIN,RES INST,DEPT CELL BIOL,NC1-145,CLEVELAND,OH 44106	Cleveland Clinic Foundation					NCI NIH HHS [CA-55536] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055536, R29CA055536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY RJ, 1986, CANCER RES, V44, P2230; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; HADDOW S, 1991, ONCOGENE, V6, P1465; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HOUCK KA, 1989, ONCOGENE, V4, P19; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HOWE PH, 1990, BIOCHEM J, V266, P537, DOI 10.1042/bj2660537; HOWE PH, 1989, CANCER RES, V49, P6024; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEOF EB, 1987, MOL CELL BIOL, V7, P2649, DOI 10.1128/MCB.7.7.2649; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Maniatis T., 1982, MOL CLONING; MANNING AM, 1991, ONCOGENE, V6, P1471; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SHIPLEY GD, 1986, CANCER RES, V46, P2068; STROM SC, 1991, DIGEST DIS SCI, V5, P642; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	38	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1549	1556						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630817				2022-12-28	WOS:A1992JE81300011
J	ZHANG, W; HU, GY; ESTEY, E; HESTER, J; DEISSEROTH, A				ZHANG, W; HU, GY; ESTEY, E; HESTER, J; DEISSEROTH, A			ALTERED CONFORMATION OF THE P53 PROTEIN IN MYELOID-LEUKEMIA CELLS AND MITOGEN-STIMULATED NORMAL BLOOD-CELLS	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; GENE-MUTATIONS; BREAST-CANCER; PHOSPHORYLATION; RETINOBLASTOMA; EXPRESSION; ONCOGENE; OCCUR	Expression of the normal p53 gene promotes cell differentiation, maturation and apoptosis. The mutant p53 gene, which does not function normally, is frequently expressed at elevated levels in tumor cells [for review see Lane, D.P. & Benchimol, S. (1990). Genes Dev., 4, 1-81. We have analysed the expression of and mutational change in the p53 gene in the peripheral blood cells of 49 primary acute myeloid leukemia (AML) patients. The p53 protein levels were elevated in 37 patients (75%) when measured by immunoprecipitation with antibodies PAb1801 and PAb421, which recognize both normal and mutant forms of the protein. The p53 protein from 32 of these 37 patients was immunoprecipitated by PAb240, which recognizes a conformation of p53 protein associated with point mutations. However, point mutations were detected by single-stranded conformation polymorphism (SSCP) assay and direct sequencing in only three patients at codons 178, 245, 273 and 290. Growth stimulation of normal lymphocytes also generated p53 which was immunoprecipitable by PAb240. Thus, alteration of p53 conformation, rather than acquisition of point mutations, could be the mechanism underlying the increased proliferation of myeloid cells in most AML patients.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 24,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BENFENATI F, 1990, J BIOL CHEM, V265, P12584; FENAUX P, 1991, BLOOD, V78, P1652; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HU G, 1992, IN PRESS BR J HAEMAT; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KASTAN MB, 1991, CANCER RES, V51, P4279; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; SUGIMOTO K, 1991, BLOOD, V77, P1153; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	25	93	94	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1645	1647						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630824				2022-12-28	WOS:A1992JE81300022
J	HAUPT, Y; HARRIS, AW; ADAMS, JM				HAUPT, Y; HARRIS, AW; ADAMS, JM			RETROVIRAL INFECTION ACCELERATES T-LYMPHOMAGENESIS IN E-MU-N-RAS TRANSGENIC MICE BY ACTIVATING C-MYC OR N-MYC	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; CELL LYMPHOMAS; PROVIRAL INSERTION; ONCOGENES; GENE; CARCINOGENESIS; INVOLVEMENT; INTEGRATION; MUTATIONS; FREQUENCY	Transgenic mice bearing a mutant, activated N-ras oncogene directed to express within hematopoietic cells by an immunoglobulin enhancer (E-mu) sporadically develop T-cell lymphomas and non-lymphoid tumors that may be of macrophage origin. To identify genes that can collaborate with N-ras in hematopoietic neoplasia, Moloney murine leukemia virus was used as an insertional mutagen. Infection of newborn E-mu-N-ras mice with the virus greatly accelerated tumorigenesis, and nearly all the tumors proved to be T-cell lymphomas. Their variable surface phenotype (CD4+ CD8-, CD4+ CD8+ and CD4-CD8-) suggested that cells at several stages of T-cell development were susceptible to tumorigenesis. Southern blot analysis revealed that 68% of the tumors bore a proviral insert 5' to the c-myc gene, while 13% had an insert within the 3' untranslated region of the N-myc gene. Insertion was associated with elevated expression of these genes. Hence, activation of a myc gene appears to be the dominant pathway to tumorigenesis by insertional mutagenesis in lymphoid cells expressing a mutant ras gene. However, since many of the tumors were not transplantable, even the partnership of myc and ras may not suffice for full lymphoid malignancy.			HAUPT, Y (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA.		Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1989, ONCOGENE, V4, P575; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BOS JL, 1989, CANCER RES, V49, P4682; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BREUER M, 1991, CANCER RES, V51, P958; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUYPERS HT, 1984, CELL, V37, P141; DAVIS BR, 1987, P NATL ACAD SCI USA, V84, P4875, DOI 10.1073/pnas.84.14.4875; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; REIK W, 1985, P NATL ACAD SCI USA, V82, P1141, DOI 10.1073/pnas.82.4.1141; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TSICHLIS PN, 1989, P NATL ACAD SCI USA, V86, P5487, DOI 10.1073/pnas.86.14.5487; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WEINBERG RA, 1989, CANCER RES, V49, P3713; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	40	44	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					981	986						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570158				2022-12-28	WOS:A1992HP64200018
J	AXELSON, H; PANDA, CK; SILVA, S; SUGIYAMA, H; WIENER, F; KLEIN, G; SUMEGI, J				AXELSON, H; PANDA, CK; SILVA, S; SUGIYAMA, H; WIENER, F; KLEIN, G; SUMEGI, J			A NEW VARIANT 15-16 TRANSLOCATION IN MOUSE PLASMACYTOMA LEADS TO THE JUXTAPOSITION OF C-MYC AND IMMUNOGLOBULIN-LAMBDA	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; CHROMOSOME TRANSLOCATIONS; GENE; LOCUS; ONCOGENE; LYMPHOMAS; ENHANCER; REGION; CELLS; MICE	Mouse plasmacytomas (MPCs) induced by pristane oil, or by a combination of pristane oil and Abelson virus, carry one of two chromosomal translocations. The typical 12; 15 translocation leads to the juxtaposition of c-myc and immunoglobulin heavy-chain sequences, whereas the 6; 15 translocation links the kappa light-chain locus with the pyt-1 (plasmacytoma variant translocation) locus, located al least 75 kb 3' of c-myc [Cory, S., Graham, M., Webb, E., Corcoran, L. & Adams, J. (1985). EMBO J., 4, 675-681]. Unlike the human Burkitt's lymphoma-associated translocation, the lambda/myc juxtaposed variant translocation has not been found previously in MPCs. Using unconventional MPC induction systems in which the tumor precursor cell was induced to proliferate in a secondary host, we have recently identified a 15; 16 Translocation in six of the derived MPCs [Wiener, F., Silva, S., Sugiyama, H., Babonits, M. & Klein, G. (1990). Genes Chromosomes Cancer, 2, 36-43]. Chromosome 16 harbors the lambda light-chain gene. To explore whether the 15; 16 translocation represents the lambda/myc juxtaposition, we have mapped the breakpoints on chromosomes 15 and 16 by pulsed-field gel electrophoresis (PFGE). The pvt-1 region was mapped to approximately 220 kb 3' of c-myc. The breakpoint on chromosome 15 in ABPC-Ch-163-10, one of the six 15; 16 translocation-carrying carrying MPCs, was situated approximately 80 kb 3' of c-myc and 140 kb 5' of pvt-1b, the major breakpoint cluster region of the previously analysed 6; 15 variant MPCs. The breakpoint on chromosone 16 was found to cut between the V1 and C3 regions of the lambda locus. Co-migration experiments showed that the C3 and the myc gene were juxtaposed head to tail on the 15; 16 translocation chromosome. On the reciprocal product V1 was juxtaposed to pvt-1.			AXELSON, H (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.				NCI NIH HHS [3R01CA4054] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CARSON S, 1989, IMMUNOGENETICS, V29, P173, DOI 10.1007/BF00373642; CAZENAVE A, 1990, EMBO J, V9, P435; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; ECCLES S, 1990, New Biologist, V2, P801; EISEN HN, 1985, ANNU REV IMMUNOL, V3, P337, DOI 10.1146/annurev.iy.03.040185.002005; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANCKE U, 1982, CYTOGENET CELL GENET, V33, P267, DOI 10.1159/000131769; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HUPPI K, 1990, CURR TOP MICROBIOL, V166, P233; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; NADEL B, 1990, EMBO J, V9, P435, DOI 10.1002/j.1460-2075.1990.tb08128.x; OHNO S, 1979, CELL, V18, P1001, DOI 10.1016/0092-8674(79)90212-5; PEAR WS, 1988, MOL CELL BIOL, V8, P441, DOI 10.1128/MCB.8.1.441; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SHTIVELMAN E, 1990, MOL CELL BIOL, V10, P1835, DOI 10.1128/MCB.10.4.1835; SILVA S, 1989, INT J CANCER, V44, P337, DOI 10.1002/ijc.2910440225; STORB U, 1989, MOL CELL BIOL, V9, P711, DOI 10.1128/MCB.9.2.711; SUGIYAMA H, 1989, INT J CANCER, V44, P348, DOI 10.1002/ijc.2910440227; TSICHLIS PN, 1989, P NATL ACAD SCI USA, V86, P5487, DOI 10.1073/pnas.86.14.5487; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WIENER F, 1990, GENE CHROMOSOME CANC, V2, P36, DOI 10.1002/gcc.2870020107; WIRSCHUBSKY Z, 1986, INT J CANCER, V38, P739, DOI 10.1002/ijc.2910380518; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	36	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2263	2270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766673				2022-12-28	WOS:A1991GX73500013
J	THORN, JT; TODD, AV; WARRILOW, D; WATT, F; MOLLOY, PL; ILAND, HJ				THORN, JT; TODD, AV; WARRILOW, D; WATT, F; MOLLOY, PL; ILAND, HJ			CHARACTERIZATION OF THE HUMAN N-RAS PROMOTER REGION	ONCOGENE			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR BINDS; DNA-BINDING; PROTO-ONCOGENE; CELL-LINE; C-FOS; PROENKEPHALIN GENE; DELETION ANALYSIS; UPSTREAM ELEMENT; GROWTH-FACTOR	Overexpression of ras proto-oncogenes has been implicated in cancer development. We therefore initiated a study of the human N-ras promoter to determine the regions that control N-ras expression and their potential for interaction with DNA-binding proteins. N-ras CAT constructs were stably integrated into K562 cells by electric field-mediated gene transfer in order to determine functional regions within the human N-ras promoter. A significant proportion of promoter activity was found to lie within a 439 bp fragment comprising an untranslated exon (exon 1) with the adjacent 5' sequence and a small CpG island. A 107 bp fragment at the 5' end of exon 1 was essential for promoter activity, while a 44 bp deletion from within this region decreased promoter activity by two-thirds. Unlike the human H-ras and mouse K-ras promoters, the N-ras promoter did not exhibit bidirectional activity. DNAase footprinting of the 439 bp fragment revealed seven protected regions, many of which contain sequences homologous to known DNA-binding protein sites (MLTF/myc, CREB/ATF, AP-1, AP-2, myb and E4TF1). In contrast, four putative Sp1 sites did not footprint. Using purified MLTF and appropriate competitors in gel shift and DNAase footprinting assays, we demonstrated binding of MLTF to the MLTF consensus sequence within exon 1.	ROYAL PRINCE ALFRED HOSP, KANEMATSU LABS, MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA; CSIRO, DIV BIOMOLEC ENGN, N RYDE, NSW 2113, AUSTRALIA	University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Molloy, Peter L/H-7931-2013	Molloy, Peter L/0000-0002-7788-3417				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; CROAKER GM, 1990, LEUKEMIA, V4, P502; DONIGER J, 1987, ONCOGENE, V1, P331; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HOFLER H, 1988, VIRCHOWS ARCH B, V55, P355; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; JORDANO J, 1988, ONCOGENE, V2, P359; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SAWADOGO M, 1986, CANCER CELL, V4, P147; SAWODOGO M, 1985, R G CELL, V43, P165; Sharpiro DJ, 1988, DNA CELL BIOL, V7, P47; SHI XP, 1986, NUCLEIC ACIDS RES, V14, P3729, DOI 10.1093/nar/14.9.3729; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SPANDIDOS DA, 1986, FEBS LETT, V203, P169, DOI 10.1016/0014-5793(86)80736-0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUAREZ HG, 1989, CANCER RES, V49, P1223; TANAKA T, 1986, CANCER RES, V46, P1465; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; TRIMBLE WS, 1987, FEBS LETT, V219, P70, DOI 10.1016/0014-5793(87)81192-4; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YAMAMOTO F, 1988, ONCOGENE RES, V3, P125	60	19	19	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1843	1850						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923508				2022-12-28	WOS:A1991GX11800017
J	TAINSKY, MA; YIM, SO; KRIZMAN, DB; KANNAN, P; CHIAO, PJ; MUKHOPADHYAY, T; BUETTNER, R				TAINSKY, MA; YIM, SO; KRIZMAN, DB; KANNAN, P; CHIAO, PJ; MUKHOPADHYAY, T; BUETTNER, R			MODULATION OF DIFFERENTIATION IN PA-1 HUMAN TERATOCARCINOMA CELLS AFTER N-RAS ONCOGENE-INDUCED TUMORIGENICITY	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; EMBRYONAL CARCINOMA-CELLS; VITAMIN-A; MOLECULAR-CLONING; LINE; EXPRESSION; IDENTIFICATION; INDUCTION; PROTEIN; PATTERN	We have been studying the effect of oncogenes on differentiation using the human ovarian teratoma-derived cell line PA-1. From this study we have characterized variants representing four stages relevant to multistage carcinogenesis, two non-tumorigenic and two tumorigenic. The two non-tumorigenic cell variants differ in that one is resistant to transformation by ras oncogenes whereas the other can be transformed to tumorigenicity. When these non-tumorigenic PA-1 variants are treated with retinoic acid (RA), a morphogen, they stop dividing, begin to express homeobox genes, and change in morphology. Transfection of an activated N-ras oncogene into ras-resistant non-tumorigenic PA-1 cells does not alter the RA responsiveness of the cells, indicating that expression of the activated oncogene is not sufficient for blocking RA-induced differentiation. Spontaneous activation of an N-ras oncogene leading to tumorigenic transformants and gene transfer-induced N-ras transformants are resistant to these effects of RA. However, another spontaneous transformant of PA-1 cells that does not contain an activated N-ras is responsive to RA. We prepared somatic cell hybrids of the RA-non-responsive, N-ras-transformed and tumorigenic PA-1 cell and the RA-responsive, ras-resistant non-tumorigenic PA-1 cell; the hybrid cell lines continue to express the oncogene but are non-tumorigenic. These non-tumorigenic hybrids are responsive to RA with regard to morphological changes, growth arrest and induction of homeobox gene expression. Tumorigenic revertants of these hybrids arise as a result of the loss of some chromosomes; these hybrid cells express the oncogene but have lost RA responsiveness. These results indicate that tumorigenic transformation in general is not sufficient to induce RA resistance, and resistance to differentiation may be oncogene-specific. In addition, the expression of an activated N-ras oncogene alone is insufficient to induce resistance to RA and ras-induced tumorigenicity is necessary. Therefore, some feature of cellular metabolism that is altered by and discordantly segregates with tumorigenic transformation controls responsiveness to RA. This controlling element is presumably a tumor suppressor.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC SURG,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	TAINSKY, MA (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [CA-09299, CA-42180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042180, T32CA009299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BORASIO GD, 1989, NEURON, V2, P1087; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUETTNER R, 1991, MOL CELL BIOL, V2, P3573; CHIAO PJ, 1991, ONCOGENE, V6, P713; CHIAO PJ, 1991, IN PRESS ONCOGENE, V6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DAVIS RC, 1987, DEV BIOL, V119, P164, DOI 10.1016/0012-1606(87)90218-1; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; EICHELE G, 1985, J CELL BIOL, V101, P1913, DOI 10.1083/jcb.101.5.1913; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRANKEL J, 1979, ADV COMP LEUKEMIA RE, P555; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HARRIS H, 1990, J CELL SCI, V97, P65; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; JETTEN AM, 1986, MOL CELL BIOL, V6, P3341, DOI 10.1128/MCB.6.10.3341; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LEE J, 1985, J EMBRYOL EXP MORPH, V90, P139; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1979, CANCER RES, V39, P1014; LUESCHER B, 1989, GENE DEV, V3, P1507; MILLER WH, 1990, ONCOGENE, V5, P511; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PEEHL DM, 1982, INT J CANCER, V30, P113, DOI 10.1002/ijc.2910300119; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SEIFTER E, 1976, J NATL CANCER I, V57, P355, DOI 10.1093/jnci/57.2.355; SEIFTER E, 1973, LIFE SCI, V13, P945, DOI 10.1016/0024-3205(73)90084-2; SHERMAN MI, 1986, CURR TOP DEV BIOL, V20, P345, DOI 10.1016/S0070-2153(08)60674-2; SHUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645, DOI 10.1073/pnas.84.16.5645; STANBRIDGE EJ, 1981, CANCER RES, V41, P573; TAINSKY MA, 1987, CANCER RES, V47, P3235; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; TAINSKY MA, 1988, ANTICANCER RES, V8, P899; TAYLOR DD, 1990, DIFFERENTIATION, V43, P123, DOI 10.1111/j.1432-0436.1990.tb00438.x; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; YOAKUM GH, 1984, BIOTECHNIQUES    JAN, P24; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	48	15	15	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1575	1582						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1681491				2022-12-28	WOS:A1991GX27400012
J	BACHNOU, N; LAUDET, V; JAFFREDO, T; QUATANNENS, B; SAULE, S; DIETERLENLIEVRE, F				BACHNOU, N; LAUDET, V; JAFFREDO, T; QUATANNENS, B; SAULE, S; DIETERLENLIEVRE, F			COOPERATIVE EFFECT OF V-MYC AND V-ERBA IN THE CHICK-EMBRYO	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; TRANSGENIC MICE; NEURORETINA CELLS; ONCOGENES; INVITRO; PROTEIN; EXPRESSION; TRANSFORMATION; INVIVO	We show that a construct designated as MAHEVA, which encodes oncogenes v-myc from MH2 virus and v-erbA from AEV under the control of the LTR of MH2, induces rapidly growing heart rhabdomyosarcomas, when it is injected in E3 but not E5 chick embryos. A similar pathology has previously been observed with MC29, within the same limited time frame. The tumors, which expressed P61-63myc, P75gag-erbA and Pr76gag proteins were detectable from E14 onwards. Compared with MC29, MAHEVA induced a secondary anomaly, not detectable prior to E17. This is the appearance of cartilage nodules within the heart rhabdomyosarcomas. The constant location of these nodules inside the rhabdomyosarcomas and their delayed appearance suggests that the chondrocytes originate from myoblasts prevented from differentiating by the expression of the v-myc product. This interpretation is supported by the appearance of chondrocytes in E3 heart muscle cells infected in vitro with MAHEVA.	CNRS, INST EMBRYOL CELLULAIRE & MOLEC, 49 BIS AV BELLE GABRIELLE, F-94736 NOGENT SUR MARNE, FRANCE; COLL FRANCE, F-94736 NOGENT SUR MARNE, FRANCE; COLL FRANCE, F-94736 NOGENT SUR MARNE, FRANCE; INST PASTEUR, INSERM, U186, F-59019 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	DIETERLENLIEVRE, F (corresponding author), CNRS, INST EMBRYOL CELLULAIRE & MOLEC, 49 BIS AV BELLE GABRIELLE, F-94736 NOGENT SUR MARNE, FRANCE.		JAFFREDO, Thierry/K-7870-2017	JAFFREDO, Thierry/0000-0002-8724-3261				ADAMSON ED, 1987, DEVELOPMENT, V99, P449; ALMOUSTAFA AE, 1988, CELL DIFFER DEV, V25, P119, DOI 10.1016/0922-3371(88)90005-6; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BETTEXGALLAND M, 1987, EXPERIENTIA, V43, P610, DOI 10.1007/BF02126349; BEUG H, 1985, MODERN TRENDS HUMAN, V4, P290; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEHAAN RL, 1967, DEV BIOL, V16, P216, DOI 10.1016/0012-1606(67)90025-5; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Gabe M., 1968, TECHNIQUES HISTOLOGI; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; ITOH Y, 1986, DEV BIOL, V115, P353, DOI 10.1016/0012-1606(86)90255-1; JAFFREDO T, 1989, DEVELOPMENT, V105, P679; JAFFREDO T, 1991, EXP CELL RES, V192, P481, DOI 10.1016/0014-4827(91)90067-5; KAWAMURA M, 1988, DEV BIOL, V130, P435, DOI 10.1016/0012-1606(88)90339-9; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; OHLSSON RI, 1987, EXP CELL RES, V173, P1, DOI 10.1016/0014-4827(87)90327-2; OKADA TS, 1983, CELL DIFFER DEV, V13, P177, DOI 10.1016/0045-6039(83)90087-8; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; RONG PM, 1987, DEV BIOL, V122, P338, DOI 10.1016/0012-1606(87)90299-5; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SAULE S, 1987, P NATL ACAD SCI USA, V84, P7982, DOI 10.1073/pnas.84.22.7982; SIMONS EV, 1971, ACTA MORPHOL NEER SC, V8, P281; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STIEFEL KARL, 1926, ANAT ANZEIGER, V61, P177; SUMIDA H, 1989, ANAT EMBRYOL, V180, P29, DOI 10.1007/BF00321897; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMADA K, 1970, HISTOCHEMISTRY, V23, P13, DOI 10.1007/BF00309485	42	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1041	1047						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1676836				2022-12-28	WOS:A1991GU62200021
J	BRAITHWAITE, AW; BLAIR, GE; NELSON, CC; MCGOVERN, J; BELLETT, AJD				BRAITHWAITE, AW; BLAIR, GE; NELSON, CC; MCGOVERN, J; BELLETT, AJD			ADENOVIRUS E1B-58 KD ANTIGEN BINDS TO P53 DURING INFECTION OF RODENT CELLS - EVIDENCE FOR AN N-TERMINAL BINDING-SITE ON P53	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; T-ANTIGEN; MONOCLONAL-ANTIBODIES; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; GENE-PRODUCTS; PROTEINS BIND; ONCOGENE; DNA; MOUSE	We show using mild extraction procedures that the p53 proto-oncogene forms a complex with adenovirus 5 E1b-58 kD during infection. These complexes are detected as coimmunoprecipitates from radiolabeled extracts of adenovirus infected cells on SDS-PAGE. Furthermore, adenovirus mutants with defects in E1b-58 kD fail to form complexes, whereas mutants in other early region genes still show evidence of complex. Using a panel of monoclonal antibodies to mouse p53, we show that antibodies reacting with N-terminal epitopes on p53, displace E1b-58 KD. This result suggests that E1b-58 kD binds to an N-terminal region of mouse p53. In addition, in a transient transfection assay in monkey COS cells, we show that an N-terminal deletion mutant of mouse p53 does not bind to E1b-58 kD but wild-type mouse p53 does bind. This result again suggests that E1b-58 kD binds an N-terminal determinant on p53.	UNIV LEEDS,DEPT BIOCHEM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 2Y2,BC,CANADA	University of Leeds; University of Victoria	BRAITHWAITE, AW (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA.		Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795				BABISS LE, 1984, J VIROL, V50, P2552; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1989, J VIROL, V63, P1792, DOI 10.1128/JVI.63.4.1792-1799.1989; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; BURGER C, 1983, VIROLOGY, V126, P19, DOI 10.1016/0042-6822(83)90459-2; CHALLBERG SS, 1981, VIROLOGY, V114, P193; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREAVES R, 1988, THESIS U LONDON; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P188; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Russell W C, 1967, J Gen Virol, V1, P495, DOI 10.1099/0022-1317-1-4-495; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHANG XL, 1990, VIROLOGY, V180, P199	45	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					781	787						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1828873				2022-12-28	WOS:A1991GT82500014
J	CARBONE, A; GUSELLA, GL; RADZIOCH, D; VARESIO, L				CARBONE, A; GUSELLA, GL; RADZIOCH, D; VARESIO, L			HUMAN HARVEY-RAS IS BIOCHEMICALLY DIFFERENT FROM KIRSTEN-RAS OR N-RAS	ONCOGENE			English	Article							PROTEIN KINASE-C; SERUM-RESPONSE ELEMENT; GROWTH-FACTOR; PHORBOL ESTER; ADENYLATE-CYCLASE; FOS EXPRESSION; TRANSFORMED FIBROBLASTS; ONCOGENE PRODUCT; NIH/3T3 CELLS; P21 PROTEINS	The biochemical effects of the human H-, N- and K-ras oncogenes were studied. We analysed the induction of c-fos mRNA and protein by the protein kinase C (PKC) activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in exponentially growing NIH3T3 fibroblasts transformed by transfection with ras oncogenes. We found that H-ras has the unique ability to inhibit c-fos induction by TPA. In contrast, normal c-fos expression was induced by TPA in fibroblasts transformed by N- or K-ras or by the ras-unrelated oncogenes dbl and trk. The inhibition of c-fos induction by H-ras was not due to alteration in the binding of TPA to the transformed cells or to the selection of idiosyncratic clones. These results provide clear evidence that H-ras is functionally different from K- or N-ras.	NCI,FREDERICK CANC RES & DEV CTR,MOLEC IMMUNOREGULAT LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; UNIV CATTOLICA DEL SACRO CUORE,IST ANAT PATOL,I-00168 ROME,ITALY; NCI,FREDERICK CANC RES & DEV CTR,INC DYN CORP,PROGRAM RESOURCES,FREDERICK,MD 21702; MCGILL UNIV,MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Catholic University of the Sacred Heart; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; McGill University	VARESIO, L (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MOLEC IMMUNOREGULAT LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702, USA.		varesio, luigi/J-8261-2016	varesio, luigi/0000-0001-5659-2218; CARBONE, Arnaldo/0000-0001-9695-5837; Radzioch, Danuta/0000-0002-1601-2757	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BRANDTRAUF PW, 1988, P NATL ACAD SCI USA, V85, P5869, DOI 10.1073/pnas.85.16.5869; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLETTA G, 1987, ONCOGENE RES, V1, P459; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GARTE SJ, 1985, BIOCHEM BIOPH RES CO, V133, P702, DOI 10.1016/0006-291X(85)90961-1; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GIARDINA SL, 1987, ANAL BIOCHEM, V161, P109, DOI 10.1016/0003-2697(87)90659-2; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; LOWY DR, 1986, CANCER SURV, V5, P275; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUZUKI H, 1989, EXP CELL RES, V184, P524, DOI 10.1016/0014-4827(89)90350-9; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TARPLEY WG, 1986, P NATL ACAD SCI USA, V83, P3703, DOI 10.1073/pnas.83.11.3703; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	42	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					731	737						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1905005				2022-12-28	WOS:A1991GT82500007
J	FRAME, MC; WILKIE, NM; DARLING, AJ; CHUDLEIGH, A; PINTZAS, A; LANG, JC; GILLESPIE, DAF				FRAME, MC; WILKIE, NM; DARLING, AJ; CHUDLEIGH, A; PINTZAS, A; LANG, JC; GILLESPIE, DAF			REGULATION OF AP-1/DNA COMPLEX-FORMATION INVITRO	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; JUN PROTO-ONCOGENE; DNA-BINDING; RAT FIBROBLASTS; GENE; EXPRESSION; PROMOTER; FOS; TPA; IDENTIFICATION	The level of AP-1 DNA-binding activity exhibited in vitro by unfractionated extracts of Hela nuclei can be stimulated by a low molecular weight fraction from rabbit reticulocyte lysate. Stimulation also requires a heat labile component of the nuclear extract, probably a protein. Stimulated and unstimulated extracts with high and low AP-1 DNA-binding activities contain the same levels of proteins reactive with antisera against Jun and Fos, proteins which are shown to be involved in the AP-1/DNA complexes detected in vitro. The low molecular weight fraction from reticulocyte lysate can be substituted by the reducing agent dithiothreitol (DTT) in the stimulation reaction and conversely oxidised glutathione greatly reduces formation of AP-1/DNA complexes. The binding activities of transcription factors SP-1, NF-1 and CBP are unaffected by DTT or oxidised glutathione. These observations, taken together, suggest that the efficiency with which pre-existing Fos and Jun proteins can bind an AP-1 target sequence in vitro can be controlled by a nuclear activity which is sensitive to oxidation/reduction and that this control mechanism is specific for AP-1.			FRAME, MC (corresponding author), BEATSON INST CANC RES,BEATSON LABS,CANC RES CAMPAIGN,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARNHART KM, 1988, MOL CELL BIOL, V8, P3215, DOI 10.1128/MCB.8.8.3215; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; FULTON R, 1990, J VIROL, V64, P1675, DOI 10.1128/JVI.64.4.1675-1682.1990; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maniatis T., 1982, MOL CLONING; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MULLER R, 1987, ONCOGENE RES, V2, P19; NISHIMURA T, 1988, ONCOGENE, V3, P659; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P63; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1990, ONCOGENE, V5, P161	25	53	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					205	209						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900354				2022-12-28	WOS:A1991FZ13400004
J	ZHAO, X; SINGH, B; BATTEN, BE				ZHAO, X; SINGH, B; BATTEN, BE			THE ROLE OF C-MOS PROTO-ONCOPROTEIN IN MAMMALIAN MEIOTIC MATURATION	ONCOGENE			English	Article							KINASE-ACTIVITY; DEVELOPMENTAL REGULATION; OOCYTE MATURATION; ONCOGENE PRODUCT; MOUSE-TISSUES; GERM-CELLS; V-MOS; EXPRESSION; EGGS; TRANSCRIPTS	The developmentally regulated expression of c-mos oncogene has led to the speculation that this gene may be involved in gametogenesis and early development. To directly test this possibility, we have used an electric field mediated transfer method to introduce an antibody against the c-mos gene product into living immature mouse oocytes. Control oocytes exposed to the electric field without antibody, non-immune IgG, or c-mos antibody pre-absorbed with the mos peptide underwent normal germinal vesicle breakdown (GVBD) (90%) and formed a polar body by 8 h. Oocytes transferred with antibody against c-mos product underwent GVBD, and chromosome condensation as judged by Hoechst 33258 staining. However, antibody transferred oocytes did not form a polar body. Confocal fluorescence microscopy using antibodies against tubulin demonstrated that 90% of the oocytes that received antibody against c-mos did not assemble a meiotic spindle. In a few instances an abnormal spindle-like structure did form. Electron microscopy confirmed that the nuclear envelope disassembled and revealed many microtubules in a disorganized manner. Western blot analysis showed the presence of p39c-mos in mouse mature oocytes, spermatocytes and granulosa cells. These results suggest a role for c-mos in regulating the assembly and/or function of the spindle during meiotic division in murine.	OHIO STATE UNIV,DEPT ANAT,COLUMBUS,OH 43210; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	Ohio State University; University of Texas System; UTMD Anderson Cancer Center								BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; HOGAN B, 1986, MANIPULATING MANIPUL; KESHET E, 1988, ONCOGENE, V2, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MINSHULL J, 1989, VIROLOGY, V56, P947; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHOLEY J M, 1985, Journal of Cell Biology, V101, p31A; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; Zhao X., 1989, TECHNIQUES J METHODS, V1, P37; ZHAO X, 1990, IN PRESS ONCOGENE	38	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					43	49						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1825139				2022-12-28	WOS:A1991EY03900006
J	LONGO, L; DONTI, E; MENCARELLI, A; AVANZI, G; PEGORARO, L; ALIMENA, G; TABILIO, A; VENTI, G; GRIGNANI, F; PELICCI, PG				LONGO, L; DONTI, E; MENCARELLI, A; AVANZI, G; PEGORARO, L; ALIMENA, G; TABILIO, A; VENTI, G; GRIGNANI, F; PELICCI, PG			MAPPING OF CHROMOSOME-17 BREAKPOINTS IN ACUTE MYELOID LEUKEMIAS	ONCOGENE			English	Article									UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY; UNIV ROME, CATTEDRA EMATOL, I-00161 ROME, ITALY; UNIV TURIN, OSPED MAGGIORE S GIOVANNI, IST MED INTERNA, I-10126 TURIN, ITALY	University of Perugia; Sapienza University Rome; University of Turin			Pelicci, Pier Giuseppe/AAL-6572-2020					BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BURGESS AW, 1980, BLOOD, V56, P947; CANAANI E, 1984, LANCET, V1, P593; CHANDLER ME, 1978, CYTOGENET CELL GENET, V22, P352, DOI 10.1159/000130970; CHANG KS, 1987, LEUKEMIA, V1, P458; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALTON WT, 1988, BLOOD, V71, P242; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DEBRAEKELEER M, 1986, CANCER GENET CYTOGEN, V19, P311, DOI 10.1016/0165-4608(86)90060-9; DONTI E, 1989, SCIENCE, V244, P824, DOI 10.1126/science.244.4906.824; DONTI E, 1989, MED ONCOL TUMOR PHAR, V6, P233; GALLAGHER R, 1979, BLOOD, V54, P713; GERHARD DS, 1981, P NATL ACAD SCI-BIOL, V78, P3755, DOI 10.1073/pnas.78.6.3755; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; JONES ME, 1978, AM J MED, V65, P673, DOI 10.1016/0002-9343(78)90856-2; KANEKO Y, 1987, JPN J CANCER RES, V78, P16; KOEFFLER HP, 1987, ANN INTERN MED, V107, P748, DOI 10.7326/0003-4819-107-5-748; KOEFFLER HP, 1985, BLOOD, V65, P484; KUN SC, 1986, BLOOD, V68, P1411; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LARSON RA, 1983, CANCER GENET CYTOGEN, V10, P219, DOI 10.1016/0165-4608(83)90050-X; LIANG JC, 1988, CANCER GENET CYTOGEN, V30, P103, DOI 10.1016/0165-4608(88)90097-0; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MISAWA S, 1986, CANCER GENET CYTOGEN, V22, P239, DOI 10.1016/0165-4608(86)90160-3; MITELMAN F, 1986, CANCER GENET CYTOGEN, V22, P95, DOI 10.1016/0165-4608(86)90168-8; MITELMAN F, 1981, HEREDITAS, V95, P79; Mitelman F., 1988, CATALOG CHROMOSOME A; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; ROWLEY JD, 1984, CANCER RES, V44, P3159; ROWLEY JD, 1983, NATURE, V301, P290, DOI 10.1038/301290a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SIMMERS RN, 1987, BLOOD, V70, P330; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TESTA JR, 1985, CANCER RES, V45, P430; TWEARDY DJ, 1987, ONCOGENE RES, V1, P209; VANDENBERGHE H, 1979, CANCER, V43, P558, DOI 10.1002/1097-0142(197902)43:2<558::AID-CNCR2820430223>3.0.CO;2-6; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WOLMAN SR, 1985, CANCER GENET CYTOGEN, V17, P133, DOI 10.1016/0165-4608(85)90023-8; XU WM, 1988, P NATL ACAD SCI USA, V85, P8563, DOI 10.1073/pnas.85.22.8563; YAMADA M, 1984, J BIOL CHEM, V259, P3021; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZILE MH, 1987, P NATL ACAD SCI USA, V84, P2208, DOI 10.1073/pnas.84.8.2208; 1978, CYTOGENET CELL GENET, V21, P399; 1987, CYTOGENET CELL GENET, V46, P22	55	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1557	1563						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	1701231				2022-12-28	WOS:A1990EK50200016
J	RAY, D; CULINE, S; TAVITIAN, A; MOREAUGACHELIN, F				RAY, D; CULINE, S; TAVITIAN, A; MOREAUGACHELIN, F			THE HUMAN HOMOLOG OF THE PUTATIVE PROTOONCOGENE SPI-1 - CHARACTERIZATION AND EXPRESSION IN TUMORS	ONCOGENE			English	Article											RAY, D (corresponding author), FAC MED LARIBOISIERE,INSERM,U248,10 AVE VERDUN,F-75010 PARIS,FRANCE.		Ray-Gallet, Dominique/A-9224-2019					BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COLLINS SJ, 1987, BLOOD, V70, P1233; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DOMEN J, 1987, ONCOGENE RES, V1, P103; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LISCIA DS, 1989, ONCOGENE, V4, P1219; MATHIS DJ, 1981, NATURE, V290, P310, DOI 10.1038/290310a0; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1989, IN PRESS LEUKEMIA; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NGUYEN VC, 1990, IN PRESS HUMAN GENET; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OLOFSSON B, 1988, ONCOGENE, V3, P231; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SILVERSTEIN RL, 1987, J CLIN INVEST, V79, P867, DOI 10.1172/JCI112896; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; THEILLET C, 1989, ONCOGENE, V4, P915; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; ZHOU DJ, 1988, ONCOGENE, V2, P279	36	63	65	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					663	668						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	1693183				2022-12-28	WOS:A1990DG37400005
J	SORVILLO, JM; MCCORMACK, ES; YANEZ, L; VALENZUELA, D; REYNOLDS, FH				SORVILLO, JM; MCCORMACK, ES; YANEZ, L; VALENZUELA, D; REYNOLDS, FH			PREPARATION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR HUMAN TRANSFORMING GROWTH FACTOR-ALPHA	ONCOGENE			English	Article											SORVILLO, JM (corresponding author), ONCOGENE SCI INC,350 COMMUNITY DR,MANHASSET,NY 11030, USA.							ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KIMBALL ES, 1984, CANCER RES, V44, P3616; KOBRIN MS, 1987, ENDOCRINOLOGY, V121, P1412, DOI 10.1210/endo-121-4-1412; KOBRIN MS, 1986, J BIOL CHEM, V261, P4414; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; KUDLOW JE, 1987, ENDOCRINOLOGY, V121, P1577, DOI 10.1210/endo-121-4-1577; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR E, 1988, MOL CELL BIOL, V8, P1247, DOI 10.1128/MCB.8.3.1247; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; LINSLEY PS, 1985, P NATL ACAD SCI USA, V82, P356, DOI 10.1073/pnas.82.2.356; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARQUARDT H, 1982, J BIOL CHEM, V257, P5220; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; NESTOR JJ, 1985, BIOCHEM BIOPH RES CO, V129, P226, DOI 10.1016/0006-291X(85)91426-3; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; TAM JP, 1986, P NATL ACAD SCI USA, V83, P8082, DOI 10.1073/pnas.83.21.8082; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHEYNINGEN V, 1983, J IMMUNOL METHODS, V62, P147, DOI 10.1016/0022-1759(83)90000-5; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WINKLER ME, 1986, J BIOL CHEM, V261, P3838; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	36	88	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					377	386						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690379				2022-12-28	WOS:A1990CW41500016
J	ADAMS, JM; HOUSTON, H; ALLEN, J; LINTS, T; HARVEY, R				ADAMS, JM; HOUSTON, H; ALLEN, J; LINTS, T; HARVEY, R			THE HEMATOPOIETICALLY EXPRESSED VAV PROTOONCOGENE SHARES HOMOLOGY WITH THE DBL GDP-GTP EXCHANGE FACTOR, THE BCR GENE AND A YEAST GENE (CDC24) INVOLVED IN CYTOSKELETAL ORGANIZATION	ONCOGENE			English	Article							CEREVISIAE CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CDNA SEQUENCE; ZINC-FINGER; BINDING; MYC; PROTEINS; PRODUCT; CDC42	The vav proto-oncogene encodes a protein of unknown function that is rendered oncogenic by loss of a short N-terminal domain. A correction reported here to the vav sequence reveals that a central domain of some 230 amino acids is similar to the products of three genes: the human dbl oncogene, now known to encode a GDP-GTP exchange factor for the Ras-like polypeptide CDC42Hs; the CDC24 gene of Saccharomyces cerevisiae, which participates with CDC42Sc in organization of the cytoskeleton for budding; and the human bcr gene, which recombines with the abl oncogene in certain forms of leukemia. Furthermore. the N-terminal portion of Vav (and of CDC24) is similar to that of certain proteins that associate with filamentous structures. These similarities suggest that Vav, and perhaps also Bcr, may function as a GDP-GTP exchange factor for a Ras-like molecule such as CDC42Hs, and that its action may coordinate cytoplasmic architecture with the cell cycle. Reported evidence that the vav proto-oncogene is widely expressed in hematopoietic cells but not other cell types is extended here by detection of vav mRNA in 49 of 50 murine hematopoietic cell lines representing diverse hematopoietic lineages, and by in situ hybridization in embryos showing expression confined to the only hematopoietic tissue, fetal liver. Thus, like Dbl in other cell types, Vav may function throughout the hematopoietic compartment to govern a Ras-like signal transduction pathway.			ADAMS, JM (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Adams, Jerry M/E-1199-2013; Lints, Thierry/K-4408-2012	Harvey, Richard/0000-0002-9950-9792; Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [R01CA012421] Funding Source: NIH RePORTER; NCI NIH HHS [CA12421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ALMENDRAL JM, 1989, EXP CELL RES, V181, P518, DOI 10.1016/0014-4827(89)90108-0; AYMESOUTHGATE A, 1989, J CELL BIOL, V108, P521, DOI 10.1083/jcb.108.2.521; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERNARD O, 1989, J NEUROSCI RES, V24, P9, DOI 10.1002/jnr.490240104; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DALEY GQ, 1991, IN PRESS ADV CANCER, V57; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EFLANTY A, 1992, IN PRESS BLOOD; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GRAZIANI G, 1989, ONCOGENE, V4, P823; GREEN A, 1992, IN PRESS ONCOGENE; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PEARLSTONE JR, 1987, J BIOL CHEM, V262, P5985; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	59	196	203	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					611	618						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565462				2022-12-28	WOS:A1992HQ68200001
J	BLAKE, TJ; LANGDON, WY				BLAKE, TJ; LANGDON, WY			A REARRANGEMENT OF THE C-CBL PROTOONCOGENE IN HUT78 T-LYMPHOMA CELLS RESULTS IN A TRUNCATED PROTEIN	ONCOGENE			English	Article							BCR GENE; CHROMOSOMAL TRANSLOCATION; ACUTE-LEUKEMIA; ALU SEQUENCES; IDENTIFICATION; BREAKPOINTS; RETROVIRUS; NEOPLASIA; REGION	The murine Cas NS-1 retrovirus carries the v-cbl oncogene and induces pro-B, pre-B and myeloid tumors in mice inoculated at birth. The human homolog of v-cbl is located on chromosome 11q23.3, which is in the region of translocation breakpoints in a range of acute leukemias. The sequencing of the human and murine c-cbl proto-oncogenes has revealed v-cbl as a markedly truncated form of c-cbl that encompasses 40% of the amino terminus. This truncation deletes a proline- and serine/threonine-rich domain and a putative leucine zipper. In this study we describe the nature of a truncated form of c-cbl present in the cutaneous T-cell lymphoma line HUT78. In these cells a genetic rearrangement involving unknown sequences and Alu repeat sequences results in the insertion of a premature stop codon that removes 259 amino acids from the carboxy terminus. This results in the translation of a 72 kDa protein, compared with the 120 kDa protein encoded by full-length c-cbl, which lacks a portion of the proline-rich domain and the entire leucine zipper.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia								BLAKE TJ, 1991, ONCOGENE, V6, P653; CHEN SJ, 1989, ONCOGENE, V4, P195; COTTER FE, 1991, GENE CHROMOSOME CANC, V3, P8, DOI 10.1002/gcc.2870030103; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; FAN YS, 1988, CANCER GENET CYTOGEN, V31, P263, DOI 10.1016/0165-4608(88)90226-9; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; GAZDAR AF, 1980, BLOOD, V55, P409; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LANGDON WY, 1984, CURR TOP MICROBIOL, V113, P241; NAGASAKA M, 1983, BLOOD, V61, P1174; ROGERS J, 1985, NATURE, V317, P559, DOI 10.1038/317559a0; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRONG RC, 1985, BLOOD, V65, P21; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TUNNACLIFFE A, 1990, GENOMICS, V8, P447, DOI 10.1016/0888-7543(90)90030-X; VANDERFELTZ MJM, 1989, NUCLEIC ACIDS RES, V17, P1, DOI 10.1093/nar/17.1.1	23	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					757	762						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565471				2022-12-28	WOS:A1992HQ68200019
J	ADACHI, M; RYO, R; YOSHIDA, A; SUGANO, W; YASUNAGA, M; SAIGO, K; YAMAGUCHI, N; SATO, T; SANO, K; KAIBUCHI, K; TAKAI, Y				ADACHI, M; RYO, R; YOSHIDA, A; SUGANO, W; YASUNAGA, M; SAIGO, K; YAMAGUCHI, N; SATO, T; SANO, K; KAIBUCHI, K; TAKAI, Y			INDUCTION OF SMG P21/RAP1A P21/KREV-1 P21 GENE-EXPRESSION DURING PHORBOL ESTER-INDUCED DIFFERENTIATION OF A HUMAN MEGAKARYOCYTIC LEUKEMIA-CELL LINE	ONCOGENE			English	Article							GTP-BINDING PROTEIN; PUTATIVE EFFECTOR DOMAIN; RAS-RELATED PROTEIN; ACTIVATING PROTEIN; BOVINE BRAIN; HUMAN-PLATELETS; KINASE-C; TYROSINE PHOSPHORYLATION; NUCLEOTIDE-SEQUENCE; MOLECULAR-WEIGHT	smg p21A and -B (smg p21s) are ras p21-like small GTP-binding proteins (G proteins) with the same putative effector domain as ras p21s. Both smg p21A mRNA and smg p21B mRNA were detected in CMK, a human megakaryocytic leukemia cell line, and their levels were markedly elevated by treatment with 12-O-tetradecanoyl-phorbol-13-acetate (TPA), which caused the differentiation of this cell line into more mature megakaryocytes. The smg p21 protein molecules also increased during the TPA-induced differentiation of CMK cells. The mRNA level of glycoprotein IIb (GPIIb), a typical marker of the megakaryocytes, was increased by this treatment, but the time course of the increase in the smg p21 mRNA levels as more rapid than that of the increase in the GPIIb mRNA level. Ha-ras p21 mRNA was undetectable, but both Ki- and N-ras p21 mRNAs were detected in CMK cells and their levels were also increased during TPA-induced differentiation of CMK cells, although to a lesser extent than those of smg p21 mRNAs. Protein kinase C inhibitors inhibited the basal and TPA-induced smg p21A mRNA level, but cyclic AMP-elevating prostaglandin E1 or Ca2+-mobilizing ionomycin did not inhibit them. Cycloheximide enhanced the basal and TPA-induced smg p21A mRNA levels. Actinomycin D blocked the TPA-induced smg p21A mRNA levels, but showed no detectable effect on the elevated smg p21A mRNA level which was induced by pretreatment with TPA. A dramatic increase in the smg p21 mRNA levels was also observed in other leukemia cell lines during TPA-induced differentiation. These results suggest that TPA stimulated expression of the smg p21A gene, presumably through the action of protein kinase C at the transcriptional level rather than at the post-transcriptional level, in hematopoietic leukemia cells.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT LAB MED,KOBE 650,JAPAN; KOBE UNIV HOSP,BLOOD TRANSFUS SERV,KOBE 650,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHIBA 280,JAPAN; KOBE UNIV,SCH MED,DEPT PEDIAT,KOBE 650,JAPAN	Kobe University; Kobe University; Kobe University; Chiba University; Kobe University								ADACHI M, 1989, CANCER RES, V49, P3805; ADACHI M, 1988, ACTA HAEMATOL JAPON, V51, P1069; ADACHI M, 1991, IN PRESS EXP HEMATOL; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BRETONGORIUS J, 1986, SEMIN HEMATOL, V23, P43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FERRERO D, 1983, BLOOD, V61, P171; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HIROSE M, 1983, ACTA HAEMATOL JAPON, V46, P729; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KAWATA M, 1991, ONCOGENE, V6, P841; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOMATSU N, 1989, BLOOD, V74, P42; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MAZUR EM, 1987, EXP HEMATOL, V15, P348; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NAGASAWA K, 1981, J CELL PHYSIOL, V109, P181, DOI 10.1002/jcp.1041090120; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHMORI T, 1988, BIOCHEM BIOPH RES CO, V157, P670, DOI 10.1016/S0006-291X(88)80302-4; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; PONCZ M, 1987, J BIOL CHEM, V262, P8476; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RYO R, 1991, CANCER, V67, P960, DOI 10.1002/1097-0142(19910215)67:4<960::AID-CNCR2820670418>3.0.CO;2-V; RYO R, 1990, EXP HEMATOL, V18, P271; SACCHI N, 1984, CELL IMMUNOL, V84, P65, DOI 10.1016/0008-8749(84)90077-7; SAKAGAMI H, 1984, LEUKEMIA RES, V8, P187, DOI 10.1016/0145-2126(84)90142-5; Sambrook J, 1989, MOL CLONING LABORATO; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TAKAI Y, 1991, IN PRESS INT REV CYT; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; YAMASHITA T, 1988, J BIOL CHEM, V263, P17181	61	19	20	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					323	329						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549353				2022-12-28	WOS:A1992HG98200018
J	OHUCHI, T; KURITA, Y; SASAI, H; MIYOSHI, J; NOMURA, T; TOYOSHIMA, K				OHUCHI, T; KURITA, Y; SASAI, H; MIYOSHI, J; NOMURA, T; TOYOSHIMA, K			ONCOGENIC ACTIVATION OF MURINE MOS PROTEIN-KINASE BY DNA REARRANGEMENT OF ITS N-TERMINAL CODING REGION	ONCOGENE			English	Article							C-MOS; SARCOMA-VIRUS; SEQUENCE; PRODUCT; MATURATION; VECTORS; CLONING; GENOME; GENES; EGGS	An activated c-mos oncogene was detected by DNA transfection assay of hamster SHOK cells with DNAs from X-ray-induced mouse osteosarcoma. It was molecularly cloned by the cosmid rescue method and found to form transformed foci of SHOK cells. Genomic DNA sequencing revealed that in this oncogene the N-terminal coding region of the mouse proto-mos gene was deleted and replaced by a hamster-derived sequence in the primary transformant, suggesting that activation was due to the rearrangement during transfection. The gene product was about 37 kDa and was immunoprecipitated with anti-mos antibody from a lysate of a SHOK cell transfectant. This truncated mos (t-mos) gene transformed SHOK cells more effectively than v-mos. A chimeric gene construct of this hamster-derived upstream sequence and normal mouse c-mos also transformed SHOK cells at a lower level, whereas neither t-mos nor the chimeric c-mos gene transformed NIH3T3 cells appreciably. The high transforming efficiency of t-mos in SHOK cells was due not only to truncation of the coding region but also to its integration under a putative promoter sequence derived from the hamster genome. This is the first report of detection of an activated c-mos gene by DNA transfection assay.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,DEPT RADIAT BIOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University								BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; BRADY G, 1984, GENE, V27, P223, DOI 10.1016/0378-1119(84)90143-4; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUJIMOTO S, 1985, P NATL ACAD SCI USA, V82, P2072, DOI 10.1073/pnas.82.7.2072; GERBAUD C, 1981, CURR GENET, V3, P173, DOI 10.1007/BF00429819; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; Maniatis T, 1989, DECONTAMINATION DILU; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MIYOSHI J, 1991, IN PRESS MOL CELL BI; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAPKOFF J, 1981, CELL, V27, P109, DOI 10.1016/0092-8674(81)90365-2; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0	27	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					331	338						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532243				2022-12-28	WOS:A1992HG98200019
J	MCDONNELL, PC; KUMAR, S; RABSON, AB; GELINAS, C				MCDONNELL, PC; KUMAR, S; RABSON, AB; GELINAS, C			TRANSCRIPTIONAL ACTIVITY OF REL FAMILY PROTEINS	ONCOGENE			English	Article							NF-KAPPA-B; LONG TERMINAL REPEAT; AVIAN RETICULOENDOTHELIOSIS VIRUS; TRANSFORMED LYMPHOID-CELLS; V-REL; CYTOPLASMIC PROTEIN; CELLULAR PROTEINS; ONCOGENE ENCODES; BINDING PROTEINS; MAMMALIAN-CELLS	Our studies originally demonstrated that the v-rel oncoprotein repressed gene expression in chicken lymphoid cells, while it activated transcription in rodent fibroblasts. Here we report that the c-rel protein can activate expression of genes linked to kappa-B motifs when low levels of endogenous kappa-B-binding activity are present. In contrast v-rel, and to a lesser extent c-rel, inhibit NF-kappa-B-mediated activation of the human immunodeficiency virus long terminal repeat (HIV LTR) in phorbol ester-stimulated HeLa cells. Competition assays show that v-rel competitively inhibits both NF-kappa-B and c-rel-mediated transcriptional activation. Analysis of mutant HIV LTR-chloramphenicol acetyltransferase (CAT) constructs in which all Sp1 or both NF-kappa-B elements have been deleted shows that NF-kappa-B motifs are required for rel-mediated effects on gene expression. Transforming v-rel mutants compete efficiently with phorbol ester-activated kappa-B factors, whereas a transformation-defective mutant of v-rel is impaired in this activity. Taken together, these results strengthen the hypothesis that v-rel functions as a dominant interfering member of rel family proteins. These results also suggest that the ability of v- and c-rel to activate or repress gene expression in specific cells may result from their capacity to compete with endogenous rel family proteins whose expression and/or activity are cell-specific.	CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center								BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BHAT GV, 1990, ONCOGENE, V5, P625; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; INOUE JI, 1991, P NATL ACAD SCI USA, V8, P3715; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOO HM, 1991, J VIROL, V65, P4769, DOI 10.1128/JVI.65.9.4769-4776.1991; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MORRISON LE, 1989, ONCOGENE, V4, P677; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THEILEN GH, 1966, J NATL CANCER I, V37, P731; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; YAMAGUCHI Y, 1989, J VIROL, V63, P1040, DOI 10.1128/JVI.63.3.1040-1048.1989	47	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					163	170						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741161				2022-12-28	WOS:A1992HC22700022
J	STACEY, DW; ROUDEBUSH, M; DAY, R; MOSSER, SD; GIBBS, JB; FEIG, LA				STACEY, DW; ROUDEBUSH, M; DAY, R; MOSSER, SD; GIBBS, JB; FEIG, LA			DOMINANT INHIBITORY RAS MUTANTS DEMONSTRATE THE REQUIREMENT FOR RAS ACTIVITY IN THE ACTION OF TYROSINE KINASE ONCOGENES	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; CELL-PROLIFERATION; H-RAS; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; GENE FAMILY; PRODUCT P21; EXPRESSION	Two inhibitory Ras mutant proteins [(Asn 17) Ras and RAS(T)] were microinjected into NIH3T3 cells in order to compare their inhibitory activity with that of a neutralizing anti-ras antibody. Both mutants were able to block efficiently the mitogenic effects of serum added to quiescent NIH3T3 cells. Furthermore, each of the inhibitors blocked cell cycle progression at the same point as the injected anti-ras antibody, just prior to the initiation of a new round of DNA synthesis. Finally, as with the injected anti-ras antibody, each of the inhibitors was efficiently able to block proliferation and reverse the transformed morphology of cells transformed by tyrosine kinase oncogenes, while cells transformed by serine kinase oncogenes were unaffected. Therefore, results with all three reagents clearly indicate that cellular Ras activity is required in the late G1 phase of the cell cycle and is essential for the maintenance of the transformed phenotype induced by tyrosine but not serine kinase oncogenes. These studies demonstrate the utility of dominant inhibitory mutants as a means of interfering with the activity of cellular oncogenes.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486	Tufts University; Merck & Company	STACEY, DW (corresponding author), CLEVELAND CLIN EDUC FDN,DEPT MOLEC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44106, USA.			Roudebush, Margaret/0000-0001-9005-3672				BALTUS E, 1988, P NATL ACAD SCI USA, V85, P502, DOI 10.1073/pnas.85.2.502; BOS JL, 1989, CANCER RES, V49, P4682; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; STACEY DW, 1988, COLD SPRING HARB SYM, V53, P871, DOI 10.1101/SQB.1988.053.01.100; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	37	106	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2297	2304						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766676				2022-12-28	WOS:A1991GX73500018
J	RADICE, P; SOZZI, G; MIOZZO, M; DEBENEDETTI, V; CARIANI, T; BONGARZONE, I; SPURR, NK; PIEROTTI, MA; DELLAPORTA, G				RADICE, P; SOZZI, G; MIOZZO, M; DEBENEDETTI, V; CARIANI, T; BONGARZONE, I; SPURR, NK; PIEROTTI, MA; DELLAPORTA, G			THE HUMAN TROPOMYOSIN GENE INVOLVED IN THE GENERATION OF THE TRK ONCOGENE MAPS TO CHROMOSOME 1Q31	ONCOGENE			English	Note							THYROID PAPILLARY CARCINOMAS; SOMATIC-CELL HYBRIDS; RET PROTO-ONCOGENE; ASSIGNMENT; EXPRESSION; KINASE; MUSCLE; TISSUE; PTC	The chromosomal localization of hTMnm, a gene coding for a cytoskeletal tropomyosin non-muscle isoform involved in the activation of the TRK proto-oncogene in various human tumors, was determined by Southern blot analysis of a panel of human-rodent somatic cell hybrids. Using as a probe an Alu-free intronic fragment related to the tropomyosin sequence fused to the TRK tyrosine kinase domain, the hTMnm gene was assigned to the long arm of chromosome 1. Subsequently, in situ hybridization of the same probe to human metaphase chromosomes localized the hTMnm gene to 1q31. Since we have recently assigned the TRK locus to chromosome 1q32-q41, the generation of the hybrid transforming sequence tropomyosin-TRK may be due to an intrachromosomal rearrangement of the long arm of chromosome 1.	IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LID,HERTS,ENGLAND	Fondazione IRCCS Istituto Nazionale Tumori Milan			Radice, Paolo/O-3119-2013; Pierotti, Marco Alessandro/AAC-4728-2022; sozzi, gabriella/G-8259-2011; Miozzo, Monica Rosa/AAC-6401-2022; Bongarzone, Italia/B-9544-2017	Radice, Paolo/0000-0001-6298-4111; Pierotti, Marco Alessandro/0000-0002-7431-8332; sozzi, gabriella/0000-0001-9360-6914; Miozzo, Monica Rosa/0000-0002-6523-4575; Bongarzone, Italia/0000-0003-2530-9170				ANDREWS PW, 1985, ANN HUM GENET, V49, P31, DOI 10.1111/j.1469-1809.1985.tb01673.x; BONGARZONE I, 1989, ONCOGENE, V4, P1457; DONGHI R, 1989, ONCOGENE, V4, P521; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; FINE RE, 1975, J MOL BIOL, V95, P447, DOI 10.1016/0022-2836(75)90202-8; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; KIELTY CM, 1982, ANN HUM GENET, V46, P307, DOI 10.1111/j.1469-1809.1982.tb01582.x; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MAYALL BH, 1975, AUTOMATION CYTOGENET, P113; MIOZZO M, 1990, ONCOGENE, V5, P1411; NABHOLZ M, 1969, NATURE, V223, P358, DOI 10.1038/223358a0; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; SEWELL WA, 1988, IMMUNOGENETICS, V28, P278, DOI 10.1007/BF00345506; SHABTAI F, 1986, HUM GENET, V73, P232, DOI 10.1007/BF00401234; SOLOMON E, 1979, ANN HUM GENET, V42, P273, DOI 10.1111/j.1469-1809.1979.tb00661.x; SOZZI G, 1991, ONCOGENE, V6, P339; VANHEYNINGEN V, 1975, ANN HUM GENET, V38, P295; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021	27	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2145	2148						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1834975				2022-12-28	WOS:A1991GX11900027
J	DOZIER, C; ANSIEAU, S; FERREIRA, E; COLL, J; STEHELIN, D				DOZIER, C; ANSIEAU, S; FERREIRA, E; COLL, J; STEHELIN, D			AN ALTERNATIVELY SPLICED C-MIL/RAF MESSENGER-RNA IS PREDOMINANTLY EXPRESSED IN CHICKEN MUSCULAR TISSUES AND CONSERVED AMONG VERTEBRATE SPECIES	ONCOGENE			English	Note							ONCOGENE V-MIL; KINASE-ACTIVITY; RAF ONCOGENE; PROTEIN; PHOSPHORYLATION; ACTIVATION; GENE; SEQUENCE; RECEPTOR; IDENTIFICATION	The chicken c-mil gene produces two mRNA species generated by an alternative splicing mechanism. These two transcripts differ at least by the presence or absence of a 60 nucleotide exon (E7a) localized at the splice junction of c-mil exons 7 and 8. By using RNAase protection assays, we have analysed the pattern of expression of these two mRNA species in several chicken tissues. Here we report that the two c-mil mRNAs are differentially expressed in chicken tissues: the mRNA lacking E7a is detected in all tissues tested, while the mRNA containing E7a is detected only in the skeletal muscle, heart and brain. Sequences homologous to E7a have also been detected in DNAs from quail, mouse and human cells and their sequencing revealed that the alternative E7a is structurally preserved in these species. By PCR analyses performed on RNAs extracted from muscular tissues of these species, we also show that the alternative splicing mechanism described in chicken also occurs in these species.			DOZIER, C (corresponding author), INST PASTEUR,CNRS,UA 1160,INSERM,U186,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		Ansieau, Stephane/I-6195-2016; DOZIER, Christine/P-1539-2014	ANSIEAU, Stephane/0000-0003-0989-2108				BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANSEN HW, 1985, VIROLOGY, V143, P359, DOI 10.1016/0042-6822(85)90376-9; JANSEN HW, 1984, VIROLOGY, V137, P217, DOI 10.1016/0042-6822(84)90028-X; KOENEN M, 1988, ONCOGENE, V2, P179; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PATCHINSKY T, 1986, MOL CELL BIOL, V6, P739; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; STORM SM, 1990, ONCOGENE, V5, P345; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809	25	14	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1307	1311						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886707				2022-12-28	WOS:A1991GX27200002
J	MITSUDOMI, T; VIALLET, J; MULSHINE, JL; LINNOILA, RI; MINNA, JD; GAZDAR, AF				MITSUDOMI, T; VIALLET, J; MULSHINE, JL; LINNOILA, RI; MINNA, JD; GAZDAR, AF			MUTATIONS OF RAS GENES DISTINGUISH A SUBSET OF NON-SMALL-CELL LUNG-CANCER CELL-LINES FROM SMALL-CELL LUNG-CANCER CELL-LINES	ONCOGENE			English	Article							BLADDER-CARCINOMA ONCOGENE; POINT MUTATION; TUMOR PROGRESSION; P53 GENE; ACTIVATION; ADENOCARCINOMA; CARCINOGENESIS; AMPLIFICATION; INITIATION; EXPRESSION	We screened a panel of 103 human lung cancer cell lines for the presence of point mutations at codons 12, 13 or 61 of the human K-, H- and N-ras genes, using restriction fragment length polymorphisms (RFLP), created through mismatched primers during polymerase chain reaction (PCR) of genomic DNA. We found ras mutations in 22/61 (36%) non-small-cell lung cancer (NSCLC) cell lines, predominantly in K-ras codon 12. Identical mutations were present in uncultured tumor materials corresponding to 11 cell lines containing mutated ras genes. ras mutations were found not only in adenocarcinoma cell lines (9/32, 28%), but also in cell lines derived from other types of NSCLC (13/29, 45%). In contrast, none of 37 small-cell lung cancer (SCLC) cell lines and five extrapulmonary small-cell cancer cell lines had ras mutations. ras mutations were not correlated with sex of the patients, tumor extent, prior therapy status or in vitro culture time. G to T or A to T transversions were the most common base substitutions, occurring in codons 12 and 61 respectively. We conclude that ras mutations play a role in the pathogenesis of a subset of NSCLC but are not involved in SCLC.	NATL NAVAL MED CTR, NCI NAVY MED ONCOL BRANCH, BDG 8, RM 5101, BETHESDA, MD 20889 USA; NCI, NAVY MED ONCOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Mitsudomi, Tetsuya/0000-0001-9860-8505; Mulshine, James/0000-0002-4648-9177				BAKER SJ, 1990, CANCER RES, V50, P7717; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Battey, 1986, BASIC METHODS MOL BI; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BOS JL, 1989, CANCER RES, V49, P4682; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CARNEY DN, 1985, CANCER RES, V45, P2913; CHIBA I, 1990, ONCOGENE, V5, P1603; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; GAZDAR AF, 1986, CANCER GENET CYTOGEN, V19, P5, DOI 10.1016/0165-4608(86)90365-1; GAZDAR AF, 1990, JNCI-J NATL CANCER I, V82, P117, DOI 10.1093/jnci/82.2.117; GAZDAR AF, 1988, CANCER RES, V48, P4078; GUERRERO I, 1984, P NATL ACAD SCI USA, V79, P2845; JIANG W, 1989, ONCOGENE, V4, P923; JOHNSON BE, 1989, J NATL CANCER I, V81, P1223, DOI 10.1093/jnci/81.16.1223; KAGIMOTO M, 1985, INT J CANCER, V35, P809, DOI 10.1002/ijc.2910350618; KUMAR R, 1989, ONCOGENE RES, V1, P235; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MILLICI A, 1986, BIOCHEM BIOPH RES CO, V140, P699; MINNA JD, 1989, CC MOL BIOL, P57; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REMICK SC, 1987, MEDICINE, V66, P457, DOI 10.1097/00005792-198711000-00004; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STEVENSON H, 1990, ANN INTERN MED, V113, P764, DOI 10.7326/0003-4819-113-10-764; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	47	310	316	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1353	1362						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679529				2022-12-28	WOS:A1991GX27200010
J	SCHUUR, ER; BALUDA, MA				SCHUUR, ER; BALUDA, MA			PROTOONCOGENE EXPRESSION IN AVIAN HEMATOPOIETIC TISSUES	ONCOGENE			English	Article							MURINE SARCOMA VIRUS-3611; C-MYB PROTEIN; NF-KAPPA-B; V-MYB; MYELOBLASTOSIS VIRUS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; TRANSFORMING GENE; PROTOONCOGENE EXPRESSION	Previous findings from this laboratory (Kim & Baluda, 1988) have shown that the proto-oncogenes ETS, FPS, MHT (RAF), MYC and REL are expressed in avian myeloblastosis virus (AMV)-transformed cells, whereas the MYB gene is repressed. In this study five different chicken hematopoietic tissues which contained varying concentrations of target cells for AMV transformation were analyzed to determine whether the expression of these proto-oncogenes resulted from, or was altered by, v-myb-induced leukemogenesis. Poly-A+ RNA from hematopoietic cells of 11-13 day yolk sac, 16 day embryonic spleen, 1 day post-hatch bursa of Fabricius, bone marrow and thymus, as well as from chicken embryonic fibroblasts (CEF) was examined by Northern blot analysis. All five proto-oncogenes were found to be expressed in the normal hematopoietic tissues. The ETS, MHT (RAF), MYC, and REL genes, but not FPS, were expressed in CEF. The expression of these five proto-oncogenes was not quantitatively or qualitatively altered in AMV-transformed myeloid cells as compared with their normal counterparts. While their expression is part of the hematopoietic phenotype of the target cells and as such is necessary for susceptibility to AMV transformation, it is not sufficient because thymocytes with a high level of expression are not transformed. This is in contrast to MYB expression, which is totally repressed in leukemic cells but probably not as a result of v-myb expression.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [R01 CA 10197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1987, J IMMUNOL, V139, P3822; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DIETERLENLIEVRE F, 1986, VERTEBRATE BLOOD CEL; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORDELLIS CS, 1985, VIROLOGY, V141, P267, DOI 10.1016/0042-6822(85)90257-0; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HUANG CC, 1984, J VIROL, V50, P125, DOI 10.1128/JVI.50.1.125-131.1984; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KIM WK, 1988, ONCOGENE RES, V3, P147; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEE WH, 1980, P NATL ACAD SCI-BIOL, V77, P2018, DOI 10.1073/pnas.77.4.2018; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LIPSICK JS, 1984, CANCER CELLS, V2, P143; MCKEON C, 1988, CANCER RES, V48, P4307; Moscovici C., 1973, Methods Cell Biol, V7, P313; MOSCOVICI MG, 1979, IN VIVO IN VITRO ERY; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PREISLER HD, 1987, LEUKEMIA RES, V11, P923, DOI 10.1016/0145-2126(87)90138-X; ROMANOFF A, 1961, AVIAN EMBRYO; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; THOMPSON CB, 1986, NATURE, V319, P380; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984	62	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1409	1415						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886713				2022-12-28	WOS:A1991GX27200017
J	DOBASHI, Y; STERN, DF				DOBASHI, Y; STERN, DF			MEMBRANE-ANCHORED FORMS OF EGF STIMULATE FOCUS FORMATION AND INTERCELLULAR COMMUNICATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; STOMATITIS-VIRUS GLYCOPROTEIN; ALTERED CYTOPLASMIC DOMAINS; CELL-SURFACE; FACTOR PRECURSOR; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; SECRETORY PROTEIN; FACTOR-ALPHA; TRANSPORT	Epidermal growth factor (EGF) is the prototype for a small family of soluble proteins that bind to and activate the EGF receptor. These proteins are derived from larger propeptides that are anchored to the plasma membrane. Although the signalling properties of soluble EGF are well-characterized, the signalling potential of the membrane-anchored form had not been determined. We therefore investigated whether membrane-anchored EGF can stimulate the EGF receptor. An EGF mini-gene expression system that we had previously constructed for expression of soluble EGF was modified to encode anchored forms of EGF. In the encoded proteins EGF was fused to the spacer in the EGF propeptide that separates EGF from the transmembrane domain. The spacer was followed by vesicular stomatitis virus G protein transmembrane and cytoplasmic domain sequences. Three forms of EGF/G fusion protein were expressed in rat fibroblasts. The plasmids for expression of anchored EGF induced focus formation in rat fibroblasts, indicating that anchored EGF can cause autocrine transformation. When mixed with indicator HeLa cells, cell lines expressing EGF/G fusion proteins activated the HeLa EGF receptor. This activation was mediated by cell-associated, rather than soluble EGF. The finding that membrane-anchored EGF is capable of activating the EGF receptor on neighboring cells has broad implications for the functions of EGF in the organism.	YALE UNIV,SCH MED,DEPT PATHOL,310 CEDAR ST,POB 3333,NEW HAVEN,CT 06510	Yale University	STERN, DF (corresponding author), YALE UNIV,SCH MED,DEPT PATHOL,310 CEDAR ST,POB 3333,NEW HAVEN,CT 06510, USA.			Dobashi, Yoh/0000-0003-0507-3332	NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [CA45708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; DAVIS C G, 1990, New Biologist, V2, P410; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GUAN JL, 1988, MOL CELL BIOL, V8, P2869, DOI 10.1128/MCB.8.7.2869; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; GUAN JL, 1988, J BIOL CHEM, V263, P5306; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	39	24	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1151	1159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861865				2022-12-28	WOS:A1991GV26000009
J	PIERCE, JH; ARNSTEIN, P; DIMARCO, E; ARTRIP, J; KRAUS, MH; LONARDO, F; DIFIORE, PP; AARONSON, SA				PIERCE, JH; ARNSTEIN, P; DIMARCO, E; ARTRIP, J; KRAUS, MH; LONARDO, F; DIFIORE, PP; AARONSON, SA			ONCOGENIC POTENTIAL OF ERBB-2 IN HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							NEU ONCOGENE; EGF RECEPTOR; AMPLIFICATION; LINES; GENE; TRANSFORMATION; OVEREXPRESSION; ADENOCARCINOMA; PROTOONCOGENE; CARCINOMAS	Introduction of the normal erbB-2 gene into immortalized human mammary epithelial cells (184B5) by transfection conferred a growth advantage to these cells both in vitro and in vivo. The 184B5 cells overexpressing erbB-2 formed colonies in semi-solid medium, frequently induced transient nodules in athymic mice and produced progressive tumors in vivo at a low frequency. Those tumors which did arise from erbB-2-transfected cells displayed substantially higher levels of normal gp185erb-2 protein when compared to the original transfectants, consistent with their selection for increased erbB-2 expression. Introduction of genes encoding genetically altered erbB-2 molecules into 184B5 cells increased their colony-forming efficiency and converted the cells to a tumorigenic phenotype at a high frequency. When the biological and biochemical properties of human mammary carcinoma cell lines known to overexpress erbB-2 were compared to the transfected 184B5 lines, they behaved most like those overexpressing the normal erbB-2 protein. Results indicate that overexpression of normal erbB-2 may directly contribute to the transformation of human mammary epithelium if sufficient levels of erbB-2 protein are expressed or if the erbB-2 gene is genetically altered.	CALIF DEPT HLTH SERV,BERKELEY,CA 94704; IST NAZL RIC,I-16132 GENOA,ITALY; UNIV ROCHESTER,SCH MED,DEPT PATHOL,ROCHESTER,NY 14627	California Department of Health Care Services; University of Rochester	PIERCE, JH (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Di Marco, Eddi/AAB-5162-2021; Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CLARK R, 1988, CANCER RES, V48, P4689; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KOZBOR D, 1984, CANCER RES, V44, P438; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEGATTO O, 1988, MOL CELL BIOL, V8, P5510; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019	23	150	152	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1189	1194						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1713661				2022-12-28	WOS:A1991GV26000014
J	PATWARDHAN, S; GASHLER, A; SIEGEL, MG; CHANG, LC; JOSEPH, LJ; SHOWS, TB; LEBEAU, MM				PATWARDHAN, S; GASHLER, A; SIEGEL, MG; CHANG, LC; JOSEPH, LJ; SHOWS, TB; LEBEAU, MM			EGR3, A NOVEL MEMBER OF THE EGR FAMILY OF GENES ENCODING IMMEDIATE-EARLY TRANSCRIPTION FACTORS	ONCOGENE			English	Article							GROWTH-FACTORS ENCODES; ZINC-FINGER GENE; C-FOS; G0/G1 TRANSITION; MOLECULAR-CLONING; CULTURED-CELLS; BINDING-SITES; MESSENGER-RNA; HUMAN GENOME; EXPRESSION	We have previously described two cellular immediate-early genes, Egr-1 (mouse) and EGR2 (human) that encode zinc finger proteins. Here we report the characterization of a new member of the Egr family referred to as EGR3 (human). This cDNA clone was isolated using low stringency hybridization with the zinc finger domain of Egr-1. The EGR3 cDNA sequence predicts a 387 amino acid (a.a.) protein containing three Cys2-His2 zinc fingers nearly identical to those of Egr-1 and EGR2. This similarity has a functional consequence: EGR3 can activate transcription of a CAT gene linked to the sequence CGCCCCCGC, a cis element which is a target for Egr-1 and EGR2. We show that EGR3 is an immediate-early growth response gene induced by mitogenic stimulation of rodent and human fibroblasts and a monkey kidney epithelial cell line. The EGR3 gene has a single intron and maps to chromosome 8 at bands p21-23.	UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, HEMATOL ONCOL SECT, CHICAGO, IL 60637 USA; NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; Roswell Park Cancer Institute	LEBEAU, MM (corresponding author), UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA.			Groh, Margaret/0000-0002-7473-597X	NCI NIH HHS [CA40046] Funding Source: Medline; NICHD NIH HHS [HD05196] Funding Source: Medline; NIGMS NIH HHS [GM20454] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA040046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; Curran T, 1988, ONCOGENE HDB, P307; DOOLITTLE RF, 1986, URFS ORFS; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARTHA S, 1987, AM J PHYSIOL, V252, pF1175, DOI 10.1152/ajprenal.1987.252.6.F1175; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEBEAU MM, 1984, NATURE, V312, P70, DOI 10.1038/312070a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAYLOR SL, 1983, J EXP MED, V157, P1020, DOI 10.1084/jem.157.3.1020; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TSUI LC, 1989, CYTOGENET CELL GENET, V51, P166, DOI 10.1159/000132791; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	56	218	225	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					917	928						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906159				2022-12-28	WOS:A1991GU62200005
J	COROMINAS, M; LEON, J; KAMINO, H; CRUZALVAREZ, M; NOVICK, SC; PELLICER, A				COROMINAS, M; LEON, J; KAMINO, H; CRUZALVAREZ, M; NOVICK, SC; PELLICER, A			ONCOGENE INVOLVEMENT IN TUMOR-REGRESSION - H-RAS ACTIVATION IN THE RABBIT KERATOACANTHOMA MODEL	ONCOGENE			English	Article							BLADDER-CARCINOMA ONCOGENE; GROWTH-FACTOR RECEPTORS; MURINE SARCOMA-VIRUS; N-RAS; PROTO-ONCOGENE; NUCLEOTIDE-SEQUENCE; K-RAS; NEURONAL DIFFERENTIATION; GENETIC MECHANISMS; CELLS	Activated H-ras genes are present in a number of skin tumors induced in animals by carcinogen treatment. The involvement of the ras oncogenes in tumorigenesis was investigated in keratoacanthomas, benign and self-regressing tumors, as well as malignant squamous cell carcinomas. Both tumors were induced in rabbit ears by repeated applications of 7,12 dimethylbenz(a)anthracene (DMBA). The rabbit H-ras gene was cloned and sequenced. PCR analysis revealed that approximately 82% of the keratoacanthoma DNAs contained an A:T to T:A transversion in codon 61. The relative levels of H-ras transcript were increased in keratoacanthomas compared to normal skin and the activated allele was expressed in tumors, even during the regressing phase. Although a G:C to A:T mutation in codon 12 of the H-ras and an activated N-ras gene were found in two squamous cell carcinomas, the frequency of H-ras activation in codon 61 was much lower (40%) in the malignant tumours induced by the same carcinogen treatment. Therefore, DMBA induced at least two types of genetic lesions in this system: H-ras activation, present in most regressing keratoacanthomas, and activation of other unidentified oncogenes which may result in the development of malignant tumors. Our observations indicate that expression of an activated H-ras gene, in this system, is neither sufficient to induce a malignant phenotype nor even capable of maintaining the growth of a benign tumor and suggest that it could be involved in tumor regression.	NYU MED CTR,DEPT PATHOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			Leon, Javier/K-4615-2014; Corominas, Montserrat/K-6528-2012	Corominas, Montserrat/0000-0002-0724-8346; Kamino, Hideko/0000-0001-9256-5284; Leon, Javier/0000-0001-5803-0112; Pellicer, Angel/0000-0002-5062-0692	NCI NIH HHS [CA 50434, CA 36327, CA 16239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050434, R37CA036327, P01CA016239, R01CA036327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1988, CANCER RES, V48, P3253; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHENG JF, 1984, J MOL BIOL, V176, P1, DOI 10.1016/0022-2836(84)90379-6; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GHADIALLY FN, 1985, J PATHOLBACTERIOL, V75, P441; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRUTKIN L, 1966, DERMATOLOGICA, V132, P16, DOI 10.1159/000254393; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAMSELAAR CG, 1976, ACTA DERM-VENEREOL, V56, P245; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIH TY, 1979, VIROLOGY, V96, P64, DOI 10.1016/0042-6822(79)90173-9; SIGALIS, 1986, P NATL ACAD SCI USA, V83, P1986; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YUSPA SH, 1983, CANCER RES, V43, P6021; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	53	26	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					645	651						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1840681				2022-12-28	WOS:A1991FR93900021
J	SCHUERMANN, M; JOOSS, K; MULLER, R				SCHUERMANN, M; JOOSS, K; MULLER, R			FOSB IS A TRANSFORMING GENE ENCODING A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article							DNA-BINDING PROTEINS; JUN PROTO-ONCOGENE; C-FOS; LEUCINE ZIPPER; CYCLIC-AMP; V-FOS; NEGATIVE REGULATOR; MOUSE FIBROBLASTS; MAMMALIAN-CELLS; GROWTH-FACTORS	The fosB gene encodes a nuclear protein that shows a high degree of homology with c-Fos in several of the known functionally crucial domains, e.g., the leucine zipper and the DNA-binding site, but shows considerable divergence in other regions. Here, we report that FosB, when placed under the control of a constitutive promoter, exhibits clear transforming properties in focus assays using mouse NIH3T3 or rat 208F fibroblasts. The transforming potential of FosB is considerably stronger than that of a corresponding c-fos construct and resembles that of viral fos genes. Using chimeric fos/fosB constructs we show that the C-terminal half of FosB is responsible for these stronger transforming properties, apparently by giving rise to significantly higher levels of protein as compared with the corresponding c-fos sequence. Surprisingly, substitution of the N-terminus of Fos with that of FosB decreases its transforming potential. These differences in the transforming potential are not related to DNA or protein expression, but rather seem to reflect differences in the molecular function(s) encoded in the N-terminal halves of Fos and FosB protein. Both, fosB- and v-fos transformed cells show increased expression of a number of endogenous genes, including c-jun, transin, alpha-1(III) collagen and tissue plasminogen activator. Transactivation by FosB and v-fos of the c-jun and alpha-1(III) collagen gene promoters and of a 3 x TRE-tk chimeric promoter could be shown in transient CAT assays. v-Fos, but not FosB-transformed cells, also show elevated levels of urokinase and plasminogen activator inhibitor mRNAs, pointing to potential differences in the gene regulatory properties of the two Fos family members.			SCHUERMANN, M (corresponding author), UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, W-3550 MARBURG, GERMANY.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LIAU G, 1985, J BIOL CHEM, V260, P531; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATSUI M, 1990, ONCOGENE, V5, P249; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; REDEMANNFIBI B, 1991, IN PRESS DIFFERENTIA; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SETOYAMA C, 1986, BIOCHEM BIOPH RES CO, V136, P1042, DOI 10.1016/0006-291X(86)90438-9; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	73	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					567	576						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903195				2022-12-28	WOS:A1991FR93900010
J	LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA				LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA			COMPLEXITY OF THE IMMEDIATE EARLY RESPONSE OF MYELOID CELLS TO TERMINAL DIFFERENTIATION AND GROWTH ARREST INCLUDES ICAM-1, JUN-B AND HISTONE VARIANTS	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania					NCRR NIH HHS [SO7-RR-05415-27] Funding Source: Medline; NICHD NIH HHS [3T32HD07152] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007152] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005415] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALONSO A, 1988, EMBO J, V7, P3003, DOI 10.1002/j.1460-2075.1988.tb03163.x; BRADSHAW RA, 1987, ONCOGENES GROWTH FAC; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIU CP, 1989, J IMMUNOL, V142, P1909; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS SJ, 1987, BLOOD, V70, P1233; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOENECKE D, 1986, J MOL BIOL, V187, P461, DOI 10.1016/0022-2836(86)90446-8; DUSTIN ML, 1988, IMMUNOL TODAY, V9, P213, DOI 10.1016/0167-5699(88)91216-9; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOLDE DW, 1988, SCI AM, V259, P62, DOI 10.1038/scientificamerican0788-62; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOFFMANLIEBERMANN B, 1978, CELL, V14, P825, DOI 10.1016/0092-8674(78)90338-0; HOFFMANLIEBERMANN B, 1981, DEV BIOL, V81, P255, DOI 10.1016/0012-1606(81)90289-X; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUANG HS, 1989, SCIENCE, V242, P1563; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LANDSCHULTZ WH, 1988, SCIENCE, V240, P1769; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIEBERMANN D, 1982, INT J CANCER, V29, P159, DOI 10.1002/ijc.2910290208; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOTEM J, 1989, LEUKEMIA RES, V13, P13, DOI 10.1016/0145-2126(89)90026-X; METCALF D, 1984, HEMOPOIETIC COLONY S, P315; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; ROCHE J, 1985, NATURE, V314, P197, DOI 10.1038/314197a0; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHABO Y, 1988, BLOOD, V72, P1543; SHABO Y, 1988, BLOOD, V72, P2070; SITTMAN DB, 1983, NUCLEIC ACIDS RES, V11, P6679, DOI 10.1093/nar/11.19.6679; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAYLORPAPADIMIT.J, 1980, INTERFERON 1980, V2, P13; TRIONE F, 1989, P NATL ACAD SCI USA, V86, P2088; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WELLS D, 1985, P NATL ACAD SCI USA, V82, P2834, DOI 10.1073/pnas.82.9.2834; WINTROBE MM, 1981, CLIN HEMATOLOGY, P35; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WUNSCH AM, 1987, DEV BIOL, V119, P94, DOI 10.1016/0012-1606(87)90210-7	56	115	121	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					387	396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690380				2022-12-28	WOS:A1990CW41500017
J	MAESTRO, R; DOLCETTI, R; GASPAROTTO, D; DOGLIONI, C; PELUCCHI, S; BARZAN, L; GRANDI, E; BOIOCCHI, M				MAESTRO, R; DOLCETTI, R; GASPAROTTO, D; DOGLIONI, C; PELUCCHI, S; BARZAN, L; GRANDI, E; BOIOCCHI, M			HIGH-FREQUENCY OF P53-GENE ALTERATIONS ASSOCIATED WITH PROTEIN OVEREXPRESSION IN HUMAN SQUAMOUS-CELL CARCINOMA OF THE LARYNX	ONCOGENE			English	Article							HUMAN P53 GENE; LUNG-CANCER; BREAST-CANCER; BLAST CRISIS; ALLELE LOSS; MUTANT P53; EXPRESSION; MUTATIONS; ONCOGENE; REARRANGEMENT	A series of 58 primary human squamous cell carcinomas of the larynx (LSCCs) was examined for the expression of the p53 tumor-suppressor gene by a combined immunohistochemical and molecular approach. About 60% of the cases displayed nuclear p53 overexpression as revealed by immunostaining with PAb1801, PAb122 and PAb240 monoclonal antibodies. This phenomenon was associated with the presence of structural and/or transcriptional alterations of the p53 gene. Our results provide evidence that p53 abnormalities constitute the most frequent genetic alteration identified so far in LSCC and indicate that the abnormal accumulation of the protein correlates with the presence of p53-mutated versions. These findings, taken together with the peculiar biochemical properties of p53, support the hypothesis of a possible pathogenetic relationship between smoke carcinogen exposure and p53 inactivation in the development of this tumor type.	CTR RIFERIMENTO ONCOL,DIV EXPTL ONCOL 1,VIA PEDEMONTANA OCCIDENTALE,I-33081 AVIANO,ITALY; OSPED FELTRE,DIV PATHOL,FELTRE,ITALY; UNIV FERRARA,DEPT OTORHINOLARYNGOL,I-44100 FERRARA,ITALY; OSPED CIVILE,DIV OTORHINOLARYNGOL,PORDENONE,ITALY; UNIV FERRARA,DEPT PATHOL,I-44100 FERRARA,ITALY	IRCCS Aviano (CRO); ULSS 1 Dolomiti; Ospedale di Feltre; University of Ferrara; University of Ferrara			Maestro, Roberta/M-1846-2015; Dolcetti, Riccardo/O-3832-2015; Maestro, Roberta/P-9748-2019; Gasparotto, Daniela/Y-2351-2019	Maestro, Roberta/0000-0002-6642-5592; Dolcetti, Riccardo/0000-0003-1625-9853; Maestro, Roberta/0000-0002-6642-5592; Gasparotto, Daniela/0000-0003-0914-1654; DOGLIONI, Claudio/0000-0002-4969-5216				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BENDAVID Y, 1988, ONCOGENE, V3, P179; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN YM, 1991, ONCOGENE, V6, P1799; CHIBA I, 1990, ONCOGENE, V5, P1603; DOLCETTI R, 1988, EUR J CANCER CLIN ON, V24, P1321, DOI 10.1016/0277-5379(88)90223-4; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLANDERS WD, 1982, AM J EPIDEMIOL, V115, P371, DOI 10.1093/oxfordjournals.aje.a113315; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KELMAN Z, 1989, BLOOD, V74, P2318; KNUDSON AG, 1985, CANCER RES, V45, P1437; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; Kriek E, 1984, Biochim Biophys Acta, V738, P181; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACKAY J, 1988, LANCET, V2, P1384; Maniatis T, 1989, DECONTAMINATION DILU; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASHAL R, 1990, BLOOD, V75, P180; MASHARANI U, 1988, NUCLEIC ACIDS RES, V16, P7757, DOI 10.1093/nar/16.15.7757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEIER R, 1988, NUCLEIC ACIDS RES, V16, P2340, DOI 10.1093/nar/16.5.2340; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STELL PM, 1972, LANCET, V1, P617; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TUYNS AJ, 1982, INT J CANCER, V30, P9, DOI 10.1002/ijc.2910300103; VERONESI U, 1979, TUMORI TESTA COLLO; WOLF D, 1985, MOL CELL BIOL, V5, P1887, DOI 10.1128/MCB.5.8.1887; WOLF D, 1984, CELL, V38, P453; 1986, MONOGRAPHS EVALUATIO, V38	57	222	226	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1159	1166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594246				2022-12-28	WOS:A1992HU64200013
J	VEILLETTE, A; CARON, L; FOURNEL, M; PAWSON, T				VEILLETTE, A; CARON, L; FOURNEL, M; PAWSON, T			REGULATION OF THE ENZYMATIC FUNCTION OF THE LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56LCK BY THE NONCATALYTIC SH2 AND SH3 DOMAINS	ONCOGENE			English	Article							AMINO-TERMINAL DOMAIN; SIGNAL TRANSDUCTION; CD4 RECEPTOR; CYTOPLASMIC DOMAINS; CROSS-LINKING; C-ABL; V-FPS; PHOSPHORYLATION; ACTIVATION; GENE	The enzymatic activity of the lymphocyte-specific tyrosine protein kinase p56lck appears to be tightly regulated by phosphorylation of the conserved carboxy-terminal tyrosine residue 505. Indeed, substitution of this tyrosine residue by a non-phosphorylatable phenylalanine results in a constitutively activated version of p56lck that can transform rodent fibroblasts. In this report, we evaluate the functions of the conserved non-catalytic Src homology (SH) domains 2 and 3 of p56lck in the regulation of its enzymatic activity in NIH3T3 fibroblasts. We found that deletion of the SH2 or, to a lesser extent, the SH3 domain of p56lck resulted in an increase in the tyrosine protein kinase activity of wild-type Lck polypeptides. The SH2 domain (but not the SH3 domain) was also required for full oncogenic transformation by Lck molecules activated through removal of tyrosine 505. This effect did not appear to be the result of a diminution of the enhanced catalytic activity of F505 Lck polypeptides. However, it may relate to the findings that the SH2 domain can bind and possibly enhance phosphorylation of specific phosphotyrosine-containing proteins. Taken together, these observations imply roles for the non-catalytic SH2 and SH3 domains in the regulation of the catalytic activity of p56lck. They suggest that the enzymatic function of this Src-related polypeptide is physiologically repressed by processes dependent on the presence of the SH2 and SH3 sequences. Moreover, they indicate that the SH2 domain also plays a positive role in the function of activated p56lck molecules in NIH3T3 cells.	MCGILL UNIV, MCGILL CANC CTR, DEPT BIOCHEM & ONCOL, MONTREAL H3G 1Y6, QUEBEC, CANADA; MONTREAL GEN HOSP, DEPT MED, DIV MED ONCOL, MONTREAL H3G 1A4, QUEBEC, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	VEILLETTE, A (corresponding author), MCGILL UNIV, MCGILL CANC CTR, DEPT MED, ROOM 701, MCINTYRE MED SCI BLDG, MONTREAL H3G 1Y6, QUEBEC, CANADA.		Pawson, Tony J/E-4578-2013					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTIER M, 1987, MOL CELL BIOL, V7, P1623, DOI 10.1128/MCB.7.5.1623; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUO K, 1990, ONCOGENE, V5, P803; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PAWSON T, 1988, ONCOGENE, V3, P491; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SEFTON BM, 1991, ONCOGENE, V6, P683; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STANNERS CP, 1971, NATURE-NEW BIOL, V230, P52, DOI 10.1038/newbio230052a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VEILLETTE A, 1989, ONCOGENES, P121; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0	48	92	93	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					971	980						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570157				2022-12-28	WOS:A1992HP64200017
J	SELS, FT; LANGER, S; SCHULZ, AS; SILVER, J; SITBON, M; FRIEDRICH, RW				SELS, FT; LANGER, S; SCHULZ, AS; SILVER, J; SITBON, M; FRIEDRICH, RW			FRIEND MURINE LEUKEMIA-VIRUS IS INTEGRATED AT A COMMON SITE IN MOST PRIMARY SPLEEN TUMORS OF ERYTHROLEUKEMIC ANIMALS	ONCOGENE			English	Article							MOUSE MYELOBLASTIC LEUKEMIAS; PUTATIVE ONCOGENE; THYMIC LYMPHOMAS; CELL-LINES; DNA; ACTIVATION; SPI-1; PROGRESSION; EXPRESSION; POLYMERASE	A common proviral integration site was identified and characterized in erythroleukaemias induced by Friend murine leukaemia virus (F-MuLV). Using inverse polymerase chain reaction, we found a proviral integration site common to at least 90% of 20 primary tumours tested. This site was identical to Fli-1, a locus recently reported by others to be rearranged in 75% (9/12) of cell lines established from spleens of erythroleukaemic mice and to code for a member of the ets gene family. Our data suggest that about half of the F-MuLV-induced erythroleukaemias contained more than one cell clone with a proviral integration in Fli-1, with different individual integration sites within Fli-1 in each cell clone. All proviruses were found to be integrated in the same transcriptional orientation with respect to flanking cellular DNA. We discuss these findings in relation to multistage models of neoplasm.	UNIV GIESSEN,INST MED VIROL,FRANKFURTER STR 107,W-6300 GIESSEN,GERMANY; HOP COCHIN,INSERM,U152,ICGM,IMMUNOL & ONCOL MALADIES RETROVIRALES LAB,F-75674 PARIS 14,FRANCE; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	Justus Liebig University Giessen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Sitbon, Marc/A-6771-2010	Sitbon, Marc/0000-0003-3616-2338				BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BEAR SE, 1989, P NATL ACAD SCI USA, V86, P7495, DOI 10.1073/pnas.86.19.7495; BELLACOSA A, 1991, MOL CELL BIOL, V11, P2864, DOI 10.1128/MCB.11.5.2864; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; CHATTOPADHYAY SK, 1981, VIROLOGY, V113, P465, DOI 10.1016/0042-6822(81)90175-6; CHATTOPADHYAY SK, 1982, NATURE, V295, P25, DOI 10.1038/295025a0; CHESEBRO B, 1983, VIROLOGY, V128, P221, DOI 10.1016/0042-6822(83)90332-X; CUYPERS HTM, 1986, J VIROL, V60, P230, DOI 10.1128/JVI.60.1.230-241.1986; DREYFUS F, 1990, LEUKEMIA, V4, P590; DUGAICZYK A, 1975, J MOL BIOL, V96, P171, DOI 10.1016/0022-2836(75)90189-8; FAMULARI NG, 1983, CURR TOP MICROBIOL, V103, P75; FRIEDRICH RW, 1990, EMBL GENBANK NUCLEOT; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; KABAT D, 1990, CURR TOP MICROBIOL I, V148, P1; KELLY M, 1983, J VIROL, V45, P291, DOI 10.1128/JVI.45.1.291-298.1983; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; OLIFF A, 1984, P NATL ACAD SCI-BIOL, V81, P5464, DOI 10.1073/pnas.81.17.5464; OLIFF A, 1981, BLOOD, V58, P244; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; RANDS E, 1981, VIROLOGY, V108, P445, DOI 10.1016/0042-6822(81)90451-7; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULZ AS, 1988, J GEN VIROL, V69, P2663, DOI 10.1099/0022-1317-69-10-2663; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SHIBUYA T, 1982, CELL, V31, P483, DOI 10.1016/0092-8674(82)90141-6; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SILVER J, 1990, J VIROL, V64, P3150; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; SITBON M, 1990, J VIROL, V64, P2135, DOI 10.1128/JVI.64.5.2135-2140.1990; SOLA B, 1986, J VIROL, V60, P718, DOI 10.1128/JVI.60.2.718-725.1986; TSICHLIS PN, 1985, J VIROL, V56, P258, DOI 10.1128/JVI.56.1.258-267.1985; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L	39	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					643	652						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565463				2022-12-28	WOS:A1992HQ68200005
J	CRUMLEY, G; BELLOT, F; KAPLOW, JM; SCHLESSINGER, J; JAYE, M; DIONNE, CA				CRUMLEY, G; BELLOT, F; KAPLOW, JM; SCHLESSINGER, J; JAYE, M; DIONNE, CA			HIGH-AFFINITY BINDING AND ACTIVATION OF A TRUNCATED FGF-RECEPTOR BY BOTH AFGF AND BFGF	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; EARLY XENOPUS EMBRYOS; CELL-GROWTH; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; FACTOR CDNA; ACIDIC FGF; GENE; EXPRESSION	We recently reported the cloning and overexpression of full-length forms of human fibroblast growth factor (FGF) receptors, bek and flg. These receptors contain three immunoglobulin (Ig)-like domains and an unusual acidic motif in the extracellular region, a single transmembrane segment and a protein tyrosine kinase cytoplasmic domain containing a 14 amino acid insert. Each of the related full-length gene products interacts at high affinity with both acidic FGF and basic FGF. We now report the isolation of cDNA clones encoding two variant forms of human bek. One variant form encodes a potentially secreted bek protein containing only the first Ig-like domain and acidic motif, whereas the other variant includes all of the full-length bek protein except the first Ig-like domain and acidic motif. Overexpression of the latter bek form in NIH3T3 cells has been used to demonstrate that the N-terminal Ig-like domain and acidic region are not required for binding or activation of bek by aFGF or bFGF.	NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University	CRUMLEY, G (corresponding author), RHONE POULENC RORER CENT RES, 680 ALLENDALE RD, KING OF PRUSSIA, PA 19406 USA.							ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BELLOT F, 1991, IN PRESS EMBO J; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; ISACCHI A, 1990, NUCLEIC ACIDS RES, V18, P1906, DOI 10.1093/nar/18.7.1906; JAYE M, 1987, J BIOL CHEM, V262, P16612; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAMHOLZ J, 1986, P NATL ACAD SCI USA, V83, P4962, DOI 10.1073/pnas.83.13.4962; KAN M, 1988, J BIOL CHEM, V263, P11306; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LOBB RR, 1985, BIOCHEMISTRY-US, V24, P4969, DOI 10.1021/bi00340a001; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PETERSON PA, 1972, P NATL ACAD SCI USA, V69, P1697, DOI 10.1073/pnas.69.7.1697; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; TOGARI A, 1985, J NEUROSCI, V5, P307; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	63	58	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2255	2262						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722570				2022-12-28	WOS:A1991GX73500012
J	LIMPENS, J; DEJONG, D; VANKRIEKEN, JHJM; PRICE, CGA; YOUNG, BD; VANOMMEN, GJB; KLUIN, PM				LIMPENS, J; DEJONG, D; VANKRIEKEN, JHJM; PRICE, CGA; YOUNG, BD; VANOMMEN, GJB; KLUIN, PM			BCL-2/JH REARRANGEMENTS IN BENIGN LYMPHOID-TISSUES WITH FOLLICULAR HYPERPLASIA	ONCOGENE			English	Article							T(14-18) CHROMOSOMAL TRANSLOCATION; BREAKPOINT-CLUSTER REGION; NON-HODGKINS-LYMPHOMA; B-CELL NEOPLASMS; RECIPROCAL PARTNERS; HISTOLOGIC SUBTYPES; STRUCTURAL-ANALYSIS; C-MYC; GENE; ABNORMALITIES	The t(14; 18)(q32; q21) chromosomal translocation, characteristic of follicular lymphoma, couples the bcl-2 proto-oncogene on chromosome 18 to the immunoglobulin heavy-chain joining region (J(H)). This results in a deregulated transcription rate of bcl-2, suggesting a major role of the t(14; 18) translocation in lymphomagenesis. By using a sensitive polymerase chain reaction technique specific for the major breakpoint region t(14; 18), we now demonstrate the presence of bcl-2/J(H), rearrangements in lymph nodes and tonsils with follicular hyperplasia in 13 of 24 cases (54%). The approximate frequency was one translocation-positive cell in 10(5) cells. No bcl-2/J(H) rearrangements were detected in reactive lymph nodes without follicular hyperplasia or in bone marrow cells. Sequence analysis showed the amplified bcl-2/J(H) fragments to be unique to each individual sample and distinct from 24 sequenced follicular lymphoma-derived t(14; 18) junctions, thus excluding contamination artifacts. The presence of random nucleotide insertions at the breakpoint junctions suggests a pre-B-cell origin of the t(14; 18) translocation, in analogy with follicular lymphomas. We conclude that the t(14; 18) translocation can occur in non-malignant tissue and will not, on its own lead to malignancy.	LEIDEN UNIV,DEPT PATHOL,2300 RC LEIDEN,NETHERLANDS; ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A BE,ENGLAND	Leiden University; Leiden University - Excl LUMC	LIMPENS, J (corresponding author), LEIDEN UNIV,SYLVIUS LAB,DEPT HUMAN GENET,WASSENAARSE WEG 72,2333 AL LEIDEN,NETHERLANDS.		van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040; Limpens, Jacqueline/0000-0002-7362-8574				ADACHI M, 1990, ONCOGENE, V5, P1653; ALTIOK E, 1989, P NATL ACAD SCI USA, V86, P6333, DOI 10.1073/pnas.86.16.6333; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; DEJONG D, 1989, J EXP MED, V169, P613, DOI 10.1084/jem.169.3.613; DEWALD GW, 1986, AM J HUM GENET, V38, P520; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HECHT F, 1987, CANCER GENET CYTOGEN, V26, P95, DOI 10.1016/0165-4608(87)90137-3; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JUNEJA S, 1990, BRIT J HAEMATOL, V76, P231, DOI 10.1111/j.1365-2141.1990.tb07877.x; KLUINNELEMANS JC, 1991, LEUKEMIA, V55, P221; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LEVINE EG, 1985, BLOOD, V66, P1414; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; NGAN BY, 1989, BLOOD, V73, P1759; NOWELL PC, 1990, AM J CLIN PATHOL, V94, P229, DOI 10.1093/ajcp/94.2.229; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PRICE CGA, 1991, LEUKEMIA, V5, P548; PRICE CGA, 1991, J CLIN ONCOL, V9, P1527, DOI 10.1200/JCO.1991.9.9.1527; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; ROWLEY JD, 1984, CANCER RES, V44, P3159; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P5407, DOI 10.1093/nar/17.13.5407; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TYCKO B, 1989, SCIENCE, V245, P1242, DOI 10.1126/science.2551037; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	42	262	264	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2271	2276						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766674				2022-12-28	WOS:A1991GX73500014
J	METZ, R; ZIFF, E				METZ, R; ZIFF, E			THE HELIX LOOP HELIX PROTEIN-RE12 AND THE C/EBP-RELATED FACTOR-RNFIL-6 BIND TO NEIGHBORING SITES WITHIN THE C-FOS SERUM RESPONSE ELEMENT	ONCOGENE			English	Article							CARDIAC ACTIN GENE; MULTIPLE SEQUENCE ELEMENTS; EPIDERMAL GROWTH-FACTOR; DYAD SYMMETRY ELEMENT; PROTO-ONCOGENE FOS; CYCLIC-AMP; TRANSCRIPTION FACTOR; 3T3 CELLS; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; MOLECULAR-CLONING	We show that members of two major families of transcription factors, the helix-loop-helix and C/EBP families, interact with the c-fos serum response element (SRE). Two cDNA clones encoding SRE binding factors (clones 9 and 21) were isolated by the direct screening of a PC12 lambda-gt11 cDNA library using SRE oligonucleotide sequences as probes. Clone 9 encodes the rat homolog of the human HLH transcription factor, E12 (called here rE12). Clone 21 encodes a b-zip domain polypeptide that is related to the liver transcription factor C/EBP, and is homologous to the human NFIL-6 transcription factor (called here rNFIL-6). Using in vitro-translated products we show that rNFIL-6 recognizes a 'CCAATT' motif which overlaps the c-fos dyad symmetry element (DSE), the binding site for serum regulatory factor (SRF). Factor rE12 binds to an E-box enhancer sequence, 'CATCTG', immediately adjacent to the rNFIL-6 site, within the SRE. Antibodies specific to rE12 and rNFIL-6 disrupt nucleoprotein complexes with these DNA-binding sites, confirming the interaction of native in vivo factors. We present evidence that rNFIL-6 and SRF binding are mutually exclusive, consistent with the overlap of their binding sites. The demonstration that rE12 and rNFIL-6 bind to the SRE at sites adjacent to the major c-fos regulatory element, the DSE, raises the possibility that helix-loop-helix and C/EBP families regulate the SRE and provide a new basis for the multifunctional properties of the SRE, including possible tissue specificity of expression.	NYU MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	Howard Hughes Medical Institute; New York University; New York University				Ziff, Edward/0000-0001-7389-8649	NCI NIH HHS [5T32CA09161, CA44042] Funding Source: Medline; NIMH NIH HHS [2P50MH35976] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009161, R01CA044042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH035976] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CURRAN T, 1988, ONCOGENE HDB, P305; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; METZ R, 1988, COLD SPRING HARB SYM, V53, P727, DOI 10.1101/SQB.1988.053.01.083; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; POLL V, 1990, CELL, V63, P643; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHROTER H, 1987, NUCLEIC ACIDS RES, V15, P10145, DOI 10.1093/nar/15.24.10145; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SOBCZAK J, 1989, ONCOGENE, V4, P1503; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	77	78	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2165	2178						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766666				2022-12-28	WOS:A1991GX73500001
J	ASKEW, DS; ASHMUN, RA; SIMMONS, BC; CLEVELAND, JL				ASKEW, DS; ASHMUN, RA; SIMMONS, BC; CLEVELAND, JL			CONSTITUTIVE C-MYC EXPRESSION IN AN IL-3-DEPENDENT MYELOID CELL-LINE SUPPRESSES CELL-CYCLE ARREST AND ACCELERATES APOPTOSIS	ONCOGENE			English	Article							HEMATOPOIETIC-CELLS; B-CELLS; UNREGULATED PROLIFERATION; IMMATURE THYMOCYTES; DNA FRAGMENTATION; PROGENITOR CELLS; MARROW CULTURES; BONE-MARROW; DIFFERENTIATION; GROWTH	In the murine interleukin 3 (IL-3)-dependent myeloid cell line 32D, down-regulation of c-myc and ornithine decarboxylase (ODC) expression is an immediate response to IL-3 deprivation. This is followed by an accumulation of cells in the G1 phase of the cell cycle, and eventual cell death. However, clones of 32D cells harboring an expression vector which constitutively expresses murine c-myc did not down-regulate ODC transcripts in response to IL-3 withdrawal, and they failed to G1 arrest. Moreover, in contrast to control cultures in which the majority of death occurred following G1 arrest, c-myc clones rapidly initiated a program of cell death characteristic of apoptosis following IL-3 deprivation, and their subsequent loss of viability occurred with accelerated kinetics. The premature induction of apoptosis in cells harboring a deregulated c-myc gene suggests that apoptosis may be an important mechanism in the elimination of hematopoietic cells harboring mutations, such as constitutive c-myc expression, which imbalance normal cell cycle regulatory controls.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	CLEVELAND, JL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA.			Askew, David/0000-0002-6477-2515	NCI NIH HHS [P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1990, CELLULAR MOL BIOL HU, P33; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; CASHMAN JD, 1988, J CLIN INVEST, V81, P87, DOI 10.1172/JCI113315; CASHMAN JD, 1990, BLOOD, V75, P96; Cleveland J L, 1988, Oncogene Res, V3, P357; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CORY S, 1987, ONCOGENE RES, V1, P61; DEAN M, 1987, ONCOGENE RES, V1, P279; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEAN PN, 1980, CELL TISSUE KINET, V13, P672; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Finney D.J., 1971, PROBIT ANAL; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IHLE JN, 1982, J IMMUNOL, V129, P2431; ISFORT RJ, 1990, SOMAT CELL MOLEC GEN, V16, P109, DOI 10.1007/BF01233041; KARN J, 1989, ONCOGENE, V4, P773; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LEARY AG, 1989, P NATL ACAD SCI USA, V86, P4535, DOI 10.1073/pnas.86.12.4535; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MAVILIO F, 1989, ONCOGENE, V4, P301; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OGAWA M, 1989, ENVIRON HEALTH PERSP, V80, P199, DOI 10.2307/3430745; PALLAVICINI MG, 1990, J CELL PHYSIOL, V143, P372, DOI 10.1002/jcp.1041430223; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PRATT RM, 1976, DEV BIOL, V54, P135, DOI 10.1016/0012-1606(76)90292-X; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RODRIGUEZTARDUC.G, 1990, EMBO J, V9, P2977; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLIE AH, 1987, BRIT J CANCER, V56, P251; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	55	918	943	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1915	1922						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923514				2022-12-28	WOS:A1991GX11800028
J	RAMSAY, RG; ISHII, S; GONDA, TJ				RAMSAY, RG; ISHII, S; GONDA, TJ			INCREASE IN SPECIFIC DNA-BINDING BY CARBOXYL TRUNCATION SUGGESTS A MECHANISM FOR ACTIVATION OF MYB	ONCOGENE			English	Article							C-MYB; V-MYB; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; HEMATOPOIETIC-CELLS; TRANSFORMING GENE; INVITRO; SEQUENCE; PROTEINS; FOS	Oncogenic forms of the c-myb protein (Myb) often exhibit amino-terminal and/or carboxyl-terminal truncations. When the transcriptional activity of these proteins was examined it was found that carboxyl-truncated Myb is more effective as a transcriptional activator than full-length or amino-truncated Myb. In order to determine the effect of such truncations on sequence-specific DNA binding, we synthesized murine Myb in vitro and assessed DNA binding by using a mobility-shift assay. Compared with the full-length protein no difference in binding was observed following deletion of the amino terminus, despite the removal of much of the first repeat of the DNA-binding domain. However, the specific DNA-binding capacity of carboxyl-truncated Myb was 4-6 times greater than that of the full-length protein; moreover, DNA binding was independent of a 'leucine zipper' motif present in Myb. These observations suggest that the increased transforming and transactivating potential of carboxyl-truncated Myb is due, at least in part, to increased sequence-specific DNA binding.	RIKEN TSUKUBA LIFE SCI CTR,INST PHYS & CHEM RES,TSUKUBA,IBARAKI 305,JAPAN	RIKEN	RAMSAY, RG (corresponding author), PO ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA.		Ramsay, Robert G/C-3291-2015; Ishii, Shunsuke/A-5271-2016	Ramsay, Robert G/0000-0001-5003-0433; Ishii, Shunsuke/0000-0002-6530-2478				BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; COOK WD, 1985, MOL CELL BIOL, V5, P390, DOI 10.1128/MCB.5.2.390; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	33	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1875	1879						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923510				2022-12-28	WOS:A1991GX11800021
J	ROYERPOKORA, B; LOOS, U; LUDWIG, WD				ROYERPOKORA, B; LOOS, U; LUDWIG, WD			TTG-2, A NEW GENE ENCODING A CYSTEINE-RICH PROTEIN WITH THE LIM MOTIF, IS OVEREXPRESSED IN ACUTE T-CELL LEUKEMIA WITH THE T(11-14)(P13-Q11)	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAKPOINT CLUSTER REGION; CHROMOSOMAL TRANSLOCATIONS; DEVELOPMENTAL REGULATION; CHAIN LOCUS; ALPHA-CHAIN; RECEPTOR; 11P13; REARRANGEMENTS; HOMEODOMAIN	We have cloned 70 kb of DNA from chromosome 11p13 at the site of a recurrent translocation in T-cell leukaemia (T-ALL): t(11;14)(p13;q11). The translocation involves the TCR-delta-gene on 14q11 and a new site on 11p13. Two new and 10 previously identified translocations all mapped within 25 kb on 11p13, the 11p13 T-cell translocation cluster (11p13 ttc). A search for expressed sequences surrounding the breakpoint cluster region on 11p13 identified a gene telomeric of all breakpoints which is overexpressed in three T-ALL samples with a t(11;14). The gene T-cell translocation gene (TTG-2) encodes a small cysteine-rich protein. Forty-eight per cent of the amino acids are identical with another translocation-deregulated gene, TTG-1 (T-cell translocation gene 1 or rhombotin) in 11p15. There are two copies of a cysteine-rich motif in both proteins. Two tandem copies of the same cysteine-rich motif are also present in the recently described lin-11, isl-1 and mec-3 gene products, and one motif is found in the CRIP protein. Therefore the proteins encoded by these two translocation-deregulated genes belong to this new class of cysteine-rich proteins with the 'LIM' motif, which are important in normal development.	KLINIKUM STEGLITZ,DEPT HEMATOL & ONCOL,W-1000 BERLIN,GERMANY		ROYERPOKORA, B (corresponding author), INST HUMANGENET & ANTHROPOL,NEUENHEIMER FELD 328,W-6900 HEIDELBERG,GERMANY.							BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; ERIKSON J, 1985, SCIENCE, V229, P784, DOI 10.1126/science.3875152; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUEBLER U, 1983, GENE, V25, P263; HARVEY RC, 1989, ONCOGENE, V4, P341; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LAMPERT F, 1988, BLUT, V56, P117, DOI 10.1007/BF00320016; LEWIS WH, 1985, NATURE, V317, P544, DOI 10.1038/317544a0; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; RAIMONDI SC, 1988, BLOOD, V72, P1560; ROYERPOKORA B, 1989, HUM GENET, V82, P264, DOI 10.1007/BF00291167; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; YOFFE G, 1989, BLOOD, V74, P374; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	29	250	263	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1887	1893						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923511				2022-12-28	WOS:A1991GX11800023
J	ZHAO, X; SINGH, B; ARLINGHAUS, RB				ZHAO, X; SINGH, B; ARLINGHAUS, RB			INHIBITION OF C-MOS PROTEIN-KINASE BLOCKS MOUSE ZYGOTES AT THE PRONUCLEI STAGE	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; V-MOS; MEIOTIC MATURATION; DEVELOPMENTAL REGULATION; PROTOONCOGENE PRODUCT; XENOPUS OOCYTES; GERM-CELLS; ONCOGENE; EXPRESSION; SEQUENCE	The c-mos gene product is required for activation of the maturation-promoting factor (MPF) during oocyte maturation. The c-mos protein also acts as a cytostatic factor which is responsible for meiotic metaphase arrest of vertebrate eggs via stabilization of MPF. Here we show that mouse zygotes contain the c-mos protein. Introduction of a kinase-inhibitory anti-mos antibody into mouse zygotes 12 h after fertilization prevented the first cleavage of zygotes at the pronuclei stage. A second anti-mos antibody, known to allow the mos kinase to function, did not interfere with the formation of two-cell embryos. In addition to its known role in MPF activation in oocyte maturation and meiotic metaphase arrest, our findings indicate that the c-mos protein kinase is also required for completion of pronuclei breakdown following fertilization of mouse eggs.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	Stanford University; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GOLDMAN DS, 1988, ONCOGENE, V3, P159; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P255; HOGAN B, 1986, MANIPULATING MOUSE E; KESHET E, 1988, ONCOGENE, V2, P235; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; ZHAO X, 1990, ONCOGENE, V5, P1727; Zhao X., 1989, TECHNIQUES J METHODS, V1, P37	31	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1423	1426						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1832216				2022-12-28	WOS:A1991GX27200019
J	SATO, M; KITAZAWA, T; IWAI, T; SEKI, J; SAKATO, N; KATO, JY; TAKEYA, T				SATO, M; KITAZAWA, T; IWAI, T; SEKI, J; SAKATO, N; KATO, JY; TAKEYA, T			ISOLATION OF CHICKEN-BEK AND A RELATED GENE - IDENTIFICATION OF STRUCTURAL VARIATION IN THE LIGAND-BINDING DOMAINS OF THE FGF-RECEPTOR FAMILY	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; AVIAN-SARCOMA VIRUS; PHOSPHOTYROSINE ANTIBODY; PURIFICATION; EXPRESSION; FLG	cDNA clones carrying the chicken-bek gene and a related gene were isolated. Deducing the amino acid sequence of chicken-bek allowed us to predict that it encodes for a receptor tyrosine kinase related to the fibroblast growth factor (FGF) receptor, and that the chicken-bek gene and Cek3 are closely related. However, a significant structural difference was identified between chicken-bek and Cek3 within the putative extracellular region, in such a manner that the structure of the immunoglobulin-like domain was conserved. A probe specific to the altered structure detected mRNA in the tissues as did a probe common to bek and Cek3, indicating heterogeneity in the FGF-receptor family in a novel manner. Furthermore, another bek-like gene was isolated and the expressions of its mRNA and protein product were analysed in tissues and cultured cells.	KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN; COSMO RES INST,SATTE,SAITAMA 34001,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	Kyoto University; Osaka University	TAKEYA, T (corresponding author), KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN.							BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI J, 1986, CANCER RES, V46, P907; TAKEYA T, 1982, J VIROL, V44, P1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	19	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1279	1283						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650446				2022-12-28	WOS:A1991GV26000026
J	WEBER, JM; SIRCAR, S; RODRIGUES, M; CAI, FX; HORVATH, J				WEBER, JM; SIRCAR, S; RODRIGUES, M; CAI, FX; HORVATH, J			DOMINANT SUPPRESSION OF ADENOVIRUS MEDIATED TRANSFORMATION AND INSUFFICIENCY OF P105RB BINDING AS A CONDITION FOR ONCOGENIC TRANSFORMATION	ONCOGENE			English	Article							LARGE T-ANTIGENS; RAT-CELLS; METHYLGLYOXAL BIS(GUANYLHYDRAZONE); RETINOBLASTOMA PROTEIN; GENE-PRODUCT; E1A PROTEINS; VIRUS; INTEGRATION; RESISTANT; RETRANSFORMATION	An adenovirus-specific transformation resistant cell line (G2) expressing biologically active E1a proteins and originally isolated as a revertant from Ad2-transformed rat cells (F4), was shown to form stable Rb-E1a and 300K-E1a complexes in immunoprecipitation experiments. Consistent with the transformation resistant phenotype, cell hybrids between G2 and F4 were all nontumorigenic. Retrovirus insertion mutagenesis resulted in tumorigenic cell lines and identified a common locus responsible for the E1a-specific dominant tumor suppressor phenotype of G2 cells.			WEBER, JM (corresponding author), UNIV SHERBROOKE,FAC MED,DEPT MICROBIOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA.							ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; HEATON MA, 1988, J CELL PHYSIOL, V136, P133, DOI 10.1002/jcp.1041360117; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LOHUIZEN M, 1989, EMBO J, V8, P133; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; RODRIGUES M, 1989, VIRUS RES, V15, P231; RYAN KW, 1985, MOL CELL BIOL, V5, P3577, DOI 10.1128/MCB.5.12.3577; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SIRCAR S, 1987, CANCER RES, V47, P1339; SIRCAR S, 1988, ONCOGENE, V3, P725; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; WEBER JM, 1990, J GEN VIROL, V71, P585, DOI 10.1099/0022-1317-71-3-585; WEBER JM, 1989, CANCER RES, V49, P5779; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	31	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					989	993						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648705				2022-12-28	WOS:A1991GU62200013
J	HEWLETT, IK; GEYER, SJ; HAWTHORNE, CA; RUTA, M; EPSTEIN, JS				HEWLETT, IK; GEYER, SJ; HAWTHORNE, CA; RUTA, M; EPSTEIN, JS			KINETICS OF EARLY HIV-1 GENE-EXPRESSION IN INFECTED H9-CELLS ASSESSED BY PCR	ONCOGENE			English	Note							HUMAN IMMUNODEFICIENCY VIRUS; POLYMERASE CHAIN-REACTION; RNA; AMPLIFICATION; DNA; CELLS	The time course of viral gene expression in H9 cells acutely infected with HIV-1 was analysed by the polymerase chain reaction (PCR). Virus-specific sequences were first detected in genomic DNA of H9 cells 1-2h after infection. RNA for the regulatory genes such as the tat and nef appeared 2-3h post-infection and RNA for the gag and env at 3 h. The results demonstrate that viral DNA synthesis occurs rapidly after infection of target cells followed by synthesis of viral RNA. Cell-associated reverse transcriptase activity increased after 24 h, while culture supernatant enzyme activity increased later, between 1-5 days. The delay in virus release after rapid integration and transcriptional activity suggests the involvement of additional factors, perhaps both cellular and viral, that control the formation and budding of mature virions.			HEWLETT, IK (corresponding author), US FDA,DIV TRANSFUS SCI,RETROVIROL LAB,BETHESDA,MD 20892, USA.			Epstein, Jay/0000-0003-2293-9062				CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GEYER SJ, 1989, 5TH INT C AIDS INT A, P636; GOTTLINGER HG, 1990, 6TH INT C AIDS; HART C, 1988, LANCET, V2, P596; HEWLETT IK, 1989, ONCOGENE, V4, P1149; HEWLETT IK, 1988, J CLIN IMMUNOASSAY, V11, P161; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; Maniatis T., 1984, MOL CLONING; MURAKAWA GJ, 1988, DNA-J MOLEC CELL BIO, V7, P287, DOI 10.1089/dna.1988.7.287; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617	15	13	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					491	493						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1707154				2022-12-28	WOS:A1991FT34400023
J	GOLDFARB, M; DEED, R; MACALLAN, D; WALTHER, W; DICKSON, C; PETERS, G				GOLDFARB, M; DEED, R; MACALLAN, D; WALTHER, W; DICKSON, C; PETERS, G			CELL-TRANSFORMATION BY INT-2 - A MEMBER OF THE FIBROBLAST GROWTH-FACTOR FAMILY	ONCOGENE			English	Article							PROTO-ONCOGENE INT-2; NUCLEOTIDE-SEQUENCE; SARCOMA DNA; FACTOR CDNA; 3T3 CELLS; MOUSE; GENE; EXPRESSION; FGF; HST	The sequence similarities between Int-2 and members of the fibroblast growth factor (FGF) family have prompted functional as well as structural comparisons with other FGFs. Here we examine the ability of int-2 sequences to induced morphological transformation of NIH3T3 cells, a characteristic property of the secreted FGFs, such as FGF-5 and Hst1/kFGF. Despite encoding a short signal sequence, which directs the product to the secretory pathway, mouse int-2 DNA is incapable of inducing foci of transformation in the standard transfection assay. However, when transfected cells are enriched by coselection with the neomycin resistance gene, a proportion of the int-2-expressing cells display a transformed phenotype, including the ability to grow as colonies in soft agar and in defined medium. Analyses of int-2 RNA and protein in these cells suggest that transformation by int-2 may require a threshold level of expression, and that the subsequent phenotype is dependent on the level of int-2 protein present in the cells.	ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND LABS,DOMINION HOUSE,59 BARTHOLOMEW CLOSE,LONDON EC1A 7BE,ENGLAND; COLUMBIA UNIV,DEPT BIOCHEM,NEW YORK,NY 10032; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; University of London; Queen Mary University London; Columbia University; Cancer Research UK								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1974, P NATL ACAD SCI USA, V71, P4648, DOI 10.1073/pnas.71.12.4648; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LOBB RL, 1989, ANAL BIOCHEM, V154, P1; MARICS I, 1989, ONCOGENE, V4, P335; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; PATERNO GD, 1989, DEVELOPMENT, V106, P79; Peters G, 1987, CELLULAR MOL BIOL MA, P307; QUARTO N, 1989, ONCOGENE RES, V5, P101; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; THOMAS KA, 1988, TRENDS BIOCHEM SCI, V13, P327, DOI 10.1016/0968-0004(88)90098-9; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	48	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					65	71						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846956				2022-12-28	WOS:A1991EY03900009
J	GOMPERTS, M; PASCALL, JC; BROWN, KD				GOMPERTS, M; PASCALL, JC; BROWN, KD			THE NUCLEOTIDE-SEQUENCE OF A CDNA-ENCODING AN EGF-INDUCIBLE GENE INDICATES THE EXISTENCE OF A NEW FAMILY OF MITOGEN-INDUCED GENES	ONCOGENE			English	Note									AFRC,INST ANIM PHYSIOL & GENET RES,DEPT BIOCHEM,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BLAY J, 1985, BIOCHEM J, V225, P85, DOI 10.1042/bj2250085; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; GOMPERTS M, 1990, IN PRESS BIOCH SOC T; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; VARNUM BC, 1989, ONCOGENE, V4, P119	13	74	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1081	1083						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695727				2022-12-28	WOS:A1990DP41500021
J	WIEHLE, RD; HELFTENBEIN, G; LAND, H; NEUMANN, K; BEATO, M				WIEHLE, RD; HELFTENBEIN, G; LAND, H; NEUMANN, K; BEATO, M			ESTABLISHMENT OF RAT ENDOMETRIAL CELL-LINES BY RETROVIRAL MEDIATED TRANSFER OF IMMORTALIZING AND TRANSFORMING ONCOGENES	ONCOGENE			English	Article									INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2X 3PX,ENGLAND; UNIV MARBURG,INST PATHOL,W-3550 MARBURG,GERMANY	Cancer Research UK; Philipps University Marburg			Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				AMSTERDAM A, 1988, P NATL ACAD SCI USA, V85, P582; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BEATO M, 1987, ENDOMETRIAL CANCER, P20; BEIER HM, 1976, J REPROD FERT      S, V25, P53; BOUK N, 1979, METHOD ENZYMOL, V58, P296; CATO ACB, 1985, ANTICANCER RES, V5, P65; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CHOU JY, 1978, P NATL ACAD SCI USA, V75, P1854, DOI 10.1073/pnas.75.4.1854; DORMAN BH, 1982, IN VITRO, V18, P911; DOTTO GP, 1985, NATURE, V318, P472; EVRARD C, 1986, EMBO J, V5, P3157, DOI 10.1002/j.1460-2075.1986.tb04623.x; GARCIA I, 1986, MOL CELL BIOL, V6, P1974, DOI 10.1128/MCB.6.6.1974; GLASSER SR, 1988, J CELL BIOL, V107, P2409, DOI 10.1083/jcb.107.6.2409; HALL JE, 1950, AM J OBSTET GYNECOL, V60, P212, DOI 10.1016/S0002-9378(16)39062-7; HEINS B, 1981, MOL CELL ENDOCRINOL, V21, P139, DOI 10.1016/0303-7207(81)90051-4; HOLINKA CF, 1986, CANCER RES, V46, P2771; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; JORDEN VC, 1978, J ENDOCRINOL, V7, P363; KURUC N, 1988, DIFFERENTIATION, V38, P177, DOI 10.1111/j.1432-0436.1988.tb00212.x; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; MCCORMACK SA, 1980, ENDOCRINOLOGY, V106, P1634, DOI 10.1210/endo-106-5-1634; MILGROM E, 1973, J BIOL CHEM, V248, P6366; MOYER MP, 1987, IN VITRO CELL DEV B, V23, P141, DOI 10.1007/BF02623595; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROBERTS BE, 1985, J VIROL, V56, P404, DOI 10.1128/JVI.56.2.404-413.1985; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCOTT DM, 1986, EXP CELL RES, V166, P391, DOI 10.1016/0014-4827(86)90485-4; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; SINGH G, 1987, EXP LUNG RES, V13, P299, DOI 10.3109/01902148709069595; SYNE JS, 1982, CANCER RES, V42, P4449; VARMA VA, 1982, IN VITRO CELL DEV B, V18, P911; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOODWORTH C, 1986, CANCER RES, V46, P4018; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076	39	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					787	794						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	1694289				2022-12-28	WOS:A1990DP55300002
J	BODNER, SM; MINNA, JD; JENSEN, SM; DAMICO, D; CARBONE, D; MITSUDOMI, T; FEDORKO, J; BUCHHAGEN, DL; NAU, MM; GAZDAR, AF; LINNOILA, RI				BODNER, SM; MINNA, JD; JENSEN, SM; DAMICO, D; CARBONE, D; MITSUDOMI, T; FEDORKO, J; BUCHHAGEN, DL; NAU, MM; GAZDAR, AF; LINNOILA, RI			EXPRESSION OF MUTANT P53 PROTEINS IN LUNG-CANCER CORRELATES WITH THE CLASS OF P53 GENE MUTATION	ONCOGENE			English	Note							CELLULAR TUMOR-ANTIGEN; FREE DEFINED MEDIUM; TRANSFORMED-CELLS; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; CLINICAL SPECIMENS; T-ANTIGEN; ONCOGENE	We investigated the immunocytochemical staining and immunoblotting characteristics of 33 different p53 mutant proteins identified in lung cancer cell lines (18 small-cell lung cancer and 15 non-small-cell lung cancer) using monoclonal antibodies pAbs 240, 421 and 1801. The p53 mutants studied were representative of those found in lung cancer and included three deletions, four nonsense, seven splicing and 19 missense lesions. Control cell lines included six B-lymphoblastoid cell lines and two lung cancer cell lines without p53 mutations. Immunocytochemistry demonstrated 16 cell lines (48%) with definite overexpression of p53 protein (the high-expresser group of mutants), while in the remainder of cases either no p53 expression or low levels of p53 protein expression were found (the low-expresser group of mutants). The type of p53 mutation correlated with the expresser group. High expresser's all had p53 missense mutations in exons 5-8, and immunocytochemistry identified 16/17 (94%) of these mutants. Several classes of p53 mutations occur in the low-expresser groups: deletions, splicing mutants, nonsense mutants and missense mutations outside of exons 5-8 all resulted in very low or undetectable levels of p53 protein. We conclude that there are low- and high-expression groups of p53 mutants in lung cancer and that the detection of protein expression in tumor cells by immunocytochemistry and immunoblotting is dependent upon the type of mutation of the p53 tumor-suppressor gene.	UNIV TEXAS, SW MED CTR, SIMMONS CANC CTR, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	BODNER, SM (corresponding author), NATL NAVAL MED CTR, NCI,NAVY MED ONCOL BRANCH,BLDG 8,RM 5101, 8901 WISCONSIN AVE, BETHESDA, MD 20889 USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BROWER M, 1986, CANCER RES, V46, P798; CARBONE D, 1991, ONCOGENE, V6, P1691; CARNEY DN, 1985, CANCER RES, V45, P2913; CHIBA I, 1990, ONCOGENE, V5, P1603; Crawford L V, 1984, Mol Biol Med, V2, P261; CURIEL DT, 1990, AM J RESP CELL MOL, V3, P405, DOI 10.1165/ajrcmb/3.5.405; CUTTITTA F, 1988, J CLIN ENDOCR METAB, V67, P576, DOI 10.1210/jcem-67-3-576; DAMICO D, 1992, IN PRESS ONCOGENE, V7; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DOHERTY PJ, 1989, ANAL BIOCHEM, V177, P7, DOI 10.1016/0003-2697(89)90003-1; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAZDAR AF, 1980, CANCER RES, V40, P3502; GAZDAR AF, 1986, CANCER RES, V46, P6011; HALVEY O, 1990, SCIENCE, V250, P113; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENSEN SM, 1990, CANCER RES, V50, P6068; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LINNOILA RI, 1988, AM J CLIN PATHOL, V90, P641, DOI 10.1093/ajcp/90.6.641; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; MITSUDOMI T, 1992, IN PRESS ONCOGENE, V7; MONROE DG, 1990, MOL CELL BIOL, V10, P3307; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STRATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	59	339	344	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					743	749						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565469				2022-12-28	WOS:A1992HQ68200017
J	MERZAK, A; SORET, J; MARTINERIE, C; SUREAU, A; CROCHET, J; PERBAL, B				MERZAK, A; SORET, J; MARTINERIE, C; SUREAU, A; CROCHET, J; PERBAL, B			TRANSFORMING POTENTIAL OF TRUNCATED V-MYB AND STIMULATION OF REPLICATION BY GAG-MYB FUSION PRODUCTS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; CHICKEN-EMBRYO FIBROBLASTS; ONCOGENE PRODUCT; FUNCTIONAL DOMAINS; DNA-REPLICATION; GENE-EXPRESSION; SEQUENCES; PROTEIN; PROTOONCOGENE; PROLIFERATION	We have previously reported that truncated forms of the v-myb oncogene of avian myeloblastosis virus (AMV) are expressed in transformed chicken embryo fibroblasts (CEF). In this paper, we show that deletion mutants encoding v-myb products altered in either the DNA-binding or the negative regulatory domains are able to induce CEF transformation. In addition, we report that recombinant plasmids expressing gag-myb fusion proteins are maintained as extrachromosomal forms in transfected cells. This observation provides an important clue for a possible role of myb in the DNA replication processes.	CTR UNIV ORSAY,INST CURIE,BATIMENT 110,F-91405 ORSAY,FRANCE; UNIV PARIS 07,F-75221 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite			Sureau, Alain/M-1998-2017	Sureau, Alain/0000-0003-1523-0207; MERZAK, Abderrahim/0000-0002-7269-2224				BADING H, 1989, ONCOGENE, V4, P33; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BEARD JW, 1963, ADV CANCER RES, V7, P1, DOI 10.1016/S0065-230X(08)60982-3; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; DARLIX JL, 1982, J MOL BIOL, V160, P147, DOI 10.1016/0022-2836(82)90172-3; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLST A, 1988, CELL, V52, P355; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KRYCEVEMARTINER.C, 1987, NUCLEIC ACIDS RES, V15, P1329; KRYCEVEMARTINERIE C, 1987, FEBS LETT, V214, P81, DOI 10.1016/0014-5793(87)80017-0; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIPSICK JS, 1984, CANCER CELLS, V2, P143; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MELANI C, 1991, CANCER RES, V51, P2897; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PERBAL B, 1985, J VIROL, V56, P240, DOI 10.1128/JVI.56.1.240-244.1985; PERBAL B, 1986, BIOCHIMIE, V68, P969, DOI 10.1016/S0300-9084(86)80040-2; PERBAL B, 1984, ADV VIRAL ONCOL, V4, P163; Perbal B., 1988, PRACTICAL GUIDE MOL; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SORET J, 1985, J VIROL, V55, P193, DOI 10.1128/JVI.55.1.193-205.1985; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VALTIERI M, 1991, BLOOD, V77, P1181; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WASYLYK C, 1990, ONCOGENE, V5, P1055; ZASTROW G, 1989, NUCLEIC ACIDS RES, V17, P1867, DOI 10.1093/nar/17.5.1867	44	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					535	542						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549366				2022-12-28	WOS:A1992HK00500020
J	KIKUCHI, A; KAIBUCHI, K; HORI, Y; NONAKA, H; SAKODA, T; KAWAMURA, M; MIZUNO, T; TAKAI, Y				KIKUCHI, A; KAIBUCHI, K; HORI, Y; NONAKA, H; SAKODA, T; KAWAMURA, M; MIZUNO, T; TAKAI, Y			MOLECULAR-CLONING OF THE HUMAN CDNA FOR A STIMULATORY GDP/GTP EXCHANGE PROTEIN FOR C-KI-RAS P21 AND SMG P21	ONCOGENE			English	Article							GTP-BINDING PROTEIN; PURIFICATION; PHOSPHORYLATION; MEMBRANES; SEQUENCES; KINASE; WEIGHT; P53	We have previously purified smg GDP dissociation stimulator (GDS) from bovine brain and isolated its cDNA from a bovine brain cDNA library. smg GDS stimulates the GDP/GTP exchange reaction of a group of small GTP-binding proteins (G proteins), including at least c-Ki-ras p21, smg p21A, smg p21B, rhoA p21 and rhoB p21, by stimulating the dissociation of GDP from and the subsequent binding of GTP to each small G protein. In this study, we have isolated and sequenced the cDNA of smg GDS from a human brain cDNA library using the cloned bovine smg GDS cDNA. The cDNA has an open reading frame encoding a protein of 558 amino acids with a calculated M(r) value of 61 122. Human smg GDS shares 93% nucleotide and 96% amino acid sequence homologies with bovine smg GDS. The isolated cDNA is expressed in Escherichia coli, and the encoded protein shows the physical and functional properties similar to those of bovine smg GDS.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FUJIOKA H, 1992, IN PRESS J BIOL CHEM; HANCOCK JF, 1989, CELL, V57, P1107; HATA Y, 1990, J BIOL CHEM, V265, P7104; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; OHMORI T, 1989, J BIOL CHEM, V264, P1877; SAIKUMAR P, 1988, ONCOGENE RES, V3, P213; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, IN PRESS INT REV CYT; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	37	40	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					289	293						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549351				2022-12-28	WOS:A1992HG98200013
J	SCHUURING, E; VERHOEVEN, E; MOOI, WJ; MICHALIDES, RJAM				SCHUURING, E; VERHOEVEN, E; MOOI, WJ; MICHALIDES, RJAM			IDENTIFICATION AND CLONING OF 2 OVEREXPRESSED GENES, U21B31/PRAD1 AND EMS1, WITHIN THE AMPLIFIED CHROMOSOME 11Q13 REGION IN HUMAN CARCINOMAS	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; PROTO-ONCOGENE; BREAST-CANCER; FREQUENT AMPLIFICATION; MOLECULAR-CLONING; ESCHERICHIA-COLI; HUMAN-TUMORS; BCL-1 LOCUS; INT-2 GENE; 5 GENES	Amplification of the chromosome 11q13 region is frequently found in human breast cancer and in squamous cell carcinomas of the head and neck, and has been associated with an unfavourable clinical course of disease. The known oncogenes within the amplified 11q13 region, INT2 and HSTF1, are rarely expressed in these tumours, indicating that another, hitherto unidentified, gene or genes confer(s) the biological (prognostic) significance to the amplification of the 11q13 region. To identify the gene or genes, we have constructed a cDNA library from a cell line with an 11q13 amplification and have performed differential cDNA cloning using [P-32]dCTP-labelled cDNAs from human squamous cell carcinoma cell lines with and without an 11q13 amplification. We isolated two cDNA clones, U21B31 and U21C8, which recognize two genes amplified and overexpressed in cell lines harbouring an 11q13 amplification. In breast carcinomas and in squamous cell carcinomas amplification of both the U21B31 and the U21C8 gene was found in most tumours with an amplification of the 11q13 region, despite the large distance between both genes. Sequence analysis of the U21C8 cDNA clone revealed no homology to known genes; we call this gene EMS1. The U21B31 cDNA clone corresponded to the 3' end of the PRAD1 proto-oncogene, recently cloned from a parathyroid adenoma. Both gene products are of interest as potential markers to identify tumours with an 11q13 amplification.	NETHERLANDS CANC INST, DIV TUMOR BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								ADNANE J, 1989, ONCOGENE, V4, P1389; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERENSON JR, 1989, ONCOGENE, V4, P1111; BERENSON JR, 1990, ONCOGENE, V5, P1343; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DEBRUIJN MHL, 1986, MOL CELL BIOL, V6, P4717, DOI 10.1128/MCB.6.12.4717; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JIN YH, 1990, GENE CHROMOSOME CANC, V2, P198, DOI 10.1002/gcc.2870020306; KITAGAWA Y, 1991, CANCER RES, V51, P1504; KODURU PRK, 1989, ONCOGENE, V4, P929; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LISCIA DS, 1989, ONCOGENE, V4, P1219; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEIROS LJ, 1990, BLOOD, V76, P2086; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RABBITTS PH, 1988, ONCOGENE, V3, P99; ROSENBERG CL, 1991, ONCOGENE, V6, P449; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOMERS KD, 1990, ONCOGENE, V5, P915; STOW MW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P7, DOI 10.1016/0167-4889(91)90171-S; THEILLET C, 1989, ONCOGENE, V4, P915; TSUDA H, 1989, CANCER RES, V49, P3104; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	49	346	356	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					355	361						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1532244				2022-12-28	WOS:A1992HG98200022
J	WERNER, S; ROTH, WK; BATES, B; GOLDFARB, M; HOFSCHNEIDER, PH				WERNER, S; ROTH, WK; BATES, B; GOLDFARB, M; HOFSCHNEIDER, PH			FIBROBLAST GROWTH-FACTOR 5 PROTOONCOGENE IS EXPRESSED IN NORMAL HUMAN FIBROBLASTS AND INDUCED BY SERUM GROWTH-FACTORS	ONCOGENE			English	Article							KAPOSIS SARCOMA-CELLS; MYC MESSENGER-RNA; C-MYC; NUCLEOTIDE-SEQUENCE; KINASE-C; GENE; INDUCTION; FAMILY; FOS; 3T3-CELLS	Fibroblast growth factor 5 (FGF-5) is a member of the fibroblast growth factor family with transforming potential. It has been found to be expressed in several human tumor cell lines, but nothing is known about expression of this growth factor in normal cells and its biological functions. Here we show that the FGF-5 gene is expressed in exponentially growing normal human fibroblasts. In quiescent fibroblasts, expression of FGF-5 is strongly induced by serum and several growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha). This induction can be mediated by at least two different pathways involving protein kinase C or cAMP-dependent kinases. Since the effect is independent of de novo protein synthesis, FGF-5 represents the product of a primary response gene. In addition our data suggest that FGF-5 is mitogenic for human fibroblasts, indicating the existence of an FGF-5-mediated positive feedback in these cells which could amplify and prolong the cellular response to the initial stimulus.	MAX PLANCK INST BIOCHEM, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA	Max Planck Society; Columbia University				Werner, Sabine/0000-0001-7397-8710				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MARICS I, 1989, ONCOGENE, V4, P335; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROTH WK, 1988, INT J CANCER, V42, P767, DOI 10.1002/ijc.2910420523; ROTH WK, 1989, ONCOGENE, V4, P483; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; WERNER S, 1989, INT J CANCER, V43, P1137, DOI 10.1002/ijc.2910430629; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	34	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					2137	2144						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658709				2022-12-28	WOS:A1991GX11900026
J	CHEN, YM; CHEN, PL; ARNAIZ, N; GOODRICH, D; LEE, WH				CHEN, YM; CHEN, PL; ARNAIZ, N; GOODRICH, D; LEE, WH			EXPRESSION OF WILD-TYPE P53 IN HUMAN A673 CELLS SUPPRESSES TUMORIGENICITY BUT NOT GROWTH-RATE	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; HUMAN PROSTATE CARCINOMA; TUMOR-ANTIGEN; RB GENE; TRANSFORMATION; ONCOGENE; SARCOMAS; CANCER; IMMORTALIZATION; MECHANISMS	The p53 gene has been found to be mutated in many different kinds of human cancers. In a previous study, expression of exogenous wild-type p53 in human osteosarcoma cells by retrovirus-mediated gene transfer resulted in marked enlargement of cell size, reduced growth rate in culture and loss of tumorigenicity in nude mice. Here we examine the effects of expression of wild-type or mutated p53 on human peripheral neuroepithelioma (PNET) A673 cells; these cells contained apparently normal alleles of the p53 gene but did not express a detectable quantity of p53 protein. Various characteristics of the p53-expressing cells were examined including morphology, growth rate, soft-agar colony formation, and tumorigenicity in nude mice. In contrast to osteosarcoma Saos-2 cells, expression of wild-type or mutant p53 protein in A673 cells had no effect on morphology or growth characteristics. However, clones expressing wild-type p53 protein had reduced ability to form colonies in soft agar and tumors in nude mice. To substantiate the genotype of wild-type p53-expressing cells, the proviral p53-encoding DNA of one cell clone was amplified by the polymerase chain reaction and sequenced. We concluded that expression of a single allele of the wild-type p53 gene was sufficient to suppress PNET A673 tumorigenicity but had no detectable effect on growth rate in culture.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio	LEE, WH (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245, USA.				NATIONAL CANCER INSTITUTE [P01CA051495] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA51495] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DREYFUS F, 1990, LEUKEMIA, V4, P590; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T., 1982, MOL CLONING; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	33	76	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1799	1805						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923505				2022-12-28	WOS:A1991GX11800012
J	RESCIGNO, J; MANSUKHANI, A; BASILICO, C				RESCIGNO, J; MANSUKHANI, A; BASILICO, C			A PUTATIVE RECEPTOR TYROSINE KINASE WITH UNIQUE STRUCTURAL TOPOLOGY	ONCOGENE			English	Note							ADHESION MOLECULE L1; IMMUNOGLOBULIN SUPERFAMILY; HUMAN CHROMOSOME-19Q; HOMOLOGY; MEMBER; SIGNAL; FAMILY; RECOGNITION; FIBRONECTIN; SEQUENCE	We have cloned a murine cDNA on the basis of homology to the tyrosine kinase domain of the bek fibroblast growth factor receptor. This cDNA encodes a putative tyrosine kinase receptor with a unique structural pattern in its extracellular domain. It is a new member of the immunoglobulin superfamily with two immunoglobulin-like domains. It also contains two fibronectin type III domains which are found on diverse proteins such as receptor tyrosine phosphatases and neural cell adhesion molecules. This protein tyrosine kinase called ark (adhesion-related kinase) is likely to represent a new class of receptor tyrosine kinase. Ark mRNA appears to be expressed in most cell lines and adult tissues examined except those of hematopoietic lineage. It is undetectable in undifferentiated teratocarcinoma cells, F9 and N Tera 2.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				Mansukhani, Alka/0000-0003-1020-3242	NCI NIH HHS [CA 42568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURRIDGE K, 1987, J CELL SCI, P211; CAVANNA JS, 1990, GENOMICS, V7, P12, DOI 10.1016/0888-7543(90)90513-T; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEUSTACHIO P, 1988, J NEUROCHEM, V50, P589, DOI 10.1111/j.1471-4159.1988.tb02951.x; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P253, DOI 10.1016/0165-4608(89)90192-1; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RINDLER MJ, 1982, J CELL BIOL, V95, pA262; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONK D, 1990, CYTOGENET CELL GENET, V54, P15; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	100	126	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1909	1913						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1840679				2022-12-28	WOS:A1991GX11800027
J	SONOBE, MH; BRAVO, R; ARMELIN, MS				SONOBE, MH; BRAVO, R; ARMELIN, MS			IMBALANCED EXPRESSION OF CELLULAR NUCLEAR ONCOGENES CAUSED BY V-SIS PDGF-2	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; TRANSFORMING GENE-PRODUCT; FACTOR-LIKE PROTEIN; C-FOS GENE; GROWTH-FACTOR; 3T3 CELLS; LEUCINE ZIPPER; MESSENGER-RNA; DNA-SYNTHESIS; ONC GENE	Two murine cell lines that overexpress v-sis/PDGF-2 were used to study the mechanism of cell transformation by SSV (simian sarcoma virus). In contrast to the parental cells that are phenotypically normal and serum-dependent for growth, v-sis-overexpressing cells grow in PDGF-free plasma medium, are unable to enter the G0 state and are highly tumorigenic. Analysis of the expression of some growth factor-induced early response genes in v-sis-overexpressing cells revealed: (a) high and constitutive c-myc mRNA levels in SSV-NRK cells; (b) unaltered levels of fra-1, fos B, jun B and krox 20 transcripts; (c) high and constitutive FOS staining due to c-FOS and FOS-related protein(s); (d) constitutive c-JUN and higher JUN D expression. These results are compatible with a model in which endogenous production of v-sis/PDGF-2 leads to deregulated expression of key cellular transregulators that, in turn, alter the cells' transcriptional program leading to the transformed state and malignancy.	UNIV SAO PAULO, INST QUIM, DEPT BIOQUIM, CP 20780, BR-01498 SAO PAULO, BRAZIL; SQUIBB INST MED RES, PRINCETON, NJ 08543 USA	Universidade de Sao Paulo			Sonobe, Martha/I-2877-2015					AARONSON SA, 1975, J VIROL, V16, P1117, DOI 10.1128/JVI.16.5.1117-1123.1975; Abate C, 1990, Semin Cancer Biol, V1, P19; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANTONIADES HN, 1987, ONCOGENES GENES GROW, P1; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CROCE CM, 1985, BLOOD, V65, P1; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DALLAFAVERA R, 1982, NATURE, V299, P61; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OWEN AJ, 1984, SCIENCE, V225, P54, DOI 10.1126/science.6328659; PANTAZIS P, 1986, P NATL ACAD SCI USA, V83, P5526, DOI 10.1073/pnas.83.15.5526; PECH M, 1989, P NATL ACAD SCI USA, V86, P2693, DOI 10.1073/pnas.86.8.2693; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMEH LE, 1991, IN PRESS ONCOGENE; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCHATZL HM, 1989, ONCOGENE, V4, P1095; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; THEILEN GH, 1971, JNCI-J NATL CANCER I, V47, P881; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VOGT PK, 1988, ONCOGENE, V3, P3; VOGT PK, 1990, CANCER BIOL, V1, P27; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	71	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1531	1537						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923519				2022-12-28	WOS:A1991GX27400006
J	LEBEAU, J; LECHALONY, C; PROSPERI, MT; GOUBIN, G				LEBEAU, J; LECHALONY, C; PROSPERI, MT; GOUBIN, G			CONSTITUTIVE OVEREXPRESSION OF A 89 KDA HEAT-SHOCK PROTEIN GENE IN THE HBL100 HUMAN MAMMARY CELL-LINE CONVERTED TO A TUMORIGENIC PHENOTYPE BY THE EJ/T24 HARVEY-RAS ONCOGENE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; MOLECULAR-CLONING; PLATELET PROTEIN; TRANSCRIPTION; EXPRESSION; DNA; FIBROBLASTS; ACTIVATION	The non tumorigenic human mammary cell line HBL100 has been transformed by the EJ/T24 human bladder carcinoma Harvey(Ha)-ras oncogene. Six cell lines were established from transformed colonies. They all expressed a high level of the ras oncogene and were tumorigenic in athymic nude mice. During an in vivo passage in animals, tumour cells presenting a growth advantage were selected, and some of the tumours revealed an amplification of the transfected ras sequences. Using this model of human cell transformation, we have isolated a cDNA clone corresponding to a heat shock protein gene (hsp89-alpha). This gene, normally transcribed at a higher rate in response to serum stimulation, was found to be constitutively overexpressed in ras-transformed HBL100 cells. In contrast, a closely related hsp gene (hsp89-beta), remained sensitive to serum stimulation, in both untransformed and ras-transformed HBL100 cells. Thus, the regulation of the expression of the hsp89 genes, upon serum stimulation, involves ras-dependent and ras-independent pathways. Constitutive overexpression of the murine homolog of the hsp89-alpha was observed in NIH3T3 cells transformed by the three ras oncogenes, but not with some other oncogenes. Therefore, alteration of the hsp89-alpha gene expression is not a general characteristic of transformed cells, but seems to be linked to ras transformation.	INST CURIE,ONCOGENESE MOLEC LAB,26 RUE ULM,F-75005 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	GOUBIN, G (corresponding author), INST CURIE,ONCOGENESE MOLEC LAB,26 RUE ULM,F-75005 PARIS,FRANCE.							BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BARNIER JV, 1987, EXP CELL RES, V170, P186, DOI 10.1016/0014-4827(87)90128-5; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHRISTIAN BJ, 1990, CANCER RES, V50, P4779; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGAG N, 1990, ONCOGENE, V5, P1481; HAIRE RN, 1988, J CELL BIOL, V106, P883, DOI 10.1083/jcb.106.3.883; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HICKEY E, 1986, GENE, V43, P147, DOI 10.1016/0378-1119(86)90018-1; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANKS KW, 1979, BIOCHIM BIOPHYS ACTA, V578, P1, DOI 10.1016/0005-2795(79)90106-5; LEGAGNEUX V, 1989, DIFFERENTIATION, V41, P42, DOI 10.1111/j.1432-0436.1989.tb00730.x; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; Maniatis T., 1982, MOL CLONING LAB MANU; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MOORE SK, 1989, J BIOL CHEM, V264, P5343; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OSHIMURA M, 1988, CANCER RES, V48, P1623; PROSPERI MT, 1987, ONCOGENE RES, V1, P121; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAINTRUF C, 1989, INT J CANCER, V44, P367, DOI 10.1002/ijc.2910440230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOW ND, 1976, J GEN VIROL, V33, P447, DOI 10.1099/0022-1317-33-3-447; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; WU BJ, 1987, P NATL ACAD SCI USA, V84, P2203, DOI 10.1073/pnas.84.8.2203; YAMAZAKI M, 1989, NUCLEIC ACIDS RES, V17, P7108, DOI 10.1093/nar/17.17.7108; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	47	50	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1125	1132						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861862				2022-12-28	WOS:A1991GV26000005
J	KALTHOFF, H; ROEDER, C; HUMBURG, I; THIELE, HG; GRETEN, H; SCHMIEGEL, W				KALTHOFF, H; ROEDER, C; HUMBURG, I; THIELE, HG; GRETEN, H; SCHMIEGEL, W			MODULATION OF PLATELET-DERIVED GROWTH FACTOR-A-CHAIN AND FACTOR-B-CHAIN C-SIS MESSENGER-RNA BY TUMOR-NECROSIS-FACTOR AND OTHER AGENTS IN ADENOCARCINOMA CELLS	ONCOGENE			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN KINASE-C; ENDOTHELIAL-CELLS; HUMAN-FIBROBLASTS; PANCREATIC ADENOCARCINOMA; MOLECULAR-CLONING; GENE-EXPRESSION; FACTOR RECEPTOR; PDGF; LINES	Human Platelet Derived Growth Factors (PDGF) are potent mitogens for mesenchymal cells and encoded by two related genes, the A- (or 1-) and B- (or 2-) chain. The latter is known as the human homolog (c-sis) of the v-sis oncogene. We investigated the expression and cytokine-mediated regulation of PDGF A- and B-chain mRNA in endoderm-derived cells, i.e. cultured human pancreatic adenocarcinoma cells. Northern blot analysis revealed that out of 14 cell lines 11 were positive for the A-chain and 10 for the B-chain. Tumor Necrosis Factor (TNF) -alpha and -beta, but not Interferon (IFN) -gamma, drastically upregulate the mRNA levels for PDGF B-chain and for the A-chain in a dose-dependent manner in nearly every pancreatic tumor cell line investigated (n = 6). With respect to the signal pathway stimulated by TNF, no evidence emerged for an activation of protein kinase A. The inhibition of protein kinase C by staurosporine (in the absence or presence of TNF) as well as its stimulation by PMA resulted in an increased mRNA level for the B-chain, indicating a functional role of PKC in this system. Furthermore, time course experiments and Cycloheximide treatment showed that the A- and B-chain mRNA are regulated by different mechanisms in transformed epithelial cells. Irrespective of these differences, the sum of their biological functions may contribute to the phenomenon of desmoplasia in pancreatic tumors by epithelial/mesenchymal interactions.			KALTHOFF, H (corresponding author), UNIV HAMBURG,MED KLIN 1,IMMUNOL ABT,MARTINSTR 52,W-2000 HAMBURG 20,GERMANY.		Kalthoff, Holger/B-1618-2010					AGGARWAL BB, 1984, THYMIC HORMONES LYMP, P235; ALITALO R, 1987, EMBO J, V6, P1213, DOI 10.1002/j.1460-2075.1987.tb02356.x; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BIRD TA, 1989, J IMMUNOL, V142, P126; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; CHEN WH, 1982, IN VITRO CELL DEV B, V18, P24; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; FAHRER C, 1989, INT J CANCER, V44, P652, DOI 10.1002/ijc.2910440416; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FRIEDMAN BA, 1990, CANCER RES, V50, P533; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HAJJAR KA, 1987, J EXP MED, V166, P235, DOI 10.1084/jem.166.1.235; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; KAKU M, 1980, GANN, V71, P596; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; METZGAR RS, 1982, CANCER RES, V42, P601; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; MOTOYAMA T, 1983, JPN J CANCER RES, V74, P679; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NOGUCHI P, 1979, IN VITRO CELL DEV B, V15, P401; OKABE T, 1983, CANCER, V51, P662, DOI 10.1002/1097-0142(19830215)51:4<662::AID-CNCR2820510419>3.0.CO;2-X; PALOMBELLA VJ, 1988, J CELL PHYSIOL, V135, P23, DOI 10.1002/jcp.1041350104; PAULSSON Y, 1989, EXP CELL RES, V180, P490, DOI 10.1016/0014-4827(89)90075-X; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PIMENTEL E, 1987, HORMONES GROWTH FACT, P195; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; REILLY CF, 1989, BIOCHEM BIOPH RES CO, V160, P1047, DOI 10.1016/S0006-291X(89)80108-1; RO J, 1989, ONCOGENE, V4, P351; ROSS R, 1989, LANCET, V1, P1179; ROZENGURT E, 1985, INT J CANCER, V36, P247, DOI 10.1002/ijc.2910360218; SARIBAN E, 1988, J CLIN INVEST, V82, P1157, DOI 10.1172/JCI113712; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEURICH P, 1989, J EXP MED, V170, P947, DOI 10.1084/jem.170.3.947; SCHMIEGEL WH, 1988, PANCREAS, V3, P180, DOI 10.1097/00006676-198804000-00012; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SUZUKI H, 1989, AM J PATHOL, V134, P35; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WILLIAMS LT, 1988, MECH CONTROL GENE EX, P351; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	58	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1015	1021						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906154				2022-12-28	WOS:A1991GU62200017
J	SENECA, S; PUNYAMMALEE, B; BAILLY, M; GHYSDAEL, J; CRABEEL, M				SENECA, S; PUNYAMMALEE, B; BAILLY, M; GHYSDAEL, J; CRABEEL, M			ETS1, WHEN FUSED TO THE GAL4 DNA-BINDING DOMAIN, EFFICIENTLY ENHANCES GALACTOSE PROMOTOR DEPENDENT GENE-EXPRESSION IN YEAST	ONCOGENE			English	Article							UPSTREAM ACTIVATING SEQUENCES; ONCOGENE C-ETS; SACCHAROMYCES-CEREVISIAE; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATOR; V-ETS; REGULATORY PROTEIN; TRANSFORMING GENE; LEUKEMIA VIRUSES; E26 RETROVIRUS	Ets1, the translation product of the c-ets1 proto-oncogene and the related Ets2 protein, act as sequence-specific transcriptional factors in transient transfection experiments in animal cells. We report here that in S. cerevisiae, expression of a lacZ test gene placed under the control of the GAL1 promoter is stimulated efficiently by a fusion protein in which the chicken Ets1 sequence starting from amino acid 37, is linked to the DNA binding domain of the yeast GAL4 transcriptional activator. This suggests that Ets1 contains one or more intrinsic transcription activation domain(s). However, the GAL4 integral Ets1 fusion protein was unable to restore growth of a gal4 deletion mutant on galactose, implying that the fusion product cannot substitute for GAL4 enhancement on all GAL genes.	VRIJE UNIV BRUSSELS, CERIA COOVI, EMILE GRYSONLAAN 1, B-1070 BRUSSELS, BELGIUM; INST PASTEUR, CNRS, UA 041160, INSERM, U186, F-59019 LILLE, FRANCE	Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			GHYSDAEL, Jacques/F-3377-2013	Seneca, Sara/0000-0002-0853-9890				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, IN PRESS EMBO J; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CRABEEL M, 1983, EMBO J, V2, P205, DOI 10.1002/j.1460-2075.1983.tb01406.x; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FINLEY RL, 1989, MOL CELL BIOL, V9, P4282, DOI 10.1128/MCB.9.10.4282; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON M, 1990, Yeast, V6, pS16; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; TAJIMA M, 1986, MOL CELL BIOL, V6, P246, DOI 10.1128/MCB.6.1.246; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1	51	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					357	360						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1901401				2022-12-28	WOS:A1991FT34400002
J	YAN, DH; CHANG, LS; HUNG, MC				YAN, DH; CHANG, LS; HUNG, MC			REPRESSED EXPRESSION OF THE HER-2/C-ERBB-2 PROTOONCOGENE BY THE ADENOVIRUS E1A GENE-PRODUCTS	ONCOGENE			English	Note							GROWTH-FACTOR-RECEPTOR; ERBB-RELATED GENE; MESSENGER-RNAS; NEU ONCOGENE; HUMAN-BREAST; TRANSCRIPTION; AMPLIFICATION; CANCER; C-ERBB-2; PROTEINS	The E3 region of adenovirus induces down-regulation of epidermal growth factor receptor (EGFR) through endocytosis. Here we report that an EGFR-related protein, the HER-2/c-erbB-2 gene product, p185, is also down-regulated by adenovirus, but via a different mechanism. We found that the adenovirus E1a gene is responsible for the repression of HER-2/c-erbB-2 at the RNA level.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT BIOL,PRINCETON,NJ 08544	University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; Princeton University			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA-45265] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045265] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CARLIN CR, 1989, CELL, V57, P135, DOI 10.1016/0092-8674(89)90179-7; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GAYNOR RB, 1982, J VIROL, V44, P276, DOI 10.1128/JVI.44.1.276-285.1982; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; NEVINS JR, 1987, MICROBIOL REV, V51, P419, DOI 10.1128/MMBR.51.4.419-430.1987; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; ROSENTHAL A, 1985, NATURE, V315, P579, DOI 10.1038/315579a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; YOUNG KS, 1989, MOL CELL BIOL, V9, P3109, DOI 10.1128/MCB.9.7.3109; ZHANG X, 1989, ONCOGENE, V4, P985	27	74	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					343	345						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1672040				2022-12-28	WOS:A1991FZ13400023
J	MCCORMICK, F				MCCORMICK, F			THE WORLD ACCORDING TO GAP	ONCOGENE			English	Review											MCCORMICK, F (corresponding author), CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRENGEL U, 1990, IN PRESS CELL; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MCCORMICK F, 1988, COLD SPRING HARB SYM, V53, P849, DOI 10.1101/SQB.1988.053.01.097; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PAWSON T, 1988, ONCOGENE, V3, P491; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; SATOH T, 1988, FEBS LETT, V236, P185, DOI 10.1016/0014-5793(88)80311-9; SCHLICHTING I, 1990, IN PRESS NATURE; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1990, IN PRESS CELL	34	61	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1281	1283						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699195				2022-12-28	WOS:A1990EC24100001
J	SZEPETOWSKI, P; OLLENDORFF, V; GROSGEORGE, J; COURSEAUX, A; BIRNBAUM, D; THEILLET, C; GAUDRAY, P				SZEPETOWSKI, P; OLLENDORFF, V; GROSGEORGE, J; COURSEAUX, A; BIRNBAUM, D; THEILLET, C; GAUDRAY, P			DNA AMPLIFICATION AT 11Q13.5-Q14 IN HUMAN BREAST-CANCER	ONCOGENE			English	Note							GENE; 11Q13; CELL; TUMORS; CHROMOSOME-11Q13; CARCINOMAS; SEQUENCES; HST	Band q13 of chromosome 11 is frequently amplified in human breast cancers, but the gene(s) responsible for the emergence of this amplicon remain(s) elusive as yet. As a tribute to the complexity of the amplification events involving 11q13 sequences in human breast cancer, we have now studied a more telomeric region at 11q13.5-q14 defined by a new transcription unit, D11S833E. We have observed that amplicons present in cell lines and primary tumors amplified for both BCL1 and D11S833E could be interrupted between these two loci. Such discontinuities were demonstrated by using a probe for the KRN1 gene, which we have localized between the BCL1/FGF4 region and D11S833E. In fact, KRN1 was not present in 4 out of 10 amplicons bearing both BCL1 and D11S833E. Furthermore, we have observed tumors in which D11S833E could be amplified in the absence of amplification of other known markers of 11q13. Therefore, D11S833E defines a new and independent amplification unit in this region.	FAC MED NICE,LGMCH,CNRS,URA 1462,F-06107 NICE,FRANCE; UNIV MONTPELLIER 2,CNRS,URA 1191,F-34095 MONTPELLIER,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)	GAUDRAY, P (corresponding author), FAC MED NICE,LGMCH,CNRS,URA 1462,F-06107 NICE,FRANCE.		Theillet, Charles/O-7634-2018	Birnbaum, Daniel/0000-0001-7920-9883; Ollendorff, Vincent/0000-0001-9751-2202; Theillet, Charles/0000-0001-5555-2759				ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; HAGEMEIJER A, 1991, GENE CHROMOSOME CANC, V3, P210, DOI 10.1002/gcc.2870030307; LAFAGE M, 1990, GENE CHROMOSOME CANC, V2, P171, DOI 10.1002/gcc.2870020302; LAFAGE M, 1992, IN PRESS GENES CHROM, V4; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MACKINNON PJ, 1991, MAMM GENOME, V1, P53, DOI 10.1007/BF00350846; OLLENDORFF V, 1992, MAMM GENOME, V2, P195, DOI 10.1007/BF00302877; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RICHARD CW, 1991, AM J HUM GENET, V49, P1189; SAITO I, 1989, MOL CELL BIOL, V9, P2445, DOI 10.1128/MCB.9.6.2445; SHILOH Y, 1985, P NATL ACAD SCI USA, V82, P3761, DOI 10.1073/pnas.82.11.3761; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SZEPETOWSKI P, 1992, ONCOGENE, V7, P751; SZEPETOWSKI P, 1992, GENOMICS, V122, P738; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3	20	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2513	2517						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461654				2022-12-28	WOS:A1992KA85600017
J	KOTANI, K; KIKUCHI, A; DOI, K; KISHIDA, S; SAKODA, T; KISHI, K; TAKAI, Y				KOTANI, K; KIKUCHI, A; DOI, K; KISHIDA, S; SAKODA, T; KISHI, K; TAKAI, Y			THE FUNCTIONAL DOMAIN OF THE STIMULATORY GDP GTP EXCHANGE PROTEIN (SMG GDS) WHICH INTERACTS WITH THE C-TERMINAL GERANYLGERANYLATED REGION OF RAP-1/KREV-1/SMG-P21	ONCOGENE			English	Article							BOVINE BRAIN MEMBRANES; BINDING PROTEIN; MOLECULAR-WEIGHT; EFFECTOR DOMAIN; HUMAN-PLATELETS; RAS PROTEINS; ACTIVATING PROTEINS; PLASMA-MEMBRANE; PURIFICATION; P21	rap1/Krev-1/smg p21 (smg p21), a member of the small GTP-binding protein (G protein) superfamily, has a geranylgeranylated cysteine residue and clustered basic amino acids in the C-terminal region. The GDP/GTP exchange reaction of smg p21 is regulated by smg GDS, which is also active on Ki-ras p21 and rho p21. The C-terminal region of smg p21 is essential for its interaction with smg GDS. Moreover, smg p21 is phosphorylated by cyclic AMP- and cyclic GMP-dependent protein kinases at the serine residue between the polybasic region and the prenylated cysteine residue, and this phosphorylation initiates the smg GDS-induced smg p21 activation. Thus, the C-terminal cationic and hydrophobic region is important for the regulation of the smg p21 activity. In the present study, we attempted to determine the functional domain of smg GDS which interacts with the C-terminal region of smg p21 by use of a cross-link method and a site-directed mutagenesis method. The region of smg GDS cross-linked with the C-terminal region of smg p21B was residues 444-492, which is located at the C-terminal fifth of smg GDS. On deletion of these residues, smg GDS became inactive on smg p21B, Ki-ras p21 and rhoA p21. These results indicate that residues 444-492 of smg GDS are at least one of the domains which interact with the C-terminal region of its substrate small G proteins.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University				kishida, shosei/0000-0003-0405-851X				BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NICE EC, 1992, J BIOL CHEM, V267, P1546; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Sambrook J, 1989, MOL CLONING LABORATO; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	33	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1699	1704						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501882				2022-12-28	WOS:A1992JJ37600004
J	LAM, EWF; ROBINSON, C; WATSON, RJ				LAM, EWF; ROBINSON, C; WATSON, RJ			CHARACTERIZATION AND CELL CYCLE-REGULATED EXPRESSION OF MOUSE B-MYB	ONCOGENE			English	Article							DNA-POLYMERASE-ALPHA; MURINE ERYTHROLEUKEMIA-CELLS; HUMAN HEMATOPOIETIC-CELLS; C-MYB; GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; BINDING ACTIVITY; MESSENGER-RNA; A-MYB; PROLIFERATION	We have isolated a full-length mouse B-myb cDNA clone and used this to examine cell cycle-regulated expression of this gene. Mouse B-Myb was predicted to comprise 704 amino acids and to be 84% homologous with human B-Myb. There were three regions of extensive amino acid homology which may indicate functional domains: the first corresponded to the c-Myb DNA-binding domain, while the second had no counterpart in c-Myb but was instead homologous to a short segment of the related A-myb protein. The third region of homology is partially conserved in both c-Myb and A-Myb and may correspond to the c-Myb negative regulator domain. Stimulation of quiescent 3T3 fibroblasts with serum was found to result in induction of B-myb expression in late G1 and to lead to high levels of gene transcripts that persisted through S phase. Similarly, maximum B-myb mRNA levels were reached in G2/M synchronized cells prior to entry into S phase. These results are consistent with a role in G1/S transition as has been suggested for c-myb.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research			Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576				BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DENTE L, 1985, DNA CLONING PRACTICA, V1, P101; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; MCMAHON J, 1988, ONCOGENE, V3, P717; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TERADA M, 1977, P NATL ACAD SCI USA, V74, P248, DOI 10.1073/pnas.74.1.248; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	30	98	100	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1885	1890						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501895				2022-12-28	WOS:A1992JJ37600027
J	PLET, A; TOURKINE, N; MECHTI, N; JEANTEUR, P; BLANCHARD, JM				PLET, A; TOURKINE, N; MECHTI, N; JEANTEUR, P; BLANCHARD, JM			INVIVO FOOTPRINTS BETWEEN THE MURINE C-MYC P1 AND P2 PROMOTERS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; TRANS-ACTIVATION; GENE-REGULATION; PROTEIN; ELEMENT; INVITRO; TRANSACTIVATION; INITIATION; EXPRESSION; ACCURATE	Assuming that when transcription starts at the P2 promoter of the c-myc gene sites located immediately upstream from P2 are occupied whereas in the absence of initiation they are not, the polymerase chain reaction (PCR)-based method of Mueller & Wold 1(1989). Science, 246, 780-7861 was used to map in vivo footprints upstream from the P2 promoter in various mouse cell lines. In cultured Friend erythroleukemic cells induced to differentiate with dimethysulfoxide (DMSO), a clear protection corresponding to ME1a2 and E2F sites was observed, consistent with in vitro band-shift and footprint data. However, in cell lines in which the gene was either silent or truncated the footprints were no longer visible. Friend c-myc transcripts decreased to a barely detectable level after 3 h of DMSO treatment. Transcription, as measured by in vitro run-on, was turned off at the level of RNA polymerase elongation rather than initiation [Mechti N., Piechaczyk, M. Blanchard, J.-M., Marty, L., Bonnieu, A., Jeanteur. Ph. & Lebler, B. (1986). Nucleic Acids Res., 24, 9653-96661. The state of occupancy of the sites did not vary from the first hours up to 9 days of DMSO treatment, suggesting that DNA occupancy per se cannot explain premature termination, which rather would involve a more complex phenomenon.			PLET, A (corresponding author), CNRS, URA 1191, 2 PL EUGENE BATAILLON, F-34095 MONTPELLIER 5, FRANCE.							ASSELIN C, 1989, ONCOGENE, V4, P549; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLANCHARD JM, 1988, BIOCHIMIE, V70, P877, DOI 10.1016/0300-9084(88)90228-3; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; HALL DJ, 1990, ONCOGENE, V5, P47; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; SACCA R, 1990, ONCOGENE, V5, P1499; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TOURKINE N, 1989, ONCOGENE, V4, P973; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938	32	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1847	1851						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501892				2022-12-28	WOS:A1992JJ37600021
J	MULLER, O; FRECH, M; GIDEON, P; WITTINGHOFER, A; SCHWARZ, M				MULLER, O; FRECH, M; GIDEON, P; WITTINGHOFER, A; SCHWARZ, M			DIFFERENCES IN GTPASE-ACTIVATING PROTEIN-ACTIVITY BETWEEN LIVER-TUMORS AND NORMAL LIVER-TISSUE IN MICE	ONCOGENE			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; RAS-P21 GTPASE; B6C3F1 MOUSE; RAS P21; GAP; PURIFICATION; IDENTIFICATION; INHIBITION; BINDING; PRODUCT	The intrinsic GTPase activity of the cellular protein p21ras is strongly increased by two cytosolic proteins, the GTPase-activating protein (GAP) produced by the neurofibromatosis type 1 gene (NF1-GAP) and a GAP of 120 kDa molecular mass (p120-GAP). The GAP-mediated stimulation of p21ras GTPase activity was measured in cytosol obtained from carcinogen-induced liver tumors and normal liver tissues of mice of two strains, namely C3H/He and C57BL/6J. For this purpose, cytosolic extracts were incubated with recombinant human p21ras complexed to [gamma-P-32]GTP and the time-dependent decrease in p21ras bound radioactivity was measured. Liver cytosolic extracts mediated an increase in the GTPase activity of wild-type p21ras. There were great differences between tumor and normal tissues in the maximal velocity (V(max)) and in the apparent Michaelis constant (K(M)) of the p21ras GTPase reaction. Both V(max), and apparent K(M) were decreased in the liver tumors. Cytosolic extracts isolated from liver tumors that harbored point mutations in codon 61 of the c-H-ras gene did not differ in their activity from extracts obtained from non-mutated liver tumors. Since both GAP proteins are important cellular regulators of the ras signaling pathway and probably also effectors of p21ras, the observed differences in GAP activity may be of relevance for the tumorigenic process in mouse liver.	GERMAN CANC RES CTR,PROJECT GRP TUMOR PROMOT LIVER,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; MAX PLANCK INST MED RES,W-6900 HEIDELBERG 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Max Planck Society								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; DOWNWARD J, 1988, COLD SPRING HARB SYM, V53, P883, DOI 10.1101/SQB.1988.053.01.101; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, G PROTEINS MEDIATORS, P173; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HATA Y, 1990, J BIOL CHEM, V265, P7104; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; REYNOLDS SH, 1986, P NATL ACAD SCI USA, V83, P33, DOI 10.1073/pnas.83.1.33; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; WOLFMAN A, 1990, FEBS LETT, V259, P245; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	29	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1407	1412						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620552				2022-12-28	WOS:A1992HZ97100020
J	SZEPETOWSKI, P; COURSEAUX, A; CARLE, GF; THEILLET, C; GAUDRAY, P				SZEPETOWSKI, P; COURSEAUX, A; CARLE, GF; THEILLET, C; GAUDRAY, P			AMPLIFICATION OF 11Q13 DNA-SEQUENCES IN HUMAN BREAST-CANCER - D11S97 IDENTIFIES A REGION TIGHTLY LINKED TO BCL1 WHICH CAN BE AMPLIFIED SEPARATELY	ONCOGENE			English	Article							FREQUENT AMPLIFICATION; GENE; CHROMOSOME-11; CARCINOMAS; TUMORS; LOCUS; MAPS	In the course of our study on the amplification of 11q13 sequences in human breast cancer, we have investigated the amplification status of the anonymous DNA fragment D11S97 in a series of 125 mammary tumors. Our results indicate that, as with bladder carcinomas, D11S97 can be amplified separately from BCL1. In addition, we have shown that D11597 is physically linked to both D11S146 and BCL1, and is less than 100 kb centromeric to the D115146. These results indicate that, in addition to other 11q13 loci, sequences located approximately 500kb centromeric from BCL1 could contribute to carcinogenesis of epithelial cells in vivo.	CNRS,URA 1462,LGMCH,F-06107 NICE 2,FRANCE; INSERM,U273,CTR BIOCHIM,F-06034 NICE,FRANCE; CTR PAUL LAMARQUE,CNRS,URA 1191,F-34094 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS)			Carle, Georges/GWC-5240-2022; Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759; Carle, Georges/0000-0002-3901-1052				ADNANE J, 1991, ONCOGENE, V6, P659; ARMOUR JAL, 1989, NUCLEIC ACIDS RES, V17, P4925, DOI 10.1093/nar/17.13.4925; BERENSON JR, 1989, ONCOGENE, V4, P1111; BERENSON JR, 1990, ONCOGENE, V5, P1343; BYSTROM C, 1990, P NATL ACAD SCI USA, V87, P1968, DOI 10.1073/pnas.87.5.1968; COOKSON WOC, 1989, LANCET, P1292; HAGEMEIJER A, 1991, GENE CHROMOSOME CANC, V3, P210, DOI 10.1002/gcc.2870030307; JULIER C, 1990, GENOMICS, V7, P335, DOI 10.1016/0888-7543(90)90167-S; LAMMIE GA, 1991, ONCOGENE, V6, P439; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P376, DOI 10.1093/nar/16.1.376; PROCTOR AJ, 1991, ONCOGENE, V6, P789; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; SZEPETOWSKI P, 1991, GENOMICS, V10, P410, DOI 10.1016/0888-7543(91)90326-A; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS BP, 1988, ONCOGENE, V3, P345	21	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					751	755						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565470				2022-12-28	WOS:A1992HQ68200018
J	SHARMA, SV				SHARMA, SV			MELITTIN RESISTANCE - A COUNTERSELECTION FOR RAS TRANSFORMATION	ONCOGENE			English	Article							SACCHAROMYCES-CEREVISIAE; SARCOMA-VIRUS; BEE VENOM; H-RAS; PROTEINS; MEMBRANE; CELLS; ONCOGENES; PHOSPHOLIPASE-A2; GENES	The prevalence of activated ras oncogenes in human primary tumors suggests a central role for this oncogene in human cancer. Despite its ubiquitous distribution, the biochemical role of the oncogene remains unclear, and hence attempts to control its activity have been frustrated. This study demonstrates the ability of melittin, a 26 amino acid, amphipathic peptide from bee venom, to specifically select against cells in culture that express high levels of the ras oncogene. Acquisition of resistance to increasing concentrations of melittin is accompanied by corresponding decreases in the levels of expression of the ras oncoprotein and the number of copies of the ras gene. This results in a concomitant reversion of transformed cells to a normal morphology in a strict dose-dependent manner. Melittin is a known activator of cellular phospholipase A2 (PLA2), and these results suggest an interrelationship between ras and PLA2. In addition these studies indicate that melittin preferentially hyperactivates PLA2 in ras oncogene-transformed cells, resulting in their selective destruction.			SHARMA, SV (corresponding author), UNIV TENNESSEE CTR HLTH SCI, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1989, ANTICANCER RES, V9, P1427; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHANG JP, 1988, J BIOL CHEM, V263, P18614; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KILLION JJ, 1986, BIOCHEM BIOPH RES CO, V139, P222, DOI 10.1016/S0006-291X(86)80102-4; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KREIL G, 1967, BIOCHEM BIOPH RES CO, V27, P275, DOI 10.1016/S0006-291X(67)80074-3; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUNOS G, 1984, P NATL ACAD SCI-BIOL, V81, P6178, DOI 10.1073/pnas.81.19.6178; LACHOWIEZ RM, 1988, FEBS LETT, V234, P195, DOI 10.1016/0014-5793(88)81332-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MARSHALL CJ, 1989, ONCOGENES; MAULET Y, 1982, ANAL BIOCHEM, V127, P61, DOI 10.1016/0003-2697(82)90144-0; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MOLLAY C, 1976, BIOCHIM BIOPHYS ACTA, V426, P317, DOI 10.1016/0005-2736(76)90340-0; MUFSON RA, 1979, NATURE, V280, P73; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J, 1989, MOL CLONING LABORATO; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SESSA G, 1969, J BIOL CHEM, V244, P3575; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; SHIER WT, 1980, P NATL ACAD SCI-BIOL, V77, P137, DOI 10.1073/pnas.77.1.137; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TOOZE J, 1980, MOL BIOL TUMOR VIRUS; TOSTESON MT, 1987, BIOCHEMISTRY-US, V26, P6627, DOI 10.1021/bi00395a010; VINCENTINI LM, 1984, J BIOL CHEM, V259, P6912; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; YUNES R, 1977, ARCH BIOCHEM BIOPHYS, V183, P105, DOI 10.1016/0003-9861(77)90424-6	57	54	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					193	201						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549345				2022-12-28	WOS:A1992HG98200001
J	BLACK, EJ; STREET, AJ; GILLESPIE, DAF				BLACK, EJ; STREET, AJ; GILLESPIE, DAF			PROTEIN PHOSPHATASE 2A REVERSES PHOSPHORYLATION OF C-JUN SPECIFIED BY THE DELTA DOMAIN INVITRO - CORRELATION WITH ONCOGENIC ACTIVATION AND DEREGULATED TRANSACTIVATION ACTIVITY OF V-JUN	ONCOGENE			English	Article							OKADAIC ACID; AP-1; FOS; TRANSFORMATION; INHIBITOR; ENCODES	Chicken c-Jun proteins synthesized in vitro in reticulocyte extract consist of several electrophoretic isoforms resulting from phosphorylation which can be specifically reversed by purified protein phosphatase 2A (PP2A). Using the phosphatase inhibitors okadaic acid and microcystin-LR, we conclude that the isoforms seen in vitro represent a balance between the action of an unidentified kinase(s) which phosphorylates c-Jun and dephosphorylation by an endogenous PP2A-like phosphatase. c-Jun proteins are also subject to phosphorylation in vivo in chick embryo fibroblasts (CEF), which can be reversed by PP2A. In contrast, the viral Jun oncoprotein encoded by ASV17 is not subject to PP2A-sensitive phosphorylation in vitro and is hypophosphorylated in comparison with c-Jun in ASV17-transformed CEF. Hybrids between c-Jun and v-Jun demonstrate that differential phosphorylation in vitro is a consequence of deletion of 27 amino acids in the N-terminal third of v-Jun. The deletion is important for oncogenic activation and lies in a domain, termed delta, which regulates c-Jun transactivation function. PP2A-sensitive phosphorylation in vitro correlates with the differential responsiveness of c-Jun and v-Jun to a recently identified cell type-specific inhibitor of transactivation function.	BEATSON INST CANC RES, CANC RES CAMPAIGN BEATSON LABS, GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, SCOTLAND; UNIV DUNDEE, INST MED SCI, DEPT BIOCHEM, MRC PROTEIN PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND	Beatson Institute; University of Dundee			Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CROUCH DH, 1990, ONCOGENE, V5, P683; CURRAN T, 1987, ONCOGENE, V2, P79; FRAME MC, 1991, ONCOGENE, V6, P205; GILLESPIE DAF, 1989, MOL CELL BIOL, V9, P865, DOI 10.1128/MCB.9.2.865; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768	24	52	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					1949	1958						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658706				2022-12-28	WOS:A1991GX11900002
J	HUANG, S; AXELROD, DE				HUANG, S; AXELROD, DE			ALTERED POSTTRANSLATIONAL PROCESSING OF P21RAS ONCOPROTEIN IN A TRANSFORMATION-SUPPRESSED CELL-LINE	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; RAS PROTO-ONCOGENE; SACCHAROMYCES-CEREVISIAE; FATTY ACYLATION; GENE FAMILY; H-RAS; PROTEINS; HARVEY; IDENTIFICATION; MUTANT	We have isolated a transformation-suppressed cell line, R35, which is altered in the maturation of p21ras. It was obtained from the transformed cell line NIH3T3(ras(EJ)) as a revertant with flat morphology and anchorage dependent growth. Immunoprecipitation of steady state labeled ras proteins reveals that the revertant produces p21ras, and in addition, accumulates a protein that migrates as 23 kD. Fusion of revertant cells with non-transformed rat2 cells yields cell hybrids which are retransformed and do not accumulate p23, suggesting that accumulation of p23 and suppression of transformation may be related. The accumulated p23 appears to be a precursor to p21 because (1) pulse labeling and cell fractionation of revertant cells shows that label chases from cytoplasmic p23 to membrane-associated p21, although at a slower rate, and (2) the p23 of revertant cells is indistinguishable from the p23 precursor of p21 in parent cells by partial V8 protease digestion and two dimensional electrophoresis. R35 cells are slower than their transformed parent in palmitylation and polyisoprenylation, but not in methylation of ras proteins. These results suggest that the transformation-suppressed cell line R35 is defective in the rate at which it post-translationally processes ras proteins, possibly because it is slower in polyisoprenylation of the cytoplasmic p23 precursor protein.	RUTGERS STATE UNIV,WAKSMAN INST,POB 759,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick	AXELROD, DE (corresponding author), RUTGERS STATE UNIV,WAKSMAN INST,POB 759,PISCATAWAY,NJ 08855, USA.				NATIONAL CANCER INSTITUTE [R01CA042795] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Aswad DW, 1989, CURR OPIN CELL BIOL, V1, P1182, DOI 10.1016/S0955-0674(89)80069-9; BARBACID H, 1987, ANN REV BIOCH, V56, P779; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COLBY WW, 1986, MOL CELL BIOL, V6, P730, DOI 10.1128/MCB.6.2.730; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEE J, 1989, UNPUB; LEE J, 1985, J CELL BIOL, V101, pA116; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; POLONIS VR, 1987, ARCH BIOCHEM BIOPHYS, V254, P541, DOI 10.1016/0003-9861(87)90135-4; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	34	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1211	1218						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861867				2022-12-28	WOS:A1991GV26000017
J	HELIN, K; VELU, T; MARTIN, P; VASS, WC; ALLEVATO, G; LOWY, DR; BEGUINOT, L				HELIN, K; VELU, T; MARTIN, P; VASS, WC; ALLEVATO, G; LOWY, DR; BEGUINOT, L			THE BIOLOGICAL-ACTIVITY OF THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR IS POSITIVELY REGULATED BY ITS C-TERMINAL TYROSINES	ONCOGENE			English	Article							ALTERED AUTOPHOSPHORYLATION SITES; FACTOR EGF RECEPTOR; KINASE-ACTIVITY; SELF-PHOSPHORYLATION; PROTEIN-KINASE; GENE-PRODUCT; INTERNALIZATION; PP60C-SRC; MUTATION; BINDING	The epidermal growth factor receptor (EGF-R) C-terminus contains three conserved tyrosines (Y-1068, Y-1148, Y-1173) which are phosphorylated upon EGF activation. To clarify the functional role of these tyrosines, each has been mutated to phenylalanine and studied as single, double and triple mutants in the full length receptor. EGF-dependent transforming ability of the single point mutants is similar to that of the wild type, while that of double mutants is decreased and an even lower activity is present in the triple mutant. In each bioassay, including EGF-dependent focal transformation, growth in agar and growth in low serum, mutant receptors display a similar hierarchy of activity. The lower activity is intrinsic in the mutants since they are expressed at similar level as the wild type and bind EGF with similar affinity. Deletion mutants lacking the last 19 or 63 amino acids (Velu et al., 1989a) show a similar decline in biological activity when compared to the corresponding point mutants, although the reduction is more pronounced than with the point mutants. Deletion of the last 123 aa, which removes all three tyrosines (Dc123), results in a receptor that is almost inactive biologically. The EGF-R kinase activity is affected by tyrosine substitution since in vitro phosphorylation of exogenous substrates is reduced in the double and triple mutants. Autophosphorylation, in vivo and in vitro, is also reduced, but not totally abolished in the triple point mutant and Dc123 indicating the existence of other autophosphorylation sites. A new site of autophosphorylation is found in the Dc123 mutant. We conclude, therefore, that the tyrosines at the extreme C-terminus positively regulate the biological and transforming activity of the EGF-R, probably via autophosphorylation.	UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK; NIH,CELLULAR ONCOL LAB,BETHESDA,MD 20892	University of Copenhagen; National Institutes of Health (NIH) - USA	BEGUINOT, L (corresponding author), UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK.		Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; 				BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BEGUINOT L, 1986, J BIOL CHEM, V261, P1801; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CLARK AJL, 1986, BIOCHIM BIOPHYS ACTA, V867, P244, DOI 10.1016/0167-4781(86)90040-0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; DOWNWARD J, 1984, NATURE, V311, P283; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALEY JD, 1989, ONCOGENE, V4, P273; HELIN K, 1991, IN PRESS J BIOL CHEM, V266; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HSUAN JJ, 1980, BIOCHEM J, V77, P1311; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNI M, 1991, IN PRESS BIOCH J; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGATTO O, 1990, New Biologist, V2, P187; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YACIUK P, 1988, ONCOGENE RES, V3, P207; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	42	44	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					825	832						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646987				2022-12-28	WOS:A1991GT82500019
J	LANEUVILLE, P; HEISTERKAMP, N; GROFFEN, J				LANEUVILLE, P; HEISTERKAMP, N; GROFFEN, J			EXPRESSION OF THE CHRONIC MYELOGENOUS LEUKEMIA-ASSOCIATED P210BCR/ABL ONCOPROTEIN IN A MURINE IL-3 DEPENDENT MYELOID CELL-LINE	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; SENSITIVE V-ABL; INTERLEUKIN-3 DEPENDENCE; TYROSINE PHOSPHORYLATION; GM-CSF; GRANULOCYTIC DIFFERENTIATION; PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC-CELLS; AUTOCRINE GROWTH; ABELSON VIRUS	We have studied the effect of a replication-defective murine retroviral vector expressing the chronic myelogenous leukemia associated oncoprotein p210bcr/abl in murine IL-3 dependent myeloid 32D C13(G) cells. This cell line can be induced to differentiate along either the granulocytic or monocytic lineages thus permitting an independent assessment of the effect of p210bcr/abl on growth and differentiation. Cells expressing p210bcr/abl displayed a complete non-autocrine abrogation of IL-3 dependence and an enhanced response to an activity in FBS which is not IGF-I or IGF-II. During the first few generations following infection with the bcr/abl vector, cells became larger with an increased fraction of cells in G2/M and monocyte/macrophage markers were expressed. Four cytoplasmic proteins phosphorylated in response to IL-3 in the parental cell line with apparent molecular weights of 98, 70, 62, and 52 Kd were amongst those constitutively phosphorylated in p210bcr/abl expressing cells. These results suggest that the functional substitution of IL-3 by p210bcr/abl is due to constitutive activation of proteins involved in IL-3 signal transduction. Alterations of cell differentiation, cell cycle and growth which cannot be attributed to IL-3 like effects indicate that p210bcr/abl has pleiotropic effects involving several other pathways of cellular regulation.	CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, MOLEC DIAG SECT, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles	LANEUVILLE, P (corresponding author), ROYAL VICTORIA HOSP, DIV HEMATOL & ONCOL, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA.		Heisterkamp, Nora/C-1698-2012; Laneuville, Pierre/AAH-2293-2021	Heisterkamp, Nora/0000-0003-2769-2273; 	NCI NIH HHS [CA 47073] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047073] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1990, ONCOGENE, V5, P317; BABIOR BM, 1981, METHODS HEMATOLOGY, V3, P1; BELL JC, 1987, NATURE, V325, P552, DOI 10.1038/325552a0; BRADY G, 1988, ONCOGENE, V3, P687; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DONAHUE RE, 1988, SCIENCE, V241, P1820, DOI 10.1126/science.3051378; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS JPM, 1987, LEUKEMIA, V1, P524; EVANS JPM, 1990, BLOOD, V75, P88; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HUHN RD, 1987, P NATL ACAD SCI USA, V84, P4408, DOI 10.1073/pnas.84.13.4408; IHLE JN, 1986, ADV IMMUNOL, V39, P1; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; KATZAV S, 1989, ONCOGENE, V4, P1129; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MAVILIO F, 1989, ONCOGENE, V4, P301; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER MR, 1978, BIOCHEMISTRY-US, V17, P1073, DOI 10.1021/bi00599a021; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; MURPHY WM, 1986, J UROLOGY, V136, P815, DOI 10.1016/S0022-5347(17)45088-9; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; REESJONES RW, 1989, MOL CELL BIOL, V9, P278, DOI 10.1128/MCB.9.1.278; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; ROVERA G, 1987, ONCOGENE, V1, P29; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SORENSEN PHB, 1989, BLOOD, V73, P406; SPIVAK JL, 1985, J CLIN INVEST, V76, P1613, DOI 10.1172/JCI112145; STRIFE A, 1988, CANCER RES, V48, P1035; SUDA T, 1985, J CELL PHYSIOL, V124, P182, DOI 10.1002/jcp.1041240203; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VONMELCHNER H, 1988, ONCOGENE, V2, P137; WATSON JD, 1987, J IMMUNOL, V139, P123; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	59	93	94	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1991	6	2					275	282						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1705688				2022-12-28	WOS:A1991FZ13400013
J	CHENEVIXTRENCH, G; LEARY, J; KERR, J; MICHEL, J; KEFFORD, R; HURST, T; PARSONS, PG; FRIEDLANDER, M; KHOO, SK				CHENEVIXTRENCH, G; LEARY, J; KERR, J; MICHEL, J; KEFFORD, R; HURST, T; PARSONS, PG; FRIEDLANDER, M; KHOO, SK			FREQUENT LOSS OF HETEROZYGOSITY ON CHROMOSOME-18 IN OVARIAN ADENOCARCINOMA WHICH DOES NOT ALWAYS INCLUDE THE DCC LOCUS	ONCOGENE			English	Article							COLORECTAL CARCINOMAS; LUNG-CANCER; ALLELE LOSS; DNA; GENE; REGION; MUTATIONS; TUMORS; P53	Inactivation of the DCC gene on chromosome 18 owing to loss of heterozygosity is a common finding in colorectal cancer. Because both ovarian and colon cancer are features of Lynch syndrome II, which has been provisionally mapped to chromosome 18, we hypothesized that loss of heterozygosity at the DCC locus may also occur in ovarian neoplasia. Fifty-two sporadic ovarian adenocarcinoma tumours were analysed by Southern blotting for loss of heterozygosity (LOH) at six chromosome 18 loci. Overall, tumours from 31 patients (60%) showed allelic loss at one or more of these loci. A similarly high level of LOH, 66%, was found at D17S5 (17p13.3). In contrast, moderate levels of LOH, of 31%, 39% and 33%, were found at MYCL1 (1p32), D1S57 (1p) and D14S20 (14q32.33) respectively. However, analysis of partial chromosome deletions in 11 patients indicates that the smallest region of overlap appears to exclude the DCC gene but to be between the D18S5 and D18S11 loci. This suggests that another locus, as well as or apart from DCC, may be involved.	QUEENSLAND INST MED RES,JOINT ONCOL PROGRAMME,RES UNIT,QUEENSLAND CANC FUND,BRISBANE,AUSTRALIA; UNIV QUEENSLAND,DEPT OBSTET & GYNAECOL,BRISBANE,QLD 4000,AUSTRALIA; UNIV SYDNEY,WESTMEAD HOSP,DEPT OBSTET & GYNAECOL,SYDNEY,NSW 2006,AUSTRALIA; UNIV SYDNEY,WESTMEAD HOSP,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA; PRINCE WALES HOSP,DEPT MED ONCOL,SYDNEY,NSW,AUSTRALIA	Cancer Council Queensland; QIMR Berghofer Medical Research Institute; University of Queensland; University of Sydney; University of Sydney			Chenevix-Trench, Georgia/AAV-2014-2020; Parsons, Peter/J-4683-2013	Chenevix-Trench, Georgia/0000-0002-1878-2587; Kefford, Richard/0000-0001-9251-9229; Parsons, Peter/0000-0002-0473-3346				ATKIN NB, 1987, CANCER GENET CYTOGEN, V26, P355, DOI 10.1016/0165-4608(87)90070-7; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BERTELSEN K, 1987, GYNECOL ONCOL, V28, P161, DOI 10.1016/0090-8258(87)90210-1; BOMAN BM, 1988, CANCER GENET CYTOGEN, V34, P153, DOI 10.1016/0165-4608(88)90182-3; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; DEVILEE P, 1991, ONCOGENE, V6, P311; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES W, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91065-3; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEBEAU MM, 1989, CYTOGENET CELL GENET, V51, P338, DOI 10.1159/000132798; LEE JH, 1990, CANCER RES, V50, P2724; LEE JH, 1989, CANCER RES, V49, P1220; LI S, 1991, J NATL CANCER I, V83, P337; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; MARHLENS F, 1987, NUCLEIC ACIDS RES, V15, P1348; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITELMAN F, 1991, CATALOG CHROMOSOME A; MULERIS M, 1987, CANCER GENET CYTOGEN, V29, P289, DOI 10.1016/0165-4608(87)90239-1; MULLER U, 1987, CYTOGENET CELL GENET, V45, P16, DOI 10.1159/000132418; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P4747, DOI 10.1093/nar/16.10.4747; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P6257, DOI 10.1093/nar/16.13.6257; NAROD SA, 1991, LANCET, V338, P82; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NISHISHO I, 1987, JPN J HUM GENET, V32, P1, DOI 10.1007/BF01876521; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OCONNELL P, 1988, GENOMICS, V3, P367, DOI 10.1016/0888-7543(88)90129-2; OKAMOTO A, 1991, CANCER RES, V51, P5171; PELTOMAKI P, 1991, CANCER RES, V51, P4135; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SILVERMAN GA, 1991, GENOMICS, V9, P219, DOI 10.1016/0888-7543(91)90245-A; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; VIEL A, 1991, TUMORI, V77, P16, DOI 10.1177/030089169107700104; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; YOUNG J, 1990, NUCLEIC ACIDS RES, V18, P7196, DOI 10.1093/nar/18.23.7196; ZHENG JP, 1991, CANCER RES, V51, P4045	47	82	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1059	1065						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594239				2022-12-28	WOS:A1992HU64200002
J	GRASSER, FA; LAMONTAGNE, K; WHITTAKER, L; STOHR, S; LIPSICK, JS				GRASSER, FA; LAMONTAGNE, K; WHITTAKER, L; STOHR, S; LIPSICK, JS			A HIGHLY CONSERVED CYSTEINE IN THE V-MYB DNA-BINDING DOMAIN IS ESSENTIAL FOR TRANSFORMATION AND TRANSCRIPTIONAL TRANSACTIVATION	ONCOGENE			English	Note							AVIAN-MYELOBLASTOSIS VIRUS; GENE-EXPRESSION; C-MYB; FUNCTIONAL DOMAINS; ONCOGENE PRODUCT; PROTEINS; FOS; JUN	The v-Myb protein is nuclear, binds to DNA in a sequence-specific fashion, regulates the transcription of various reporter genes and transforms myelomonocytic cells. Cysteine is one of the most conserved residues during protein evolution and has been implicated in DNA binding, protein-protein interaction and redox regulation of various proteins. Therefore, we have now individually substituted each of the seven cysteines of v-Myb with a serine. All seven mutant proteins bound to DNA when they were expressed in E. coli. However, mutant C65S neither trans-activated transcription in vivo nor transformed myeloid cells, although it was transported into the nucleus. This cysteine is conserved in the Myb-related proteins of animals, plants, yeast and the cellular slime mold Dictyostelium discoideum. The C65S mutation and a nearby codon insertion mutation also abolished trans-activation by fusion proteins containing the v-Myb DNA-binding domain and the strong constitutive activation domain of herpes simplex virus (HSV) VP16. Because this domain of VP16 appears to activate transcription whenever it is bound upstream of an appropriate promoter, these results imply that C65 may be required for high-affinity DNA binding in vivo. In support of this hypothesis, we have also shown that, in contrast to wild-type v-Myb, mutant C65S is unable to block transcription from a reporter gene in which Myb binding sites overlap the initiation site.	SUNY STONY BROOK, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA; UNIV SAARLANDES KLINIKEN, INST MED MIKROBIOL & HYG, VIROL ABT, W-6650 HOMBURG, GERMANY	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universitatsklinikum des Saarlandes					NATIONAL CANCER INSTITUTE [P01CA028146, R01CA043592, K04CA001457] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-43592, P01-CA-28146, KO4-CA-01457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; Fersht A., 1985, ENZYME STRUCTURE MEC; GARCIA A, 1991, ONCOGENE, V6, P265; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LOEBER G, 1991, IN PRESS J VIROL; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOSCOVICI C, 1985, RETROVIRUSES HUMAN P, P177; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; STOBERGRASSER U, 1992, IN PRESS ONCOGENE; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	38	61	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					1005	1009						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570148				2022-12-28	WOS:A1992HP64200022
J	WEI, C; LUTZ, R; SINENSKY, M; MACARA, IG				WEI, C; LUTZ, R; SINENSKY, M; MACARA, IG			P23RAB2, A RAS-LIKE GTPASE WITH A -GGGCC C-TERMINUS, IS ISOPRENYLATED BUT NOT DETECTABLY CARBOXYMETHYLATED IN NIH3T3 CELLS	ONCOGENE			English	Article							BINDING YPT1 PROTEIN; ESCHERICHIA-COLI; CARBOXYL-METHYLATION; PLASMA-MEMBRANE; PALMITIC ACID; P21RAS; YEAST; SECRETION; CYSTEINE; EXPRESSION	With the development of a specific anti-rab2 antiserum, p23rab2, a ras-like GTPase with a -GGGCC C-terminus, has been localized mainly to the particulate (P100) fraction in NIH3T3 cells, although a small amount of this protein also appears in the soluble fraction. The endogenous p23rab2 is isoprenylated in intact cells, and recombinant murine p23rab2 is also isoprenylated in an in vitro system using reticulocyte lysate. Both the cytosolic and membrane-bound forms of p23rab2 are isoprenylated in intact cells. Recombinant p23rab2 is specifically geranyl-geranylated at one or both of the C-terminal cysteine residues in the in vitro system. Blocking isoprenoid synthesis with lovastatin results in an accumulation of a totally cytosolic unisoprenylated form, indicating that isoprenylation is a prerequisite for membrane association of p23rab2. Surprisingly, unlike p21ras and p25rab3A, no carboxymethylation of p23rab2 is detectable in either the soluble or particulate fractions.	UNIV VERMONT, DEPT PATHOL, BURLINGTON, VT 05405 USA; ELEANOR ROOSEVELT INST CANC RES, DENVER, CO 80206 USA	University of Vermont	WEI, C (corresponding author), UNIV ROCHESTER, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NATIONAL CANCER INSTITUTE [R01CA056300, R01CA043551] Funding Source: NIH RePORTER; NCI NIH HHS [CA43551, CA56300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Gooderham K, 1984, Methods Mol Biol, V1, P193, DOI 10.1385/0-89603-062-8:193; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WINGROVE TG, 1988, J BIOL CHEM, V263, P8918; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	29	34	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					467	473						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549360				2022-12-28	WOS:A1992HK00500010
J	BENNETT, WP; HOLLSTEIN, MC; HE, A; ZHU, SM; RESAU, JH; TRUMP, BF; METCALF, RA; WELSH, JA; MIDGLEY, C; LANE, DP; HARRIS, CC				BENNETT, WP; HOLLSTEIN, MC; HE, A; ZHU, SM; RESAU, JH; TRUMP, BF; METCALF, RA; WELSH, JA; MIDGLEY, C; LANE, DP; HARRIS, CC			ARCHIVAL ANALYSIS OF P53 GENETIC AND PROTEIN ALTERATIONS IN CHINESE ESOPHAGEAL CANCER	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; TRANSFORMED-CELLS; BREAST-CANCER; SV40-TRANSFORMED CELLS; MATE DRINKING; LUNG-CANCER; WILD-TYPE; KI-RAS; MUTATIONS; EXPRESSION	A strategy and methods for archival analysis of genetic and protein alterations in the p53 tumor-suppressor gene are presented. The tumor series includes 43 paraffin-embedded esophageal carcinomas from two high-incidence regions in the People's Republic of China. More than half contained elevated p53 protein levels which were detected by a high-titer polyclonal antiserum and a sensitive immunohistochemical method. To estimate the frequency of underlying mutations, DNA was isolated from conventional paraffin sections, amplified by the polymerase chain reaction, and examined by dideoxy termination sequencing. Analysis of exons 5-8 in a subset of 10 tumors revealed mis-sense point mutations in 4 out of 5 immunostain-positive tumors and a mutation encoding a stop codon in 1 of 5 immunostain-negative tumors. In this report of archival material, we conclude that detectable levels of p53 protein correlate closely with the occurrence of mis-sense mutations. Furthermore, these methods render large repositories of paraffin-embedded tumor and non-tumor tissues accesible to analysis. Immunohistochemical screening for elevated protein levels followed by sequence analysis represents an efficient strategy for the evaluation of the p53 mutational spectrum.	NCI, HUMAN CARCINOGENESIS LAB, BLDG 37, ROOM 2C05, BETHESDA, MD 20892 USA; CHINA MED UNIV, CANC RES INST, SHENYANG, PEOPLES R CHINA; SUN YAT-SAN UNIV MED SCI, GUANGZHOU, PEOPLES R CHINA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; UNIV DUNDEE, INST MED SCI, CANC RES CAMPAIGN LAB, DUNDEE DD1 4HN, SCOTLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); China Medical University; Sun Yat Sen University; University System of Maryland; University of Maryland Baltimore; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARRA S, 1990, INT J CANCER, V46, P1017, DOI 10.1002/ijc.2910460612; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BONHAM K, 1989, MOL CARCINOGEN, V2, P34, DOI 10.1002/mc.2940020106; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHANGCLAUDE JC, 1990, CANCER RES, V50, P2268; CHIBA I, 1990, ONCOGENE, V5, P1603; DESTEFANI E, 1990, CANCER RES, V50, P426; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVI F, 1990, INT J CANCER, V45, P852, DOI 10.1002/ijc.2910450511; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEB LA, 1989, CANCER RES, V49, P5489; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCMAHON G, 1990, P NATL ACAD SCI USA, V87, P1104, DOI 10.1073/pnas.87.3.1104; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VICTORA CG, 1990, CANCER RES, V50, P7112; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; [No title captured]	54	210	211	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1779	1784						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923503				2022-12-28	WOS:A1991GX11800009
J	GUSTERSON, BA; ANBAZHAGAN, R; WARREN, W; MIDGELY, C; LANE, DP; OHARE, M; STAMPS, A; CARTER, R; JAYATILAKE, H				GUSTERSON, BA; ANBAZHAGAN, R; WARREN, W; MIDGELY, C; LANE, DP; OHARE, M; STAMPS, A; CARTER, R; JAYATILAKE, H			EXPRESSION OF P53 IN PREMALIGNANT AND MALIGNANT SQUAMOUS EPITHELIUM	ONCOGENE			English	Article							CARCINOMA CELL-LINES; MONOCLONAL-ANTIBODIES; LUNG-CANCER; PROTO-ONCOGENE; BREAST-CANCER; TUMOR-ANTIGEN; GENE; MUTATIONS; TRANSFORMATION; CHROMOSOME-17	Using three antibodies (JG8, CM-1 and 1081) directed to the p53 protein, strong positivity was found in 16/47 (34.0%) of mucosal squamous cell carcinomas of the head and neck and in two squamous carcinoma cell lines (LICR-LON- HN5 and HN6Rr). The presence of the mutant p53 was confirmed in the cell lines as substitutions in exon 7 (codon 238, TGT > AGT) and exon 5 (codon 152, CCG > CTG) respectively. Positive staining was seen only in the undifferentiated cells and progressively lost as the cells keratinized, both in the tumour specimens and in the cell lines. Similar results were seen in areas of dysplasia, well removed from the site of the primary tumour. Staining of epidermal lesions showed positivity in 2/12 (16.6%) cases of Bowen's disease, 0/12 (0.0%) cases of solar keratosis, 0/10 (0.0%) basal cell carcinomas and in 3/20 (15.0%) squamous cell carcinomas. These results are discussed in relation to the multifocal origin of squamous cell carcinomas, the role of p53 mutations in squamous cell carcinomas from different sites and the significance of the 'basal' distribution of p53 as a normal growth regulator. The possible significance of the distribution of p53 in squamous epithelium as it relates to papilloma virus infection is also considered.	INST CANC RES,HADDOW LABS,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND	University of London; Institute of Cancer Research - UK; University of Dundee	GUSTERSON, BA (corresponding author), INST CANC RES,HADDOW LABS,PATHOL SECT,COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		gusterson, barry a/D-3752-2009; Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BARTEK J, 1990, ONCOGENE, V5, P893; BERG L, 1986, CELL, V46, P753, DOI 10.1016/0092-8674(86)90351-X; BURMAN JF, 1988, HEAD NECK ONCOLOGY R, P11; CARTER RL, 1985, CRC CR REV CL LAB SC, V22, P275, DOI 10.3109/10408368509165845; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOW LT, 1987, CANCER CELLS, V5, P57; Cowley GO, 1984, CANCER CELL, V1, P5; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EASTY DM, 1981, BRIT J CANCER, V43, P772, DOI 10.1038/bjc.1981.115; EASTY DM, 1981, BRIT J CANCER, V43, P363; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREAVES R, 1988, THESIS U LONDON; GUSTERSON BA, 1986, DIFFERENTIATION, V30, P102; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KNIGHT J, 1985, ULTRASTRUCT PATHOL, V7, P133; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MACKAY J, 1988, LANCET, V2, P1384; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MCKEE PH, 1990, PATHOLOGY SKIN; MITCHELL D, 1985, J HISTOCHEM CYTOCHEM, V33, P491, DOI 10.1177/33.5.3921605; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PFISTER H, 1984, REV PHYSIOL BIOCH P, V99, P111, DOI 10.1007/BFb0027716; RAYTER Z, 1989, EXP CELL RES, V183, P443, DOI 10.1016/0014-4827(89)90403-5; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STYLES JM, 1990, INT J CANCER, V45, P320, DOI 10.1002/ijc.2910450219; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	49	269	272	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1785	1789						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1717923				2022-12-28	WOS:A1991GX11800010
J	SHAY, JW; BABA, TO; ZHAN, QM; KAMIMURA, N; CUTHBERT, JA				SHAY, JW; BABA, TO; ZHAN, QM; KAMIMURA, N; CUTHBERT, JA			HELATG CELLS HAVE MITOCHONDRIAL-DNA INSERTED INTO THE C-MYC ONCOGENE	ONCOGENE			English	Article							HEPATOMA-CELLS; SEQUENCES; EXPRESSION; MUTATIONS; GENES; CARCINOMA; NUCLEUS; RNAS	To determine whether mitochondrial DNA (mtDNA) fragments found within the nucleus are transcribed, we have differentially screened a HeLaTG cDNA library. A clone that hybridized to mtDNA as well as to c-myc was identified. Analysis of the cDNA disclosed that it contained a mtDNA sequence, encoding cytochrome-c oxidase subunit III (coxIII) that was contiguous with and 5' of a c-myc sequence corresponding to part of exon 2 and exon 3. Hybridization of ScaI-digested DNA with a 1.05 kb c-myc probe revealed a unique band in HeLaTG cells, as well as a band common to HeLaTG and 13 other cell types examined. Solution hybridization of HeLaTG RNA with a radiolabeled, single-stranded cDNA probe containing the coxIII-c-myc junction demonstrated a nuclease-resistant band that matched the full length of the junctional cDNA probe. A smaller band that equaled the size of the c-myc portion alone was also detected. Only the smaller band coinciding with the c-myc sequences was protected from nuclease digestion by RNA from other cells. When a radiolabeled probe synthesized in the opposite orientation was used, nuclease-resistant bands equal in length to the coxIII portion of the probe were detected after hybridization with RNA from all cells. These results indicate that insertion of mtDNA fragments into nuclear genes occurs and that subsequent transcription of a 'chimaeric' or 'fusion' mRNA containing both mitochondrial and nuclear sequences can ensue.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SHAY, JW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.		Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA40065, CA50195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195, R01CA040065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1987, BIOESSAYS, V5, P34; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORRAL M, 1989, BIOCHEM BIOPH RES CO, V162, P258, DOI 10.1016/0006-291X(89)91990-6; CORRAL M, 1989, NUCLEIC ACIDS RES, V17, P5191, DOI 10.1093/nar/17.13.5191; CUTHBERT JA, 1989, J BIOL CHEM, V264, P1298; ERISMAN MD, 1988, ONCOGENE HDB, P341; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GELLISSEN G, 1987, ANN NY ACAD SCI, V503, P391, DOI 10.1111/j.1749-6632.1987.tb40625.x; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYASHI JI, 1986, CANCER RES, V46, P4001; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERRDT BG, 1990, CANCER RES, V50, P1596; KAMIMURA N, 1989, J MOL BIOL, V210, P703, DOI 10.1016/0022-2836(89)90103-4; KOCH I, 1989, VIROLOGY, V170, P591, DOI 10.1016/0042-6822(89)90454-6; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; SHAY JW, 1990, MECHANISMS DIFFERENT, V1, P135; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THORSNESS PE, 1990, NATURE, V346, P376, DOI 10.1038/346376a0; TOURMENTE S, 1990, CELL DIFFER DEV, V31, P137, DOI 10.1016/0922-3371(90)90017-Q; Tzagoloff A, 1982, MITOCHONDRIA	30	37	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1869	1874						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923509				2022-12-28	WOS:A1991GX11800020
J	ZHAO, YH; BAKER, H; WALAAS, SI; SUDOL, M				ZHAO, YH; BAKER, H; WALAAS, SI; SUDOL, M			LOCALIZATION OF P62C-YES PROTEIN IN MAMMALIAN NEURAL TISSUES	ONCOGENE			English	Article							AVIAN-SARCOMA VIRUS; CEREBELLAR MUTANT MOUSE; SRC GENE-PRODUCT; VIRAL YES GENE; C-SRC; RETINAL DEGENERATION; TRANSFORMING GENE; MESSENGER-RNA; CELLULAR-YES; RAT-BRAIN	Expression of the c-yes proto-oncogene in mammalian brain, retina and adrenal gland was studied by immunohistochemistry and immune assays with affinity-purified anti-yes IgG. Immunohistochemical staining with anti-yes IgG showed that in the central nervous system p62c-yes is highly expressed in mitral cells of the olfactory bulb, Purkinje cells of the cerebellum, hippocampal neurons and granule neurons of the dentate gyrus and ependymal cells lining central nervous system ventricles. Less intense labeling by anti-yes IgG was observed in most neuronal cell bodies in the brain. In addition, we observed intense c-yes immunoreactivity in the ganglion cells of the retina, the inner segment layer of rods and cones and medullary cells of the adrenal gland. Mapping p62c-yes expression to specific areas of mammalian neural tissues points to attractive experimental systems which could be used to investigate the function of the proto-oncogene product in neural processes.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021; UNIV OSLO,NEUROCHEM LAB,N-0317 OSLO 3,NORWAY; CORNELL UNIV,COLL MED,BURKE MED INST,MOLEC NEUROBIOL LAB,WHITE PLAINS,NY 10605	Rockefeller University; University of Oslo; Cornell University					NCI NIH HHS [CA 45757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1987, FUNCTIONAL HISTOLOGY; BAKER H, 1986, J COMP NEUROL, V252, P206, DOI 10.1002/cne.902520206; BLANKS JC, 1982, J COMP NEUROL, V212, P231, DOI 10.1002/cne.902120303; BLOOM W, 1975, TEXT BOOK HISTOLOGY; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GREEN MC, 1981, GENETIC VARIANTS STR, P276; Ham A.W., 1979, HISTOLOGY, P866; HANLEY MR, 1988, NEURON, V1, P175, DOI 10.1016/0896-6273(88)90137-7; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAVAIL MM, 1982, J COMP NEUROL, V212, P217, DOI 10.1002/cne.902120302; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mitro A., 1981, MORPHOLOGY RAT BRAIN; MULLEN RJ, 1977, NATURE, V270, P245, DOI 10.1038/270245a0; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; Steward O, 1989, PRINCIPLES CELLULAR; SUDOL M, 1989, J NEUROSCI RES, V24, P1, DOI 10.1002/jnr.490240103; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUKEGAWA J, 1990, ONCOGENE, V5, P611; YOSHIDA MC, 1985, JPN J CANCER RES, V76, P556; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XF, 1989, ONCOGENE, V4, P99	46	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1725	1733						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923498				2022-12-28	WOS:A1991GX11800002
J	GILL, S; STRATTON, MR; PATTERSON, H; SPURR, NK; FISHER, C; GUSTERSON, BA; COOPER, CS				GILL, S; STRATTON, MR; PATTERSON, H; SPURR, NK; FISHER, C; GUSTERSON, BA; COOPER, CS			DETECTION OF TRANSFORMING GENES BY TRANSFECTION OF DNA FROM PRIMARY SOFT-TISSUE TUMORS	ONCOGENE			English	Note							SARCOMA CELL-LINES; STRUCTURAL ALTERATIONS; HUMAN-TUMORS; ONCOGENE; IDENTIFICATION; SEQUENCES; RAS	A series of adult soft-tissue tumours were screened for the presence of activated oncogenes by transfecting tumour DNA into NIH3T3 mouse fibroblasts. In these studies an activated K-ras gene that contained a mutation at the second position of codon 12 (GGT --> GAT) was found in a leiomyosarcoma. In addition, following transfection of DNA from a liposarcoma, we identified an activated gene that failed to hybridize to probes prepared from 10 known human oncogenes (K-ras, H-ras, N-ras, ret, met, trk, mas, dbl, raf and hst) that have previously been detected in DNA transfection experiments. BamHI-BamHI fragments of this activated gene of 3.5 and 8.5 kb were cloned from NIH3T3 secondary transfectants using a probe that detects the human alu family of highly repetitive DNA sequences. Repeat-free subclones of these BamHI fragments were used to map this gene to human chromosome 19 (p13.2-q13.3). Our studies also demonstrate that a subclone from one of the BamHI fragments detects a 3.0 kb transcript in primary and secondary transfectants.	IMPERIAL CANC RES FUND,POTTERS BAR EN6 3LD,HERTS,ENGLAND; ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,LONDON SW3 6JJ,ENGLAND; INST CANC RES,CELL BIOL & EXPTL PATHOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	GILL, S (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		gusterson, barry a/D-3752-2009					BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER CS, 1991, CARCINOGENESIS, V12, P155, DOI 10.1093/carcin/12.2.155; COOPER CS, 1989, CHEM CARCINOGENESIS, V2, P319; Enzinger RM., 2011, SOFT TISSUE TUMORS, P1178; EVA A, 1987, ONCOGENE, V1, P355; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HALL A, 1989, CHEM CARCINOGENESIS, V2, P271; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MARTINZANCA D, 1986, NATURE, V328, P527; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; STRATTON MR, 1989, CANCER RES, V49, P6324; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	23	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1651	1656						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923531				2022-12-28	WOS:A1991GX27400021
J	HALEVY, O; RODEL, J; PELED, A; OREN, M				HALEVY, O; RODEL, J; PELED, A; OREN, M			FREQUENT P53 MUTATIONS IN CHEMICALLY-INDUCED MURINE FIBROSARCOMA	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; WILD-TYPE P53; TRANSFORMED-CELLS; MUTANT P53; GENE-EXPRESSION; SARCOMA-CELLS; FRIEND-VIRUS; LUNG-CANCER; COS CELLS; ONCOGENE	Patterns of p53 expression were investigated in chemically induced fibrosarcoma tumors and cell lines. Most, if not all, cell lines were found to carry alterations at the protein level, reflected in the overproduction of greatly stabilized p53 proteins. In many cases, this was accompanied by formation of complexes with hsc70. Hence, all of these lines may be expressing one sort or another of mutant p53. The mutant nature of the p53 gene was directly verified, in a number of cases, by PCR-amplified cDNA cloning. In one line, no p53 protein was made at all; this turned out to be because of a mutation in a splice donor site, resulting in the production of an aberrant mRNA. In all other cases, mRNAs carrying mis-sense mutations were present, and were sometimes expressed along with wt p53 mRNA. When tested in an in vitro transformation assay, all cloned mutants possessed a discrete oncogenic activity, while having lost the ability to interfere with oncogene-mediated transformation. The system described here could potentially be very helpful in elucidating the significance of p53 mutations.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,POB 26,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,FAC AGR,DEPT ANIM SCI,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem					NCI NIH HHS [R01 CA 40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BENDAVID Y, 1987, J VIROL, V61, P2771; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOW V, 1985, NATURE, V314, P633; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELIYAHU D, 1990, ONCOGENES CANCER RES, P125; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOTI A, 1990, BRIT J HAEMATOL, V76, P143, DOI 10.1111/j.1365-2141.1990.tb07849.x; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; IGGO R, 1990, LANCET, V335, P651; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MALTZMAN W, 1981, VIROLOGY, V112, P145, DOI 10.1016/0042-6822(81)90620-6; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PHILLIPS DH, 1979, CHEM CARCINOGENS DNA, V2; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	57	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1593	1600						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923526				2022-12-28	WOS:A1991GX27400014
J	ISHIZAKA, Y; KOBAYASHI, S; USHIJIMA, T; HIROHASHI, S; SUGIMURA, T; NAGAO, M				ISHIZAKA, Y; KOBAYASHI, S; USHIJIMA, T; HIROHASHI, S; SUGIMURA, T; NAGAO, M			DETECTION OF RETTPC PTC TRANSCRIPTS IN THYROID ADENOMAS AND ADENOMATOUS GOITER BY AN RT PCR METHOD	ONCOGENE			English	Article							CARCINOMA CELL-LINE; PROTO-ONCOGENE; PAPILLARY CARCINOMAS; TYROSINE KINASE; HIGH-FREQUENCY; II ONCOGENE; ACTIVATION; CLONING; REARRANGEMENT; EXPRESSION	A reverse transcriptase-polymerase chain reaction (RT-PCR) method was adopted for detecting transcripts specific for ret(TPC)/PTC, an activated form of the ret proto-oncogene reported to be found specifically in human papillary thyroid carcinomas. By this sensitive method ret(TPC)/PTC transcript could be detected in about 500 fg of total RNA of TPC-1, a ret(TPC)/PTC transcript-positive cell line. In Japanese patients, one of 11 papillary thyroid carcinomas, four of 19 follicular adenomas and one of two adenomatous goiters were positive for the transcript, indicating that the involvement of ret(TPC)/PTC is not specific to papillary thyroid carcinomas. In several independent RT-PCR experiments using different portions of the same positive carcinoma tissue, ret(TPC)/PTC transcript was always detected. On the other hand, the transcript was not always positive in different RNA samples from benign cases, suggesting that positive carcinomas are probably composed of clonal cell populations all expressing ret(TPC)/PTC, whereas adenomas and adenomatous goiter comprise heterogeneous populations: both positive and negative for ret(TPC)/PTC transcript. Activation of the ret proto-oncogene might therefore be involved in malignant conversion to thyroid carcinomas.	NAGOYA CITY UNIV,SCH MED,DEPT SURG,NAGOYA,AICHI 467,JAPAN; NATL CANC CTR,RES INST,DIV PATHOL,TOKYO 104,JAPAN	Nagoya City University; National Cancer Center - Japan	ISHIZAKA, Y (corresponding author), NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5,CHUO KU,TOKYO 104,JAPAN.		Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817				BONGARZONE I, 1989, ONCOGENE, V4, P1457; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hedinger CE., 1988, HISTOLOGICAL TYPING; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LEMOINE NR, 1989, ONCOGENE, V4, P159; OSADA H, 1989, JPN J CANCER RES, V80, P711, DOI 10.1111/j.1349-7006.1989.tb01702.x; Sambrook J, 1989, MOL CLONING LABORATO; SAMPSON RJ, 1969, J AMER MED ASSOC, V209, P65; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; YAGAWA K, 1966, 25 P JAP CANC ASS AN, P106; YAGAWA K, 1962, 25TH P JAP CANC ASS, P106; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; 1988, HISTOLOGICAL TYPING	27	123	125	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1667	1672						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1717926				2022-12-28	WOS:A1991GX27400023
J	AVIVI, A; ZIMMER, Y; YAYON, A; YARDEN, Y; GIVOL, D				AVIVI, A; ZIMMER, Y; YAYON, A; YARDEN, Y; GIVOL, D			FLG-2, A NEW MEMBER OF THE FAMILY OF FIBROBLAST GROWTH-FACTOR RECEPTORS	ONCOGENE			English	Note							CLONING; GENE	Two genes, flg and bek, have been recently shown to encode receptors for fibroblast growth factors (FGF). Here we report the molecular cloning and sequence of a new member of the FGF receptor family, denoted flg-2, which was isolated from a human keratinocyte cDNA library. The cDNA sequence predicts an extracellular region possessing three immunoglobulin-like domains, a single transmembrane region and a cytoplasmic portion containing the tyrosine kinase domain split by a short inter-kinase segment. The amino acid sequence of flg-2 shows 68% and 64% identity with bek and flg, respectively. The most variable domain among the three genes is the amino-terminal immunoglobulin-like domain. Comparison with the chicken FGF receptor genes suggests that flg-2 is homologous to cek-2, whereas flg and bek are homologous to cek-1 and cek-3, respectively. Analysis of mRNA from various tissues shows that flg-2 is expressed predominantly in skin, brain and lung.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	GIVOL, D (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		YARDEN, YOSEF/K-1467-2012					BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; RAZ V, 1991, IN PRESS ONCOGENE; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	19	61	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1089	1092						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648703				2022-12-28	WOS:A1991GU62200029
J	COLLETTA, G; CIRAFICI, AM; DICARLO, A; CIARDIELLO, F; SALOMON, DS; VECCHIO, G				COLLETTA, G; CIRAFICI, AM; DICARLO, A; CIARDIELLO, F; SALOMON, DS; VECCHIO, G			CONSTITUTIVE EXPRESSION OF TRANSFORMING GROWTH FACTOR-ALPHA DOES NOT TRANSFORM RAT-THYROID EPITHELIAL-CELLS	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; ACCOMPANIES VIRAL TRANSFORMATION; TGF-ALPHA; INDUCTION; PHENOTYPE; BETA; RESPONSIVENESS; PROTOONCOGENE; KERATINOCYTES; FIBROBLASTS	To evaluate the role of transforming growth factor-alpha (TGF-alpha) in transformed rat thyroid epithelial cells, expression and production of TGF-alpha were measured in a normal rat thyroid epithelial cell line, FRTL-5, and in the same cells transformed by the Ki-ras oncogene. FRTL-5 cells transformed with Ki-ras exhibit a 5- to 7-fold increase in the levels of TGF-alpha-specific mRNA and a 3- to 4-fold enhancement of the amounts of TGF-alpha protein in the conditioned medium, as compared with the normal thyroid cells. Although conditioned medium from the Ki-ras transformed FRTL-5 cells or authentic epidermal growth factor or TGF-alpha are able to stimulate the anchorage-dependent growth of nontransformed FRTL-5 cells, neither conditioned medium nor the growth factors are able to induce the anchorage-independent growth of these cells in soft agar. FRTL-5 cells were then transfected with an expression vector plasmid containing the human TGF-alpha cDNA to directly ascertain if overexpression of this growth factor is able to induce transformation in these cells. The TGF-alpha-transfected FRTL-5 clones constitutively produced high amounts of TGF-alpha at a level equivalent to or greater than the level found in the conditioned medium from the Ki-ras transformed FRTL-5 clones. Moreover, in contrast to the Ki-ras transformed cells, the TGF-alpha transfectants were unable to grow in soft agar, did not form tumors in nude mice, and showed no reduction in the secretion of thyroglobulin. These data demonstrate that unlike Ki-ras, the constitutive expression of biologically active TGF-alpha is not entirely sufficient to elicit a transformed phenotype in these cells.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	COLLETTA, G (corresponding author), FAC MED & CHIRURG NAPLES,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80121 NAPLES,ITALY.			Ciardiello, Fortunato/0000-0002-3369-4841				AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COLLETTA G, 1988, FEBS LETT, V228, P37, DOI 10.1016/0014-5793(88)80579-9; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1986, J CELL BIOCHEM, V32, P293, DOI 10.1002/jcb.240320406; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIMARCO E, 1989, ONCOGENE, V4, P831; FREIBERGER R, 1989, FRTL5 TODAY, P177; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V2, P337; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; IBERG N, 1989, J BIOL CHEM, V264, P19951; JAKOWLEW SB, 1988, ONCOGENE RES, V2, P135; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; MCGEADY ML, 1989, ONCOGENE, V4, P1375; RIZZINO A, 1986, CANCER RES, V46, P2816; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TRAMONTANO D, 1989, FRTL5 TODAY, P177; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386	29	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					583	587						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1709483				2022-12-28	WOS:A1991FR93900012
J	CARTER, R; COSENZA, SC; PENA, A; LIPSON, K; SOPRANO, DR; SOPRANO, KJ				CARTER, R; COSENZA, SC; PENA, A; LIPSON, K; SOPRANO, DR; SOPRANO, KJ			A POTENTIAL ROLE FOR C-JUN IN CELL-CYCLE PROGRESSION THROUGH LATE G1 AND S	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; HUMAN-DIPLOID FIBROBLASTS; TUMOR NECROSIS FACTOR; PROTO-ONCOGENE; GROWTH-FACTOR; G0/G1 TRANSITION; FOS; BINDING; GENE; EXPRESSION	When the level of c-jun mRNA was analyzed in WI-38 human fibroblasts exciting short- and long-term quiescence, two peaks of c-jun mRNA accumulation were found. The first occurred one hour after stimulation and lasted three to five hours, whereas the second occurred at the G1/S border and was coupled to the time of entry to S phase rather than to the time of stimulation. The early peak is well documented and in agreement with the proposed role of c-Jun/AP-1 in mediating cellular responses to receptor-generated signals. The later peak, however, has not been previously reported. Additional follow-up studies showed that late G1/S expression was not solely a phenomenon of cells exiting a quiescent state, nor was it restricted only to human cells. Gel retardation studies confirmed that there is AP-1 specific DNA binding activity in nuclear extracts isolated in late G1 and S phase, and that this AP-1 binding activity is due to the presence of Jun protein. An anti-Fos antibody was able to significantly decrease AB-1 binding activity in early G1 extracts, but had no effect on extracts isolated in late G1 and S phase, indicating that the complexes observed in late G1 and S phase are clearly different from those seen in early G1. These studies are among the first to suggest a functional dissociation of c-Jun from c-Fos. Our results identify a new, previously unreported role for c-Jun/AP-1 in regulation of cell cycle progression and mammalian cell growth.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,3400 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Borghaei, Ruth/0000-0003-4206-0231; Lipson, Kenneth/0000-0001-8847-6051				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUGENLICHT LH, 1974, EXP CELL RES, V89, P255, DOI 10.1016/0014-4827(74)90789-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; CRESS AE, 1977, EXP CELL RES, V110, P347, DOI 10.1016/0014-4827(77)90301-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FLOROS J, 1978, CELL BIOL INT REP, V2, P259, DOI 10.1016/0309-1651(78)90006-1; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OWEN TA, 1987, J BIOL CHEM, V262, P15111; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAO PN, 1984, J CELL PHYSIOL, V119, P77, DOI 10.1002/jcp.1041190113; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAUVE G, IN PRESS; SCHUTTE J, 1989, CELL, V59, P989; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; SOPRANO KJ, 1987, MOL CELL BIOCHEM, V75, P61, DOI 10.1007/BF00231609; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; THOMAS P, 1980, P NATL ACAD SCI USA, V77, P54201; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; TOLMACH LJ, 1988, CELL TISSUE KINET, V23, P125; TOSCANI A, 1987, ANAL BIOCHEM, V165, P309, DOI 10.1016/0003-2697(87)90274-0; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TUSCHINSKI R, 1977, P NATL ACAD SCI USA, V74, P2357; WASYLYK C, 1990, ONCOGENE, V5, P1055; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	65	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					229	235						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900357				2022-12-28	WOS:A1991FZ13400008
J	DRIVAS, GT; SHIH, A; COUTAVAS, EE; DEUSTACHIO, P; RUSH, MG				DRIVAS, GT; SHIH, A; COUTAVAS, EE; DEUSTACHIO, P; RUSH, MG			IDENTIFICATION AND CHARACTERIZATION OF A HUMAN HOMOLOG OF THE SCHIZOSACCHAROMYCES-POMBE RAS-LIKE GENE YPT-3	ONCOGENE			English	Article							ADENYLATE-CYCLASE; CODING SEQUENCES; CELL-LINE; YEAST; PROTEINS; SECRETION; CDNAS; ACTIVATION; ONCOGENE; PRODUCTS	The Polymerase Chain Reaction was used to amplify ras and ras-like sequences from two human cDNA libraries. Members corresponding to each of the three major ras-subfamilies (ras, rho, and rab/YPT) were identified. The one homologous to rab/YPT, referred to here as YL8, appears to be the human homolog of the recently reported Schizosaccharomyces pombe YPT3 gene. The YL8 gene could encode a guanine nucleotide binding protein of 216 amino acids with about 70% amino acid sequence identity to S. pombe YPT3, and is transcriptionally active in a variety of human cell lines.	NYU,SCH MED,DEPT BIOCHEM,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University				Coutavas, Elias/0000-0003-4904-0081; D'Eustachio, Peter/0000-0002-5494-626X	NIGMS NIH HHS [GM07827] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P34; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; FUKUI Y, 1986, EMBO J, V5, P1991, DOI 10.1002/j.1460-2075.1986.tb04454.x; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MISRA R, 1989, NUCLEIC ACIDS RES, V17, P8327, DOI 10.1093/nar/17.20.8327; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; OLOFSSON B, 1988, ONCOGENE, V3, P231; PIZON V, 1988, ONCOGENE, V3, P201; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIH A, 1989, J VIROL, V63, P64, DOI 10.1128/JVI.63.1.64-75.1989; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SOMMER R, 1989, NUCLEIC ACIDS RES, V17, P6749, DOI 10.1093/nar/17.16.6749; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	37	30	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					3	9						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1704119				2022-12-28	WOS:A1991EY03900001
J	ISOMURA, M; KIKUCHI, A; OHGA, N; TAKAI, Y				ISOMURA, M; KIKUCHI, A; OHGA, N; TAKAI, Y			REGULATION OF BINDING OF RHOB P20 TO MEMBRANES BY ITS SPECIFIC REGULATORY PROTEIN, GDP DISSOCIATION INHIBITOR	ONCOGENE			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN; GUANINE-NUCLEOTIDE; GENE-PRODUCT; SUBCELLULAR-DISTRIBUTION; CLOSTRIDIUM-BOTULINUM; KINETIC-ANALYSIS; RAS; RIBOSYLATION; SEQUENCE	We have previously purified from bovine brain cytosol a novel regulatory protein for the GTP-binding proteins of the rho gene family. This regulatory protein, designated as rho GDP dissociation inhibitor (GDI), makes a complex stoichiometrically with the GDP-bound form of the rho gene products and thereby regulates the GDP/GTP exchange reaction by inhibiting the dissociation of GDP from and the subsequent binding of GTP to them. We show here that rho GDI also regulates the binding of rhoB p20, a member of the rho gene products, to various membranes including rat brain synaptic plasma membranes and human erythrocyte ghosts. Both the GDP- and GTP-bound forms of rhoB p20 bound to the membranes. This binding was not inhibited by prior treatment of the membranes with boiling or tryptic digestion, suggesting that a protein molecule of the membranes is not essential for the binding of rhoB p20 to the membranes. rho GDI inhibited the binding of the GDP-bound form of rhoB p20, but not that of the GTP-bound form, to the membranes. Moreover, rho GDI induced the dissociation of the GDP-bound form, but not that of the GTP-bound form, of rhoB p20 exogenously bound to the membranes from them. These results suggest that the rho gene products bind to the membranes, presumably in a reversible manner and that this binding is regulated by their specific GDI.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ADAMVIZI V, 1988, FEBS LETT, V238, P277, DOI 10.1016/0014-5793(88)80496-4; AKTORIES K, 1987, BIOCHEM J, V247, P363, DOI 10.1042/bj2470363; ARAKI S, 1990, J BIOL CHEM, V265, P13007; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNU, 1989, FEBS LETT, V243, P70; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FUKUMOTO Y, 1990, IN PRESS ONCOGENE; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KIM S, 1989, MOL BRAIN RES, V6, P167, DOI 10.1016/0169-328X(89)90051-X; KURODA S, 1989, BIOCHEM BIOPH RES CO, V163, P674, DOI 10.1016/0006-291X(89)92276-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUOKA I, 1989, J BIOL CHEM, V264, P706; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OHASHI Y, 1987, J BIOL CHEM, V262, P1430; OHGAN, 1989, BIOCHEM BIOPH RES CO, V163, P1523; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SHOJI I, 1989, BIOCHEM BIOPH RES CO, V162, P273, DOI 10.1016/0006-291X(89)91992-X; Steck T L, 1974, Methods Enzymol, V31, P172; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	38	107	108	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					119	124						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899476				2022-12-28	WOS:A1991EY03900016
J	FERRELL, JE; NOBLE, JA; MARTIN, GS; JACQUES, YV; BAINTON, DF				FERRELL, JE; NOBLE, JA; MARTIN, GS; JACQUES, YV; BAINTON, DF			INTRACELLULAR-LOCALIZATION OF PP60C-SRC IN HUMAN PLATELETS	ONCOGENE			English	Article									UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PATHOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	FERRELL, JE (corresponding author), UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,401 BARKER HALL,BERKELEY,CA 94720, USA.				NCI NIH HHS [CA-17542] Funding Source: Medline; NHLBI NIH HHS [HL-31610] Funding Source: Medline; NIGMS NIH HHS [GM11507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017542, R37CA017542] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031610, R01HL031610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINTON DF, 1987, J EXP MED, V166, P1641, DOI 10.1084/jem.166.6.1641; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; COCHET C, 1984, J BIOL CHEM, V259, P2553; CORASH L, 1984, BLOOD, V64, P185; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; HAINFELD JF, 1988, NATURE, V333, P281, DOI 10.1038/333281a0; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; RENDU F, 1989, BLOOD, V73, P1545; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; STENBERG PE, 1984, HISTOCHEM J, V16, P983, DOI 10.1007/BF01003853; STENBERG PE, 1984, J CELL BIOL, V98, P748, DOI 10.1083/jcb.98.2.748; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STENBERG PE, 1986, BIOCH PLATELETS, P257; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WHITE JG, 1984, BLOOD PLATELET FUNCT, P15	34	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1033	1036						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695725				2022-12-28	WOS:A1990DP41500011
J	MIN, SY; TAPAROWSKY, EJ				MIN, SY; TAPAROWSKY, EJ			V-MYC, BUT NOT MAX, POSSESSES DOMAINS THAT FUNCTION IN BOTH TRANSCRIPTION ACTIVATION AND CELLULAR-TRANSFORMATION	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; DNA-BINDING PROTEINS; HUMAN C-MYC; RETINOBLASTOMA GENE-PRODUCT; LEUCINE ZIPPER; ADENOVIRUS E1A; MULTISTEP TRANSFORMATION; NUCLEAR-LOCALIZATION; NEGATIVE REGULATOR; LARGE-T	Deregulated expression of myc gene family members is associated with the development of malignant neoplasms in several species. Despite the evidence linking expression of this family of nuclear proteins with the proper control of cellular growth and development, the function of the myc protein remains unknown. Intrigued by the observed structural similarity between the myc protein and several eukaryotic transcription factors, we have investigated the ability of the MC29 viral myc protein to activate transcription of a heterologous promoter in C3H10T1/2 cells. Overlapping portions of v-myc coding sequences were inserted 3' to the yeast GAL4 DNA-binding domain and tested for their ability to activate transcription of a chloramphenicol acetyl transferase reporter gene containing GAL4 binding sites. Two transcription activation domains were identified within the amino terminus of v-Myc. The importance of these regions for cellular transformation was examined using ras/myc co-transformation assays. Our results demonstrate that deletion of either of the transcription activation domains, or the DNA-binding and protein oligomerization domains, abolishes the ability of v-Myc to cooperate with Ras to transform C3H10T1/2 cells. Similarly, we investigated whether Max, the protein-binding partner of Myc, also possesses the potential to activate transcription. Interestingly, chimeric GAL4/Max proteins were not functional in our assays, suggesting that the potential of the Myc-Max complex to influence gene expression and function in cellular transformation relies primarily on sequences found within the amino terminus of Myc.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Min, Soyoung/0000-0001-7511-1520	NATIONAL CANCER INSTITUTE [R01CA042835, R23CA042835] Funding Source: NIH RePORTER; NCI NIH HHS [CA42835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVENPORT EA, 1990, MOL CARCINOGEN, V3, P83, DOI 10.1002/mc.2940030206; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DEAN M, 1986, J BIOL CHEM, V261, P9161; DENIS N, 1987, EXP CELL RES, V172, P212, DOI 10.1016/0014-4827(87)90107-8; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IGVARSSO S, 1990, SEM CANCER BIOL, V1, P359; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KITCHENER G, 1980, P NATL ACAD SCI-BIOL, V77, P1637, DOI 10.1073/pnas.77.3.1637; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	63	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1531	1540						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630816				2022-12-28	WOS:A1992JE81300009
J	TAYLOR, WR; EGAN, SE; MOWAT, M; GREENBERG, AH; WRIGHT, JA				TAYLOR, WR; EGAN, SE; MOWAT, M; GREENBERG, AH; WRIGHT, JA			EVIDENCE FOR SYNERGISTIC INTERACTIONS BETWEEN RAS, MYC AND A MUTANT FORM OF P53 IN CELLULAR-TRANSFORMATION AND TUMOR DISSEMINATION	ONCOGENE			English	Article							C-MYC; MURINE FIBROBLASTS; EMBRYO FIBROBLASTS; MULTISTAGE CARCINOGENESIS; METASTATIC PHENOTYPE; GENE-PRODUCT; ONCOGENES; CELLS; EXPRESSION; INHIBITION	Mouse 10T1/2 cells were transfected with combinations of F24 H-ras, human c-myc and the proline 193 mutant form of p53. The three-gene ras/myc/p53 combination was significantly more efficient than single genes or double gene combinations in inducing transformed foci in vitro. An analysis of cell lines isolated after transfections with ras, ras/myc, ras/p53 and ras/myc/p53 indicated that the last combination contained significantly higher levels of ras protein than the other combinations, produced tumors in syngeneic mice with a shorter latency period, and exhibted an increased ability to form lung tumors in an in vivo experimental metastasis assay. Synergistic interactions between ras, myc and mutant p53 genes were observed in focus formation and metastasis assays, suggesting that the action of the three oncogenes in malignant transformation occurs along separate but interactive pathways. These results support a working model of oncogene cooperativity in which alterations in myc and p53 permit elevated expression of ras, which is important in a mechanism affecting both cellular transformation in vitro and tumor dissemination in vivo.	UNIV MANITOBA,MANITOBA INST CELL BIOL,100 OLIVIA ST,WINNIPEG R3E 0V9,MANITOBA,CANADA	University of Manitoba								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BICHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENEVIXTRENCH G, 1990, ONCOGENE, V5, P1187; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DAMEN JE, 1989, J NATL CANCER I, V81, P628, DOI 10.1093/jnci/81.8.628; DENHARDT DT, 1987, ONCOGENE, V2, P55; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1989, INT J CANCER, V43, P443, DOI 10.1002/ijc.2910430317; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; EGAN SE, 1989, J CELL BIOCH B, V13, P62; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GINGRAS MC, 1990, CANCER RES, V50, P4061; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V80, P5602; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; KOHL NE, 1987, ONCOGENE, V2, P41; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RULEY HE, 1987, ADV VIRAL ONCOL, V6, P1; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Schwarz LC, 1990, GROWTH FACTORS, V3, P115, DOI 10.3109/08977199009108274; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUGARBAKER EV, 1981, CANCER BIOL REV, V2, P235; TANIGUCHI S, 1989, CANCER RES, V49, P6738; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WAITZ W, 1991, ONCOGENE, V6, P29; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	55	56	59	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1383	1390						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620551				2022-12-28	WOS:A1992HZ97100017
J	SHIROUZU, M; FUJITAYOSHIGAKI, J; ITO, Y; KOIDE, H; NISHIMURA, S; YOKOYAMA, S				SHIROUZU, M; FUJITAYOSHIGAKI, J; ITO, Y; KOIDE, H; NISHIMURA, S; YOKOYAMA, S			A GLUTAMIC-ACID RESIDUE AT POSITION-31 OF RAS PROTEIN IS ESSENTIAL TO THE SIGNAL TRANSDUCTION FOR NEURITE OUTGROWTH OF PC12 CELLS AND THE STIMULATION OF GTPASE ACTIVITY BY GAPRAS	ONCOGENE			English	Article							PUTATIVE EFFECTOR DOMAIN; ACTIVATING PROTEIN; GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; ONCOGENE PROTEIN; CATALYTIC DOMAIN; BINDING DOMAIN; RAS-P21 GTPASE; BOVINE BRAIN; P21 GTPASE	The roles of residues at positions 23-31 adjacent to the 'effector region' and residues at positions 61-65 in a phosphoryl binding loop of the human c-Ha-ras protein were studied by changing each residue of the normal (Gly-12 type) and oncogenic (Val-12 type) Ras proteins to the corresponding residue of the K-rev-1 protein. Firstly, the signal-transducing activities of the mutant Ras proteins of Val-12 type were examined by analysis of their ability to induce neurite outgrowth of phaeochromocytoma (PC12) cells upon expression of the mutant ras gene. Thus, replacement of Glu-31 by Lys was found to impair the signal-transducing activity of the oncogenic Ras protein. Furthermore, it was shown that expression of the Gly-12 --> Val/Glu-31 --> Lys mutant Ras protein in PC12 cells suppresses neurite outgrowth induced either by microinjection of the oncogenic Ras protein or by addition of nerve growth factor to the medium. As for the Glu-31 --> Lys mutant Ras protein (Gly-12 type), the GTPase activity in the presence of GTPase-activating protein for Ras (GAP(Ras)) is much lower than that of the normal Ras protein, whereas the intrinsic GTPase activity is nearly the same as that of the normal Ras protein. Therefore, Gly-31 is one of the determinants for the signal transduction and the correct interaction with GAP(Ras) on the other hand, the GTPase activity of the Gln-61 --> Thr mutant Ras protein (Gly-12 type) is negligibly low both in the absence and in the presence of GAP(Ras).	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	University of Tokyo; National Cancer Center - Japan			Ito, Yutaka/P-2604-2015; Koide, Hiroshi/E-9000-2011; Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016; Yoshigaki, Junko/AAE-6702-2020	Ito, Yutaka/0000-0002-1030-4660; Yokoyama, Shigeyuki/0000-0003-3133-7338; Koide, Hiroshi/0000-0001-5916-3179				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HA JM, 1989, BIOCHEMISTRY-US, V28, P8411, DOI 10.1021/bi00447a021; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1990, J BIOL CHEM, V265, P7104; HATATANAKA A, 1989, BIOCHEMISTRY-US, V28, P9550, DOI 10.1021/bi00450a045; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIURA K, 1986, JPN J CANCER RES, V77, P45; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PIZON V, 1988, ONCOGENE, V3, P201; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SCHLICHTING I, 1990, BIOCHEMISTRY-US, V29, P504, DOI 10.1021/bi00454a026; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; SZERBERENYI J, 1990, MOL CELL BIOL, V10, P5324; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	44	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					475	480						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549361				2022-12-28	WOS:A1992HK00500011
J	MITCHELL, PJ; COOPER, CS				MITCHELL, PJ; COOPER, CS			NUCLEOTIDE-SEQUENCE ANALYSIS OF HUMAN TPR CDNA CLONES	ONCOGENE			English	Note							PROTEIN TYROSINE KINASE; HEAVY-CHAIN GENE; MET ONCOGENE; CELL-LINE; TROPOMYOSIN; ACTIVATION; REARRANGEMENT; POLYPEPTIDE; MECHANISM; DOMAINS	In this study we have characterized cDNA clones corresponding to a gene, called tpr, that has been implicated in the activation of the met and raf proto-oncogenes. Sequencing of tpr clones isolated from an HT1080 human fibrosarcoma cell line cDNA library identified an open reading frame (ORF) of 726 amino acids. In addition we have established that alternative splicing can result in the deletion of a 30 bp sequence that spans the translation termination site of this ORF. This modification generates mRNAs encoding a tpr protein that has an extended C-terminal domain. The 726 amino acid tpr-protein is predicted to have extensive regions of alpha-helix and bas three stretches of a heptad repeat motif that is characteristic of proteins adopting a coiled-coil conformation. The tpr protein exhibits weak homology (28-39%) to the alpha-helical domains of several proteins including tropomyosin, spectrin, laminin B1, the Drosophila glued protein and the tail region of myosin heavy chain.			MITCHELL, PJ (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Mitchell, Philip J/F-6393-2013					BARLOW DP, 1984, EMBO J, V3, P2355, DOI 10.1002/j.1460-2075.1984.tb02140.x; CHAN AML, 1987, ONCOGENE, V1, P229; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARVIN AJ, 1986, AM J PATHOL, V125, P208; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P226; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KING HWS, 1988, ONCOGENE, V2, P617; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAFLAMME SE, 1988, GENE DEV, V2, P853, DOI 10.1101/gad.2.7.853; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACLEOD AR, 1986, NUCLEIC ACIDS RES, V14, P8413, DOI 10.1093/nar/14.21.8413; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; SAEZ L, 1986, NUCLEIC ACIDS RES, V14, P2951, DOI 10.1093/nar/14.7.2951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; YAMAWAKIKATAOKA Y, 1987, J BIOL CHEM, V262, P10791	30	25	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					383	388						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549355				2022-12-28	WOS:A1992HG98200025
J	PATEL, G; MACDONALD, MJ; KHOSRAVIFAR, R; HISAKA, MM; DER, CJ				PATEL, G; MACDONALD, MJ; KHOSRAVIFAR, R; HISAKA, MM; DER, CJ			ALTERNATE MECHANISMS OF RAS ACTIVATION ARE COMPLEMENTARY AND FAVOR AND FORMATION OF RAS-GTP	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; H-RAS; ENCODED PROTEINS; BINDING DOMAIN; P21; GAP; MUTANTS; SIGNAL; CELLS; IDENTIFICATION	The mechanisms of ras activation by mutations in residue 61 and in the NKXD guanine nucleotide-binding consensus sequence (ras residues 116-119) have been evaluated. Weakly transforming mutations that either reduce intrinsic and GTPase-activating protein (GAP)stimulated GTPase activities (61P) or enhance guanine nucleotide exchange rates (116H, 119E) were combined into the same H-ras proteins. The resulting double-mutant proteins exhibited significantly stronger transforming activities than are observed with each individual mutation, suggesting that the consequences of these two different mechanisms of activation favor maintenance of ras in the active form, which is GTP bound. In vivo nucleotide association analysis demonstrated a direct relationship between ras-GTP formation and transforming activity. Although both 61P and 61L mutations result in reduced intrinsic GTPase activity and loss of GAP stimulation in vitro, only H-ras(61L) exhibits strong transforming activity. While H-ras(61L) is found predominantly in the GTP-bound form, H-ras(61P) is predominantly complexed with GDP in vivo. Thus, in vitro GAP stimulation of GTPase activity does not directly correlate with transforming potential, suggesting that other ras-specific regulatory components may also be important in regulating the cycling of ras between GDP- and GTP-bound states.	LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute			Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA052072, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA52072, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; DER CJ, 1988, ONCOGENE, V3, P105; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PROUD CG, 1986, TRENDS BIOCHEM SCI, V11, P73, DOI 10.1016/0968-0004(86)90269-0; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	39	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					283	288						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549350				2022-12-28	WOS:A1992HG98200012
J	HIBI, K; TAKAHASHI, T; SEKIDO, Y; UEDA, R; HIDA, T; ARIYOSHI, Y; TAKAGI, H; TAKAHASHI, T				HIBI, K; TAKAHASHI, T; SEKIDO, Y; UEDA, R; HIDA, T; ARIYOSHI, Y; TAKAGI, H; TAKAHASHI, T			COEXPRESSION OF THE STEM-CELL FACTOR AND THE C-KIT GENES IN SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							GROWTH-FACTOR; SI-LOCUS; EXPRESSION; LIGAND; MOUSE; AMPLIFICATION; PROLIFERATION; RECEPTOR; INVITRO; P53	Stem cell factor (SCF) is a pluripotent growth factor which is suggested to play an important role in proliferation and differentiation in various types of fetal and adult tissues as the ligand of the c-kit proto-oncogene product. However, very little is known about expression of the SCF gene in human malignancies. We analysed DNA and RNA extracted from 28 cell lines and 16 fresh tumor specimens of lung cancer as well as 24 cancer cell lines of various origin for SCF expression. Now we report that the SCF gene is expressed in a wide variety of human cancers including lung cancer, in marked contrast to c-kit, which is expressed in very few types of cancers. As a consequence, coexpression of both the ligand and the receptor is seen only in small-cell lung cancer, suggesting possible involvement of autocrine stimulation via this ligand-receptor system in the pathogenesis of this aggressive cancer. In addition, this study revealed that the human SCF gene is transcribed into two major forms of alternatively spliced mRNAs with different molar ratio in fetal, adult and malignant tissues.	AICHI CANC CTR,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,DEPT INTERNAL MED,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT SURG 2,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Nagoya University			Takahashi, Takashi/I-7262-2014; Sekido, Yoshitaka/P-9756-2015	Takahashi, Takashi/0000-0003-0615-7001; Sekido, Yoshitaka/0000-0002-2428-3848				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MINNA JD, 1986, COLD SPRING HARB SYM, V51, P843, DOI 10.1101/SQB.1986.051.01.098; MINNA JD, 1989, CC MOL BIOL, P57; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; SEKIDO Y, 1991, CANCER RES, V51, P2416; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VOSTREJS M, 1988, J CLIN INVEST, V82, P331, DOI 10.1172/JCI113591; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	21	265	296	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2291	2296						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722571				2022-12-28	WOS:A1991GX73500017
J	CARBONE, D; CHIBA, I; MITSUDOMI, T				CARBONE, D; CHIBA, I; MITSUDOMI, T			POLYMORPHISM AT CODON-213 WITHIN THE P53-GENE	ONCOGENE			English	Note							P53 GENE; LUNG-CANCER; MUTATIONS; FREQUENT; PROTEIN; MUTANT	This report describes a rare polymorphism at codon 213 (silent alteration of CGA to CGG) within the coding region of the p53 gene. The rare polymorphic allele was present in six cases out of 189 lung and breast cancer DNAs analyzed (3.2%) and resulted in the loss of a TaqI site. This allele could be mistaken for a mutation when screening methods of mutation analysis are used without comparison with normal tissue DNA.	USN,MED ONCOL BRANCH,BETHESDA,MD 20889	United States Department of Defense; United States Navy	CARBONE, D (corresponding author), UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,2523 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505				AHUJA HG, 1990, ONCOGENE, V5, P1409; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHIBA I, 1990, ONCOGENE, V5, P1603; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GROMPE M, 1989, P NATL ACAD SCI USA, V86, P5888, DOI 10.1073/pnas.86.15.5888; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	14	159	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1691	1692						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923533				2022-12-28	WOS:A1991GX27400027
J	MA, QF; HERSCHMAN, HR				MA, QF; HERSCHMAN, HR			A CORRECTED SEQUENCE FOR THE PREDICTED PROTEIN FROM THE MITOGEN-INDUCIBLE TIS11 PRIMARY RESPONSE GENE	ONCOGENE			English	Article							SWISS 3T3 CELLS; TETRADECANOYL	We previously reported the sequence of a cDNA, TIS11, cloned from TPA-treated Swiss 3T3 cells. Two laboratories have reported sequences for cDNAs that have a region of identity with the TIS11 cDNA, but differ in their 5' and 3' flanking regions. We now report that the original TIS11 cDNA is likely to be a chimeric molecule, and find that the TIS11 gene encodes a protein identical to the TTP and Nup475 genes.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	HERSCHMAN, HR (corresponding author), UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DUBOIS RN, 1990, J BIOL CHEM, V265, P19186; LAI WS, 1990, J BIOL CHEM, V265, P16556; LIM RW, 1987, ONCOGENE, V1, P263; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; VARNUM BC, 1989, ONCOGENE, V4, P119; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	6	49	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1277	1278						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861870				2022-12-28	WOS:A1991GV26000025
J	GINSBERG, D; HIRAI, S; PINHASIKIMHI, O; YANIV, M; OREN, M				GINSBERG, D; HIRAI, S; PINHASIKIMHI, O; YANIV, M; OREN, M			TRANSFECTED MOUSE C-JUN CAN INHIBIT TRANSFORMATION OF PRIMARY RAT EMBRYO FIBROBLASTS	ONCOGENE			English	Note							DNA-BINDING; GLUCOCORTICOID RECEPTOR; GROWTH-FACTORS; FOS; CELLS; GENE; ONCOGENE; DIFFERENTIATION; EXPRESSION; ENCODES	The c-jun gene, which encodes a transcriptional regulatory protein, is the cellular homologue of the transforming gene of avian sarcoma virus 17. In an attempt to assess the biological activities of mouse c-jun, we studied the consequences of its overproduction in an in vitro transformation assay. A c-jun expression plasmid failed to cooperate with either ras, myc or mutant p53 in this focus formation assay. On the other hand, it dramatically inhibited the ability of various oncogene combinations to elicit foci upon transfection into primary rat embryo fibroblasts. Deletion plasmids lacking either the trans-activating domain or the leucine repeat of c-jun still displayed a pronounced inhibitory activity. On the contrary, a plasmid encoding only the first 187 amino acids of c-jun had no such activity. The data suggests that enhanced c-jun expression may interfere with the induction or proliferation of transformed cells in this system, and that the inhibitory activity residues in the C-terminal half of the molecule.	INST PASTEUR, CNRS, DEPT BIOTECHNOL, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	GINSBERG, D (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.			ginsberg, doron/0000-0002-1257-4920				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LORD KA, 1990, ONCOGENE, V5, P387; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MOAV B, 1986, GENE, V48, P297, DOI 10.1016/0378-1119(86)90089-2; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; POLLACK R, 1974, P NATL ACAD SCI USA, V71, P4792, DOI 10.1073/pnas.71.12.4792; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	36	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					669	672						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903196				2022-12-28	WOS:A1991FR93900025
J	KOCHEL, T; MUSHINSKI, JF; RICE, NR				KOCHEL, T; MUSHINSKI, JF; RICE, NR			THE V-REL AND C-REL PROTEINS EXIST IN HIGH-MOLECULAR-WEIGHT COMPLEXES IN AVIAN AND MURINE CELLS	ONCOGENE			English	Article							NF-KAPPA-B; VIRUS-STRAIN-T; TRANSFORMED LYMPHOID-CELLS; DNA-BINDING SUBUNIT; BONE-MARROW CELLS; RETICULOENDOTHELIOSIS VIRUS; ONCOGENE PRODUCT; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS	We reported previously that the v-rel protein (p59v-rel) exists in a high molecular weight complex with at least four other proteins in the cytoplasm of v-rel-transformed chicken pre-B lymphoid cells (Simek, S. & Rice, N.R., J. Virol., 62, 4730-4736, 1989). One of these proteins is the chicken c-rel protein, but the identities of the others (of about 36 kDa, 115kDa, and 124 kDa) are unknown. In this report we extend that observation to additional v-rel-transformed cell lines of both pre-B and B cell phenotypes. We also introduced and expressed v-rel in several other avian cell lines (a chicken T cell line, chick embryo fibroblasts, and quail fibroblasts) and found that in these cells p59v-rel was complexed with the same proteins as observed in the v-rel-transformed cells. Thus, the associated proteins are not limited to pre-B cells, but occur and complex with p59v-rel in B cells, T cells, and fibroblasts. We next examined five uninfected avian cells and tissues and found that, with only one exception, p75c-rel was complexed with p36, p115, and p124. Thus, in most cases complex formation is not limited to or dependent on the presence of the transforming v-rel protein, but also occurs with the normal c-rel protein. To determine whether a mammalian c-rel protein is similarly associated with other proteins, we screened murine cell lines for the presence of c-rel mRNA. In agreement with our earlier findings, we found the highest expression in mature B cells, although several pre-B and myeloid cell lines were also strongly positive. Using one of the B cell lines, we detected the murine c-rel protein. We found that, like its avian counterpart, it is a protein of about 75 kDa and is associated with proteins of 36 kDa and 115 kDa. Sephacryl S-400 chromatography revealed that both the avian and murine complexes are of high molecular weight, with an average size of about 400 kDa.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,FREDERICK,MD 21701; NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; CHEN L, 1988, P NATL ACAD SCI USA, V85, P549, DOI 10.1073/pnas.85.2.549; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DORN PL, 1988, J VIROL, V62, P3522, DOI 10.1128/JVI.62.9.3522-3526.1988; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; Maniatis T., 1982, MOL CLONING; MOORE BE, 1989, ONCOGENE, V4, P845; MORRISON LE, 1989, ONCOGENE, V4, P677; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUSHINSKI JF, 1987, CANCER INVEST, V5, P345; RICE NR, 1982, J VIROL, V42, P237, DOI 10.1128/JVI.42.1.237-252.1982; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WONG TC, 1981, VIROLOGY, V111, P289, DOI 10.1016/0042-6822(81)90674-7; ZABELU, 1990, CELL, V61, P255	51	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					615	626						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851550				2022-12-28	WOS:A1991FR93900017
J	NALDINI, L; VIGNA, E; NARSIMHAN, RP; GAUDINO, G; ZARNEGAR, R; MICHALOPOULOS, GK; COMOGLIO, PM				NALDINI, L; VIGNA, E; NARSIMHAN, RP; GAUDINO, G; ZARNEGAR, R; MICHALOPOULOS, GK; COMOGLIO, PM			HEPATOCYTE GROWTH-FACTOR (HGF) STIMULATES THE TYROSINE KINASE-ACTIVITY OF THE RECEPTOR ENCODED BY THE PROTOONCOGENE C-MET	ONCOGENE			English	Article							FULMINANT HEPATIC-FAILURE; CARCINOMA CELL-LINE; HEPATOPOIETIN-A; MOLECULAR-CLONING; SCATTER FACTOR; MESSENGER-RNA; PURIFICATION; EXPRESSION; SEQUENCE; PROTOONCOGENE	The human proto-oncogene c-MET encodes a heterodimeric 190 KDa transmembrane protein (p190c-met) with structural features of a tyrosine kinase receptor. The ligand for this putative receptor has not yet been identified. By Northern blot hybridization we found that, among a restricted number of human tissues, c-MET is highly expressed in the liver. This prompted us to test the hypothesis of a functional interaction between the c-MET receptor and Hepatocyte Growth Factor (HGF), a heparin-binding polypeptide consisting of heavy and light chains of 65 and 35 kDa. Nanomolar concentrations of highly purified HGF added to GTL-16 cells, which overexpress the c-MET receptor, enhanced the phosphorylation on tyrosine of the p190c-met kinase. Addition of other known growth factors or serum was ineffective. The kinase activity of the c-MET receptor was also stimulated by HGF in an in vitro assay, after detergent solubilization and partial purification of p190c-met. Moreover, elution of immunoprecipitates obtained with anti-MET antibodies from GTL-16 cell lysates yielded an HGF-responsive kinase activity. These results suggest that HGF, or a growth factor structurally related to HGF, is a candidate ligand for the receptor encoded by c-MET.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	University of Turin; Duke University			Naldini, Luigi/E-9083-2012	NALDINI, Luigi/0000-0002-7835-527X; Comoglio, Paolo/0000-0002-7056-5328; Vigna, Elisa/0000-0001-9787-5732				CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; LINDROOS PM, 1990, IN PRESS HEPATOLOGY; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NAKAYAMA H, 1985, BIOMED RES-TOKYO, V6, P231; NALDINI L, 1990, IN PRESS MOL CELL BI; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1990, IN PRESS ONCOGENE; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; THALER FJ, 1985, CANCER RES, V45, P2545; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZARNEGAR R, 1990, IN PRESS BIOCH BIOPH	30	744	783	0	20	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					501	504						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827664				2022-12-28	WOS:A1991FR93900002
J	RYSECK, RP; BRAVO, R				RYSECK, RP; BRAVO, R			C-JUN, JUN-B, AND JUN-D DIFFER IN THEIR BINDING AFFINITIES TO AP-1 AND CRE CONSENSUS SEQUENCES - EFFECT OF FOS PROTEINS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING; LEUCINE ZIPPER; PROTO-ONCOGENE; GROWTH-FACTORS; BASIC REGION; GENE FAMILY; CYCLIC-AMP; EXPRESSION; ACTIVATION	We have compared the binding properties of c-JUN, JUN B, and JUN D in the absence or in the presence of c-FOS, FOS B, and FRA-1 to different AP-1 and CRE-containing oligonucleotides. The results demonstrate that for a given AP-1-containing oligonucleotide the binding affinities of the different JUN proteins are always c-JUN > JUN D > JUN B. The three JUN proteins have the capacity to bind to a CRE consensus sequence with very high affinity. We have found that c-JUN, JUN B, and JUN D bind with different affinities to different oligonucleotides containing an identical AP-1 or CRE binding site, implying that the adjacent sequences influence the stability of the JUN/DNA complexes. Interestingly, an AP-1-containing oligonucleotide which binds the JUN proteins with high affinity can be converted to a CRE-containing oligonucleotide which will also bind the different JUNs very efficiently. The heterodimers formed between the different JUN and FOS proteins have an enhanced binding activity compared to the JUN:JUN homodimers. In all cases the half-lives of the JUN:FOS/DNA complexes are longer than those of the JUN:JUN/DNA complexes. The most stable complexes were obtained in the presence of FOS B, followed by FRA-1 and c-FOS.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543	Bristol-Myers Squibb								ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1989, GENE DEV, V3, P2082; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; QUANTIN B, 1988, NATURE, V334, P530; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	49	595	602	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					533	542						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827665				2022-12-28	WOS:A1991FR93900006
J	STETTER, G; BRAUN, MA; MONTENARH, M				STETTER, G; BRAUN, MA; MONTENARH, M			A NEW DNA-BINDING ASSAY TO STUDY SUBCLASSES OF SV40 LARGE T-ANTIGEN BINDING TO INDIVIDUAL BINDING-SITES ON THE SV40 DNA	ONCOGENE			English	Article							LARGE-TUMOR-ANTIGEN; SIMIAN-VIRUS 40; PRODUCTIVELY INFECTED-CELLS; ORIGIN DNA; SV40-TRANSFORMED CELLS; TRANSCRIPTION INVITRO; REPLICATION INVITRO; MUTATIONAL ANALYSIS; REGULATORY MUTANTS; CONTROL REGION	SV40 large T antigen interacts specifically with three different sequences, termed sites I, II or III, within the control region of the SV40 DNA to regulate transcription as well as the initiation and progress of SV40 DNA replication. We have biotinylated three different DNAs containing either site I, II or III and immobilized these constructs on a streptavidin agarose matrix. All three immobilized DNAs were shown to bind T antigen from a total cell extract of SV40 infected monkey cells although with different affinities. Pulse chase experiments revealed that newly synthesized T antigen bound efficiently to all three binding sites whereas mature T antigen bound only to site I and site III DNA. The analysis of non-binding and DNA-bound T antigen on sucrose density gradients showed that only low molecular weight forms of T antigen were bound to all three immobilized DNAs. However, incubation of T antigen in the total cell extract with site I DNA resulted in high molecular weight forms of T antigen, indicating that the presence of site I DNA influences the quaternary structure of T antigen which might result in a detachment from the DNA.	UNIV ULM,DEPT BIOCHEM,W-7900 ULM,GERMANY	Ulm University			Montenarh, Mathias/AAB-6689-2020					ARTHUR AK, 1988, J VIROL, V62, P1999, DOI 10.1128/JVI.62.6.1999-2006.1988; BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, P99; DIMAIO D, 1980, J MOL BIOL, V140, P129, DOI 10.1016/0022-2836(80)90359-9; DIMAIO D, 1982, J MOL BIOL, V156, P531, DOI 10.1016/0022-2836(82)90265-0; DORN A, 1982, EUR J BIOCHEM, V128, P53; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; FANNING E, 1982, EMBO J, V1, P1023, DOI 10.1002/j.1460-2075.1982.tb01290.x; FIELDS BN, 1985, VIROLOGY; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIDONI D, 1982, J VIROL, V42, P456, DOI 10.1128/JVI.42.2.456-466.1982; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; JONES KA, 1984, EMBO J, V3, P3247, DOI 10.1002/j.1460-2075.1984.tb02286.x; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KLAUSING K, 1988, J VIROL, V62, P1258, DOI 10.1128/JVI.62.4.1258-1265.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEBLONDFRANCILLARD M, 1987, EUR J BIOCHEM, V166, P351, DOI 10.1111/j.1432-1033.1987.tb13522.x; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARGOLSKEE R, 1984, J VIROL, V49, P385; MASTRANGELO IA, 1985, P NATL ACAD SCI USA, V82, P3626, DOI 10.1073/pnas.82.11.3626; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MONTENARH M, 1983, J VIROL, V45, P531, DOI 10.1128/JVI.45.2.531-538.1983; MONTENARH M, 1986, FEBS LETT, V204, P51, DOI 10.1016/0014-5793(86)81386-2; MONTENARH M, 1980, FEBS LETT, V114, P107, DOI 10.1016/0014-5793(80)80870-2; MULLER D, 1987, VIROLOGY, V161, P81, DOI 10.1016/0042-6822(87)90173-5; Rigby P. W. J., 1983, ADV VIRAL ONCOL, V3, P31; RIO D, 1980, P NATL ACAD SCI-BIOL, V77, P5706, DOI 10.1073/pnas.77.10.5706; RUNZLER R, 1987, J VIROL, V61, P2076, DOI 10.1128/JVI.61.7.2076-2083.1987; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SCHELLER A, 1982, CELL, V29, P375, DOI 10.1016/0092-8674(82)90154-4; SCHIRMBECK R, 1988, VIROLOGY, V165, P527, DOI 10.1016/0042-6822(88)90597-1; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SCHURMANN C, 1985, VIROLOGY, V146, P1, DOI 10.1016/0042-6822(85)90047-9; SHALLOWAY D, 1980, CELL, V20, P411, DOI 10.1016/0092-8674(80)90627-3; SHORTLE DR, 1979, P NATL ACAD SCI USA, V76, P6128, DOI 10.1073/pnas.76.12.6128; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STETTER G, 1988, VIROLOGY, V164, P309, DOI 10.1016/0042-6822(88)90543-0; STETTER G, 1989, ONCOGENE, V4, P1353; TEGTMEYER P, 1983, J VIROL, V46, P151, DOI 10.1128/JVI.46.1.151-161.1983; TENEN DG, 1982, J MOL BIOL, V157, P473, DOI 10.1016/0022-2836(82)90472-7; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; VOGT B, 1986, J VIROL, V58, P765, DOI 10.1128/JVI.58.3.765-772.1986; WACHTER M, 1985, J VIROL, V56, P520, DOI 10.1128/JVI.56.2.520-526.1985; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643	58	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					389	396						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849245				2022-12-28	WOS:A1991FT34400006
J	WILLEMS, L; KETTMANN, R; BURNY, A				WILLEMS, L; KETTMANN, R; BURNY, A			THE AMINO-ACID (157-197) PEPTIDE SEGMENT OF BOVINE LEUKEMIA-VIRUS P34TAX ENCOMPASS A LEUCINE-RICH GLOBALLY NEUTRAL ACTIVATION DOMAIN	ONCOGENE			English	Note							TRANSCRIPTIONAL ACTIVATOR; MAMMALIAN-CELLS; FUNCTIONAL DISSECTION; GENE-EXPRESSION; TRANS-ACTIVATOR; GAL4; PROTEINS; YEAST; ELEMENTS; ESTROGEN	The specific DNA-binding Ga14 amino-terminal portion (amino acids 1 to 147) was fused to protein segments of BLV transactivator p34tax and tested for its capacity to activate CAT-gene expression in mammalian cells. The p34tax peptide segment 157 to 197 encompasses an activating region. The segment is approximately located in the middle of p34tax and is globally neutral (net charge zero). The tax (157-197) domain contains 24% of leucine residues, possibly involved in heterologous protein interactions.	UNIV BRUSSELS,DEPT MOLEC BIOL,B-1640 RHODE ST GENESE,BELGIUM; FAC AGRON GEMBLOUX,DEPT MOLEC BIOL,B-5030 GEMBLOUX,BELGIUM	University of Liege	WILLEMS, L (corresponding author), FAC AGRON GEMBLOUX,DEPT MOLEC BIOL,B-5800 GEMBLOUX,BELGIUM.			Willems, Luc/0000-0002-0563-2213				BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BURNY A, 1987, CANCER SURV, V6, P139; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DERSE D, 1987, J VIROL, V61, P2462, DOI 10.1128/JVI.61.8.2462-2471.1987; DERSE D, 1988, J VIROL, V62, P1115, DOI 10.1128/JVI.62.4.1115-1119.1988; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KETTMANN R, 1982, P NATL ACAD SCI-BIOL, V79, P2465, DOI 10.1073/pnas.79.8.2465; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER JM, 1969, JNCI-J NATL CANCER I, V43, P1297; PORTETELLE D, 1978, ANN RECH VET, V9, P667; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLEMS L, 1987, EMBO J, V6, P3385, DOI 10.1002/j.1460-2075.1987.tb02661.x; WILLEMS L, 1987, VIROLOGY, V160, P55, DOI 10.1016/0042-6822(87)90043-2; WILLEMS L, 1989, VIROLOGY, V171, P615, DOI 10.1016/0042-6822(89)90633-8; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	31	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					159	163						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846955				2022-12-28	WOS:A1991EY03900023
J	KURY, FD; SCHNEEBERGER, C; SLIUTZ, G; KUBISTA, E; SALZER, H; MEDL, M; LEODOLTER, S; SWOBODA, H; ZEILLINGER, R; SPONA, J				KURY, FD; SCHNEEBERGER, C; SLIUTZ, G; KUBISTA, E; SALZER, H; MEDL, M; LEODOLTER, S; SWOBODA, H; ZEILLINGER, R; SPONA, J			DETERMINATION OF HER-2/NEU AMPLIFICATION AND EXPRESSION IN TUMOR-TISSUE AND CULTURED-CELLS USING A SIMPLE, PHENOL FREE METHOD FOR NUCLEIC-ACID ISOLATION	ONCOGENE			English	Editorial Material									UNIV VIENNA,DEPT OBSTET & GYNECOL 1,DIV MOLEC ENDOCRINOL,SPITALGASSE 23,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,LUDWIG BOLTZMANN INST PRENATAL & EXPTL GENOME ANAL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT OTOLARYNGOL,A-1090 VIENNA,AUSTRIA; KRANKENHAUS STADT VIENNA LAINZ,A-1130 VIENNA,AUSTRIA	University of Vienna; Ludwig Boltzmann Institute; University of Vienna; University of Vienna				Zeillinger, Robert/0000-0001-6771-4591				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; ANDERSSON K, 1985, PLASMID, V13, P78, DOI 10.1016/0147-619X(85)90059-9; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; Carter C., 1983, BIOTECHNIQUES, V1, P142; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Favaloro J, 1980, Methods Enzymol, V65, P718; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HIGGINS SJ, 1978, BIOCHEM J, V174, P543, DOI 10.1042/bj1740543; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIRKES PE, 1985, ANAL BIOCHEM, V148, P376, DOI 10.1016/0003-2697(85)90242-8; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WEEKS DP, 1986, ANAL BIOCHEM, V152, P376, DOI 10.1016/0003-2697(86)90423-9; ZARLENGA DS, 1987, ANAL BIOCHEM, V162, P569, DOI 10.1016/0003-2697(87)90435-0; ZEILLINGER R, 1989, ONCOGENE, V4, P109; ZHOU DJ, 1988, ONCOGENE, V2, P279	22	51	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1403	1408						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699198				2022-12-28	WOS:A1990EC24100019
J	CHIARIOTTI, L; BERLINGIERI, MT; DEROSA, P; BATTAGLIA, C; BERGER, N; BRUNI, CB; FUSCO, A				CHIARIOTTI, L; BERLINGIERI, MT; DEROSA, P; BATTAGLIA, C; BERGER, N; BRUNI, CB; FUSCO, A			INCREASED EXPRESSION OF THE NEGATIVE GROWTH-FACTOR, GALACTOSIDE-BINDING PROTEIN, GENE IN TRANSFORMED THYROID-CELLS AND IN HUMAN THYROID CARCINOMAS	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; EPITHELIAL-CELLS; MESSENGER-RNA; LECTIN GENE; RAT; SEQUENCE; PLASMIDS; CLONING; BLOCK; CDNA	Murine beta-galactoside-binding protein has been shown to be a cell growth regulatory molecule and a cytostatic factor. We analysed the beta-galactoside-binding protein gene expression in a thyroid cell system including two normal cell lines (FRTL-5 and PC Cl 3) and the same cells transfected by several oncogenes that induce different degrees of malignancy and differentiation. We show that beta-galactoside-binding protein mRNA levels correlate with the expression of the malignant phenotype. Run-on experiments suggest that a transcriptional effect accounts at least in part for such a difference. We also show that the beta-galactoside-binding protein gene expression is increased in most human papillary thyroid carcinomas compared with normal thyroid.	NAPLES UNIV,CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CALIFANO,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY; HOP ANTIQUAILLE,ANAT PATHOL LAB,F-69321 LYON,FRANCE	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; CHU Lyon			Chiariotti, Lorenzo/AAC-5262-2022	Fusco, Alfredo/0000-0003-3332-5197; CHIARIOTTI, Lorenzo/0000-0001-6097-4171				Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; BERLINGIERI MT, 1989, EXP CELL RES, V183, P277, DOI 10.1016/0014-4827(89)90388-1; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P2261, DOI 10.1128/MCB.8.5.2261; CARDING SR, 1985, BIOCHEM BIOPH RES CO, V127, P680, DOI 10.1016/S0006-291X(85)80215-1; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; FUSCO A, 1989, ONCOGENES TUMOUR ANT, P17; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GREENBERG ME, 1984, NATURE, V311, P432; LEHARACH H, 1977, BIOCHEMISTRY-US, V16, P4743; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; RAZ A, 1987, INT J CANCER, V39, P353, DOI 10.1002/ijc.2910390314; RAZ A, 1988, CANCER RES, V48, P645; RAZ A, 1987, EXP CELL RES, V173, P109, DOI 10.1016/0014-4827(87)90336-3; RAZ A, 1986, CANCER RES, V46, P3667; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G	31	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2507	2511						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461653				2022-12-28	WOS:A1992KA85600016
J	ROUER, E; BENAROUS, R				ROUER, E; BENAROUS, R			ALTERNATIVE SPLICING IN THE HUMAN LCK GENE LEADS TO THE DELETION OF EXON-1' AND RESULTS IN A NEW TYPE-II LCK TRANSCRIPT	ONCOGENE			English	Note							TYROSINE-PROTEIN-KINASE; MESSENGER-RNAS; CELL-LINES; EXPRESSION; P56LCK; ACID; CD4	In this study we describe a new lck mRNA transcribed from the type II promoter, resulting from alternative splicing, in the deletion of exon 1' which comprises the AUG initiation codon. In this type IIB lck transcript, as a consequence of exon 1' deletion, a new AUG codon in exon 1, located 35 nt upstream from the regular initiation codon in exon 1', and normally out of frame, is now in frame with exon 2 and the following lck coding sequence. In this type IIB lck transcript, 10 residues encoded by exon 1 from the new AUG codon replace the first 35 residues encoded by exon 1'. Strikingly, in this new N-terminal amino acid sequence, a glycine residue, needed for myristylation and anchorage in the plasma membrane, is present at position 2. This alternative splicing has been observed in T-cell lines, normal mature T cells and in peripheral blood lymphocytes from different leukemic patients. Different ratios of regular type IIA lck mRNA (with exon 1') to spliced type IIB lck mRNA (without exon 1') have been observed depending on the patient.			ROUER, E (corresponding author), ICGM,INSERM,U332,22 RUE MECHAIN,F-75014 PARIS,FRANCE.							CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357	17	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2535	2538						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461657				2022-12-28	WOS:A1992KA85600021
J	NAKAGOSHI, H; KANEIISHII, C; SAWAZAKI, T; MIZUGUCHI, G; ISHII, S				NAKAGOSHI, H; KANEIISHII, C; SAWAZAKI, T; MIZUGUCHI, G; ISHII, S			TRANSCRIPTIONAL ACTIVATION OF THE C-MYC GENE BY THE C-MYB AND B-MYB GENE-PRODUCTS	ONCOGENE			English	Article							RNA INHIBITS PROLIFERATION; DNA-BINDING ACTIVITY; V-MYB; PROTO-ONCOGENE; OLIGOMER COMPLEMENTARY; NUCLEOTIDE-SEQUENCE; CELLULAR PROGENITOR; MYELOID-LEUKEMIA; EXPRESSION; CELLS	To identify the target genes modulated by the myb gene product (Myb), a co-transfection assay with a Myb expression plasmid was performed. Both c-Myb and B-Myb, another member of the myb gene family, trans-activated the human c-myc promoter. DNAase I footprint analysis using the bacterially expressed c-Myb, identified multiple c-Myb binding sites in the c-myc promoter region. Deletion analysis of the c-myc promoter suggested that some number of Myb binding sites, not a specific Myb binding site, is important for the c-Myb-induced trans-activation of the c-myc promoter. Using the c-myc-chloramphenicol acetyltransferase (CAT) construct as a reporter in a co-transfection assay, the domains of c-Myb required for trans-activation were examined. The functional domains of c-Myb identified using the c-myc promoter were almost the same as those identified previously with the artificial target gene containing Myb binding sites, but unlike the case with the artificial target gene the N-terminal half of the previously identified negative regulatory domains and the C-terminal 136 amino acids were required for the maximal trans-activation of the c-myc promoter. These results indicate that there are some differences in the regulation of Myb-dependent trans-activation in different target genes.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; SCI UNIV TOKYO,DEPT PHARMACEUT SCI,SHINJUKU KU,TOKYO 162,JAPAN	RIKEN; Osaka University; Tokyo University of Science			NAKAGOSHI, Hideki/B-2145-2011; Ishii, Shunsuke/A-5271-2016	NAKAGOSHI, Hideki/0000-0003-0850-1814; Ishii, Shunsuke/0000-0002-6530-2478				ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GEARWIRTZ AM, 1988, SCIENCE, V242, P1303; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; NAGASE T, 1990, GENE, V94, P249, DOI 10.1016/0378-1119(90)90395-8; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; ZOBEL A, 1991, ONCOGENE, V6, P1397	47	133	134	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1233	1240						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594249				2022-12-28	WOS:A1992HU64200022
J	HAMEL, PA; GILL, RM; PHILLIPS, RA; GALLIE, BL				HAMEL, PA; GILL, RM; PHILLIPS, RA; GALLIE, BL			REGIONS CONTROLLING HYPERPHOSPHORYLATION AND CONFORMATION OF THE RETINOBLASTOMA GENE-PRODUCT ARE INDEPENDENT OF DOMAINS REQUIRED FOR TRANSCRIPTIONAL REPRESSION	ONCOGENE			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; VIRUS-40 LARGE-T; SV40 LARGE-T; CELL-CYCLE; SUSCEPTIBILITY GENE; PHOSPHORYLATION SITES; RNA-POLYMERASE; NUCLEAR LAMINA; CDC2 KINASE	Cell cycle-dependent phosphorylation appears to control the function of the retinoblastoma gene product, p110RB1. We have previously shown that both the N-terminal portion and the portion corresponding to exon 23 are important in the hyperphosphorylation of p110RB1. To gain further insight into the domains involved in these phosphorylations, we have created a series of mutations in the murine cDNA and investigated their effects on phosphorylation, protein conformation and transcription of genes controlled by an E2 element. Three series of p110RB1 constructs were made: (1) mutations and/or deletions in the cluster of potential p34cdc2 consensus sequences of exon 23, (2) deletions for the entire region C-terminal to the large T antigen (TAg)-binding domains or (3) mutations in eight potential p34cdc2 sites, including four in exon 23. Following transfections into COS cells, phosphorylation, TAg binding and protein conformation were evaluated. Constructs were also tested for their ability to repress transcription from the adenovirus early promoter. All mutant proteins bound to SV40 TAg. Mutation of Ser-781, Ser-787 and Ser-788 had no detectable effect on the phosphorylation pattern of p110RB1, producing both the fast-migrating, hypophosphorylated and slower migrating, hyperphosphorylated bands on SDS-PAGE gels. However, mutation or deletion of Ser-800 and Ser-804 resulted in proteins which failed to show the characteristic shift in molecular weight associated with the hyperphosphorylated form of p110RB1. A protein mutated only at Pro-805, the residue adjacent to Ser-804, behaved similarly to mutants with both Ser-800 and Ser-804 altered; mutation of Pro-801 had no effect on the mobility of the hyperphosphorylated species. While differences were seen in the ability of these proteins to be hyperphosphorylated, the wild-type function of repression of adenovirus early promoter activity was retained. These results are consistent with the large shift in apparent molecular weight of p110RB1 upon hyperphosphorylation being due to phosphorylation of Ser-804. Phosphorylation of this p34cdc2 consensus sequence and the subsequent conformational change in p110RB1 detected in denaturing gels is not necessary, however, for the phosphorylation-dependent modulation of p110RB1-TAg interaction.	UNIV TORONTO,DEPT IMMUNOL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MINERAL & PETROL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT OPHTHALMOL,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto	HAMEL, PA (corresponding author), HOSP SICK CHILDREN,RES INST,DIV IMMUNOL & CANC,ROOM 8130,TORONTO M5G 1X8,ONTARIO,CANADA.			Gallie, Brenda/0000-0002-9697-9211				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRADBURY EM, 1974, NATURE, V249, P553, DOI 10.1038/249553a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4594; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHULZEGAHMEN U, 1988, J BIOL CHEM, V263, P17100; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH CL, 1989, J VIROL, V63, P1569, DOI 10.1128/JVI.63.4.1569-1577.1989; STARNAUD R, 1988, ONCOGENE, V3, P553; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	47	58	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					693	701						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565466				2022-12-28	WOS:A1992HQ68200011
J	SITHANANDAM, G; DRUCK, T; CANNIZZARO, LA; LEUZZI, G; HUEBNER, K; RAPP, UR				SITHANANDAM, G; DRUCK, T; CANNIZZARO, LA; LEUZZI, G; HUEBNER, K; RAPP, UR			B-RAF AND A B-RAF PSEUDOGENE ARE LOCATED ON 7Q IN MAN	ONCOGENE			English	Note							COMPLETE CODING SEQUENCE; GAUCHER DISEASE; HUMAN HOMOLOGS; X-CHROMOSOME; MIL ONCOGENE; A-RAF; C-RAF; V-RAF; GENE; FAMILY	The B-raf gene was lozalized to human chromosome region 7p11-7qter by Southern blot analysis of its segregation in a panel of rodent-human hybrids, using a B-raf cDNA clone. Chromosomal in situ hybridization refined the localization to 7q33-36. Analysis of genomic B-raf clones identified a B-raf pseudogene in addition to the active gene. Based on the chromosomal mapping data we conclude that the pseudogene is located near the active gene.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; PRI DYNCORP,FREDERICK CANC RES & DEV CTR,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER SR, 1988, IMMUNOGENETICS, V28, P328, DOI 10.1007/BF00364231; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLEEKERWAGEMAKERS LM, 1985, HUM GENET, V71, P211, DOI 10.1007/BF00284575; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CANNIZZARO LA, 1990, GENOMICS, V6, P197, DOI 10.1016/0888-7543(90)90557-B; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; GRECO A, 1989, GENOMICS, V4, P240, DOI 10.1016/0888-7543(89)90326-1; GUSELLA JF, 1986, COLD SPRING HARB SYM, V51, P359, DOI 10.1101/SQB.1986.051.01.043; HUEBNER K, 1988, ONCOGENE, V3, P449; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KIECHLESCHWARZ M, 1991, CANCER GENET CYTOGEN, V53, P125, DOI 10.1016/0165-4608(91)90124-D; KNOWLES BB, 1977, J EXP MED, V145, P314, DOI 10.1084/jem.145.2.314; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KWAN S-P, 1988, Genomics, V3, P39, DOI 10.1016/0888-7543(88)90156-5; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MARI O, 1991, J BIOL CHEM, V266, P23753; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MIHALY A, 1990, NEUROSCI LETT, V116, P45, DOI 10.1016/0304-3940(90)90384-L; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1989, CELL, V58, P648; RAPP UR, 1985, RECENT RES CANCER, V99, P221; RAPP UR, 1991, ONCOGENE, V6, P495; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHAFITZAGARDO B, 1981, AM J HUM GENET, V33, P564; SHULTZ AM, 1988, ONCOGENE, V2, P187; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STORM SM, 1990, ONCOGENE, V5, P345; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; ZIMRAN A, 1990, J CLIN INVEST, V85, P219, DOI 10.1172/JCI114415	39	38	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					795	799						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565476				2022-12-28	WOS:A1992HQ68200026
J	BAI, W; SINGH, B; YANG, Y; RAMAGLI, LS; NASH, M; HERZOG, NK; ARLINGHAUS, RB				BAI, W; SINGH, B; YANG, Y; RAMAGLI, LS; NASH, M; HERZOG, NK; ARLINGHAUS, RB			THE PHYSICAL INTERACTIONS BETWEEN P37ENV-MOS AND TUBULIN STRUCTURES	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; V-MOS; SACCHAROMYCES-CEREVISIAE; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; ONCOGENE PRODUCT; XENOPUS OOCYTES; BETA-TUBULIN; P85GAG-MOS	The c-mos protein has been reported to be complexed with tubulin and to co-localize with microtubules in unfertilized Xenopus eggs as well as in NIH3T3 cells transformed by the Xenopus c-mos gene. We performed experiments to determine whether the viral mos protein, p37v-mos, also associates with tubulin. Both mouse c-mos and v-mos proteins synthesized in vitro co-polymerized with tubulin. Upon incubation at 37-degrees-C, essentially all of the mos protein (both viral and cellular) co-polymerized with tubulin, while more than 50% of the tubulin remained in the depolymerized state. The mos-tubulin interaction was specific, as indicated by the insolubility of the v-mos protein following a second cycle of temperature-dependent depolymerization/polymerization. Beta-tubulin was shown to co-precipitate with p37v-mos and to be phosphorylated by the mos kinase in vitro. Although both v-mos and c-mos proteins co-polymerize with tubulin, p37v-mos behaved differently from p39c-mos on gel filtration columns under conditions that favor disassembly of microtubules. Like Xenopus c-mos, the bulk of the mouse c-mos protein synthesized in vitro appeared in structures that fractionate at about 500 kDa. In contrast to c-mos, the majority of the v-mos protein, either isolated from stably transformed NIH3T3 cells or synthesized in vitro, eluted in the 100 kDa fraction, cofractionating with tubulin dimers. Therefore, the v-mos protein appears to have a higher affinity for unpolymerized tubulin than c-mos, under conditions that favor disassembly of microtubules.	UNIV TEXAS, MD ANDERSON CANCER CTR,DEPT MOLEC PATHOL,BOX 89, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA45125, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAI WL, 1991, ONCOGENE, V6, P1715; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1991, MOL CELL BIOL, V11, P1713, DOI 10.1128/MCB.11.3.1713; FRIEL J, 1987, J VIROL, V61, P889, DOI 10.1128/JVI.61.3.889-897.1987; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; HERZOG NK, 1988, ONCOGENE, V3, P225; HERZOG NK, 1990, J VIROL, V64, P3093, DOI 10.1128/JVI.64.6.3093-3096.1990; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KATZ W, 1990, MOL CELL BIOL, V10, P5286, DOI 10.1128/MCB.10.10.5286; KLOETZER WS, 1983, P NATL ACAD SCI-BIOL, V80, P412, DOI 10.1073/pnas.80.2.412; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LIU JX, 1990, ONCOGENE, V5, P171; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1991, CELL GROWTH DIFFER, V2, P115; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WONG PKY, 1978, J VIROL, V25, P187, DOI 10.1128/JVI.25.1.187-192.1978; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	41	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					493	500						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1532247				2022-12-28	WOS:A1992HK00500014
J	MAHESWARAN, S; MCCORMACK, JE; SONENSHEIN, GE				MAHESWARAN, S; MCCORMACK, JE; SONENSHEIN, GE			CHANGES IN PHOSPHORYLATION OF MYC ONCOGENE AND RB ANTIONCOGENE PROTEIN PRODUCTS DURING GROWTH ARREST OF THE MURINE LYMPHOMA WEHI-231 CELL-LINE	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; C-MYC; EXPRESSION; IMMUNOGLOBULIN; CYCLE; TRANSLOCATION; ACTIVATION; SARCOMA; VIRUS; RNA	The expression of the protein products of the c-myc oncogene and retinoblastoma susceptibility gene (RB) was investigated during either goat anti-mouse immunoglobulin (GaMIg)- or phorbol ester (TPA)-induced growth arrest of the murine B-lymphoma cell line WEHI 231. Previously we have demonstrated that c-myc mRNA levels increase within 1-2 h of treatment, return to control levels by 4 h, and decline below these values by 24 h of treatment. Here we demonstrate that the level of c-myc protein synthesis and mRNA change in parallel. The predominant c-myc protein expressed during the time course is the one initiated at the AUG codon (P2). The myc protein synthesized following 1-2 h of anti-immunoglobulin or TPA treatment migrates more slowly in a polyacrylamide gel as a result of increased phosphorylation. This hyperphosphorylation was no longer detectable by 4-6 h of treatment. Furthermore, the hyper-phosphorylated myc protein appears to be more readily extractable with salt than the hypophosphorylated form. The product of the RB gene is present in multiple phosphorylation states in exponentially growing WEHI 231 cells. By 8 h of GaMIg or TPA treatment, a hypophosphorylated form begins to be detectable and significant levels were seen by 15 h. Thus post-translational control of both c-myc and RB expression occurs during the growth arrest of WEHI 231 cells. These changes in phosphorylation may play a role in mediating the cessation of proliferation of these cells.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Boston University					NCI NIH HHS [CA 36355] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1982, P NATL ACAD SCI-BIOL, V79, P6966, DOI 10.1073/pnas.79.22.6966; BISTER K, 1980, J VIROL, V36, P617, DOI 10.1128/JVI.36.2.617-621.1980; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOYD AW, 1981, J IMMUNOL, V126, P2266; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1988, CELL, V56, P67; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; GUY GR, 1989, BIOCHEM J, V263, P57, DOI 10.1042/bj2630057; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HORNBECK P, 1986, J BIOL CHEM, V261, P4817; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PONTE PA, 1981, NATURE, V291, P594, DOI 10.1038/291594a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RALPH P, 1979, IMMUNOL REV, V48, P107, DOI 10.1111/j.1600-065X.1979.tb00300.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHEW JY, 1989, ONCOGENE RES, V4, P205; STRAUSS F, 1984, CELL, V33, P741; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; XU HJ, 1989, ONCOGENE, V4, P807	39	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1965	1971						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719463				2022-12-28	WOS:A1991GX11900004
J	SCHEK, N; BARTENSCHLAGER, R; KUHN, C; SCHALLER, H				SCHEK, N; BARTENSCHLAGER, R; KUHN, C; SCHALLER, H			PHOSPHORYLATION AND RAPID TURNOVER OF HEPATITIS-B VIRUS X-PROTEIN EXPRESSED IN HEPG2 CELLS FROM A RECOMBINANT VACCINIA VIRUS	ONCOGENE			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; TRANSFORMED-CELLS; MAMMALIAN-CELLS; DNA; BINDING; GENOME; ANTIBODIES	The human hepatitis B viral (HBV) genome contains a conserved open reading frame known as the X-gene which is capable of encoding a polypeptide of 16.565 kDa. The corresponding protein has so far not been identified directly in HBV-infected cells, but in transient transfection assays the X-gene encodes a product that functions as a transcriptional transactivator. To characterize the subcellular distribution, stability and post-translational modifications of X-protein in human hepatoma HepG2 cells, we have established a vaccinia virus expression system. As the major X-gene product, a protein with an apparent molecular weight of 16 kDa, and reacting with an X-protein-specific antiserum, was expressed from recombinant vaccinia virus. In indirect immunofluorescence assay, X-protein appeared to be distributed throughout the cells, with a tendency to localize at the nuclear periphery and to accumulate in granules as its levels increased. By subcellular fractionation, we found about one-third of X-protein associated with the fraction defined as the nuclear framework. In pulse-chase experiments, X-protein decayed with a bimodal half-life of 15 min and 3 h. X-protein having a half-life of about 15 min was found associated with the Triton X-100 detergent-soluble fraction of HepG2 cells, while that associated with the insoluble fraction turned over more slowly. By metabolic labeling with [P-32]orthophosphate, we show that X-protein is capable of being phosphorylated. Modification by phosphorylation could play an important role in the regulation of X-protein function.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL HEIDELBERG,IM NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Bartenschlager, Ralf/L-2582-2015	Bartenschlager, Ralf/0000-0001-5601-9307				AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BARTENSCHLAGER R, 1988, EMBO J, V7, P4185, DOI 10.1002/j.1460-2075.1988.tb03315.x; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BENZEEV A, 1981, VIROLOGY, V111, P475, DOI 10.1016/0042-6822(81)90350-0; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BRANTON PE, 1985, J VIROL, V56, P633, DOI 10.1128/JVI.56.2.633-638.1985; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; CHANG CM, 1987, EMBO J, V6, P675, DOI 10.1002/j.1460-2075.1987.tb04807.x; CHISAKA O, 1987, GENE, V60, P183; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; DEMAGISTRIS L, 1988, NUCLEIC ACIDS RES, V16, P3141, DOI 10.1093/nar/16.8.3141; ELFASSI E, 1986, P NATL ACAD SCI USA, V83, P2219, DOI 10.1073/pnas.83.7.2219; FRANKE CA, 1989, J VIROL, V63, P4285, DOI 10.1128/JVI.63.10.4285-4291.1989; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1988, ANTIBODIES LABORATOR, P460; HESS J, 1988, MED MICROBIOL IMMUN, V177, P195, DOI 10.1007/BF00211219; HILLER G, 1985, J VIROL, V55, P651, DOI 10.1128/JVI.55.3.651-659.1985; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1988, CELL, V55, P123; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KAY A, 1985, EMBO J, V4, P1287, DOI 10.1002/j.1460-2075.1985.tb03774.x; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KOSHY R, 1989, CURR TOP MICROBIOL, V144, P265; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LEUTZ A, 1988, J BIOL CHEM, V263, P3905; LEVRERO M, 1990, VIROLOGY, V174, P299, DOI 10.1016/0042-6822(90)90079-7; MERRIL CR, 1981, SCIENCE, V211, P1436; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PENMAN S, 1966, J MOL BIOL, V17, P117, DOI 10.1016/S0022-2836(66)80098-0; PFAFF E, 1987, VIROLOGY, V158, P456, DOI 10.1016/0042-6822(87)90221-2; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEK N, 1991, HEPADNAVIRAL X PROTE, P181; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SEIFER M, 1990, VIROLOGY, V179, P287, DOI 10.1016/0042-6822(90)90297-5; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; STAMATOS NM, 1987, J VIROL, V61, P516, DOI 10.1128/JVI.61.2.516-525.1987; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZAHM P, 1988, ONCOGENE, V3, P169	58	79	84	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1735	1744						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923499				2022-12-28	WOS:A1991GX11800003
J	WRIGHT, PA; LEMOINE, NR; GORETZKI, PE; WYLLIE, FS; BOND, J; HUGHES, C; ROHER, HD; WILLIAMS, ED; WYNFORDTHOMAS, D				WRIGHT, PA; LEMOINE, NR; GORETZKI, PE; WYLLIE, FS; BOND, J; HUGHES, C; ROHER, HD; WILLIAMS, ED; WYNFORDTHOMAS, D			MUTATION OF THE P53-GENE IN A DIFFERENTIATED HUMAN THYROID-CARCINOMA CELL-LINE, BUT NOT IN PRIMARY THYROID-TUMORS	ONCOGENE			English	Note							P53 GENE; ENZYMATIC AMPLIFICATION; RAS ONCOGENE; LUNG-CANCER; CDNA CLONE; TRANSFORMATION; ANTIGEN; DNA; PROTEIN; GROWTH	The p53 gene has been implicated as a tumour suppressor, with mutations occurring in many carcinomas, such as colon, breast and lung. We have sequenced exons 5, 7 and 8 containing conserved gene regions in the only available differentiated thyroid follicular carcinoma cell line and found a mutation at position 273, Arg --> His, with no normal allele present. The same mutation was also present in DNA from the tumour of origin. However immunohistochemical analysis of 129 human thyroid tumours using a panel of p53 antibodies was unequivocally negative. Southern blotting in 20 cases failed to demonstrate any deletion or rearrangement, and direct genomic sequencing of 20 carcinomas showed normal DNA sequence for exons 5, 7 and 8. Thus p53 abnormalities may not be important in human thyroid carcinogenesis, in contrast to colon, breast and lung. However, the FTC 133 cell line was only established after 132 unsuccessful attempts with other differentiated thyroid follicular tumours. Since this line and the corresponding tumour of origin have a p53 mutation, we propose that p53 mutation may confer on thyroid follicular tumour cells the ability to grow in culture. This has potential applications for the future development of thyroid carcinoma cell lines.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOLEC ONCOL UNIT,LONDON W12 0HS,ENGLAND; UNIV DUSSELDORF,DEPT SURG,W-4000 DUSSELDORF 1,GERMANY	Cancer Research UK; Imperial College London; Heinrich Heine University Dusseldorf	WRIGHT, PA (corresponding author), UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL RES GRP,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							ALLISON J, 1981, BIOCHEM J, V199, P725, DOI 10.1042/bj1990725; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BENDAVID Y, 1988, ONCOGENE, V3, P179; Boenisch T, 1989, HDB IMMUNOCHEMICAL S, P13; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORETZKI PE, 1989, ANN ENDOCRINOL, V50, P145; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; WRIGHT PA, 1990, J PATHOL, V162, P99, DOI 10.1002/path.1711620203; WYNFORDTHOMAS D, 1985, EXP CELL RES, V159, P191, DOI 10.1016/S0014-4827(85)80048-3; WYNFORDTHOMAS D, 1990, MOL CELL BIOL, V10, P5365, DOI 10.1128/MCB.10.10.5365	32	111	112	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1693	1697						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923534				2022-12-28	WOS:A1991GX27400028
J	LEE, NG; YAMAGUCHI, J; SUBRAMANIAN, KN				LEE, NG; YAMAGUCHI, J; SUBRAMANIAN, KN			EFFICIENT REPLICATION OF PLASMIDS CONTAINING THE SV40 ORIGIN IN N-MYC OVEREXPRESSING HUMAN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article								Using test plasmids containing the SV40 origin, we found a wide spectrum of permissiveness to their replication in different human cell lines. N-myc overexpressing neuroblastoma cells were highly permissive. LA-N-1 neuroblastoma cells were the most permissive of all the cell lines that we tested including the homologous CV-1 or COS-1 monkey kidney cells. Other human cell lines expressing various amounts of c-myc, and the 293 cell line expressing adenovirus E1A and E1B exhibited intermediate levels of permissiveness. T24 and EJ bladder carcinoma cells, which do not express the myc genes, were nonpermissive. Transient expression of c-myc or N-myc from plasmid vectors resulted in a modest stimulation of replication. Replication of test plasmids containing different configurations of the SV40 origin region was activated by the myc proteins. The high efficiency of replication in LA-N-1 cells is due to a combination of reasons including the overproduction of N-myc, high efficiency of expression of the SV40 replication initiator protein large T antigen from a cotransfected expression plasmid (containing the T antigen gene under the RSV LTR control), and other unknown host cell replication stimulatory factors. Replication of test plasmids was not detected in N-myc or c-myc overexpressing cells when the T antigen expression plasmid was not provided, showing that the myc proteins cannot substitute for T antigen in SV40 DNA replication.	UNIV ILLINOIS, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	LEE, NG (corresponding author), UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60612 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035872] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 R01 GM 35872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; ALWINE JC, 1985, MOL CELL BIOL, V5, P1034, DOI 10.1128/MCB.5.5.1034; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERGSMA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P381, DOI 10.1073/pnas.79.2.381; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; CHANDRASEKHARAPPA SC, 1987, J VIROL, V61, P2973, DOI 10.1128/JVI.61.10.2973-2980.1987; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLASSON M, 1990, ONCOGENE, V5, P1371; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; Flint S. J, 1981, DNA TUMOR VIRUSES; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTZELL SW, 1984, P NATL ACAD SCI-BIOL, V81, P6335, DOI 10.1073/pnas.81.20.6335; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERTZ GZ, 1986, MOL CELL BIOL, V6, P3513, DOI 10.1128/MCB.6.10.3513; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1987, NUCLEIC ACIDS RES, V15, P4889, DOI 10.1093/nar/15.12.4889; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1984, CANCER CELL, V2, P539; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOZBOR D, 1984, CANCER RES, V44, P438; KUMAR R, 1988, MOL CELL BIOL, V8, P1509, DOI 10.1128/MCB.8.4.1509; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEBKOWSKI JS, 1985, NATURE, V317, P169, DOI 10.1038/317169a0; LEECHEN GJ, 1986, MOL CELL BIOL, V6, P3086, DOI 10.1128/MCB.6.9.3086; LEWIS ED, 1985, NATURE, V317, P172, DOI 10.1038/317172a0; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NISEN PD, 1986, CANCER RES, V46, P6217; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	60	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1161	1169						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650440				2022-12-28	WOS:A1991GV26000010
J	NISHIKURA, K; KIM, U; MURRAY, JM				NISHIKURA, K; KIM, U; MURRAY, JM			DIFFERENTIATION OF F9 CELLS IS INDEPENDENT OF C-MYC EXPRESSION	ONCOGENE			English	Article									UNIV PENN, SCH MED, DEPT ANAT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	NISHIKURA, K (corresponding author), WISTAR INST, 36TH & SPRUCE ST, PHILADELPHIA, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA046676] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA46676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KURKINEN M, 1983, NUCLEIC ACIDS RES, V11, P6199, DOI 10.1093/nar/11.18.6199; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHIKURA K, 1988, ONCOGENE, V2, P493; PETERSON MG, 1986, EUR J BIOCHEM, V160, P579, DOI 10.1111/j.1432-1033.1986.tb10077.x; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WAGNER RW, 1989, IN PRESS P NATL ACAD; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	54	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1990	5	7					981	988						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695728				2022-12-28	WOS:A1990DP41500005
J	APEL, TW; MAUTNER, J; POLACK, A; BORNKAMM, GW; EICK, D				APEL, TW; MAUTNER, J; POLACK, A; BORNKAMM, GW; EICK, D			2 ANTISENSE PROMOTERS IN THE IMMUNOGLOBULIN MU-SWITCH REGION DRIVE EXPRESSION OF C-MYC IN THE BURKITTS-LYMPHOMA CELL-LINE BL67	ONCOGENE			English	Article							HEAVY-CHAIN LOCUS; TRANSCRIPTIONAL ACTIVATION; EPSILON-TRANSCRIPTS; GENE; ENHANCER; INTERLEUKIN-4; SP1; TRANSFORMATION; TRANSLOCATION; MUTATIONS	In the Burkitt's lymphoma (BL) cell line BL67 the first exon of the c-myc gene is fused to the mu-switch region of the immunoglobulin heavy-chain gene (IgH). BL67 cells express IgH/c-myc hybrid RNAs which are initiated in the immunoglobulin locus, transcribed across the chromosomal breakpoint into the first exon of c-myc and spliced using the physiological splice donor and acceptor sites of the c-myc gene. We have isolated cDNAs of these hybrid RNAs and characterized the start points in the Ig heavy-chain gene. Two promoters were identified in the mu-switch region of BL67 cells which give rise to antisense transcription of the mu-gene. These promoters are also active in other BL cell lines, in B cells without Ig translocation and in a T-cell line. Both promoters co-localize with DNAase I-hypersensitive sites. HNF and HSW, in the mu-switch region. The structures of IgH/c-myc hybrid RNAs and of the corresponding promoters are described.	GSF MUNICH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,W-8000 MUNICH,GERMANY; UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,W-7800 FREIBURG,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Freiburg								ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FISCHER KD, 1990, NUCLEIC ACIDS RES, V18, P5685, DOI 10.1093/nar/18.19.5685; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GUBLER U, 1983, GENE, V25, P262; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; JULIUS MA, 1988, ONCOGENE, V2, P469; KAKKIS E, 1988, NUCLEIC ACIDS RES, V16, P77, DOI 10.1093/nar/16.1.77; KEMP DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7400, DOI 10.1073/pnas.77.12.7400; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPENCER CA, 1991, ADV CANCER RES, P1; SYMONDS G, 1989, ONCOGENE, V4, P285; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798	29	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1267	1271						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620543				2022-12-28	WOS:A1992HZ97100003
J	LAZARUS, P				LAZARUS, P			THE REGULATION OF TRANSLATION BY THE 5' UNTRANSLATED REGION OF XENOPUS C-MYC-I MESSENGER-RNA DURING EARLY DEVELOPMENT	ONCOGENE			English	Note							NONCODING REGION; EMBRYONIC-DEVELOPMENT; CELL-DIFFERENTIATION; SECONDARY STRUCTURE; MAMMALIAN-CELLS; DNA-REPLICATION; PROTO-ONCOGENE; EXPRESSION; LAEVIS; TRANSITION	The translational efficiency of chloramphenicol acetyltransferase (CAT) mRNA containing 5' untranslated region (UTR) sequences of Xenopus c-myc I mRNA was examined in the Xenopus oocyte and early embryo. In contrast to their reduced translation in the oocyte, CAT mRNAs containing 5' UTR sequences located between the c-myc I P0 and P2 promoters translate as efficiently as CAT mRNA controls when injected into early embryos. This pattern of differential regulation of c-myc I translation is similar to that observed for mouse c-myc 5' UTR-containing CAT transcripts during Xenopus oogenesis and early embryogenesis [Lazarus, P., Parkin, N. & Sonenberg, N. (1988). Oncogene, 3, 517-521]. Ooctye-specific translational inhibition was not observed for CAT mRNAs containing c-myc I 5' UTR sequences located 3' of the P2 promoter. No significant alteration in c-myc I 5' UTR/CAT mRNA stability was observed in the oocyte as compared with CAT mRNA controls. The significance of this promoter-dependent translational regulation with respect to c-myc expression and early Xenopus development is discussed.			LAZARUS, P (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA.							BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOURDRY J, 1988, DEVELOPMENT, V104, P631; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; LAZARUS P, 1988, ONCOGENE, V3, P517; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PRINCIPAUD F, 1991, NUCLEIC ACIDS RES, V19, P3081; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; SCHWEINFEST CW, 1988, MOL CELL BIOL, V8, P3080, DOI 10.1128/MCB.8.8.3080; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770	27	15	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1037	1041						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570150				2022-12-28	WOS:A1992HP64200028
J	KYPRIANOU, N; TAYLORPAPADIMITRIOU, J				KYPRIANOU, N; TAYLORPAPADIMITRIOU, J			ISOLATION OF AZATYROSINE-INDUCED REVERTANTS FROM RAS-TRANSFORMED HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article								Non-transformed revertant clones were isolated from the ras-transformed MTSV1-7 (ras) cell line, after treatment with the antibiotic azatyrosine. Azatyrosine significantly inhibited the growth of the ras-transformed cells but not of the normal MTSV1-7. After 7 days of azatyrosine treatment, approximately 30% of MTSV1-7 (ras) cells survived, and revertant cell lines were selected by random cloning. The azatyrosine-induced revertants (six clones) were considered non-transformed on the basis of (a) their substantially reduced ability to form colonies in soft agar, and (b) their inability to produce tumours in nude mice. Molecular analysis of the revertants revealed that each contains multiple copies of the v-H-ras gene and expresses high levels of v-H-ras mRNA, and all revertants sustain elevated levels of p21ras protein. Thus, the revertant phenotype induced by azatyrosine does not result from inactivation of v-H-ras oncogene or inhibition of its expression. In vivo guanine nucleotide binding to p21ras in the revertant cell lines demonstrated binding of both GTP and GDP, indicating that reversion to the non-transformed phenotype was not due to inability of p21ras to bind GTP. The expression of the human K-rev-1 gene, a known tumour-suppressor gene in ras-transformed NIH3T3 cells, was studied in the isolated azatyrosine revertants. All six revertants showed a significant increase in the K-rev-1 transcript levels compared with the ras-transformed MTSVI-7 cells. These results suggest that tumorigenic transformation of human mammary epithelial cells by v-H-ras may be influenced by the level of expression of the tumour-suppressor gene, K-rev-1.	IMPERIAL CANC RES FUND, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BOS JL, 1989, CANCER RES, V49, P4682; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HSIAO WLW, 1985, MOL CELL BIOL, V5, P1800, DOI 10.1128/MCB.5.7.1800; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NAKAYASU M, 1988, P NATL ACAD SCI USA, V85, P9066, DOI 10.1073/pnas.85.23.9066; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PATERSON H, 1989, CIBA F SYMP, V142, P134; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SAMID D, 1984, BIOCHEM BIOPH RES CO, V119, P21, DOI 10.1016/0006-291X(84)91612-7; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; TAYLORPAPADIMITRIOU J, 1977, J NATL CANCER I, V58, P1563, DOI 10.1093/jnci/58.6.1563; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YANAGIHARA K, 1990, ONCOGENE, V5, P1179	30	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					57	63						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741165				2022-12-28	WOS:A1992HC22700008
J	MORRISON, LE; BOEHMELT, G; BEUG, H; ENRIETTO, PJ				MORRISON, LE; BOEHMELT, G; BEUG, H; ENRIETTO, PJ			EXPRESSION OF V-REL IN A REPLICATION COMPETENT VIRUS - TRANSFORMATION AND BIOCHEMICAL-CHARACTERIZATION	ONCOGENE			English	Article							AVIAN RETICULOENDOTHELIOSIS VIRUS; NF-KAPPA-B; DNA-BINDING SUBUNIT; LYMPHOID-CELLS; C-REL; MONOCLONAL-ANTIBODIES; CHICKEN FIBROBLASTS; EMBRYO FIBROBLASTS; ONCOGENE ENCODES; LEUKEMIA VIRUSES	The avian reticuloendotheliosis virus strain T (REV-T) transforms bone marrow cells and may cause phenotypic changes in fibroblasts. Both events are thought to result from expression of the v-rel oncoprotein, a member of the NF-kappa-B family of transcription factors. Most REV stocks contain a cytopathic and immunosuppressive helper virus (REV-A) unrelated to standard avian retroviruses, and thus the degree to which v-rel expression alone contributes to the transformed phenotype in bone marrow cells and fibroblasts is complicated by helper virus expression. To gain a more accurate picture of how v-rel contributes to transformation, we have cloned the v-rel gene into a replication-competent avian retrovirus vector (RCAS) and have expressed it in both chick embryo fibroblasts (CEF) and bone marrow cells. Transfection of RCAS-rel into CEF readily produced a partially transformed phenotype, demonstrating that expression of the v-rel protein is sufficient for fibroblast transformation. The RCAS-rel virus also transformed bone marrow cells in vitro, but required culture conditions different from those normally required for transformation by REV-T. The v-rel protein expressed in transformed CEF was biochemically indistinguishable from that expressed in transformed bone marrow cells, being localized to the cytoplasm and the nucleus, and forming a complex with cellular proteins. We also demonstrate that the RCAS-rel-transformed hematopoietic cells exhibited a distinct differentiation phenotype.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BAUERLE PA, 1988, CELL, V53, P211; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CLH, 1982, J IMMUNOL, V129, P2580; CHEN CLH, 1986, J EXP MED, V164, P375, DOI 10.1084/jem.164.1.375; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; FUHRMANN U, 1989, GENE DEV, V3, P2027; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KABRUN N, 1990, P NATL ACAD SCI USA, V88, P1095; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORRISON LE, 1989, ONCOGENE, V4, P677; PALMERI S, 1982, VIROLOGY, V123, P209; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; RUSJHLOW AC, 1990, CELL, V59, P1165; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK S, 1988, ONCOGENE RES, V2, P102; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	44	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1657	1666						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1656369				2022-12-28	WOS:A1991GX27400022
J	SZPIRER, C; SZPIRER, J; RIVIERE, M; INGVARSSON, S; VENNSTROM, B; ISLAM, MQ; LEVAN, G				SZPIRER, C; SZPIRER, J; RIVIERE, M; INGVARSSON, S; VENNSTROM, B; ISLAM, MQ; LEVAN, G			CHROMOSOMAL ASSIGNMENT OF 5 CANCER-ASSOCIATED RAT GENES - 2 THYROID-HORMONE RECEPTOR (ERBA) GENES, 2 ERBB GENES AND THE RETINOBLASTOMA GENE	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; AVIAN ERYTHROBLASTOSIS VIRUS; SOMATIC-CELL HYBRIDIZATION; C-ERBA; NEU ONCOGENE; LUNG-CANCER; MALIGNANT MESOTHELIOMA; DNA-SEQUENCE; AMPLIFICATION	Using a panel of somatic cell hybrids that segregate rat chromosomes, the localization of five cancer-related rat genes was determined: (i) two thyroid receptor genes, THRA1/ERBA1 and THRB/ERBA2 on chromosomes 10 and 15 respectively, (ii) two ERBB genes, namely the epidermal growth factor gene (EGFR, also called ERBB1) and the ERBB2 gene (also designated neu) on chromosomes 14 and 10 respectively, and (iii) the retinoblastoma gene, RB1, on chromosome 15. The THRA1/ERBA1 and ERBB2/neu genes are thus included in a synteny group, conserved on rat chromosomes 10 and human chromosome arm 17q.	KAROLINSKA INST,DEPT MOLEC BIOL,S-10401 STOCKHOLM 60,SWEDEN; GOTHENBURG UNIV,DEPT GENET,S-40033 GOTHENBURG,SWEDEN	Karolinska Institutet; University of Gothenburg	SZPIRER, C (corresponding author), UNIV LIBRE BRUXELLES,DEPT BIOL MOLEC,RUE CHEVAUX 67,B-1640 RHODE ST GENESE,BELGIUM.		Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOUIZAR Z, 1989, CANCER RES, V49, P5199; BUCHBERG AM, 1989, GENETICS, V122, P153; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOBROVIC A, 1988, CANCER RES, V48, P682; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EHLEN T, 1990, ONCOGENE, V5, P219; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; FULCHIGNONILATAUD MC, 1990, CYTOGENET CELL GENET, V53, P172, DOI 10.1159/000132922; GEORGE DL, 1981, HUM GENET, V57, P138; GILL TJ, 1989, SCIENCE, V245, P269, DOI 10.1126/science.2665079; HAAG MM, 1984, CANCER RES, V44, P784; HAYMAN MJ, 1986, TRENDS GENET, V2, P260, DOI 10.1016/0168-9525(86)90259-3; HEIMER S, 1987, CANCER CYTOGENETICS; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISLAM MQ, 1987, HEREDITAS, V107, P127, DOI 10.1111/j.1601-5223.1987.tb00277.x; JACKSONGRUSBY LL, 1988, ENDOCRINOLOGY, V122, P2462, DOI 10.1210/endo-122-6-2462; KANOTANAKA K, 1982, INT J CANCER, V30, P495, DOI 10.1002/ijc.2910300417; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KNUDSON AG, 1976, NEW ENGL J MED, V295, P1120, DOI 10.1056/NEJM197611112952007; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOVI J, 1978, JNCI-J NATL CANCER I, V61, P495; LALLEY PA, 1989, CYTOGENET CELL GENET, V51, P503, DOI 10.1159/000132806; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEVAN G, 1975, HEREDITAS, V79, P161; Levan G., 1990, Genetic maps: locus of complex genomes.; LEVAN G, 1974, HEREDITAS, V77, P263; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; LIBBUS BL, 1988, CANCER RES, V48, P6455; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MATTEI MG, 1991, IN PRESS GENOMICS, V10; MCMAHON G, 1990, P NATL ACAD SCI USA, V87, P1104, DOI 10.1073/pnas.87.3.1104; MITELMAN F, 1971, HEREDITAS-GENETISK A, V69, P155; MITELMAN F, 1986, CANCER GENET CYTOGEN, V22, P95, DOI 10.1016/0165-4608(86)90168-8; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NADEAU JH, 1990, GENETIC VARIANTS STR, P506; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; POPESCU NC, 1988, CANCER RES, V48, P142; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEARLE AG, 1989, ANN HUM GENET, V53, P89, DOI 10.1111/j.1469-1809.1989.tb01777.x; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHEER D, 1985, ANN HUM GENET, V49, P167, DOI 10.1111/j.1469-1809.1985.tb01690.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STONE JC, 1989, GENOMICS, V5, P70, DOI 10.1016/0888-7543(89)90088-8; SUGIYAMA T, 1978, J NATL CANCER I, V60, P153, DOI 10.1093/jnci/60.1.153; SZPIRER C, 1989, CYTOGENET CELL GENET, V50, P23, DOI 10.1159/000132712; SZPIRER C, 1988, CURR TOP MICROBIOL, V137, P33; SZPIRER J, 1984, CYTOGENET CELL GENET, V38, P142, DOI 10.1159/000132047; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WIENER F, 1982, INT J CANCER, V29, P431, DOI 10.1002/ijc.2910290412; YAMAMOTO T, 1986, CANCER RES, V46, P414; YANGFENG TL, 1985, CYTOGENET CELL GENET, V40, P784; YOKOTA J, 1988, ONCOGENE, V2, P283; YOSHIDA MC, 1978, CYTOGENET CELL GENET, V22, P606, DOI 10.1159/000131034; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	79	13	13	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1319	1324						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679528				2022-12-28	WOS:A1991GX27200004
J	PRIBYL, LJ; WATSON, DK; SCHULZ, RA; PAPAS, TS				PRIBYL, LJ; WATSON, DK; SCHULZ, RA; PAPAS, TS			D-ELG, A MEMBER OF THE DROSOPHILA-ETS GENE FAMILY - SEQUENCE, EXPRESSION AND EVOLUTIONARY COMPARISON	ONCOGENE			English	Article								We have cloned a cDNA from the Drosophila elg gene, a new member of the ets family of genes. The D-elg gene is located at 97D on chromosome 3R and is expressed as a 2.0 kb RNA in the embryos, pupae and adults, with no detectable expression in third instar larvae. D-elg expression is observed in all cells of early stage embryos, prior to transcriptional activation of the zygotic genome, and is maintained throughout embryogenesis with no regional localization. The cDNA encodes a predicted protein of 15.4 kD that has an 86 amino acid sequence with 72% similarity to the carboxy terminal region of the Drosophila ets-2 gene. Comparison with all known ets genes allows us to define a minimal region required for assignment to the ets gene family.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	PRIBYL, LJ (corresponding author), NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA.							ANGERER LM, 1987, METHOD ENZYMOL, V152, P649; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHEN JH, 1990, ONCOGENE RES, V5, P277; CHEN JH, 1988, ONCOGENE RES, V2, P371; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1989, CURR TOP MICROBIOL, V147, P1; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; LINDSLEY DL, 1967, CARNEGIE I WASHINGTO, V627, P1; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; Pardue M L, 1975, Methods Cell Biol, V10, P1, DOI 10.1016/S0091-679X(08)60727-X; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; POGNONEC P, 1989, ONCOGENE, V4, P691; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SAINT R, 1988, NATURE, V334, P151, DOI 10.1038/334151a0; SCHULZ RA, 1989, DEV BIOL, V131, P515, DOI 10.1016/S0012-1606(89)80022-3; SCHULZ RA, 1991, DEV BIOL, V143, P206, DOI 10.1016/0012-1606(91)90068-E; SETH A, 1990, ONCOGENE, V5, P1761; SHILO BZ, 1987, TRENDS GENET, V3, P69, DOI 10.1016/0168-9525(87)90178-8; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1990, ADV AP BIOT, V6, P221; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1988, VIROLOGY, V167, P1, DOI 10.1016/0042-6822(88)90047-5; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; WATSON DK, 1990, ONCOGENESIS, P207	44	38	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1175	1183						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1713660				2022-12-28	WOS:A1991GV26000012
J	GIORDANO, A; MCCALL, C; WHYTE, P; FRANZA, BR				GIORDANO, A; MCCALL, C; WHYTE, P; FRANZA, BR			HUMAN CYCLIN-A AND THE RETINOBLASTOMA PROTEIN INTERACT WITH SIMILAR BUT DISTINGUISHABLE SEQUENCES IN THE ADENOVIRUS E1A-GENE PRODUCT	ONCOGENE			English	Note							LARGE T-ANTIGEN; E1A PROTEINS; FUNCTIONAL DOMAINS; SEPARATE DOMAINS; TERMINAL REGION; DNA-SYNTHESIS; CELL-CYCLE; M-PHASE; TRANSFORMATION; GROWTH	The adenovirus early region 1A (E1A) proteins associate with several cellular proteins in adenovirus infected or transformed cells. Recently, two of the cellular proteins that bind to E1A encoded proteins have been identified. p105 has been shown to be the product of the retinoblastoma tumor suppressing gene. p60 has been shown to be a human cyclin A. Previously studies have shown that E1A protein sequences encoded by conserved domains 1 and 2 are required for interactions with the retinoblastoma protein (pRB). We have demonstrated here that amino acids 30 to 60 and 121 to 127 within the E1A proteins are required for interaction with p60/cyclin A. These are the same sites within conserved domains 1 and 2 that are required for E1A protein association with pRB. However, the association of p60/cyclin A does not appear to require pRB. We also demonstrate that another cellular protein, 130K, interacts with E1A at essentially the same sites. It is interesting that mutations in these regions destroy the ability of E1A to function as an oncogene, thereby raising the possibility that interaction with several different cellular proteins may be needed for transformation by E1A.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center	GIORDANO, A (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; NEVINS JR, 1979, J VIROL, V32, P727, DOI 10.1128/JVI.32.3.727-733.1979; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SPECTOR DJ, 1978, J MOL BIOL, V126, P395, DOI 10.1016/0022-2836(78)90048-7; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	54	135	136	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					481	485						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1826347				2022-12-28	WOS:A1991FT34400021
J	CHEN, JM; HELLER, D; POON, B; KANG, L; WANG, LH				CHEN, JM; HELLER, D; POON, B; KANG, L; WANG, LH			THE PROTOONCOGENE C-ROS CODES FOR A TRANSMEMBRANE TYROSINE PROTEIN-KINASE SHARING SEQUENCE AND STRUCTURAL HOMOLOGY WITH SEVENLESS PROTEIN OF DROSOPHILA-MELANOGASTER	ONCOGENE			English	Article							AVIAN-SARCOMA VIRUS-UR2; HUMAN INSULIN-RECEPTOR; NUCLEOTIDE-SEQUENCE; TRANSFORMING SEQUENCE; GENETIC-STRUCTURE; C-ROS-1 GENE; SRC GENE; EXPRESSION; CDNA; PRODUCT	Our earlier study predicted that proto-oncogene c-ros codes for a receptor-like tyrosine protein kinase (TPK). To further understand its protein structure and physiological function, we have analysed its expression in various tissues of chicken and have isolated and sequenced cDNA clones containing the entire coding region of the gene. Confirming our earlier study, we found that kidney is the organ that expresses the highest level of c-ros mRNA, in addition, we found a lower level of expression in gonad, thymus, bursa and brain. A distinctive 8.3 kb c-ros mRNA is present in kidney. No detectable amount of c-ros mRNA was found in the rest of tissues examined. Nucleotide sequence of the c-ros cDNA predicts that it codes for a transmembrane (TM) TPK molecule of 2311 amino acids (aa). The extracellular domain consists of 1873 amino acids which share 20 to 43% homology with that of the Drosophila sevenless protein and TPK domains of the two genes have 58 to 74% homology. The extracellular domain containing 37 potential N-linked glycosylation sites is preceded by a 5' hydrophobic sequence resembling a typical signal peptide. An internal hydrophobic domain of 26 amino acids, the presumed transmembrane domain, is followed by a spacer sequence of 58 amino acids, a TPK domain of 270 amino acids and a carboxyl tail of 84 amino acids. Overall, our result indicates that c-ros codes for a glycosylated transmembrane TPK molecule which shares a remarkable sequence and structural homology with that of Drosophila sevenless protein.	CUNY MT SINAI SCH MED,DEPT MICROBIOL,ONE GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA29339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASLER K, 1988, CELL, V54, P299; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P1122; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DORAI T, 1990, MOL CELL BIOL, V10, P4068, DOI 10.1128/MCB.10.8.4068; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FELDMAN RA, 1982, J VIROL, V42, P228, DOI 10.1128/JVI.42.1.228-236.1982; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JONG SMJ, 1987, ONCOGENE RES, V1, P7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P6568, DOI 10.1073/pnas.83.17.6568; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PODELL SB, 1987, ONCOGENE, V2, P9; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA S, 1989, ONCOGENE RES, V5, P91; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LH, 1981, J VIROL, V40, P258, DOI 10.1128/JVI.40.1.258-267.1981; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	40	37	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					257	264						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900358				2022-12-28	WOS:A1991FZ13400011
J	ZIEGLER, SF; PLEIMAN, CM; PERLMUTTER, RM				ZIEGLER, SF; PLEIMAN, CM; PERLMUTTER, RM			STRUCTURE AND EXPRESSION OF THE MURINE HCK GENE	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; COLONY-STIMULATING FACTOR; NF-KAPPA-B; TERMINAL REGION; CD4 RECEPTOR; CELL-LINE; C-SRC; ACTIVATION; SEQUENCE; IDENTIFICATION	The hck gene encodes a src-like protein-tyrosine kinase that is expressed predominantly in cells of myeloid origin. To examine the molecular basis of hck expression, we have cloned and characterized the murine hck gene and defined a set of transcriptional regulatory sequences. Transcripts from the hck gene have heterogeneous 5' ends, with one major and several minor transcriptional start sites. The promoter lacks a TATA-like sequence, but has three Sp-1 and two AP-2 binding sites. Constructs containing 2.5 Kb or 0.6 Kb of sequence 5' to the major transcription start site were capable of directing expression of a reporter gene transfected into fibroblasts. Expression of the former construct, but not the latter, was inducible with LPS. We conclude that LPS induction of hck transcripts, previously demonstrated in myeloid cells, results from the presence of an LPS-responsive element located within the hck promoter.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	ZIEGLER, SF (corresponding author), IMMUNEX CORP,DEPT MOLEC BIOL,51 UNIV ST,SEATTLE,WA 98101, USA.							ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; COOKE M P, 1989, New Biologist, V1, P66; COOPER JA, 1988, PEPTIDES PROTEIN PHO; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GRAVALLESE EM, 1989, MOL CELL BIOL, V9, P3184, DOI 10.1128/MCB.9.8.3184; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8315; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INTRONA M, 1986, J IMMUNOL, V137, P2711; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KLEMSZ MJ, 1987, NUCLEIC ACIDS RES, V15, P9600, DOI 10.1093/nar/15.22.9600; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; METCALF D, 1985, LEUKEMIA RES, V9, P35, DOI 10.1016/0145-2126(85)90020-7; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NIGHIZAWA M, 1986, MOL CELL BIOL, V6, P511; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; PATEL M, 1990, ONCOGENE, V5, P201; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RAHMSDORF HJ, 1986, J IMMUNOL, V136, P2293; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHENONG GLC, 1987, P NATL ACAD SCI USA, V84, P199, DOI 10.1073/pnas.84.1.199; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TSUCHIYA M, 1987, EUR J BIOCHEM, V165, P7, DOI 10.1111/j.1432-1033.1987.tb11187.x; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; YI TL, 1989, ONCOGENE, V4, P1081; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	41	19	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					283	288						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1705689				2022-12-28	WOS:A1991FZ13400014
J	KIM, CM; VOGEL, J; JAY, G; RHIM, JS				KIM, CM; VOGEL, J; JAY, G; RHIM, JS			THE HIV TAT GENE TRANSFORMS HUMAN KERATINOCYTES	ONCOGENE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; EPIDERMAL LANGERHANS CELLS; NEOPLASTIC TRANSFORMATION; KAPOSIS-SARCOMA; VIRUS-INFECTION; AIDS; PSORIASIS; ONCOGENE; LESIONS; INVITRO	Skin disorders are frequently seen in patients with the acquired immune deficiency syndrome (AIDS). Since many of these cutaneous manifestations are accompanied by an early onset of epidermal hyperplasia, the keratinocyte is a candidate for infection by the human immunodeficiency virus (HIV). We now report that the HIV tat gene, under the control of the viral long terminal repeat (LTR), can efficiently transform human keratinocytes in culture. Our finding suggests that this activity of the tat gene may be responsible for the epidermal hyperplasia that accompanies psoriasis and precedes the development of squamous cell and basal cell carcinomas in AIDS patients.	JEROME H HOLLAND LAB,VIROL,ROCKVILLE,MD 20855; NCI,CELL & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jay, Gregory/C-6346-2013		NATIONAL CANCER INSTITUTE [R01CA053633] Funding Source: NIH RePORTER; NCI NIH HHS [CA53633] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; COCKERELL CJ, 1990, J AM ACAD DERMATOL, V22, P1260, DOI 10.1016/0190-9622(90)70172-E; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; JOHNSON TM, 1985, NEW ENGL J MED, V313, P1415; KANITAKIS J, 1989, AIDS RES HUM RETROV, V5, P293, DOI 10.1089/aid.1989.5.293; Kaplan M H, 1987, Am J Med, V82, P389, DOI 10.1016/0002-9343(87)90435-9; KAPLAN MK, 1987, J AM ACAD DERMATOL, V17, P485; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KRUEGER G, 1990, J INVEST DERMATOL, V94, P1355; LAZAR AP, 1987, CUTIS, V39, P347; MAHONEY SE, 1991, J CLIN INVEST, V88, P174, DOI 10.1172/JCI115275; MANN DL, 1988, J IMMUNOL, V141, P1131; MATHES BM, 1985, J AM ACAD DERMATOL, V13, P947, DOI 10.1016/S0190-9622(85)70243-5; NIEDT GW, 1985, ARCH PATHOL LAB MED, V109, P727; OVERLY WL, 1987, ANN INTERN MED, V106, P334, DOI 10.7326/0003-4819-106-2-334_1; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RHIM JS, 1989, ANTICANCER RES, V9, P1345; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1989, ONCOGENE, V4, P1403; SADICK NS, 1990, J AM ACAD DERMATOL, V22, P1270, DOI 10.1016/0190-9622(90)70173-F; SITZ KV, 1987, JAMA-J AM MED ASSOC, V257, P340, DOI 10.1001/jama.257.3.340; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; STEIGLEDER GK, 1985, Z HAUTKRANKHEITEN, V60, P1913; STINGL G, 1990, J AM ACAD DERMATOL, V22, P1210, DOI 10.1016/0190-9622(90)70165-E; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TINDALL B, 1989, J AM ACAD DERMATOL, V20, P587, DOI 10.1016/S0190-9622(89)70068-2; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WELCH K, 1984, JAMA-J AM MED ASSOC, V252, P1152, DOI 10.1001/jama.252.9.1152	33	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1525	1529						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630815				2022-12-28	WOS:A1992JE81300008
J	PICKSLEY, SM; MEEK, DW; LANE, DP				PICKSLEY, SM; MEEK, DW; LANE, DP			THE CONFORMATIONAL CHANGE OF A MURINE TEMPERATURE-SENSITIVE P53 PROTEIN IS INDEPENDENT OF A CHANGE IN PHOSPHORYLATION STATUS	ONCOGENE			English	Note							LARGE T-ANTIGEN; MONOCLONAL-ANTIBODY; SIMIAN VIRUS-40; CELL-CYCLE; ACTIVATING MUTATIONS; GENE-PRODUCT; MUTANT P53; 3T3 CELLS; TRANSFORMATION; ONCOGENE	Wild-type and mutant p53 proteins exhibit opposing activities in respectively suppressing and promoting tumour development. In a rat embryo fibroblast cell line transformed with a murine temperature-sensitive p53 gene, p53 functions as a oncogene at 37-degrees-C and as a tumour suppressor at 32-degrees-C [Michalovitz, D., Halevy, O. & Oren, M. (1990). Cell, 62, 671-6801. We have used this cell line to investigate whether this temperature-dependent switching of function involves changes in the phosphorylation of p53 protein. Monoclonal antibodies PAb246 and PAb240 were used to immunoprecipitate metabolically P-32-labelled p53 protein in the `wild-type' or mutant conformation from cells grown at 32-degrees-C or 37-degrees-C. Tryptic phosphopeptide maps were prepared from the isolated `wild-type' and mutant p53 proteins. At 32-degrees-C and 37-degrees-C phosphopeptide maps of the `wild-type' and mutant protein were identical. This demonstrates that the temperature-dependent conformation change, and associated functional change, in the p53 protein does not involve a change in the state of phosphorylation.	UNIV DUNDEE,CANC RES CAMPAIGN,CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,MRC,PHOSPHORYLAT GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARTEK J, 1990, ONCOGENE, V5, P893; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1987, ONCOGENE, V1, P453; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PATCHINSKY T, 1990, ONCOGENE, V5, P1071; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SOUSSI T, 1987, ONCOGENE, V1, P71; STURZBECHER HW, 1987, VIROLOGY, V160, P445; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	25	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1649	1651						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630825				2022-12-28	WOS:A1992JE81300023
J	HARPUR, AG; ANDRES, AC; ZIEMIECKI, A; ASTON, RR; WILKS, AF				HARPUR, AG; ANDRES, AC; ZIEMIECKI, A; ASTON, RR; WILKS, AF			JAK2, A 3RD MEMBER OF THE JAK FAMILY OF PROTEIN TYROSINE KINASES	ONCOGENE			English	Article							MEMBRANE GUANYLATE-CYCLASE; POLYMERASE CHAIN-REACTION; CATALYTIC DOMAINS; RECEPTOR; GENE; SEQUENCE; PHOSPHATASES; EXPRESSION; DIVERSITY; CELLS	We have isolated cDNA clones encoding a third, widely expressed, member of the JAK family of protein tyrosine kinases (PTKs). The anticipated amino acid sequence of JAK2 predicts the presence of two kinase-related domains, a feature characteristic of this family of PTKs. The structural similarity of JAK2 to the other members of this family extends towards their N-termini, beyond the two kinase-related domains, and reveals five further domains of substantial amino acid similarity. The C-terminal portion of one of these domains, the JH4 domain, bears an intriguing, albeit tenuous, similarity to the core element of the SH2 domain, whereas the remaining JAK homology domains do not appear to be a feature of other known proteins.	LUDWIG INST CANC RES,MELBOURNE TUMOR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; UNIV BERN,INST CLIN & EXPTL CANC RES,CH-3004 BERN,SWITZERLAND	Ludwig Institute for Cancer Research; University of Bern			Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSK SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; Maniatis T., 1982, MOL CLONING; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; PAWSON T, 1988, ONCOGENE, V3, P491; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WILKS A F, 1990, Progress in Growth Factor Research, V2, P97, DOI 10.1016/0955-2235(90)90026-G; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237	35	289	298	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1347	1353						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620548				2022-12-28	WOS:A1992HZ97100013
J	OUELLETTE, MM; CHEN, J; WRIGHT, WE; SHAY, JW				OUELLETTE, MM; CHEN, J; WRIGHT, WE; SHAY, JW			COMPLEXES CONTAINING THE RETINOBLASTOMA GENE-PRODUCT RECOGNIZE DIFFERENT DNA MOTIFS RELATED TO THE E2F-BINDING SITE	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; CELL-CYCLE; SUSCEPTIBILITY GENE; BINDING ACTIVITY; RB GENE; PHOSPHORYLATION; ACTIVATION; PROMOTER; SUPPRESSION	The retinoblastoma tumor-suppressor gene encodes a 105-kDa nuclear phosphoprotein (RB) that can associate with DRTF-1 and E2F. These two transcription factors can recognize the same DNA motif in the adenovirus E2A promoter and can bind to it by themselves or in association with RB. In the present report, we describe the use of CASTing (cyclic amplification and selection of targets) to determine the consensus binding site of RB-containing complexes. An anti-human RB antibody was used to isolate RB-containing complexes formed after mixing nuclear extracts obtained from human diploid fibroblasts with a pool of random oligonucleotides flanked with polymerase chain reaction (PCR) primers. After the immunoselection, the DNA was isolated, amplified, mixed with fresh nuclear extract and reselected. After six CASTing cycles, the DNA was cloned and sequenced. We found that the highest affinity motifs recognized by RB-containing complexes are related to the E2F/DRTF-I binding site and fall into three classes: TTTTCCCGCCAAAA, TTTTCCCGCCTTTTTT or TTTTCCCGCGCTTTTTT. Competition experiments revealed that these three classes are functionally equivalent to each other and to the E2F/DRTF-1 binding site in the adenovirus E2A promoter. Screening these sequences against a DNA database identified their presence in non-coding regions of many oncogenes, growth factor genes and in the RB gene itself.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA50195] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1990, CANCER SURV, V9, P529; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LASANTHA AB, 1991, CELL, V352, P249; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	31	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1075	1081						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1534398				2022-12-28	WOS:A1992HU64200004
J	MAZARS, GR; JEANTEUR, P; LYNCH, HT; LENOIR, G; THEILLET, C				MAZARS, GR; JEANTEUR, P; LYNCH, HT; LENOIR, G; THEILLET, C			NUCLEOTIDE-SEQUENCE POLYMORPHISM IN A HOTSPOT MUTATION REGION OF THE P53 GENE	ONCOGENE			English	Note							PROTEIN; CANCER	By screening for mutations in the p53 coding sequence by means of single-strand conformation polymorphism (SSCP) in a series of breast tumors we detected a novel polymorphism. This change in the SSCP pattern was detected in 6.2% of the tumor DNAs analysed and implied an A to G substitution at the last base of codon 213, thus representing a neutral change. First suspecting a somatic mutation we confirmed its presence in matched sets of DNAs from normal tissues. Extending our study to a series of 60 ovarian carcinomas and 70 healthy blood donors we noticed that this polymorphism represented only 3% and 2.6% respectively. We wondered if the difference in frequency in the breast cancer population might not be related to familial breast cancer and analysed 26 DNAs from patients showing predisposition to the disease. Two patients presented this polymorphism and one corresponding kindred was analysed, revealing a mendelian mode of transmission but no correlation with the cancer phenotype.	UNIV MONTPELLIER 2,BIOL MOLEC LAB,CNRS,URA 1191,F-34060 MONTPELLIER,FRANCE; UNIV LYON 1,INT AGCY RES CANC,F-69373 LYONS 2,FRANCE; CREIGHTON UNIV,DEPT PREVENT MED,OMAHA,NE 68178	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; World Health Organization; International Agency for Research on Cancer (IARC); Creighton University			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CARBONE D, 1991, ONCOGENE, V6, P1691; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MAZARS R, 1991, ONCOGENE, V6, P1685; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0	10	49	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					781	782						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565474				2022-12-28	WOS:A1992HQ68200023
J	NAKANO, T; GRAF, T				NAKANO, T; GRAF, T			IDENTIFICATION OF GENES DIFFERENTIALLY EXPRESSED IN 2 TYPES OF V-MYB-TRANSFORMED AVIAN MYELOMONOCYTIC CELLS	ONCOGENE			English	Article							AMINO-ACID-SEQUENCE; CALCIUM-BINDING PROTEINS; LEUKEMIA-VIRUS; C-MYB; GROWTH-FACTOR; ETS ONCOGENE; TARGET-CELLS; EGG-WHITE; DNA; TRANSCRIPTION	In an earlier study we found that different forms of the v-myb oncogene transform myeloid cells which resemble either monoblasts [when v-myb of avian myeloblastosis virus (AMV) was used] or promyelocytes [when a point mutant in v-myb of AMV was used; Introna, M., Golay, J., Frampton J., Nakano, T., Ness, S.A. & Graf, T. (1990). Cell, 63, 1287-1297]. In the present study we have searched for genes expressed in AMV mutant-transformed promyelocytes that are not expressed in AMV-transformed monoblasts using a differential screening approach. Eight different genes were identified among more than 500 differentially expressed clones. The most abundant of these was the previously identified myb-regulated mim-1 gene. The others were found to encode a small calcium-binding (MRP-like) protein; the p20K protein; goose-type lysozyme; a ribonuclease A/angiogenin-related protein; and three non-identified proteins. Although these genes appear to be rather lineage restricted, their expression varied in different subtypes of transformed myelomonocytic cells, and only two of them (goose lysozyme and ribonuclease) showed a similar expression pattern in normal promyelocytes and macrophages, suggesting an aberrant gene regulation in the transformed cells. Co-transfection experiments of a reporter construct containing the promoter of the ribonuclease A-related gene indicated that this promoter is regulated by the v-Myb oncoprotein without the involvement of Myb-specific binding sequences.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARTLETT JA, 1986, BIOTECHNIQUES, V4, P208; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEINTEMA JJ, 1985, EUR J BIOCHEM, V153, P305, DOI 10.1111/j.1432-1033.1985.tb09301.x; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BOYLE WJ, 1984, P NATL ACAD SCI USA, V84, P6795; CARSANA A, 1988, NUCLEIC ACIDS RES, V16, P5491, DOI 10.1093/nar/16.12.5491; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUYNH TV, 1985, DNA CLONING PRACTICA, V1; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; KUWANO R, 1986, FEBS LETT, V202, P87; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; MOSCOVICI C, 1982, ADV VIRAL ONCOLOGY O, V1; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNN M, 1989, NATURE, V306, P391; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; QUEVA C, 1992, IN PRESS DEVELOPMENT; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LABORATO; SHOENTGEN F, 1982, EUR J BIOCHEM, V123, P489; SIMPSON RJ, 1980, BIOCHEMISTRY-US, V19, P1814, DOI 10.1021/bi00550a013; SIMPSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V744, P349, DOI 10.1016/0167-4838(83)90210-8; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	48	32	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					527	534						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549365				2022-12-28	WOS:A1992HK00500019
J	CHARLES, CH; ABLER, AS; LAU, LF				CHARLES, CH; ABLER, AS; LAU, LF			CDNA SEQUENCE OF A GROWTH FACTOR-INDUCIBLE IMMEDIATE EARLY GENE AND CHARACTERIZATION OF ITS ENCODED PROTEIN	ONCOGENE			English	Note							EXPRESSION; CELLS; SET	We report the cDNA sequence of 3CH134, an immediate early gene whose transcription is rapidly and transiently stimulated by serum growth factors. 3CH134 encodes a 367 amino acid protein that does not share significant sequence similarity with any known protein. 3CH134 is inducible through multiple signal transduction pathways, and in the adult mouse is expressed predominantly in the lung. Using affinity-purified antibodies, we have identified the 3CH134 protein in serum-stimulated Balb/c 3T3 cells and determined that it has a short half-life.	UNIV ILLINOIS,COLL MED,DEPT GENET,808 S WOOD ST,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [R01 CA46565] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115	15	239	247	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					187	190						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741163				2022-12-28	WOS:A1992HC22700025
J	LIU, C; PARK, M; TSAO, MS				LIU, C; PARK, M; TSAO, MS			OVEREXPRESSION OF C-MET PROTOONCOGENE BUT NOT EPIDERMAL GROWTH-FACTOR RECEPTOR OR C-ERBB-2 IN PRIMARY HUMAN COLORECTAL CARCINOMAS	ONCOGENE			English	Note							HUMAN GASTRIC-CARCINOMA; HUMAN-BREAST CANCER; EGF RECEPTOR; NEU ONCOGENE; TYROSINE KINASE; ENHANCED EXPRESSION; GENE AMPLIFICATION; HUMAN-COLON; CELL-LINE; PHOSPHORYLATION	The epidermal growth factor receptor (EGFR) and the protein products of c-erbB-2 and c-met proto-oncogenes belong to a family of growth factor receptors with tyrosine kinase activity. In human colonic carcinomas, the expression of the EGFR and c-erbB-2 have been studied at the protein level only, while c-met expression has not been reported. We have examined the mRNA expression of these genes in human normal colorectal mucosa and primary carcinomas. The results demonstrate that the normal mucosa shows highly variable levels of EGFR and c-erbB-2 mRNAs, but expresses consistently low amounts of c-met mRNA. Colorectal carcinomas did not express significantly higher levels of the EGFR and c-erbB-2 mRNAs than the normal mucosa. In contrast, c-met was consistently and significantly overexpressed (mean sixfold) in carcinomas as compared with normal mucosa. Seventy percent of paired normal-tumor specimens showed a tumor to normal c-met mRNA ratio of greater than 4. The expression of c-met mRNA was also enhanced in the adenomas, suggesting that overexpression of this proto-oncogene may have mechanistic significance in the early stages of human colorectal carcinogenesis.	MONTREAL GEN HOSP,DEPT PATHOL,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3G 1A4,QUEBEC,CANADA; LUDWIG INST CANC RES,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; McGill University; Ludwig Institute for Cancer Research			Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; 				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERGER MS, 1988, CANCER RES, V48, P1238; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; COHEN JA, 1989, ONCOGENE, V4, P81; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEMILIA J, 1989, ONCOGENE, V4, P1233; Dukes CE, 1940, J PATHOL BACTERIOL, V50, P527, DOI 10.1002/path.1700500314; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLEY GG, 1989, ONCOGENE, V4, P963; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GREEN MR, 1985, J INVEST DERMATOL, V85, P239, DOI 10.1111/1523-1747.ep12276708; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; KAHN P, 1986, ONCOGENES GROWTH FAC; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KORETZ K, 1990, VIRCHOWS ARCH A, V416, P343, DOI 10.1007/BF01605295; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MAGUIRE HC, 1989, J INVEST DERMATOL, V89, P786; MCCLARE JT, 1988, STATISTICS; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; NANNEY LB, 1984, J INVEST DERMATOL, V82, P165, DOI 10.1111/1523-1747.ep12259731; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PARK M, 1986, CELL, V45, P894; PFEIFFER A, 1990, GASTROENTEROLOGY, V98, P961, DOI 10.1016/0016-5085(90)90020-2; ROTHBAUER E, 1989, KLIN WOCHENSCHR, V67, P518, DOI 10.1007/BF01719776; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TSAO MS, 1989, MOL CARCINOGEN, V2, P144, DOI 10.1002/mc.2940020307; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEIDNER U, 1990, CANCER RES, V50, P4504; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, CANCER RES, V46, P414; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YASUI W, 1988, INT J CANCER, V41, P211, DOI 10.1002/ijc.2910410209; YASUI W, 1988, CANCER RES, V48, P137; YONEMURA Y, 1989, ONCOLOGY, V46, P158	44	154	173	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					181	185						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741162				2022-12-28	WOS:A1992HC22700024
J	MOROY, T; VERBEEK, S; MA, A; ACHACOSO, P; BERNS, A; ALT, F				MOROY, T; VERBEEK, S; MA, A; ACHACOSO, P; BERNS, A; ALT, F			E-MU N-MYC AND E-MU L-MYC COOPERATE WITH E-MU PIM-1 TO GENERATE LYMPHOID TUMORS AT HIGH-FREQUENCY IN DOUBLE-TRANSGENIC MICE	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; C-MYC; NEOPLASTIC TRANSFORMATION; EMBRYO FIBROBLASTS; CELL LYMPHOMAS; T DEVELOPMENT; EXPRESSION; ENHANCER; ONCOGENE; GENES	Transgenic mice that contain the L-myc gene under the control of the immunoglobulin heavy-chain enhancer (E-mu) express the transgene preferentially in T cells, develop thymic hyperplasia and are predisposed to T-cell lymphomas. An analogous E-mu N-myc transgene is expressed preferentially in pre-B and B cells and provokes the development of B-cell neoplasias. Animals with an E-mu pim-1 construct express the transgene in both B and T cells, but succumb to T-cell lymphomas. Complementation of the E-mu N- and L-myc transgenic mice by breeding with E-mu pim-1 animals leads to much more rapid development and a dramatically higher incidence of lymphoid malignancies, but the lineage specificity prescribed by the E-mu N- and L-myc transgenes is maintained. The different oncogenic potential of myc genes is illustrated by the average latency period of tumor manifestation in double transgenics. Whereas c-myc/pim-1 animals develop pre-B-cell leukemia prenatally, the mean latency period for N-myc/pim-1 and L-myc/pim-1 mice is 36 and 94 days respectively. The N- and L-myc transgenes are expressed at high levels in tumors from double transgenic mice, but expression of the endogenous c- and N-myc genes is undetectable, directly implicating the myc transgenes in the tumor formation process.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,701 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,DEPT BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University; Netherlands Cancer Institute; University of Amsterdam			Moroy, Tarik/D-9923-2011		NCI NIH HHS [CA23767, CA42335] Funding Source: Medline; NIAID NIH HHS [AI 20047] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042335, P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, R01AI020047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; COLLUM R, 1990, CANCER CELLS, V3, P69; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DEPINHO R, 1987, GENE DEV, V8, P1311; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; HOGAN B, 1986, MANIPULATION MOUSE E; IWAMOTO A, 1987, J EXP MED, V165, P591, DOI 10.1084/jem.165.3.591; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; MA A, 1991, MOL CELL BIOL, V11, P440, DOI 10.1128/MCB.11.1.440; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MANIATIS T, 1983, MOL CLONING; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; NISEN PD, 1986, CANCER RES, V46, P6217; PERRY RP, 1980, P NATL ACAD SCI-BIOL, V77, P1937, DOI 10.1073/pnas.77.4.1937; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7202; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; YANCOPOULOS G, 1984, P NATL ACAD SCI USA, V82, P5455; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	39	94	96	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1941	1948						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658705				2022-12-28	WOS:A1991GX11900001
J	BAI, WL; SINGH, B; KARSHIN, WL; SHONK, RA; ARLINGHAUS, RB				BAI, WL; SINGH, B; KARSHIN, WL; SHONK, RA; ARLINGHAUS, RB			PHOSPHORYLATION OF V-MOS SER 47 BY THE MITOTIC FORM OF P34CDC2	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; MATURATION-PROMOTING FACTOR; CELL-CYCLE CONTROL; ONCOGENE PRODUCT; NUCLEOTIDE-SEQUENCE; MEIOTIC MATURATION; XENOPUS HOMOLOG; GENE; OOCYTES	P85gag-mos is hyperphosphorylated during mitosis in normal rat kidney (NRK) cells transformed by Moloney murine sarcoma virus ts110. We now report that P85gag-mos is phosphorylated in vitro by the mitotic form of the cdc2 kinase (p34cdc2, known as M-phase kinase) derived from virus-transformed cells. The major site of P85gag-mos phosphorylation by the M-phase kinase in vitro lies within the amino-terminal portion of the viral mos protein sequence spanning residues 45-53, as determined by tryptic peptide mapping. A synthetic peptide corresponding to amino acids 37-55 of v-mos was specifically phosphorylated by the M-phase kinase, whereas v-mos peptides either lacking Ser 47 or substituted with Ala at residue 47 were not phosphorylated. Protein sequencing analyses established that the M-phase kinase specifically phosphorylates Ser 47. Tryptic phosphopeptide mapping of the in vivo-phosphorylated gag-mos protein from mitotic cells indicated that the 45-53 v-mos region was also phosphorylated within mitotic cells. These findings demonstrate that the M-phase kinase phosphorylates the viral mos protein at Ser 47. These results were unexpected in view of earlier reports regarding cdc2 kinase activation/stabilization by the c-mos kinase in maturing oocytes.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NCI NIH HHS [CA16672, CA45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAGDADI F, 1990, ONCOGENE, V5, P1251; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HERZOG NK, 1988, ONCOGENE, V3, P225; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIU JX, 1990, ONCOGENE, V5, P171; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; PAULES RS, 1988, ONCOGENE, V3, P59; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SINGH B, 1986, VIROLOGY, V152, P502, DOI 10.1016/0042-6822(86)90156-X; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WEINMASTER G, 1983, J VIROL, V46, P29, DOI 10.1128/JVI.46.1.29-41.1983; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHAO X, 1990, ONCOGENE, V5, P1727	48	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1715	1723						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1833715				2022-12-28	WOS:A1991GX11800001
J	PEREGO, R; RON, D; KRUH, GD				PEREGO, R; RON, D; KRUH, GD			ARG ENCODES A WIDELY EXPRESSED 145 KDA PROTEIN TYROSINE KINASE	ONCOGENE			English	Note							CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; PHILADELPHIA-CHROMOSOME; GENE-PRODUCT; ONCOGENE; PHOSPHORYLATION; TRANSDUCTION; ACTIVATION; CELLS; K562	Arg encodes a protein highly related to the c-abl gene product with regard to overall structural architecture as well as the amino acid sequences of their tyrosine kinase, and src-homologous 2 and 3 domains. The two genes form a distinct subfamily of non-receptor tyrosine kinases and share a common homolog in Drosophila. In this study we characterized the arg protein product by expression of its coding sequence in bacteria. The recombinant arg protein was detected in bacterial lysates by immunoblotting and exhibited a molecular mass of 145 kDa. Phosphoamino acid analysis of the arg gene product following an immune complex autokinase reaction revealed tyrosine phosphorylation and established that it possesses tyrosine kinase activity. High-titer antibody capable of detecting the cellular arg gene product was generated by expressing a carboxy-terminal segment of arg in bacteria and using the recombinant protein as an immunogen. The arg gene product was identified in cultured human cells as a 145 kDa protein that exhibited autokinase activity. Analysis of arg expression in murine tissues revealed that arg, like c-abl, is widely expressed, further extending the similarities between the two genes, and suggesting that arg probably functions in signaling pathways fundamental to many cell types.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV MILAN,INST GEN PATHOL,I-20122 MILAN,ITALY; CNR,CTR RES CELL PATHOL,I-20133 MILAN,ITALY; TECHNION ISRAEL INST TECHNOL,FAC BIOL,IL-32000 HAIFA,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Technion Israel Institute of Technology								BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAWSON T, 1988, ONCOGENE, V3, P491; PONTICELLI AS, 1982, CELL, V3, P953; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V21, P129, DOI 10.1016/0165-4608(86)90039-7; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANETTEN ER, 1989, CELL, V4, P669; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG JYJ, 1982, J BIOL CHEM, V257, P13181; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WITTE ON, 1979, NATURE, V281, P396, DOI 10.1038/281396a0	24	44	45	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1899	1902						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923513				2022-12-28	WOS:A1991GX11800025
J	HAMER, PJ; LAVECCHIO, J; NG, S; DELELLIS, R; WOLFE, H; CARNEY, WP				HAMER, PJ; LAVECCHIO, J; NG, S; DELELLIS, R; WOLFE, H; CARNEY, WP			ACTIVATED VAL-12 RAS P21 IN CELL-CULTURE FLUIDS AND MOUSE PLASMA	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; MONOCLONAL-ANTIBODIES; HUMAN CARCINOMAS; POINT MUTATIONS; GENE-MUTATIONS; PROTO-ONCOGENE; HUMAN-COLON; HUMAN-LUNG; ADENOCARCINOMA; EXPRESSION	Activation of ras oncogenes has been associated with a variety of cancers as well as their precursor lesions. Ras proteins activated by substitutions at amino acid positions 12, 13 or 61 have not been identified in normal tissues and therefore their detection may have clinical value. In this study our objective was to determine whether activated ras proteins could be released into the extracellular environment. To test this hypothesis, we used ras-transformed NIH3T3 cells that express an activated p21 containing valine (Val-12 p21) at position 12 instead of the normal glycine (Gly-12 p21) and a monoclonal antibody (mAb) designated DWP that is specific for the activated Val-12 ras proteins. Culture fluids collected from NIH3T3 cells transformed by the activated Val-12 p21 were shown, using mAb DWP in a sandwich ELISA format, to contain the activated Val-12 p21. In contrast, culture fluids from non-Val-12-containing cells were unreactive with mAb DWP. PSV-LM-EJ cells which overexpress the activated Val-12 p21 were injected subcutaneously (SQ) into nude mice to produce tumors. At the time of gross tumor appearance (14-21 days after tumor cell inoculation), plasma was collected from the PSV-LM-EJ tumor-bearing mice as well as from a series of control mice. Employing mAb DWP as a detection reagent in the sandwich ELISA format, we were able to detect the Val-12 p21 in the plasma of the PSV-LM-EJ tumor-bearing mice. Activated Val-12 p21 was not present in the plasma of non-tumor-bearing mice, or in the plasma of mice bearing SQ tumors composed of non-Val-12 p21 ras-transformed cells. This report is the first description of an activated ras protein (Val-12 p21) in the plasma of tumor-bearing mice and demonstrates that the results of the Val-12 p21-specific ELISA could be validated with Western blot format.	DUPONT CO,DEPT MED PROD,BIOTECHNOL SYST,331 TREBLE COVE RD,N BILLERICA,MA 01862; TUFTS NEW ENGLAND MED CTR,DEPT PATHOL,BOSTON,MA 02115	DuPont; Tufts Medical Center								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; BRANDTRAUF PW, 1988, BRIT J IND MED, V45, P689; BRANDTRAUF PW, 1991, IN PRESS J SOC OCCUP; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARNEY WP, 1986, J CELL BIOCHEM, V32, P207, DOI 10.1002/jcb.240320307; CARNEY WP, 1986, P NATL ACAD SCI USA, V83, P7485, DOI 10.1073/pnas.83.19.7485; CARNEY WP, 1989, HUMAN TUMOR ANTIGENS, P53; CARUSO A, 1986, INT J CANCER, V38, P587, DOI 10.1002/ijc.2910380420; CLAIR T, 1987, CANCER RES, V47, P5290; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GREENBERG PL, 1979, AM J MED, V66, P951, DOI 10.1016/0002-9343(79)90450-9; HAMER PJ, 1990, HYBRIDOMA, V9, P573, DOI 10.1089/hyb.1990.9.573; KAKKANAS A, 1990, In Vivo (Attiki), V4, P115; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; LAVECCHIO JA, 1990, ONCOGENE, V5, P1173; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; NIMAN HL, 1985, P NATL ACAD SCI USA, V82, P7924, DOI 10.1073/pnas.82.23.7924; PADUA RA, 1988, LEUKEMIA, V2, P503; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TOKSOZ D, 1987, ONCOGENE, V1, P409; UPDYKE TV, 1984, J IMMUNOL METHODS, V73, P83, DOI 10.1016/0022-1759(84)90034-6; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YANEZ L, 1987, ONCOGENE, V1, P315	35	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1609	1615						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923528				2022-12-28	WOS:A1991GX27400016
J	TERMAN, BI; CARRION, ME; KOVACS, E; RASMUSSEN, BA; EDDY, RL; SHOWS, TB				TERMAN, BI; CARRION, ME; KOVACS, E; RASMUSSEN, BA; EDDY, RL; SHOWS, TB			IDENTIFICATION OF A NEW ENDOTHELIAL-CELL GROWTH-FACTOR RECEPTOR TYROSINE KINASE	ONCOGENE			English	Note							PDGF RECEPTOR; CLONING; FAMILY; RECOGNITION; EXPRESSION; SEQUENCES; MITOGEN; REGION; GENES	A new growth factor receptor tyrosine kinase (RTK) gene (designated KDR) has been cloned from a human endothelial cell cDNA library. The gene was identified using the polymerase chain reaction (PCR) and degenerate oligonucleotide primers complementary to conserved tyrosine kinase domains that flank the insert domain, characteristic of known type Ill RTKs [e.g. platelet-derived growth factor receptor (PDGF-R), colony-stimulating-1 receptor (CSF-1-R), fibroblast growth factor receptor (FGF-R) and ckit]. The DNA product from PCR was then used as a probe to isolate larger DNA segments encoding the receptor from the cDNA library. The predicted amino acid sequence contained multiple characteristics (i.e. an ATP-binding site, a membrane-spanning region, split tyrosine kinase regions) typical of a type III receptor tyrosine kinase. The KDR gene is expressed as a 7.0 kb transcript, and is localized to human chromosome 4.	NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263	Roswell Park Cancer Institute	TERMAN, BI (corresponding author), AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005196] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000333] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00333] Funding Source: Medline; NICHD NIH HHS [HD05196] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; FOLKMAN J, 1986, CANCER RES, V46, P467; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; RUTA M, 1988, ONCOGENE, V3, P9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; SHOWS TB, 1983, ISOZYMES CURRENT TOP; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1988, CELL, V61, P203	27	481	562	1	19	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1677	1683						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1656371				2022-12-28	WOS:A1991GX27400025
J	KAUFFMAN, MG; ROSE, PA; KELLY, TJ				KAUFFMAN, MG; ROSE, PA; KELLY, TJ			MUTATIONS IN THE THYMIDINE KINASE GENE THAT ALLOW EXPRESSION OF THE ENZYME IN QUIESCENT (G0) CELLS	ONCOGENE			English	Article							SERUM-STIMULATED CELLS; MESSENGER-RNA; MOLECULAR-CLONING; NUCLEAR ANTIGEN; S-PHASE; CYCLE; PROMOTER; PROGRESSION; SEQUENCE; LEVEL	Thymidine kinase (TK) is a nucleotide salvage pathway enzyme whose activity is highly dependent on the growth state and cell cycle phase of a cell. Cells in the resting or quiescent (G0) phase express very low levels of TK mRNA and protein. When quiescent cells are stimulated to enter the cell cycle by the addition of serum, TK mRNA, activity and polypeptide increase coordinately after about 10-15 h, at the beginning of S phase. When growth-independent heterologous promoters are substituted for the natural TK promoter, TK mRNA can be expressed in quiescent cells. Despite the presence of TK mRNA in such G0 cells, there is little expression of TK polypeptide; the normal increase in enzyme at S phase is observed following serum stimulation. Deletion of the introns and 3' untranslated sequences does not affect the expression of the TK gene in serum stimulation experiments. In contrast, deletion of the C-terminal 40 amino acids or fusion of a small segment of a beta-galactosidase to the C-terminus overcomes the block to expression of the TK polypeptide in G0 cells. These C-terminal alterations are the same as those which lead to constitutive expression of TK during the cell cycle of proliferating cells, suggesting that mechanisms which control the levels of TK in cycling cells may also operate in quiescent cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309, R01GM042780] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42780-02, 5-T32-GM-07309-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BRADSHAW HD, 1983, P NATL ACAD SCI-BIOL, V80, P5588, DOI 10.1073/pnas.80.18.5588; CHEETHAM BF, 1982, J CELL PHYSIOL, V110, P114, DOI 10.1002/jcp.1041100203; CHEETHAM BF, 1982, MOL CELL BIOL, V2, P1295, DOI 10.1128/MCB.2.10.1295; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; FEDER JN, 1989, J BIOL CHEM, V264, P20583; GROSS MK, 1987, DEV BIOL, V122, P439, DOI 10.1016/0012-1606(87)90308-3; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; GROUDINE M, 1984, NUCLEIC ACIDS RES, V12, P1427, DOI 10.1093/nar/12.3.1427; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; ITO M, 1990, J BIOL CHEM, V265, P6954; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KAUFFMAN MG, 1990, ANAL BIOCHEM, V191, P41, DOI 10.1016/0003-2697(90)90384-L; KAUFFMAN MG, 1991, IN PRESS MOL CELL BI, V11; KIT S, 1965, J BIOL CHEM, V240, P2565; KREIDBERG JA, 1986, MOL CELL BIOL, V6, P2903, DOI 10.1128/MCB.6.8.2903; KWOH TJ, 1984, NUCLEIC ACIDS RES, V23, P39595; LEWIS JA, 1986, MOL CELL BIOL, V6, P2262, DOI 10.1128/MCB.6.6.2262; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; MERRILL GF, 1984, MOL CELL BIOL, V4, P1769, DOI 10.1128/MCB.4.9.1769; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; PEDEN KWC, 1989, EXP CELL RES, V185, P60, DOI 10.1016/0014-4827(89)90037-2; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SCHLOSSER CA, 1981, P NATL ACAD SCI USA, V74, P5463; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016	34	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1427	1435						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1909430				2022-12-28	WOS:A1991GX27200020
J	KAHN, SM; JIANG, W; CULBERTSON, TA; WEINSTEIN, IB; WILLIAMS, GM; TOMITA, N; RONAI, Z				KAHN, SM; JIANG, W; CULBERTSON, TA; WEINSTEIN, IB; WILLIAMS, GM; TOMITA, N; RONAI, Z			RAPID AND SENSITIVE NONRADIOACTIVE DETECTION OF MUTANT K-RAS GENES VIA ENRICHED PCR AMPLIFICATION	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; POINT MUTATIONS; HUMAN CANCER; ONCOGENES; ACTIVATION; DIAGNOSIS; ADENOCARCINOMA; CARCINOGENESIS; TUMORIGENESIS; ANTIONCOGENES	We have developed a rapid and highly sensitive nonradioactive method for the detection of a mutant codon 12 human c-K-ras allele in the presence of as many as 10(4) copies of the wild type codon 12 allele. This sensitivity is achieved by selective polymerase chain reaction (PCR) amplification of mutant K-ras gene sequences employing a two stage procedure. The first stage entails the amplification of both K-ras mutant and wild type codon 12 sequences, followed by a selective restriction enzyme digestion of only wild type sequences. The second stage involves a subsequent amplification of undigested amplified fragments, enriched in mutant codon 12 sequences. These products are subject to restriction length polymorphism analysis for the detection of point mutations at codon 12. This technique is rapid, nonradioactive, and eliminates the need for either oligonucleotide hybridization or DNA sequencing. Variations of this selective amplification procedure may prove promising for the detection of specific point mutations in heterogenous cell populations.	COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032; AMER HLTH FDN,MOLEC CARCINOGENESIS PROGRAM,VALHALLA,NY 10595; AMER HLTH FDN,DIV PATHOL & TOXICOL,VALHALLA,NY 10595	Columbia University; Columbia University; American Health Foundation; American Health Foundation	RONAI, Z (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032, USA.			Jiang, Wei/0000-0002-2309-9571	NATIONAL CANCER INSTITUTE [P01CA021111, P30CA017613, R01CA039545] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39545, CA021111, CA17613] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; BOS JL, 1988, MUTAT RES, V195, P225; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; JIANG W, 1989, ONCOGENE, V4, P923; KAHN SM, 1990, AMPLIFICATIONS, V4, P22; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUMAR R, 1989, CANCER CEL, V7, P151; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUMAR R, 1988, ONCOGENE, V3, P647; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; MCCORMICK F, 1989, CANCER CELL-MON REV, V1, P56; MIYAOTO S, 1990, MOL CELL BIOL, V19, P1593; NASSAL M, 1990, NUCLEIC ACIDS RES, V18, P3077, DOI 10.1093/nar/18.10.3077; PERUCHO M, 1989, CANCER CEL, V7, P137; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINSTEIN IB, 1988, CANCER RES, V48, P4135	29	205	223	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1079	1083						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1676837				2022-12-28	WOS:A1991GU62200027
J	CROOK, T; WREDE, D; VOUSDEN, KH				CROOK, T; WREDE, D; VOUSDEN, KH			P53 POINT MUTATION IN HPV NEGATIVE HUMAN CERVICAL-CARCINOMA CELL-LINES	ONCOGENE			English	Note							HUMAN FORESKIN KERATINOCYTES; HUMAN PAPILLOMAVIRUS TYPE-16; EARLY GENES; CANCER; IMMORTALIZATION; TRANSCRIPTION; ASSOCIATION; EXPRESSION; SEQUENCES; DNAS	Clinical and experimental evidence is consistent with a key role for transforming human papilloma viruses (HPVs) in the aetiology of anogenital carcinoma. Cervical carcinoma does, however, occasionally occur in the absence of HPV sequences (Riou et al., 1990). We have used a direct cDNA/PCR sequencing protocol to analyse the sequence of p53 mRNA expressed by HPV positive and negative cervical carcinoma cell lines. Six cell lines which contain HPV sequences express p53 mRNA which has wild-type sequence throughout conserved boxes 2, 3, 4 and 5. The two HPV negative cell lines (C33a and HT3) express mutant p53 mRNA. In each case the mutation. occurs in an evolutionarily conserved amino acid. Our data suggest that loss of wild-type p53 function is important in development of cervical carcinoma, and that this might be achieved either by mutation within the p53 gene or the presence of a virally encoded p53 binding protein.	SAMARITAN HOSP WOMEN,DEPT GYNAECOL ONCOL,LONDON NW1,ENGLAND		CROOK, T (corresponding author), ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND.							CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; RIOU G, 1990, LANCET, V335, P1171; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSSI T, 1987, ONCOGENE, V1, P71; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YEE C, 1985, AM J PATHOL, V119, P361	17	314	317	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					873	875						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646990				2022-12-28	WOS:A1991GT82500026
J	ABDOLLAHI, A; LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA				ABDOLLAHI, A; LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA			SEQUENCE AND EXPRESSION OF A CDNA-ENCODING MYD118 - A NOVEL MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE INDUCED BY MULTIPLE CYTOKINES	ONCOGENE			English	Note							LEUKEMIA-INHIBITORY FACTOR; HEPATOCYTE-STIMULATING FACTOR; NEURONAL DIFFERENTIATION; CELLS; DISSECTION; IDENTITY; CLONING; PROTEIN	We report here the full length cDNA sequence and the deduced amino acid sequence of MyD118, a novel myeloid differentiation primary response gene transiently expressed in M1D + myeloid precursors following induction of terminal differentiation and growth arrest by IL6. MyD118 expression was observed to be induced also in the absence of protein synthesis, following stimulation of M1D + cells by IL1, LPS and Leukemia Inhibitory Factor (LIF). Detectable levels of MyD118 RNA were observed in myeloid precursor enriched murine bone marrow, but not in several other nonmyeloid murine tissues.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007152] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA43618-01] Funding Source: Medline; NICHD NIH HHS [5T32HD07152] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUMANN H, 1989, J IMMUNOL, V143, P1163; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SHABO Y, 1988, BLOOD, V72, P1543; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	15	131	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					165	167						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899477				2022-12-28	WOS:A1991EY03900024
J	PATEL, M; LEEVERS, SJ; BRICKELL, PM				PATEL, M; LEEVERS, SJ; BRICKELL, PM			STRUCTURE OF THE COMPLETE HUMAN C-FGR PROTOONCOGENE AND IDENTIFICATION OF MULTIPLE TRANSCRIPTIONAL START SITES	ONCOGENE			English	Article									UNIV COLL & MIDDLESEX SCH MED,DEPT BIOCHEM,MED MOLEC BIOL UNIT,WINDEYER BLDG,CLEVELAND ST,LONDON W1P 6DB,ENGLAND	University of London; University College London								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRICKELL PM, 1988, BRIT J CANCER, V58, P704, DOI 10.1038/bjc.1988.294; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GRIFFIN BE, 1984, NATURE, V309, P78, DOI 10.1038/309078a0; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE K, 1987, ONCOGENE, V1, P301; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KIOUSSIS D, 1987, EMBO J, V6, P355, DOI 10.1002/j.1460-2075.1987.tb04762.x; KLEIN C, 1988, INT J CANCER, V42, P29, DOI 10.1002/ijc.2910420107; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROONEY C, 1989, J VIROL, V63, P1531, DOI 10.1128/JVI.63.4.1531-1539.1989; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978	31	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					201	206						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	1690869				2022-12-28	WOS:A1990CU02900006
J	KWONG, YY; HUSAIN, Z; BISWAS, DK				KWONG, YY; HUSAIN, Z; BISWAS, DK			C-HA-RAS GENE MUTATION AND ACTIVATION PRECEDE PATHOLOGICAL-CHANGES IN DMBA-INDUCED INVIVO CARCINOGENESIS	ONCOGENE			English	Article							MULTISTEP CARCINOGENESIS; CELLULAR ONCOGENES; COLORECTAL CANCERS; CARCINOMA; NEOPLASIA; MODEL; DNA	We have previously reported a stage-specific and sequential overexpression of the c-Ha-ras and c-erhB genes in 7, 12-dimethylbenzanthracene (DMBA)-induced in vivo carcinogenesis in hamster buccal pouch epithelium (HBPE). In this investigation, the immunoreactive protein product of the c-Ha-ras gene (p21 protein) was identified in HBPE cells, specifically in treated tissues and cultured cells established after 3 weeks of DMBA treatment. Microscopic examination did not show any histopathological changes in these tissues. The p21 protein was detected in a few selective cells, which were dispersed away from the more densely populated basal layer. The overexpression of the c-Ha-ras gene was accompanied by a point mutation of A --> T in codon 61 (CAA), inducing an amino acid substitution from the wild-type glutamine to leucine in the- peptide. The concurrent molecular modifications preceded any detectable histopathological changes. The cellular morphology and orientation in treated HBPE at this early stage was indistinguishable from the control tissue. Yet the genetic alterations, such as the point mutation and overexpression of the gene, were evident at the predysplastic stage. Amplification and overexpression of the second proto-oncogene, c-erbB, and its product, epidermal growth factor receptor (EGFR), were detected in HBPE cells at the later stages of extensive cell proliferation and invasion. By using double antibodies and two immunoreporter systems, we demonstrated overexpression of both c-Ha-ras and c-erbB genes in the same HBPE cells during this chemically induced in vivo carcinogenesis.	HARVARD UNIV,SCH DENT MED,MOLEC BIOL LAB,188 LONGWOOD AVE,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED,BOSTON,MA 02115	Harvard University; Harvard School of Dental Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HEIM, 1987, CANCER CYTOGENETICS; HUSAIN Z, 1989, P NATL ACAD SCI USA, V86, P1264, DOI 10.1073/pnas.86.4.1264; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUMAR R, 1990, ONCOGENE, V5, P1271; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; MIYAMOTO S, 1990, MOL CELL BIOL, V10, P1593, DOI 10.1128/MCB.10.4.1593; NUZUM EO, 1990, MOL CARCINOGEN, V3, P287, DOI 10.1002/mc.2940030509; POLVERINI PJ, 1986, LAB INVEST, V54, P432; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SOLT DB, 1988, CARCINOGENESIS, V9, P2173, DOI 10.1093/carcin/9.12.2173; SUKUMAR S, 1990, CANCER CELL-MON REV, V2, P199; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; WONG DTW, 1987, ONCOGENE, V2, P67	31	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1481	1489						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630811				2022-12-28	WOS:A1992JE81300003
J	MOBERG, KH; LOGAN, TJ; TYNDALL, WA; HALL, DJ				MOBERG, KH; LOGAN, TJ; TYNDALL, WA; HALL, DJ			3 DISTINCT ELEMENTS WITHIN THE MURINE C-MYC PROMOTER ARE REQUIRED FOR TRANSCRIPTION	ONCOGENE			English	Article							RNA POLYMERASE-II; ADENOVIRUS E1A PROTEINS; TRANS-ACTIVATION; UPSTREAM ELEMENT; GROWTH-FACTOR; GENE; INITIATION; BINDING; STIMULATION; ONCOGENE	We have undertaken a detailed analysis of the cis-acting elements that are required for optimal transcription initiation from P2, the major promoter of the murine c-myc gene. We find that three elements contribute to promoter strength, termed ME1a2, E2F and ME1a1 at positions -85, -64 and -46 respectively (relative to P2). Individually the elements are weak, but combined they contribute to full promoter activity, all acting in a positive fashion. The E2F element is the site at which the SV40 large T antigen transactivates the c-myc promoter. However, transactivation requires the presence of the ME1a2 or ME1a1 elements in addition to E2F. By a number of criteria it appears that the ME1a2 and ME1a1 elements bind the same or a very closely related protein (monomer M(r) 94000). It was found that Hela cells contain a novel factor that is capable of binding to the ME1a1 and ME1a2 elements but only in the presence of the protein-dissociating agents deoxycholate or formamide. Finally, the E2F factor binds DNA both as a monomer and as a multiprotein complex; the latter is cell type specific. Both types of bound E2F factor form less stable protein-DNA complexes than the ME1a2/ME1a1 factor.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107	Jefferson University			Moberg, Ken/J-4849-2017	Moberg, Ken/0000-0002-9820-5543	NATIONAL CANCER INSTITUTE [R29CA051170] Funding Source: NIH RePORTER; NCI NIH HHS [CA51170-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELIN C, 1989, ONCOGENE, V4, P549; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAUERLE PA, 1988, CELL, V53, P211; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DEAN M, 1986, J BIOL CHEM, V261, P9161; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HALL DJ, 1990, ONCOGENE, V5, P47; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HEIBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LIPP M, 1989, ONCOGENE, V4, P535; LOEKEN MR, 1986, MOL CELL BIOL, V6, P2020, DOI 10.1128/MCB.6.6.2020; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEISINGER G, 1988, ONCOGENE, V3, P635	32	70	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					411	421						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549358				2022-12-28	WOS:A1992HK00500003
J	GAUTHIERROUVIERE, C; BASSET, M; LAMB, NJC; FERNANDEZ, A				GAUTHIERROUVIERE, C; BASSET, M; LAMB, NJC; FERNANDEZ, A			ROLE OF FOS-AP-1 BINDING SEQUENCE (FAP) IN THE INDUCTION OF C-FOS EXPRESSION BY PURIFIED C-KINASE AND IN C-FOS DOWN-REGULATION FOLLOWING SERUM INDUCTION	ONCOGENE			English	Article							RESPONSE ELEMENT; PROTO-ONCOGENE; AUTO-REGULATION; DNA-BINDING; GENE; TRANSCRIPTION; AP-1; JUN; IDENTIFICATION; PROMOTER	Microinjection of purified calcium phospholipid-dependent protein kinase (C-kinase) resulted in the rapid and transient induction of c-fos in quiescent rat embryo fibroblast. This C-kinase-induced expression of c-fos was prevented by in vivo competition using co-injection of oligonucleotides corresponding to the sequence of either the serum response element (SRE) or the fos AP-1 binding sequence (FAP) adjacent to SRE. This indicates that both these sequences must be involved in the binding/activation of protein factors required for the induction of c-fos by C-kinase. In contrast, the induction of c-fos by serum or by casein kinase II microinjection, which is also inhibited by injection of SRE oligonucleotides, is only delayed and then markedly prolonged by injecting TRE/FAP sequence, demonstrating that the FAP site plays a prominent role in vivo in the down-regulation of the endogenous c-fos gene expression.	CNRS,INSERM,BP5051,CRBM,CELL BIOL,ROUTE MENDE,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier				GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, GENE DEV, V7, P4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P324; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	26	23	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					363	369						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549354				2022-12-28	WOS:A1992HG98200023
J	IIDA, S; YOSHIDA, T; NAITO, K; SAKAMOTO, H; KATOH, O; HIROHASHI, S; SATO, T; ONDA, M; SUGIMURA, T; TERADA, M				IIDA, S; YOSHIDA, T; NAITO, K; SAKAMOTO, H; KATOH, O; HIROHASHI, S; SATO, T; ONDA, M; SUGIMURA, T; TERADA, M			HUMAN HST-2 (FGF-6) ONCOGENE - CDNA CLONING AND CHARACTERIZATION	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; TRANSFORMING GENE; CELL-LINE; NUCLEOTIDE-SEQUENCE; INT-2 GENE; EXPRESSION; RECEPTOR; PROTEIN; ORGANIZATION; PURIFICATION	The hst-2 gene was previously identified by its close homology to the hst-1 gene. Cosmid clones containing the hst-2 gene were cloned from a normal human genomic library. Focus-forming activity was observed for the hst-2 cosmids when NIH3T3 transfection assay was performed in a serum-free medium, whereas induction of morphological transformation was difficult to detect in an ordinary serum-supplemented medium. The hst-2 cDNA was cloned from the NIH3T3 transformant. Nucleotide sequence analysis of the cDNA indicates that the hst-2 gene encodes a 198 amino acid transforming protein containing a signal peptide with the characteristics of a heparin-binding growth factor. The coding sequence was almost identical to the published portion of the exon sequence of the FGF-6 gene, indicating that hst-2 is identical to FGF-6. The hst-2 cDNA fragment, when inserted into an expression vector, was able to transform NIH3T3 cells effectively, and the resulting transformant formed a well-vascularized tumor in nude mice, thus suggesting an angiogenic property similar to some other members of the family. RNA blot analysis revealed the expression of the hst-2 gene in human leukemia cell lines with platelet/megakaryocytic differentiation potential.	NATL CANC CTR,DIV GENET,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN; NATL CANC CTR,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN; NIPPON MED COLL,DEPT SURG 1,BUNKYO KU,TOKYO 113,JAPAN; TAKEDA CHEM IND LTD,BIOL RES LABS,DIV RES & DEV,YODOGAWA KU,OSAKA 532,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHIBA 280,JAPAN	National Cancer Center - Japan; National Cancer Center - Japan; Nippon Medical School; Takeda Chemical Industries; Chiba University								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BROOKES S, 1989, ONCOGENE, V4, P429; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T., 1982, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; MIYAGAWA K, 1988, ONCOGENE, V3, P383; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAKAMOTO H, 1988, BIOCHEM BIOPH RES CO, V151, P965, DOI 10.1016/S0006-291X(88)80460-1; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; YOSHIDA T, 1987, BIOCHEM BIOPH RES CO, V142, P1019, DOI 10.1016/0006-291X(87)91516-6; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	33	25	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					303	309						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549352				2022-12-28	WOS:A1992HG98200015
J	FUJII, M; TSUCHIYA, H; SEIKI, M				FUJII, M; TSUCHIYA, H; SEIKI, M			HTLV-1 TAX HAS DISTINCT BUT OVERLAPPING DOMAINS FOR TRANSCRIPTIONAL ACTIVATION AND FOR ENHANCER SPECIFICITY	ONCOGENE			English	Note							CELL LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; LEUCINE ZIPPER STRUCTURE; C-FOS; TRANS-ACTIVATION; MAMMALIAN-CELLS; GENE-EXPRESSION; DNA-BINDING; PROTEIN; INTERLEUKIN-2	Tax1 of human T-cell leukemia virus type 1 (HTLV-1) activates viral transcription dependent upon three 21-bp enhancer elements in the long terminal repeat. Difficulties in detecting any association of Tax1 with the viral enhancer have hampered elucidation of the molecular mechanisms of Tax1-mediated transcriptional activation. By constructing a fusion protein with the heterologous DNA-binding domain of yeast GAL4, Tax1 was shown to be a potent transcriptional activator dependent on the presence of GAL4-binding sites. Deletions of the Tax1 portion of the fusion protein revealed that almost the entire region of Tax1 (amino acids 2-337) is required for activation, and the activity correlated well with that of the viral enhancer. The GAL/Tax1 mutant lacking 41 residues of the C-terminus of Tax1. GAL/Tax1(2-312). was inactive for the viral enhancer, but activity was recovered by adding the heterologous activation domain of herpes simplex virus VP16. These results indicate that Tax1 has two distinct but overlapping functional domains for transcriptional activation and for enhancer specificity. Thus, Tax1 is thought to be a transcription factor acting in the enhancer complex rather than as a catalytic or allosteric modifier of pre-existing cellular transcription factors.	KANAZAWA UNIV,SCH MED,DEPT INTERNAL MED 3,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University	FUJII, M (corresponding author), KANAZAWA UNIV,SCH MED,CANC RES INST,DEPT VIROL,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN.		Seiki, Motoharu/K-9443-2015					ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BEIMLING P, 1989, ONCOGENE, V4, P511; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SADOWSKI I, 1986, NATURE, V332, P853; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; WILLEMS L, 1991, ONCOGENE, V6, P159; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	37	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2349	2352						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766679				2022-12-28	WOS:A1991GX73500025
J	PARTANEN, J; ARMSTRONG, E; BERGMAN, M; MAKELA, TP; HIRVONEN, H; HUEBNER, K; ALITALO, K				PARTANEN, J; ARMSTRONG, E; BERGMAN, M; MAKELA, TP; HIRVONEN, H; HUEBNER, K; ALITALO, K			CYL ENCODES A PUTATIVE CYTOPLASMIC TYROSINE KINASE LACKING THE CONSERVED TYROSINE AUTOPHOSPHORYLATION SITE (Y416SRC)	ONCOGENE			English	Article							AMINO-TERMINAL DOMAIN; ROUS-SARCOMA VIRUS; PROTEIN-KINASE; ONC GENES; CELL-LINE; PP60C-SRC; PHOSPHORYLATION; TRANSFORMATION; ACTIVATION; SRC	We have isolated a cDNA encoding a novel tyrosine kinase family member, named cyl (consensus tyrosine-lacking kinase), from the K562 human leukemia cell line. The deduced cyl protein lacks signal and transmembrane sequences but contains features of known cytoplasmic tyrosine kinases, including amino-terminal SH3 and SH2 domains. However, having very short amino and carboxy termini, cyl does not seem to belong to any of the previously characterized subfamilies of cytoplasmic tyrosine kinases. Furthermore, cyl lacks the highly conserved tyrosine autophosphorylation site (Y416src) in the tyrosine kinase catalytic domain. The cyl gene is located on human chromosome 15. It is expressed ubiquitously as two independently regulated mRNA species of 2.6 and 3.4 kb in human leukemia cell lines and fetal tissues.	UNIV HELSINKI,DEPT VIROL,CANC BIOL LAB,SF-00290 HELSINKI 29,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU 52,FINLAND; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	University of Helsinki; University of Turku; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	PARTANEN, J (corresponding author), UNIV HELSINKI,DEPT PATHOL,CANC BIOL LAB,HAARTMANINK 3,SF-00290 HELSINKI 29,FINLAND.		makela, tomi/B-3734-2009; Alitalo, Kari K/J-5013-2014	makela, tomi/0000-0002-4869-8044; Alitalo, Kari K/0000-0002-7331-0902; Partanen, Juha/0000-0001-8850-4825				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P4714, DOI 10.1073/pnas.79.15.4714; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GREENBERG SM, 1988, BLOOD, V72, P1968; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HUEBNER K, 1988, ONCOGENE, V3, P449; HUEBNER K, 1985, SCIENCE, V230, P1282, DOI 10.1126/science.2999978; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LETWIN K, 1988, ONCOGENE, V3, P621; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LOZZIO CB, 1975, BLOOD, V45, P335; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8670; MUSTELIN T, 1990, ONCOGENE, V5, P809; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P9103; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PONCZ M, 1987, BLOOD, V69, P219; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1990, CELL, V61, P243; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V64, P511; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	58	87	90	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2013	2018						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945408				2022-12-28	WOS:A1991GX11900011
J	YU, DH; HUNG, MC				YU, DH; HUNG, MC			EXPRESSION OF ACTIVATED RAT NEU ONCOGENE IS SUFFICIENT TO INDUCE EXPERIMENTAL METASTASIS IN 3T3 CELLS	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; TUMOR EFFECTS INVIVO; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODIES; POINT MUTATION; PROTO-ONCOGENE; INVITRO ASSAY; GENE; PHENOTYPE; AMPLIFICATION	Amplification or overexpression of the human neu oncogene has been shown to correlate with the number of lymph node metastases in breast cancer patients, suggesting that expression of the neu oncogene may be associated with increased metastatic potential. However, there has been no systematic study on the role of the neu oncogene in metastasis to support this correlation. In our study, mouse embryo fibroblast 3T3 cells transformed by the mutation-activated rat neu oncogene exhibited metastatic properties both in vitro and in vivo, while parental 3T3 cells did not. Monoclonal antibodies capable of inducing down-regulation of the neu-encoded p185 protein reduced the metastatic potential induced by neu. These data provide strong experimental evidence that neu oncogene expression is sufficient for the induction of metastasis in the 3T3 cell system and supply a molecular basis supporting the correlations found in clinical observation. The results also suggest that neu-specific monoclonal antibodies may have preventative or therapeutic potential for neu-induced metastasis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045265] Funding Source: NIH RePORTER; NCI NIH HHS [R03 CAS4989-01, CA-16672, CA-45265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLONI PN, 1988, J CELL PHYSIOL, V136, P398, DOI 10.1002/jcp.1041360303; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HUNG M-C, 1988, Cancer Bulletin (Houston), V40, P300; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; INOKUCHI J, 1990, CANCER RES, V50, P6731; LEMOINE NR, 1990, ONCOGENE, V5, P237; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MATIN A, 1990, ONCOGENE, V5, P111; MENSING H, 1983, EUR J CELL BIOL, V29, P268; NICOLSON GL, 1982, BIOCHIM BIOPHYS ACTA, V695, P113, DOI 10.1016/0304-419X(82)90020-8; NICOLSON GL, 1987, CANCER RES, V47, P1473; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; REPESH LA, 1989, INVAS METAST, V9, P192; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; Tressler R J, 1989, Cancer Commun, V1, P55; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; YAN DH, 1991, ONCOGENE, V6, P343; YAN DH, 1991, MOL CELL BIOL, V11, P1875, DOI 10.1128/MCB.11.4.1875; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YUSA K, 1990, J NATL CANCER I, V82, P1633, DOI 10.1093/jnci/82.20.1633; ZHANG X, 1989, ONCOGENE, V4, P985	46	115	119	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1991	1996						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1682865				2022-12-28	WOS:A1991GX11900008
J	CASEY, G; LOHSUEH, M; LOPEZ, ME; VOGELSTEIN, B; STANBRIDGE, EJ				CASEY, G; LOHSUEH, M; LOPEZ, ME; VOGELSTEIN, B; STANBRIDGE, EJ			GROWTH SUPPRESSION OF HUMAN BREAST-CANCER CELLS BY THE INTRODUCTION OF A WILD-TYPE P53 GENE	ONCOGENE			English	Article							PHENOL-CHLOROFORM EXTRACTION; CELLULAR TUMOR-ANTIGEN; SINGLE-STEP METHOD; SHORT ARM; RNA ISOLATION; LUNG-CANCER; ALLELE LOSS; MUTANT P53; TRANSFORMATION; MUTATIONS	Mutations in the p53 gene are associated with a wide variety of human tumors, including those of the breast. To assess functionally the role of the p53 gene in the development of human breast cancer, we introduced either wild-type or mutant p53 cDNA into three human breast cancer cell lines by DNA transfection. The cell lines MDA-MB 468 and T47 D contain only single mutated copies of the p53 gene, whereas the status of p53 in the breast cancer cell line MCF 7 remains equivocal. Following transfection, MCF 7 cells continued to grow unaffected both in vitro and in vivo in the presence of high levels of expression of the exogenous wild-type p53 gene. In contrast, however, the continued expression of an exogenous wild-type p53 gene was incompatible with cellular growth in both the MDA-MB 468 and T47 D cell lines. Elevated levels of expression of the exogenous mutant p53 gene did not alter the growth of the cell lines in vitro. These data strongly suggest that the wild-type p53 gene can function as a suppressor of cellular growth in breast cancer cells. That the wild-type p53 gene does not suppress the growth of MCF 7 cells indicates that at least some human breast tumors can arise without functional inactivation of the p53 gene by mutation. These tumors may represent a separate prognostic group.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; UNIV CALIF IRVINE,DEPT MICROBIOL,IRVINE,CA 92717	Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California Irvine	CASEY, G (corresponding author), UNIV CALIF IRVINE,DEPT PHARM,IRVINE,CA 92717, USA.				NATIONAL CANCER INSTITUTE [R01CA043460, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLARD MW, 1991, BIOTECHNIQUES, V10, P24; ALTHERR MR, 1989, GENOMICS, V5, P581, DOI 10.1016/0888-7543(89)90026-8; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKER SJ, 1990, SCIENCE, V249, P217; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Crawford L V, 1984, Mol Biol Med, V2, P261; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J, 1989, MOL CLONING LABORATO; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	47	258	273	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1791	1797						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923504				2022-12-28	WOS:A1991GX11800011
J	GONNEVILLE, L; MARTINS, TJ; BEDARD, PA				GONNEVILLE, L; MARTINS, TJ; BEDARD, PA			COMPLEX EXPRESSION PATTERN OF THE CEF-4 CYTOKINE IN TRANSFORMED AND MITOGENICALLY STIMULATED CELLS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; 9E3 MESSENGER-RNA; HUMAN-FIBROBLASTS; GENOMIC STRUCTURE; PLATELET PROTEIN; GENE-EXPRESSION; GROWTH-FACTOR; SEQUENCES; PHOSPHORYLATION; TRANSCRIPTION	The transformation of chicken embryo fibroblasts (CEF) by the Rous sarcoma virus leads to the constitutive expression of the cellular gene designated CEF-4. With specific antisera, we confirmed that transformed cells actively synthesize and secrete a 6 kDa polypeptide corresponding to the CEF-4 gene product. The expression of CEF-4 was investigated by Northern and immunoprecipitation analyses. Upon activation of pp60v-src in cells infected by a ts mutant of RSV, the expression of CEF-4 was biphasic with an early transient and a late constitutive period of expression. CEF-4 was expressed in cells transformed by a variety of oncogenes, but the level of constitutive expression differed quantitatively among transformed cells. Cells transformed by v-myc alone did not express CEF-4. Unlike other members of the interleukin 8 gene family, CEF-4 was induced in response to a broad spectrum of growth factors and inflammatory agents. Dexamethasone repressed the induction of CEF-4 by liposaccharides but had little or no effect on the response to serum or pp60v-src. These data emphasize the complexity of CEF-4 expression and suggest the existence of multiple levels or pathways of CEF-4 regulation in normal and transformed cells.	UNIV MONTREAL,DEPT BIOCHEM,CP 6128 SUCC A,MONTREAL H3C 3J7,QUEBEC,CANADA; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,BIOL LABS,CAMBRIDGE,MA 02138	Universite de Montreal; Harvard University								ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BARKER K, 1990, MOL CELL BIOL, V10, P3813, DOI 10.1128/MCB.10.7.3813; BARKER K, 1989, J VIROL, V63, P2929, DOI 10.1128/JVI.63.7.2929-2935.1989; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL SM, 1990, J BIOL CHEM, V265, P1333; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DESJARDINS P, 1986, SOMAT CELL MOLEC GEN, V12, P133, DOI 10.1007/BF01560660; DOLBERG DS, 1985, SCIENCE, V230, P676, DOI 10.1126/science.2996144; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; LANGLOIS AJ, 1976, CANCER RES, V36, P3894; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEW W, 1988, J IMMUNOL, V140, P1895; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; OBARU K, 1989, MOL IMMUNOL, V26, P423; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; SCHRODER JM, 1990, J IMMUNOL, V144, P2223; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SPRANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017; STOECKLE M Y, 1990, New Biologist, V2, P313; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; STOECKLE MY, 1988, MOL CELL BIOL, V8, P2675, DOI 10.1128/MCB.8.7.2675; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Summers MD, 1987, TEXAS AGR EXPT STATI; TANABE O, 1988, J IMMUNOL, V141, P3875; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YAMAMURA Y, 1989, J CLIN INVEST, V84, P1707, DOI 10.1172/JCI114353; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; ZINKEWICHPOETTI K, 1991, LAB INVEST, V63, P807; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	38	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1825	1833						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656364				2022-12-28	WOS:A1991GX11800015
J	SCHUUR, ER; BALUDA, MA				SCHUUR, ER; BALUDA, MA			EXPRESSION OF MYB PROTEINS IN AVIAN HEMATOPOIETIC TISSUES	ONCOGENE			English	Article							HUMAN C-MYB; MYELOBLASTOSIS VIRUS; V-MYB; TRANSFORMING GENE; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; CHICKEN DNA; DIFFERENTIAL EXPRESSION; STRUCTURAL ORGANIZATION; MYELOID-LEUKEMIA	MYB gene products are thought to be regulators of cellular replication and of differentiation. The major product of the avian MYB gene is a 75 kDa nuclear phosphoprotein which can activate transcription. A minor 89 kDa MYB protein of unknown function has also been described in murine and human cells. Additional heterogeneity at the level of MYB RNA which could affect the structure of MYB proteins has been described in several species. Such heterogeneity could explain the diverse effects of the MYB gene. To investigate the possible existence of heterogeneous and/or cell lineage-specific MYB proteins, five different avian hematopoietic tissues (bone marrow, bursa of Fabricius, embryonic spleen, thymus and yolk sac) were examined by immunoprecipitation with several MYB-specific antisera and SDS-PAGE analysis. In all five tissues there was a 75 kDa protein of uniform size which varied in abundance in a tissue-specific manner paralleling that observed for the 4.0 kb MYB RNA. A less abundant 89 kDa protein was also detected by several antisera in bone marrow, spleen, thymus and yolk sac but not in bursa. This 89 kDa MYB protein appears to be analogous to the 89 kDa MYB protein encoded by a minor but larger (360 nucleotides) MYB mRNA in murine and human cells. Immunoprecipitation of MYB proteins with an antiserum specific for exons 8 and 9 revealed a 74 kDa protein which coprecipitated and appeared to be complexed with p75 in normal hematopoietic cells and with the 48 kDa product of v-myb in leukemic cells.	UNIV CALIF LOS ANGELES,SCH MED,MED LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONNSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BALUDA MA, 1990, ONCOGENESIS ONCOGENE, P131; BENDER TP, 1987, J IMMUNOL, V139, P3822; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DAVIS JN, 1990, ONCOGENE, V5, P1109; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GARCIA A, 1991, IN PRESS ONCOGENE; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Moscovici C., 1973, Methods Cell Biol, V7, P313; NUNN MF, 1985, VIROLOGY, V139, P330; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SORET J, 1988, FEBS LETT, V232, P227, DOI 10.1016/0014-5793(88)80422-8; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VELLARD M, 1991, ONCOGENE, V6, P505; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	57	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1923	1929						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923515				2022-12-28	WOS:A1991GX11800029
J	BARTEK, J; BARTKOVA, J; VOJTESEK, B; STASKOVA, Z; LUKAS, J; REJTHAR, A; KOVARIK, J; MIDGLEY, CA; GANNON, JV; LANE, DP				BARTEK, J; BARTKOVA, J; VOJTESEK, B; STASKOVA, Z; LUKAS, J; REJTHAR, A; KOVARIK, J; MIDGLEY, CA; GANNON, JV; LANE, DP			ABERRANT EXPRESSION OF THE P53-ONCOPROTEIN IS A COMMON FEATURE OF A WIDE SPECTRUM OF HUMAN MALIGNANCIES	ONCOGENE			English	Note							P53 GENE-MUTATIONS; BREAST-CANCER; LUNG-CANCER; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; ONCOGENE; TRANSFORMATION; DELETIONS; SUPPRESSOR; FREQUENT	Accumulation of the p53 protein was analysed in 212 human malignant lesions. Immunohistochemical staining with new polyclonal (CM-1) and monoclonal antibodies (BP 53-12 and BP53-24) to p53 on methacarn-fixed paraffin sections showed positive staining in 161 (76%). The positive tumours were found across a wide range of human malignancies including breast, colon, stomach, bladder and testis carcinomas, soft-tissue sarcomas and melanomas. The staining was always confined to the malignant lesion. Immunoprecipitation and quantitative ELISA assays established that the positive staining was associated with accumulation of the protein and that the protein was frequently in a mutant conformation. Accumulation of mutant p53 protein is therefore a common feature of human malignant disease.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; MASARYK INST ONCOL, DEPT IMMUNOL & MOLEC BIOL, CS-65653 BRNO, CZECHOSLOVAKIA; CLARE HALL LABS, IMPERIAL CANC RES FUND, MOLEC IMMUNOCHEM LAB, S MIMMS EN6 3LD, HERTS, ENGLAND; UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND	University of Dundee; Masaryk Memorial Cancer Institute; University of Dundee			Lane, David P/C-4920-2008; Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Lane, David/0000-0003-0551-3545				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHIBA I, 1990, ONCOGENE, V5, P1603; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HANSEN MF, 1987, CANCER RES, V47, P5518; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KNUDSON AG, 1985, CANCER RES, V45, P1437; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	31	581	594	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1699	1703						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923535				2022-12-28	WOS:A1991GX27400029
J	BRONDYK, WH; BOECKMAN, FA; FAHL, WE				BRONDYK, WH; BOECKMAN, FA; FAHL, WE			N-MYC ONCOGENE ENHANCES MITOGENIC RESPONSIVENESS OF DIPLOID HUMAN FIBROBLASTS TO GROWTH-FACTORS BUT FAILS TO IMMORTALIZE	ONCOGENE			English	Article							MALIGNANT TRANSFORMATION; HUMAN NEUROBLASTOMAS; PROTO-ONCOGENE; NEOPLASTIC TRANSFORMATION; ANCHORAGE-INDEPENDENCE; EMBRYO FIBROBLASTS; SIMIAN VIRUS-40; MAMMALIAN-CELLS; NEURO-BLASTOMA; GENE FAMILY	The N-myc gene is amplified in several types of human tumors. To assess the role of the N-myc gene in the transformation of normal human cells, we transfected an N-myc expression vector into diploid human fibroblasts. Transfected clones were isolated and found to express the N-myc gene at levels similar to those seen in a tumor cell line (neuroblastoma LA-N-1) which contains an amplified N-myc gene. The level of N-myc expression decreased as the N-myc clones senesced. Clones expressing N-myc had an increased saturation density and an altered morphology but did not have an extended lifespan. Under low serum conditions, neither the clones expressing N-myc nor the control cells showed anchorage-independent growth. Clones expressing N-myc were compared to control cells to determine if different growth factors would affect the ability of cells to grow in soft agarose. Clones expressing N-myc and the control cells did not grow in soft agarose supplemented with epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-alpha). However, compared to control cells, clones expressing N-myc grew in agarose 2.8- to 18-fold higher in response to basic fibroblast growth factor (bFGF) and 5.5- to 55-fold higher in response to platelet-derived growth factor B-chain homodimer (PDGF-BB).	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	FAHL, WE (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706, USA.				NATIONAL CANCER INSTITUTE [P30CA007175, R37CA042024] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA07175, R37-CA42024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERNARD O, 1989, J NEUROSCI RES, V24, P9, DOI 10.1002/jnr.490240104; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CURATOLO L, 1984, IN VITRO CELL DEV B, V20, P597; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DIAS P, 1990, INT J CANCER, V45, P593, DOI 10.1002/ijc.2910450403; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GARSON JA, 1986, LANCET, V1, P1496; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; HURLIN PJ, 1987, CANCER RES, V47, P5752; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MACIEIRACOELHO A, 1980, GERONTOLOGY, V26, P276, DOI 10.1159/000212428; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MATLASHEWSKI G, 1988, INT J CANCER, V42, P232, DOI 10.1002/ijc.2910420215; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NORWOOD TH, 1985, HDB BIOL AGING, P291; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PALMER H, 1988, J CELL PHYSIOL, V137, P588, DOI 10.1002/jcp.1041370328; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9585, DOI 10.1073/pnas.85.24.9585; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH JR, 1980, SCIENCE, V207, P82; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; STEVENS CW, 1989, J CANCER RES CLIN, V115, P118, DOI 10.1007/BF00397911; STINSKI MF, 1985, J VIROL, V55, P431, DOI 10.1128/JVI.55.2.431-441.1985; STRAUSS M, 1990, ONCOGENE, V5, P1223; TUBO RA, 1987, ONCOGENE RES, V1, P407; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	59	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1269	1276						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861869				2022-12-28	WOS:A1991GV26000024
J	STENMAN, G; SAHLIN, P; MARK, J; LANDYS, D				STENMAN, G; SAHLIN, P; MARK, J; LANDYS, D			STRUCTURAL ALTERATIONS OF THE C-MOS LOCUS IN BENIGN PLEOMORPHIC ADENOMAS WITH CHROMOSOME-ABNORMALITIES OF 8Q12	ONCOGENE			English	Article								Recent mapping studies have assigned the human c-mos proto-oncogene to chromosome 8, bands q11-12. This region is frequently affected by chromosomal translocations in benign pleomorphic adenomas of the salivary glands. Using Southern blot analysis we report here that the c-mos gene and its flanking sequences are structurally altered in pleomorphic adenomas with chromosomal rearrangements of 8q12. Rearrangements were detected in two out of 23 tumors. Restriction fragment analysis indicated that the rearrangements were due to multiple, subtle mutations involving the c-mos open reading frame and its flanking sequences. There was no direct evidence of translocation of mos in any of the tumors. Control DNAs from the two patients showed a normal restriction pattern for all enzymes tested, indicating that the rearrangements are tumor specific. Collectively, our cytogenetic and molecular data suggest involvement of the c-mos gene in the pathogenesis of pleomorphic adenomas.	CENT HOSP SKOVDE, DEPT PATHOL, S-54185 SKOVDE, SWEDEN		STENMAN, G (corresponding author), GOTHENBURG UNIV, DEPT ORAL PATHOL, CYTOGENET LAB, S-40033 GOTHENBURG, SWEDEN.							BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BLAIR DG, 1984, CANCER CELL, V2, P281; BULLERDIEK J, 1989, CYTOGENET CELL GENET, V51, P973; BULLERDIEK J, 1989, CANCER, V64, P876, DOI 10.1002/1097-0142(19890815)64:4<876::AID-CNCR2820640419>3.0.CO;2-J; CAUBET JF, 1985, EMBO J, V4, P2245, DOI 10.1002/j.1460-2075.1985.tb03921.x; DALLAFAVERA R, 1987, RECENT ADV LEUKEMIA, P165; DIAZ MO, 1985, SCIENCE, V229, P767, DOI 10.1126/science.3860954; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GROFFEN J, 1989, PROG NUCLEIC ACID RE, V36, P281; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; KUFF EL, 1983, NATURE, V302, P547, DOI 10.1038/302547a0; LIDEREAU R, 1985, P NATL ACAD SCI USA, V82, P7068, DOI 10.1073/pnas.82.20.7068; MAGUIRE RT, 1983, P NATL ACAD SCI-BIOL, V80, P1947, DOI 10.1073/pnas.80.7.1947; MARK J, 1988, CANCER GENET CYTOGEN, V33, P229, DOI 10.1016/0165-4608(88)90033-7; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORRIS CM, 1989, HUM GENET, V81, P339, DOI 10.1007/BF00283687; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RENPING Z, 1991, IN PRESS SCIENCE; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SEIFERT G, 1986, DISEASES SALIVARY GL; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P184, DOI 10.1073/pnas.84.1.184; TESTA J R, 1988, Genomics, V3, P44, DOI 10.1016/0888-7543(88)90157-7; VANDEWOUDE GF, 1987, ADV VIRAL ONCOL, V6, P71; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	30	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1105	1108						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1677749				2022-12-28	WOS:A1991GV26000002
J	MOLL, J; SANSIG, G; FATTORI, E; VANDERPUTTEN, H				MOLL, J; SANSIG, G; FATTORI, E; VANDERPUTTEN, H			THE MURINE RAC1 GENE - CDNA CLONING, TISSUE DISTRIBUTION AND REGULATED EXPRESSION OF RAC1 MESSENGER-RNA BY DISASSEMBLY OF ACTIN MICROFILAMENTS	ONCOGENE			English	Note							5' NONCODING REGION; RNA SECONDARY STRUCTURE; MESSENGER-RNA; TRANSLATIONAL EFFICIENCY; EUKARYOTIC RIBOSOMES; CPG ISLANDS; RAS; PROTEIN; FAMILY; SECRETION	A 886 bp cDNA encoding the murine rac1 protein has been isolated. The abundance of rac1 mRNA was determined in fourteen tissues from both mouse and pig. The mRNA 5' non-coding sequence is very rich in G + C, and has the potential to form several stable secondary structures. In addition, this region contains a putative open reading frame of 57 amino acids. Disruption of the actin microfilament network by cytochalasin B in LLC-PK1 cells results in down regulation of rac1 mRNA. In agreement with the proposed role of rac1 in exocytosis, these results could explain the inhibitory effect of cytochalasin B on secretory processes.	CIBA GEIGY AG,DEPT BIOTECHNOL,DIV PHARMA,K 681447,CH-4002 BASEL,SWITZERLAND	Novartis	VANDERPUTTEN, H (corresponding author), CIBA GEIGY AG,DEPT BIOTECHNOL,DIV PHARMA,K 681447,CH-4002 BASEL,SWITZERLAND.							AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BOTTERI FM, 1990, SERINE PROTEASES THE, P105; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOYNE RD, 1982, PROC R SOC SER B-BIO, V216, P111, DOI 10.1098/rspb.1982.0064; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; COCKROFT S, 1987, J CELL BIOL, V5105, P2745; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P814; DRENCKHAHN D, 1983, EUR J CELL BIOL, V30, P167; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLDSTEIN AL, 1977, P NATL ACAD SCI USA, V74, P725, DOI 10.1073/pnas.74.2.725; KITIYAMA H, 1989, CELL, V56, P77; KNIGHT DE, 1985, NATURE, V317, P719, DOI 10.1038/317719a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; ORCI L, 1972, SCIENCE, V175, P1128, DOI 10.1126/science.175.4026.1128; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PELLETIER J, 1988, J VIROL, V62, P2219, DOI 10.1128/JVI.62.7.2219-2227.1988; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SIMPSON LL, 1981, PHARMACOL REV, V33, P158; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	51	78	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					863	866						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1905006				2022-12-28	WOS:A1991GT82500024
J	COWELL, JK; WADEY, RB; HABER, DA; CALL, KM; HOUSMAN, DE; PRITCHARD, J				COWELL, JK; WADEY, RB; HABER, DA; CALL, KM; HOUSMAN, DE; PRITCHARD, J			STRUCTURAL REARRANGEMENTS OF THE WT1 GENE IN WILMS-TUMOR CELLS	ONCOGENE			English	Article							HUMAN RETINOBLASTOMA GENE; PHYSICAL MAP; HUMAN CHROMOSOME-11; WAGR COMPLEX; BAND 11P13; SHORT ARM; ANIRIDIA; HETEROZYGOSITY; DELETIONS; MUTATIONS	We have analysed 55 Wilms' tumour DNAs using the cDNA from the candidate Wilms' predisposition gene, WT1. One tumour, GOS 129, shows a partial homozygous deletion involving only the 3'-most exon of the gene. An adjacent 3' DNA sequence, J7-18, which lies on the same NotI fragment as WT1, is present in GOS 129. Thus, this partial deletion does not extend to the adjacent unmethylated 3' HTF island. These data support the candidature of WT1 as a Wilms' predisposition gene. Tumour GOS 129 has become homozygous as a result of a mitotic recombination event proximal to WT1. Three other tumours showed abnormally sized bands on Southern blot analysis which appear to reflect internal heterozygous rearrangements involving the 5' end of the gene. One of these tumours was from a bilaterally-affected patient and the other 3 were from stage III or IV tumours.	MIT,CTR CANC RES,CAMBRIDGE,MA 02193	Massachusetts Institute of Technology (MIT)	COWELL, JK (corresponding author), INST CHILD HLTH,DEPT HAEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,LONDON WC1,ENGLAND.							BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; COUILLIN P, 1989, HUM GENET, V82, P171, DOI 10.1007/BF00284053; COWELL JK, 1989, HUM GENET, V82, P123, DOI 10.1007/BF00284042; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GESSLER M, 1989, GENOMICS, V5, P43, DOI 10.1016/0888-7543(89)90084-0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1988, NATURE, V336, P375; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HIGGINS MJ, 1989, MOL CELL BIOL, V9, P1; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MITCHELL CD, 1989, ONCOGENE, V4, P253; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; WADEY RB, 1990, ONCOGENE, V5, P901; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	35	89	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					595	599						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851548				2022-12-28	WOS:A1991FR93900014
J	DOSAKAAKITA, H; ROSENBERG, RK; MINNA, JD; BIRRER, MJ				DOSAKAAKITA, H; ROSENBERG, RK; MINNA, JD; BIRRER, MJ			A COMPLEX PATTERN OF TRANSLATIONAL INITIATION AND PHOSPHORYLATION IN L-MYC PROTEINS	ONCOGENE			English	Article							CELL LUNG-CANCER; FIBROBLAST GROWTH-FACTOR; CASEIN KINASE-II; NON-AUG CODONS; C-MYC; MESSENGER-RNAS; EMBRYO FIBROBLASTS; GENE FAMILY; LINES; TRANSFORMATION	Molecular analysis of the human proto-oncogene L-myc revealed a complex pattern of gene expression including alternative splicing and polyadenylation site selection of mRNA, giving rise to at least four mRNAs. These mRNAs in turn can code for several proteins. In this report, we characterize and define the origins of the major L-myc proteins. In vitro translation revealed that (i) two L-myc proteins (p59 and p65) were derived through alternative translational initiation at a non-AUG (CUG) site in intron 1 and at an AUC site in exon 2 of L-myc, and that (ii) extensive post-translational phosphorylation of these proteins yielded three additional proteins (p60, p66, and p68). Transfection experiments in rat embryo cells revealed the in vivo existence of this unusual CUG-initiated protein and demonstrated that it possessed transforming activity. Further, immuno-precipitation using high titered anti-L-myc peptide antisera, of two L-myc expressing small-cell lung cancer cell lines revealed three major L-myc proteins (p60, p66 and p68) all of which were derived from extensive phosphorylation of a p59 protein.	NCI,USN,MED ONCOL BRANCH,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Uniformed Services University of the Health Sciences - USA								BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BISTER K, 1987, ONCOGENE, V1, P97; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CARNEY DN, 1985, CANCER RES, V45, P2913; CLEAVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RAMSAY G, 1982, EMBO J, V9, P1111; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SAKSELA K, 1989, INT J CANCER, V44, P182, DOI 10.1002/ijc.2910440132; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					371	378						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849244				2022-12-28	WOS:A1991FT34400004
J	TSAI, LH; NANU, L; SMITH, RG; OZANNE, B				TSAI, LH; NANU, L; SMITH, RG; OZANNE, B			OVEREXPRESSION OF C-FOS IN A HUMAN PRE-B-CELL ACUTE LYMPHOCYTIC-LEUKEMIA DERIVED CELL-LINE, SMS-SB	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; OSTEO-SARCOMA VIRUS; PROTO-ONCOGENE FOS; MESSENGER-RNA; MOLECULAR-CLONING; GENE-EXPRESSION; BINDING-SITES; V-FOS; TRANSCRIPTION; DNA	The c-fos proto-oncogene is found to be overexpressed at least 30-fold in SMS-SB, a pre-B leukemic cell line compared to other cell types. No gross alteration of the c-fos gene structure in SMS-SB cells can be detected by karyotypic or Southern analyses. C-fos in SMS-SB cells can still be induced by serum, TPA and the calcium inophore, A23187, and superinduced by the combination of serum and cyloheximide. The elevated levels of c-fos transcripts are not due merely to an increased life span of mRNA, as the half-life of steady state c-fos mRNA in SMS-SB cells is about 40 min. Nuclear run-on transcription assays demonstrate that the transcription rate of c-fos in SMS-SB cells is up-regulated about 30-fold as compared to another pre-B leukemic cell line, NALM-6. In order to determine whether this is a cis- or transacting effect, we sequenced the 550 base pairs upstream of the SMS-SB c-fos coding region and found no mutations upstream of the mRNA CAP site. However, two point mutations at positions + 23 and + 98, respectively, were found in the 5' noncoding region of the first exon. Consistant with the overexpression of c-fos mRNA, the 55 kD c-fos protein is present in SMS-SB cells through detection by immunoprecipitation, but could not be detected in NALM-6 cells. SMS-SB cells however, do not appear to contain more abundant AP-1 DNA binding activity than NALM-6 cells.	BEATSON INST CANC RES,CANC RES CAMPAIGN LABS,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND; SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	Beatson Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas								ANGEL P, 1985, CANCER CELL, V3, P315; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BONNIEU A, 1989, ONCOGENE, V4, P881; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KLEMSZ MJ, 1989, J IMMUNOL, V143, P1032; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEPRINCE D, 1983, EMBO J, V2, P1073, DOI 10.1002/j.1460-2075.1983.tb01548.x; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NISHIKURA K, 1987, MOL CELL BIOL, V7, P629; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PINTO A, 1987, BLOOD, V70, P1450; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMITH RG, 1984, CANCER, V54, P471, DOI 10.1002/1097-0142(19840801)54:3<471::AID-CNCR2820540315>3.0.CO;2-4; SMITH RG, 1981, J IMMUNOL, V126, P596; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WELHAM MJ, 1990, ONCOGENE, V5, P161; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUAN D, 1984, J EXP MED, V160, P564, DOI 10.1084/jem.160.2.564; ZACK J, 1987, LEUKEMIA, V1, P737	54	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					81	88						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1704120				2022-12-28	WOS:A1991EY03900011
J	CHENEVIXTRENCH, G; MARTIN, NG; ELLEM, KAO				CHENEVIXTRENCH, G; MARTIN, NG; ELLEM, KAO			GENE-EXPRESSION IN MELANOMA CELL-LINES AND CULTURED MELANOCYTES - CORRELATION BETWEEN LEVELS OF C-SRC-1, C-MYC AND P53	ONCOGENE			English	Article									UNIV QUEENSLAND,DEPT PATHOL,BRISBANE,QLD 4000,AUSTRALIA	University of Queensland	CHENEVIXTRENCH, G (corresponding author), QUEENSLAND INST MED RES,JOINT ONCOL PROGRAM,BRAMSTON TERRACE,HERSTON,QLD 4006,AUSTRALIA.			Chenevix-Trench, Georgia/0000-0002-1878-2587				ADELAIDE J, 1988, ONCOGENE, V2, P413; ALBINO AP, 1988, ADV PIGMENT CELL RES, V256, P361; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1981, NATURE, V292, P31; de Vries J E, 1974, Int J Cancer, V14, P427, DOI 10.1002/ijc.2910140402; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; EDLUND T, 1983, P NATL ACAD SCI-BIOL, V80, P349, DOI 10.1073/pnas.80.2.349; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; ELLEM KAO, 1988, CARCINOGENESIS, V9, P797, DOI 10.1093/carcin/9.5.797; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GERHARD DS, 1987, NATURE, V325, P73, DOI 10.1038/325073a0; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOSS P, 1977, CANCER RES, V37, P152; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1988, ONCOGENE RES, V3, P177; Halaban R, 1988, PIGM CELL RES, V1, P18; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HAYWARD NK, 1988, HUM GENET, V78, P115, DOI 10.1007/BF00278178; IMANISHI K, 1989, BRIT J CANCER, V59, P761, DOI 10.1038/bjc.1989.159; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KODA T, 1987, JPN J CANCER RES, V78, P325; KUROKAWA T, 1987, FEBS LETT, V213, P189, DOI 10.1016/0014-5793(87)81489-8; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LINNENBACH AJ, 1988, P NATL ACAD SCI USA, V85, P74, DOI 10.1073/pnas.85.1.74; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOORE GE, 1980, CANCER-AM CANCER SOC, V45, P2311, DOI 10.1002/1097-0142(19800501)45:9<2311::AID-CNCR2820450914>3.0.CO;2-W; MURRAY JC, 1986, NUCLEIC ACIDS RES, V14, P7136, DOI 10.1093/nar/14.17.7136; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OGISO Y, 1988, J INVEST DERMATOL, V90, P841, DOI 10.1111/1523-1747.ep12462078; PADUA RA, 1984, NATURE, V311, P671, DOI 10.1038/311671a0; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; POPE JH, 1979, PATHOLOGY, V11, P191, DOI 10.3109/00313027909061945; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RONAI ZA, 1988, ONCOGENE, V2, P201; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SEMBA K, 1985, SCIENCE, V227, P1038, DOI 10.1126/science.2983418; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VANHAERINGEN A, 1989, GENOMICS, V5, P61, DOI 10.1016/0888-7543(89)90086-4; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; 1988, SPSS PC ADV STATISTI	64	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1187	1193						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	1697409				2022-12-28	WOS:A1990DX36100011
J	KOVAR, H; DWORZAK, M; STREHL, S; SCHNELL, E; AMBROS, IM; AMBROS, PF; GADNER, H				KOVAR, H; DWORZAK, M; STREHL, S; SCHNELL, E; AMBROS, IM; AMBROS, PF; GADNER, H			OVEREXPRESSION OF THE PSEUDOAUTOSOMAL GENE MIC2 IN EWINGS-SARCOMA AND PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR	ONCOGENE			English	Note									UNIV VIENNA,INST PATHOL ANAT,VIENNA BONE TUMOR REGISTRY,A-1090 VIENNA,AUSTRIA	University of Vienna	KOVAR, H (corresponding author), ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,KINDERSPITALGASSE 6,A-1090 VIENNA,AUSTRIA.		Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Kovar, Heinrich/0000-0001-6873-9109; Strehl, Sabine/0000-0002-0179-0628				AMBROSSCHRATTER IM, 1988, 1ST P M EUR MUSC ONC, P56; AUBRIT F, 1989, EUR J IMMUNOL, V19, P1431, DOI 10.1002/eji.1830190813; BANTING GS, 1989, MOL IMMUNOL, V26, P181, DOI 10.1016/0161-5890(89)90100-4; BERNARD A, 1988, J IMMUNOL, V140, P1802; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; DARLING SM, 1986, COLD SPRING HARB SYM, V51, P205, DOI 10.1101/SQB.1986.051.01.025; Ewing, 1921, P NEW YORK PATHOL S, V21, P17; FELLINGER EJ, 1989, INT S LIMB SALVAGE M, P219; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GOODFELLOW P, 1983, DIFFERENTIATION S, V23, P35; GOODFELLOW PJ, 1986, SCIENCE, V234, P740, DOI 10.1126/science.2877492; HAMILTON G, 1988, CANCER RES, V48, P6127; LATRON F, 1987, BIOCHEM J, V247, P757, DOI 10.1042/bj2470757; LEVY R, 1979, P NATL ACAD SCI USA, V76, P6552, DOI 10.1073/pnas.76.12.6552; LIPINSKI M, 1987, CANCER RES, V47, P183; MCDERMID HE, 1989, GENOMICS, V5, P1, DOI 10.1016/0888-7543(89)90079-7; MILLER SC, 1977, J CELL BIOL, V72, P511, DOI 10.1083/jcb.72.3.511; MUJOO K, 1987, CANCER RES, V47, P1098; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TRENT J M, 1988, Cytogenetics and Cell Genetics, V49, P236, DOI 10.1159/000132669; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3	23	172	173	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1067	1070						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695726				2022-12-28	WOS:A1990DP41500018
J	MERCOLA, D; CARPENTER, PM; GROVERBARDWICK, A; MERCOLA, M				MERCOLA, D; CARPENTER, PM; GROVERBARDWICK, A; MERCOLA, M			RAPID, COMPLETE AND REVERSIBLE TRANSFORMATION BY V-SIS PRECEDES IRREVERSIBLE TRANSFORMATION	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; HUMAN-TUMOR CELLS; FACTOR A-CHAIN; GROWTH-FACTOR; HUMAN-FIBROBLASTS; B-CHAIN; C-FOS; AUTOCRINE STIMULATION; PDGF RECEPTORS; ANTISENSE RNA	v-sis is the oncogene of simian sarcoma virus, but whether tumor growth is maintained by v-sis expression alone or requires additional changes is unknown. To distinguish these possibilities we studied a model of reversible transformation including tumorigenicity using NIH3T3 cells bearing a metallothionein promoter-v-sis construction. Cells subcultured from 10 out of 18 tumors from athymic mice, all < 0.1 g and less-than-or-equal-to 21 days in age, reverted to a normal phenotype but exhibited transformation upon addition of zinc as judged by morphology, growth rate, saturation density and anchorage independence of growth. Thus, activation of v-sis alone is sufficient for initiation and early autocrine-based growth of tumors. However, the cells from the remaining and predominantly larger, 0.5 +/- 0.7 g, tumors did not revert and exhibited zinc-independent transformation as judged by the same criteria. Southern analysis and examination of the regulation of v-sis product expression in cells derived from these tumors showed no change in zinc-dependent and reversible regulation of v-sis sequences. These results suggest that subsequent tumor growth strongly favors acquisition of additional irreversible change(s) in the tumor cell genome at high frequency (44%). Thus an earl event of a multistep process stimulated by v-sis-dependent transformation best accounts for the sum of results.	UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; DEPT VET AFFAIRS MED CTR, SAN DIEGO, CA 92161 USA; HARVARD UNIV, DEPT PHYSIOL, BOSTON, MA 02115 USA	University of California System; University of California San Diego; Harvard University	MERCOLA, D (corresponding author), UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA 49963] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049963] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BISHOP JM, 1982, MOL BIOL TUMOR VIR 3; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; CAVENEE W, 1988, RECESSIVE ONCOGENES; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DER CJ, 1988, ONCOGENE, V3, P105; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FAVERA RD, 1981, NATURE, V292, P31; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRY DG, 1988, MUTAT RES, V199, P341, DOI 10.1016/0027-5107(88)90213-8; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GRAVES D, 1984, P NATL ACAD SCI USA, V83, P4636; GROVER A, 1985, J BIOL CHEM, V260, P2252; GROVERBARDWICK A, 1991, BIOTECHNOLOGY CELL R, V4, P227; HAMMER RE, 1984, NATURE, V311, P65, DOI 10.1038/311065a0; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HUANG SS, 1988, J BIOL CHEM, V263, P12608; IGARASHI H, 1987, ONCOGENE, V1, P79; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KELLY JD, 1985, EMBO J, V4, P3399, DOI 10.1002/j.1460-2075.1985.tb04096.x; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEKUTH M, 1990, BIOCHIM BIOPHYS ACTA, V103, P1; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MERCOLA D, 1989, BIOCHEM BIOPH RES CO, V147, P854; MERCOLA D, 1991, GENE REGULATION ANTI, P329; MERCOLA D, 1991, PROSPECTS APPLICATIO, P83; MERCOLA D, 1992, 1991 OST RES C; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; NOWELL PC, 1986, CANCER RES, V46, P2203; OSNOBE MH, 1991, ONCOGENE, V6, P1531; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PECH M, 1989, P NATL ACAD SCI USA, V86, P2693, DOI 10.1073/pnas.86.8.2693; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROBBINS K, 1988, SCIENCE, V241, P1346; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; SUKUMAR S, 1989, CURR TOP MICROBIOL, V148, P93; VANDENBERG S, 1991, MOL CARCINOGEN, V4, P460, DOI 10.1002/mc.2940040609; VERSNEL MA, 1988, ONCOGENE, V2, P601; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WU JX, 1990, ONCOGENE, V5, P989; [No title captured]	59	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1793	1803						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501889				2022-12-28	WOS:A1992JJ37600016
J	ZERRAHN, J; DEPPERT, W; WEIDEMANN, D; PATSCHINSKY, T; RICHARDS, F; MILNER, J				ZERRAHN, J; DEPPERT, W; WEIDEMANN, D; PATSCHINSKY, T; RICHARDS, F; MILNER, J			CORRELATION BETWEEN THE CONFORMATIONAL PHENOTYPE OF P53 AND ITS SUBCELLULAR LOCATION	ONCOGENE			English	Article							LARGE-T-ANTIGEN; CELLULAR TUMOR-ANTIGEN; SV40 LARGE-T; TRANSFORMATION-RELATED PROTEIN; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; 3T3 CELLS; COMPLEX-FORMATION; NUCLEAR MATRIX	In order to obtain insight into the parameters determining the subcellular localization of mutant and wild-type forms of p53, we analysed the subcellular distribution of p53 in four Balb/c mouse-derived cell lines ranging in their cellular phenotypes from normal (3T3), via minimal transformant (T3T3), to maximally transformed (3T3tx, Meth A). Epitope mapping showed the p53 proteins in 3T3 and in T3T3 cells to be in a wild-type conformation, as they reacted with PAb246, whereas p53 in 3T3tx and in Meth A cells were PAb246 negative and thus displayed a mutant conformation. Despite its reactivity with PAb246, p53 in T3T3 cells had an extended half-life and accumulated to abnormally high levels. We show that the conformationally wild-type p53 in 3T3 and T3T3 cells predominantly localized to the cell nucleus, with about half of it being tightly associated with nuclear structures. In contrast, approximately 60% of mutant p53 in 3T3tx and Meth A cells localized to the cytoplasm, the rest residing in the cell nucleus, all the nuclear p53 in these cells appeared to be structurally bound. The cytoplasmic location of mutant p53 in 3T3tx and Meth A cells was not seen by immunofluorescence microscopic analysis, and required cell fractionation for its detection. Both cytoplasmic and nuclear p53 of the mutant phenotype bound to hsc proteins with a similar stoichiometry, suggesting that hsc binding is not directly related to the subcellular distribution of these proteins. We suggest that the conformational phenotype of p53 is a major determinant of its subcellular location.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 13,GERMANY; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE,ENGLAND	Heinrich Pette Institute; University of Hamburg; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BOONE C, 1965, J NATL CANCER I, V34, P725; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; COLLEDGE WH, 1986, MOL CELL BIOL, V6, P4136, DOI 10.1128/MCB.6.11.4136; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1988, VIROLOGY, V165, P457, DOI 10.1016/0042-6822(88)90589-2; DEPPERT W, 1989, NATO ASI SERIES H, V34, P4399; DEPPERT W, 1990, J VIROL, V2, P838; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINZPETER M, 1987, ONCOGENE, V1, P119; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIT S, 1969, INT J CANCER, V4, P384, DOI 10.1002/ijc.2910040403; KLOCKMANN U, 1983, EMBO J, V2, P1151, DOI 10.1002/j.1460-2075.1983.tb01560.x; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SCHIRMBECK R, 1987, J VIROL, V61, P3561, DOI 10.1128/JVI.61.11.3561-3569.1987; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHMIEG FI, 1984, J VIROL, V52, P350, DOI 10.1128/JVI.52.2.350-355.1984; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHAT O, 1987, ONCOGENE, V1, P277; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WALSER A, 1989, J VIROL, V63, P3926, DOI 10.1128/JVI.63.9.3926-3933.1989; WALSER A, 1986, EMBO J, V5, P883, DOI 10.1002/j.1460-2075.1986.tb04299.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	62	68	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1371	1381						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620550				2022-12-28	WOS:A1992HZ97100016
J	ADLER, HT; SEFTON, BM				ADLER, HT; SEFTON, BM			GENERATION AND CHARACTERIZATION OF TRANSFORMING VARIANTS OF THE LCK TYROSINE PROTEIN-KINASE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; RETROVIRUS PROMOTER INSERTION; COMPLETE NUCLEOTIDE-SEQUENCE; RIBOSOMAL-RNA GENE; CELLULAR ONCOGENE; MAMMALIAN-CELLS; CD4 RECEPTOR; CDNA CLONE; SRC GENE; PHOSPHORYLATION	p56lck, a tyrosine protein kinase of the src family, is overexpressed in two murine thymoma cell lines, LSTRA and Thy19, as a result of the integration of Moloney murine leukemia virus sequences upstream of the kk gene. The majority of the p56lck in these cell lines is translated from a hybrid mRNA comprised of the 5' untranslated region of the murine leukemia virus env mRNA and lck coding sequences. The retroviral promoter giving rise to this transcript has been molecularly cloned. To examine whether overexpression of unmutated p56lck might induce cellular transformation, we constructed a plasmid in which the murine leukemia virus promoter from LSTRA cells directed the expression of p56lck. This construct gave rise to foci when transfected into rat 208F fibroblasts. Cells from many of the foci also grew in soft agar. Tryptic peptide mapping showed that the p56lck in the transformed cells was phosphorylated at Tyr-394, the autophosphorylation site, but not detectably at Tyr-505, an inhibitory site. Because an antiserum made to the carboxy terminus of p56lck could not immunoprecipitate p56lck from these transformed cells, the possibility arose that the proteins expressed in the transformed fibroblasts contained mutations that altered the carboxy terminus of the protein. cDNAs derived from the 3' ends of the lck mRNAs in two of the foci were cloned, and both were found to be derived from an kk gene that was truncated upstream of the codon for Tyr-505 and fused to random sequences derived from other parts of the construct used for transfection. kk therefore resembles several other src family members in that it can be rendered oncogenic by replacement of the region encoding the inhibitory, carboxyterminal phosphorylation site by random amino acid sequences.	SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego					NCI NIH HHS [CA14195, CA42350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GLYNN JP, 1964, CANCER RES, V24, P502; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HURLEY TR, 1989, ONCOGENE, V4, P265; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KAPLAN PL, 1987, J VIROL, V61, P1731, DOI 10.1128/JVI.61.5.1731-1734.1987; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MILLER AD, 1984, CELL, V36, P51; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SWANSTROM R, 1983, P NATL ACAD SCI-BIOL, V80, P2519, DOI 10.1073/pnas.80.9.2519; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	41	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1191	1199						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594248				2022-12-28	WOS:A1992HU64200017
J	GREEN, AR; LINTS, T; VISVADER, J; HARVEY, R; BEGLEY, CG				GREEN, AR; LINTS, T; VISVADER, J; HARVEY, R; BEGLEY, CG			SCL IS COEXPRESSED WITH GATA-1 IN HEMATOPOIETIC-CELLS BUT IS ALSO EXPRESSED IN DEVELOPING BRAIN	ONCOGENE			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; ERYTHROID TRANSCRIPTION FACTOR; DNA-BINDING PROTEIN; C-MYC GENES; INDUCED-DIFFERENTIATION; CHROMOSOMAL TRANSLOCATION; GLOBIN GENE; GM-CSF; LEUKEMIA; LINE	The SCL gene encodes a putative transcription factor with a basic helix-loop-helix (B-HLH) motif and is known to be predominantly expressed in erythroid cells. Here we also demonstrate expression of SCL mRNA in normal mast cells, mast cell lines and megakaryocytic cell lines. SCL is therefore expressed in the same three lineages as GATA-1, a well-recognized hemopoietic transcription factor. SCL and GATA-1 mRNA were also co-expressed in interleukin 3-dependent primitive myeloid lines. In murine erythroleukemia (MEL) cells SCL and GATA-1 underwent coordinated biphasic modulation during hexamethylene bisacetamide (HMBA)-induced erythroid differentiation. The kinetics of SCL and GATA-1 mRNA expression was inversely correlated with changes in ID, a negative regulator of B-HLH proteins, and was distinct from changes in MYC, MYB and erythropoietin receptor transcripts. During myeloid differentiation of K562 celts, SCL and GATA-1 mRNA levels also underwent biphasic modulation. Thus SCL and GATA-1 are coordinately expressed in multiple hemopoietic lineages and coordinately regulated during induced erythroid and myeloid differentiation. In non-hemopoietic tissues SCL was only detected in adult and developing brain where GATA-1 is reportedly not expressed. In day 14.5 embryos analysed by in situ hybridization, SCL transcripts were detected in post-mitotic neurons in the metencephalon and roof of the mesencephalon. This suggests a previously unexpected role for SCL in neural differentation.	DEPT HAEMATOL, MRC BLDG, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND; ROYAL MELBOURNE HOSP, DEPT DIAGNOST HAEMATOL, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute			Lints, Thierry/K-4408-2012	Harvey, Richard/0000-0002-9950-9792; Green, Anthony/0000-0002-9795-0218				BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1991, IN PRESS P NATL ACAD; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COOPER PC, 1982, LEUKEMIA RES, V6, P313, DOI 10.1016/0145-2126(82)90093-5; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; DUNN TB, 1957, J NATL CANCER I, V18, P587; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FURTH J, 1957, P SOC EXP BIOL MED, V95, P824; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1991, IN PRESS EMBO J; GREENBERG SM, 1988, BLOOD, V72, P1968; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HARA K, 1988, EXP HEMATOL, V16, P256; HARVEY RP, 1991, IN PRESS P NATL ACAD; HASTHORPE S, 1981, CANCER RES, V41, P3985; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1989, ENVIRON HEALTH PERSP, V80, P181, DOI 10.2307/3430743; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MCCARTHY JH, 1980, EXP HEMATOL, V8, P562; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OGURA M, 1985, BLOOD, V66, P1384; OGURA M, 1988, BLOOD, V72, P49; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; REID L, 1990, CELL, V63, P875, DOI 10.1016/0092-8674(90)90491-V; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SERFLING E, 1989, TRENDS GENET, V5, P131, DOI 10.1016/0168-9525(89)90049-8; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VISVADER J, 1991, ONCOGENE, V6, P187; VONMELCHNER H, 1981, BLOOD, V57, P906; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	59	149	149	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					653	660						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565464				2022-12-28	WOS:A1992HQ68200006
J	LARGAESPADA, DA; KAEHLER, DA; MISHAK, H; WEISSINGER, E; POTTER, M; MUSHINSKI, JF; RISSER, R				LARGAESPADA, DA; KAEHLER, DA; MISHAK, H; WEISSINGER, E; POTTER, M; MUSHINSKI, JF; RISSER, R			A RETROVIRUS THAT EXPRESSES V-ABL AND C-MYC ONCOGENES RAPIDLY INDUCES PLASMACYTOMAS	ONCOGENE			English	Note							MURINE LEUKEMIA-VIRUS; DROSOPHILA-MELANOGASTER ABL; ABELSON VIRUS; MOUSE PLASMACYTOMAS; NUCLEOTIDE-SEQUENCE; FIBROBLAST LINES; MAMMALIAN-CELLS; BALB/C MICE; H-RAS; GENE	ABL-MYC, a murine retrovirus that encodes the v-abl and c-myc oncogenes, was constructed from Abelson murine leukemia virus (A-MuLV) in order to assess the biological consequences of co-expression of these genes in lymphoid cells. When inoculated into mice this retrovirus induced plasmacytomas in up to 100% of infected mice and less frequently induced pre-B lymphomas. Both tumor types contained genome-length proviruses in one or a few chromosomal locations, were mono- or oligoclonal as judged by immunoglobulin gene rearrangement and had unrearranged endogenous c-myc loci. The type of tumor induced depended upon the age and strain of mouse, and whether helper virus was present in the inoculated virus pool. ABL-MYC induced plasmacytomas with or without helper virus, with or without pretreatment of the mice with pristane, and in strains of mice resistant to pristane-induced plasmacytomas. Pristane treatment prior to ABL-MYC infection shortened the latent period of plasmacytomagenesis and produced mostly IgM-secreting tumors rather than IgA-secreting tumors, which predominantly arose in the absence of pristane. Control viruses for ABL-MYC with either a deletion in v-abl or a frameshift mutation in c-myc caused predominantly monocyte/macrophage tumors and pre-B-cell lymphomas respectively. Histopathological analysis of ABL-MYC-infected mice showed foci of transformed plasma cells as early as 14 days after infection. These results indicate that v-abl and c-myc act synergistically to transform mature B cells with high efficiency.	NCI, GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LARGAESPADA, DA (corresponding author), UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA.		Largaespada, David/C-9832-2014		NATIONAL CANCER INSTITUTE [R01CA041302, T32CA009135] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41302, T32-CA09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHUMAKOV I, 1982, J VIROL, V42, P1088, DOI 10.1128/JVI.42.3.1088-1098.1982; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLYNES R, 1988, P NATL ACAD SCI USA, V85, P6067, DOI 10.1073/pnas.85.16.6067; COLLEDGE WH, 1989, ONCOGENE, V4, P753; CORY S, 1987, ONCOGENE RES, V1, P61; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREEN PL, 1989, J VIROL, V63, P1989, DOI 10.1128/JVI.63.5.1989-1994.1989; GREEN PL, 1988, ONCOGENE, V2, P585; GREEN PL, 1985, J IMMUNOL, V134, P1268; GREEN PL, 1987, P NATL ACAD SCI USA, V84, P5932, DOI 10.1073/pnas.84.16.5932; HOLLAND GD, 1990, J VIROL, V64, P2226, DOI 10.1128/JVI.64.5.2226-2235.1990; HOROWITZ JM, 1982, J VIROL, V44, P950, DOI 10.1128/JVI.44.3.950-957.1982; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KESSLER SW, 1975, J IMMUNOL, V115, P1617; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATHEYPREVOT B, 1985, EMBO J, V4, P1769, DOI 10.1002/j.1460-2075.1985.tb03849.x; MAX EE, 1979, P NATL ACAD SCI USA, V76, P3450, DOI 10.1073/pnas.76.7.3450; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; POTTER M, 1973, SEMIN HEMATOL, V10, P19; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RISSER R, 1989, CURR TOP MICROBIOL, V147, P129; RISSER R, 1978, J EXP MED, V148, P714, DOI 10.1084/jem.148.3.714; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WEISSINGER EM, 1991, P NATL ACAD SCI USA, V88, P8735, DOI 10.1073/pnas.88.19.8735; WEISSINGER EM, 1990, CURR TOP MICROBIOL, V166, P121; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596	52	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					811	819						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565479				2022-12-28	WOS:A1992HQ68200029
J	YAMAOKA, S; TOBE, T; HATANAKA, M				YAMAOKA, S; TOBE, T; HATANAKA, M			TAX PROTEIN OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I IS REQUIRED FOR MAINTENANCE OF THE TRANSFORMED PHENOTYPE	ONCOGENE			English	Article							HTLV-I; TRANSCRIPTIONAL ACTIVATOR; NEOPLASTIC TRANSFORMATION; GENE; INTERLEUKIN-2; EXPRESSION; ONCOGENES; RECEPTOR; LINES; RETROVIRUS	We have isolated and characterized revertants of a clonal cell line (40MRatcl-1) of human T-cell leukemia virus type I Tax-transformed Rat1 cells. The 40MRatcl-1 cells contain a single copy of tax gene, form large colonies in soft agar, elicit tumors rapidly in nude mice and revert to the normal phenotype at low frequency. From one of its subclones (B7) bearing pSV2gpt DNA as a marker gene, four morphologically reverse-transformed cell lines were isolated. They display contact inhibition at confluency, lose the ability to form colonies in soft agar, fail to form tumors in nude mice and restore the transformed phenotype similar to that of 40MRatcl-1 cells by retransfection with the tax-expression plasmid. Southern blot analysis revealed that they have lost the tax gene. Our results indicate that transformation of Rat1 cells by Tax is not the consequence of secondary mutations of cellular genes and that tax functions are directly required for establishment and maintenance of the transformed phenotype.	KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT SURG 1,SAKYO KU,KYOTO 606,JAPAN	Kyoto University; Kyoto University								CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GOH WC, 1985, SCIENCE, V227, P1227, DOI 10.1126/science.2983419; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KOBAYASHI N, 1984, EMBO J, V3, P1339, DOI 10.1002/j.1460-2075.1984.tb01974.x; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; Maniatis T., 1982, MOL CLONING; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; SLAMON DJ, 1984, SCIENCE, V226, P61, DOI 10.1126/science.6089351; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS RA, 1990, CANCER CELL-MON REV, V2, P281; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	38	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					433	437						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549359				2022-12-28	WOS:A1992HK00500005
J	INGRAHAM, CA; COOKE, MP; CHUANG, YN; PERLMUTTER, RM; MANESS, PF				INGRAHAM, CA; COOKE, MP; CHUANG, YN; PERLMUTTER, RM; MANESS, PF			CELL TYPE AND DEVELOPMENTAL REGULATION OF THE FYN PROTOONCOGENE IN NEURAL RETINA	ONCOGENE			English	Article								The product of the proto-oncogene c-fyn (p59fyn) is a non-receptor tyrosine kinase of unknown function. The expression of the p59fyn tyrosine kinase was analysed by immunoperoxidase staining of the different neuronal cell types in the developing chick neural retina. p59fyn was primarily localized in the cell bodies of mature retinal neurons. p59fyn immunoreactivity was most abundant in cell bodies of differentiated ganglion, amacrine and photoreceptor cells. The onset of p59fyn expression in developing photoreceptors occurred coordinately with terminal neuronal differentiation. p59fyn was also found within the outer plexiform layer, which contains synaptic terminals of the photoreceptors. At embryonic stages prior to photoreceptor differentiation, p59fyn was most highly concentrated in the cell bodies of differentiating ganglion and amacrine cells. p59fyn autokinase activity in retinal extracts decreased concomitant with the final stages of maturation of retinal neurons, suggesting that the p59fyn kinase is developmentally regulated. Thus, the expression of p59fyn is regulated in both a developmental and cell type-specific manner. The existence of p59fyn in some of the same neuronal cells as p60c-src suggests the possibility of functional redundancy of these non-receptor tyrosine kinases.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM, CHAPEL HILL, NC 27599 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT IMMUNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, DIV MED GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NCI NIH HHS [CA45682] Funding Source: Medline; NEI NIH HHS [EY08975] Funding Source: Medline; NINDS NIH HHS [NS26620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045682] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARCLAY AN, 1981, IMMUNOLOGY, V44, P727; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, IN PRESS CELL; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1987, PEPTIDES PHOSPHORYLA; Dowling J. E., 1987, RETINA APPROACHABLE; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUGHES WF, 1974, ANAT REC, V179, P297, DOI 10.1002/ar.1091790302; KAHN AJ, 1974, DEV BIOL, V38, P30, DOI 10.1016/0012-1606(74)90256-5; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; LEMMON V, 1986, J NEUROSCI, V6, P2987; LINSER P, 1979, P NATL ACAD SCI USA, V76, P6476, DOI 10.1073/pnas.76.12.6476; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; PEARSON R, 1972, AVIAN BRAIN; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHORES CG, 1989, J NEUROSCI RES, V24, P59, DOI 10.1002/jnr.490240109; SINCLAIR CM, 1986, BRAIN RES, V398, P91, DOI 10.1016/0006-8993(86)91254-0; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TOWLE AC, 1984, J HISTOCHEM CYTOCHEM, V32, P766, DOI 10.1177/32.7.6145741; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEBB M, 1984, J NEUROCHEM, V43, P1061, DOI 10.1111/j.1471-4159.1984.tb12844.x; WONG ROL, 1987, J COMP NEUROL, V255, P159, DOI 10.1002/cne.902550202	39	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					95	100						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741169				2022-12-28	WOS:A1992HC22700013
J	MITRA, G				MITRA, G			MUTATIONAL ANALYSIS OF CONSERVED RESIDUES IN THE TYROSINE KINASE DOMAIN OF THE HUMAN TRK-ONCOGENE	ONCOGENE			English	Article							BIOCHEMICAL-CHARACTERIZATION; ACTIVATION; SEQUENCES; RECOMBINATION; PROTOONCOGENE; MUTAGENESIS	The human trk oncogene (originally identified in a colon carcinoma) was activated by a genetic rearrangement which resulted in replacement of the extracellular ligand-binding domain of the proto-trk transmembrane receptor by non-muscle tropomyosin sequences. The product of the trk oncogene, a protein of 70 kDa (p70trk), possesses tyrosine-specific protein kinase activity, is autophosphorylated in vitro on tyrosine and is phosphorylated on serine, threonine and tyrosine residues in trk-transformed cells. By site-directed mutagenesis of trk oncogene cDNA, the codon for lysine (367) at the putative ATP-binding site was changed to that for methionine and the codons for tyrosines (503 and 504) at the putative autophosphorylation sites were changed to those for phenylalanine. Replacement of Lys-367 by methionine results in a biologically inactive, kinase-negative mutant. Phe-ala mutants of trk showed drastically reduced ability to induce morphologic transformation, anchorage-independent growth and tumorigenicity in mouse NIH3T3 cells and showed reduced in vitro tyrosine kinase activity when assayed by autophosphorylation and phosphorylation of histone as exogenous substrate. The present study indicates the role of these specific conserved residues in regulating the biochemical and biological properties of p70trk oncoprotein.			MITRA, G (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							BONGARZONE I, 1989, ONCOGENE, V4, P1457; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; GEER PV, 1990, MOL CELL BIOL, V10, P2991; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; ULRICH A, 1990, CELL, V61, P203; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	25	26	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2237	2241						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1837350				2022-12-28	WOS:A1991GX73500009
J	DUIGOU, GJ; SU, ZZ; BABISS, LE; DRISCOLL, B; FUNG, YKT; FISHER, PB				DUIGOU, GJ; SU, ZZ; BABISS, LE; DRISCOLL, B; FUNG, YKT; FISHER, PB			ANALYSIS OF VIRAL AND CELLULAR GENE-EXPRESSION DURING PROGRESSION AND SUPPRESSION OF THE TRANSFORMED PHENOTYPE IN TYPE 5 ADENOVIRUS-TRANSFORMED RAT EMBRYO CELLS	ONCOGENE			English	Article							PROTEIN-KINASE-C; ANCHORAGE-INDEPENDENT GROWTH; RETINOBLASTOMA GENE; TUMOR PROMOTERS; MOLECULAR-CLONING; NEOPLASTIC TRANSFORMATION; CHEMICAL CARCINOGENS; FIBROBLAST CELLS; THYROID-HORMONE; VIRUS GENOME	Transformation of secondary Sprague-Dawley rat embryo (RE) cells with type 5 adenovirus (Ad5) results in morphologically transformed cells which can undergo a series of sequential changes resulting in enhanced expression of the transformed phenotype, a process termed progression. Selection for a progressed phenotype often occurs after growth in agar or tumor formation in nude mice, and this process is reversible following treatment of cells with 5-azacytidine. In the present study we have analyzed a series of clonal populations of Ad5-transformed RE cells representing different stages in a defined progression lineage. Progression was not associated with alterations in the steady-state levels of mRNA produced by the viral transforming genes, E1A and E1B, or the cellular gene, c-myc. In addition, the tumor-promoting agent 12-O-tetradecanoyl-phorbol-13-acetate (TPA), which induces expression of a progressed phenotype in Ad5-transformed RE cells, did not significantly alter the RNA transcription rates of the Ad5 E1A or E1B genes, the TPA-inducible gene TPA-S1 or the TPA-responsive genes Pro1 or protein kinase C. TPA did, however, increase by 1 h the steady-state level of c-fos mRNA, but this effect was similar in both progressed and unprogressed cells. Progression also did not involve a change in the RNA transcription rate of a number of cellular and viral genes, including actin, c-Ha-ras, c-myc, v-fos, erbB, TGF-alpha, TGF-beta, Pro-2, transin, TPA-R1, v-myb and c-mos, or other adenovirus genes in addition to E1A and E1B, including E2A and E4. Immunoblotting analysis using E1B polyclonal antiserum further indicated that progression was not associated with changes in the levels of an M(r) 21 000 polypeptide encoded by E1B. Similarly, immunoprecipitation analysis with an Ad2 E1A monoclonal antibody indicated similar levels of the M(r) 55 000 and 48 000 E1A polypeptides, as well as co-precipitated proteins of M(r) 300 000, 107 000 and 105 000 [which is the retinoblastoma (Rb) protein], in E11 and E11-NMT cells. Immunoprecipitation of cell lysates with a monoclonal antibody specific for the M(r) 105 000 Rb protein further demonstrated that progression also was not associated with a change in the level or state of phosphorylation of the Rb protein. However, transfection of a human Rb gene (also containing a neomycin resistance gene) into Ad5-transformed RE cells was more inhibitory, with respect to formation of G418-resistant colonies, in unprogressed than in progressed Ad5-transformed RE cells. These findings suggest that progression of the transformed phenotype in Ad5-transformed RE cells does not involve the altered expression of virus-encoded transforming genes. Moreover, progression of these cells is not associated with an alteration of genes previously shown to be associated with enhanced expression of the transformed cell phenotype in other progression model cell culture systems. It appears that regulation of the progression phenotype in Ad5-transformed RE cells is controlled by a cellular-encoded gene(s) which remains to be identified. This gene(s) modulates the stage of progression in these cells without directly altering expression of viral genes or the Rb tumor-suppressor gene, which is associated with expression of the transformed phenotype.	COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES,DEPT PATHOL,CTR CANC,650 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, DEPT UROL, CTR CANC, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, DEPT NEUROL SURG, CTR CANC, NEW YORK, NY 10032 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; CHILDRENS HOSP, DEPT OPHTHALMOL, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, LOS ANGELES, CA 90054 USA	Columbia University; Columbia University; Columbia University; Rockefeller University; Children's Hospital Los Angeles; University of Southern California					NCI NIH HHS [CA35675, CA43208, CA44754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044754, R29CA044754, R01CA035675, R01CA043208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BABISS LE, 1983, J VIROL, V46, P454, DOI 10.1128/JVI.46.2.454-465.1983; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; BABISS LE, 1985, CANCER RES, V45, P6017; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3297, DOI 10.1073/pnas.75.7.3297; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COLBURN NH, 1987, J CELL BIOCHEM, V34, P129, DOI 10.1002/jcb.240340207; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DORSCHHASLER K, 1980, J VIROL, V34, P305; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DUIGOU GJ, 1989, ANN NY ACAD SCI, V567, P302, DOI 10.1111/j.1749-6632.1989.tb16487.x; DYSON N, 1989, CELL, V30, P491; FISHER PB, 1983, P NATL ACAD SCI-BIOL, V80, P196, DOI 10.1073/pnas.80.1.196; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1979, NATURE, V281, P591, DOI 10.1038/281591a0; FISHER PB, 1979, CANCER RES, V39, P3051; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; FUNG YKT, 1991, IN PRESS SCIENCE; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HEPPNER GH, 1984, CANCER RES, V44, P2259; HERBST RS, 1988, J VIROL, V62, P4634, DOI 10.1128/JVI.62.12.4634-4643.1988; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; JOHNSON MD, 1987, ENVIRON HEALTH PERSP, V76, P89, DOI 10.2307/3430469; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LERMAN MI, 1986, INT J CANCER, V37, P293, DOI 10.1002/ijc.2910370219; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; NICOLSON GL, 1987, CANCER RES, V47, P1473; NOWELL PC, 1986, CANCER RES, V46, P2203; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SU ZZ, 1990, MOL CARCINOGEN, V3, P309, DOI 10.1002/mc.2940030512; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VANDEREB AJ, 1989, CURR TOP MICROBIOL, V144, P197; VARLEY JM, 1989, ONCOGENE, V4, P725; VENNSTROM B, 1980, J VIROL, V36, P575; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	69	12	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1813	1824						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923506				2022-12-28	WOS:A1991GX11800014
J	GROSSI, M; CALCONI, A; TATO, F				GROSSI, M; CALCONI, A; TATO, F			V-JUN ONCOGENE PREVENTS TERMINAL DIFFERENTIATION AND SUPPRESSES MUSCLE-SPECIFIC GENE-EXPRESSION IN ASV-17-INFECTED MUSCLE-CELLS	ONCOGENE			English	Article							MYOGENIC CELLS; DNA-BINDING; ENHANCER BINDING; PROTO-ONCOGENE; C-JUN; MYOBLASTS; MYC; PROTEINS; AP-1; FOS	Infection of replicating quail myoblasts with avian sarcoma virus 17 (ASV-17) results in the inhibition of terminal differentiation into multinucleated myotubes and in the acquisition of anchorage-independent proliferation. Expression of v-jun, the ASV-17 oncogene, concomitantly leads to the accumulation of the gag-jun polyprotein P65 in the nucleus and to the lack of expression of typical differentiation-specific genes such as myosin heavy chain (MHC) and alpha-actinin. Surprisingly, expression of desmin, the muscle-specific subunit of intermediate filaments, is conserved in ASV-17-transformed myoblasts. Analysis of clonal strains of transformed myoblasts suggests that (i) suppression of morphological and biochemical differentiation depends on the absence of muscle-specific gene transcripts; (ii) inhibition of muscle differentiation by v-jun does not depend on the transcriptional silencing of MyoD, a muscle-specific regulatory gene; (iii) expression of desmin is compatible with proliferation of ASV-17-transformed cells and is independent of v-jun and MyoD levels of expression. The present data suggest that nuclear localization of v-jun prevents terminal differentiation in myoblasts and selectively down-regulates muscle-specific genes in terminally differentiated myotubes. In this respect, the behaviour of v-jun is quite different from that of v-myc, thus suggesting that these two oncogenes, although both encoding nuclear proteins, may have different mechanisms of action.	UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,SEZ SCI MICROBIOL,I-00185 ROME,ITALY	Sapienza University Rome			Grossi, Milena/D-2955-2009					ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; CAPETANAKI YG, 1984, COLD SPRING HARB SYM, P415; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GROSSI M, 1989, PATHOLOGY GENE EXPRE, P313; HASTINGS KEM, 1982, MUSCLE DEV MOL CELLU, P215; HILL CS, 1986, J CELL BIOL, V103, P2185, DOI 10.1083/jcb.103.6.2185; HOLTZER H, 1975, Q REV BIOPHYS, V8, P523, DOI 10.1017/S0033583500001980; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SU HY, 1991, ONCOGENE, V6, P1759; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180; VOGT PK, 1988, ONCOGENE, V3, P3; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	30	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1767	1773						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923502				2022-12-28	WOS:A1991GX11800007
J	DHUT, S; CHAPLIN, T; YOUNG, BD				DHUT, S; CHAPLIN, T; YOUNG, BD			NORMAL C-ABL GENE PROTEIN - A NUCLEAR-COMPONENT	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASES; BCR; LOCALIZATION; ONCOGENE; PRODUCT; VIRUS; CELLS; PHOSPHORYLATION; ACTIVATION	The subcellular distribution of the c-abl and bcr-abl gene products from KG1A and K562 cells has been studied by two different techniques. Firstly, physical disruption followed by subcellular fractionation was used to demonstrate that normal c-abl (p145) was recovered from the cytosol and the nuclear fractions of KG1A cells. In contrast, bcr-abl products were recovered exclusively from the cytosol fraction of K562 cells. Secondly, indirect immunofluorescence was used to localize c-abl protein to the cytoplasm, nuclear membrane and infrequently to the nucleus of KG1A cells and bcr-abl protein to only the cytoplasm of K562 cells. Thus both the approaches indicate that there is a component of normal c-abl products which appears to be nuclear and this is not reflected in the distribution of the bcr-abl 210 kDa protein, which remains cytosolic.			DHUT, S (corresponding author), ST BARTHOLOMEWS HOSP, MED ONCOL LAB, IMPERIAL CANC RES FUND, LONDON EC1 7BA, ENGLAND.							BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; DHUT S, 1988, ONCOGENE, V3, P561; DHUT S, 1991, LEUKEMIA, V5, P49; DHUT S, 1990, LEUKEMIA, V4, P745; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FOULKES JG, 1985, J BIOL CHEM, V260, P8070; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUNTER T, 1986, ENZYMES, V17, P191; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KITAZAWA S, 1990, MED ONCOL TUMOR PHAR, V7, P35; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; PAWSON T, 1988, ONCOGENE, V3, P491; Potts W M, 1988, Oncogene Res, V3, P343; REDDY EP, 1988, ONCOGENE HDB, P3; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WATANABE SM, 1984, J VIROL, V51, P620, DOI 10.1128/JVI.51.3.620-627.1984; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	31	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1459	1464						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886716				2022-12-28	WOS:A1991GX27200024
J	BAIRD, P; WADEY, R; COWELL, J				BAIRD, P; WADEY, R; COWELL, J			LOSS OF HETEROZYGOSITY FOR CHROMOSOME REGION 11P15 IN WILMS-TUMORS IS NOT RELATED TO HRAS GENE TRANSFORMING MUTATIONS	ONCOGENE			English	Note							BECKWITH-WIEDEMANN SYNDROME; TUMORS; EXPRESSION; CARCINOMA; DELETION; ANIRIDIA; ALLELES; ASSOCIATION; ONCOGENE; LOCUS	Although a candidate Wilms' tumour gene-WT1-has been identified in chromosome region 11p13, there is strong evidence from loss of heterozygosity studies suggesting that a second relevant gene is present in region 11p15. The Harvey-Ras proto-oncogene also lies in this region. In other types of tumours mutations in RAS genes have been associated with the development and/or progression of a number of tumour types. We therefore analysed the sequence of the Ras oncogene for possible mutations in six Wilms' tumours showing loss of heterozygosity for chromosome region 11p15. No tumour analysed showed HRAS sequence mutations. We conclude that loss of heterozygosity at 11p15 does not implicate HRAS mutations in the molecular pathogenesis of Wilms' tumour.			BAIRD, P (corresponding author), INST CHILD HLTH,DEPT HAEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,LONDON WC1N 1EH,ENGLAND.			Cowell, John/0000-0002-2079-5950; Baird, Paul/0000-0002-1305-3502				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEK J, 1990, ONCOGENE, V5, P893; Beckwith JB, 1963, W SOC PEDIAT RES; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; Maniatis T., 1982, MOL CLONING; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MATSUNAGA E, 1981, HUM GENET, V57, P231; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; TURLEAU C, 1984, HUM GENET, V67, P219, DOI 10.1007/BF00273006; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WADEY RB, 1990, ONCOGENE, V5, P901; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WIEDEMANN H. R., 1964, J GENET HUM, V13, P223; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807	29	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1147	1149						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861864				2022-12-28	WOS:A1991GV26000008
J	BERNARDS, A				BERNARDS, A			PREDICTED TYK2 PROTEIN CONTAINS 2 TANDEM PROTEIN-KINASE DOMAINS	ONCOGENE			English	Note							TYROSINE KINASES; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; CLONING; GENES	Tyk2 was recently described as an 1187 amino acid protein with a putative protein-tyrosine kinase domain near its C-terminus and no similarity to other proteins in the approximately 900 amino acids preceding the kinase domain. I report here, however, that tyk2 contains an additional protein kinase domain, and that the two tandem kinase domains are preceded by an SH2-like, putative regulatory domain.			BERNARDS, A (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,DEPT MOLEC GENET,BLDG 149,13TH ST,BOSTON,MA 02129, USA.							BUSS JE, 1984, J VIROL, V53, P7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; PAWSON T, 1988, ONCOGENE, V3, P491; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	13	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1185	1187						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861866				2022-12-28	WOS:A1991GV26000013
J	BARNEKOW, A; JAHN, R; SCHARTL, M				BARNEKOW, A; JAHN, R; SCHARTL, M			SYNAPTOPHYSIN - A SUBSTRATE FOR THE PROTEIN TYROSINE KINASE PP60C-SRC IN INTACT SYNAPTIC VESICLES	ONCOGENE			English	Article									UNIV GIESSEN,INST MED VIROL,W-6300 GIESSEN,GERMANY; MAX PLANCK INST PSYCHIAT,W-8033 MARTINSRIED,GERMANY; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Justus Liebig University Giessen; Max Planck Society; Max Planck Society				Schartl, Manfred/0000-0001-9882-5948; Jahn, Reinhard/0000-0003-1542-3498				BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BARNEKOW A, 1984, BIOCHIM BIOPHYS ACTA, V782, P94, DOI 10.1016/0167-4781(84)90110-6; BARNEKOW A, 1989, Critical Reviews in Oncogenesis, V1, P277; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ERIKSON RL, 1980, COLD SPRING HARB SYM, V4, P907; FINDIK D, 1988, FEBS LETT, V235, P51, DOI 10.1016/0014-5793(88)81232-8; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HEUSER JE, 1981, J CELL BIOL, V88, P560; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANESS PF, 1986, J NEUROSCI RES, V16, P127, DOI 10.1002/jnr.490160113; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTINEZ R, 1987, SCIENCE, V237, P441; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; PANG D T, 1988, Society for Neuroscience Abstracts, V14, P106; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P734; RAULF F, 1989, ONCOGENE RES, V5, P39; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SCHARTL M, 1982, DIFFERENTIATION, V23, P109, DOI 10.1111/j.1432-0436.1982.tb01273.x; SCHARTL M, 1989, ONCOGENE, V4, P1185; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1988, ONCOGENE RES, V2, P345; WALAAS SI, 1988, MOL BRAIN RES, V3, P215, DOI 10.1016/0169-328X(88)90044-7; ZIEMIECKI A, 1980, J GEN VIROL, V50, P211, DOI 10.1099/0022-1317-50-1-211	40	109	111	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1019	1024						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695724				2022-12-28	WOS:A1990DP41500009
J	ONNO, M; NAKAMURA, T; HILLOVA, J; HILL, M				ONNO, M; NAKAMURA, T; HILLOVA, J; HILL, M			REARRANGEMENT OF THE HUMAN TRE ONCOGENE BY HOMOLOGOUS RECOMBINATION BETWEEN ALU REPEATS OF NUCLEOTIDE-SEQUENCES FROM 2 DIFFERENT CHROMOSOMES	ONCOGENE			English	Note							B-CELL NEOPLASMS; BCR GENE; FAMILIAL HYPERCHOLESTEROLEMIA; STRUCTURAL ALTERATIONS; RECIPROCAL PARTNERS; MOLECULAR-CLONING; TRANSFORMING GENE; ACUTE LEUKEMIAS; DNA FRAGMENTS; C-MYC	The rearranged region of the tre oncogene originating from chromosomes 5q23q31 and 18q12 was cloned from tumor genomic DNA, sequenced and aligned with wild-type sequences cloned from a normal human genomic library. In the breakpoint region each wild-type sequence contained two Alu repeats. The recombination occurred between the 3'-most Alu from chromosome 5 and the 5'-most Alu from chromosome 18 and, consequently, resulted in a hybrid Alu flanked with one Alu on either side. The recombinant joint was located to a 20-bp homology region in left arms of the Alu repeats involved in recombination. The same homology region was identified in the hybrid Alu of the rearranged tre. At its 5' extremity the homology region overlaps the B box of Alu-borne RNA polymerase III promoter. The 100% identity score in the region of homology suggests that the recombination process was conservative and not error prone.	INST CANC & IMMUNOGENET, CELLULAR & MOLEC BIOL LAB, 14 AVE PAUL VAILLANT COUTURIER, F-94804 VILLEJUIF, FRANCE; INST CANC & IMMUNOGENET, CNRS, UNITE SDI 6204, F-94804 VILLEJUIF, FRANCE	Centre National de la Recherche Scientifique (CNRS)								ANACHKOVA B, 1985, BIOCHEM BIOPH RES CO, V128, P101, DOI 10.1016/0006-291X(85)91650-X; ANDERSON RA, 1986, MOL CELL BIOL, V6, P3246, DOI 10.1128/MCB.6.9.3246; AVIDI L, 1980, HUMAN GENET, V55, P281; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHEN SJ, 1989, ONCOGENE, V4, P195; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; EVA A, 1987, ONCOGENE, V1, P355; HALVERSON D, 1990, ONCOGENE, V5, P1085; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRST MC, 1991, ONCOGENE, V6, P153; HUEBNER K, 1988, ONCOGENE, V3, P449; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; IHLE JN, 1989, J VIROL, V63, P2959, DOI 10.1128/JVI.63.7.2959-2966.1989; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KORNREICH R, 1990, J BIOL CHEM, V265, P9319; LANGLOIS S, 1988, AM J HUM GENET, V43, P60; LAZO PA, 1988, J VIROL, V62, P788, DOI 10.1128/JVI.62.3.788-794.1988; LEBEAU MM, 1986, BLOOD, V67, P849; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; MARKERT ML, 1988, J CLIN INVEST, V81, P1323, DOI 10.1172/JCI113458; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; MONTIEL JF, 1984, NUCLEIC ACIDS RES, V12, P1049, DOI 10.1093/nar/12.2.1049; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NALBANTOGLU J, 1988, J MOL BIOL, V200, P449, DOI 10.1016/0022-2836(88)90535-9; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; NOTTENBURG C, 1987, J VIROL, V61, P1828, DOI 10.1128/JVI.61.6.1828-1833.1987; PAOLELLA G, 1983, EMBO J, V2, P691, DOI 10.1002/j.1460-2075.1983.tb01486.x; PICCOLI SP, 1984, NATURE, V310, P327, DOI 10.1038/310327a0; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	49	37	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2519	2523						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461655				2022-12-28	WOS:A1992KA85600018
J	FEINSTEIN, E; GALE, RP; REED, J; CANAANI, E				FEINSTEIN, E; GALE, RP; REED, J; CANAANI, E			EXPRESSION OF THE NORMAL P53 GENE INDUCES DIFFERENTIATION OF K562 CELLS	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; WILD-TYPE P53; CYCLE CONTROL; LINE; GROWTH; SUPPRESSION; MECHANISMS; PROTEIN	The multistep nature of human cancers is well illustrated by chronic myelogenous leukemia (CML), a clonal hematologic malignancy with two distinct phases: chronic and acute. Transition between these phases is characterized by unregulated growth and loss of differentiation of myeloid cells and their progenitors. We recently reported that loss of normal p53 expression correlates with transition from the chronic to acute phase in at least 25% of cases of CML. However, the precise relationship between this loss and biologic features of acute-phase CMI, is uncertain. To study this question, we artificially expressed normal p53 in K562, an erythroid acute-phase CML cell line lacking normal p53 expression. Biological effects were assessed by determining several growth parameters and by measuring synthesis of hemoglobin, a feature of mature erythroid cells. K562 cells expressing normal p53 had an increased proportion of cells in G1 versus S + G2, a longer doubling time and a lower growth saturation density than control K562 cells or K562 cells with antisense p53. Cells with normal p53 also expressed up to 50-fold more hemoglobin than controls. These data are consistent with the notion that loss of p53 expression may be responsible for many of the features of acute-phase CML cells. The data also demonstrate direct involvement of p53 in differentiation processes.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19103; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL,PHILADELPHIA,PA 19107	Weizmann Institute of Science; University of California System; University of California Los Angeles; University of Pennsylvania; Jefferson University								ARLINGHAUS RB, 1991, MOL APPROACHES STUDY; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EISBRUCH A, 1988, CANCER-AM CANCER SOC, V62, P1171, DOI 10.1002/1097-0142(19880915)62:6<1171::AID-CNCR2820620621>3.0.CO;2-8; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FEINSTEIN E, 1987, NATURE, V330, P386; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; LUFTIG RB, 1977, J VIROL, V23, P799, DOI 10.1128/JVI.23.3.799-810.1977; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; REED JC, 1989, ONCOGENE, V4, P1123; RICHARDSON JM, 1987, CANCER RES, V47, P4066; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410	24	118	123	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1853	1857						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501893				2022-12-28	WOS:A1992JJ37600022
J	GILLADOGA, AD; EDELHOFF, S; BLACKWOOD, EM; EISENMAN, RN; DISTECHE, CM				GILLADOGA, AD; EDELHOFF, S; BLACKWOOD, EM; EISENMAN, RN; DISTECHE, CM			MAPPING OF MAX TO HUMAN CHROMOSOME-14 AND MOUSE CHROMOSOME-12 BY INSITU HYBRIDIZATION	ONCOGENE			English	Note							GENE; ABNORMALITIES; LOCALIZATION	The protein encoded by the MAX gene is a member of the class of basic region-helix-loop-helix-zipper proteins and has been demonstrated to associate with N-, L-, and c-Myc proteins both in vitro and in vivo. Heterodimers formed between c-Myc and Max proteins have been shown to possess sequence-specific DNA-binding activity. Here we report the mapping of the MAX gene to a single region on human chromosome 14 (bands q22-q24) and to mouse chromosome 12 (region D). Chromosome abnormalities linked to several neoplasms have been previously associated with this region on human chromosome 14. The mapping results also confirm a region of homology between human chromosome 14q22-24 and mouse chromosome 12 region D.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [R01CA057138, T32CA009437] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09437, R01CA57138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERBERICH SJ, IN PRESS ONCOGENE; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLACKWOOD EM, 1992, IN PRESS CURR OPIN G; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; EISEMAN RN, ONCOGENES MOL ORIGIN, P175; GAHRTON G, 1980, BLOOD, V56, P640; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; MAGRATH I, 1990, ADV CANCER RES, V55, P137; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; TEDDER TF, 1988, J IMMUNOL, V141, P4388; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; 1990, CYTOGENET CELL GENET, V55, P1	16	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1249	1251						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594250				2022-12-28	WOS:A1992HU64200024
J	TAKAYAMA, H; SUZUKI, T; MUGISHIMA, H; FUJISAWA, T; OOKUNI, M; SCHWAB, M; GEHRING, M; NAKAMURA, Y; SUGIMURA, T; TERADA, M; YOKOTA, J				TAKAYAMA, H; SUZUKI, T; MUGISHIMA, H; FUJISAWA, T; OOKUNI, M; SCHWAB, M; GEHRING, M; NAKAMURA, Y; SUGIMURA, T; TERADA, M; YOKOTA, J			DELETION MAPPING OF CHROMOSOME-14Q AND CHROMOSOME-1P IN HUMAN NEUROBLASTOMA	ONCOGENE			English	Article							N-MYC AMPLIFICATION; NEURO-BLASTOMA; CELL CARCINOMA; HETEROZYGOSITY; CANCER; TUMOR; GENES; DNA; ADENOCARCINOMA; ABNORMALITIES	It has been suggested that loss of heterozygosity (LOH) on the short arm of chromosome 1 is a critical event for the development of neuroblastoma, and we have previously shown frequent LOH on chromosome 14 in neuroblastoma. To pursue these observations, especially to define further the regions which are commonly deleted in the tumor, we examined for allelic losses in 27 cases of neuroblastomas by using a number of polymorphic DNA markers for chromosomes 14q and 1p. LOH was observed in 10 out of the 25 informative cases (40%) on chromosome 14q and in eight out of the 21 informative cases (38%) on 1p. The commonly deleted regions were distal to the D14S13 locus (14q32-qter) on chromosome 14 and distal to the D1S112 locus (1p36.1-pter) on chromosome 1. These results strongly suggest that tumor-suppressor genes important in the pathogenesis of human neuroblastoma are located on the distal part of both chromosomes 14q and 1p.	NATL CANC CTR,RES INST,1-1 TSUKIJI,5-CHOME,TOKYO 104,JAPAN; NIHON UNIV,SCH MED,DEPT PEDIAT,ITABASHI KU,TOKYO 173,JAPAN; GERMAN CANC RES CTR,INST EXPTL PATHOL,W-6900 HEIDELBERG 1,GERMANY; JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOKYO 170,JAPAN	National Cancer Center - Japan; Nihon University; Helmholtz Association; German Cancer Research Center (DKFZ); Japanese Foundation for Cancer Research				Licka, Manuela/0000-0002-5270-5294				BRODEUR GM, 1981, CANCER RES, V41, P4678; DEVILEE P, 1991, CANCER RES, V51, P1020; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GILBERT F, 1984, CANCER RES, V44, P5444; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; KEATS BJB, 1990, CYTOGENET CELL GENET, V55, P387, DOI 10.1159/000133023; KIDD KK, 1989, CYTOGENET CELL GENET, V51, P622, DOI 10.1159/000132810; KOVACS G, 1989, CANCER RES, V49, P651; LEISTER I, 1990, CANCER RES, V50, P7232; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; NAKAMURA Y, 1989, GENOMICS, V4, P76, DOI 10.1016/0888-7543(89)90317-0; SASAKI M, 1989, CANCER RES, V49, P4402; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIMON D, 1991, ONCOGENE, V6, P765; SUZUKI T, 1989, CANCER RES, V49, P1095; TSAI YC, 1990, CANCER RES, V50, P44; TSUDA T, 1987, CANCER, V60, P820, DOI 10.1002/1097-0142(19870815)60:4<820::AID-CNCR2820600418>3.0.CO;2-Y; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; YAMADA H, 1986, JPN J CANCER RES, V77, P370; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	29	95	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1185	1189						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594247				2022-12-28	WOS:A1992HU64200016
J	RAO, VN; REDDY, ESP				RAO, VN; REDDY, ESP			A DIVERGENT ETS-RELATED PROTEIN, ELK-1, RECOGNIZES SIMILAR C-ETS-1 PROTOONCOGENE TARGET SEQUENCES AND ACTS AS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article							LONG TERMINAL REPEAT; AVIAN LEUKEMIA-VIRUS; DNA-BINDING; V-ETS; ERG GENE; C-ETS; CELLS; E26; TRANSLOCATION; LOCALIZATION	The ets oncogene superfamily consists of a family of sequence-specific DNA-binding proteins that activate transcription. We have previously identified two new members of the ets oncogene superfamily, namely elk-1 and elk-2. In this report we show that the recombinant elk-1 protein expressed in bacteria, like the c-ets-1 proto-oncogene, binds in a sequence-specific manner to Moloney murine sarcoma virus long terminal repeat, E74 target sequences and the PEA3 motif (polyoma enhancer), but does not bind to PU box sequences. Thus analysis of the DNA-binding specificity of ets-related proteins supports the view that different members show similar DNA-binding specificity, which is a general feature of the homeobox proteins. Our data using the chloramphenicol acetyltransferase gene linked to a thymidine kinase promoter containing multimers of the elk-1 target sequence indicates that elk-1 functions as a transcriptional activator. Interestingly, although elk-1 is the most divergent of all the members of the ets gene family, it shows very close similarities with c-ets-1 in some of its sequence-specific DNA-binding specificities. Here, we propose a new function for the elk-1 gene to act as a transcriptional activator of retroviruses and DNA tumor viruses.	TEMPLE UNIV,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOLLAND CA, 1987, P NATL ACAD SCI USA, V84, P8662, DOI 10.1073/pnas.84.23.8662; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, IN PRESS ONCOGENE, V6; REDDY ESP, 1991, ERG ELK 1 ELK 2 GUID; REDDY ESP, 1990, CANCER RES, V50, P5013; Sambrook J, 1989, MOL CLONING LABORATO; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK D, 1990, NATURE, V3346, P191; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	43	77	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					65	70						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741166				2022-12-28	WOS:A1992HC22700009
J	HAASE, VH; SNIJDERS, AJ; COOKE, SM; TENG, MN; KAUL, D; LEBEAU, MM; BRUNS, GAP; BERNARDS, A				HAASE, VH; SNIJDERS, AJ; COOKE, SM; TENG, MN; KAUL, D; LEBEAU, MM; BRUNS, GAP; BERNARDS, A			ALTERNATIVELY SPLICED LTK MESSENGER-RNA IN NEURONS PREDICTS A RECEPTOR WITH A LARGER PUTATIVE EXTRACELLULAR DOMAIN	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; TYROSINE KINASE; SEVENLESS PROTEIN; TISSUE; GENES; IDENTIFICATION; LYMPHOCYTES; EXPRESSION; BRAIN	Ltk is a new member of the ros/insulin receptor family of tyrosine kinases that is expressed in murine B-lymphocyte precursors and forebrain neurons. We previously reported that lymphoid ltk cDNAs predict a 69kDa transmembrane glycoprotein, which uses a CUG translational start codon and has a 110 amino acid putative extracellular domain. We now show that the predominant ltk mRNA in brain is alternatively spliced and predicts a protein with a substantially larger extracellular part. The human ltk gene maps to chromosome 15, bands q13-21, a region containing the breakpoint of a recurring chromosomal abnormality in B-cell non-Hodgkin lymphomas.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02129; UNIV CHICAGO,HEMATOL ONCOL SECT,CHICAGO,IL 60637; CHILDRENS HOSP MED CTR,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Chicago; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Haase, Volker Hans/A-6758-2013; Haase, Volker Hans/AAJ-5061-2021; Teng, Michael N./I-5006-2012	Haase, Volker Hans/0000-0002-7051-8994; Teng, Michael N./0000-0002-0722-3659	NATIONAL CANCER INSTITUTE [R35CA042557] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42557] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASLER K, 1988, CELL, V54, P299; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BROOK JD, 1985, HUM GENET, V69, P282; BRUNS GAP, 1979, BIOCHEM GENET, V17, P1031, DOI 10.1007/BF00504344; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX DW, 1989, CYTOGENET CELL GENET, V51, P280, DOI 10.1159/000132795; DONLON TA, 1990, CYTOGENET CELL GENET, V55, P189, DOI 10.1159/000133011; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LATT SA, 1976, CHROMOSOMA, V57, P135, DOI 10.1007/BF00292912; LEBEAU MM, 1984, NATURE, V312, P70, DOI 10.1038/312070a0; LEVINE EG, 1989, BLOOD, V74, P1796; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MARU Y, 1990, ONCOGENE RES, V5, P199; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROWLEY JD, 1977, LANCET, V1, P549; SCOTT AF, 1979, P NATL ACAD SCI USA, V76, P4563, DOI 10.1073/pnas.76.9.4563; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TAHIRA T, 1990, ONCOGENE, V5, P97; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	8	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2319	2325						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662793				2022-12-28	WOS:A1991GX73500021
J	SHAULSKY, G; GOLDFINGER, N; TOSKY, MS; LEVINE, AJ; ROTTER, V				SHAULSKY, G; GOLDFINGER, N; TOSKY, MS; LEVINE, AJ; ROTTER, V			NUCLEAR-LOCALIZATION IS ESSENTIAL FOR THE ACTIVITY OF P53 PROTEIN	ONCOGENE			English	Article							TRANSFORMATION-RELATED PROTEIN; COLI BETA-GALACTOSIDASE; VIRUS-40 TUMOR-ANTIGENS; CELL-CYCLE CONTROL; LARGE-T-ANTIGEN; MONOCLONAL-ANTIBODY; WILD-TYPE; SV40-TRANSFORMED CELLS; SEQUENCE REQUIREMENTS; DNA-REPLICATION	p53 appears to be a growth regulator, the perturbation of which induces changes in normal cell proliferation. Wild-type p53 protein is thought to function as a growth arrest gene, whereas mutant p53, which accumulates in transformed cells, has been shown to enhance malignant transformation. Both wild-type and mutant p53 migrate into the cell nucleus by means of identical nuclear localization signals (NLS) inherent in their primary sequences. Results presented here show that the suppressive activity of wild-type p53 measured as the reduction of transformation of primary rat fibroblasts induced by cotransfection with ras and either E1A or mutant p53, as well as the transformation enhancement of mutant p53 estimated by cooperation with ras in transformation of primary rat fibroblasts, is dependent upon nuclear localization signals in p53 protein. While transfection of unmodified wild-type p53 significantly reduces the number of rat embryonic fibroblast-transformed foci induced by E1A and ras or mutant p53 and ras, the wild-type p53 protein without NLS has completely lost this suppressive activity. Partially defective NLS wild-type p53, with a reduced nuclear accumulation ability, still exhibits some suppressive activity. In addition, we found that plasmids coding for intact mutant p53 protein efficiently cooperate with the ras oncogene, whereas the corresponding plasmids without NLS are totally inert. On this basis we conclude that nuclear localization of both wild-type and mutant p53 is a fundamental feature for manifesting the activities of these proteins. Both the suppressor activity mediated by the wild-type p53 and enhancement of transformation mediated by the mutant p53 require nuclear localization of the proteins to function.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544	Princeton University	ROTTER, V (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.			Shaulsky, Gad/0000-0002-0532-0551				ADDISON C, 1990, ONCOGENE, V5, P423; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DANG CV, 1989, J BIOL CHEM, V264, P18019; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KELMAN Z, 1989, BLOOD, V74, P2318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINGJUN Z, 1988, CELL, V55, P1005; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; MORIN N, 1989, MOL CELL BIOL, V9, P4372, DOI 10.1128/MCB.9.10.4372; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROTTER V, 1983, J IMMUNOL, V181, P329; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6567; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WYCHOWSKI C, 1986, EMBO J, V5, P2569, DOI 10.1002/j.1460-2075.1986.tb04536.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	63	204	206	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2055	2065						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719467				2022-12-28	WOS:A1991GX11900017
J	SUGIYAMA, A; MIYAGI, Y; SHIRASAWA, Y; KUCHINO, Y				SUGIYAMA, A; MIYAGI, Y; SHIRASAWA, Y; KUCHINO, Y			DIFFERENT USAGE OF 2 POLYADENYLYLATION SIGNALS IN TRANSCRIPTION OF THE N-MYC GENE IN RAT-TUMOR CELLS	ONCOGENE			English	Article							CASEIN KINASE-II; DNA-BINDING PROTEINS; LARGE T-ANTIGEN; C-MYC; NUCLEOTIDE-SEQUENCE; ADENOVIRUS E1A; CODING REGION; EXPRESSION; ELEMENTS; FAMILY	The complete nucleotide sequence of a rat genomic DNA fragment of 6.9 kbp containing the entire N-myc gene was determined. A unique structural feature of the rat N-myc gene is the presence of two polyadenylation signals in the exon 3 region resulting in formation of two poly(A)+ N-myc mRNAs of 2.9 and 2.2 kb length. Elevated expression of the 2.9 kb mRNA, which was not due to gene amplification, was observed in normal rat tissues such as brain, adrenal and testis, and in rat tumor cells such as ascites hepatoma AH130, AH70Btc and AH7974 cells, and pituitary tumor GH3 cells. In contrast, expression of 2.2 kb mRNA, for which transcription was terminated at the upstream polyadenylation site, was observed only in GH3 cells.	NATL CANC CTR,RES INST,DIV BIOPHYS,5-1-1 TSUKIJI,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								ASSELIN C, 1989, ONCOGENE, V4, P549; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHELLAPPAN SP, 1990, P NATL ACAD SCI USA, V87, P5878, DOI 10.1073/pnas.87.15.5878; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORRAL M, 1988, EXP CELL RES, V174, P107, DOI 10.1016/0014-4827(88)90146-2; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FOUREL G, 1990, NUCLEIC ACIDS RES, V18, P4918, DOI 10.1093/nar/18.16.4918; HIRVONEN H, 1990, ONCOGENE, V5, P1787; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KATOH K, 1988, NUCLEIC ACIDS RES, V16, P3589, DOI 10.1093/nar/16.8.3589; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KUCHINO Y, 1990, GENETIC BASIS CARCIN, P239; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISEN PD, 1986, CANCER RES, V46, P6217; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; ROSEN N, 1986, CANCER RES, V46, P4139; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAWAI S, 1990, MOL CELL BIOL, V10, P2017, DOI 10.1128/MCB.10.5.2017; SCHWAB M, 1988, ONCOGENE HDB, P381; SHAW APW, 1988, ONCOGENE, V3, P143; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; WEISINGER G, 1988, ONCOGENE, V3, P635; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	43	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2027	2032						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719466				2022-12-28	WOS:A1991GX11900013
J	ROSNET, O; MARCHETTO, S; DELAPEYRIERE, O; BIRNBAUM, D				ROSNET, O; MARCHETTO, S; DELAPEYRIERE, O; BIRNBAUM, D			MURINE FLT3, A GENE ENCODING A NOVEL TYROSINE KINASE RECEPTOR OF THE PDGFR CSF1R FAMILY	ONCOGENE			English	Article							FMS PROTO-ONCOGENE; C-KIT RECEPTOR; GROWTH-FACTOR; CSF-1 RECEPTOR; CDNA CLONING; W-LOCUS; CELL DIFFERENTIATION; EXTRACELLULAR DOMAIN; MOUSE EMBRYOGENESIS; POINT MUTATIONS	Receptor-type tyrosine kinases presenting an extracellular region with five immunoglobulin-like domains, and strongly related by sequence similarities in the intracellular region, constitute a family of receptors involved in development and function of various cell lineages. We have isolated and characterized the mouse Flt3 gene, encoding the sixth member of this family. The Flt3 gene possesses an open reading frame of 3000 nucleotides, and therefore appears to code for a protein of 1000 amino acids. The deduced structure of the FLT3 protein presents all the characteristics of a receptor-type kinase of this family. The gene is expressed in placenta, in various adult tissues including gonads and brain, and in hematopoietic cells. The Flt3 transcript is 3.7 kb long, except in the testis, where two shorter post-meiotic transcripts are detected. These results suggest a role for this novel receptor and its yet unidentified ligand in placenta, gonads and hematopoietic and nervous systems.	INSERM, U119, 27 BLD LEI ROURE, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Rosnet, Olivier/G-3536-2013	Birnbaum, Daniel/0000-0001-7920-9883; Rosnet, Olivier/0000-0002-3020-910X				BAGOT M, 1988, MED SCI, V5, P287; BAIROCH A, 1990, PROSITE DICT PROTEIN; BARKER W, 1978, ATLAS PROTEIN SEQUEN, V5; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRUCE J, 1981, J IMMUNOL, V127, P2496; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DUBREUIL P, 1988, LYMPHOCYTE ACTIVATIO, P351; GALLAND F, 1990, BIOCHIMIE, V72, P759, DOI 10.1016/0300-9084(90)90161-9; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; HALABAN R, 1991, IN PRESS CANCER META; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MULLER R, 1983, MOL CELL BIOL, V3, P1062; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1990, ONCOGENE, V5, P25; RUGH R, 1990, MOUSE ITS REPRODUCTI; RUTA M, 1988, ONCOGENE, V3, P9; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SORRENTINO V, 1991, ONCOGENE, V6, P149; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STEWART W, 1989, Methods in Molecular and Cellular Biology, V1, P73; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	68	308	327	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1641	1650						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1656368				2022-12-28	WOS:A1991GX27400020
J	GISHIZKY, ML; MCLAUGHLIN, J; PENDERGAST, AM; WITTE, ON				GISHIZKY, ML; MCLAUGHLIN, J; PENDERGAST, AM; WITTE, ON			THE 5' NONCODING REGION OF THE BCR/ABL ONCOGENE AUGMENTS ITS ABILITY TO STIMULATE THE GROWTH OF IMMATURE LYMPHOID-CELLS	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL ONCOGENE; PHILADELPHIA-CHROMOSOME; BONE-MARROW; V-ABL; FUSED TRANSCRIPT; TRANSGENIC MICE	The Philadelphia chromosome (Ph1, t9: 22; 34:q11) is a reciprocal translocation between chromosome 22 and chromosome 9 which results in the formation of the chimeric BCR/ABL oncogene. Alternative forms of BCR/ABL are produced by splicing different sets of exons of the BCR gene to a common set of c-ABL sequences. This results in the formation of an 8.7 kilobase mRNA that encodes the P210 BCR/ABL gene product or a 7.0 kilobase mRNA that encodes the P185 BCR/ABL gene product. Both BCR/ABL transcripts derive their 5' non-coding sequences from the BCR gene locus. This 5' region is over 500 nucleotides in length, has a GC content > 75% and has a short open reading frame. To determine if this unusual 5' non-coding region plays a role in BCR/ABL transformation, we prepared retroviral vectors containing identical BCR/ABL coding regions but differing in the length of the BCR 5' non-coding region. Matched viral stocks were evaluated for their ability to transform bone marrow in vitro and for their ability to cause tumors when inoculated into 3- to 4-week-old mice. In this report we present the unexpected finding that the BCR/ABL 5' non-coding region augments the transforming activity of both P210 and P185 BCR/ABL in vitro. In vivo, BCR/ABL is a weak tumorigenic agent and its potency is enhanced by the presence of the 5' non-coding region.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles				Pendergast, Ann Marie/0000-0002-1250-6880				ABELSON HT, 1970, CANCER RES, V30, P2208; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; CLARK SS, 1989, ANNU REV MED, V40, P113; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; Hariharan I K, 1988, Oncogene Res, V3, P387; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LANDAU NR, 1984, P NATL ACAD SCI-BIOL, V81, P5836, DOI 10.1073/pnas.81.18.5836; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MELTON DA, 1989, CIBA F SYMP, V144, P16; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROSENBERG N, 1978, J EXP MED, V147, P1126, DOI 10.1084/jem.147.4.1126; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SHEN FW, 1985, P NATL ACAD SCI USA, V82, P7360, DOI 10.1073/pnas.82.21.7360; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608	50	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1299	1306						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886706				2022-12-28	WOS:A1991GX27200001
J	FISHER, F; JAYARAMAN, PS; GODING, CR				FISHER, F; JAYARAMAN, PS; GODING, CR			C-MYC AND THE YEAST TRANSCRIPTION FACTOR PHO4 SHARE A COMMON CACGTG-BINDING MOTIF	ONCOGENE			English	Article							LOOP-HELIX PROTEIN; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; LEUCINE ZIPPER; REGULATORY PROTEINS; PHOSPHATASE REGULON; EXPRESSION; DIFFERENTIATION; GENE; ONCOGENE	The basic-helix-loop-helix (b-HLH) motif is common to a number of proteins involved in transcriptional regulation and cell-type determination. The b-HLH motif is also present in the S. cerevisiae transcription factor PHO4 which positively regulates the acid phosphatase gene PHO5. In this report we show that the b-HLH region of PHO4 is sufficient to confer specific DNA-binding to the sequence CACGTG and, by comparison of the basic regions of PHO4 with those of other recently isolated CACGTG-binding proteins, we identify a specific subset of conserved amino acids in the basic region likely to confer DNA-binding specificity. On the basis of these observations we predict successfully the effect of substituting the PHO4 basic region with that from c-myc and show that the chimaeric protein activates transcription from the CACGTG elements present in the PHO5 UAS. From these data it is clear that the myc basic region confers specific binding to the sequence CACGTG.	MARIE SKLODOWSKA CURIE MEM INST,CHART,OXTED RH8 0TL,SURREY,ENGLAND		GODING, CR (corresponding author), MARIE SKLODOWSKA CURIE MEM INST,CHART,OXTED RH8 0TL,SURREY,ENGLAND.			Goding, Colin/0000-0002-1614-3909; /0000-0002-6500-9095				ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; ARIMA K, 1983, NUCLEIC ACIDS RES, V11, P1657, DOI 10.1093/nar/11.6.1657; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEGRAIN M, 1986, NUCLEIC ACIDS RES, V14, P3059, DOI 10.1093/nar/14.7.3059; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; YOSHIDA K, 1989, MOL GEN GENET, V217, P31, DOI 10.1007/BF00330939	36	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1099	1104						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861859				2022-12-28	WOS:A1991GV26000001
J	VANDERHOORN, FA; SPIEGEL, JE; MAYLIEPFENNINGER, MF; NORDEEN, SK				VANDERHOORN, FA; SPIEGEL, JE; MAYLIEPFENNINGER, MF; NORDEEN, SK			A 43 KD C-MOS PROTEIN IS ONLY EXPRESSED BEFORE MEIOSIS DURING RAT SPERMATOGENESIS	ONCOGENE			English	Article							DISTINCT DEVELOPMENTAL PATTERNS; MOUSE GERM-CELLS; ONCOGENE PRODUCT; PROTOONCOGENE EXPRESSION; MEIOTIC MATURATION; XENOPUS OOCYTES; SEQUENCE; RNA; FEMALE; TRANSCRIPTS	We have investigated the RNA and protein expression pattern of the rat c-mos proto-oncogene during spermatogenesis. In mouse testis a 43 kD c-mos protein is expressed throughout spermatogenesis, which is in agreement with one report detecting a 1.7 kb c-mos RNA in pachytene spermatocytes and in early spermatids. However, several other reports show that the mouse 1.7 kb c-mos RNA is exclusively expressed in postmeiotic male germ cells. We report that in rat male germ cells three c-mos RNA species of 5, 3.6 and 1.7 kb are detectable by Northern blotting analysis both before and after meiosis, with highest levels in early spermatids. However, western immuno-blot analysis reveals the presence of a 43 kD c-mos protein in total testis and pachytene spermatocytes, but not in post-meiotic cells. These findings combined with those made in the mouse system strongly suggest that c-mos protein may be a regulator of meiosis during spermatogenesis.	UNIV COLORADO,DEPT PATHOL,BOULDER,CO 80309; UNIV COLORADO,DEPT CELLULAR & STRUCT BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	VANDERHOORN, FA (corresponding author), UNIV CALGARY,DEPT MED BIOCHEM,3330 HOSP DR NW,CALGARY T2N 4N1,ALBERTA,CANADA.							BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GROOTEGOED JA, 1977, BIOCHEM J, V168, P23, DOI 10.1042/bj1680023; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; KESHET E, 1988, ONCOGENE, V2, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; VANDERHOORN F, 1986, NUCLEIC ACIDS RES, V14, P8771, DOI 10.1093/nar/14.22.8771; VANDERHOORN FA, 1985, MOL CELL BIOL, V5, P2204, DOI 10.1128/MCB.5.9.2204; VANDERHOORN FA, 1987, J MOL BIOL, V193, P255, DOI 10.1016/0022-2836(87)90217-8; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; VANDERHOORN FA, 1989, BIOCHEM BIOPH RES CO, V161, P8, DOI 10.1016/0006-291X(89)91552-0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0	28	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					929	932						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1712445				2022-12-28	WOS:A1991GU62200006
J	STAPLETON, P; TAKAYAMA, Y; HARTSHORN, A; KALAIZIS, A; ROWE, PB; SYMONDS, G				STAPLETON, P; TAKAYAMA, Y; HARTSHORN, A; KALAIZIS, A; ROWE, PB; SYMONDS, G			TUMOR PROGRESSION FOLLOWING TRANSFORMATION OF MURINE MONOCYTES BY V-MYC - ACQUISITION OF IMMORTALIZATION AND TUMORIGENICITY	ONCOGENE			English	Article							C-FOS EXPRESSION; NUCLEOTIDE-SEQUENCE; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; MACROPHAGE DIFFERENTIATION; AUTOCRINE GROWTH; MOUSE MACROPHAGE; LEUKEMIA VIRUSES	Monocyte transformation by the v-myc oncogene has been used to study myelomonocytic tumor progression in vitro. Murine monocytes transformed by a recombinant retrovirus containing MC29 v-myc were found to exhibit a proliferative burst to day 28-40 post-infection. Thereafter growth slowed and cell number remained relatively static-to day 80-90 post-infection. During both the proliferative and quiescent periods, the cells were dependent on the myelomonocytic growth factor CSF-1 for growth and viability. Analysis of this transformation revealed that the initial transformants were polyclonal, non-immortal, and non-tumorigenic in syngeneic mice. At day 80-90 post infection, a fresh round of cellular proliferation occurred and, in contrast to the initial burst, growth was sustained allowing the establishment of cell lines. These lines were found to be monoclonal, immortal, growth factor independent and, in certain cases, tumorigenic in syngeneic mice. Associated with the establishment of growth factor independent cell lines was the constitutive synthesis of the myelomonocytic growth factor, CSF-1. Proto-oncogene screening of the initial transformants and the cell lines also revealed the expression of c-raf and the CSF-1 receptor, c-fms. Our results indicate that, following transformation by v-myc, monocytes can progress in vitro to become growth factor independent and immortal and that both monocyte transformation and immortalization can be dissociated from tumorigenicity.	CHILDRENS MED RES FDN,LEUKAEMIA RES & VIRAL PATHOL UNIT,POB 61,CAMPERDOWN,NSW 2050,AUSTRALIA; CHILDRENS MED RES FDN,DEV BIOL UNIT,CAMPERDOWN,NSW 2050,AUSTRALIA	Children's Medical Research Institute - Australia; Children's Medical Research Institute - Australia	SYMONDS, G (corresponding author), CHILDRENS MED RES FDN,LEUKAEMIA RES & VIRAL PATHOL UNIT,POB 61,CAMPERDOWN,NSW 2050,AUSTRALIA.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ALEXANDER RW, 1979, J NATL CANCER I, V62, P359; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BISHOP JM, 1985, MOL BIOL TUMOR VIRUS, P249; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CALABRETTA B, 1987, MOL CELL BIOL, V7, P769, DOI 10.1128/MCB.7.2.769; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; Cleveland J L, 1988, Oncogene Res, V3, P357; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; CORY S, 1987, ONCOGENE RES, V1, P61; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DEAN M, 1987, ONCOGENE RES, V1, P279; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DUESBERG PH, 1979, P NATL ACAD SCI USA, V76, P1633, DOI 10.1073/pnas.76.4.1633; FALK A, 1980, INT J CANCER, V26, P595, DOI 10.1002/ijc.2910260511; FRYKBERG L, 1987, ONCOGENE, V1, P415; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREEN SM, 1989, ONCOGENE, V4, P737; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HAYMAN MJ, 1983, CURR TOP MICROBIOL, V103, P109; HIGUCHI Y, 1988, ONCOGENE, V2, P515; HO MK, 1982, J IMMUNOL, V128, P1221; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KLEMENT V, 1977, METHOD VIROL, V6, P97; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF D, 1984, HEMOPOIETIC COLONIES; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; SARIBAN E, 1987, BLOOD, V69, P1437; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1981, J BIOL CHEM, V256, P3833; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STORM SM, 1990, ONCOGENE, V5, P345; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; SYMONDS G, 1982, EMBO J, V1, P1343, DOI 10.1002/j.1460-2075.1982.tb01320.x; SYMONDS G, 1989, ONCOGENE, V4, P285; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VOGT M, 1989, ONCOGENE RES, V4, P19; VONWEIZSACKER F, 1986, EMBO J, V5, P1521, DOI 10.1002/j.1460-2075.1986.tb04392.x; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146	67	14	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					807	817						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1711191				2022-12-28	WOS:A1991GT82500017
J	ALEXANDRE, C; VERRIER, B				ALEXANDRE, C; VERRIER, B			4 REGULATORY ELEMENTS IN THE HUMAN C-FOS PROMOTER MEDIATE TRANSACTIVATION BY HTLV-1 TAX PROTEIN	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; SERUM RESPONSE ELEMENT; MULTIPLE SEQUENCE ELEMENTS; CYCLIC-AMP; GROWTH-FACTOR; RAPID INDUCTION; AUTO-REGULATION; ONCOGENE FOS; ACTIN GENES; T-CELLS	Expression of the human c-fos proto-oncogene is activated in trans by the Tax protein encoded by human T-cell leukemia virus type-1 (HTLV-1). Indeed, we show here that a HeLa clone stably transfected by Tax expresses Fos at a high level. We also show that multiple elements of the human c-fos promoter, i.e. the v-sis conditioned medium inducible element (SIE), the dyad symmetry element (DSE) necessary for growth factor induction, the octanucleotide direct repeat element (DR), and the cyclic AMP response element (CRE) centred at -60, can all mediate Tax transactivation. In the DSE, the 10 bp central core that binds the serum response factor (SRF) is, by itself, sufficient to mediate Tax transactivation. Moreover, a CRE-binding protein is involved in Tax activation through the CRE-60 element. Since Fos is a transregulator of cellular genes, our results suggest that the oncoprotein plays a crucial role in T-cell transformation by HTLV-1 in conjunction with other Tax-inducible genes.	ECOLE NORMALE SUPER LYON,CNRS,UNITE BIOMERIEUX 103,46 ALLEE ITALIE,F-69364 LYONS 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)			verrier, bernard/J-4094-2017	verrier, bernard/0000-0002-8478-7095				ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; BALLARD D W, 1989, New Biologist, V1, P83; BEIMLING P, 1990, ONCOGENE, V5, P361; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOHNLEIN E, 1989, J VIROL, V63, P1578; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Curran T, 1988, ONCOGENE HDB, P307; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1212; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RUBEN S M, 1989, New Biologist, V1, P275; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SEIKI M, 1985, GANN, V76, P1127; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	60	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					543	551						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827666				2022-12-28	WOS:A1991FR93900007
J	CECI, JD; KOVATCH, RM; SWING, DA; JONES, JM; SNOW, CM; ROSENBERG, MP; JENKINS, NA; COPELAND, NG; MEISLER, MH				CECI, JD; KOVATCH, RM; SWING, DA; JONES, JM; SNOW, CM; ROSENBERG, MP; JENKINS, NA; COPELAND, NG; MEISLER, MH			TRANSGENIC MICE CARRYING A MURINE AMYLASE-2.2/SV40 T-ANTIGEN FUSION GENE DEVELOP PANCREATIC ACINAR CELL AND STOMACH CARCINOMAS	ONCOGENE			English	Article							AMYLASE GENE; ALPHA-AMYLASES; DIABETIC MICE; HYBRID GENE; EXPRESSION; INSULIN; TUMORS; NEOPLASIA; DNA; ONCOGENES	The mouse pancreatic amylase Amy-2.2 gene was fused to the structural gene for SV40 T antigen, and 51 independent transgenic founder mice carrying the fusion gene were generated. The majority of the founders and 100% of their offspring in the derived transgenic lines developed pancreatic acinar cell carcinomas and stomach carcinomas. Transgenic animals also had a high incidence of metastatic carcinomas in other tissues. The development of stomach carcinomas was unexpected because the Amy-2.2 promoter was not previously known to be expressed in stomach. Northern blot analyses and ribonuclease protection assays showed that Amy-2.2 is expressed in stomach, at approximately 0.05% of the level in pancreas. Expression of the fusion gene in stomach, therefore, appears to represent a previously unrecognized activity of the Amy-2.2 promoter. Examination of young transgenic mice demonstrated that preneoplastic lesions were present in pancreas and stomach before the development of neoplastic lesions in either tissue, consistent with the notion that stomach neoplasms are primary neoplasms and not metastases from the pancreas. Ribonuclease protection assays demonstrated that properly initiated large T and small t antigen transcripts were present in pancreas and stomach during tumorigenesis. T antigen protein was also detected in pancreas and stomach by immunohistochemistry. A time course for tumorigenesis was established for several transgenic mouse lines in which distinct types of lesions appeared at predictable times. This study provides the basis for future analysis of the role of SV40 T antigen in the progression and maintenance of pancreatic and stomach carcinomas.	SQUIBB INST MED RES,DEPT MOLEC BIOL,PRINCETON,NJ 08543; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024872] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIGMS NIH HHS [GM 24872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; CARDESA A, 1979, PATHOLOGY TUMOURS LA, V2, P235; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; DRANGINIS A, 1984, J BIOL CHEM, V259, P2216; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; FOX N, 1989, SCIENCE, V244, P460, DOI 10.1126/science.2785714; GUMUCIO DL, 1985, J BIOL CHEM, V260, P3483; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARDING JD, 1978, J BIOL CHEM, V253, P8736; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Karn R.C., 1978, ADVANCES IN COMPARATIVE PHYSIOLOGY AND BIOCHEMISTRY, V7, P1; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KOIKE K, 1989, P NATL ACAD SCI USA, V86, P5615, DOI 10.1073/pnas.86.14.5615; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Merritt A D, 1977, Adv Hum Genet, V8, P135; MESSING A, 1988, ONCOGENE RES, V3, P87; ODASHIMA S, 1979, PATHOLOGY TUMOURS LA, V2, P147; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; OSBORN L, 1988, J BIOL CHEM, V263, P16519; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PATEL PH, 1987, HOSP PRACT, V22, P131; ROSSINI AA, 1977, DIABETES, V26, P916, DOI 10.2337/diabetes.26.10.916; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMUELSON LC, 1988, MOL CELL BIOL, V8, P3857, DOI 10.1128/MCB.8.9.3857; SANDGREN EP, 1989, ONCOGENE, V4, P715; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SIRACUSA LD, 1987, GENETICS, V117, P85; TOOZE J, 1980, DNA TUMOR VIRUSES, P799; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987	40	40	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					323	332						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1705690				2022-12-28	WOS:A1991FZ13400020
J	RIGHI, M; SASSANO, M; VALSASNINI, P; SHAMMAH, S; RICCIARDICASTAGNOLI, P				RIGHI, M; SASSANO, M; VALSASNINI, P; SHAMMAH, S; RICCIARDICASTAGNOLI, P			ACTIVATION OF THE M-CSF GENE IN MOUSE MACROPHAGES IMMORTALIZED BY RETROVIRUSES CARRYING A V-MYC ONCOGENE	ONCOGENE			English	Article							AVIAN LEUKEMIA VIRUSES; C-MYC; NUCLEOTIDE-SEQUENCE; MURINE RETROVIRUSES; MESSENGER-RNA; GROWTH-FACTOR; CELL-LINES; MONOCLONAL-ANTIBODY; TUMORS INVIVO; TRANSFORMATION	We have recently immortalized murine brain macrophages (microglial cells) with a complex of retroviruses (3RV) transducing separately the myc and mil oncogenes. Surprisingly, the immortalized cells harboured an exogenous v-myc oncogene, but no v-mil sequences. The transformed macrophage cell lines grew in vitro without the addition of exogenous growth factors and were also able to grow in vivo in nude mice. In addition, they released oncogenic retroviruses able to immortalize mouse macrophages from primary splenic or thymic cultures. Molecular cloning of the provirus (VN-11) harboured in a microglial clone demonstrated that no cell-derived sequences apart from an avian v-myc gene were transduced by the recombinant retrovirus. When cells were tested for production of myeloid growth factors, they were found to transcribe and synthesize the Macrophage-Colony Stimulating Factor (M-CSF). The correlation between viral infection and activation of the M-CSF gene was tested using a M-CSF dependent cells line from which growth factor independent clones could be readily obtained after infection. The synthesis of M-CSF was detected only in cells expressing the avian v-myc protein. These data support the hypothesis that, in our conditions, macrophages can be immortalized by the expression of v-myc and the concomitant establishment of an autocrine loop triggered by viral infection.			RIGHI, M (corresponding author), UNIV MILAN,DEPT PHARMACOL,CNR,CTR CYTOPHARMACOL,VIA VANVITELLI 32,I-20129 MILAN,ITALY.		Righi, Marco/P-4332-2019; Righi, Marco Giovanni Enea/M-9003-2019; Righi, Marco Giovanni Enea/G-5171-2011	Righi, Marco Giovanni Enea/0000-0003-1181-0327; Righi, Marco Giovanni Enea/0000-0003-1181-0327				AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; CORY S, 1987, ONCOGENE RES, V1, P61; DEAN M, 1987, ONCOGENE RES, V1, P279; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREEN SM, 1989, ONCOGENE, V4, P737; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HERR W, 1984, J VIROL, V49, P471, DOI 10.1128/JVI.49.2.471-478.1984; HOLLON T, 1989, J VIROL, V63, P3353, DOI 10.1128/JVI.63.8.3353-3361.1989; JANSEN HW, 1985, VIROLOGY, V142, P248, DOI 10.1016/0042-6822(85)90333-2; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; KAN NC, 1983, P NATL ACAD SCI USA, V81, P3004; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; METCALF D, 1982, INT J CANCER, V30, P773, DOI 10.1002/ijc.2910300616; METCALF D, 1984, HEMOPOIETIC COLONIES; MORI L, 1985, EMBO J, V4, P2025, DOI 10.1002/j.1460-2075.1985.tb03887.x; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RIGHI M, 1989, ONCOGENE, V4, P223; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; SAULE S, 1982, J VIROL, V42, P71, DOI 10.1128/JVI.42.1.71-82.1982; SAULE S, 1984, EXP CELL RES, V155, P496, DOI 10.1016/0014-4827(84)90209-X; SHER E, 1989, J CELL BIOL, V108, P2291, DOI 10.1083/jcb.108.6.2291; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SYMONDS G, 1989, ONCOGENE, V4, P285; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VOGT M, 1989, ONCOGENE RES, V4, P19; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	44	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					103	111						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1825138				2022-12-28	WOS:A1991EY03900014
J	WILSON, LK; PARSONS, SJ				WILSON, LK; PARSONS, SJ			ENHANCED EGF MITOGENIC RESPONSE IS ASSOCIATED WITH ENHANCED TYROSINE PHOSPHORYLATION OF SPECIFIC CELLULAR PROTEINS IN FIBROBLASTS OVEREXPRESSING C-SRC	ONCOGENE			English	Article									UNIV VIRGINIA, HLTH SCI CTR,SCH MED,CANC RES CTR,DEPT MICROBIOL, BOX 441, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, INST MOLEC BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA 40042, CA 39438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R01CA039438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHAPRON Y, 1989, BIOCHEM BIOPH RES CO, V158, P527, DOI 10.1016/S0006-291X(89)80081-6; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COHEN S, 1980, J BIOL CHEM, V255, P4834; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EARP HS, 1988, J BIOL CHEM, V263, P13868; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; JOHANSEN JW, 1986, P NATL ACAD SCI USA, V83, P207, DOI 10.1073/pnas.83.2.207; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1989, ONCOGENE, V4, P295; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MULDOON LL, 1988, J BIOL CHEM, V263, P18834; NAKAMURA KD, 1983, MOL CELL BIOL, V3, P380, DOI 10.1128/MCB.3.3.380; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PHILLIPS SA, 1987, FEBS LETT, V212, P141, DOI 10.1016/0014-5793(87)81573-9; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROTHENBERG P, 1983, J BIOL CHEM, V258, P2644; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SQUINTO SP, 1989, MOL ENDOCRINOL, V3, P433, DOI 10.1210/mend-3-3-433; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	46	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1471	1480						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	1701230				2022-12-28	WOS:A1990EK50200005
J	KOLCH, W; WEISSINGER, E; MISCHAK, H; TROPPMAIR, J; SHOWALTER, SD; LLOYD, P; HEIDECKER, G; RAPP, UR				KOLCH, W; WEISSINGER, E; MISCHAK, H; TROPPMAIR, J; SHOWALTER, SD; LLOYD, P; HEIDECKER, G; RAPP, UR			PROBING STRUCTURE AND FUNCTION OF THE RAF PROTEIN-KINASE DOMAIN WITH MONOCLONAL-ANTIBODIES	ONCOGENE			English	Article									NCI,FREDERICK CANC RES FACIL,VIRAL CARCINOGENESIS,FREDERICK,MD 21701; NCI,GENET LAB,BETHESDA,MD 20892; FREDERICK CANC RES FACIL,PROGRAM RESOURCES INC,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kolch, Walter/ABF-2102-2021; Mischak, Harald/E-8685-2011	Troppmair, Jakob/0000-0002-0611-3837; Mischak, Harald/0000-0003-0323-0306; Kolch, Walter/0000-0001-5777-5016				BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; BRYANT D, 1983, J VIROL, V45, P1211, DOI 10.1128/JVI.45.3.1211-1216.1983; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P327, DOI 10.1093/nar/14.1.327; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRERA R, 1986, J BIOL CHEM, V261, P1980; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; HUNTER T, 1986, ENZYMES, V17, P191; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOLCH W, 1988, BIOCHIM BIOPHYS ACTA, V949, P233, DOI 10.1016/0167-4781(88)90087-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVIN LR, 1988, SCIENCE, V240, P68, DOI 10.1126/science.2832943; MOELDERS H, 1985, EMBO (European Molecular Biology Organization) Journal, V4, P693; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1987, P INT C HORMONES GRO; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SOBEL E, 1985, NUCLEIC ACIDS RES, V14, P363; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	39	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					713	720						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	1693184				2022-12-28	WOS:A1990DG37400012
J	ADAMKIEWICZ, J; BRULLER, HJ; GAUSEPOHL, H; FRANK, R; MULLER, R				ADAMKIEWICZ, J; BRULLER, HJ; GAUSEPOHL, H; FRANK, R; MULLER, R			MAPPING OF FUNCTIONAL DOMAINS IN FOS AND JUN PROTEINS USING EPITOPE-SPECIFIC ANTIBODIES	ONCOGENE			English	Article									EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	ADAMKIEWICZ, J (corresponding author), UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADAMSON ED, 1985, EMBO J, V4, P941, DOI 10.1002/j.1460-2075.1985.tb03722.x; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CASTRO B, 1977, J CHEM RES, V182, P2118; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANK R, 1988, MODERN METHODS PROTE, V3, P42; FRANZA BR, 1987, ONCOGENE, V1, P213; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MULLER R, 1987, ONCOGENE RES, V2, P19; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RISSE G, 1989, IN PRESS EMBO J; RIVIER J, 1984, J CHROMATOGR, V288, P303, DOI 10.1016/S0021-9673(01)93709-4; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	45	19	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					525	533						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1691478				2022-12-28	WOS:A1990DB85300011
J	RUGGERI, B; ZHANG, SY; CAAMANO, J; DIRADO, M; FLYNN, SD; KLEINSZANTO, AJP				RUGGERI, B; ZHANG, SY; CAAMANO, J; DIRADO, M; FLYNN, SD; KLEINSZANTO, AJP			HUMAN PANCREATIC CARCINOMAS AND CELL-LINES REVEAL FREQUENT AND MULTIPLE ALTERATIONS IN THE P53 AND RB-1 TUMOR-SUPPRESSOR GENES	ONCOGENE			English	Article							HUMAN PROSTATE CARCINOMA; HUMAN BREAST-CANCER; RETINOBLASTOMA GENE; LUNG-CANCER; MONOCLONAL-ANTIBODIES; POLYPOSIS-COLI; OVARIAN-CANCER; EXPRESSION; MUTATIONS; TRANSFORMATION	The molecular pathology of human pancreatic cancer is poorly understood, particularly with regard to the role of known tumor-suppressor genes. We have examined the expression of the p53 and Rb-1 tumor-suppressor genes in seven human pancreatic carcinoma cell lines and 10 primary pancreatic carcinomas. Examination of the Rb-1 gene by Northern hybridization and immunoprecipitation analyses revealed the absence of Rb-1 protein expression in two cell lines. Moreover, regions of absent nuclear staining in two primary pancreatic carcinomas were detected by immunohistochemical analysis. Investigation of p53 by Southern, Northern, immunohistochemical and immunoprecipitation analyses revealed multiple abnormalities, including gross rearrangements in two cell lines, the absence of detectable p53 transcript in two cell lines and a truncated transcript in one line. Six cell lines overexpressed p53 protein, while one line revealed the absence of p53 product by immunohistochemical and immunoprecipitation analyses. Sequence analysis of exons 5-8 of the p53 gene confirmed these analyses, revealing missense mutations in all seven cell lines in codons 181, 220, 248, 249, 265, 272 and 273. Of 10 mutations identified, nine were transitions and 50% were in codon 273. Immunohistochemical analyses of frozen primary pancreatic carcinomas revealed positive nuclear staining for p53 in 40% of cases. Mutations were identified in codons 238 and 286 and in intron 9 in several representative specimens. Alterations in the p53 and Rb-1 genes may be important features in the development of human pancreatic cancer.	FOX CHASE CANC INST,INST CANC RES,DEPT PATHOL,7701 BURHOLME AVE,PHILADELPHIA,PA 19111; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510	Fox Chase Cancer Center; Yale University			Klein-Szanto, A./E-6218-2010; Caamano, Jorge/O-7530-2019; Caamano, Jorge/I-6778-2012	Caamano, Jorge/0000-0003-3530-7056; Caamano, Jorge/0000-0003-3530-7056	NCI NIH HHS [CA-06927, CA-09035-16] Funding Source: Medline; NCRR NIH HHS [RR-05895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, ONCOGENE, V5, P893; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOS JL, 1989, CANCER RES, V49, P4682; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CAAMANO J, 1991, IN PRESS AM J PATHOL; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CELLO JP, 1989, GASTROINTESTINAL DIS, P1872; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAJOWER MM, 1983, ANN INTERN MED, V98, P111, DOI 10.7326/0003-4819-98-1-111_2; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUNEWALD K, 1989, INT J CANCER, V43, P1037, DOI 10.1002/ijc.2910430614; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HENSEL CH, 1990, CANCER RES, V50, P3067; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLINGSWORTH RE, 1991, J NATL CANCER I, V83, P91, DOI 10.1093/jnci/83.2.91; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAGELMAN DG, 1987, CANCER GENET CYTOGEN, V27, P319, DOI 10.1016/0165-4608(87)90014-8; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEMOINE NR, 1990, BAILLIERE CLIN GASTR, V4, P815, DOI 10.1016/0950-3528(90)90021-8; LEMOINE NR, 1992, J PATHOL, V166, P7, DOI 10.1002/path.1711660103; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; LYNCH HT, 1985, BRIT J CANCER, V52, P271, DOI 10.1038/bjc.1985.187; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARKS JR, 1991, CANCER RES, V51, P2979; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MICHELASSI F, 1989, Italian Journal of Surgical Sciences, V19, P341; MILLER CW, 1990, CANCER RES, V50, P7950; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO A, 1991, CANCER RES, V51, P5632; POSTON GJ, 1991, GUT, V32, P800, DOI 10.1136/gut.32.7.800; Sambrook J, 1989, MOL CLONING LABORATO; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; SOUSSI T, 1990, ONCOGENE, V5, P945; STRATTON MR, 1990, ONCOGENE, V5, P1297; TADA M, 1990, CANCER-AM CANCER SOC, V66, P930, DOI 10.1002/1097-0142(19900901)66:5<930::AID-CNCR2820660519>3.0.CO;2-W; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VARLEY JM, 1989, ONCOGENE, V4, P725; VARLEY JM, 1991, ONCOGENE, V6, P413; WASYLYSHYN ML, 1991, SURGERY, V110, P265; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	74	176	177	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1503	1511						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630814				2022-12-28	WOS:A1992JE81300006
J	YAN, ZF; HSU, S; WINAWER, S; FRIEDMAN, E				YAN, ZF; HSU, S; WINAWER, S; FRIEDMAN, E			TRANSFORMING GROWTH FACTOR-BETA-1 (TGF-BETA-1) INHIBITS RETINOBLASTOMA GENE-EXPRESSION BUT NOT PRB PHOSPHORYLATION IN TGF-BETA-1-GROWTH STIMULATED COLON-CARCINOMA CELLS	ONCOGENE			English	Note							SV40 LARGE-T; SUSCEPTIBILITY GENE; HEXAMETHYLENE BISACETAMIDE; RB GENE; PRODUCT; SUPPRESSION; DIFFERENTIATION; BINDING; CYCLE; TRANSCRIPTION	The response of the retinoblastoma (RB) gene and its product (pRB) to transforming growth factor-beta-1 (TGF-beta-1) was studied in three types of colon carcinoma cells derived from the same parental line. TGF-beta-1 was a growth inhibitor for two enterocytic-differentiated lines, a growth stimulator for two undifferentiated lines, and had no effect on two goblet cell-differentiated lines. TGF-beta-1 treatment for 3 days decreased RB gene expression and pRB level two- to threefold in each responsive line. When treated with TGF-beta-1 beginning in early G1, enterocytic cells were arrested in G1 and pRB remained under-phosphorylated and in low abundance. Neither goblet cell line exhibited these responses to TGF-beta-1 because they were shown to lack TGF-beta-1 type I and II receptors. Thus during colonocyte differentiation goblet cells lose responsiveness to TGF-beta-1 by down-regulating TGF-beta-1 receptors, while enterocytic cells retain and exhibit responsiveness to TGF-beta-1 through modulations of pRB. Both of the undifferentiated lines exhibited mixed responses to TGF-beta-1: a decrease in total amount of RB mRNA and pRB protein yet an increase in pRB phosphorylation consistent with increased cell cycling. Therefore, TGF-beta-1 controls RB function by two separable mechanisms, the regulation of pRB phosphorylation and the control of RB mRNA and protein level.	MEM SLOAN KETTERING CANC CTR,DEPT MED,GASTROENTEROL SERV,BOX 244,1275 YORK AVE,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center								BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Fan D, 1989, Cancer Commun, V1, P117; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KAPUSCINSKI J, 1987, J BIOMOL STRUCT DYN, V5, P127, DOI 10.1080/07391102.1987.10506381; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHROY P, 1990, CANCER RES, V50, P261; SCHROY PC, 1988, CANCER RES, V48, P5487; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1991, ONCOGENE, V6, P1139	37	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					801	805						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565477				2022-12-28	WOS:A1992HQ68200027
J	LUBBERT, M; MIRRO, J; KITCHINGMAN, G; MCCORMICK, F; MERTELSMANN, R; HERRMANN, F; KOEFFLER, HP				LUBBERT, M; MIRRO, J; KITCHINGMAN, G; MCCORMICK, F; MERTELSMANN, R; HERRMANN, F; KOEFFLER, HP			PREVALENCE OF N-RAS MUTATIONS IN CHILDREN WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID-LEUKEMIA	ONCOGENE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; GENE-MUTATIONS; OLIGONUCLEOTIDE PROBES; ONCOGENE ACTIVATION; TUMOR INITIATION; CARCINOGENESIS; PROGRESSION; ADENOCARCINOMA; MECHANISMS; CHILDHOOD	The ras proto-oncogene family encodes a group of 21 kDa nucleotide-binding proteins. Activating mutations of ras genes are associated with certain types of malignancies, indicating that they are related in some way to the malignant process. We have examined bone marrow cells from nine children with myelodysplastic syndromes (MDS) and 35 with acute myeloid leukemia (AML) for activating point mutations of ras genes by in vitro amplification using polymerase chain reaction (PCR), oligonucleotide hybridization and sequencing of PCR products. We found N-ras mutations in cells from 3 of 9 children (33%) with MDS and only 2 of 35 children with AML (6%; 95% confidence interval is 0.7-19%). All mutations the second nucleotide of codon 12 or the first nucleotide of codon 61 of N-ras. There was no apparent correlation with clinical or laboratory characteristics, including karyotype; however, an association of N-ras activation with the most aggressive type of MDS was noted. Among the patients with MDS, 2 of 6 with monosomy 7 had N-ras mutations; however, three children with monosomy 7 which presented with AML lacked ras mutations. One patient was studied at time of diagnosis of MDS and again after progression to AML. At the preleukemic stage of disease, an N-ras mutation was identified; however, after development of AML this mutation was not present in the leukemic clone. In conclusion, these data show that ras mutations, while not necessary for leukemic transformation, may be important for the initiation of preleukemias evolving into overt AML.	UNIV PITTSBURGH, SCH MED, DIV PEDIAT HEMATOL ONCOL, PITTSBURGH, PA 15213 USA; ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38101 USA; CETUS CORP, DEPT MOLEC BIOL, EMERYVILLE, CA 94608 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90048 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; St Jude Children's Research Hospital; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	LUBBERT, M (corresponding author), UNIV FREIBURG, MED CTR, DEPT HEMATOL ONCOL, W-7800 FREIBURG, GERMANY.				NCI NIH HHS [CA42710, CA33936] Funding Source: Medline; PHS HHS [AZ6038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710, P30CA042710, R01CA033936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTRAM CR, 1989, LEUKEMIA, V3, P247; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLOOMFIELD CD, 1987, SEMIN ONCOL, V14, P372; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARDY KJ, 1985, P NATL ACAD SCI USA, V82, P8173, DOI 10.1073/pnas.82.23.8173; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LUBBERT M, 1990, ONCOGENE, V5, P583; LUBBERT M, 1990, BLOOD, V75, P1163; LYONS J, 1988, BLOOD, V71, P1707; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NEUBAUER A, 1991, BLOOD, V77, P594; PADUA RA, 1988, LEUKEMIA, V2, P503; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1986, BLOOD, V67, P1698; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOUSDEN KH, 1984, EMBO J, V3, P913, DOI 10.1002/j.1460-2075.1984.tb01905.x	34	53	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					263	268						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549347				2022-12-28	WOS:A1992HG98200009
J	PRITCHARDJONES, K; FLEMING, S				PRITCHARDJONES, K; FLEMING, S			CELL-TYPES EXPRESSING THE WILMS-TUMOR GENE (WT1) IN WILMS-TUMORS - IMPLICATIONS FOR TUMOR HISTOGENESIS	ONCOGENE			English	Article							TRANSLOCATION BREAKPOINTS; EPIDEMIOLOGICAL FEATURES; GENITOURINARY DYSPLASIA; HUMAN CHROMOSOME-11; BAND 11P13; ANIRIDIA; DELETION; LOCUS; HETEROZYGOSITY; MAP	Wilms' tumour (nephroblastoma), a childhood embryonal kidney tumour, is believed to arise from malignant transformation of abnormally persistent metanephric blastemal cells. At a histological level, tumours show a remarkable mimicry of the normal nephrogenic pathway. There is histological and epidemiological evidence for at least two pathogenetic groupings within Wilms' tumour which may reflect different timings of the tumorigenic insult in this pathway and/or involvement of different genes. Tumorigenesis is thought to result from loss of function of a so-called tumour-suppressor gene which has an essential role in control of normal genitourinary development. Such a candidate, Wilms' tumour gene (WT1) mapping to chromosome 11p13, has been isolated and is known to be mutated in some tumours. We have examined the cell types expressing this gene in 32 Wilms' tumours and in nephroblastomatosis by in situ mRNA hybridization. Our results show that WT1 is expressed only in neoplastic structures whose normal counterparts also express the gene and that abnormally persistent high levels of expression are common in both these lesions. Thus, WT1 expression is a good marker for tumour differentiation and reveals how the normal pattern of differentiation is disrupted in Wilms' tumours. We postulate that mutation of the WT1 gene at the 11p13 locus results in Wilms' tumours associated with intralobar nephrogenic rests, which frequently show stromal-predominant histology. We have used our results and ideas to reinterpret current theories on tumour histogenesis and propose a model which explains how patterns of epithelial differentiation are disrupted in Wilms' tumour 2nd how malignant stroma can result from mutation in WT1.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Pritchard-Jones, Kathy/F-4286-2014	Pritchard-Jones, Kathy/0000-0002-2384-9475				BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BEHESHTI M, 1984, UROLOGY, V24, P130, DOI 10.1016/0090-4295(84)90413-8; BENNINGTON JL, 1975, ATLAS TUMOR PATHOLOG; BICKMORE WA, 1989, GENOMICS, V5, P685, DOI 10.1016/0888-7543(89)90109-2; Bove K E, 1976, Perspect Pediatr Pathol, V3, P185; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; DAO DD, 1987, AM J HUM GENET, V41, P202; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS LM, 1988, SCIENCE, V241, P840, DOI 10.1126/science.2841760; DELEMARRE JFM, 1982, PEDIATRIC ONCOLOGY, P261; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; EKBLOM P, 1981, MED BIOL, V59, P139; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FLEMING S, 1985, HISTOPATHOLOGY, V9, P729, DOI 10.1111/j.1365-2559.1985.tb02859.x; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLASER T, 1986, NATURE, V321, P882, DOI 10.1038/321882a0; GREENBERG F, 1988, AM J MED GENET, V29, P773, DOI 10.1002/ajmg.1320290406; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HOU LT, 1967, J PATHOL BACTERIOL, V93, P477; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JONES KL, 1988, SMITHS RECOGNIZABLE, P136; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LANGDALEBROWN B, 1990, J PATHOL, V160, pA162; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MAKIN CA, 1984, J CLIN PATHOL, V37, P975, DOI 10.1136/jcp.37.9.975; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PASTORE G, 1988, MED PEDIATR ONCOL, V16, P7, DOI 10.1002/mpo.2950160103; PENDERGRASS TW, 1976, CANCER, V37, P403, DOI 10.1002/1097-0142(197601)37:1<403::AID-CNCR2820370152>3.0.CO;2-H; PERLMAN M, 1973, J PEDIATR-US, V83, P414, DOI 10.1016/S0022-3476(73)80264-1; PING AJ, 1989, AM J HUM GENET, V44, P720; PORTEOUS DJ, 1987, P NATL ACAD SCI USA, V84, P5355, DOI 10.1073/pnas.84.15.5355; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHMIDT D, 1982, PATHOBIOL ANN, V12, P281; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SHANNON RS, 1982, ARCH DIS CHILD, V57, P685, DOI 10.1136/adc.57.9.685; TURLEAU C, 1984, CLIN GENET, V26, P356; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WADEY RB, 1990, ONCOGENE, V5, P901	57	73	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2211	2220						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722569				2022-12-28	WOS:A1991GX73500006
J	DIRENZO, MF; NARSIMHAN, RP; OLIVERO, M; BRETTI, S; GIORDANO, S; MEDICO, E; GAGLIA, P; ZARA, P; COMOGLIO, PM				DIRENZO, MF; NARSIMHAN, RP; OLIVERO, M; BRETTI, S; GIORDANO, S; MEDICO, E; GAGLIA, P; ZARA, P; COMOGLIO, PM			EXPRESSION OF THE MET HGF RECEPTOR IN NORMAL AND NEOPLASTIC HUMAN TISSUES	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; MOLECULAR-CLONING; SCATTER FACTOR; HEPATOPOIETIN-A; CELL-LINE; ONCOGENE; SEQUENCE; GENE; CDNA	The MET oncogene encodes a transmembrane tyrosine kinase receptor. Recently, hepatocyte growth factor (HGF), a potent growth factor for hepatocytes involved in liver regeneration, has been proposed as a ligand. In this paper, the physiological role of the human Met/HGF receptor is investigated by studying its specific distribution in normal and neoplastic tissues. Northern blot analysis has shown that the MET gene is selectively expressed in several epithelial tissues. High levels of MET mRNA have been found in liver, gastrointestinal tract, thyroid and kidney. Western blot analysis has shown that the levels of the Met protein generally correspond to those of the mRNA. However, in the thyroid, where there is a high level of MET mRNA, the protein was barely detectable, suggesting translational or post-translational regulation. The protein was also detected in the brain. Normal or increased levels of MET mRNA and Met protein were consistently found in fresh samples of carcinomas as well as in epithelial tumor cell lines. In thyroid carcinomas of a specific histiotype the amount of Met protein, almost undetectable in the normal counterpart, was found to be increased more than 100-fold. The tissue distribution of the Met/HGF receptor indicates that this molecule is involved in growth control of epithelial cells other than hepatocytes and suggests that its increased expression may confer a growth advantage to neoplastic cells.	S GIOVANNI HOSP,TURIN,ITALY		DIRENZO, MF (corresponding author), UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,SEZIONE ISTOL C MDAZEGLIO 52,I-10126 TURIN,ITALY.		Giordano, Silvia/J-9858-2018; olivero, martina/J-4811-2018; DI RENZO, Maria Flavia/B-6091-2012	Giordano, Silvia/0000-0003-1854-1086; olivero, martina/0000-0002-6815-3498; DI RENZO, Maria Flavia/0000-0002-5093-3373; Comoglio, Paolo/0000-0002-7056-5328				BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; CHAN AML, 1987, ONCOGENE, V1, P229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, IN PRESS INT J CANCE; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEIDNER KM, 1990, J CELL BIOL, V111, P2907; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZHAO YH, 1990, ONCOGENE, V5, P1629	38	494	513	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1997	2003						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719465				2022-12-28	WOS:A1991GX11900009
J	FLINT, KJ; JONES, NC				FLINT, KJ; JONES, NC			DIFFERENTIAL REGULATION OF 3 MEMBERS OF THE ATF CREB FAMILY OF DNA-BINDING PROTEINS	ONCOGENE			English	Article							CELLULAR TRANSCRIPTION FACTOR; VIRUS TYPE-I; LEUCINE ZIPPER PROTEINS; CAMP-RESPONSIVE ELEMENT; ADENOVIRUS E1A PROTEIN; LONG TERMINAL REPEAT; CYCLIC-AMP; CDNA CLONES; ACTIVATION; PROMOTERS	The ATF/CRE binding site can mediate transcriptional activation by cAMP, the adenovirus EIA protein and the human T-cell leukaemia virus 1 (HTLV1) tax protein. A large number of different proteins bind specifically to this element either as homodimers or as heterodimers. Using GAL4-ATF/CREB fusions, we have investigated the regulatory functions of three members of this family. CREB1 (CREB) is strongly activated by cAMP and weakly activated by the E1A protein. In contrast, CREB2 (CRE-BP1, ATF2) is strongly activated by E1A but is insensitive to cAMP stimulation. ATF1 is weakly activated by cAMP but is not activated by E1A. All three proteins are insensitive to activation by the HTLV1 tax protein. The N-terminal region of CREB2, from amino acid residues 19 to 112, is both necessary and sufficient for E1A activation. This region contains a putative C2H2 metal-binding finger, and single amino acid substitutions of the cysteine residues severely decreased CREB2 activity. In contrast, mutations affecting a potential protein kinase A and casein kinase II phosphorylation site within this region had little effect.	IMPERIAL CANC RES FUND,GENE REGULAT LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; HURST HC, 1991, IN PRESS NUCLEIC ACI; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JAMESON JL, 1990, MOL ENDOCRINOL, V4, P1087; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JONES RH, 1989, P NATL ACAD SCI USA, V86, P2176, DOI 10.1073/pnas.86.7.2176; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIN YS, 1989, P NATL ACAD SCI USA, V86, P109, DOI 10.1073/pnas.86.1.109; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P6063; SADROWSKI J, 1989, NUCLEIC ACIDS RES, V17, P7539; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	53	93	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2019	2026						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658708				2022-12-28	WOS:A1991GX11900012
J	HU, YL; RAMSAY, RG; KANEIISHII, C; ISHII, S; GONDA, TJ				HU, YL; RAMSAY, RG; KANEIISHII, C; ISHII, S; GONDA, TJ			TRANSFORMATION BY CARBOXYL-DELETED MYB REFLECTS INCREASED TRANSACTIVATING CAPACITY AND DISRUPTION OF A NEGATIVE REGULATORY DOMAIN	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; GENE V-MYB; C-MYB; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL DOMAINS; PROTO-ONCOGENE; CELLULAR PROGENITOR; FOS PROTEIN; EXPRESSION; SEQUENCE	Carboxyl-truncated forms of the product of the c-myb proto-oncogene (Myb) are encoded by the v-myb oncogene, the rearranged c-myb genes of certain murine cell lines and a transforming recombinant c-myb retrovirus. We report here an examination of the abilities of a series of carboxyl deletions of Myb to transform hemopoietic cells. Increasing degrees of truncation resulted in increasing transforming capacity until the deletions removed the region responsible for transactivation by Myb. Because the effects of these deletions on transformation paralleled their previously described effects on the transactivating capacity of Myb but did not correlate with their ability to repress transcription, our results imply that removal of a domain which negatively regulates transactivation is responsible for oncogenic activation of carboxyl-truncated forms of Myb. Moreover, these data support the view that activated forms of myb transform by increasing and/or deregulating the expression of other genes.	ROYAL MELBOURNE HOSP,MELBOURNE TUMOUR BIOL BRANCH,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; RIKEN			Hu, Yinling/G-5682-2015; Ramsay, Robert G/C-3291-2015; Ishii, Shunsuke/A-5271-2016; Gonda, Thomas J/A-3620-2012	Hu, Yinling/0000-0002-4795-8537; Ramsay, Robert G/0000-0001-5003-0433; Ishii, Shunsuke/0000-0002-6530-2478; 				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; DUDEK H, 1989, ONCOGENE, V4, P1489; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frykberg L, 1988, Oncogene Res, V3, P313; GELINAS C, 1988, ONCOGENE, V3, P349; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MILLER AD, 1984, CELL, V36, P51; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1991, IN PRESS ONCOGENE; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	37	114	115	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1549	1553						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923521				2022-12-28	WOS:A1991GX27400008
J	MAZARS, R; PUJOL, P; MAUDELONDE, T; JEANTEUR, P; THEILLET, C				MAZARS, R; PUJOL, P; MAUDELONDE, T; JEANTEUR, P; THEILLET, C			P53 MUTATIONS IN OVARIAN-CANCER - A LATE EVENT	ONCOGENE			English	Article							PROTO-ONCOGENE; HUMAN-BREAST; TUMOR-ANTIGEN; LUNG-CANCER; ALLELE LOSS; MUTANT P53; GENE; TRANSFORMATION; CHROMOSOME-17; CELLS	Using a combination of polymerase chain reaction and single-strand conformation polymorphism techniques we analyzed 34 ovarian cancer samples (30 primary tumors and four matched metastases) for the presence of mutations in exons 5, 6, 7, 8 and 9 of the p53 gene. Mutations in this portion of the gene are known to lead to the loss of the oncosuppressive potential of p53. Thirty-six percent (11/30) of the ovarian carcinomas tested presented a mutated p53 allele. Mutations were clustered in exons 5 and 7 to the exclusion of the other exons screened. Most mutations (10/11) were point mutations, but no preferential pattern of nucleotide substitution could be observed. In three tumors the mutation of one allele was concomitant with the loss of the wild-type counterpart. Another sample presented both alleles independently mutated. These observations are in agreement with the recessive nature of the p53 mutation. However, analysis of tissue sections from two tumors showed that the portion composed of 100% cancer cells could hold both the mutated and the wild-type form. Moreover analysis of serial sections gave evidence of a heterogeneous cellular content in one of these tumors, suggesting that p53 mutations may, in some cases, occur late during ovarian cancer evolution. It is, moreover, noticeable that, in matched sets of primary tumors and metastases, the same mutation was observed in both tumor samples. Therefore, even as a late event, p53 mutation occurs before metastatic spread.	CTR PAUL LAMARQUE,BIOCHIM LAB,CNRS,UA 1191,VAL AURELLE,F-34094 MONTPELLIER 5,FRANCE; CHR MONTPELLIER,BIOL CELLULAIRE LAB,F-34090 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Montpellier			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				ADNANE J, 1991, ONCOGENE, V6, P659; ADNANE J, 1989, ONCOGENE, V4, P1389; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BIRD A, 1987, TRENDS GENED, V3, P32; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FILMUS JE, 1985, CANCER RES, V45, P4468; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE JH, 1989, CANCER RES, V49, P1220; LOEB LA, 1990, MUTAT RES, V238, P297, DOI 10.1016/0165-1110(90)90021-3; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, ONCOGENE, V5, P973; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NANDA RR, 1990, P NATL ACAD SCI USA, V87, P7555; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SOUSSI T, 1990, ONCOGENE, V5, P945; STATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	36	201	204	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1685	1690						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923532				2022-12-28	WOS:A1991GX27400026
J	NERLOV, C; RORTH, P; BLASI, F; JOHNSEN, M				NERLOV, C; RORTH, P; BLASI, F; JOHNSEN, M			ESSENTIAL AP-1 AND PEA3 BINDING-ELEMENTS IN THE HUMAN UROKINASE ENHANCER DISPLAY CELL TYPE-SPECIFIC ACTIVITY	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR GENE; MIDDLE-T-ONCOGENE; HUMAN-TUMOR-CELLS; TRANSCRIPTION FACTOR; C-JUN; GLUCOCORTICOID RECEPTOR; POLYOMAVIRUS ENHANCER; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; PHORBOL-ESTER	We have characterized a transcriptional enhancer of the human urokinase-type plasminogen activator (uPA) gene in three transformed human cell lines: HeLa, HepG2 and HT1080. The enhancer is located approximately 2 kbp upstream of the mRNA cap site and is active in all three cell lines. By footprinting and gel retardation analysis we found that it contained two binding sites for transcription factor AP-1, encoded by the fos and jun proto-oncogene families. The most upstream of these sites was juxtaposed to a binding site for PEA3, a product of the ets/Spi proto-oncogene family. By transient transfection analysis of deletions, point mutations and subcloned fragments, we found these sites to be crucial for enhancer activity. However, the sites displayed differences in activity in the three different cell lines. The downstream AP-1 site was almost exclusively responsible for enhancer activity in HeLa cells, whereas the AP-1/PEA3 site played a major role in HT1080 and HepG2 cells. The implications of our findings for the known regulation of uPA expression by transforming oncogenes, adenovirus E1A protein and glucocorticoids are discussed.	UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK	University of Copenhagen			Johnsen, Morten/L-8016-2014; Rørth, Pernille/H-3020-2011	Johnsen, Morten/0000-0003-3763-2362; Blasi, Francesco/0000-0001-9406-1784				ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Blasi F, 1990, Semin Cancer Biol, V1, P117; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; ELLIS V, 1989, J BIOL CHEM, V264, P1180; FRISCH SM, 1990, ONCOGENE, V5, P75; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1990, CELL, V61, P1165; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; QUAX P, 1991, UNPUB; REICH R, 1988, CANCER RES, V48, P3307; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SKRIVER L, 1984, Journal of Cell Biology, V99, P752; STOPPELLI MP, 1986, J CELL BIOL, V102, P1235, DOI 10.1083/jcb.102.4.1235; TANG WJ, 1987, MOL CELL BIOL, V7, P1681, DOI 10.1128/MCB.7.5.1681; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WILLIAMS RL, 1988, CELL, V52, P121; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	48	186	189	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1583	1592						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923525				2022-12-28	WOS:A1991GX27400013
J	COULIER, F; BATOZ, M; MARICS, I; DELAPEYRIERE, O; BIRNBAUM, D				COULIER, F; BATOZ, M; MARICS, I; DELAPEYRIERE, O; BIRNBAUM, D			PUTATIVE STRUCTURE OF THE FGF6 GENE-PRODUCT AND ROLE OF THE SIGNAL PEPTIDE	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR RECEPTOR GENES; NUCLEOTIDE-SEQUENCE; ACID SEQUENCES; FACTOR FAMILY; CELL-GROWTH; EXPRESSION; MESODERM; INT-2; HST	The human FGF6 gene is an oncogene related by sequence similarities to the fibroblast growth factor (FGF) gene family, which encodes mitogenic peptides implicated in various physiological processes including angiogenesis, morphogenesis, tissue regeneration and survival and oncogenesis. Nucleotide sequence analysis of the FGF6 gene and of cDNA clones revealed an open reading frame able to code for a protein of 208 residues. The FGF6 protein shares 32-70% residues with the other members of the family within the C-terminal two-thirds of the molecule. In vitro, three in-frame ATG codons are able to initiate the translation of three peptides of 175, 198 and 208 residues. These three peptides differ at their amino termini with respect to the relative position of a hydrophobic leader peptide, which extends from residues 16 to 40, and is therefore absent from the shorter (175 amino acids) form. In-vitro analysis indicates that this signal peptide is able to drive the FGF6 protein through the endoplasmic reticulum, where it becomes glycosylated. The presence of this signal peptide sequence appears essential for the in vivo transforming capacity of the FGF6 gene.			COULIER, F (corresponding author), INSERM, UNITE 119, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE.		Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BLAM SB, 1988, ONCOGENE, V3, P129; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEESEY J, 1987, BIOCH INFORMATION; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARICS I, 1989, ONCOGENE, V4, P335; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1989, ONCOGENE RES, V5, P101; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1988, ONCOGENE, V3, P9; Sambrook J, 1989, MOL CLONING LABORATO; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THEILLET C, 1989, ONCOGENE, V4, P915; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; XERRI L, 1991, AM J PATHOL, V138, P9; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	57	11	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1437	1444						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886714				2022-12-28	WOS:A1991GX27200021
J	DARLAND, T; SAMUELS, M; EDWARDS, SA; SUKHATME, VP; ADAMSON, ED				DARLAND, T; SAMUELS, M; EDWARDS, SA; SUKHATME, VP; ADAMSON, ED			REGULATION OF EGR-1 (ZFP-6) AND C-FOS EXPRESSION IN DIFFERENTIATING EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							GENE-EXPRESSION; PROTO-ONCOGENE; 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; CULTURED-CELLS; GROWTH-FACTORS; ENCODES; SERUM; JUN; PRODUCT	The Egr-1 gene (zfp-6) encodes a 'zinc finger'-type transcription factor that is one of the early growth response genes induced, together with c-fos proto-oncogene, in many cell types. Our earlier work indicated that Egr-1 and c-fos may also play roles in differentiation and we now present data to show some features of their regulation. Transcriptional regulation accounts at least partly for the increased steady-state levels of Egr-1 mRNA in differentiating teratocarcinoma cells; this rate increases threefold over the 7-10 days of differentiation of P]9 embryonal carcinoma cells with both 0.5% DMSO (to give predominantly cardiac muscle) and 1-mu-M retinoic acid (to give nerve and glial cells). The stability of Egr-1 transcripts remains the same (T1/2 = 90 min) in undifferentiated EC and differentiated cell products. In contrast, transcripts for c-fos are barely detectable in EC cells and increase 20-fold during differentiation. The basis for this is a marked increase in stability of c-fos mRNA after differentiation. The protein products of both genes parallel the steady-state levels of their mRNAs, but both proteins become more stable in differentiated cells. This is particularly marked for c-Fos protein, which appears as a distinct 58 kDa species in terminally differentiated P19 cells. Both Egr-1 and c-Fos proteins remain at high constitutive levels in differentiated cells indicating a distinct role for these transcription factors. For instance, it appears that this form of Fos protein may not repress the synthesis of the Egr-1 gene as it does during transient expression of serum-stimulated genes.	LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037; MEHARRY MED COLL,NASHVILLE,TN 37208; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Sanford Burnham Prebys Medical Discovery Institute; Meharry Medical College; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [P30CA 30199] Funding Source: Medline; NICHD NIH HHS [R01 HD 21957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021957] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON ED, 1984, DIFFERENTIATION, V27, P152, DOI 10.1111/j.1432-0436.1984.tb01421.x; ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Ausubel FM, 1988, MOL REPROD DEV; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CURRAN T, 1984, CELL, V36, P259; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; EDWARDS SA, 1986, EXP CELL RES, V165, P473, DOI 10.1016/0014-4827(86)90600-2; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; EDWARDS SA, 1991, UNPB DEV BIOL; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Maniatis T., 1982, MOL CLONING; MARX JL, 1987, SCIENCE, V237, P854, DOI 10.1126/science.3039659; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; PATWARDHAN S, 1991, ONCOGENE, V6, P917; RAUSCHER FJ, 1988, NATURE, V334, P314; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAYLOR R, 1990, J NIH RES, V2, P49; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; WATERS CM, 1990, ONCOGENE, V5, P669	46	47	47	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1367	1376						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1909429				2022-12-28	WOS:A1991GX27200012
J	ENDO, K; BORER, CH; TSUJIMOTO, Y				ENDO, K; BORER, CH; TSUJIMOTO, Y			MODULATION OF LFA-1 SURFACE-ANTIGEN EXPRESSION BY ACTIVATED H-RAS BUT NOT C-MYC ONCOGENE IN EBV-INFECTED HUMAN B-LYMPHOBLAST CELLS	ONCOGENE			English	Article							BURKITTS-LYMPHOMA; ADHESION RECEPTORS; MOLECULAR-CLONING; DOWN-REGULATION; BETA-SUBUNIT; GENE; FAMILY; VIRUS; P150,95; PROTEIN	The lymphocyte-associated antigen 1 (LFA-1) involved in a wide range of cellular adhesion-dependent immunological functions, including interaction of cytotoxic T lymphocytes with their target, is implicated in tumorigenesis. The modulation of the LFA-1 antigen expression was studied in Epstein-Barr virus (EBV)-immortalized human B-lymphoblastoid cell lines, transfected with human oncogenes, H-ras and c-myc. We observed by flow cytometry that the activated H-ras (EJ) gene, but not its normal counterpart, consistently enhanced LFA-1 expression. The RNA analysis revealed that induction of the LFA-1 surface antigen by the EJ gene occurred through the level of the alpha-chain but not the beta-chain mRNA of LFA-1. The LFA-1 molecules induced by the EJ gene were functional; cells with the EJ gene revealed an elevated level of homocytic cellular adhesion, which was blocked by the anti-LFA-1 monoclonal antibody. Flow cytometry analysis indicated that the modulation of the LFA-1 antigen expression was a phenomenon specific to the EJ gene. The high levels of expression of c-myc and blc-2 gene did not affect LFA-1 antigen expression. The system used here provides a tool by which the signal transduction pathway involving the H-ras gene and the molecular mechanism of LFA-1 gene expression can be genetically dissected.	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA	The Wistar Institute					NATIONAL CANCER INSTITUTE [R01CA051864, R01CA050551] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51864, CA-50551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BILLAUD M, 1987, LANCET, V2, P1327; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYBERGER C, 1987, LANCET, V2, P533; CORBI AL, 1988, J EXP MED, V167, P1597, DOI 10.1084/jem.167.5.1597; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MASUCCI MG, 1987, P NATL ACAD SCI USA, V84, P4567, DOI 10.1073/pnas.84.13.4567; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; NASI S, 1990, ONCOGENE, V5, P117; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PATARROYO M, 1988, INT J CANCER, V41, P901, DOI 10.1002/ijc.2910410623; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; ROONEY CM, 1985, NATURE, V317, P629, DOI 10.1038/317629a0; ROOSSIEN FF, 1990, CANCER RES, V50, P3509; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROUSSET F, 1989, J IMMUNOL, V143, P1490; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	31	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1391	1396						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1653411				2022-12-28	WOS:A1991GX27200015
J	MAGUIRE, K; SHI, XP; HORIKOSHI, N; RAPPAPORT, J; ROSENBERG, M; WEINMANN, R				MAGUIRE, K; SHI, XP; HORIKOSHI, N; RAPPAPORT, J; ROSENBERG, M; WEINMANN, R			INTERACTIONS BETWEEN ADENOVIRUS-E1A AND MEMBERS OF THE AP-1 FAMILY OF CELLULAR TRANSCRIPTION FACTORS	ONCOGENE			English	Note							RNA POLYMERASE-II; ESCHERICHIA-COLI; GENE-PRODUCT; CYCLIC-AMP; LEUCINE ZIPPER; E1A PROTEIN; BINDING; DNA; ACTIVATION; PROMOTER	We have studied interactions between bacterially produced E1A linked to Sepharose and the various DNA-binding proteins present in HeLa cell nuclear extracts (NE). DNA-binding activities and cross-reactive polypeptides recognizing the cAMP-responsive element (CRE) and the activator protein 1 (AP1) sites were bound to the E1A column, whereas nuclear factor 1 (NF1) and the activator protein 2 (AP2) DNA-binding activities were not retained by E1A. The binding activities that were retained belonged to the CRE and JUN protein family, as judged by Western blot analysis. Authentic CRE-BP1, c-Jun and c-Fos proteins produced by in-vitro translation also bound to the E1A column. However, efficient binding of in-vitro-translated CRE-BP1 and c-Fos proteins to E1A required preincubation with NE. We show here that immobilized E1A sequesters several cellular upstream transcription activators, and suggest a role for members of the AP1 family of transcription factors in E1A-mediated gene regulation.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; SMITHKLINE BEECHAM CORP,KING OF PRUSSIA,PA 19406	The Wistar Institute; GlaxoSmithKline			Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NCI NIH HHS [F32 CA08338, CA44466, CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA044466, F32CA008338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERK AJ, 1990, GENE DEV, V4, P151; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P80; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; EGAN C, 1987, VIROLOGY, V160, P292, DOI 10.1016/0042-6822(87)90077-8; FERGUSON B, 1984, SCIENCE, V224, P1343, DOI 10.1126/science.6374895; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARCIA J, 1987, NUCLEIC ACIDS RES, V15, P8367, DOI 10.1093/nar/15.20.8367; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LEFF T, 1985, NUCLEIC ACIDS RES, V13, P1209, DOI 10.1093/nar/13.4.1209; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SHI XP, 1986, NUCLEIC ACIDS RES, V14, P3729, DOI 10.1093/nar/14.9.3729; SIVARAMAN L, 1987, P NATL ACAD SCI USA, V84, P6112, DOI 10.1073/pnas.84.17.6112; SOPTA M, 1985, J BIOL CHEM, V260, P353; SPANGLER R, 1987, SCIENCE, V237, P1044, DOI 10.1126/science.2956686; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; WEBSTER LC, 1991, IN PRESS MOL CELL BI; WEEKS DL, 1985, NUCLEIC ACIDS RES, V13, P5389, DOI 10.1093/nar/13.14.5389; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YACIUK P, 1990, J VIROL, V64, P4421; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZOPF D, 1990, NATURE, V346, P87, DOI 10.1038/346087a0	40	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1417	1422						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1832215				2022-12-28	WOS:A1991GX27200018
J	BAETSCHER, M; SCHMIDT, E; SHIMIZU, A; LEDER, P; FISHMAN, MC				BAETSCHER, M; SCHMIDT, E; SHIMIZU, A; LEDER, P; FISHMAN, MC			SV40 T-ANTIGEN TRANSFORMS CALCITONIN CELLS OF THE THYROID BUT NOT CGRP-CONTAINING NEURONS IN TRANSGENIC MICE	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; C-MYC; GENE; EXPRESSION; CARCINOMA; ONCOGENE; BRAIN	Neurons are postmitotic for the adult life of animals. Tumors rarely, if ever, arise from neurons in the adult, although they do from other cells from the same lineage, such as the neuroendocrine C cells of the thyroid. We have found that 2 kb of the calcitonin gene-related peptide (CGRP)/calcitonin gene suffices to target expression to CGRP-containing neurons, such as those in the dorsal root ganglia (DRG), and to the clacitonin-secreting C cells of the thyroid. Using this promoter we have examined the effect of two potentially transforming oncogenes in these two different populations. Overexpression of c-myc for periods of up to two years does not transform either cell type, whereas SV40 Tag causes early onset medullary thyroid carcinoma, but does not transform the dorsal root ganglia neurons. This suggests that as part of the terminal differentiation process of these neurons, the cessation of mitosis is accompanied by a relative refractoriness to oncogenes that may transform other cells of the same lineage.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEV BIOL LAB,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,BOSTON,MA 02114; HOWARD HUGHES MED INST,BOSTON,MA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute	FISHMAN, MC (corresponding author), MASSACHUSETTS GEN HOSP,DEV BIOL LAB,MGH E,149 13TH ST,4TH FLOOR,BOSTON,MA 02129, USA.							AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BARASCH JM, 1987, J NEUROSCI, V7, P2874; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DEBUSTROS A, 1990, MOL CELL BIOL, V10, P1773, DOI 10.1128/MCB.10.4.1773; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGROOT LJ, 1979, ENDOCRINOLOGY, V2; DeLellis R A, 1981, Methods Achiev Exp Pathol, V10, P190; DELELLIS RA, 1978, AM J CLIN PATHOL, V70, P587, DOI 10.1093/ajcp/70.4.587; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; GRAZIADEI PPC, 1979, NEUROSCIENCE, V4, P713, DOI 10.1016/0306-4522(79)90002-2; HAMMANG JP, 1990, NEURON, V4, P775, DOI 10.1016/0896-6273(90)90204-S; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOGAN B, 1986, MANIPULATING MOUSE E; JOHANNESSEN JV, 1978, HUM PATHOL, V9, P385, DOI 10.1016/S0046-8177(78)80025-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; REYNOLDS RK, 1988, P NATL ACAD SCI USA, V85, P3135, DOI 10.1073/pnas.85.9.3135; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; RUPPERT JM, 1986, AM J SURG PATHOL, V10, P513, DOI 10.1097/00000478-198607000-00009; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TRIGGS SM, 1977, ACTA ENDOCRINOL-COP, V85, P84	31	27	27	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1133	1138						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650439				2022-12-28	WOS:A1991GV26000006
J	JENSEN, DE; FRANKIS, RC; SANDO, JJ				JENSEN, DE; FRANKIS, RC; SANDO, JJ			DEFECTIVE INDUCTION OF JUN AND FOS-RELATED PROTEINS IN PHORBOL ESTER-RESISTANT EL4 MOUSE THYMOMA CELLS	ONCOGENE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR AP-1; HUMAN INTERLEUKIN-2 GENE; C-JUN; GROWTH-FACTOR; PROTO-ONCOGENE; AUTO-REGULATION; LYMPHOCYTES-T; DNA; EXPRESSION	Treatment of sensitive EL4 mouse thymoma cells with phorbol esters causes growth inhibition, adherence to substrate and production of several lymphokines including Interleukin 2. Resistant cells lack all of these responses. Since production of Interleukin 2 mRNA is dependent on protein synthesis, and the Interleukin 2 gene has a phorbol ester responsive element, we examined both cell lines for expression of the various Jun and Fos species which bind to this element. Phorbol ester induced c-fos, jun-B, and jun-D RNAs within 20 min in both cell lines. Fos-B was similarly induced in sensitive cells but induction was delayed and greatly enhanced in resistant cells. C-jun RNA induction was detected only in sensitive cells. Western analysis confirmed the induction of c-Jun and a Fos-related protein in sensitive cells only. Southern analysis indicated that both cell lines contain c-jun and fra-1 genes. These results suggest that defective induction of c-Jun and/or Fos-related proteins may contribute to the absence of phorbol ester-induced lymphokine production in resistant EL4 cells.	UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,CTR CANC,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	JENSEN, DE (corresponding author), UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599, USA.				NIDDK NIH HHS [DK40031] Funding Source: Medline; NIGMS NIH HHS [GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK040031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031184] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; EISELONIS B, 1987, TRANSFER IMMOBILIZAT, P5; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; FUSE A, 1984, NUCLEIC ACIDS RES, V12, P93; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GIARDINA SL, 1987, ANAL BIOCHEM, V161, P109, DOI 10.1016/0003-2697(87)90659-2; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON JR, 1987, J BIOL CHEM, V262, P234; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KASHIMA N, 1985, NATURE, V313, P402, DOI 10.1038/313402a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI L, 1990, J BIOL CHEM, V265, P1556; LORD KA, 1990, ONCOGENE, V5, P387; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOVAK TJ, 1990, MOL CELL BIOL, V10, P6325, DOI 10.1128/MCB.10.12.6325; PEARLSTEIN KT, 1983, J NATL CANCER I, V71, P583; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J, 1989, MOL CLONING LABORATO; SANDO JJ, 1982, CANCER RES, V42, P1676; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAPIRO DJ, 1988, DNA CELL BIOL, V7, P44; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Strauss WM, 1987, CURRENT PROTOCOLS MO, P631; Suggs S. V., 1981, ICN UCLA S DEV BIOL, V23, P683; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	56	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1219	1225						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1713662				2022-12-28	WOS:A1991GV26000018
J	MORRIS, CM; HAO, QL; HEISTERKAMP, N; FITZGERALD, PH; GROFFEN, J				MORRIS, CM; HAO, QL; HEISTERKAMP, N; FITZGERALD, PH; GROFFEN, J			LOCALIZATION OF THE TRK PROTOONCOGENE TO HUMAN-CHROMOSOME BANDS 1Q23-1Q24	ONCOGENE			English	Note							DIFFERENT CELLULAR SEQUENCES; RECEPTOR KINASE DOMAIN; BIOCHEMICAL-CHARACTERIZATION; ACTIVATION; RECOMBINATION; GENE; MAPS	A FER-related sequence isolated from a human genomic library was found to be homologous to TRK. In situ hybridization of a 0.92 kb probe, isolated from this sequence, localized the TRK gene to the long arm of chromosome 1 within bands 1q23-1q24. This is a significantly more proximal location of TRK than the 1q32-1q41 site published recently (Miozzo et al., 1990).	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAG SECT,LOS ANGELES,CA	Children's Hospital Los Angeles	MORRIS, CM (corresponding author), CHRISTCHURCH HOSP,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND.		Heisterkamp, Nora/C-1698-2012; Morris, Christine/G-1690-2011	Heisterkamp, Nora/0000-0003-2769-2273; 	NCI NIH HHS [1RO-CA47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONGARZONE I, 1989, ONCOGENE, V4, P1457; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MIOZZO M, 1990, ONCOGENE, V5, P1411; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P196, DOI 10.1159/000132929; MORRIS CM, 1987, LEUKEMIA RES, V11, P163, DOI 10.1016/0145-2126(87)90022-1; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807	13	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1093	1095						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829807				2022-12-28	WOS:A1991GU62200030
J	TANIGUCHI, M; IWAMOTO, T; NAKASHIMA, I; NAKAYAMA, A; OHBAYASHI, M; MATSUYAMA, M; TAKAHASHI, M				TANIGUCHI, M; IWAMOTO, T; NAKASHIMA, I; NAKAYAMA, A; OHBAYASHI, M; MATSUYAMA, M; TAKAHASHI, M			ESTABLISHMENT AND CHARACTERIZATION OF A MALIGNANT MELANOCYTIC TUMOR-CELL LINE EXPRESSING THE RET ONCOGENE	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; PROTEINS; CLONING; PI3-KINASE; PRODUCTS; DOMAINS; GENE	We established a cell line (designated Mel-ret) from a melanocytic tumor developed in a metallothionein/ret transgenic mouse. Unlike primary melanocytic tumors, which did not show malignant features, when the Met-ret cells were transplanted into nude mice they invaded into surrounding tissues and had metastatic ability. Although the Ret proteins were expressed at similar levels in the cell fine and the primary tumors, the level of tyrosine phosphorylation in the Mel-ret cells was much higher than that in the primary tumors. In particular, an 85-kDa tyrosine-phosphorylated band was specifically detected in the Mel-ret cells. These results suggest that the increase in tyrosine phosphorylation may be responsible for malignant transformation of the Mel-ret cells. Immunofluorescence and cell fractionation studies showed that the Ret proteins and most of tyrosine-phosphorylated proteins in the Mel-ret cells localized in the membrane fraction. No activation of phosphatidyl-inositol-3 kinase (PI-3 kinase), a target protein for several tyrosine kinases, was detected in the Mel-ret cells.	NAGOYA UNIV,SCH MED,DEPT PATHOL,65 TSURUMAI CHO,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT IMMUNOL,NAGOYA,AICHI 466,JAPAN	Nagoya University; Nagoya University			Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4	11	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1491	1496						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630812				2022-12-28	WOS:A1992JE81300004
J	SETO, M; YAMAMOTO, K; IIDA, S; AKAO, Y; UTSUMI, KR; KUBONISHI, I; MIYOSHI, I; OHTSUKI, T; YAWATA, Y; NAMBA, M; MOTOKURA, T; ARNOLD, A; TAKAHASHI, T; UEDA, R				SETO, M; YAMAMOTO, K; IIDA, S; AKAO, Y; UTSUMI, KR; KUBONISHI, I; MIYOSHI, I; OHTSUKI, T; YAWATA, Y; NAMBA, M; MOTOKURA, T; ARNOLD, A; TAKAHASHI, T; UEDA, R			GENE REARRANGEMENT AND OVEREXPRESSION OF PRAD1 IN LYMPHOID MALIGNANCY WITH T(11/14)(Q13/Q32) TRANSLOCATION	ONCOGENE			English	Article							BCL-1 LOCUS; MOLECULAR-CLONING; CHROMOSOME 11Q13; SQUAMOUS-CELL; AMPLIFICATION; ESTABLISHMENT; BREAKPOINT; ONCOGENE; TUMORS; EXPRESSION	The proto-oncogene PRAD1 (parathyroid adenoma 1) on chromosome 11q13 was found to be overexpressed in all five B-cell lines with t(11;14)(q13;q32) translocation tested. One B-cell lymphoma and four myeloma cell lines with this translocation demonstrated more than 10-fold overexpression as determined by Northern blot analysis, when compared with normal lymphoid tissues such as thymus, spleen and lymph node. Hematopoietic cell lines without the translocation were also examined, but none of these demonstrated the overexpression, confirming that overexpression of the PRAD1 gene is associated with t(11;14) translocation. A truncated form of mRNA was seen in one of five cell lines with the translocation, SP-49. Hybridization with different regions of the PRAD1 cDNA revealed that the truncated form of mRNA retained the coding region but had lost the 3' untranslated region. Southern blot analysis demonstrated a gene rearrangement in this SP-49 cell line. To study the genetic alteration responsible for the truncated form of mRNA in this cell line, the rearranged allele as well as the germline allele were cloned. The restriction map revealed that the rearranged portion was at the 3' end of the PRAD1 gene, eliminating the mRNA-destabilizing signal AUUUA. Human-rodent hybrid cell analysis demonstrated that the region introduced 3' of PRAD1 was derived from chromosome 11. suggesting that the PRAD1 gene region is deleted at the 3' end. Overexpression of the PRAD1 gene in association with t(11;14)(q13;q32) translocation suggested that in these cases the regulation of PRAD1 was altered by the juxtaposed gene, most likely the immunoglobulin heavy-chain gene from chromosome 14.	AICHI CANC CTR, DEPT HEMATOL & CHEMOTHERAPY, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR, ULTRASTRUCT RES LAB, NAGOYA, AICHI 464, JAPAN; KOCHI MED SCH, DEPT INTERNAL MED, NANKOKU, KOCHI 78151, JAPAN; KAWASAKI MED SCH, DEPT INTERNAL MED, KURASHIKI, OKAYAMA 70101, JAPAN; OKAYAMA UNIV, SCH MED,INST CANC RES,DEPT PATHOL, OKAYAMA 700, JAPAN; MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; AICHI CANC CTR, IMMUNOL LAB,CHIKUSA KU, NAGOYA, AICHI 464, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Kochi University; Kawasaki Medical School; Okayama University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Aichi Cancer Center	SETO, M (corresponding author), AICHI CANC CTR, CHEMOTHERAPY LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN.		Motokura, Toru/X-3682-2019		NCI NIH HHS [CA55909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1989, ONCOGENE, V4, P89; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BERENSON JR, 1989, ONCOGENE, V4, P1111; CROCE CM, 1985, BLOOD, V65, P1; DAIBATA M, 1987, JPN J CANCER RES, V78, P1182; DAIBATA M, 1989, CANCER, V64, P1248, DOI 10.1002/1097-0142(19890915)64:6<1248::AID-CNCR2820640614>3.0.CO;2-5; LAMMIE GA, 1991, ONCOGENE, V6, P439; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEIROS LJ, 1990, BLOOD, V76, P2086; MEEKER TC, 1989, BLOOD, V74, P1801; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAGAI T, 1991, INT J HEMATOL, V54, P141; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; OHTSUKI T, 1989, BRIT J HAEMATOL, V73, P199, DOI 10.1111/j.1365-2141.1989.tb00252.x; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RABBITTS PH, 1988, ONCOGENE, V3, P99; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SETO M, 1991, JPN J CANCER RES, V82, P65, DOI 10.1111/j.1349-7006.1991.tb01747.x; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SILVERMAN GA, 1990, P NATL ACAD SCI USA, V87, P9913, DOI 10.1073/pnas.87.24.9913; THEILLET C, 1989, ONCOGENE, V4, P915; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS ME, 1991, BLOOD, V78, P493; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	27	233	235	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1401	1406						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1535701				2022-12-28	WOS:A1992HZ97100019
J	MOSNER, J; DEPPERT, W				MOSNER, J; DEPPERT, W			CONFORMATIONAL-ANALYSIS OF P53 IN RESTING AND CONCANAVALIN A-STIMULATED MOUSE LYMPHOCYTES	ONCOGENE			English	Article							CELL-CYCLE CONTROL; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; MUTANT P53; NORMAL 3T3; PROTEIN; EXPRESSION; MUTATIONS; ANTIGENS; CANCER	We report that p53 in resting and concanavalin A-stimulated Balb/c mouse lymphocytes cannot be distinguished on the basis of different reactivity with various epitope-specific monoclonal antibodies, regardless of whether the lymphocytes are stimulated with concanavalin A in the presence or absence of serum. Our results thus question the 'conformational hypothesis' put forward by Milner [Milner, J. (1991). Curr. Op. Cell Biol., 3, 282-286], according to which wild-type p53, depending on its conformational status, can act as a negative or a positive growth regulator.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	Heinrich Pette Institute; University of Hamburg								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BOYUM A, 1968, SCAND J CLIN LAB INV, V97, P76; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DEPPERT W, 1990, ONCOGENE, V5, P1701; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS AL, 1990, J PATHOL, V162, P5, DOI 10.1002/path.1711620103; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; STEINMEYER K, 1990, ONCOGENE, V5, P1691; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	22	13	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					661	666						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565465				2022-12-28	WOS:A1992HQ68200007
J	HATTORI, S; MAEKAWA, M; NAKAMURA, S				HATTORI, S; MAEKAWA, M; NAKAMURA, S			IDENTIFICATION OF NEUROFIBROMATOSIS TYPE-I GENE-PRODUCT AS AN INSOLUBLE GTPASE-ACTIVATING PROTEIN TOWARD RAS P21	ONCOGENE			English	Article							GAP; PURIFICATION; ENCODES; CLONING; DOMAIN; LOCUS; BRAIN; CELLS	The neurofibromatosis type I (NF1) gene was cloned as a gene whose structural change is closely related to the onset of a neurocutaneous disorder, neurofibromatosis type I. The predicted amino acid sequence of the NF1 gene product shows significant similarity to the catalytic domain of GTPase-activating protein (GAP) for ras p21. This GAP-related domain has been shown to have GAP activity when expressed by recombinant DNA technique, however little is known about the NF1 gene product expressed in tissues. Antibodies against the carboxy terminus and the GAP-related domain of the NF1 gene product were made to identify and characterize NF1 protein expressed in vivo. Both antibodies specifically reacted with a polypeptide with apparent molecular weight of 235 kDa in immunoblot and immunoprecipitation analyses. This 235 kDa protein is detected in brain but not in spleen, thymus, kidney, liver, lung and heart. The subcellular distribution of NF1 and GAP was studied using rat brain extract and was identified by the activity which was inhibited by antibodies against GAP-related domain of NF1 and anti-GAP respectively. The results show that NF1 protein mainly resides in the particulate fraction, in contrast to GAP, which is a soluble protein. We also found that a GAP activity which is not inhibited by anti-NF1 and anti-GAP exists in both the soluble and particulate fractions. The result suggests that there may be another GAP molecule.			HATTORI, S (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,4-1-1 OGAWAHIGASHI,TOKYO 187,JAPAN.							BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BORISY GG, 1975, ANN NY ACAD SCI, V253, P107, DOI 10.1111/j.1749-6632.1975.tb19196.x; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; GLENNEY JR, 1982, CELL, V28, P845; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG K, 1977, BIOCHEMISTRY-US, V16, P1857, DOI 10.1021/bi00628a015; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	21	45	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					481	485						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549362				2022-12-28	WOS:A1992HK00500012
J	NEGISHI, Y; IGUCHIARIGA, SMM; ARIGA, H				NEGISHI, Y; IGUCHIARIGA, SMM; ARIGA, H			PROTEIN COMPLEXES BEARING MYC-LIKE ANTIGENICITY RECOGNIZE 2 DISTINCT DNA-SEQUENCES	ONCOGENE			English	Article							HEAVY-CHAIN PROMOTER; TRANSCRIPTIONAL ENHANCER; REPLICATION; BINDING; INITIATION; CELLS; GENE; ELEMENTS; ORIGIN; SYSTEM	The products of the myc proto-oncogene family have been suggested to carry functions important for cell proliferation, differentiation and neoplasia, but the molecular mechanisms of such biological effects have not vet been clarified. We have previously reported that the c-myc protein or protein(s) complexed with the c-myc protein bind to a specific sequence in the region upstream of the c-myc gene, where there exist an origin of cellular DNA replication (ori) and also a transcriptional enhancer. It was recently reported that the c-myc protein forms complexes with a novel helix-loop-helix leucine zipper protein (Max), and that the Myc-Max complex specifically recognizes a DNA sequence different from the sequence we have defined in the c-myc gene. In this report we examine the nuclear extract prepared from human Raji cells for binding to the two different sequences which have been reported as specific binding sequences for c-myc protein or c-myc protein complexes. The binding to one sequence was inhibited in the presence of excess amount of the other sequence, suggesting that the same protein(s) may be necessary for binding to either of the two sequences. Since binding to both sequences was cancelled by pretreatment of the Raji extract with an anti-c-myc protein antibody, it is suggested that proteins carrying myc-like antigenicity are necessary for efficient binding of the nucleoprotein complexes to the two distinct DNA sequences.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA 12 NISHI 6,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,COLL MED TECHNOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University			Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; ARIIZUMI K, 1989, MOL CELL BIOL, V9, P4032, DOI 10.1128/MCB.9.9.4032; ARIIZUMI K, 1989, MOL CELL BIOL, V9, P4026, DOI 10.1128/MCB.9.9.4026; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6501; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IGUCHIARIGA SMM, 1987, NUCLEIC ACIDS RES, V15, P4889, DOI 10.1093/nar/15.12.4889; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KITAURA H, 1991, FEBS LETT, V290, P147, DOI 10.1016/0014-5793(91)81246-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SUDO K, 1990, NUCLEIC ACIDS RES, V18, P5425, DOI 10.1093/nar/18.18.5425; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787	24	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549367				2022-12-28	WOS:A1992HK00500021
J	STOBERGRASSER, U; BRYDOLF, B; BIN, X; GRASSER, F; FIRTEL, RA; LIPSICK, JS				STOBERGRASSER, U; BRYDOLF, B; BIN, X; GRASSER, F; FIRTEL, RA; LIPSICK, JS			THE MYB DNA-BINDING DOMAIN IS HIGHLY CONSERVED IN DICTYOSTELIUM-DISCOIDEUM	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; MOUSE ERYTHROLEUKEMIA-CELLS; AMINO-TERMINAL REGION; HUMAN LYMPHOCYTES-T; ONCOGENE C-MYB; V-MYB; PROTO-ONCOGENE; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; CELLULAR PROGENITOR	The c-myb proto-oncogene encodes a protein that is highly conserved among birds and mammals. The amino-terminal domain of c-Myb contains three imperfect tandem repeats of approximately 50 amino acids each. This domain is required for DNA binding and has also been conserved to varying degrees in invertebrates, plants and yeast. Given that myb-related genes appear to control cellular differentiation in a variety of eucaryotic systems, the presence of a myb gene in the cellular slime mold Dictyostelium discoideum might provide a tractable system for studying the role of myb in differentiation. Degenerate oligonucleotide primers encoding regions that are highly conserved in the vertebrate and Drosophila Myb DNA-binding domains were used to amplify a related domain from Dictyostelium genomic DNA, which was then used to isolate a genomic clone. The putative DNA-binding domain of Dictyostelium Myb is as closely related to vertebrate c-Myb as is Drosophila Myb (65% identity), whereas the known Myb-related proteins of plants and yeast are more distantly related. The conserved domain of Dictyostelium Myb is capable of binding to the same DNA sequence as the vertebrate and Drosophila Myb proteins. The remainder of the deduced amino acid sequence of Dictyostelium Myb shows no homology to the divergent domains of the known animal, plant and yeast Myb-related proteins. Evolutionary analysis implies that the duplications that generated the repeats of the Myb DNA-binding domain began prior to the divergence of animals, plants, cellular slime molds and yeast.	SUNY STONY BROOK, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [P01-CA-28146, K04-CA-01457] Funding Source: Medline; NIGMS NIH HHS [GM-30693] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001457, P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030693] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P659; DOONER HK, 1983, MOL GEN GENET, V189, P136, DOI 10.1007/BF00326066; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; DVORAK M, 1989, NUCLEIC ACIDS RES, V17, P5651; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P9093, DOI 10.1073/pnas.87.23.9093; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MAROCCO A, 1989, MOL GEN GENET, V216, P183, DOI 10.1007/BF00334354; MCCLINTOCK B, 1989, YB 48, P142; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; MOSSING MC, 1990, SCIENCE, V250, P1712, DOI 10.1126/science.2148648; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Spudich JA, 1987, METHODS CELL BIOL, V28; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	71	58	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					589	596						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549373				2022-12-28	WOS:A1992HK00500029
J	QURESHI, SA; RIM, M; ALEXANDROPOULOS, K; BERG, K; SUKHATME, VP; FOSTER, DA				QURESHI, SA; RIM, M; ALEXANDROPOULOS, K; BERG, K; SUKHATME, VP; FOSTER, DA			SUSTAINED INDUCTION OF EGR-1 BY V-SRC CORRELATES WITH A LACK OF FOS-MEDIATED REPRESSION OF THE EGR-1 PROMOTER	ONCOGENE			English	Article								Serum stimulation of quiescent fibroblasts leads to a transient induction of the transcription factor egr-1. However, the induction of egr-1 by v-src was found to be sustained rather than transient. The proto-oncogene fos has been reported to be co-regulated with egr-1 and to repress serum-induced egr-1 expression. We found that c-fos prevents v-src-induced gene expression regulated by the egr-1 promoter. Thus, the sustained induction of egr-1 by v-src could be explained by a lack of c-fos induction by v-src. Consistent with this hypothesis, egr-1 and c-fos were co-induced by serum, but not by v-src, in Balb/c 3T3 cells, v-src did not induce c-fos expression in these cells. We propose that sustained expression of egr-1 induced by v-src in Balb/c 3T3 cells is due to a lack of c-fos down-regulation of egr-1.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PARK AVE, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT BIOL RES, NEW YORK, NY 10021 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Howard Hughes Medical Institute; University of Chicago; University of Chicago			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; Battey, 1986, BASIC METHODS MOL BI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1988, ONCOGENE HDB, P305; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRAY GM, 1988, J BIOL CHEM, V263, P10714; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JAHNER D, 1991, ONCOGENE, V6, P1259; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PATWARDHAN S, 1991, ONCOGENE, V6, P917; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VOGT PK, 1988, ONCOGENE, V3, P3; WELHAM MJ, 1990, ONCOGENE, V5, P161; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x	48	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					121	125						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741159				2022-12-28	WOS:A1992HC22700016
J	JONVEAUX, P; FENAUX, P; QUIQUANDON, I; PIGNON, JM; LAI, JL; LOUCHEUXLEFEBVRE, MH; GOOSSENS, M; BAUTERS, F; BERGER, R				JONVEAUX, P; FENAUX, P; QUIQUANDON, I; PIGNON, JM; LAI, JL; LOUCHEUXLEFEBVRE, MH; GOOSSENS, M; BAUTERS, F; BERGER, R			MUTATIONS IN THE P53-GENE IN MYELODYSPLASTIC SYNDROMES	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; CHRONIC MYELOGENOUS LEUKEMIA; P53 GENE-MUTATIONS; TUMOR-ANTIGEN; POINT MUTATIONS; CDNA SEQUENCE; RAS ONCOGENES; BLAST CRISIS; DNA; EXPRESSION	We have examined p53 alleles in 151 DNAs from patients with myelodysplastic syndrome using single-strand conformation polymorphism analysis of polymerase chain reaction products. We focused our study on the four highly conserved regions of the p53 gene and detected five patients with aberrantly migrating fragments. We confirmed the putative mutation in each case by direct sequencing analysis. Of these five patients, three had chromosome 17 monosomy associated with p53 mutation, one patient showed one mutated p53 allele and one wild-type allele, and the last patient demonstrated only the mutant allele, suggesting a homozygous state. Unlike many other types of human cancers, point mutations in the p53 tumor-suppressor gene appear to be a rare event in myelodysplastic syndromes.	INSERM,U124,INST RECH CANC,F-59045 LILLE,FRANCE; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE; CHU LILLE,SERV HEMATOL & CYTOGENET,F-59037 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille	JONVEAUX, P (corresponding author), INSERM,U301,INST GENET MOLEC,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.							AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AINSWORTH PJ, 1991, NUCLEIC ACIDS RES, V19, P405, DOI 10.1093/nar/19.2.405; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARNDEN DG, 1985, CYTOGENET CELL GENET; HARNDEN DG, 1985, ISCN 1985 INT SYSTEM; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KELMAN Z, 1989, BLOOD, V74, P2318; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P284; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LYONS J, 1988, BLOOD, V71, P1707; Maniatis T., 1982, MOL CLONING; MASHAL R, 1990, BLOOD, V75, P180; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PADUA RA, 1988, LEUKEMIA, V2, P503; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; ROMANO JW, 1989, ONCOGENE, V4, P1483; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SOUSSI T, 1990, ONCOGENE, V5, P945; SUGIMOTO K, 1991, BLOOD, V77, P1153; SUZUKI Y, 1990, ONCOGENE, V5, P1037; VARLEY JM, 1991, ONCOGENE, V6, P413; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	42	139	142	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2243	2247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766671				2022-12-28	WOS:A1991GX73500010
J	MANNING, AM; WILLIAMS, AC; GAME, SM; PARASKEVA, C				MANNING, AM; WILLIAMS, AC; GAME, SM; PARASKEVA, C			DIFFERENTIAL SENSITIVITY OF HUMAN COLONIC ADENOMA AND CARCINOMA-CELLS TO TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) - CONVERSION OF AN ADENOMA CELL-LINE TO A TUMORIGENIC PHENOTYPE IS ACCOMPANIED BY A REDUCED RESPONSE TO THE INHIBITORY EFFECTS OF TGF-BETA	ONCOGENE			English	Article							POLYPOSIS COLI PATIENTS; LIVER EPITHELIAL-CELLS; PROLIFERATION; CANCER; CARCINOGENESIS; PROGRESSION; RESISTANCE; RECEPTORS; ONCOGENE; GENE	The growth of three non-tumorigenic human colonic adenoma cell lines, designated AA/C1, RG/C2 and RR/C1, was inhibited by low concentrations of transforming growth factor-beta (TGF-beta) (0.05-0.5 ng ml-1). However, the growth of five human colon cancer cell lines under identical conditions was resistant to high concentrations of TGF-beta (2-10 ng ml-1). This is the first report of well-characterized premalignant human colonic cells showing sensitivity to TGF-beta. The TGF-beta-sensitive adenoma cell line AA/C1 was derived from a relatively large adenoma with a K-ras gene mutation and represents a relatively late-stage adenoma, indicating that loss of response to TGF-beta occurs at a relatively late stage in colorectal carcinogenesis and that the presence of a ras gene mutation does not necessarily confer resistance to TGF-beta. Of further interest, the RG/CZ cell line has a p53 mutation showing that p53 mutations do not necessarily lead to TGF-B insensitivity. Furthermore, in this paper we show that the conversion of the AA/C1 adenoma cell line to a tumorigenic phenotype [Williams et al., (1990) Cancer Res., 50, 4724] is accompanied by a reduced response to the growth-inhibitory effects of TGF-beta up to 10 ng ml-1. Reduced responsiveness to the inhibitory effects of TGF-beta may be an important event in the loss of growth control in colorectal carcinogenesis.	UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BRISTOL,DENT SCH & HOSP,DEPT ORAL MED,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol; University of Bristol				Williams, Ann/0000-0002-6009-7137				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; BAKER SJ, 1990, CANCER RES, V50, P777; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; COFFEY RJ, 1988, CANCER RES, V48, P1596; COFFEY RJ, 1986, CANCER RES, V46, P1164; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GAME SM, 1990, CARCINOGENESIS, V11, P965, DOI 10.1093/carcin/11.6.965; HADDOW S, 1991, ONCOGENE, V6, P1467; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HOUCK KA, 1989, ONCOGENE, V4, P19; HUBBS AF, 1989, CARCINOGENESIS, V10, P1599, DOI 10.1093/carcin/10.9.1599; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAMPRECHT SA, 1989, ANTICANCER RES, V9, P1877; MACIEWICZ RA, 1989, INT J CANCER, V43, P478, DOI 10.1002/ijc.2910430323; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCMAHON JB, 1986, CANCER RES, V46, P4665; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1985, CANCER CELL, V3, P65; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PARASKEVA C, 1990, BRIT J CANCER, V61, P828, DOI 10.1038/bjc.1990.185; PARASKEVA C, 1989, CANCER RES, V49, P1282; PARKINSON K, 1990, CARCINOGENESIS, V11, P195, DOI 10.1093/carcin/11.2.195; PIGNATELLI M, 1989, INT J CANCER, V44, P518, DOI 10.1002/ijc.2910440324; Reddel R R, 1988, Oncogene Res, V3, P401; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROLLINS BJ, 1989, J CELL PHYSIOL, V139, P455, DOI 10.1002/jcp.1041390302; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SONG MKH, 1985, EXP CELL RES, V156, P271, DOI 10.1016/0014-4827(85)90281-2; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILLIAMS AC, 1990, CANCER RES, V50, P4724	39	183	189	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1471	1476						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886718				2022-12-28	WOS:A1991GX27200026
J	TRAVALI, S; FERBER, A; REISS, K; SELL, C; KONIECKI, J; CALABRETTA, B; BASERGA, R				TRAVALI, S; FERBER, A; REISS, K; SELL, C; KONIECKI, J; CALABRETTA, B; BASERGA, R			EFFECT OF THE MYB GENE-PRODUCT ON EXPRESSION OF THE PCNA GENE IN FIBROBLASTS	ONCOGENE			English	Article							CELL NUCLEAR ANTIGEN; TEMPERATURE-SENSITIVE MUTANTS; KINASE MESSENGER-RNA; C-MYB; THYMIDINE KINASE; DNA-REPLICATION; PROTO-ONCOGENE; GROWTH-FACTOR; CDNA CLONES; NUCLEOTIDE-SEQUENCE	Tk-ts13 cells are BHK-derived fibroblasts that have a G1-specific temperature sensitive (ts) mutation so that the cells arrest in the G1 phase of the cell cycle at the restrictive temperature of 39.6-degrees. We have introduced into these cells a plasmid carrying the human c-myb cDNA under the control of the early SV40 promoter. The resulting cell line, ts13 myb cells, express the c-myb RNA and protein and, when serum-stimulated, they undergo one round of DNA replication even at the restrictive temperature. Under the same conditions, the parent cell line (tk-ts13 cells) are blocked in G1 and fail to replicate DNA. We have investigated the expression of two late growth-regulated genes, PCNA and histone H3, in tk-ts13 and in ts 13 myb cells, both at permissive and restrictive temperature. At the permissive temperature of 34-degrees, the mRNA levels for PCNA and histone H3 increase markedly after serum stimulation in both cell lines, reaching a peak at the time of DNA synthesis. At the restrictive temperature of 39.6-degrees, the mRNA's for PCNA, and histone H3 are detectable in serum-stimulated ts13 myb cells while they are not detectable in the parent tk-ts13 cell line. Run-on transcription assays indicate that these 2 genes are transcribed in tk-ts13 cells equally well at permissive and nonpermissive temperatures, and that the presence of the myb product does not significantly increase their rates of transcription. The stability of the respective mRNA's is roughly the same at either temperature and in both types of cells. These results indicate: (1) a constitutively expressed c-myb gene product confers to fibroblasts the ability of temporarily by-passing a ts block in the G1 phase of the cell cycle and (2) the myb product, under these conditions, regulates the mRNA levels of PCNA and histone H3 either directly or indirectly by a post-transcriptional mechanism.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,3400 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	BASERGA, R (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,3400 N BROAD ST,PHILADELPHIA,PA 19140, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BAUMBACH LL, 1987, BIOCHEMISTRY-US, V26, P6178, DOI 10.1021/bi00393a034; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CAMPISI J, 1984, MOL CELL BIOL, V4, P1807, DOI 10.1128/MCB.4.9.1807; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; Gai X X, 1988, Oncogene Res, V3, P377; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HIRSCHHORN RR, 1984, BIOCHEMISTRY-US, V23, P3731, DOI 10.1021/bi00311a025; IDE T, 1986, BIOCHEMISTRY-US, V25, P7041, DOI 10.1021/bi00370a043; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KONIECKI J, 1991, IN PRESS CANCER RES; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; LIU HT, 1985, J BIOL CHEM, V260, P3269; LIU HT, 1985, MOL CELL BIOL, V5, P2926; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NINOMIYATSUJI J, 1987, EXP CELL RES, V171, P509, DOI 10.1016/0014-4827(87)90183-2; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OHNO K, 1984, SOMAT CELL GENET, V10, P9; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; ROSSINI M, 1979, P NATL ACAD SCI USA, V76, P4441, DOI 10.1073/pnas.76.9.4441; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; THOMAS PS, 1983, METHOD ENZYMOL, V100, P225; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TRAVALI S, IN PRESS MOL CELL BI; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTIN K, 1989, CELL, V85, P93; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WONG SW, 1988, EMBO J, V7, P3767	63	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					887	894						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1712444				2022-12-28	WOS:A1991GU62200001
J	ONG, G; SIKORA, K; GULLICK, WJ				ONG, G; SIKORA, K; GULLICK, WJ			INACTIVATION OF THE RETINOBLASTOMA GENE DOES NOT LEAD TO LOSS OF TGF-BETA RECEPTORS OR RESPONSE TO TGF-BETA IN BREAST-CANCER CELL-LINES	ONCOGENE			English	Note							TRANSFORMING GROWTH-FACTOR; INHIBITION; EXPRESSION; PATTERN; PRODUCT		HAMMERSMITH HOSP,ICRF,ONCOL GRP,CYCLOTRON BLDG,DU CANE RD,LONDON W12 0HS,ENGLAND	Imperial College London	GULLICK, WJ (corresponding author), HAMMERSMITH HOSP,ICRF,ONCOL GRP,CYCLOTRON BLDG,DU CANE RD,LONDON W12 0HS,ENGLAND.							CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIKE B, 1986, J BIOL CHEM, V261, P3426; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; XU HJ, 1989, ONCOGENE, V4, P807	17	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					761	763						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646985				2022-12-28	WOS:A1991GT82500011
J	IKEGAKI, N; KENNETT, RH				IKEGAKI, N; KENNETT, RH			MOLECULAR GENETIC-CHARACTERIZATION OF EPITOPE-SPECIFIC MONOCLONAL-ANTIBODIES AGAINST THE MYC FAMILY PROTEINS	ONCOGENE			English	Article											IKEGAKI, N (corresponding author), UNIV PENN, SCH MED, DEPT HUMAN GENET, PHILADELPHIA, PA 19104 USA.				NCI NIH HHS [CA 24263] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024263] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Ikegaki N, 1988, Prog Clin Biol Res, V271, P133; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; Maniatis T., 1982, MOL CLONING; MEHRA V, 1986, P NATL ACAD SCI USA, V83, P7013, DOI 10.1073/pnas.83.18.7013; MOCARSKI ES, 1985, P NATL ACAD SCI USA, V82, P1266, DOI 10.1073/pnas.82.4.1266; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; REINACH FC, 1985, J MOL BIOL, V181, P411, DOI 10.1016/0022-2836(85)90229-3; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	45	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1990	5	3					397	403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690381				2022-12-28	WOS:A1990CW41500018
J	TORMANEN, VT; PFEIFER, GP				TORMANEN, VT; PFEIFER, GP			MAPPING OF UV PHOTOPRODUCTS WITHIN RAS PROTOONCOGENES IN UV-IRRADIATED CELLS - CORRELATION WITH MUTATIONS IN HUMAN SKIN-CANCER	ONCOGENE			English	Article							LIGATION-MEDIATED PCR; N-RAS; PYRIMIDINE DIMERS; METHYLATION ANALYSIS; ESCHERICHIA-COLI; XERODERMA PIGMENTOSUM; 6-4 PHOTOPRODUCTS; POINT MUTATIONS; MAMMALIAN-CELLS; DNA DAMAGE	Mutations in ras proto-oncogenes have been found in human skin cancers. Since ultraviolet light is implicated in the development of skin cancers, we have investigated the formation of UV-induced photoproducts along exons 1 and 2 of the three ras proto-oncogenes, H-ras, K-ras, and N-ras, in UV-irradiated human cells. The two major types of DNA photoproducts, cyclobutane pyrimidine dimers and pyrimidine (6-4) pyrimidone photoproducts [(6-4) photoproducts], were mapped at the DNA sequence level by ligation-mediated polymerase chain reaction (LMPCR). No significant differences were seen between irradiated purified DNA and irradiated cells, implying that local chromatin structure does not influence the distribution of photoproducts along exons 1 and 2 of the three ras genes. We find that the transcribed strand near codon 61 in H-ras, K-ras and N-ras shows a high frequency of potentially mutagenic cyclobutane dimers and (6-4) photoproducts. Codon 12 of H-ras, K-ras and N-ras displays only barely detectable photoproducts at a CpC dinucleotide. In human skin cancers, mutations were most frequently detected at codon 12 of H-ras and K-ras. These results imply that the initial frequency distribution of a mutagenic DNA adduct may not correlate with mutation spectra in human tumors.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope								ALBINO AP, 1989, ONCOGENE, V4, P1363; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOURRE F, 1987, NUCLEIC ACIDS RES, V15, P8861, DOI 10.1093/nar/15.21.8861; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COLLINS SJ, 1988, ONCOGENE RES, V3, P117; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GROSSMAN L, 1988, FASEB J, V2, P2696, DOI 10.1096/fasebj.2.11.3294078; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; KEIJZER W, 1989, CANCER RES, V49, P1229; KOEHLER DR, 1991, J BIOL CHEM, V266, P11766; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MEULLER PR, 1989, SCIENCE, V246, P780; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1992, METHODS MOL BIOL PCR; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PIERCEALL WE, 1991, ONCOGENE, V6, P2085; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SARASIN A, 1991, 9TH P INT C RAD RES, P42; SCOTTO J, 1983, NIH832433 PUBL; SHUKLA VK, 1989, ONCOGENE RES, V5, P121; STEIGERWALD SD, 1990, NUCLEIC ACIDS RES, V18, P1435, DOI 10.1093/nar/18.6.1435; SUAREZ HG, 1989, CANCER RES, V49, P1223; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; VANDERLUBBE JLM, 1988, ONCOGENE RES, V3, P9; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	58	70	70	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1729	1736						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501884				2022-12-28	WOS:A1992JJ37600008
J	DUBIK, D; SHIU, RPC				DUBIK, D; SHIU, RPC			MECHANISM OF ESTROGEN ACTIVATION OF C-MYC ONCOGENE EXPRESSION	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; DEOXYRIBONUCLEIC-ACID BINDING; RAT PROLACTIN GENE; RESPONSIVE ELEMENT; TRANSCRIPTIONAL ACTIVATION; PROTO-ONCOGENE; SINGLE DOMAIN; DNA-BINDING; PS2 GENE; RECEPTOR	The estrogen receptor complex is a known trans-acting factor that regulates transcription of specific genes through an interaction with a specific estrogen-responsive cis-acting element (ERE). In previous studies we have shown that in estrogen-responsive human breast cancer cells estrogen rapidly activates c-myc expression. This activated expression occurs through enhanced transcription and does not require the synthesis of new protein intermediates; therefore, an ERE is present in the human c-myc gene regulatory region. To localize the ERE, constructs containing varying lengths of the c-myc 5'-flanking region ranging from - 2327 to + 25 (relative to the PI promoter) placed adjacent to the chloramphenicol acetyl transferase reporter gene (CAT) were prepared. They were used in transient transfection studies in MCF-7 and HeLa cells co-transfected with an estrogen receptor expression vector. These studies reveal that at] constructs containing the P2 promoter region exhibited estrogen-regulated CAT expression and that a 116-bp region upstream and encompassing the P2 TATA box is necessary for this activity. Analysis of this 116-bp region failed to identify a cis-acting element with sequences resembling the consensus ERE; however, co-transfection studies with mutant estrogen receptor expression vectors showed that the DNA-binding domain of the receptor is essential for estrogen-regulated CAT gene expression. We have also observed that anti-estrogen receptor complexes can weakly trans-activate from this 116-bp region but fail to do so from the ERE-containing ApoVLDLII-CAT construct. To explain these results we propose a new mechanism of estrogen trans-activation in the c-myc gene promoter.	UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG R3E 0W3, MANITOBA, CANADA	University of Manitoba								BASERGA R, 1984, EXP CELL RES, V151, P1, DOI 10.1016/0014-4827(84)90349-5; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1988, MOL CELL BIOL, V8, P5323, DOI 10.1128/MCB.8.12.5323; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1988, J BIOL CHEM, V263, P12705; GARCIA I, 1989, CANCER RES, V49, P6675; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOWLEY PM, 1983, METHOD ENZYMOL, V101, P387; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANG JC, 1988, BRIT J CANCER, V58, P62; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1988, CURR TOP MICROBIOL, V141, P253; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; PENTECOST BT, 1990, MOL ENDOCRINOL, V4, P1000, DOI 10.1210/mend-4-7-1000; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; WATSON PH, 1991, CANCER RES, V51, P3996; WU X, 1991, 73RD END SOC PROGR A	43	282	288	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1587	1594						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630819				2022-12-28	WOS:A1992JE81300015
J	EYCHENE, A; BARNIER, JV; APIOU, F; DUTRILLAUX, B; CALOTHY, G				EYCHENE, A; BARNIER, JV; APIOU, F; DUTRILLAUX, B; CALOTHY, G			CHROMOSOMAL ASSIGNMENT OF 2 HUMAN B-RAF(RMIL) PROTOONCOGENE LOCI - B-RAF-1 ENCODING THE P94(BRAF RMIL) AND B-RAF-2, A PROCESSED PSEUDOGENE	ONCOGENE			English	Note							RAF FAMILY; C-MIL; B-RAF; KINASE; TRANSDUCTION; EXPRESSION; RETROVIRUS; SEQUENCE; GENES; VIRUS	The B-raf gene is the human homolog of the avian c-Rmil proto-oncogene encoding a 94-kDa serine/threonine kinase detected in avian cells. We have previously shown that this protein contains amino-terminal sequences not found in other proteins of the mil/raf gene family. These sequences are encoded by three exons in the avian genome. We report that these three exons are conserved in the human B-raf gene and that they encode an amino acid sequence similar to that of the avian c-Rmil gene, indicating that in both avian and mammalian species the product of the B-raf/c-Rmil gene is a 94-kDa protein. We also identified two human B-raf loci: B-raf-1, located on chromosome 7q34, which encodes the functional B-raf/Rmil gene product, and B-raf-2, an inactive processed pseudogene located on chromosome Xq13.	CTR UNIV ORSAY,INST CURIE,CNRS,URA 1443,F-91405 ORSAY,FRANCE; INST CURIE,CNRS,URA 620,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225				BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; EYCHENE A, 1989, NUCLEIC ACIDS RES, V17, P1250, DOI 10.1093/nar/17.3.1250; EYCHENE A, 1992, IN PRESS ONCOGENE; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; LEMIEUX N, 1992, IN PRESS CYTOGENET C; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; Maniatis T, 1989, DECONTAMINATION DILU; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; RAPP UR, 1991, ONCOGENE, V6, P495; REEVES BR, 1989, ONCOGENE, V4, P373; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STORM SM, 1990, ONCOGENE, V5, P345; VANIN EF, 1984, BIOCHIM BIOPHYS ACTA, V782, P231, DOI 10.1016/0167-4781(84)90057-5; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122	19	38	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1657	1660						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630826				2022-12-28	WOS:A1992JE81300025
J	FAGIOLI, M; ALCALAY, M; PANDOLFI, PP; VENTURINI, L; MENCARELLI, A; SIMEONE, A; ACAMPORA, D; GRIGNANI, F; PELICCI, PG				FAGIOLI, M; ALCALAY, M; PANDOLFI, PP; VENTURINI, L; MENCARELLI, A; SIMEONE, A; ACAMPORA, D; GRIGNANI, F; PELICCI, PG			ALTERNATIVE SPLICING OF PML TRANSCRIPTS PREDICTS COEXPRESSION OF SEVERAL CARBOXY-TERMINALLY DIFFERENT PROTEIN ISOFORMS	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; GLYCOGEN-SYNTHASE; MYELOID-LEUKEMIA; ALPHA GENE; TRANSLOCATION; CHROMOSOME-17; MECHANISM; ONCOGENE; KINASE; RNA	The acute promyelocytic leukaemia (APL)-specific chromosome 15;17 translocation leads to the fusion of a newly identified putative transcription factor, PML, and the retinoic acid receptor alpha. We have characterized the structure of the PML genomic locus and preliminarily characterized its expression pattern. The PML locus spans a minimum of 35 kb and is subdivided into nine exons. The putative PML DNA binding site is encoded by exons 2 and 3. We isolated a large number of alternatively spliced PML transcripts that encode numerous PML isoforms. Two groups of isoforms were identified that differed either in their C-terminal region or in the length of their central region, but retained the putative DNA-binding and dimerization domains. RNAase protection experiments revealed that the different PML isoforms are equally expressed in established cell lines of different histological origin.	UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; CNR,IST GENET & BIOFIS,I-80125 NAPLES,ITALY	University of Perugia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Alcalay, Myriam/B-3182-2016; Alcalay, Myriam/AAB-4300-2019; Simeone, Antonio/ABG-5269-2020; Grignani, Francesco/AAC-2565-2022; Acampora, Dario/C-2156-2013; Pelicci, Pier Giuseppe/AAL-6572-2020	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Simeone, Antonio/0000-0003-2693-9836; 				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BERG JM, 1990, J BIOL CHEM, V265, P6513; BIONDI A, 1991, BLOOD, V77, P1418; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CANAANI E, 1984, LANCET, V1, P593; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GIGUERE V, 1987, NATURE, V330, P324; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LONGO L, 1990, ONCOGENE, V5, P1557; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITELMAN F, 1988, CATALOG CHROMOSOME A; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PANDOLFI PP, 1992, IN PRESS EMBO J; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SHEORAIN VS, 1984, J BIOL CHEM, V259, P7024; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	31	168	172	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1083	1091						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594241				2022-12-28	WOS:A1992HU64200005
J	BARTEK, J; VOJTESEK, B; GRAND, RJA; GALLIMORE, PH; LANE, DP				BARTEK, J; VOJTESEK, B; GRAND, RJA; GALLIMORE, PH; LANE, DP			CELLULAR-LOCALIZATION AND T-ANTIGEN BINDING OF THE RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article								Mutation of the retinoblastoma (Rb) gene is found frequently in human sarcomas, lung, bladder and breast carcinomas and is the molecular basis for hereditary predisposition to retinoblastoma. The Rb protein is a nuclear phosphoprotein that is differentially phosphorylated during the cell cycle. Its precise function is unknown but it has been suggested that it may act as a transcriptional regulator or as a regulator of cellular DNA synthesis. The Rb protein forms specific complexes with the oncogenes of three different groups of DNA tumour viruses. We have prepared a new monoclonal antibody to the Rb protein and used it to establish sensitive immunoassays for Rb complexed to T antigen. In SV40-infected and transformed cells these assays showed that Rb enters a trimolecular complex containing p53. Rb and T. A large panel of human tumour cell lines was tested for expression, cellular localization and T-binding activity of Rb using the new antibody.	UNIV DUNDEE, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; MASARYK INST ONCOL, CS-65653 BRNO, CZECHOSLOVAKIA; UNIV BIRMINGHAM, DEPT CANC STUDIES, CANC RES CAMPAIGN LABS, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Dundee; Masaryk Memorial Cancer Institute; University of Birmingham			Lane, David P/C-4920-2008; Bartek, Jiri/G-5870-2014	Lane, David/0000-0003-0551-3545				AKIYAMA T, 1990, ONCOGENE, V5, P179; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTEK J, 1990, ONCOGENE, V5, P893; BENEDICT WF, 1987, ADV VIRAL ONCOL, P19; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAND RJA, 1989, ONCOGENE, V4, P1291; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1; LANE DP, 1981, J IMMUNOL METHODS, V47, P303, DOI 10.1016/0022-1759(81)90286-6; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; XU HJ, 1991, ONCOGENE, V6, P1139; YOKOTA J, 1988, ONCOGENE, V3, P471	57	61	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					101	108						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741157				2022-12-28	WOS:A1992HC22700014
J	ROUX, P; VERRIER, B; KLEIN, B; NICCOLINO, M; MARTY, L; ALEXANDRE, C; PIECHACZYK, M				ROUX, P; VERRIER, B; KLEIN, B; NICCOLINO, M; MARTY, L; ALEXANDRE, C; PIECHACZYK, M			RETROVIRUS-MEDIATED GENE-TRANSFER OF A HUMAN C-FOS CDNA INTO MOUSE BONE-MARROW STROMAL CELLS	ONCOGENE			English	Note							STEM-CELLS; PROTO-ONCOGENE; T-ANTIGEN; V-FOS; EXPRESSION; PROTEINS; TRANSCRIPTION; CONSTRUCTION; SEQUENCE; SIGNALS	A cDNA encoding a complete human c-fos protein was isolated and inserted into two different murine MoMuLV-derived recombinant retroviruses allowing expression of c-fos protein in different cell types. One c-fos-expressing retrovirus, chosen for its ability to express high levels of proteins in fibroblast-like cells, was shown to potentiate long-term cultures of mouse bone marrow stromal cells in vitro and therefore constitutes a potential tool for immortalizing such cells. Moreover, when tested in an in vitro differentiation assay, stromal cells constitutively expressing c-fos favor the granulocyte differentiation of hematopoietic precursors. Interestingly, retroviruses expressing v-src and v-abl oncogenes, included as controls in our experiments, do not produce any detectable effects, whereas those expressing polyoma virus middle T antigen facilitate long-term growth in vitro of stromal cells that favor the macrophage differentiation pathway of bone marrow stem cells. Our observation supports the idea that constitutive expression of some oncogenes, including c-fos and polyoma virus middle T antigen, may influence cytokine production by bone marrow stromal cells.	UNIV MONTPELLIER 2,CNRS,UA 1191,PL E BATAILLON,F-34095 MONTPELLIER 05,FRANCE; FAC ALEXIS CARREL,IMMUNOVIROL MOLEC LAB,CNRS,UMR 005,F-69372 LYONS 07,FRANCE; CTR VAL AURELLE PAUL LAMARQUE,BIOCHIM LAB,F-34994 MONTPELLIER 05,FRANCE; ECOLE NATL SUPER LYON,CNRS BIOMERIEUX,UMR 103,LYONS 07,FRANCE; INSERM,U191,ZOLAD,F-34000 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			Roux, Pierre/D-8833-2017; PIECHACZYK, Marc/E-7896-2013; verrier, bernard/J-4094-2017	PIECHACZYK, Marc/0000-0003-1367-2597; verrier, bernard/0000-0002-8478-7095				BORELLI E, 1984, NATURE, V312, P608; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Curran T, 1988, ONCOGENE HDB, P307; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5567; FRANZA BR, 1987, ONCOGENE, V1, P213; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILD BC, 1988, J VIROL, V62, P3795, DOI 10.1128/JVI.62.10.3795-3801.1988; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; METCALF D, 1984, HEMOPOIETIC COLONIES; MOLDERS H, 1987, ONCOGENE, V1, P337; MULLER R, 1986, EMBO J, V5, P311, DOI 10.1002/j.1460-2075.1986.tb04214.x; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUTHER U, 1989, ONCOGENE, V4, P861; SALMON SE, 1979, CANCER RES, V39, P1133; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEISS R, 1985, RNA TUMOR VIRUSES, V2, P893; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3664; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	34	12	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2155	2160						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658710				2022-12-28	WOS:A1991GX11900029
J	GALIEN, R; MERCIER, G; GARCETTE, M; EMANOILRAVIER, R				GALIEN, R; MERCIER, G; GARCETTE, M; EMANOILRAVIER, R			RAS ONCOGENE ACTIVATES THE INTRACISTERNAL A PARTICLE LONG TERMINAL REPEAT PROMOTER THROUGH A CAMP RESPONSE ELEMENT	ONCOGENE			English	Article							LEUCINE ZIPPER PROTEINS; CYCLIC-AMP; ADENYLATE-CYCLASE; DIACYLGLYCEROL PRODUCTION; TRANSCRIPTION FACTOR; POSSIBLE INVOLVEMENT; GENE-TRANSCRIPTION; JUN PROTEINS; DNA ELEMENTS; CROSS-TALK	To understand the mechanism responsible for the high expression of Intracisternal A Particles (IAP) in murine cells transformed by the Kirsten Mouse Sarcoma Virus (Ki-MSV), we have investigated the effect of p21ras on IAP transcription. By transient cotransfections of IAP LTR-CAT plasmids with v-Ki-ras and c-Ki-ras expression vectors, we have found that p21v-Ki-ras, and the p21c-Ki-ras to a lesser extent, stimulate the promoter activity of the 5' IAP LTR. We constructed several plasmids containing the CAT gene under control of IAP LTRs deleted in different regions. CAT assays demonstrate that the ras responsive sequence is a 16 bp oligonucleotide containing an effective c-AMP Response Element (CRE) TGACGTCA, which is located in the U3 region, 20 bp upstream of the CAAT box.	HOP ST LOUIS,RETROVIRUS & RETROTRANSPOSONS VERTEBRES LAB,CNRS,UPR 0043,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	EMANOILRAVIER, R (corresponding author), HOP ST LOUIS,RETROVIRUS & RETROTRANSPOSONS VERTEBRES LAB,CNRS,UPR 0043,F-75010 PARIS,FRANCE.							ARENZANASEISDEDOS F, 1989, ONCOGENE, V4, P1359; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLUNDELL MC, 1989, J VIROL, V63, P4814, DOI 10.1128/JVI.63.11.4814-4823.1989; CHAPON D, 1983, NATURE, V302, P33; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DOTTO GP, 1985, NATURE, V318, P472; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FALZON M, 1989, J BIOL CHEM, V264, P21915; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GATTONICELLI S, 1983, NATURE, V306, P795, DOI 10.1038/306795a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HAWLEY RG, 1982, P NATL ACAD SCI-BIOL, V79, P7425, DOI 10.1073/pnas.79.23.7425; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; Kuff E. L., 1988, Eukaryotic transposable elements as mutagenic agents.., P79; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1985, MOL CELL BIOL, V5, P474, DOI 10.1128/MCB.5.3.474; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LILLIE JW, 1989, NATURE, V341, P279, DOI 10.1038/341279a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; LURIA S, 1986, J VIROL, V57, P998, DOI 10.1128/JVI.57.3.998-1003.1986; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MERCIER G, 1987, CANCER J, V1, P314; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICOLAS JF, 1983, TERATOCARCINOMA STEM, P469; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OWEN RD, 1990, MOL CELL BIOL, V10, P1; Pace-Asciak CR, 1983, ENZYMES LIPID ENZYMO, VXVI, P543; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SATAKE M, 1988, ONCOGENE, V3, P69; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; TREPEL JB, 1987, MOL CELL BIOL, V7, P2644, DOI 10.1128/MCB.7.7.2644; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WIEVEL NA, 1971, INT J CANCER, V7, P165; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOTSUYANAGI Y, 1984, ULTRASTRUCTURE REPRO, P218	54	20	20	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					849	855						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1828874				2022-12-28	WOS:A1991GT82500022
J	DOWNING, JR; REYNOLDS, AB				DOWNING, JR; REYNOLDS, AB			PDGF, CSF-1, AND EGF INDUCE TYROSINE PHOSPHORYLATION OF P120, A PP60SRC TRANSFORMATION-ASSOCIATED SUBSTRATE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; FMS PROTO-ONCOGENE; GTPASE ACTIVATING PROTEIN; CELLULAR SRC GENE; FACTOR-I RECEPTOR; KINASE-ACTIVITY; GROWTH-FACTOR; STRUCTURAL ALTERATION; CARBOXY TERMINUS; POINT MUTATION	Transformation by activated pp60c-src has been correlated by genetic analysis with the tyrosine phosphorylation of a 120 kilodalton (kDa) protein, p120. We now demonstrate tyrosine phosphorylation of p120 following stimulation of cells by growth factors whose receptors have intrinsic tyrosine-specific protein kinase activity. Stimulation of quiescent NIH3T3 cells with platelet-derived growth factor (PDGF) resulted in the tyrosine phosphorylation of p120 that was maximal by 5 min and returned to background levels by 30 min. p120 was also phosphorylated on tyrosine after addition of colony-stimulating factor 1 (CSF-1) or epidermal growth factor (EGF) to NIH3T3 cells engineered to express high levels of their respective receptors. Two additional src substrates, p110 and p85, were analysed under identical assay conditions. PDGF, CSF-1, and EGF induced only a minimal increase in the tyrosine phosphorylation of p85 and no change in the phosphorylation of p110. Thus, the marked ligand-induced tyrosine phosphorylation of p120 was a property not shared by the other src substrates examined. Immunoblotting with antibodies to p120 and the ras GTPase activating protein, GAP, suggests that p120 and GAP are unrelated. In addition, the amino acid sequences of four cyanogen bromide peptides derived from p120 showed no homology to GAP or to sequences in either the PIR or Swiss-Prot databases. These data suggest that tyrosine phosphorylation of p120 may contribute to both signal transduction through growth factor receptors and pp60src induced transformation.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital			Downing, James R./N-8102-2018		NATIONAL CANCER INSTITUTE [P30CA021765, K08CA001429] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, CA-01429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DANIEL TO, 1985, P NATL ACAD SCI USA, V82, P2684, DOI 10.1073/pnas.82.9.2684; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KANNER SB, IN PRESS MOL CELL BI; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OHTSUKA M, 1984, INT J CANCER, V34, P855, DOI 10.1002/ijc.2910340618; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; Shalloway D., 1984, CANCER CELL, V2, P9; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	55	127	132	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					607	613						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851549				2022-12-28	WOS:A1991FR93900016
J	HILLION, J; MECUCCI, C; AVENTIN, A; LEROUX, D; WLODARSKA, I; VANDENBERGHE, H; LARSEN, CJ				HILLION, J; MECUCCI, C; AVENTIN, A; LEROUX, D; WLODARSKA, I; VANDENBERGHE, H; LARSEN, CJ			A VARIANT TRANSLOCATION T(2-18) IN FOLLICULAR LYMPHOMA INVOLVES THE 5' END OF BCL-2 AND IG-KAPPA LIGHT CHAIN GENE	ONCOGENE			English	Note							T(14-18) CHROMOSOMAL TRANSLOCATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL; REGION; PRODUCT; CLONING	We have examined three cases of human lymphoma bearing a t(2;18)(p11;q21) chromosome translocation. The bcl-2 gene appeared to be rearranged in all three cases and breakpoints were clustered in the 5' flanking region of the gene. In all three cases, bcl-2 was juxta-posed to J segments of the Igk gene. This juxtaposition of the bcl-2 and Igk genes is very similar to the variant chromosome translocations of Burkitt lymphoma that juxtapose the c-myc locus to IgL genes.	INST GENET MOLEC,INSERM,U301,27 RUE J DODU,F-75010 PARIS,FRANCE; INST GENET MOLEC,CNRS,SDI 15954 I,F-75010 PARIS,FRANCE; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM; UNIV PERUGIA,MED CLIN,I-06100 PERUGIA,ITALY; HOSP SAN PAU,SERV HEMATOL,BARCELONA,SPAIN; UNIV JOSEPH FOURIER,FAC MED GRENOBLE,DEPT CYTOGENET,F-38706 LA TRONCHE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); KU Leuven; University of Perugia; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)			Leroux, Dominique/G-7309-2014					ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1989, ONCOGENE, V4, P1073; AVENTIN A, 1990, BRIT J HAEMATOL, V74, P367, DOI 10.1111/j.1365-2141.1990.tb02599.x; BAKSHI A, 1985, CELL, V41, P899; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY JM, 1987, J EXP MED, V164, P315; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CROCE CM, 1986, COLD SPRING HARB SYM, V51, P891, DOI 10.1101/SQB.1986.051.01.102; HEITER PA, 1982, J BIOL CHEM, V257, P1516; LEROUX D, 1990, BRIT J HAEMATOL, V75, P290, DOI 10.1111/j.1365-2141.1990.tb02669.x; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; PEZZELLA F, 1990, AM J PATHOL, V137, P225; SCHLISSEL MS, 1989, CELL, V59, P1035; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TAKAHASHI N, 1980, NUCLEIC ACIDS RES, V8, P5983, DOI 10.1093/nar/8.24.5983; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	26	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					169	172						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899478				2022-12-28	WOS:A1991EY03900025
J	LEMOINE, NR; STADDON, S; BOND, J; WYLLIE, FS; SHAW, JJ; WYNFORDTHOMAS, D				LEMOINE, NR; STADDON, S; BOND, J; WYLLIE, FS; SHAW, JJ; WYNFORDTHOMAS, D			PARTIAL TRANSFORMATION OF HUMAN THYROID EPITHELIAL-CELLS BY MUTANT HA-RAS ONCOGENE	ONCOGENE			English	Note							EMBRYO FIBROBLASTS; GENE-PRODUCT; HARVEY; CARCINOGENESIS; ACTIVATION; INVITRO; TUMORS; VIRUS; MYC	We have previously shown that activation of ras oncogenes by mutation is a frequent early event in human thyroid neoplasia. Using amphotropic retroviral vectors to achieve gene transfer, we demonstrate here that human primary thyroid epithelial cells can be partially transformed by an activated cellular or viral Ha-ras oncogene, in the absence of a cooperating oncogene. The transformation event induced by ras involves temporary rescue from senescence for up to 20 rounds of cell division together with morphological alteration, growth factor independence and anchorage independence. It has therefore been possible to reconstruct in vitro a key early event in the genesis of human epithelial neoplasia.	UNIV COLL CARDIFF,CANC RES CTR,THYROID TUMOUR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University	LEMOINE, NR (corresponding author), HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOLEC ONCOL GRP,DUCANE RD,LONDON W12 0HS,ENGLAND.							BARTEK J, 1989, MONOCLONAL ANTIBODIE; BOS JL, 1989, CANCER RES, V49, P4682; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; COMPERE SJ, 1989, MOL CELL BIOL, V9, P6, DOI 10.1128/MCB.9.1.6; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DOTTO GP, 1985, NATURE, V318, P472; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; HARLOW E, 1988, ANTIBODIES LABORATOR; HUBER BE, 1988, ONCOGENE, V3, P245; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1988, ONCOGENE, V3, P541; LEMOINE NR, 1990, MOL BIOL CANCER GENE, P82; LEMOINE NR, 1990, GENES CANCER, P19; REDMOND SMS, 1988, ONCOGENE, V2, P259; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SEYAMA T, 1988, MOL CARCINOGEN, V1, P89, DOI 10.1002/mc.2940010204; SUAREZ HG, 1990, ONCOGENE, V5, P565; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	27	65	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1833	1837						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	1704496				2022-12-28	WOS:A1990ET43600014
J	CHIU, IM; WANG, WP; LEHTOMA, K				CHIU, IM; WANG, WP; LEHTOMA, K			ALTERNATIVE SPLICING GENERATES 2 FORMS OF MESSENGER-RNA CODING FOR HUMAN HEPARIN-BINDING GROWTH FACTOR-I	ONCOGENE			English	Article									OHIO STATE UNIV, MOLEC CELLULAR & DEV BIOL PROGRAM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	CHIU, IM (corresponding author), OHIO STATE UNIV, DAVIS MED RES CTR, DEPT INTERNAL MED, ROOM S2052, 480 W 9TH AVE, COLUMBUS, OH 43210 USA.		Chiu, Ing-Ming/B-1534-2008		NCI NIH HHS [CA45611] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BUGAISKY L, 1986, HEART CARDIOVASCULAR, P1491; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU IM, 1990, GENET ANAL-BIOMOL E, V7, P18, DOI 10.1016/0735-0651(90)90039-I; CHIU IM, 1990, IN PRESS TROPHIC FAC; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DISORBO D, 1988, BIOCHEM BIOPH RES CO, V157, P1007, DOI 10.1016/S0006-291X(88)80974-4; DOBNER PR, 1981, P NATL ACAD SCI-BIOL, V78, P2230, DOI 10.1073/pnas.78.4.2230; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GOODRICH SP, 1989, NUCLEIC ACIDS RES, V17, P2867, DOI 10.1093/nar/17.7.2867; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GOUGH N, 1987, TRENDS GENET, V3, P238, DOI 10.1016/0168-9525(87)90252-6; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; GUSSOW D, 1987, IMMUNOL TODAY, V8, P220, DOI 10.1016/0167-5699(87)90170-8; HALL JA, 1989, IN PRESS J CELL BIOC; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUANG SS, 1986, J BIOL CHEM, V261, P9568; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KLAGSBRUN M, 1987, P NATL ACAD SCI USA, V84, P1839, DOI 10.1073/pnas.84.7.1839; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LOBB RR, 1986, BIOCHEM BIOPH RES CO, V139, P861, DOI 10.1016/S0006-291X(86)80257-1; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MANASEK FJ, 1971, DEV BIOL, V26, P42, DOI 10.1016/0012-1606(71)90106-0; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; PASYK S, 1982, AM J PHYSIOL, V242, P1031; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1989, J BIOL CHEM, V264, P17606; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; WITTE DP, 1989, LAB INVEST, V60, P353; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	70	54	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1990	5	5					755	762						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	1693186				2022-12-28	WOS:A1990DG37400017
J	HIRAI, H; FUJISAWA, J; SUZUKI, T; UEDA, K; MURAMATSU, M; TSUBOI, A; ARAI, N; YOSHIDA, M				HIRAI, H; FUJISAWA, J; SUZUKI, T; UEDA, K; MURAMATSU, M; TSUBOI, A; ARAI, N; YOSHIDA, M			TRANSCRIPTIONAL ACTIVATOR TAX OF HTLV-1 BINDS TO THE NF-KAPPA-B PRECURSOR P105	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; LONG TERMINAL REPEATS; NECROSIS-FACTOR-ALPHA; DNA-BINDING; TRANS-ACTIVATION; NUCLEAR PROTEINS; GENE-EXPRESSION; REL ONCOGENE	Human T-cell leukemia virus type 1 (HTLV-1) induces adult T-cell leukemia and also a neurological disease, tropical spastic paraparesis. Tax protein (p40tax) of HTLV-1 activates in trans its own transcriptional enhancer in the long terminal repeat and also those in some cellular genes such as interleukin 2 receptor-alpha, granulocyte-macrophage colony-stimulating factor, Fos, Jun and MHC class I. Thus, Tax has been proposed to play a critical role in the pathogenesis induced by HTLV-1 infection. Here, we report formation of a complex of Tax protein with the precursor protein p105 of the NF-kappa-B p50 subunit. p105 was co-immunoprecipitated with Tax protein from cells infected with HTLV-1 from cells transfected with the Tax expression plasmid, but not from cells transfected with inactive mutants of Tax. Furthermore, a GST-p105 fusion protein produced in Escherichia coli bound to Tax protein. These results strongly suggest that the trans-activator Tax protein forms a complex with precursor NF-kappa-B p105 and plays a role in trans-activation of transcriptional initiation.	UNIV TOKYO,INST MED SCI,DEPT CELLULAR & MOLEC BIOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,TOKYO 108,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA	University of Tokyo; University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.				Tsuboi, Akio/0000-0002-4790-4512				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GESSAIN A, 1985, LANCET, V2, P407; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3635; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KIYOKAWA T, 1984, GANN, V75, P747; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RODGERSJOHNSON P, 1985, LANCET, V2, P1247; SAWADA M, 1990, J VIROL, V64, P4002, DOI 10.1128/JVI.64.8.4002-4006.1990; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V226, P177; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	45	149	150	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1737	1742						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501885				2022-12-28	WOS:A1992JJ37600009
J	JONES, MH; NAKAMURA, Y				JONES, MH; NAKAMURA, Y			DELETION MAPPING OF CHROMOSOME-3P IN FEMALE GENITAL-TRACT MALIGNANCIES USING MICROSATELLITE POLYMORPHISMS	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; PRIMARY BREAST-CANCER; SHORT ARM; SIMPLE SEQUENCES; OVARIAN-CANCER; LUNG-CANCER; DNA MARKERS; HETEROZYGOSITY; ALLELOTYPE; PROGRESSION	We have constructed deletion maps of chromosome 3p for cancers of the female genital tract (uterine endometrium, uterine cervix and ovary). The tumours were tested for loss of heterozygosity using CA-repeat polymorphisms. The high degree of informativeness of these markers allowed the construction of detailed deletion maps from a relatively small number of samples. A common region of deletion was identified at chromosome 3p13-21.1 in endometrial cancer and at 3p13-14.3 in cervical cancer; 5 out of 13 (38%) endometrial cancers and six out of eight (75%) cervical cancers showed loss of heterozygosity at these regions. In ovarian cancer a separate common region of deletion was identified at 3p21.1-22; two out of four (50%) ovarian cancers had alleles deleted at this region. These data suggest the presence of a tumour-suppressor gene(s) for endometrial and cervical cancer at 3p13-21.3 and a separate gene at 3p21.1-22 that is involved in the carcinogenesis of ovarian cancer.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research				Jones, Michael/0000-0002-2251-1990				ANGLARD P, 1991, CANCER RES, V51, P1071; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; JONES MH, 1992, IN PRESS GENES CHROM; JONES MH, 1992, IN PRESS HUM MOL GEN; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LITT M, 1989, AM J HUM GENET, V44, P397; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MORITA R, 1991, CANCER RES, V51, P820; NAKAMURA Y, 1987, SCIENCE, V325, P939; PATHAK S, 1982, NEW ENGL J MED, V301, P592; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; TRENT JM, 1985, CANCER GENET CYTOGEN, V14, P153, DOI 10.1016/0165-4608(85)90226-2; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K; YOKOJAMA S, 1992, IN PRESS CANCER RES, V52; YOKOTA J, 1989, CANCER RES, V49, P3598	30	106	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1631	1634						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630822				2022-12-28	WOS:A1992JE81300020
J	MILNE, DM; PALMER, RH; CAMPBELL, DG; MEEK, DW				MILNE, DM; PALMER, RH; CAMPBELL, DG; MEEK, DW			PHOSPHORYLATION OF THE P53 TUMOR-SUPPRESSOR PROTEIN AT 3 N-TERMINAL SITES BY A NOVEL CASEIN KINASE I-LIKE ENZYME	ONCOGENE			English	Article							LARGE T-ANTIGEN; GLYCOGEN-SYNTHASE; DNA-REPLICATION; MOUSE P53; WILD-TYPE; SV40-TRANSFORMED CELLS; 3T3 CELLS; ONCOGENE; TRANSFORMATION; IDENTIFICATION	Wild-type mouse p53, expressed in Escherichia coli, was phosphorylated by highly purified casein kinase I (CKI) from rabbit muscle. The major site of phosphorylation in the p53 was identified as serine 6, which is known to be phosphorylated in vivo. Serines 4 and 9 were also phosphorylated. To determine whether CKI is likely to be a physiological p53 kinase, SV3T3 cell lysates were fractionated on a Mono Q column and assayed for p53 kinase and casein kinase activities. Four p53 kinase activities were detected, one of which co-purified with CKI activity. This p53 kinase (designated PK270) further co-purified with CKI on sucrose gradients and had a native molecular weight, like CKI, in the range of 35000-45000. However, PK270 was separated from the bulk of CKI activity on a phosvitin-Sepharose affinity column, and was therefore likely to be a CKI-related kinase. In support of these conclusions, phosphorylation of p53, by both CKI and PK270, was inhibited by a peptide corresponding to a consensus CKI target sequence, but not by a non-specific peptide. Moreover, phosphopeptide analyses of p53 phosphorylated by CKI or by PK270 gave similar results, indicating that these two kinases phosphorylate the same sites in p53.	UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Campbell, David G/K-1874-2015	Campbell, David G/0000-0003-2278-2149				ADDISON C, 1990, ONCOGENE, V5, P423; AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GRAESSER FA, 1988, VIROLOGY, V165, P13; GREEN MR, 1989, CELL, V51, P1; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HERRMANN CPE, 1991, ONCOGENE, V6, P877; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, ONCOGENE, V5, P973; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; PATCHINSKY T, 1990, ONCOGENE, V5, P1071; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POTTER V, 1980, J VIROL, V36, P547; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, VIROLOGY, V160, P445; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG YH, 1986, J BIOL CHEM, V261, P6909; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	57	164	165	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1361	1369						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620549				2022-12-28	WOS:A1992HZ97100015
J	DOBBELSTEIN, M; ARTHUR, AK; DEHDE, S; VANZEE, K; DICKMANNS, A; FANNING, E				DOBBELSTEIN, M; ARTHUR, AK; DEHDE, S; VANZEE, K; DICKMANNS, A; FANNING, E			INTRACISTRONIC COMPLEMENTATION REVEALS A NEW FUNCTION OF SV40 T-ANTIGEN THAT COOPERATES WITH RB AND P53 BINDING TO STIMULATE DNA-SYNTHESIS IN QUIESCENT CELLS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; LARGE TUMOR-ANTIGEN; ADENOVIRUS E1A PROTEINS; SIMIAN VIRUS-40; CELLULAR DNA; PRODUCT; PHOSPHORYLATION; TRANSFORMATION; GROWTH; CYCLE	The ability of the oncogene products of DNA tumor viruses to induce DNA sythesis in quiescent cells is thought to depend on their capacity to bind to cellular proteins such as the retinoblastoma-suppressor protein Rb and the tumor suppressor p53, thereby abolishing the growth-arresting properties of these proteins. We have tested this hypothesis using SV40 T antigens carrying lesions that affect Rb binding, p53 binding or other functions involved in cell transformation. The results demonstrate that Rb binding is not essential for growth stimulation by T antigen. However, detailed analysis, including intracistronic complementation, suggests that at least three functions, Rb binding, a novel second activity localized to the DNA-binding domain and a function residing in the carboxy terminus, probably p53 binding, cooperate to generate the full growth induction potential of T antigen.	INST BIOCHEM, KARLSTR 23, W-8000 MUNICH 2, GERMANY					Dobbelstein, Matthias/0000-0001-5052-3967				ARTHUR AK, 1988, J VIROL, V62, P1999, DOI 10.1128/JVI.62.6.1999-2006.1988; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BAUMANN EA, 1985, J VIROL, V54, P882, DOI 10.1128/JVI.54.3.882-885.1985; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLE CN, 1986, J VIROL, V57, P539, DOI 10.1128/JVI.57.2.539-546.1986; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1982, EMBO J, V1, P1023, DOI 10.1002/j.1460-2075.1982.tb01290.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GLUZMAN Y, 1982, VIROLOGY, V123, P78, DOI 10.1016/0042-6822(82)90296-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTL M, 1990, J VIROL, V64, P2884, DOI 10.1128/JVI.64.6.2884-2894.1990; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KERN SE, 1991, ONCOGENE, V6, P131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LEVINSON A, 1984, Journal of Molecular and Applied Genetics, V2, P507; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STILLMAN B, 1985, EMBO J, V4, P2933, DOI 10.1002/j.1460-2075.1985.tb04026.x; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TJIAN R, 1978, P NATL ACAD SCI USA, V75, P1279, DOI 10.1073/pnas.75.3.1279; TORNOW J, 1983, P NATL ACAD SCI-BIOL, V80, P6312, DOI 10.1073/pnas.80.20.6312; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116	84	72	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					837	847						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570154				2022-12-28	WOS:A1992HP64200002
J	BERBERICH, S; HYDEDERUYSCHER, N; ESPENSHADE, P; COLE, M				BERBERICH, S; HYDEDERUYSCHER, N; ESPENSHADE, P; COLE, M			MAX ENCODES A SEQUENCE-SPECIFIC DNA-BINDING PROTEIN AND IS NOT REGULATED BY SERUM GROWTH-FACTORS	ONCOGENE			English	Note							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; MYC; DAUGHTERLESS; EXPRESSION; UPSTREAM; MYOD; GENE	Max and c-Myc proteins, produced in bacteria, were studied for DNA-binding activity using the electrophoretic band-shift assay (EMSA). Both Max homodimers and c-Myc-Max heterodimers selected the same sequence CA(C/T)GTG from an initial pool of 10(6) DNA molecules. From the pool of sequence-specific binding sites, the palindromic site (CACGTG) was preferentially selected over the CATGTG site using two different degenerate oligonucleotide probes. max expression is identical in myc-induced tumor cell lines relative to other cells. Furthermore, max expression is constant in both confluent and serum-stimulated A31 fibroblasts, in contrast to c-myc expression, which is barely detectable in confluent fibroblasts and induced 20-fold by serum growth factors. Based on recognition of the same DNA sequence by Max and c-Myc-Max complexes and differential expression of the two genes, we propose that Max homodimers and c-Myc-Max heterodimers may bind to a common set of cellular target genes.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University					NIGMS NIH HHS [GM14675-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CLINE TW, 1989, CELL, V59, P231, DOI 10.1016/0092-8674(89)90280-8; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	17	101	102	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					775	779						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565473				2022-12-28	WOS:A1992HQ68200022
J	ROELINK, H; WAGENAAR, E; NUSSE, R				ROELINK, H; WAGENAAR, E; NUSSE, R			AMPLIFICATION AND PROVIRAL ACTIVATION OF SEVERAL WNT GENES DURING PROGRESSION AND CLONAL VARIATION OF MOUSE MAMMARY-TUMORS	ONCOGENE			English	Article							ONCOGENE INT-1; NUCLEOTIDE-SEQUENCE; TRANSGENIC MICE; CELL-LINE; VIRUS; EXPRESSION; REGION; TUMORIGENESIS; INTEGRATION; GROWTH	Mammary tumors in the GR strain are caused by a dominant locus containing an endogenous mouse mammary tumor provirus. Expression of this locus results in high virus titers, inducing tumors that progress from a hormone-dependent to a hormone-independent tumor state. We previously studied the activation of the Wnt-1 and int-2 oncogenes in several series of transplanted GR tumors and found that hormone-dependent early passages are generally oligoclonal for proviral integration at these genes. We have now re-examined several such tumor series for activation of other Wnt genes. In one series, the transition to hormone-independent growth was marked by the loss of the oligoclonal genotype and outgrowth of a hormone-independent cell population, clonal for the activation of Wnt-3. We show two examples of series of transplanted tumors that in later hormone-independent passages contain an amplified and overexpressed Wnt-2 gene, a novel mode of activation of these genes.	STANFORD UNIV,BECKMAN CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,BECKMAN CTR,DEPT DEV BIOL,STANFORD,CA 94305; NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS	Howard Hughes Medical Institute; Stanford University; Stanford University; Netherlands Cancer Institute								BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; DEAN M, 1987, Genomics, V1, P167, DOI 10.1016/0888-7543(87)90009-7; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; MESTER J, 1987, J VIROL, V61, P1073, DOI 10.1128/JVI.61.4.1073-1078.1987; MICHALIDES R, 1981, CELL, V23, P165, DOI 10.1016/0092-8674(81)90281-6; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Sambrook J, 1989, MOL CLONING LABORATO; SCHUURING E, 1990, ONCOGENE, V5, P459; SLUYSER M, 1974, CANCER RES, V34, P3253; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; VANNIE R, 1977, INT J CANCER, V19, P588; VANNIE R, 1981, MAMMARY TUMORS MOUSE, P202; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	31	47	48	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					487	492						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549363				2022-12-28	WOS:A1992HK00500013
J	GEBERT, JF; MOGHAL, N; FRANGIONI, JV; SUGARBAKER, DJ; NEEL, BG				GEBERT, JF; MOGHAL, N; FRANGIONI, JV; SUGARBAKER, DJ; NEEL, BG			HIGH-FREQUENCY OF RETINOIC ACID RECEPTOR BETA ABNORMALITIES IN HUMAN LUNG-CANCER	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN HEPATOCELLULAR-CARCINOMA; TRACHEAL EPITHELIAL-CELLS; SQUAMOUS DIFFERENTIATION; T(15-17) TRANSLOCATION; RESPONSIVE ELEMENT; MESSENGER-RNAS; GENE; EXPRESSION; GAMMA	One of the three human retinoic acid receptors, RAR-beta, maps to a region on the short arm of chromosome 3 frequently deleted in lung cancer. Because retinoic acid is required for normal epithelial cell growth and regulation, and loss of a retinoic acid receptor might be expected to contribute to oncogenesis, we examined RAR-beta RNA and DNA in normal lung, 33 lung cancer cell lines and nine primary lung tumors. Normally, RAR-beta is expressed as two transcripts, of sizes 3.1 kb and 2.8 kb, which are strongly induced by retinoic acid. At least 50% of the cell lines and 30% of the tumor samples show altered RAR-beta expression and/or inducibility, including examples of absence or specific loss of one of the RAR-beta transcripts. Abnormalities in the expression patterns of RAR-alpha and RAR-gamma also are found, but at a lower frequency than RAR-beta abnormalities. Southern analysis reveals alteration of the RAR-beta gene in three of the cell lines. Our data suggest that abnormalities in structure and expression of the RAR-beta gene may be involved in the pathogenesis of lung cancer.	BETH ISRAEL HOSP,MOLEC MED UNIT,330 BROOKLINE AVE,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DIV THORAC SURG,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital					NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 49152-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; IBSON JM, 1987, J CELL BIOCHEM, V33, P267, DOI 10.1002/jcb.240330405; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; JETTEN AM, 1987, LAB INVEST, V56, P654; JETTEN AM, 1985, RETINOIDS DIFFERENTI, P61; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1989, CANCER RES, V49, P651; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LECHNER JF, 1981, CANCER RES, V41, P2294; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REARICK JI, 1987, J CELL PHYSIOL, V133, P573, DOI 10.1002/jcp.1041330320; ROBERTS AB, 1984, RETINOIDS, V2, P209; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1988, NATURE, V333, P15; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WU R, 1990, AM J RESP CELL MOL, V3, P467, DOI 10.1165/ajrcmb/3.5.467; WU R, 1982, IN VITRO CELL DEV B, V18, P800; WU R, 1986, IN VITRO MODELS RESP, P1; YOKOTA J, 1989, CANCER RES, V49, P3598; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; [No title captured]	60	220	224	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1859	1868						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1717924				2022-12-28	WOS:A1991GX11800019
J	MARSHALL, J; SMITH, AE; CHENG, SH				MARSHALL, J; SMITH, AE; CHENG, SH			MONOCLONAL-ANTIBODY SPECIFIC FOR BK VIRUS LARGE-T ANTIGEN ALLOWS DISCRIMINATION AMONG THE DIFFERENT PAPOVAVIRAL LARGE-T ANTIGENS	ONCOGENE			English	Note							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; DEFICIENCY SYNDROME AIDS; JC VIRUS; SIMIAN VIRUS-40; TRANSGENIC MICE; POLYOMAVIRUS-BK; BRAIN-TUMORS; DNA; IDENTIFICATION; TRANSFORMATION	The human papovaviruses BK virus (BKV) and JC virus (JCV) both encode a large-tumor (T) antigen which are highly homologous to each other as well as to simian virus 40 (SV40) large-T antigen. This high conservation of amino acid sequence has resulted in overlapping antigenicity such that immunological differentiation of the large-T antigens from the three different viruses has been difficult. Here we describe the generation and characterization of a new monoclonal antibody (BK-T.1) which is specific for BKV large-T antigen and which does not cross-react with the other papovaviral T antigens. We show that when BK-T.1 is used in conjunction with preexisting monoclonal antibodies against SV40 large-T antigen, it is possible to identify the origin of papovavirus T antigens.	GENZYME CORP,CELLULAR REGULAT LAB,1 MT RD,FRAMINGHAM,MA 01701	Sanofi-Aventis; Genzyme Corporation			Cheng, Seng H/AAC-6564-2022	Marshall, John/0000-0003-1361-2869	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N44CP085655] Funding Source: NIH RePORTER; NCI NIH HHS [N44-CP-85655] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BETH E, 1977, INT J CANCER, V20, P551, DOI 10.1002/ijc.2910200412; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Carrol SB, 1987, DNA CLONING PRACTICA, V3, P89; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; COLEMAN DV, 1980, J INFECT DIS, V142, P1, DOI 10.1093/infdis/142.1.1; COLEMAN DV, 1978, J CLIN PATHOL, V31, P338, DOI 10.1136/jcp.31.4.338; COLEMAN DV, 1980, RECENT ADV CLIN VIRO, V2, P89; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GARDNER SD, 1971, LANCET, V1, P1253; GARDNER SD, 1973, BRIT MED J, V1, P74; GARDNER SD, 1977, RECENT ADV CLINICAL, V1, P93; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; KITAMURA T, 1990, J INFECT DIS, V161, P1128, DOI 10.1093/infdis/161.6.1128; KRUPP LB, 1985, ANN NEUROL, V17, P344, DOI 10.1002/ana.410170407; LAI CJ, 1979, J VIROL, V30, P141, DOI 10.1128/JVI.30.1.141-147.1979; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MOLE SE, 1987, DNA CLONING, V3, P113; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; PADGETT B, 1981, DNA TUMOR VIRUSES MO, P334; PADGETT BL, 1971, LANCET, V1, P1257; PATER MM, 1982, MOL CELL BIOL, V2, P837, DOI 10.1128/MCB.2.7.837; PATER MM, 1980, VIRUSES NATURALLY OC, P329; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; RYDER K, 1983, VIROLOGY, V129, P239, DOI 10.1016/0042-6822(83)90412-9; SCHREIRER AA, 1986, J NATL CANCER I, V76, P1255; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; STONER GL, 1986, P NATL ACAD SCI USA, V83, P2271, DOI 10.1073/pnas.83.7.2271; TAKEMOTO KK, 1973, J VIROL, V12, P625, DOI 10.1128/JVI.12.3.625-631.1973; WALKER DL, 1978, HDB CLIN NEUROLOGY 2, V34, P207; WALKER DL, 1973, SLOW VIRUS DISEASE, P45; WILEY CA, 1988, ACTA NEUROPATHOL, V76, P338, DOI 10.1007/BF00686970	34	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1673	1676						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1656370				2022-12-28	WOS:A1991GX27400024
J	SUBRAMANIAN, T; MALSTROM, SE; CHINNADURAI, G				SUBRAMANIAN, T; MALSTROM, SE; CHINNADURAI, G			REQUIREMENT OF THE C-TERMINAL REGION OF ADENOVIRUS-E1A FOR CELL-TRANSFORMATION IN COOPERATION WITH E1B	ONCOGENE			English	Note							GROWTH-FACTOR; PROTEINS; ONCOGENE; IMMORTALIZATION; INDUCTION; GENES; POLYPEPTIDES; ASSOCIATION; ANTIGEN; DOMAINS	We have previously reported that adenovirus E1a mutants lacking the C-terminal 61 or 67 amino acids were severely defective in immortalization, but cooperated more efficiently (than wt E1a) with activated T24 ras oncogene in transformation of primary rat kidney (BRK) cells (Subramanian et al., 1989; Oncogene, 4:415-420). Here, we show that in contrast to these previous results, transformation of BRK cells in cooperation with the Ad2 E1b region is dependent on the C-terminal region of E1a. Mutational analysis of the C-terminal region has revealed that a region located between residues 266 and 276 may be important for E1a/E1b cooperative transformation. Like E1a/T24 ras cooperative transformation, E1a/E1b cooperative transformation also requires two essential domains involved in the binding of two cellular proteins (300K and 105K) within the N-terminal half of E1a. E1a/E1b cooperative transformation therefore requires an additional E1a activity encoded within the C-terminal region of E1a.	ST LOUIS UNIV,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110	Saint Louis University	CHINNADURAI, G (corresponding author), ST LOUIS UNIV,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110, USA.				NCI NIH HHS [CA-31719, CA-33616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031719, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BRUSCA JS, 1981, J VIROL, V39, P300, DOI 10.1128/JVI.39.1.300-305.1981; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	20	30	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1171	1173						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1830644				2022-12-28	WOS:A1991GV26000011
J	ELLIS, C; LIU, XQ; ANDERSON, D; ABRAHAM, N; VEILLETTE, A; PAWSON, T				ELLIS, C; LIU, XQ; ANDERSON, D; ABRAHAM, N; VEILLETTE, A; PAWSON, T			TYROSINE PHOSPHORYLATION OF GAP AND GAP-ASSOCIATED PROTEINS IN LYMPHOID AND FIBROBLAST CELLS EXPRESSING LCK	ONCOGENE			English	Article							GTPASE ACTIVATING PROTEIN; KINASE P56LCK; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOLIPASE-C; VIRAL ONCOGENE; CD4 RECEPTOR; BINDING; TRANSFORMATION; DOMAINS	The Ras GTPase activating protein (GAP) is a strong candidate for the protein that links protein-tyrosine kinases to the Ras mitogenic pathway. GAP and two associated proteins, p62 and p190, were shown to be phosphorylated on tyrosine in the LSTRA thymoma cell line, in which the p56lck tyrosine kinase is overexpressed as a result of retroviral promoter insertion. In NIH3T3 fibroblasts expressing specific oncogenic and transformation-defective variants of p56lck, we found that the tyrosine phosphorylation of GAP complexes required both enzymatic activation and myristylation of p56lck, and correlated with lck transforming activity. The interaction between p62 and p190 from lck-transformed fibroblasts and GAP could be reconstituted in vitro using bacterial TrpE fusion proteins containing GAP Src homology 2 (SH2) domains. In vitro complex formation was insensitive to the prior denaturation of SH2 ligands, suggesting that SH2-binding sites are formed by linear peptide sequences. These results suggest that the tyrosine phosphorylation of GAP, and its interactions with SH2-binding proteins, may be involved in fibroblast transformation by activated lck, and may participate in signal transduction and cellular transformation in lymphoid cells.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; MCGILL UNIV, MCGILL CANC CTR, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; McGill University	PAWSON, T (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Abraham, Ninan/K-5572-2012; Pawson, Tony J/E-4578-2013	Abraham, Ninan/0000-0002-2747-1246; Liu, X. Johne/0000-0003-3381-5030				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN M, 1990, IN PRESS P NATL ACAD; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	32	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					895	901						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906156				2022-12-28	WOS:A1991GU62200002
J	KAWATA, M; KAWAHARA, Y; SUNAKO, M; ARAKI, S; KOIDE, M; TSUDA, T; FUKUZAKI, H; TAKAI, Y				KAWATA, M; KAWAHARA, Y; SUNAKO, M; ARAKI, S; KOIDE, M; TSUDA, T; FUKUZAKI, H; TAKAI, Y			THE MOLECULAR HETEROGENEITY OF THE SMG-21 KREV-1 RAP1 PROTEINS, A GTP-BINDING PROTEIN HAVING THE SAME EFFECTOR DOMAIN AS RAS P21S, IN BOVINE AORTIC SMOOTH-MUSCLE MEMBRANES	ONCOGENE			English	Article							GENE-PRODUCT; ACTIVATING PROTEIN; HUMAN-PLATELETS; BRAIN MEMBRANES; CARBOXYL-METHYLATION; RAS-P21 GTPASE; PURIFICATION; IDENTIFICATION; PHOSPHORYLATION; KINASE	smg p21 is a member of the ras p21/ras p21-like small GTP-binding protein (G protein) superfamily, having the same putative effector domain as ras p21s. In the preceding report, we showed that smg p21 was a major G protein in bovine aortic smooth muscle membranes. Recently, two different smg p21 cDNA clones, designated smg-21A and -B, were isolated from a bovine brain cDNA library. In the present studies, we resolved the bovine aortic smg p21 fraction into two distinct G protein fractions on hydroxyapatite column chromatography and purified them separately to near homogeneity (22K G1 and -2). Both 22K G1 and -2 were specifically recognized by an anti-smg p21 polyclonal antibody. 22K G1 and -2 were identified as smg p21B and -A, respectively, by peptide map and amino acid sequence analyses. Purified smg p21A and -B showed GDP/GTP-binding and GTPase activities similar to each other. The GTPase activities of smg p21A and -B were equally stimulated by smg p21 GTPase activating protein 1 and -2. Moreover, both smg p21A and -B were phosphorylated by cyclic AMP-dependent protein kinase with a stoichiometry of one phosphate/molecule of protein. These results indicate that smg p21A and -B coexist in bovine aortic smooth muscle membranes and suggest that smg p21A and -B may serve as intermediates for cyclic AMP actions.	KOBE UNIV,SCH MED,DEPT INTERNAL MED,DIV 1,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University; Kobe University	KAWAHARA, Y (corresponding author), KOBE UNIV,SCH MED,DEPT INTERNAL MED,DIV 1,KOBE 650,JAPAN.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FISCHER TH, 1987, BIOCHEM BIOPH RES CO, V149, P700, DOI 10.1016/0006-291X(87)90424-4; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Haslam R J, 1978, Adv Cyclic Nucleotide Res, V9, P533; HATA Y, 1990, J BIOL CHEM, V265, P7104; HIROYOSHI M, 1991, IN PRESS J BIOL CHEM; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KASERGLANZMANN R, 1979, BIOCHIM BIOPHYS ACTA, V558, P344, DOI 10.1016/0005-2736(79)90271-2; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1989, BIOCHEM BIOPH RES CO, V163, P1418, DOI 10.1016/0006-291X(89)91137-6; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOESBERG C, 1985, EXP CELL RES, V160, P117, DOI 10.1016/0014-4827(85)90241-1; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; NILLSON J, 1984, ATHEROSCLEROSIS, V53, P77; OHMORI T, 1988, BIOCHEM BIOPH RES CO, V157, P670, DOI 10.1016/S0006-291X(88)80302-4; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1164; TADA M, 1975, J BIOL CHEM, V250, P2640; TAKAI Y, 1984, ADV CYCLIC NUCL PROT, V18, P119; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YOSHIDA K, 1988, CANCER RES, V48, P5503	49	6	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					841	848						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646988				2022-12-28	WOS:A1991GT82500021
J	BARTEK, J; IGGO, R; GANNON, J; LANE, DP				BARTEK, J; IGGO, R; GANNON, J; LANE, DP			GENETIC AND IMMUNOCHEMICAL ANALYSIS OF MUTANT P53 IN HUMAN BREAST-CANCER CELL-LINES	ONCOGENE			English	Article									RES INST CLIN & EXPTL ONCOL, BRNO, CZECHOSLOVAKIA		BARTEK, J (corresponding author), IMPERIAL CANC RES FUND, MOLEC IMMUNOCHEM LAB, CLARE HALL LABS, POTTERS BAR EN6 3LD, HERTS, ENGLAND.		Bartek, Jiri/G-5870-2014; Iggo, Richard/G-3546-2014; Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				AUSUBEL F, 1987, CURRENT PROTOCOLS MO, P412; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; Crawford L V, 1984, Mol Biol Med, V2, P261; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVID YB, 1988, ONCOGENE, V3, P179; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, IN PRESS EMBO J; GREAVES R, 1988, THESIS U LONDON; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MACKAY J, 1988, LANCET, V2, P1384; MILNER J, 1989, ONCOGENE, V4, P665; MILNER J, 1987, ONCOGENE, V1, P453; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; SOUSSI T, 1987, ONCOGENE, V1, P71; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYLORPAPADIMITRIOU J, 1980, J CELL PHYSIOL, V102, P317, DOI 10.1002/jcp.1041020306; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WILLIAMS JG, 1985, NUCLEIC ACID HYBRIDI, P152; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	36	714	729	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1990	5	6					893	899						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	1694291				2022-12-28	WOS:A1990DP55300016
J	CARTIER, N; MIQUEROL, L; TULLIEZ, M; LEPETIT, N; LEVRAT, F; GRIMBER, G; BRIAND, P; KAHN, A				CARTIER, N; MIQUEROL, L; TULLIEZ, M; LEPETIT, N; LEVRAT, F; GRIMBER, G; BRIAND, P; KAHN, A			DIET-DEPENDENT CARCINOGENESIS OF PANCREATIC-ISLETS AND LIVER IN TRANSGENIC MICE EXPRESSING ONCOGENES UNDER THE CONTROL OF THE L-TYPE PYRUVATE-KINASE GENE PROMOTER	ONCOGENE			English	Article							C-MYC GENE; HORMONAL-REGULATION; ACINAR-CELLS; RAT; NEOPLASIA; ISOZYMES; TUMORS; TRANSCRIPTION	The liver-type pyruvate kinase (L-PK) gene is controlled positively by insulin and carbohydrates, negatively by glucagon and fasting. Diet-inducible models of carcinogenesis were obtained using the L-PK gene promoter and regulatory sequences to control the expression of c-myc and SV40 T oncogenes in transgenic mice. L-PK/c-myc and L-PK/Tag animals fed a carbohydrate-rich diet developed hepatocarcinomas. In addition, L-PK/Tag animals developed diet-dependent, aggressive endocrine pancreatic tumors, preceded by islet hyperplasia involving the different analysed cell populations (alpha, beta and delta). Expression of the L-PK gene was demonstrated in pancreatic tumors, in rat isolated islets and in rat insulinoma-derived cells (RIN line), revealing a new tissue specificity of the L-PK gene. Our results suggest that this gene may be expressed in islet progenitor cells from which the different mature endocrine cells derive.	HOP COCHIN,ANAT PATHOL LAB,F-75674 PARIS 14,FRANCE; HOP ST VINCENT DE PAUL,INSERM,U342,F-75674 PARIS 14,FRANCE; INSERM,INST COCHIN GENET MOLEC GENET & PATHOL EXPTL,F-75014 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	CARTIER, N (corresponding author), INSERM,INST COCHIN GENET MOLEC GENET & PATHOL MOLEC,U129,F-75014 PARIS,FRANCE.		cartier, nathalie/C-3103-2012	cartier, nathalie/0000-0003-2298-5261				AKLI S, 1991, GENOMICS, V11, P124, DOI 10.1016/0888-7543(91)90109-R; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; CECI JD, 1991, ONCOGENE, V6, P323; CHATTERTON TA, 1982, BIOCHEM J, V204, P605, DOI 10.1042/bj2040605; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIMBALA MA, 1984, MOL BASIS INSULIN AC; COGNET M, 1987, J MOL BIOL, V196, P11, DOI 10.1016/0022-2836(87)90507-9; COGNET M, 1991, J BIOL CHEM, V266, P7368; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; Denton R M, 1979, Essays Biochem, V15, P37; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; DYER KR, 1989, AM J PATHOL, V135, P401; EFRAT S, 1990, MOL CELL BIOL, V10, P1779, DOI 10.1128/MCB.10.4.1779; FONTAINE J, 1977, J EMBRYOL EXP MORPH, V41, P209; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; HALL ER, 1978, INT J BIOCHEM, V9, P785, DOI 10.1016/0020-711X(78)90027-7; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HOGAN B, 1986, MANIPULATING MOUSE E; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; KAHN A, 1982, METHOD ENZYMOL, V90, P131; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; MACDONALD MJ, 1985, MOL CELL BIOCHEM, V68, P115; Maniatis T., 1982, MOL CLONING; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1991, NEW BIOL, V3, P592; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RINDI G, 1990, AM J PATHOL, V136, P1349; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SOUTHERN EM, 1975, J MOL BIOL, V98, P505; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TREMP GL, 1989, J BIOL CHEM, V264, P19904; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409	48	57	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1413	1422						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620553				2022-12-28	WOS:A1992HZ97100021
J	SAKAI, E; TSUCHIDA, N				SAKAI, E; TSUCHIDA, N			MOST HUMAN SQUAMOUS-CELL CARCINOMAS IN THE ORAL CAVITY CONTAIN MUTATED P53 TUMOR-SUPPRESSOR GENES	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; EPIDERMAL GROWTH-FACTOR; LUNG-CANCER; HUMAN HEAD; C-MYC; EXPRESSION; AMPLIFICATION; FREQUENT; DNA; MUTATIONS	Oral squamous cell carcinoma cell lines and tumor tissues used for cell line establishment were examined for p53 tumor-suppressor gene mutation using cellular DNAs and RNAs. For sensitive and rapid detection, a newly designed two-stage filtration strategy was used. Full advantage was taken of the single-strand conformation polymorphism (SSCP) of cDNA and cellular DNA fragments amplified by the polymerase chain reaction (PCR), followed by DNA sequencing of mutated fragments. Fourteen out of 15 cell lines and the corresponding five tumor tissues had p53 mutations within the region of exons 5-8. Loss of normal alleles was noted in 14 lines, but not in one in which only mutated transcripts were detected. DNA sequencing indicated six out of 14 mutations to be in positions that have so far not been reported. In two special cases, novel mutations were found in the splicing donor sequence of exon 6, and consequently the cryptic splice site had to be used. Extremely frequent p53 gene mutations indicated that the mutations are likely be intimately involved in the carcinogenesis of oral squamous cell carcinoma.	TOKYO MED & DENT UNIV,FAC DENT,DEPT MOLEC CELLULAR ONCOL & MICROBIOL,1-5-45 YUSHIMA,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEK J, 1990, ONCOGENE, V5, P893; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOS JL, 1989, CANCER RES, V49, P4682; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Favaloro J, 1980, Methods Enzymol, V65, P718; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1989, ONCOGENE, V4, P1463; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GEY G, 1952, CANCER RES, V12, P246; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAMATA N, 1986, CANCER RES, V46, P1648; KOIKE K, 1983, NUCLEIC ACIDS RES, V11, P5391, DOI 10.1093/nar/11.16.5391; Maniatis T., 1982, MOL CLONING; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P725; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RIKIMARU K, 1992, IN PRESS HEAD NECK; ROMANO JW, 1989, ONCOGENE, V4, P1483; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHENG ZM, 1990, BRIT J CANCER, V62, P398, DOI 10.1038/bjc.1990.306; SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3; SOMERS KD, 1990, ONCOGENE, V5, P915; TADOKORO K, 1989, ONCOGENE, V4, P499; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; UEDA M, 1990, JPN J ORAL MAXILLOFA, V36, P2211; VARLEY JM, 1991, ONCOGENE, V6, P413; WEISS R, 1982, RNA TUMOUR VIRUSES M; YAMAMOTO K, 1991, IN PRESS EXP GERONTO; YAMAMOTO T, 1986, CANCER RES, V46, P414; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	55	253	255	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					927	933						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570156				2022-12-28	WOS:A1992HP64200012
J	KOCHEL, T; RICE, NR				KOCHEL, T; RICE, NR			V-REL- AND C-REL- PROTEIN COMPLEXES BIND TO THE NF-KAPPA-B SITE INVITRO	ONCOGENE			English	Article							AVIAN RETICULOENDOTHELIOSIS VIRUS; TRANSFORMED LYMPHOID-CELLS; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATOR; ONCOGENE ENCODES; GENE; DNA; FIBROBLASTS; EXPRESSION; NUCLEAR	Previous work by others has revealed homology between the rel oncogene and the transcription factor NF-kappa-B. Further, in vitro-translated v-rel protein and c-rel protein are able to bind to an oligonucleotide containing the kappa-B binding site. Unlike the in vitro-translated product, cellular Rel protein exists in high molecular weight complexes with several other proteins. In this report we show that immunopurified cellular complexes containing the v-rel protein and/or the c-rel protein are also able to bind to an oligonucleotide containing the kappa-B site. These cellular complexes are heterogeneous in size, and all sizes appeared to have binding activity. UV cross-linking demonstrated that the Rel proteins themselves were bound to the DNA. Thus it is likely that the Rel proteins play a direct role in transcriptional regulation.	NCI,FREDERICK CANC RES & DEV CTR,MOLECUL VIROL & CARCINOGENESIS LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; GRUMONT RJ, 1990, CELL GROWTH DIFFER, V1, P345; GRUMONT RJ, 1990, ONCOGENE RES, V5, P245; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MORRISON LE, 1989, ONCOGENE, V4, P677; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1988, ONCOGENE HDB, P495; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	39	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					567	572						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549370				2022-12-28	WOS:A1992HK00500025
J	OSIPOVICH, OA; MISUNO, NI; KOLESNIKOVA, TS; SUDARIKOV, AB; VOITENOK, NN				OSIPOVICH, OA; MISUNO, NI; KOLESNIKOVA, TS; SUDARIKOV, AB; VOITENOK, NN			THE DIFFERENCE IN P53 ANTIONCOGENE TRANSCRIPTION IN HUMAN MONOCYTES AND LYMPHOCYTES	ONCOGENE			English	Article							MESSENGER-RNA; CELL-LINES; GENE; ERYTHROLEUKEMIA; EXPRESSION; INDUCTION; ANTIGEN	The p53 gene is associated with malignant transformation as well as 'antioncogene' activity. In this report expression of p53 in resting and activated human blood monocytes and lymphocytes was studied. It is shown that human monocytes freshly isolated by continuous Percoll-gradient centrifugation contain detectable levels of p53 mRNA. Stimulation of monocytes by the potent activation inducer Staphylococcus aureus Cowan I (SAC) for 3-5 h caused the disappearance of p53 mRNA. In contrast, induction of a high level of tumor necrosis factor alpha mRNA was detected. The addition of cycloheximide did not increase the p53 mRNA content in stimulated monocytes, and decreased the mRNA level in resting cells. p53 mRNA was absent in freshly isolated lymphocytes and in resting cells cultured for 20 h. Activation of lymphocytes by phytohemagglutinin caused accumulation of p53 mRNA. We suggest that p53 gene regulation and functions might be different in human monocytes and lymphocytes.	MOSCOW EXPT HEMATOL & BIOTECHNOL INST,NOVOZYKOVSKY LANE 4,MOSCOW 125167,USSR; BYELORUSSIAN INST HEMATOL & BLOOD TRANSFUS,MINSK,BELORUSSIA,USSR				Sudarikov, Andrey/E-7528-2013	Sudarikov, Andrey/0000-0001-9463-9187				BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD LV, 1981, P NATL ACAD SCI USA, V78, P1695; GMELIGMEYLING F, 1980, J IMMUNOL METHODS, V33, P1, DOI 10.1016/0022-1759(80)90077-0; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LING NR, 1968, LYMPHOCYTE STIMULATI, pCH4; LUBBERT M, 1989, ONCOGENE, V4, P643; Maniatis T., 1982, MOL CLONING; MISUNO N I, 1990, Cytokine, V2, P464, DOI 10.1016/1043-4666(90)90056-Y; MUNROE DG, 1988, ONCOGENE, V2, P621; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TURPIN JA, 1991, NAT IMMUN CELL GROW, V10, P19; VANFURTH R, 1979, BLOOD, V54, P485; VOITENOK NN, 1989, IMMUNOL LETT, V20, P77, DOI 10.1016/0165-2478(89)90072-2	22	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					549	552						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549368				2022-12-28	WOS:A1992HK00500022
J	WILLIAMS, RT; CARBONAROHALL, DA; HALL, FL				WILLIAMS, RT; CARBONAROHALL, DA; HALL, FL			COPURIFICATION OF P34CDC2/P58CYCLIN-A PROLINE-DIRECTED PROTEIN-KINASE AND THE RETINOBLASTOMA TUMOR SUSCEPTIBILITY GENE-PRODUCT - INTERACTION OF AN ONCOGENIC SERINE THREONINE PROTEIN-KINASE WITH A TUMOR-SUPPRESSOR PROTEIN	ONCOGENE			English	Article							CELL-CYCLE CONTROL; HISTONE H-1 KINASE; M-PHASE; OSTEO-SARCOMA; CDC2 PROTEIN; DNA-REPLICATION; E1A PROTEINS; PHOSPHORYLATION; EXPRESSION; P53	Proline-directed protein kinase (PDPK) is characterized as a cytoplasmic oncogenic serine/theonine kinase that is activated by growth factor-mediated mechanisms and is proposed to function in mammalian somatic cells as an S phase promoting factor. The present study was undertaken to assess the hypothesis that p34cdc2/p58cyclin A PDPK is a physiologically relevant form of the p34cdc2 protein kinase that phosphorylates and inactivates the product of the retinoblastoma/osteosarcoma tumor susceptibility gene (Rb protein). In the course of these studies it was determined (fortuitously) that the p34cdc2/p58cyclin A PDPK purified from the cytosol of FM3A mouse mammary carcinoma cells was 'contaminated' by several high molecular weight substrate proteins that essentially co-purified with the protein kinase, one of which was identified as the Rb protein itself (p105Rb). High-resolution fast protein liquid chromatography (FPLC) revealed that the Rb protein co-purified with a particular subset of the PDPK heterodimer, i.e. with a single species of the 58 kDa cyclin A doublet. The subset of PDPK associated with the Rb protein exhibited somewhat lower specific enzyme activity, as judged by in vitro kinase assays and comparative Western blotting. Immunoprecipitation studies confirmed that p105Rb is physically associated with the p34cdc2/p58cyclin A PDPK. Further studies confirmed that the underphosphorylated Rb protein (p105Rb) present in G1 lysates of synchronized human MG63 osteosarcoma cells could be readily phosphorylated by purified PDPK in vitro, resulting in the characteristic shift in the apparent molecular mass (SDS-PAGE) of the Rb protein that is reported to accompany the hyperphosphorylation and functional inactivation of this protein. Moreover, the induction of the cyclin A subunit of PDPK in these synchronized MG63 cells was found to be closely correlated with the cell cycle-dependent phosphorylation of the Rb protein. From these studies it is concluded that the growth factor-sensitive PDPK is a physiological Rb kinase, which may function to inactivate the Rb protein in vivo.	CHILDRENS HOSP, DIV ORTHOPAED SURG, 4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH MED, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH PHARM, LOS ANGELES, CA 90089 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California								ADDISON C, 1990, ONCOGENE, V5, P423; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; Braun R K, 1989, Proc West Pharmacol Soc, V32, P15; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; Hall F L, 1989, Proc West Pharmacol Soc, V32, P1; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; HALL FL, 1991, J BONE JT SURG ORTHO, V15, P454; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kulp K S, 1990, Proc West Pharmacol Soc, V33, P219; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGAN TA, 1980, PROTEIN PHOSPHORYLAT, P70; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MATTHEWS HR, 1984, MOL CELL BIOCHEM, V59, P81; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER CW, 1990, CANCER RES, V50, P7950; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARLEY JM, 1989, ONCOGENE, V4, P725; Vulliet P R, 1988, Proc West Pharmacol Soc, V31, P255; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471	70	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					423	432						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1532245				2022-12-28	WOS:A1992HK00500004
J	BECHADE, C; CALOTHY, G				BECHADE, C; CALOTHY, G			CELL-DIVISION IS REQUIRED FOR EXPRESSION OF V-MYC TRANSFORMING PROPERTIES IN CHICKEN EMBRYONIC NEURORETINA CELLS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; AVIAN MYELOCYTOMATOSIS VIRUS; NUCLEAR-LOCALIZATION; AUTOCRINE GROWTH; DNA-BINDING; SRC GENE; ONCOGENES; PROLIFERATION; MIL; PROTEINS	We previously reported that avian retrosiruses carrying the v-myc oncogene alone fail to induce sustained proliferation and transformation of non-dividing chicken neuroretina (CNR) cells from 7-day-old embryos. However, v-myc is capable of transforming CNR cells which have been induced to multiply by the v-mil oncogene. These results suggest that entry into the cell cycle is required for the transformation of CNR cells by v-myc. To further assess the role of cell division, we investigated the transforming properties of v-myc in CNR cells conditionally induced to divide by the v-src gene or by modified culture conditions. We show that v-myc transforms CNR cells infected with Rous sarcoma virus mutants which induce cell proliferation in the absence of transformation. Expression of these transforming properties in CNR cells infected with temperature-sensitive v-src mutants depends on the continuous mitogenic activity of p60v-src. We also report that v-myc is able to transform CNR cells and to increase their growth potential under culture conditions which allow transient multiplication of uninfected cells. However, these v-myc-transformed cells rapidly cease to divide when returned to culture conditions that restrict the growth of normal cells. Taken together, these results indicate that transformation of CNR cells by the v-myc oncogene continuously depends on their ability to enter the cell Cycle.	CTR UNIV ORSAY,INST CURIE BIOL,BAT 110,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Bechade, Catherine/K-5528-2017	Bechade, Catherine/0000-0003-2070-2993				ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BECHADE C, 1988, J VIROL, V88, P1211; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BUNTE T, 1983, EMBO J, V2, P1087, DOI 10.1002/j.1460-2075.1983.tb01550.x; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; CASALBORE P, 1987, NATURE, V316, P188; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; EYCHENE A, 1990, J VIROL, V64, P231; FERRE F, 1986, CR ACAD SCI III-VIE, V303, P633; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	38	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2311	2317						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662792				2022-12-28	WOS:A1991GX73500020
J	CAIRNS, P; PROCTOR, AJ; KNOWLES, MA				CAIRNS, P; PROCTOR, AJ; KNOWLES, MA			LOSS OF HETEROZYGOSITY AT THE RB-LOCUS IS FREQUENT AND CORRELATES WITH MUSCLE INVASION IN BLADDER-CARCINOMA	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; NON-OCULAR CANCER; HEREDITARY RETINOBLASTOMA; SOMATIC MUTATIONS; TUMORS; EXPRESSION; RELATIVES; SEQUENCE; IDENTIFICATION; CHROMOSOME-11	Studies of second, non-ocular tumours in surviving retinoblastoma patients and their families have reported a higher than expected incidence and lower age at diagnosis of bladder tumors. This suggests that RB mutations may predispose to bladder cancer. To determine whether this gene is involved in the development of sporadic bladder tumours we have examined 162 bladder tumours for evidence of structural alterations to the RB gene. Ninety-four patients were informative with one or more intragenic RB probes, and 28 of these (29%) showed loss of heterozygosity (LOH). Of these, two tumours showed homozygous deletions with the 5' intragenic probe p123M1.8. The probe p68RS2.0, which recognizes a variable number of tandem repeats site in intron 17 of the RB gene, detected new alleles in 5 of 162 tumours, one of which also showed LOH at another polymorphic site within the gene. The 28 tumours with RB LOH were screened with the RB cDNA probes pR3.8 and pR0.9, which revealed two homozygous deletions and one rearrangement. The tumours with RB LOH were also screened for loss of three markers which flank RB, D13S1 which maps proximal and D13S2 and D13S3 which map distal to RB on chromosome 13q. Two tumours showed retention of heterozygosity for flanking markers on one side of RB and another for markers on both sides. These results suggest that RB is the target gene on 13q in these bladder tumours. When RB loss was compared with tumour grade and stage, an association between high tumour grade and RB loss (0.005 > P > 0.001) and between muscle invasion and RB loss (P < 0.001) was found. Twenty-six of the 28 tumours with LOH were muscle-invasive. This represents 56% of invasive tumours. Only 2/48 (4%) superficial tumours showed RB allele loss, and one of these has progressed rapidly to invasive disease. These results show that LOH at the RB locus is a frequent genetic event in bladder tumours and may identify a subset of more aggressive tumours.			CAIRNS, P (corresponding author), MARIE SKLODOWSKA CURIE MEM INST,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.			Knowles, Margaret/0000-0002-9363-8657				AHERNE G, 1974, T OPHTHAL SOC UK, V94, P938; ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN H, 1977, J NATL CANCER I, V58, P205, DOI 10.1093/jnci/58.2.205; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CUTLER SJ, 1982, AUA MONOGRAPHS BLADD, V1, P35; DERKINDEREN DJ, 1988, INT J CANCER, V41, P499, DOI 10.1002/ijc.2910410405; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAYE KW, 1982, J UROLOGY, V128, P31, DOI 10.1016/S0022-5347(17)52738-X; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEPPERT M, 1986, AM J HUM GENET, V39, P425; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; PROCTOR AJ, 1991, ONCOGENE, V6, P789; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TARKKANEN A, 1984, OPHTHALMOLOGICA, V189, P143, DOI 10.1159/000309401; VARLEY JM, 1989, ONCOGENE, V4, P725; WADEY RB, 1990, ONCOGENE, V5, P901; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YANDELL DW, 1991, CANCER RES, V32, P459; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0; 1978, UNION INT CANCER	32	173	176	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2305	2309						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766677				2022-12-28	WOS:A1991GX73500019
J	FISHER, RJ; MAVROTHALASSITIS, G; KONDOH, A; PAPAS, TS				FISHER, RJ; MAVROTHALASSITIS, G; KONDOH, A; PAPAS, TS			HIGH-AFFINITY DNA PROTEIN INTERACTIONS OF THE CELLULAR ETS1 PROTEIN - THE DETERMINATION OF THE ETS BINDING MOTIF	ONCOGENE			English	Article							LONG TERMINAL REPEAT; GEL-ELECTROPHORESIS; SEQUENCE; PHOSPHORYLATION; OPERATOR; COMPLEX; DOMAIN; VIRUS; GENE	ETS1 protein purified from CEM cells was used to select its optimum DNA-binding sequence (pu) G/CC(a)GGA-AGT(c) (py). The sequence CCGGAAGT (ETS1-3) was preferred 5:1 over CAGGAAGT (PEA3). Quantitative electrophoretic mobility-shift assays (EMSA) indicated that the purified ETS1 protein binds to either ETS1-3 or PEA3 oligonucleotide probes with high affinity (K(a) = 0.5-4.0 x 10(10) M-1) and that the purified ETS1 has different binding capacities for ETFS1-3 and PEA3 oligonucleotide probes. The ETS1 protein binds 2-5 times more ETS1-3 than PEA3. Competitive binding experiments showed that the ETS1-3 and PEA3 probes effectively compete for the binding of ETS1-3. However, changing the core DNA-binding sequence from GGAA to AGAA eliminates competition. Since the human ETS1 protein selected the same DNA sequence from a mixture of random oligonucleotides as did the Drosophila E74A protein (one of the most divergent members of the ETS family), this strongly suggests that all proteins containing the ETS 85 amino acid domain (sequences which define the ETS family) will bind to the same sequence.	NCI,FREDERICK CANC RES & DEV CTR,MOLEC ONCOL LAB,POB B,FREDERICK,MD 21702; DYNCORP,PROGRAM RESOURCES INC,FREDERICK CANC RES & DEV CTR,CELLULAR BIOCHEM LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Fisher, Robert/B-1431-2009					BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CANN JR, 1989, J BIOL CHEM, V264, P17032; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HUBBARD AJ, 1990, BIOCHEMISTRY-US, V29, P9241, DOI 10.1021/bi00491a019; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LABARCA C, 1980, ANAL BIOCHEM, V100, P188; LIN S, 1972, J MOL BIOL, V72, P71; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SETH A, 1991, IN PRESS TRENDS GENE; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; ZABEL U, 1991, J BIOL CHEM, V266, P252	23	94	95	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2249	2254						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766672				2022-12-28	WOS:A1991GX73500011
J	TAHIRA, T; ISHIZAKA, Y; ITOH, F; NAKAYASU, M; SUGIMURA, T; NAGAO, M				TAHIRA, T; ISHIZAKA, Y; ITOH, F; NAKAYASU, M; SUGIMURA, T; NAGAO, M			EXPRESSION OF THE RET PROTOONCOGENE IN HUMAN NEUROBLASTOMA CELL-LINES AND ITS INCREASE DURING NEURONAL DIFFERENTIATION INDUCED BY RETINOIC ACID	ONCOGENE			English	Article							BLASTOMA CELLS; MESSENGER-RNA; PROTOONCOGENE; SEQUENCE; MORPHOLOGY; INVITRO; TISSUES; FAMILY; GENE	Previously we observed specific expression of the ret proto-oncogene (proto-ret) in human neuroblastoma cell lines. A neuronal subline and non-neuronal sublines were isolated from the SK-N-SH cell line, which is composed of a heterogeneous cell population. Expression of proto-ret was defected in the neuronal subline, named SH-4305, but not in three non-neuronal sublines. Expression of proto-ret in the SH-4305 cells increased markedly after treatment with retinoic acid for 1 day, with concomitant morphological change, namely neurite outgrowth, and induction of neurofilament mRNA expression. Induction of proto-ret mRNA was observed in all seven neuroblastoma cell lines tested, being highest in the line with the lowest basal level of proto-ret expression. The induction of proto-ret expression seemed to be correlated with neurite outgrowth and increase of neurofilament mRNA expression. These data suggest that the proto-ret product plays a role in neuronal differentiation.	NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; BIEDLER JL, 1973, CANCER RES, V33, P2643; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARONE V, 1989, CANCER RES, V49, P219; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HALL BK, 1988, NEURAL CREST, P96; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIKAWA S, 1977, ACTA PATHOL JAPON, V27, P697; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ITOH F, 1989, Tumor Research, V24, P1; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; RETTIG WJ, 1987, CANCER RES, V47, P1383; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, V2, P291; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1980, ADV NEUROBLASTOMA RE, P151; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SIDELL N, 1986, EXP CELL BIOL, V54, P287; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TSOKOS M, 1987, AM J PATHOL, V128, P484; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110	30	70	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2333	2338						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766678				2022-12-28	WOS:A1991GX73500023
J	CHANG, Y; SPICER, DB; SONENSHEIN, GE				CHANG, Y; SPICER, DB; SONENSHEIN, GE			EFFECTS OF IL-3 ON PROMOTER USAGE, ATTENUATION AND ANTISENSE TRANSCRIPTION OF THE C-MYC ONCOGENE IN THE IL-3-DEPENDENT BA F3 EARLY PRE-B CELL-LINE	ONCOGENE			English	Article							INTERLEUKIN-3 DEPENDENCE; GENE; TRANSLOCATION; LYMPHOCYTES; ACTIVATION; ABROGATION; ELEMENT	The c-myc gene uses two major promoters, P1 and P2, for production of mRNA. In most proliferating normal cells, transcripts initiated from P2 predominate over the ones from P1. Furthermore, transcription of normal and translocated c-myc genes is bidirectional and overlapping. In this study, we have measured the effects of interleukin 3 (IL-3) deprivation and restimulation on c-myc promoter usage in the IL-3-dependent pre-B cell line Ba/F3. The rapid drop in c-myc mRNA expression observed in Ba/F3 cells upon IL-3 deprivation is reversible upon restimulation with interleukin. The use of P1 and P2 promoters, as judged by P1/P2 ratio, shifted from 0.2 in cells in exponential growth or in quiescence to 1.3 following IL-3 stimulation. This change was not due to selective instability of one of the two myc transcripts. In vitro nuclear run-on experiments indicated that IL-3 addition resulted in a large release of transcriptional attenuation, as well as a significant increase in transcriptional initiation. These results are consistent with the hypothesis that P1/P2 promoter usage is involved in the control of transcriptional elongation. Furthermore, deprivation of IL-3 resulted in a dramatic increase in antisense transcription, whereas little change was observed in the rate of initiation or elongation of c-myc mRNA precursors. This correlation suggests a negative role for antisense transcription in expression of c-myc mRNA levels in IL-3-deprived Ba/F3 cells.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118	Boston University					NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007429] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36355] Funding Source: Medline; NHLBI NIH HHS [T32 HL07429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; DEAN M, 1987, ONCOGENE RES, V1, P279; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALL DJ, 1990, ONCOGENE, V5, P47; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; Maniatis T., 1982, MOL CLONING; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; REICIN A, 1986, MOL CELL BIOL, V6, P4088, DOI 10.1128/MCB.6.11.4088; SPENCER C, 1990, IN PRESS ADV CANCER; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	22	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1979	1982						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1682864				2022-12-28	WOS:A1991GX11900006
J	MELLSTROM, B; ACHAVAL, M; MONTERO, D; NARANJO, JR; SASSONECORSI, P				MELLSTROM, B; ACHAVAL, M; MONTERO, D; NARANJO, JR; SASSONECORSI, P			DIFFERENTIAL EXPRESSION OF THE JUN FAMILY MEMBERS IN RAT-BRAIN	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; IMMEDIATE EARLY GENES; DNA-BINDING DOMAINS; NERVE GROWTH-FACTOR; C-JUN; PROTO-ONCOGENE; LEUCINE ZIPPERS; V-JUN; FOS; INDUCTION	The transcription factor AP-1 is phorbol ester-regulated and, as such, is considered to be a nuclear target of the signal transduction pathway involving protein kinase C. AP-1 is constituted by the various products of the jun and fos gene family members. These genes belong to the early response class and are inducible in different ways by growth factors, phorbol esters and depolarization. We studied the transcript distribution of c-jun,junB and junD in the rat brain. Our results show that the transcripts for these three genes are differentially distributed in various neuronal tissues. We also provide evidence for developmentally regulated expression of jun genes in post-natal brain. The spatiotemporal pattern of expression of c-jun, junB and junD offers clues to the understanding of the links between gene regulation and neuronal processes.	CSIC,INST CAJAL NEUROCIENCIA,DOCTOR ARCE 37,E-28002 MADRID,SPAIN; FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Consejo Superior de Investigaciones Cientificas (CSIC); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			NARANJO, Jose R/K-1950-2014; Sassone-Corsi, Paolo/H-6182-2011	NARANJO, Jose R/0000-0002-0270-3469; 				AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BERRIDGE M, 1986, NATURE, V323, P294, DOI 10.1038/323294a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FREMEAU RT, 1986, SCIENCE, V234, P1265, DOI 10.1126/science.3775385; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; HERDEGEN T, 1990, 6TH P WORLD C PAIN; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NARANJO JR, 1991, ONCOGENE, V6, P223; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; WU BY, 1989, J BIOL CHEM, V264, P9000	42	75	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1959	1964						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719462				2022-12-28	WOS:A1991GX11900003
J	AOKI, M; AKIYAMA, T; MIYOSHI, J; TOYOSHIMA, K				AOKI, M; AKIYAMA, T; MIYOSHI, J; TOYOSHIMA, K			IDENTIFICATION AND CHARACTERIZATION OF PROTEIN PRODUCTS OF THE COT ONCOGENE WITH SERINE KINASE-ACTIVITY	ONCOGENE			English	Article							GROWTH-FACTORS; ACTIVATION; INVITRO; INSULIN; FAMILY	The products of the cot gene, a novel oncogene isolated by DNA transfection assay using the hamster cell line SHOK, were identified as 46 kDa and 52 kDa proteins by using anti-peptide antibodies. The 46kDa and 52kDa proteins both showed autophosphorylation activity at serine residues. The two forms of the Cot protein were suggested to differ in their amino-terminal structures as a result of alternative initiation of translation. Subcellular fractionation revealed that the 46kDa and 52kDa proteins are both predominantly localized in the cytosol. These Cot proteins are the fourth oncogene products with serine kinase activity identified.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,3-1 YAMADA OKA,SUITA,OSAKA 565,JAPAN	Osaka University			Aoki, Masahiro/A-5149-2016	Aoki, Masahiro/0000-0003-4316-9490				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MIYOSHI J, 1991, IN PRESS MOL CELL BI; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P606; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	25	37	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1515	1519						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1833717				2022-12-28	WOS:A1991GX27400004
J	OKUNO, H; SUZUKI, T; YOSHIDA, T; HASHIMOTO, Y; CURRAN, T; IBA, H				OKUNO, H; SUZUKI, T; YOSHIDA, T; HASHIMOTO, Y; CURRAN, T; IBA, H			INHIBITION OF JUN TRANSFORMATION BY A MUTATED FOS GENE - DESIGN OF AN ANTIONCOGENE	ONCOGENE			English	Article							CHICKEN-EMBRYO FIBROBLASTS; GROWTH-STIMULATING ACTIVITY; TRANSCRIPTION FACTOR AP-1; LEUCINE ZIPPER PROTEINS; OSTEO-SARCOMA VIRUS; DNA-BINDING DOMAIN; PROTO-ONCOGENE; C-JUN; V-FOS; ANTISENSE RNA	The protein products of the fos and jun oncogenes (Fos and Jun) function as transcriptional regulators in the form of homo- or heterodimeric complexes that bind to DNA. Dimerization is mediated by a leucine zipper structure that serves to juxtapose-alpha-helical regions of each protein, rich in basic amino acids, that form a bipartite DNA-binding domain. Although Fos participates exclusively in heterodimeric complexes, Jun can function either as a homodimer that has a low apparent affinity for DNA or as a more stable heterodimer with Fos that has a higher apparent affinity for DNA. We have used these properties of Fos and Jun to design a mutated fos gene, lacking a functional DNA-binding domain (supfos1), that suppresses the transforming activity of jun in trans. Here we show that chicken embryo fibroblasts transformed by jun revert to a normal phenotype after infection by a retroviral vector encoding supFos1. Furthermore, infection of normal cells with the supfos1 vector renders them resistant to subsequent transformation by jun. Inhibition of jun transformation was associated with the appearance of supFos1-Jun heterodimers and a reduction in the AP-1 DNA-binding activity contributed by Jun homodimers. These findings demonstrate that the function of leucine zipper-containing transcription factors can be investigated by the procedure of intracellular immunization.	UNIV TOKYO,INST MED SCI,DEPT TUMOR VIRUS RES,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	University of Tokyo; Roche Holding			Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; OKUNO, HIROYUKI/0000-0001-6237-6503				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; IBA H, 1988, ONCOGENE RES, V2, P121; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KORNBLUTH S, 1986, MOL CELL BIOL, V6, P1545, DOI 10.1128/MCB.6.5.1545; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MILLER AD, 1984, CELL, V36, P259; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	51	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1491	1497						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923517				2022-12-28	WOS:A1991GX27400001
J	WANG, WP; QUICK, D; BALCERZAK, SP; NEEDLEMAN, SW; CHIU, IM				WANG, WP; QUICK, D; BALCERZAK, SP; NEEDLEMAN, SW; CHIU, IM			CLONING AND SEQUENCE-ANALYSIS OF THE HUMAN ACIDIC FIBROBLAST GROWTH-FACTOR GENE AND ITS PRESERVATION IN LEUKEMIA PATIENTS	ONCOGENE			English	Article							NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; FACTOR-I; FGF FAMILY; CELL; DNA; RECEPTOR; BINDING; EXPRESSION; REGION	Acidic fibroblast growth factor (aFGF), also known as heparin-binding growth factor 1, is a mitogen for a variety of mesoderm- and neuroectoderm-derived cells. Several different aFGF mRNA species resulting from alternative splicing have been reported. These results suggest that the gene structure and regulatory mechanism for gene expression of aFGF are complex. As a first step toward understanding aFGF gene structure, we have isolated nine overlapping genomic DNA clones spanning 54 kbp and determined the complete DNA sequences of all three coding exons. Comparison of the nucleotide sequences between the human and bovine DNA showed that the sequence similarity extended 2400 bp downstream from the coding region. Cloning of the aFGF gene allowed us to characterize this locus in acute nonlymphocytic leukemia (ANLL) patients. A fraction of ANLL patients (10-20%) have a deletion in the long arm of chromosome 5, whose distal breakpoint overlaps the aFGF locus. Therefore, a prospective cohort of eight ANLL patients was screened using three different repetitive sequence-free probes derived from the aFGF locus. Using beta-globin gene as a normalization probe for hybridizing band intensities, we conclude that there is no allelic loss or gross rearrangement within the 40 kbp stretch of the aFGF gene locus in ANLL patients with or without 5q - deletion. Consistent with this observation, the aFGF mRNA was not detected in the mononuclear cells derived from either an ANLL patient or a normal individual as judged by the reverse transcription and polymerase chain reaction. We also identified a DNA fragment, 10.7 kbp upstream from the first coding exon of human aFGF, whose sequence is conserved in both the primate and rodent genomes. Further characterization of this fragment is likely to provide insight into the significance of this high degree of conservation.	OHIO STATE UNIV,DAVIS MED RES CTR,MOLEC CELLULAR & DEV BIOL PROGRAM,480 W 9TH AVE,ROOM S2052,COLUMBUS,OH 43210; OHIO STATE UNIV,DAVIS MED RES CTR,DEPT INTERNAL MED,COLUMBUS,OH 43210; UNIV MARYLAND HOSP,BALTIMORE,MD 21201	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Maryland; University of Maryland Baltimore			Chiu, Ing-Ming/B-1534-2008		NCI NIH HHS [R01 CA45611, T32 CA09388, K04 CA01369] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045611, K04CA001369] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1988, MOL REPROD DEV; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU IM, 1990, ONCOGENE, V5, P755; CHIU IM, 1990, TROPHIC FACTORS NERV, P57; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; CRUMLEY G, 1990, BIOCHEM BIOPH RES CO, V171, P7, DOI 10.1016/0006-291X(90)91348-V; CRUMLEY GR, 1989, GENE, V85, P489, DOI 10.1016/0378-1119(89)90443-5; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GOODRICH SP, 1989, NUCLEIC ACIDS RES, V17, P2867, DOI 10.1093/nar/17.7.2867; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; HALL JA, 1990, J CELL BIOCHEM, V43, P17, DOI 10.1002/jcb.240430103; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUEBNER K, 1990, AM J HUM GENET, V46, P26; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAN M, 1988, J BIOL CHEM, V263, P11306; KANAS GS, 1985, J IMMUNOL, V134, P2995; KE YQ, 1990, BIOCHEM BIOPH RES CO, V171, P963, DOI 10.1016/0006-291X(90)90778-L; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LEBEAU MM, 1989, BLOOD, V73, P647; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; MANE SM, 1990, GENE CHROMOSOME CANC, V2, P71, DOI 10.1002/gcc.2870020113; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; NIMER SD, 1987, BLOOD, V70, P1705; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROWLEY JD, 1985, CANCER PRINCIPLES PR, P67; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; VANDILLA MA, 1990, CYTOMETRY, V11, P208, DOI 10.1002/cyto.990110124; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUNIS J J, 1989, Cancer Bulletin (Houston), V41, P283; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	63	14	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1521	1529						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1717925				2022-12-28	WOS:A1991GX27400005
J	BERNARD, O; LECOINTE, N; JONVEAUX, P; SOUYRI, M; MAUCHAUFFE, M; BERGER, R; LARSEN, CJ; MATHIEUMAHUL, D				BERNARD, O; LECOINTE, N; JONVEAUX, P; SOUYRI, M; MAUCHAUFFE, M; BERGER, R; LARSEN, CJ; MATHIEUMAHUL, D			2 SITE-SPECIFIC DELETIONS AND T(1,14) TRANSLOCATION RESTRICTED TO HUMAN T-CELL ACUTE LEUKEMIAS DISRUPT THE 5' PART OF THE TAL-1 GENE	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; LEUCINE ZIPPER; SCL GENE; COMMON; LINE; ENCODES; RECOMBINATION	Analysis of several cases of t(1:14)(p32;q11) translocation present in 3% of T-cell acute leukemias (T-ALL) has revealed the tal-1 gene. This gene encodes a helix-loop-helix protein. It has been found to be expressed in normal bone marrow and in leukemic T-cell and erythroleukemia cell lines, but not in normal T cells. Recently, a site-specific deletion, tal(d), renamed tal(d1) in this paper, has been detected in a high proportion of pediatric T-ALL, which arose by a site-specific DNA recombination between tal-1 and a new locus termed SIL. In this study we searched for structural rearrangements within tal-1 in a panel of 134 non-selected leukemic patients (including 66 with T-ALL). Only 6% of patients with T-ALL harbored the tal(d1) deletion. A second specific deletion termed tal(d2) was observed in another 6% of T-ALL patients; it involves another site within tal-1 plus the same site as tal(d1) in the SIL locus. Similarly to tal(d1) deletion, tal dl junctions harbor structural characteristics that are reminiscent of aberrant recombinase activity. Moreover, we report a detailed analysis of the tal-1 gene structure. Transcription analysis and in vitro translation data are consistent with the differential expression of several TAL-1 protein species containing the HLH motif but differing in their amino terminus. Taken together, our data indicate that t(1;14) translocations and both tal(d) deletions disrupt the 5' part of the tal-1 gene, placing its entire coding sequences under the control of the regulatory elements of the TCR-delta-gene or the SIL gene, both of which are normally expressed in T-cell lineage.	INST GENET MOLEC,INSERM,U301,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE; HOP COCHIN,INSERM,U148,F-75674 PARIS 14,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Bernard, Olivier A./E-5721-2016; Souyri, Michele/L-5845-2017; Mathieu, Daniele/G-6092-2012	Bernard, Olivier/0000-0002-0463-9747				APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1989, NUCLEIC ACIDS RES, V17, P6427, DOI 10.1093/nar/17.15.6427; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CROCE CM, 1987, ADV VIRAL ONCOL, V7, P35; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HERSHFIELD MS, 1984, P NATL ACAD SCI-BIOL, V81, P253, DOI 10.1073/pnas.81.1.253; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KURTZBERG J, 1985, J EXP MED, V162, P1561, DOI 10.1084/jem.162.5.1561; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATHIEUMAHUL D, 1986, CR ACAD SCI III-VIE, V302, P525; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; SAIKI RK, 1988, SCIENCE, V239, P488	34	147	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1477	1488						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886719				2022-12-28	WOS:A1991GX27200027
J	DENIS, N; KITZIS, A; KRUH, J; DAUTRY, F; CORCOS, D				DENIS, N; KITZIS, A; KRUH, J; DAUTRY, F; CORCOS, D			STIMULATION OF METHOTREXATE RESISTANCE AND DIHYDROFOLATE-REDUCTASE GENE AMPLIFICATION BY C-MYC	ONCOGENE			English	Article							PRIMARY EMBRYO FIBROBLASTS; TUMOR PROMOTERS; MOUSE 3T6-CELLS; GROWTH-FACTOR; CELLS; EXPRESSION; DNA; ONCOGENES; MECHANISMS; RADIATION	We have hypothesized that the c-myc oncogene might promote DNA amplification. Resistance to methotrexate (MTX), a widely used cancer chemotherapeutic agent, often results from amplification of the gene coding for the target enzyme, dihydrofolate reductase (DHFR). We report here that gratuitously induced expression of c-myc in rat fibroblasts grown in the presence of MTX greatly increases the number of colonies resistant to the drug. This effect is not related to an alteration of cell growth, and it can also be observed to a lesser extent when c-myc is induced prior to selection in MTX. The DHFR gene is amplified in nearly half of the colonies cultured under selection conditions. Given the likely role of the c-myc product in DNA replication, these results strongly suggest that expression of c-myc plays a role in methotrexate resistance by promoting DNA amplification.	INST COCHIN GENET MOLEC,CNRS,URA 1147,24 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,CNRS,UNITE 257,F-75251 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			Corcos, Daniel/M-1296-2016	Corcos, Daniel/0000-0002-4572-186X				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BARSOUM J, 1983, P NATL ACAD SCI-BIOL, V80, P5330, DOI 10.1073/pnas.80.17.5330; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; CERNI C, 1987, EXP CELL RES, V168, P438; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DENIS N, 1988, NUCLEIC ACIDS RES, V16, P2354, DOI 10.1093/nar/16.5.2354; DOTTO GP, 1985, NATURE, V318, P472; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HANSON C, 1990, CYTOGENET CELL GENET, V53, P23, DOI 10.1159/000132888; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEINBERGER T, 1988, MOL CELL BIOL, V8, P1366, DOI 10.1128/MCB.8.3.1366; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUCKEHUHLE C, 1987, INT J CANCER, V39, P94, DOI 10.1002/ijc.2910390117; NICOLAIEW N, 1986, EXP CELL RES, V166, P357, DOI 10.1016/0014-4827(86)90482-9; NOWELL PC, 1986, CANCER RES, V46, P2203; RONAI ZA, 1988, ONCOGENE, V2, P201; SAGER R, 1985, P NATL ACAD SCI USA, V82, P7015, DOI 10.1073/pnas.82.20.7015; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMKE RT, 1984, CANCER RES, V44, P1735; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; SHARMA RC, 1989, CANCER RES, V49, P3861; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TLSTY TD, 1984, MOL CELL BIOL, V4, P1050, DOI 10.1128/MCB.4.6.1050; VARSHAVSKY A, 1981, CELL, V25, P561, DOI 10.1016/0092-8674(81)90074-X; WAHL GM, 1989, CANCER RES, V49, P1333; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; [No title captured]	34	56	57	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1453	1457						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886715				2022-12-28	WOS:A1991GX27200023
J	ERLANDSSON, R; BOLDOG, F; PERSSON, B; ZABAROVSKY, ER; ALLIKMETS, RL; SUMEGI, J; KLEIN, G; JORNVALL, H				ERLANDSSON, R; BOLDOG, F; PERSSON, B; ZABAROVSKY, ER; ALLIKMETS, RL; SUMEGI, J; KLEIN, G; JORNVALL, H			THE GENE FROM THE SHORT ARM OF CHROMOSOME-3, AT D3F15S2, FREQUENTLY DELETED IN RENAL-CELL CARCINOMA, ENCODES ACYLPEPTIDE HYDROLASE	ONCOGENE			English	Note							ACYL-PEPTIDE HYDROLASE; ACID-RELEASING ENZYME; RAT-LIVER; SEQUENCE-ANALYSIS; LUNG-CANCER; PURIFICATION; ALPHA; DNF15S2; CLONING; LOCI	Loss or inactivation of a gene on the short arm of chromosome 3 may contribute to the genesis of renal cell carcinoma. A gene that corresponds to the most frequently lost RFLP site (D3F15S2) is expressed in a variety of human tissues, and at a particularly high level in the kidney. Its expression is markedly reduced in renal cell carcinoma. A database search showed that the gene product is closely related to or identical with acylpeptide hydrolase. The nucleotide identity between the rat acylpeptide hydrolase and the human gene at D3F15S2 is 88%, compatible with normal species differences. It is therefore likely that the human gene product is acylpeptide hydrolase. The renal cell carcinoma is then associated with a decrease of acylpeptide hydrolase activity. The gene may represent a tumor suppressor gene, whose loss contributes to the development of renal cell carcinoma. It might be speculated that it could act e.g. by affecting the activity of a small acetylated growth factor. Alternatively, its decreased expression may merely reflect the impairment of differentiation in RCC, compared to normal kidney. Loss of a linked but irrelevant gene by the 3p deletion is another possibility.	KAROLINSKA INST,DEPT CHEM 1,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet	ERLANDSSON, R (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Zabarovsky, Eugene R/A-6645-2010; Allikmets, Rando/ABD-4533-2021		NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA14054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGERHEIM U, 1989, CANCER RES, V49, P1390; BODENMULLER H, 1981, NATURE, V293, P579, DOI 10.1038/293579a0; BOLDOG F, 1989, CANCER GENET CYTOGEN, V42, P295, DOI 10.1016/0165-4608(89)90098-8; BOLDOG F, IN PRESS GENES CHROM; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; GADE W, 1978, J BIOL CHEM, V253, P5012; HARRIS JI, 1959, BIOCHEM J, V71, P451, DOI 10.1042/bj0710451; JONES WM, 1985, BIOCHEM BIOPH RES CO, V126, P933, DOI 10.1016/0006-291X(85)90275-X; JONES WM, 1986, BIOCHEM BIOPH RES CO, V139, P244, DOI 10.1016/S0006-291X(86)80105-X; KAISER R, 1989, BIOCHEMISTRY-US, V28, P8432, DOI 10.1021/bi00447a024; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MARKS N, 1983, J NEUROCHEM, V41, P201, DOI 10.1111/j.1471-4159.1983.tb13670.x; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; TSUNASAWA S, 1975, J BIOCHEM, V77, P89; VANDERHOUT AH, 1988, CANCER GENET CYTOGEN, V32, P281, DOI 10.1016/0165-4608(88)90292-0; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; YOUNG LJS, 1988, HUM GENET, V79, P137, DOI 10.1007/BF00280552; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	25	50	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1293	1295						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861871				2022-12-28	WOS:A1991GV26000028
J	PANDOLFI, PP; GRIGNANI, F; ALCALAY, M; MENCARELLI, A; BIONDI, A; LOCOCO, F; GRIGNANI, F; PELICCI, PG				PANDOLFI, PP; GRIGNANI, F; ALCALAY, M; MENCARELLI, A; BIONDI, A; LOCOCO, F; GRIGNANI, F; PELICCI, PG			STRUCTURE AND ORIGIN OF THE ACUTE PROMYELOCYTIC LEUKEMIA MYL/RAR-ALPHA CDNA AND CHARACTERIZATION OF ITS RETINOID-BINDING AND TRANSACTIVATION PROPERTIES	ONCOGENE			English	Article							HUMAN ESTROGEN-RECEPTOR; THYROID-HORMONE; ACID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL DOMAINS; RESPONSIVE ELEMENT; NUCLEAR RECEPTORS; GENE; DIFFERENTIATION; CELLS	Acute promyelocytic leukemia (APL) is characterized by the 15;17 chromosomal translocation. Cloning experiments have established that the chromosome 17 breakpoint maps to the RAR-alpha and the 15 to the myl locus. The resulting chimeric gene is transcribed as a myl/RAR-alpha fusion mRNA. By isolating both normal myl and APL myl/RAR-alpha cDNAs, we showed that the myl/RAR-alpha mRNA encodes for a putative fusion protein with a molecular weight of about 103 kDa, which is made up of 530 amino acids derived from the myl N-terminus and 402 amino acids originating from the RAR-alpha C-terminus. The protein includes the RAR-alpha DNA and retinoid-binding regions but lacks the A portion of the N-terminal region (A/B region) which is thought to contain one of the RAR-alpha transactivation domains. The myl/RAR-alpha protein acted as a retinoid-inducible transcription factor with both ligand-independent repressor and ligand-dependent activator functions in transactivation experiments of a retinoic acid-responsive gene. Myl/RAR-alpha exerted this dual function three times more effectively than RAR-alpha exerted this dual function three times more effectively than RAR-alpha and had about 10-fold greater affinity for RA than RAR-alpha. Comparison of myl/RAR-alpha genomic and cDNA sequences from the same case demonstrated that both chromosome 15 and 17 breakpoints occurred within introns and the myl and RAR-alpha sequences are spliced in the same polyadenylated RNA.	UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; UNIV MILAN,OSPED S GERARDO,PEDIATR CLIN,I-20052 MONZA,ITALY; UNIV ROME,DEPT BIOPATOL,DIV EMATOL,I-00161 ROME,ITALY	University of Perugia; San Gerardo Hospital; University of Milan; Sapienza University Rome	PELICCI, PG (corresponding author), UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY.		Grignani, Francesco/AAC-2565-2022; Biondi, Andrea/K-9997-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Biondi, Andrea/AAX-1865-2020; Alcalay, Myriam/B-3182-2016	Biondi, Andrea/0000-0002-6757-6173; Alcalay, Myriam/0000-0002-5558-4272				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHOMIENNE C, 1990, BLOOD, V76, P1710; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LOCOCO F, 1991, BLOOD, V77, P1657; LONGO L, 1990, ONCOGENE, V5, P1557; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MENGER H, 1988, BLOOD, V72, P567; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MITELMAN F, 1988, CATALOG CHROMOSOME A; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROWLEY JD, 1977, LANCET, V1, P549; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SULTAN C, 1973, BRIT J HAEMATOL, V24, P255, DOI 10.1111/j.1365-2141.1973.tb05746.x; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0	43	340	344	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1285	1292						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650447				2022-12-28	WOS:A1991GV26000027
J	FUJII, M; NIKI, T; MORI, T; MATSUDA, T; MATSUI, M; NOMURA, N; SEIKI, M				FUJII, M; NIKI, T; MORI, T; MATSUDA, T; MATSUI, M; NOMURA, N; SEIKI, M			HTLV-1 TAX INDUCES EXPRESSION OF VARIOUS IMMEDIATE EARLY SERUM RESPONSIVE GENES	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; JUN PROTO-ONCOGENE; LEUCINE ZIPPER STRUCTURE; C-FOS PROTEIN; TRANSCRIPTIONAL ACTIVATOR; TRANS-ACTIVATION; RECEPTOR EXPRESSION; HUMAN INTERLEUKIN-2	Human T-cell leukemia virus type 1 (HTLV-1) is an etiological agent of adult T-cell leukemia (ATL). We showed here by mobility-shift assay that T-cell lines transformed with the virus contained high levels of AP-1 activities. Consistent with this result, these cell lines expressed increased levels of mRNAs encoding the AP-1 proteins, c-Fos, Fra-1, c-Jun, JunB, and JunD. Previously, transcription of the c-fos gene has been reported to be transactivated by the viral transcription factor, Tax1. By using the human T-cell line (JPX-9), in which expression of the Tax1 is inducible, we showed that expression of mRNAs for Fra-1, c-Jun, and JunD was also transactivated by Tax1. Moreover, Tax1 activated expression of two other transcription factors having zinc finger motifs, Egr-1 and Egr-2, in the same cells. The Tax1-inducible transcription factors identified here are encoded by the members of immediate early genes under the control of growth signals. Thus, Tax1 was suggested to replace growth signals, at least in part, by this mechanism.	KANAZAWA UNIV, CANC RES INST, DEPT VIROL, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, DEPT INTERNAL MED 3, KANAZAWA, ISHIKAWA 920, JAPAN; NIPPON MED COLL, INST GERONTOL, MOLEC BIOL LAB, KAWASAKI, KANAGAWA 211, JAPAN	Kanazawa University; Kanazawa University; Nippon Medical School	SEIKI, M (corresponding author), KANAZAWA UNIV, CANC RES INST, DEPT VIROL, KANAZAWA, ISHIKAWA 920, JAPAN.		Matsui, Minami/A-5235-2016; Seiki, Motoharu/K-9443-2015	Matsui, Minami/0000-0001-5162-2668; 				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FALLER DV, 1988, J VIROL, V62, P2942, DOI 10.1128/JVI.62.8.2942-2950.1988; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; HATAKEYAMA M, 1985, NATURE, V318, P467, DOI 10.1038/318467a0; HATTORI T, 1981, BLOOD, V58, P645; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATSUI M, 1990, ONCOGENE, V5, P249; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WANO Y, 1988, P NATL ACAD SCI USA, V63, P3234; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	66	192	192	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1023	1029						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906155				2022-12-28	WOS:A1991GU62200018
J	HIBSHOOSH, H; JOHNSON, M; WEINSTEIN, IB				HIBSHOOSH, H; JOHNSON, M; WEINSTEIN, IB			EFFECTS OF OVEREXPRESSION OF ORNITHINE DECARBOXYLASE (ODC) ON GROWTH-CONTROL AND ONCOGENE-INDUCED CELL-TRANSFORMATION	ONCOGENE			English	Article							POLYAMINE-BIOSYNTHETIC ENZYMES; PROTEIN KINASE-C; VITAMIN-A ACID; IRREVERSIBLE INHIBITION; GENE AMPLIFICATION; MOUSE EPIDERMIS; TUMOR PROMOTION; INDUCTION; FIBROBLASTS; DIFLUOROMETHYLORNITHINE	The enzyme ornithine decarboxylase (ODC) has been implicated in the control of cell growth, differentiation and tumor promotion. To further elucidate its precise role a murine ODC cDNA was inserted into the retrovirus-derived vector pMV7 and retrovirus-like particles were used to infect NIH3T3 and rat 6(R6) fibroblasts. Derivatives were obtained that stably express a 5-40 fold increase in ODC enzyme activity. Despite these high levels of enzyme activity the cells retained a normal morphology and displayed no major changes in growth properties in monolayer culture or in agar suspension. On the other hand, R6 cells that expressed high levels of ODC displayed a marked increase in susceptibility to morphologic transformation by an activated c-H-ras oncogene. These results provide the first evidence that ODC can cooperate with an activated oncogene in the process of cell transformation. Although the mechanism is not known, these findings may be relevant to the multistage carcinogenic process.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University	HIBSHOOSH, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032, USA.							ALHONENHONGISTO L, 1987, BIOCHEM J, V247, P651, DOI 10.1042/bj2470651; Bachrach U., 1973, FUNCTION NATURALLY O; BOLLAG W, 1971, EXPERIENTIA, V27, P90, DOI 10.1007/BF02137760; BOLLAG W, 1972, EUR J CANCER, V8, P689, DOI 10.1016/0014-2964(72)90153-3; BOUTWELL RK, 1979, ADV ENZYME REGUL, P89; BOUTWELL RK, 1979, NATURALLY OCCURRING, P287; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cohen S.S., 1971, INTRO POLYAMINES; FOZARD JR, 1982, ARCH PHARM, V320, P72; GAZITT Y, 1980, CANCER RES, V40, P1727; HADDOX MK, 1979, CANCER RES, V39, P4930; HADDOX MK, 1979, CANCER RES, V39, P2476; HADDOX MK, 1980, CANCER RES, V40, P604; HISTON WDW, 1982, PROSTATE, V3, P383; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; JANNE J, 1968, ACTA CHEM SCAND, V22, P1349, DOI 10.3891/acta.chem.scand.22-1349; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWE NJ, 1983, CARCINOGENESIS, V4, P671, DOI 10.1093/carcin/4.6.671; LOWE NJ, 1982, CLIN RES, V30, pA158; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; OBRIEN TG, 1975, CANCER RES, V35, P2426; OBRIEN TG, 1975, CANCER RES, V35, P1662; POLVINEN K, 1988, BIOCHEM BIOPH RES CO, V155, P373, DOI 10.1016/S0006-291X(88)81095-7; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RUSSELL D, 1968, P NATL ACAD SCI USA, V60, P1420, DOI 10.1073/pnas.60.4.1420; RUSSELL DH, 1985, DRUG METAB REV, V16, P1, DOI 10.3109/03602538508991430; RUSSELL DH, 1971, P NATL ACAD SCI USA, V68, P523, DOI 10.1073/pnas.68.3.523; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; RUSSELL DH, 1973, POLYAMINES NORMAL NE, P1; RUSSELL DH, 1978, POLYAMINES MARKERS N; SPORN MB, 1976, FED PROC, V35, P1332; STEGLICH C, 1985, SOMAT CELL MOLEC GEN, V11, P11, DOI 10.1007/BF01534730; TAKIGAWA M, 1983, CANCER RES, V43, P3732; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	42	94	103	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					739	743						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1711188				2022-12-28	WOS:A1991GT82500008
J	PONZETTO, C; GIORDANO, S; PEVERALI, F; DELLAVALLE, G; ABATE, ML; VAULA, G; COMOGLIO, PM				PONZETTO, C; GIORDANO, S; PEVERALI, F; DELLAVALLE, G; ABATE, ML; VAULA, G; COMOGLIO, PM			C-MET IS AMPLIFIED BUT NOT MUTATED IN A CELL-LINE WITH AN ACTIVATED MET TYROSINE KINASE	ONCOGENE			English	Article							CYSTIC-FIBROSIS GENE; PROTO-ONCOGENE; AMPLIFICATION; PROTOONCOGENE; EXPRESSION; RECEPTOR; SEQUENCE; OVEREXPRESSION; IDENTIFICATION; FIBROBLASTS	The putative tyrosine kinase receptor encoded by the oncogene c-met is activated (tyrosine-phosphorylated in vivo) in the human gastric carcinoma cell line GTL-16. The corresponding gene is amplified and over-expressed. In this study we show that c-met is part of an amplification unit measuring more than 3000 kb. The multiple copies of the amplicon are located on a novel chromosome different from chromosome 7. We have previously shown that the c-met protein present in GTL-16 cells is indistinguishable from that found in other cells. Kinase activation could be due to over-expression of the normal c-met protein or to the presence of activating mutation(s). To verify the primary structure of the c-met protein in GTL-16 cells we sequenced a series of overlapping cDNAs obtained from GTL-16 cell RNA by reverse transcription and polymerase chain reaction. Two differences were found in the c-met coding region with respect to the published human c-met cDNA: (1) the lack of 54 nucleotides corresponding to a stretch of 18 amino acids located in the extracellular domain of the receptor, and (2) the substitution of the codon specifying alanine 1209 (located in the tyrosine kinase domain) with one coding for glycine. However, we also obtained cDNAs identical to that just described from a number of control cell lines. These results suggest: (1) that the present c-met cDNA presumably reflects the sequence of the most abundant transcript in several cell types, and (2) that overexpression of the normal c-met protein, alone or in combination with an autocrine loop, is most probably responsible for the activation of the c-met kinase in GTL-16 cells.	UNIV PAVIA,DEPT GENET & MICROBIOL,I-27100 PAVIA,ITALY	University of Pavia	PONZETTO, C (corresponding author), UNIV TURIN,DEPT BIOMED SCI & ONCOL,C SO M DAZEGLIO 52,I-10126 TURIN,ITALY.		Giordano, Silvia/J-9858-2018; Peverali, Fiorenzo/J-2660-2012	Giordano, Silvia/0000-0003-1854-1086; Peverali, Fiorenzo/0000-0001-6717-6586; Comoglio, Paolo/0000-0002-7056-5328				AMBROOK J, 1989, MOL CLONING LABORATO; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORNAGLIAFERRARIS P, 1990, PEDIATR RES, V27, P1, DOI 10.1203/00006450-199001000-00001; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; ESTIVILL X, 1987, NATURE, V326, P840, DOI 10.1038/326840a0; FARRALL M, 1988, AM J HUM GENET, V43, P471; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HUDZIAK RM, 1990, CELL GROWTH DIFFER, V1, P129; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LAWRENCE JB, 1988, CELL, V52, P51; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TRENT JM, 1987, CANCER GENET CYTOGEN, V26, P187, DOI 10.1016/0165-4608(87)90150-6; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x	32	175	187	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					553	559						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1674365				2022-12-28	WOS:A1991FR93900008
J	KHAZAIE, K; PANAYOTOU, G; AGUZZI, A; SAMARUT, J; GAZZOLO, L; JURDIC, P				KHAZAIE, K; PANAYOTOU, G; AGUZZI, A; SAMARUT, J; GAZZOLO, L; JURDIC, P			EGF PROMOTES INVIVO TUMORIGENIC GROWTH OF PRIMARY CHICKEN-EMBRYO FIBROBLASTS EXPRESSING V-MYC AND ENHANCES INVITRO TRANSFORMATION BY THE V-ERBA ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; C-MYC; LEUKEMIA VIRUSES; HORMONE RECEPTOR; THYROID-HORMONE; CELLS; GENE; PROLIFERATION; RAS; RESPONSIVENESS	We report that the activation of the endogenous chicken EGF receptor leads to the tumorigenic growth in vivo of early passage chicken embryo fibroblasts (CEFs) that express a nonsarcomagenic oncogene, v-myc. To provide a continuous paracrine source of this growth factor in vivo, we employed irradiated Rat-1 cells which had been stably transfected with a synthetic cDNA to human EGF. Expression of another non-sarcomagenic nuclear oncogene, v-erbA, prones the CEFs to in vitro transformation by EGF, but does not cause EGF dependent tumorigenicity in vivo. The short period of incubation in the in vivo assay employed by our study (10 days), together with the genetic stability of primary chicken embryo fibroblasts, make it very likely that the reported alterations in cellular behaviour are a direct and primary effect of the expression of the relevant oncogenes and their cooperation with the EGF induced response. Dose response and ligand binding assays suggest that the EGF response is transmitted via the chicken c-erbB molecule, which by virtue of its preference for TGF-alfa is distinct from the mammalian EGF receptors studied so far. The level of expression of the endogenous chicken EGF receptor is within the same range as that reported for primary human fibroblasts (5-7 x 10(3) per cell). The cooperative effect of v-myc with chicken c-erbB probably takes place at a post receptor level, as its expression did not affect the steady state level or affinity for ligand of the chicken EGF receptor.	UNIV CLAUDE BERNARD LYON,FAC MED ALEXIS CARREL,CNRS,UMR 0005,F-69372 LYONS 8,FRANCE; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; ECOLE NORM SUPER,F-69364 LYONS 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ludwig Institute for Cancer Research; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Ecole Normale Superieure de Lyon (ENS de LYON)			Aguzzi, Adriano/A-3351-2008; Samarut, Jacques/AAD-2587-2019	Aguzzi, Adriano/0000-0002-0344-6708				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P290; BISHOP JM, 1982, MOL BIOL TUMOR VIRUS, V1, P1047; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; Colburn N H, 1985, Carcinog Compr Surv, V10, P235; COMPERE SJ, 1989, P NATL ACAD SCI USA, V86, P2224, DOI 10.1073/pnas.86.7.2224; CROOK T, 1989, P NATL ACAD SCI USA, V86, P5713, DOI 10.1073/pnas.86.15.5713; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; ENGELBRETH-HOLM J., 1935, Acta Pathologica et Microbiologica Scandinavica, V12, P352; ENGSTROM W, 1986, J CELL SCI, V86, P47; FRYKBERG L, 1987, ONCOGENE, V1, P415; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FULTON R, 1987, NATURE, V326, P190, DOI 10.1038/326190a0; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GHYSDAEL J, 1981, VIROLOGY, V111, P386, DOI 10.1016/0042-6822(81)90342-1; GRAF T, 1977, CANCER RES, V37, P59; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; HAMBURGER V, 1960, MANUAL EXPT EMBRYOLO, P160; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; JANSSON M, 1987, ONCOGENE, V1, P167; KHAN P, 1986, ONCOGENES GROWTH CON; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; MELLON P, 1978, P NATL ACAD SCI USA, V75, P5874, DOI 10.1073/pnas.75.12.5874; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MOSCOVICI C, 1978, NEW MICROBIOL, V1, P1; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; ROYERPOKORA B, 1977, CELL, V13, P751; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1987, ONCOGENE, V1, P271; VENNSTROM B, 1980, J VIROL, V36, P575; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; VOGT P, 1965, FUNDAMENTAL TECHNIQU, P198; VONWEIZSACKER F, 1986, EMBO J, V5, P1521, DOI 10.1002/j.1460-2075.1986.tb04392.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZELLER NK, 1980, VIROLOGY, V104, P239, DOI 10.1016/0042-6822(80)90383-9; ZERLIN M, 1987, ONCOGENE, V1, P19	55	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					21	28						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1671532				2022-12-28	WOS:A1991EY03900003
J	HORVATH, AR; ELMORE, MA; KELLIE, S				HORVATH, AR; ELMORE, MA; KELLIE, S			DIFFERENTIAL TYROSINE-SPECIFIC PHOSPHORYLATION OF INTEGRIN IN ROUS-SARCOMA VIRUS-TRANSFORMED CELLS WITH DIFFERING TRANSFORMED PHENOTYPES	ONCOGENE			English	Article									ROYAL COLL SURG ENGLAND,INST HUNTERIAN,DEPT BIOCHEM & CELL BIOL,LONDON WC2A 3PN,ENGLAND	Royal College of Surgeons of England			Kellie, Stuart/A-6036-2010	Kellie, Stuart/0000-0002-8163-1474; Horvath, Andrea/0000-0002-7474-3240				ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; AKIYAMA SK, 1990, CANCER RES, V50, P1601; ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; ANTLER AM, 1985, MOL CELL BIOL, V5, P263, DOI 10.1128/MCB.5.1.263; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BELL SM, 1990, J BIOL CHEM, V265, P1333; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASTELLANI P, 1986, J CELL BIOL, V103, P1671, DOI 10.1083/jcb.103.5.1671; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; ENRIETTO PJ, 1983, VIROLOGY, V127, P397, DOI 10.1016/0042-6822(83)90153-8; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FINCHAM VJ, 1982, VIROLOGY, V116, P72, DOI 10.1016/0042-6822(82)90404-4; GAVAZZI I, 1989, J CELL SCI, V94, P89; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HAYMAN EG, 1981, J CELL BIOL, V88, P352, DOI 10.1083/jcb.88.2.352; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KELLIE S, 1986, J CELL SCI, V82, P129; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KNUDSEN KA, 1985, EXP CELL RES, V157, P218, DOI 10.1016/0014-4827(85)90164-8; KOZMA LM, 1990, MOL CELL BIOL, V10, P837, DOI 10.1128/MCB.10.2.837; KRUEGER JG, 1984, MOL CELL BIOL, V4, P454, DOI 10.1128/MCB.4.3.454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEFF NT, 1982, J CELL BIOL, V95, P654, DOI 10.1083/jcb.95.2.654; NIGG EA, 1982, P NATL ACAD SCI-BIOL, V79, P5322, DOI 10.1073/pnas.79.17.5322; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; PERKINS RM, 1982, EXP CELL RES, V141, P231, DOI 10.1016/0014-4827(82)90211-7; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RADZIEJEWSKI C, 1989, BIOCHEMISTRY-US, V28, P9047, DOI 10.1021/bi00449a013; RESH MD, 1985, MOL CELL BIOL, V5, P916, DOI 10.1128/MCB.5.5.916; ROHRSCHNEIDER L, 1983, MOL CELL BIOL, V3, P731, DOI 10.1128/MCB.3.4.731; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; TAPLEY P, 1989, ONCOGENE, V4, P325; WAGNER DD, 1981, J BIOL CHEM, V256, P1708; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217	57	50	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1349	1357						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699197				2022-12-28	WOS:A1990EC24100011
J	THE, SM; XIE, XL; SMYTH, F; PAPAS, TS; WATSON, DK; SCHULZ, RA				THE, SM; XIE, XL; SMYTH, F; PAPAS, TS; WATSON, DK; SCHULZ, RA			MOLECULAR CHARACTERIZATION AND STRUCTURAL ORGANIZATION OF D-ELG, AN ETS PROTO-ONCOGENE-RELATED GENE OF DROSOPHILA	ONCOGENE			English	Article							PUTATIVE 2ND-CELL-DERIVED ONCOGENE; AVIAN LEUKEMIA RETROVIRUS-E26; LONG TERMINAL REPEAT; DNA-BINDING; C-ETS; C-ETS-1 PROTOONCOGENE; V-ETS; DEVELOPMENTAL EXPRESSION; TRANSCRIPTION FACTORS; TRANSFORMING GENE	We have continued the molecular analysis of D-elg, a member of the Drosophila ets gene family. Based on the characterization of cDNA and genomic sequences, the D-elg gene contains five exons and four introns and produces a mRNA with an open reading frame of 464 amino acids. Consistent with this analysis, in vitro translation of a near full-length D-elg cRNA yields a protein with a molecular weight of approximately 56 kDa. D-elg shows significant homology to other ets proteins in the amino-terminal A domain and strong homology in the carboxy-terminal ETS domain. The D-elg protein is most similar to the alpha-subunit of the mouse GA-binding protein.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURDETT LA, 1992, NUCLEIC ACIDS RES, V20, P371, DOI 10.1093/nar/20.2.371; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1990, ONCOGENE RES, V5, P277; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CHEN ZQ, 1988, DEV BIOL, V125, P432, DOI 10.1016/0012-1606(88)90224-2; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FISHER RJ, 1991, ONCOGENE, V6, P2249; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCHULZ RA, 1989, DEV BIOL, V131, P515, DOI 10.1016/S0012-1606(89)80022-3; SETH A, 1990, ONCOGENE, V5, P1761; SETH A, 1992, CELL GROWTH DIFFER, V30, P327; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1992, IN PRESS CELL GROWTH; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	60	12	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2471	2478						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461651				2022-12-28	WOS:A1992KA85600012
J	BRUGGEMAN, LA; BURBELO, PD; YAMADA, Y; KLOTMAN, PE				BRUGGEMAN, LA; BURBELO, PD; YAMADA, Y; KLOTMAN, PE			A NOVEL SEQUENCE IN THE TYPE-IV COLLAGEN PROMOTER BINDS NUCLEAR PROTEINS FROM ENGELBRETH-HOLM-SWARM TUMOR	ONCOGENE			English	Article							HEAD-TO-HEAD; BASEMENT-MEMBRANE; EXTRACELLULAR-MATRIX; TRANSCRIPTIONAL REGULATION; BIDIRECTIONAL PROMOTER; GENE-REGULATION; CHAIN; CELLS; IDENTIFICATION; ALPHA-1(IV)	The production of extracellular matrix proteins is an important element of tumor formation, and alterations in matrix protein metabolism may be critical to the process of tumor metastasis. Abundant expression of type IV collagen, the major structural protein of the basement membrane, is characteristic of the Engelbreth-Holm-Swarm (EHS) mouse sarcoma. In the present study, we evaluated mechanisms of transcriptional regulation of type IV collagen genes by analysing nuclear factors that bind to the promoter region. Gel mobility-shift assays indicated that specific proteins from EHS tumor bound the promoter and generated several unique shift patterns. The specific sequences to which these proteins bound were determined using DNAase I protection assays. DNA-binding proteins protected two regions from DNAase I digestion. The first region was similar to a GC box, the binding site for the transcription factor Spl. The other footprint was a 30-bp region that contained the novel sequence motif, `CCCTCCC' present in several other extracellular matrix promoters. Nuclear extracts isolated from tissues that variably express type IV collagen bound to this protected sequence with distinctly different shift patterns. Furthermore, in highly expressing tissues, unlabeled oligonucleotides containing the `CCCTCCC' motif effectively inhibited nuclear protein binding with the entire promoter. Thus, it is likely that a novel protein or protein complex binds to these sequences. Furthermore, these sequences appear to be unique to the genes that encode basement membrane proteins, suggesting a specific role in their regulation.	NIH,DEV BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA			Burbelo, Peter D./B-1027-2009					ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BACHINGER HP, 1982, J BIOL CHEM, V257, P9796; BRUGGEMAN LA, 1991, AM J KIDNEY DIS, V18, P134, DOI 10.1016/S0272-6386(12)80305-2; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DYAN WS, 1985, NATURE, V316, P774; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; KAYTES P, 1988, J BIOL CHEM, V263, P19274; KILLEN PD, 1988, J BIOL CHEM, V263, P12310; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; LIOTTA LA, 1983, LAB INVEST, V49, P636; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MEYERS JC, 1987, COLLAGEN REL RES, V7, P149; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRISON KE, 1991, J BIOL CHEM, V266, P34; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OGAWA K, 1986, CANCER, V58, P269, DOI 10.1002/1097-0142(19860715)58:2<269::AID-CNCR2820580212>3.0.CO;2-7; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUTKA JT, 1987, CAN J NEUROL SCI, V14, P25; SAKR WA, 1987, HUM PATHOL, V18, P1043, DOI 10.1016/S0046-8177(87)80221-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SOININEN R, 1988, J BIOL CHEM, V263, P17217; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1	36	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1497	1502						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630813				2022-12-28	WOS:A1992JE81300005
J	CONRAD, KE; GUTIERREZHARTMANN, A				CONRAD, KE; GUTIERREZHARTMANN, A			THE RAS AND PROTEIN KINASE-A PATHWAYS ARE MUTUALLY ANTAGONISTIC IN REGULATING RAT PROLACTIN PROMOTER ACTIVITY	ONCOGENE			English	Article								In an attempt to characterize the ras signaling pathway, we studied the effects of expression vectors encoding the valine 12 mutant ras oncogene on rat prolactin (rPRL) promoter activity. Using this approach we have been able to dissect the interplay between the ras and the protein kinase A (PKA) pathways as they relate to neuroendocrine gene activation. Here we show that the ras oncogene product induces rPRL promoter activity selectively from 5- to 14-fold in GH, rat pituitary tumor cells, whereas it has a minimal effect on the SV40 early promoter and no effect on the Rous sarcoma virus (RSV) or rat growth hormone promoters. By contrast, an inactivated form of ras (N-17 ras) did not stimulate the rPRL promoter, but rather inhibited it to 40% of control. Of note, activation of the PKA pathway by two different methods decreased the fold activation mediated by ras by at least 50%, whereas inhibition of the PKA pathway accentuated ras activation of the rPRL promoter. Although rPRL promoter activity is consistently induced by PKA activation in control GH4 cells, acute ras oncogene expression inhibited forskolin induction of rPRL promoter activity. Moreover, this ras-mediated interference of the forskolin activation of rPRL promoter activity was also noted in GH, cells stably expressing ras. Taken together, these data show that the valine 12 ras oncogene activates the rPRL promoter selectively and, more importantly, that the ras and PKA signaling pathways are mutually antagonistic with respect to specific transcriptional activation of a neuroendocrine gene.	UNIV COLORADO, HLTH SCI CTR,DEPT MED,PROGRAM MOLEC BIOL, 4200 E 9TH AVE,BOX B-151, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, COLORADO CANC CTR, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Gutierrez-Hartmann, Arthur/F-1295-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037667] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BERK AJ, 1989, BIOCHIM BIOPHYS ACTA, V1009, P103, DOI 10.1016/0167-4781(89)90087-0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; GALIEN R, 1991, ONCOGENE, V6, P849; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GUTIERREZHARTMA.A, 1991, MOL CLIN ADV PITUITA, P47; GUTIERREZHARTMANN A, 1987, P NATL ACAD SCI USA, V84, P5211, DOI 10.1073/pnas.84.15.5211; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOEFFLER JP, 1990, TRENDS ENDOCRIN MET, V1, P155, DOI 10.1016/1043-2760(90)90028-2; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KEECH CA, 1991, MOL CELL ENDOCRINOL, V78, P55, DOI 10.1016/0303-7207(91)90185-U; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; LACAL JC, 1990, MOL CELL BIOL, V10, P2983, DOI 10.1128/MCB.10.6.2983; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ONALI P, 1981, P NATL ACAD SCI-BIOL, V78, P6531, DOI 10.1073/pnas.78.10.6531; OSBORNE R, 1981, ENDOCRINOLOGY, V108, P1164, DOI 10.1210/endo-108-4-1164; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; SCHONTHAL A, 1990, CELL SIGNAL, V2, P215, DOI 10.1016/0898-6568(90)90049-G; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STANLEY F, 1988, J BIOL CHEM, V263, P13444; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WHITE BA, 1983, J BIOL CHEM, V258, P4618; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	61	56	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1279	1286						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620544				2022-12-28	WOS:A1992HZ97100005
J	WARREN, W; EELES, RA; PONDER, BAJ; EASTON, DF; AVERILL, D; PONDER, MA; ANDERSON, K; EVANS, AM; DEMARS, R; LOVE, R; DUNDAS, S; STRATTON, MR; TROWBRIDGE, P; COOPER, CS; PETO, J				WARREN, W; EELES, RA; PONDER, BAJ; EASTON, DF; AVERILL, D; PONDER, MA; ANDERSON, K; EVANS, AM; DEMARS, R; LOVE, R; DUNDAS, S; STRATTON, MR; TROWBRIDGE, P; COOPER, CS; PETO, J			NO EVIDENCE FOR GERMLINE MUTATIONS IN EXONS 5-9 OF THE P53 GENE IN 25 BREAST-CANCER FAMILIES	ONCOGENE			English	Note							RISK	Recent studies have demonstrated that families with the Li-Fraumeni syndrome carry inherited point mutations of the p53 gene. In the present study 25 families with strong histories of breast cancer were screened for the presence of such mutations. Polymerase chain reaction products of exons 5-9 of the p53 gene were examined by single-stranded conformational polymorphism analysis and, in addition, exon 7 was further screened by direct sequencing. No mutations were detected in constitutive DNA by either method. These results indicate that familial breast cancer does not usually result from germ-line point mutations in the p53 gene.	ROYAL MARSDEN HOSP,ACAD UNIT RADIOTHERAPY,SUTTON SM2 5PT,SURREY,ENGLAND; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT HAEMATOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT PREVENT ONCOL,MADISON,WI 53706; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; DEPT PATHOL,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1QP,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of London; Institute of Cancer Research - UK; CRUK Cambridge Institute	WARREN, W (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.			Eeles, Rosalind/0000-0002-3698-6241	NIGMS NIH HHS [GM06993] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; HALL JM, 1990, SCIENCE, V250, P84; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LI FP, 1988, CANCER RES, V48, P5358; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OTTMAN R, 1983, LANCET, V2, P556; PROSSER J, 1990, ONCOGENE, V5, P1573; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VARLEY JM, 1991, ONCOGENE, V6, P413	13	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1043	1046						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570151				2022-12-28	WOS:A1992HP64200029
J	PRONK, GJ; POLAKIS, P; WONG, G; DEVRIESSMITS, AMM; BOS, JL; MCCORMICK, F				PRONK, GJ; POLAKIS, P; WONG, G; DEVRIESSMITS, AMM; BOS, JL; MCCORMICK, F			ASSOCIATION OF A TYROSINE KINASE-ACTIVITY WITH GAP COMPLEXES IN V-SRC TRANSFORMED FIBROBLASTS	ONCOGENE			English	Note							GTPASE-ACTIVATING PROTEIN; RAS P21 GTPASE; PHOSPHOLIPASE-C; GENE-PRODUCT; VIRAL ONCOGENE; DOMAIN; PHOSPHORYLATION; RECEPTORS; BINDING; IDENTIFICATION	p21ras GAP is phosphorylated on tyrosine residues and associates with 62 kDa and 190 kDa tyrosine phosphorylated proteins in v-src-transformed fibroblasts. We were interested in identifying the tyrosine kinase responsible for phosphorylation of GAP and the two associated proteins. Here, we report that GAP-immunoprecipitates from v-src transformed cells contain a tyrosine kinase activity that phosphorylates GAP, p62 and p190. Tryptic peptide analysis indicated that the sites phosphorylated in vitro and in vivo are indistinguishable, suggesting that the precipitated kinase could be responsible for tyrosine phosphorylation of GAP in vivo. The GAP-associated kinase activity might be due to v-src itself, because pp60v-src is able to associate with GAP in vitro and GAP can be phosphorylated by pp60v-src immunecomplexes.	UNIV UTRECHT,PHYSIOL CHEM LAB,VONDELLAAN 24,3521 GG UTRECHT,NETHERLANDS; CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608	Utrecht University								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOYLE WJ, 1991, IN PRESS METHODS ENZ; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	33	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					389	394						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549356				2022-12-28	WOS:A1992HG98200026
J	COOPER, CS				COOPER, CS			THE MET ONCOGENE - FROM DETECTION BY TRANSFECTION TO TRANSMEMBRANE RECEPTOR FOR HEPATOCYTE GROWTH-FACTOR	ONCOGENE			English	Review							PROTEIN TYROSINE KINASE; CYSTIC-FIBROSIS LOCUS; HUMAN CELL-LINE; MOLECULAR-CLONING; SCATTER FACTOR; MNNG-HOS; ACTIVATION; GENE; REARRANGEMENT; EXPRESSION				COOPER, CS (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND.							BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; CHAN AML, 1987, ONCOGENE, V1, P229; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; ESTIVILL X, 1987, NATURE, V326, P840, DOI 10.1038/326840a0; GANDINO L, 1990, ONCOGENE, V5, P721; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KING HWS, 1988, ONCOGENE, V2, P617; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1988, P NATL ACAD SCI USA, V85, P2667, DOI 10.1073/pnas.85.8.2667; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; RHIM JS, 1975, J NATL CANCER I, V55, P1291, DOI 10.1093/jnci/55.6.1291; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAWYER RH, 1983, EPITHELIAL MESENCHYM; SCAMBLER PJ, 1990, HUM GENET, V84, P274; SCAMBLER PJ, 1986, NUCLEIC ACIDS RES, V14, P7159, DOI 10.1093/nar/14.18.7159; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TEMPEST PR, 1988, BRIT J CANCER, V58, P1; TESTA JR, 1990, ONCOGENE, V5, P1565; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0	47	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					3	7						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1531516				2022-12-28	WOS:A1992HC22700001
J	CAPOBIANCO, AJ; GILMORE, TD				CAPOBIANCO, AJ; GILMORE, TD			REPRESSION OF THE CHICKEN C-REL PROMOTER BY VREL IN CHICKEN-EMBRYO FIBROBLASTS IS NOT MEDIATED THROUGH A CONSENSUS NF-KAPPA-B BINDING-SITE	ONCOGENE			English	Article							VIRUS STRAIN-T; V-REL; RETICULOENDOTHELIOSIS VIRUS; PROTO-ONCOGENE; CELLULAR HOMOLOG; MAMMALIAN-CELLS; SPLEEN-CELLS; DNA; EXPRESSION; GENE	To understand the regulation of expression of the chicken c-rel gene, we cloned genomic sequences upstream of the start site of transcription of c-rel Sequence analysis shows that the c-rel promoter is a GC-rich promoter that lacks a TATA box. In addition, there are putative binding sites for several transcription factors, including an NF-kappa-B consensus binding site. Primer extension showed that there is one major start site (site 1) for transcription in chicken embryo fibroblasts and two major start sites in a v-rel-transformed chicken spleen cell line. In transient assays using c-rel promoter sequences and the CAT reporter gene, we found that vRel repressed expression from the c-rel promoter. Other viral oncoproteins and a non-transforming v-rel deletion mutant did not repress the: c-rel promoter. Repression occurred through sequences located within 125 bp of the start of transcription. However, mutation of the consensus NF-kappa-B binding site did not affect the level of transcription from the c-rel promoter, nor did it interfere with repression by v-Rel, even though vRel could bind to the wild-type, but not the mutant, version of this sequence in vitro. These results suggest that the vRel protein can repress transcription through an indirect mechanism.	BOSTON UNIV, DEPT BIOL, BOSTON, MA 02215 USA	Boston University				Capobianco, Anthony/0000-0002-3706-6797	NCI NIH HHS [CA-47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Ausubel FM, 1988, MOL REPROD DEV; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1991, IN PRESS TRENDS GENE; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUMONT RJ, 1990, ONCOGENE RES, V5, P245; HANNINK M, 1990, ONCOGENE, V5, P1843; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IP YT, 1991, CELL, V64, P439; JORCYK CL, 1991, ONCOGENE, V6, P523; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE BE, 1989, ONCOGENE, V4, P845; MOSIALOS G, 1991, IN PRESS MOL CELL BI; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMEK S, 1988, ONCOGENE RES, V2, P103; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	55	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2203	2210						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766669				2022-12-28	WOS:A1991GX73500005
J	HAHN, S; WODNARFILIPOWICZ, A; NAIR, APK; MORONI, C				HAHN, S; WODNARFILIPOWICZ, A; NAIR, APK; MORONI, C			RAS ONCOGENES AMPLIFY LYMPHOKINE (INTERLEUKIN-3, GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR) INDUCTION BY CALCIUM IONOPHORE	ONCOGENE			English	Article							CSF MESSENGER-RNA; GM-CSF; MAST-CELLS; GROWTH-FACTORS; EXPRESSION; GENE; TRANSFORMATION; TUMOR; ACTIVATION; TRANSCRIPTION	Interleukin 3 (IL-3) expression in PB-3c mastocytes is transiently induced in vitro by treatment with the drug A23187, a calcium ionophore, or constitutively following ras-dependent transformation in vivo. While the mechanism of oncogenically induced IL-3 expression is not clear, A23187-mediated lymphokine mRNA accumulation is primarily the result of calcium-dependent mRNA stabilization. We investigated whether the expression of various ras alleles influenced IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA induction by A23187. It was found that activated forms of ras potentiated ionophore-mediated lymphokine mRNA accumulation. This enhancement involves a post-transcriptional mechanism, as ionophore-induced lymphokine mRNAs are significantly more stable in ras oncogene-expressing lines than in the control line. We propose that one way by which ras genes exert their oncogenic potential is by extending the half-life of short-lived growth factor mRNAs.	UNIV BASEL, INST MED MIKROBIOL, CH-4003 BASEL, SWITZERLAND	University of Basel								ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GRIMALDI JC, 1989, BLOOD, V73, P2081; HOFSTETTER P, 1987, MOL CELL BIOL, V7, P4535, DOI 10.1128/MCB.7.12.4535; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; METCALF D, 1984, HEMOPOIETIC COLONIES; METZGER H, 1988, ADV IMMUNOL, V43, P277; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	28	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2327	2332						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722572				2022-12-28	WOS:A1991GX73500022
J	AGUILARCORDOVA, E; STRANGE, R; YOUNG, LJT; BILLY, HT; GUMERLOCK, PH; CARDIFF, RD				AGUILARCORDOVA, E; STRANGE, R; YOUNG, LJT; BILLY, HT; GUMERLOCK, PH; CARDIFF, RD			VIRAL HA-RAS MEDIATED MAMMARY-TUMOR PROGRESSION	ONCOGENE			English	Article							MOUSE SKIN CARCINOGENESIS; TRANSGENIC MICE; EPITHELIAL-CELLS; ENZYMATIC AMPLIFICATION; MOLECULAR-BIOLOGY; HARVEY; TISSUE; VIRUS; GENE; DNA	An immortal mammary epithelial cell line, Comma 1D, and primary cultures of mammary epithelial cells were used to examine the effects of vHa-ras on mammary tumor development. In culture, Comma 1D and primary cells were morphologically indistinguishable. Infection with a replication defective vHa-ras retroviral vector (psi-ras) did not alter their in vitro phenotype. Uninfected Comma 1D cells implanted into gland-cleared mammary fat pads gave rise to dysplastic outgrowths, while implants of primary cells gave rise to normal gland structures. After psi-ras infection, implants of Comma 1D cells progressed to adenocarcinomas and those of primary cells resulted in initiated dysplastic outgrowths. High level infection of either cell type with replication competent HaMSV (psi-ras plus helper virus) resulted in in vitro transformation and undifferentiated in vivo tumors. Thus, in vivo analysis was necessary to detect the observed correlation between tumorigenic stage and level of infection. In this system, expression of vHa-ras was vital but not sufficient for mammary tumor initiation and progression, which resulted from an accumulation of events that did not need to occur in a specific order.	UNIV CALIF DAVIS,SCH MED,DEPT PATHOL,DAVIS,CA 95616; UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT INTERNAL MED,DIV HEMATOL ONCOL,SACRAMENTO,CA 95817	University of California System; University of California Davis; University of California System; University of California Davis								ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ASCH BB, 1986, CANCER RES, V46, P1255; ASHLEY RL, 1980, CANCER RES, V40, P4232; BALL RK, 1988, MOL ENDOCRINOL, V2, P133, DOI 10.1210/mend-2-2-133; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; COHEN JC, 1979, J VIROL, V32, P483, DOI 10.1128/JVI.32.2.483-496.1979; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; EDWARDS PAW, 1988, ONCOGENE, V2, P402; EHMANN UK, 1987, JNCI-J NATL CANCER I, V78, P751; EHMANN UK, 1984, J CELL BIOL, V98, P1026, DOI 10.1083/jcb.98.3.1026; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HENNINGS H, 1985, J NATL CANCER I, V74, P735; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KAWABE TT, 1986, LAB MED, V17, P143, DOI 10.1093/labmed/17.3.143; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATO Y, 1986, AM J PATHOL, V125, P431; SINN E, 1987, CELL, V49, P466; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRANGE R, 1989, ONCOGENE, V4, P309; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	32	13	13	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1601	1607						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923527				2022-12-28	WOS:A1991GX27400015
J	BAMEZAI, A; ROCK, KL				BAMEZAI, A; ROCK, KL			EFFECT OF RAS-ACTIVATION ON THE EXPRESSION OF GLYCOSYL-PHOSPHATIDYLINOSITOL-ANCHORED PROTEINS ON THE PLASMA-MEMBRANE	ONCOGENE			English	Article							T-CELL ACTIVATION; EPIDERMAL GROWTH-FACTOR; KINASE-C; MONOCLONAL-ANTIBODY; TRANSFORMED-CELLS; DOWN-REGULATION; INSULIN ACTION; LYMPHOCYTES-T; LY-6 LOCUS; STIMULATION	NIH3T3 cells were transfected with a vector containing c-H-ras under the transcriptional control of the mouse metallothionein-I promoter. When c-H-ras expression was induced with heavy metal ions there was a marked reduction in the expression of two glycosyl-phosphatidylinositol (GPI) anchored proteins, TAP/Ly-6A.2 and Thy-1, on the plasma membrane of the transformed cells. In contrast the cell-surface expression of other non-GPI-anchored proteins was unaltered. The major loss of Thy-1 induced by ras activation occurred from the pool of molecules expressed on the cell surface. The Thy-1 molecules that were preferentially lost from the surface of the ras-transformed cells could not be recovered from the extracellular fluid by immunoprecipitation. In contrast, the rate of internalization of Thy-1 was increased approximately 69% subsequent to ras activation. The possible significance of these findings to the function of c-H-ras is discussed.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV LYMPHOCYTE BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	BAMEZAI, A (corresponding author), HARVARD UNIV, SCH MED, DEPT PATHOL, 44 BINNEY ST, BOSTON, MA 02115 USA.			Bamezai, Anil/0000-0002-2447-7706	NIGMS NIH HHS [5 RO1 GM 38535] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMEZAI A, 1988, J IMMUNOL, V141, P1423; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; CHIARUGI VP, 1989, FEBS LETT, V252, P129, DOI 10.1016/0014-5793(89)80904-4; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ESPINAL J, 1987, NATURE, V328, P574, DOI 10.1038/328574a0; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HSIAO WLW, 1990, ONCOGENE, V5, P417; IVANYI D, 1986, INT J CANCER, V38, P575, DOI 10.1002/ijc.2910380418; KAMATA T, 1987, ONCOGENE, V1, P37; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MALEK TR, 1986, J EXP MED, V164, P709, DOI 10.1084/jem.164.3.709; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROBINSON PJ, 1989, NATURE, V342, P85, DOI 10.1038/342085a0; ROCK KL, 1982, J IMMUNOL, V129, P1360; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROCK KL, 1989, IMMUNOL REV, V111, P195, DOI 10.1111/j.1600-065X.1989.tb00547.x; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SANDRIGOLDIN RM, 1981, MOL CELL BIOL, V1, P743, DOI 10.1128/MCB.1.8.743; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STALLCUP KC, 1981, J IMMUNOL, V127, P923; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WEYMAN CM, 1988, CANCER RES, V48, P6535; WILKISON WO, 1989, ONCOGENE, V4, P625; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7; YEH ETH, 1987, J IMMUNOL, V138, P91	46	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1445	1451						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679532				2022-12-28	WOS:A1991GX27200022
J	MAY, E; JENKINS, JR; MAY, P				MAY, E; JENKINS, JR; MAY, P			ENDOGENOUS HELA P53 PROTEINS ARE EASILY DETECTED IN HELA-CELLS TRANSFECTED WITH MOUSE DELETION MUTANT P53 GENE	ONCOGENE			English	Article							T-ANTIGEN; ONCOGENE	It has been reported [Matlashewski et al. (1986). Eur. J. Biochem., 154, 665-6721 that HeLa cells contain no detectable p53 protein, although they contain p53 mRNA which is translationally active. Here it is shown that endogenous HeLa p53 proteins were easily detected in HeLa cells transiently expressing mouse deletion mutant p53 gene after transfection with the appropriate recombinant plasmid. This detection was obtained by immunoprecipitation coupled with SDS-PAGE as well as by Western blotting experiments. Our results strongly suggest that HeLa p53 mRNA is actually translated in vivo, generating an extremely unstable p53 protein. Considering that the HeLa cell line is a HPV-18-positive human cervical carcinoma cell line, this high instability of HeLa p53 proteins is in keeping with the finding that E6 oncoprotein encoded by human papillomavirus 16 or 18 promotes the degradation of p53 proteins [Scheffner et al. (1990). Cell, 63, 1129-1136].	MARIE SKLODOWSKA CURIE MEM INST,OXTED RH8 0TL,SURREY,ENGLAND		MAY, E (corresponding author), INST RECH SCI CANC,7 RUE GUY MOQUET,F-94801 VILLEJUIF,FRANCE.							CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8	11	37	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1363	1365						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886712				2022-12-28	WOS:A1991GX27200011
J	YIU, KC; HUANG, DP; CHAN, MKM; FOO, W				YIU, KC; HUANG, DP; CHAN, MKM; FOO, W			THE PHYSICAL STATE OF HUMAN PAPILLOMAVIRUS TYPE-16 DNA IN CERVICAL CARCINOMAS OF HONG-KONG CHINESE	ONCOGENE			English	Article							GENITAL TUMORS; CELL-LINES; MOLECULAR ANALYSIS; INTEGRATION SITES; SEQUENCES; GENE; P53; TRANSFORMATION; E6; IDENTIFICATION	The presence of human papillomavirus (HPV) in 15 cervical carcinoma specimens obtained from Hong Kong Chinese patients was analyzed by Southern blot hybridization studies. In nine (60%) of them, HPV 16 genomes were detected, while two others (13.3%) were found to harbor HPV DNA of unknown type closely related to HPV 16. All of them were classified as squamous cell carcinomas according to WHO guidelines. In addition, the presence of HPV 18 was shown in another two (13.3%) squamous cell carcinoma samples. Among the nine tumors harboring HPV 16, four specimens (44.4%) have HPV in integrated forms, while four others (44.4%) have HPV in episomal forms. The simultaneous presence of both episomal and integrated forms was demonstrated in the remaining tissue sample (11.2%). The result obtained here indicates a strong association between HPV infection and cervical carcinogenesis in Hong Kong Chinese, with HPV 16 prevalent in squamous cell carcinoma. Moreover, the persistence of HPV 16 episomes in some of the tumor specimens suggests that extrachromosomal HPV DNA, possibly acting synergistically with other oncogenic factors, is also capable of inducing cervical cancer.	CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT ANAT & CELLULAR PATHOL, SHA TIN, HONG KONG; QUEEN ELIZABETH HOSP, INST RADIOL & ONCOL, KOWLOON, HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital								ANDERSON MC, 1987, HAINES TAYLOR OBSTET, P255; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; CHOO KB, 1989, J VIROL, V63, P782, DOI 10.1128/JVI.63.2.782-789.1989; CHOO KB, 1987, J MED VIROL, V21, P101, DOI 10.1002/jmv.1890210202; DANOS O, 1984, J INVEST DERMATOL, V83, pS7, DOI 10.1111/1523-1747.ep12281115; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILUCA D, 1986, J GEN VIROL, V67, P583, DOI 10.1099/0022-1317-67-3-583; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P177; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUKUSHIMA M, 1985, CANCER RES, V45, P3252; GISSMANN L, 1984, J INVEST DERMATOL, V83, pS26, DOI 10.1111/1523-1747.ep12281143; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HOWLEY PM, 1988, AM J MED, V85, P155; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KOSS L G, 1987, Applied Pathology, V5, P7; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCCANCE DJ, 1983, BRIT MED J, V287, P784, DOI 10.1136/bmj.287.6395.784; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SCHNEIDERMAUNOURY S, 1987, J VIROL, V61, P3295, DOI 10.1128/JVI.61.10.3295-3298.1987; SMITH PP, 1989, INT J CANCER, V44, P1124, DOI 10.1002/ijc.2910440631; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WATTS SL, 1984, SCIENCE, V225, P634, DOI 10.1126/science.6330900; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YIU KC, 1990, ANTICANCER RES, V10, P917	33	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1339	1342						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1653409				2022-12-28	WOS:A1991GX27200007
J	LU, D; THOMPSON, JD; GORSKI, GK; RICE, NR; MAYER, MG; YUNIS, JJ				LU, D; THOMPSON, JD; GORSKI, GK; RICE, NR; MAYER, MG; YUNIS, JJ			ALTERATIONS AT THE REL LOCUS IN HUMAN LYMPHOMA	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; C-REL; V-REL; RETICULOENDOTHELIOSIS VIRUS; PROTO-ONCOGENE; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; CELL-LINE	The rel proto-oncogene has been mapped to chromosome region 2p11.2-14, a site associated with nonrandom rearrangements in non-Hodgkin's lymphoma. We have characterized an abnormal rel mRNA from a cell line derived from a diffuse large cell lymphoma, in which the evolutionarily conserved N-terminal half of the rel coding region was fused with the C-terminal coding region of an unrelated gene. In addition, rearrangement or amplification of the rel locus was found in the lymphomatous tissue of two follicular and one diffuse large cell lymphoma. The findings suggest involvement of rel in the pathogenesis of large cell lymphoma.	HAHNEMANN UNIV,SCH MED,DEPT NEOPLAST DIS,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA 19102; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Drexel University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	YUNIS, JJ (corresponding author), HAHNEMANN UNIV,SCH MED,DEPT NEOPLAST DIS,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA 19102, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, CA3314] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRENNAND J, 1983, J BIOL CHEM, V258, P9593; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1988, ONCOGENE, V2, P527; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GOLLIN SM, 1986, CANCER GENET CYTOGEN, V20, P331, DOI 10.1016/0165-4608(86)90092-0; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HECHT BK, 1985, CANCER GENET CYTOGEN, V14, P205, DOI 10.1016/0165-4608(85)90186-4; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEIN E, 1968, CANCER RES, V28, P1300; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MINOWADA J, 1982, MALIGNANT LYMPHOMAS, P53; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TONEGUZZO F, 1986, MOL CELL BIOL, V6, P703, DOI 10.1128/MCB.6.2.703; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	52	109	110	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1235	1241						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650444				2022-12-28	WOS:A1991GV26000020
J	TAKEDA, J; MAEKAWA, T; SUDO, T; SEINO, Y; IMURA, H; SAITO, N; TANAKA, C; ISHII, S				TAKEDA, J; MAEKAWA, T; SUDO, T; SEINO, Y; IMURA, H; SAITO, N; TANAKA, C; ISHII, S			EXPRESSION OF THE CRE-BP1 TRANSCRIPTIONAL REGULATOR BINDING TO THE CYCLIC-AMP RESPONSE ELEMENT IN CENTRAL-NERVOUS-SYSTEM, REGENERATING LIVER, AND HUMAN TUMORS	ONCOGENE			English	Article							ADENYLATE-CYCLASE; PROTEIN-KINASE; GENE; FAMILY; BRAIN; YEAST; CDNA; FORM	CRE-BP1 is a transcriptional regulator binding to the cyclic AMP response element (CRE). To understand the role of CRE-BP1 in vivo, we studied the expression of the CRE-BP1 gene in monkey tissues including the central nervous system, in rat regenerating liver, and in human cancer tissues compared with normal tissues. The CRE-BP1 mRNA was detected in all tissues examined, and was fairly abundant in brain. The CRE-BP1 mRNA was expressed in monkey brain tissues with different region specificities. In the hippocampus, frontal lobe, and parietal lobe, the CRE-BP1 mRNA was abundant and two mRNA species 4.0 kb and 3.7 kb in length were expressed. In rat liver, the expression of the CRE-BP1 gene was increased up to 4- to 5-fold of the normal level within 12-24 h after partial hepatectomy. Furthermore, the levels of CRE-BP1 mRNA in some clinical samples of human tumors were apparently higher than that in normal tissues. These results suggest that CRE-BP1 may be important for both the signal transduction in brain and cellular proliferation.	KYOTO UNIV,SCH MED,DEPT INTERNAL MED 2,KYOTO 606,JAPAN; KYOTO UNIV,SCH MED,DIV METAB & CLIN NUTR,KYOTO 606,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN; KOBE UNIV,SCH MED,DEPT PHARMACOL,KOBE 650,JAPAN	Kyoto University; Kyoto University; RIKEN; University of Tokyo; Kobe University	ISHII, S (corresponding author), KYOTO UNIV,SCH MED,DEPT INTERNAL MED 2,KYOTO 606,JAPAN.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BLOOMFIELD CD, 1987, CYTOGENET CELL GENET, V46, P344, DOI 10.1159/000132485; BUCHANAN PD, 1983, AM J MED GENET, V15, P121, DOI 10.1002/ajmg.1320150116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; Curran T, 1988, ONCOGENE HDB, P307; DALLAPICCOLA B, 1988, HUM GENET, V79, P92, DOI 10.1007/BF00291721; FRIEDMAN DL, 1984, HDB EXP PHARM, V58, P151; GONZALEZ GA, 1989, NATURE, V337, P794; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; ITO A, 1990, P NATL ACAD SCI USA, V87, P3195, DOI 10.1073/pnas.87.8.3195; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1990, IN PRESS ONCOGENE; Maniatis T., 1982, MOL CLONING; MATSUMOTO K, 1983, CELL, V32, P417, DOI 10.1016/0092-8674(83)90461-0; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAGASE T, 1990, J BIOL CHEM, V265, P17300; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; YAMADA Y, 1990, BIOCHEM BIOPH RES CO, V168, P1274, DOI 10.1016/0006-291X(90)91166-P; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	30	61	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1009	1014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829805				2022-12-28	WOS:A1991GU62200016
J	SEFTON, BM				SEFTON, BM			THE LCK TYROSINE PROTEIN-KINASE	ONCOGENE			English	Review							T-CELL RECEPTOR; RETROVIRUS PROMOTER INSERTION; AMINO-TERMINAL DOMAIN; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAINS; LYMPHOCYTES-T; CD4 RECEPTOR; PHOSPHORYLATION; P56LCK				SEFTON, BM (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186, USA.							ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; HURLEY TR, 1989, ONCOGENE, V4, P265; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; THOM RE, 1987, FEBS LETT, V222, P104, DOI 10.1016/0014-5793(87)80200-4; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	39	73	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					683	686						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1905004				2022-12-28	WOS:A1991GT82500001
J	VELLARD, M; SORET, J; VIEGASPEQUIGNOT, E; GALIBERT, F; VANCONG, N; DUTRILLAUX, B; PERBAL, B				VELLARD, M; SORET, J; VIEGASPEQUIGNOT, E; GALIBERT, F; VANCONG, N; DUTRILLAUX, B; PERBAL, B			C-MYB PROTOONCOGENE - EVIDENCE FOR INTERMOLECULAR RECOMBINATION OF CODING SEQUENCES	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; HUMAN ACUTE LEUKEMIAS; GENE V-MYB; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; CHICKEN DNA; DIFFERENTIAL EXPRESSION; INSITU HYBRIDIZATION; ONC GENES	We have characterized a novel chicken c-myb exon whose sequences are specifically expressed in thymic cells. In situ hybridization experiments indicate that this thymus-specific coding exon is localized on a small chromosome, distinct from the large acrocentric chromosome 3 on which we recently mapped the bulk of 15 exons, common to the c-myb mRNA species expressed in hematopoietic cells of both B and T lineages. These observations indicate that intermolecular recombination is required for the tissue-specific expression of the c-myb proto-oncogene. We also show that these thymus-specific sequences are conserved in human DNA and lie on chromosome 17q25, whereas the human c-myb locus is localized on chromosome 6q22-23. Sequencing data obtained from genomic DNA and PCR analyses performed with c-myb mRNA species expressed in chicken thymic cells strongly suggest that a repeated decameric sequence plays a key role in the recombination process.	CTR UNIV ORSAY,INST CURIE,BATIMENT 110,F-91405 ORSAY,FRANCE; INST CURIE,F-75005 PARIS,FRANCE; CTR HAYEM,F-75010 PARIS,FRANCE; UNIV PARIS 06,F-75230 PARIS 05,FRANCE; HOP NECKER ENFANTS MALAD,F-75730 PARIS 15,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite								BADING H, 1908, ONCOGENE, V3, P257; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BLICK M, 1984, BLOOD, V64, P1234; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CHINSKY J, 1985, P NATL ACAD SCI USA, V82, P565, DOI 10.1073/pnas.82.2.565; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P4714, DOI 10.1073/pnas.79.15.4714; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOZIER C, 1986, NUCLEIC ACIDS RES, V14, P1928, DOI 10.1093/nar/14.4.1928; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DUTRILLAUX B, 1971, CR ACAD SCI D NAT, V272, P2638; FU XY, 1988, MOL CELL BIOL, V8, P3582, DOI 10.1128/MCB.8.9.3582; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HILDEBRAND M, 1988, P NATL ACAD SCI USA, V85, P372, DOI 10.1073/pnas.85.2.372; HOLLIDAY R, 1989, TRENDS GENET, V5, P355, DOI 10.1016/0168-9525(89)90150-9; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; JANSSEN JWG, 1986, CYTOGENET CELL GENET, V41, P129, DOI 10.1159/000132217; KAHN PM, 1971, ARCH BIOCHEM BIOPHYS, V145, P470; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MAVILIO F, 1986, P NATL ACAD SCI USA, V83, P4394, DOI 10.1073/pnas.83.12.4394; MCMAHON J, 1988, ONCOGENE, V3, P717; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NGUYEN VC, 1986, ANN GENET-PARIS, V29, P20; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; Perbal B., 1988, PRACTICAL GUIDE MOL; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROYBURMAN P, 1983, INT J CANCER, V32, P185, DOI 10.1002/ijc.2910320208; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SORET J, 1988, FEBS LETT, V232, P227, DOI 10.1016/0014-5793(88)80422-8; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; SORET J, 1985, J VIROL, V55, P227; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; URBANEK P, 1988, NUCLEIC ACIDS RES, V16, P11521, DOI 10.1093/nar/16.24.11521; UZAN G, 1987, CYTOGENET CELL GENET, V46, P707; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; VLACH J, 1989, BIOCHEM BIOPH RES CO, V158, P737, DOI 10.1016/0006-291X(89)92783-6; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	60	28	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					505	514						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1840680				2022-12-28	WOS:A1991FR93900003
J	BORG, A; BALDETORP, B; FERNO, M; KILLANDER, D; OLSSON, H; SIGURDSSON, H				BORG, A; BALDETORP, B; FERNO, M; KILLANDER, D; OLSSON, H; SIGURDSSON, H			ERBB2 AMPLIFICATION IN BREAST-CANCER WITH A HIGH-RATE OF PROLIFERATION	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; HER-2 NEU ONCOGENE; TYROSINE PHOSPHORYLATION; BIOPSY SAMPLES; CARCINOMA; PROTEIN; GENE; DNA; EXPRESSION; SURVIVAL	The ERBB2 proto-oncogene was studied in 539 invasive primary breast tumors and was found amplified (2- > 30 copies) in 19%. Amplification was correlated to most known risk factors, including; large tumor size, lymph node positivity and many tumor involved nodes, advanced stage, low patient age (< 40 years), non-diploidy and hypertetraploidy, and most significantly (P < 0.00001) to the absence of steroid receptors and to a high rate of proliferation (flow cytometric determined S phase fraction). ERBB2 amplification was strongly associated (P < 0.0001) with early recurrence and death in breast cancer among node-positive patients. This connection did not, however, remain in multivariate analyses. No correlations to clinical outcome were seen among node-negative patients. Similarly, non-diploid, but not diploid, amplified tumors were particularly aggressive. Furthermore, ERBB2 amplification was associated with a high rate of proliferation and poor prognosis in steroid receptor positive, but not receptor negative tumors. In progesterone receptor positive breast cancer, amplification was an independent and with node status equally powerful (P < 0.0001) predictor of poor survival. It is concluded that ERBB2 activity is related to an increased tumor growth rate but not directly to metastasizing ability. Its clinical relevance as a prognostic factor may be in selecting a high risk subgroup of breast cancer, in general considered as being of good prognosis.			BORG, A (corresponding author), UNIV LUND HOSP, DEPT ONCOL, S-22185 LUND, SWEDEN.		Baldetorp, Bo/HDM-9924-2022	Olsson, Hakan/0000-0002-8794-9635				ALLRED D, 1990, P ASCO, V9, P23; BAISCH H, 1975, RADIAT ENVIRON BIOPH, V12, P31, DOI 10.1007/BF02339807; BALDETORP B, 1989, CYTOMETRY, V10, P695, DOI 10.1002/cyto.990100605; BERGER MS, 1988, CANCER RES, V48, P1238; BORG A, 1990, CANCER RES, V50, P4332; BORG A, 1989, LANCET, V1, P1268; BRESLOW NE, 1975, INT STAT REV, V43, P45, DOI 10.2307/1402659; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; COX DR, 1972, J R STAT SOC B, V34, P187; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FERNO M, 1989, ACTA ONCOL, V28, P19, DOI 10.3109/02841868909111175; FERNO M, 1986, ACTA ONCOL, V25, P171, DOI 10.3109/02841868609136398; GUERIN M, 1989, INT J CANCER, V43, P201, DOI 10.1002/ijc.2910430205; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE GM, 1984, ANAL BIOCHEM, V137, P221, DOI 10.1016/0003-2697(84)90374-9; LIPPMAN ME, 1990, P ASCO, V9, P24; MANGEL WF, 1988, J STEROID BIOCHEM, V30, P79, DOI 10.1016/0022-4731(88)90079-9; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARX D, 1990, J CANCER RES CLIN, V116, P15, DOI 10.1007/BF01612634; NORGREN A, 1982, ANTICANCER RES, V2, P315; NOWELL PC, 1986, CANCER RES, V46, P2203; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; ROCHEFORT H, 1988, BIOCHIMIE, V70, P943, DOI 10.1016/0300-9084(88)90236-2; SAINSBURY JRC, 1987, LANCET, V1, P1398; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; SIGURDSSON H, 1990, BRIT J CANCER, V62, P786, DOI 10.1038/bjc.1990.380; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THORNTHWAITE JT, 1980, CYTOMETRY, V1, P229, DOI 10.1002/cyto.990010309; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VOGELSTEIN B, 1989, CC MOL BIOL, P73; WRIGHT C, 1989, CANCER RES, V49, P2087; ZEILLINGER R, 1989, ONCOGENE, V4, P109	47	222	226	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1991	6	1					137	143						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1671531				2022-12-28	WOS:A1991EY03900019
J	NICKLIN, MJH; CASARI, G				NICKLIN, MJH; CASARI, G			A SINGLE SITE MUTATION IN A TRUNCATED FOS PROTEIN ALLOWS IT TO INTERACT WITH THE TRE INVITRO	ONCOGENE			English	Article							DNA-BINDING DOMAIN; LEUCINE ZIPPER; C-JUN; GCN4; TRANSCRIPTION; SPECIFICITY; HETERODIMER; COMMON; C/EBP; AP-1	The Fos and Jun proteins, which are components of the transcription factor AP1, associate through the interaction of their so-called leucine zipper domains and bind strongly and specifically to DNA at phorbol esterresponsive elements. Jun also homodimerizes and binds the same element whereas Fos seems to have no specific affinity for DNA. We show that a single amino-acid change in the leucine zipper of Fos is sufficient to allow a truncated Fos protein to homodimerize and thus form a complex with DNA, even in the absence of Jun. This Fos-derived homodimer recognizes the consensus phorbol-ester responsive element specifically, in vitro. We conclude that the structural requirements for specific DNA binding are present in the Fos protein itself, with the exception of its lack of self-affinity.			NICKLIN, MJH (corresponding author), FORSCHUNGSINST MOLEK PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nicklin, Martin/0000-0002-0127-1131				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; CURRAN T, 1984, CELL, V36, P259; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	31	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					173	179						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899479				2022-12-28	WOS:A1991EY03900026
J	LAUTENBERGER, JA; BURDETT, LA; GUNNELL, MA; QI, SM; WATSON, DK; OBRIEN, SJ; PAPAS, TS				LAUTENBERGER, JA; BURDETT, LA; GUNNELL, MA; QI, SM; WATSON, DK; OBRIEN, SJ; PAPAS, TS			GENOMIC DISPERSAL OF THE ETS GENE FAMILY DURING METAZOAN EVOLUTION	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; PROTO-ONCOGENE; C-ETS; CHROMOSOMAL LOCALIZATION; TRANSCRIPTION FACTOR; DEVELOPMENTAL EXPRESSION; MOLECULAR-ORGANIZATION; C-ETS-1 PROTOONCOGENE; TRANSFORMING GENE; LEUKEMIA-VIRUS	Evolutionary homologs of the ets proto-oncogene have been discovered in the genomes of widely divergent eucaryote species from Drosophila to sea urchin to vertebrates. The prototype mammalian ets-1 and ets-2 genes are divided into three coding domains that differ in their rate of accumulation of sequence divergence. An analysis of sequence divergence of ets gene homologs in various species has produced a phylogenetic history of the ets gene family in the context of metazoan evolutionary radiation. A minimum of five duplication events of ets primordial genes were evident, namely (1) a duplication that separates primitive ets genes (Drosophila precursor of 74E, mouse PU.1 and human ELK1) from the ets-1, ets-2, erg ancestor; (2) and (3) two duplications that established separate ets, erg and elg/GABP-alpha lineages which occurred prior to invertebrate-vertebrate divergence; (4) divergence of ets-1 and ets-2 gene family also associated with vertebrate-invertebrate divergence; (5) duplication of ets-1 and ets-2 in Xenopus laevis to produce two ets-1 genes and two ets-2 genes during genomic tetraploidation in the recent ancestry of this species.	FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC, FREDERICK, MD 21702 USA; NCI, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LAUTENBERGER, JA (corresponding author), NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA.		OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757				BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURDETT LA, 1992, NUCLEIC ACIDS RES, V20, P371, DOI 10.1093/nar/20.2.371; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1990, ONCOGENE RES, V5, P277; CHEN ZQ, 1988, DEV BIOL, V125, P432, DOI 10.1016/0012-1606(88)90224-2; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DEVEREAUX J, 1991, SEQUENCE ANAL SOFTWA; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; JORCYK CL, 1991, ONCOGENE, V6, P523; JUNIEN C, 1990, CYTOGENET CELL GENET, V55, P153, DOI 10.1159/000133007; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KINGSLEY DM, 1989, GENETICS, V123, P165; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1990, ONCOGENE, V5, P941; MYERS G, 1991, HUMAN RETROVIRUSES A, P25; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REEVES RH, 1988, J VIROL, V62, P4372, DOI 10.1128/JVI.62.11.4372-4375.1988; REITZ MS, 1991, NATURE, V351, P358, DOI 10.1038/351358a0; SACCHI N, 1988, Genomics, V3, P110, DOI 10.1016/0888-7543(88)90140-1; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; SWOFFORD DL, 1984, PHYLOGENETIC ANAL US; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VALENTINE JW, 1991, EVOLUTIONARY BIOL, V25, P279; VANCONG N, 1990, HUM GENET, V84, P542; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1990, ADV AP BIOT, V6, P221; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; [No title captured]	58	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1713	1719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501883				2022-12-28	WOS:A1992JJ37600006
J	CHINNADURAI, G				CHINNADURAI, G			ADENOVIRUS E1A AS A TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Review							RAT EMBRYO CELLS; TRANSCRIPTIONAL REPRESSION; FUNCTIONAL DOMAINS; EPITHELIAL-CELLS; TRANSFORMATION; INDUCTION; ONCOGENES; PROTEINS; TRANSACTIVATION; IMMORTALIZATION	The E1a gene of group C adenoviruses is one of the most studied transforming genes of DNA tumor viruses. These transforming genes have been conventionally considered as dominant oncogenes since they transform cells in vitro and many of the resulting transformed cell lines induce tumors in experimental animals. It now appears that, in addition to its well-known transforming activities, E1a possesses activities which suppress transformation, tumorigenesis and malignant progression (metastasis) of tumor cells. Thus, E1a appears to meet the definition of both a dominant oncogene and a tumor-suppressor gene.			CHINNADURAI, G (corresponding author), ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110, USA.				NCI NIH HHS [CA-33616, CA-31719] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031719, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1990, ONCOGENE, V5, P75; GARBISA S, 1987, CANCER RES, V47, P1523; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5853; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KUPPUSWAMY M, 1988, ONCOGENE, V2, P567; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LINDER S, 1992, IN PRESS ONCOGENE; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEEG PS, 1988, CANCER RES, V48, P6550; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	38	50	59	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1255	1258						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1535700				2022-12-28	WOS:A1992HZ97100001
J	NAKAMURA, T; HILLOVA, J; MARIAGESAMSON, R; ONNO, M; HUEBNER, K; CANNIZZARO, LA; BOGHOSIANSELL, L; CROCE, CM; HILL, M				NAKAMURA, T; HILLOVA, J; MARIAGESAMSON, R; ONNO, M; HUEBNER, K; CANNIZZARO, LA; BOGHOSIANSELL, L; CROCE, CM; HILL, M			A NOVEL TRANSCRIPTIONAL UNIT OF THE TRE ONCOGENE WIDELY EXPRESSED IN HUMAN CANCER-CELLS	ONCOGENE			English	Article							NUCLEIC-ACID; PLASMID DNA; SEQUENCES; PROTEIN; DOMAINS; AGAROSE	Tre is a recombinant gene isolated from NIH3T3 cells transfected with human Ewing's sarcoma DNA. It is composed of three major genetic elements derived, 5' to 3', from human chromosomes 5, 18 and 17. We report here on transcripts from the 3' domain of tre. The transcripts were cloned from a cDNA library of cytoplasmic poly(A)+ RNA from tre-transfected NIH3T3 tumor cells. The complete cDNA sequence, 8201 nucleotides, possessed an unusually long non-coding region and a translatable region with two open reading frames. In one cDNA clone, the presence of two insertions suggested the possibility of alternative splicing. The sequence mapped to the centromere-proximal region of 17q. Transfection-tumorigenicity assays with the open reading frames subcloned into expression vectors were positive for the reading frame adjacent to the 5' noncoding region and negative for the second, downstream, reading frame and the possible alternatively spliced versions of both reading frames. Analysis of the 786 amino acid sequence deduced from the 5' reading frame predicted a highly hydrophilic protein with two charge clusters suggesting nucleic acid-binding properties. When used as probe, the cloned sequence detected RNA transcripts in a wide variety of human cancer cells regardless of their lineage of origin from different tissues, but not in human cells from normal tissue.	INST CANC & IMMUNOGENET,CELLULAR & MOLEC BIOL LAB,14 AVE PAUL VAILLANT COUTURIER,F-94804 VILLEJUIF,FRANCE; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; INST CANC & IMMUNOGENET,CNRS,UNITE SDI 6204,F-94804 VILLEJUIF,FRANCE	Jefferson University; Centre National de la Recherche Scientifique (CNRS)			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Xie, Xinmin Simon/0000-0002-4049-6499	NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1983, NEW ENGL J MED, V309, P469; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILLOVA J, 1990, ANTICANCER RES, V10, P181; HILLOVA J, 1986, J NATL CANCER I, V77, P721, DOI 10.1093/jnci/77.3.721; HUEBNER K, 1991, AM J HUM GENET, V48, P726; HUEBNER K, 1988, ONCOGENE, V3, P449; KARLIN S, 1989, J MOL BIOL, V205, P165, DOI 10.1016/0022-2836(89)90373-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NAKAMURA T, 1990, DNA CELL BIOL, V9, P697, DOI 10.1089/dna.1990.9.697; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG AA, 1988, CANCER RES, V48, P1049; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WICKS RJ, 1986, INT J BIOCHEM, V18, P277, DOI 10.1016/0020-711X(86)90118-7; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	25	119	129	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					733	741						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565468				2022-12-28	WOS:A1992HQ68200016
J	NARAYANAN, R; LAWLOR, KG; SCHAAPVELD, RQJ; CHO, KR; VOGELSTEIN, B; TRAN, PBV; OSBORNE, MP; TELANG, NT				NARAYANAN, R; LAWLOR, KG; SCHAAPVELD, RQJ; CHO, KR; VOGELSTEIN, B; TRAN, PBV; OSBORNE, MP; TELANG, NT			ANTISENSE RNA TO THE PUTATIVE TUMOR-SUPPRESSOR GENE DCC TRANSFORMS RAT-1 FIBROBLASTS	ONCOGENE			English	Article							ANTI-SENSE RNA; HUMAN RETINOBLASTOMA GENE; THYMIDINE KINASE GENE; PROTO-ONCOGENE; MYC EXPRESSION; CELL-ADHESION; OSTEO-SARCOMA; GROWTH-FACTOR; WILMS TUMOR; C-MYC	Allelic deletions involving chromosomes 18q occur in a significant number of colorectal cancers. Recently, a highly conserved gene called 'deleted in colorectal cancer' (DCC) has been identified on chromosome 18q. DCC has been postulated to be a colorectal tumor-suppressor gene. In order to understand the role of DCC in cell transformation, we have established a stable Rat-1 cell line expressing dexamethasone-inducible DCC antisense RNA. High levels of dexamethasone-inducible DCC antisense RNA were detected in the Rat-1 transfectants. The antisense DCC-expressing Rat-1 cells showed a faster growth rate, anchorage independence and tumorigenicity in nude mice. Exposure of the parental Rat-1 cells to antisense oligodeoxyribonucleotides to DCC resulted in inhibition of cell adhesion to the substratum which could be abrogated by various extracellular matrices. On the other hand, a bone marrow-derived stromal cell line which does not express DCC showed no detachment from the substratum when treated with the antisense oligo to DCC. These results suggest that the DCC gene is involved in cell adhesion and provide the first direct biological evidence for the possible role of DCC as a tumor-suppressor gene.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; MEM SLOAN KETTERING CANC CTR,DEPT SURG,BREST CANC RES LAB,NEW YORK,NY 10021	Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center	NARAYANAN, R (corresponding author), HOFFMANN LA ROCHE INC,DEPT MOLEC GENET,340 KINGSLAND ST,NUTLEY,NJ 07110, USA.			Narayanan, Ramaswamy/0000-0001-9346-9083; Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [R01CA035494, R37CA035494, R29CA044741] Funding Source: NIH RePORTER; NCI NIH HHS [CA35494, R29 CA 44741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CULP LA, 1986, CIBA F SYMP, V124, P158; DEVILEE P, 1991, ONCOGENE, V6, P311; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; ITO E, 1989, ONCOGENE, V4, P1193; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JULIANO RL, 1987, BIOCHIM BIOPHYS ACTA, V907, P261, DOI 10.1016/0304-419X(87)90009-6; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; NARAYANAN R, 1989, EXP HEMATOL, V17, P832; NISHIKURA K, 1990, ONCOGENE, V5, P981; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TELANG NT, 1991, BREAST CANCER RES TR, V18, P155, DOI 10.1007/BF01990031; TELANG NT, 1990, CELL REGUL, V1, P863, DOI 10.1091/mbc.1.11.863; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; UCKER DS, 1983, MOL CELL BIOL, V3, P551, DOI 10.1128/MCB.3.4.551; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3385; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	54	90	92	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					553	561						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549369				2022-12-28	WOS:A1992HK00500023
J	BORRELLO, MG; PIEROTTI, MA; TAMBORINI, E; BIASSONI, D; RIZZETTI, MG; PILOTTI, S; DELLAPORTA, G				BORRELLO, MG; PIEROTTI, MA; TAMBORINI, E; BIASSONI, D; RIZZETTI, MG; PILOTTI, S; DELLAPORTA, G			DNA METHYLATION OF CODING AND NONCODING REGIONS OF THE HUMAN H-RAS GENE IN NORMAL AND TUMOR-TISSUES	ONCOGENE			English	Article							ONCOGENE; EXPRESSION; HYPOMETHYLATION; CHROMOSOME; CHROMATIN; ISLANDS; GENOME; LOCUS	To study a possible role of DNA methylation in the regulation of expression of the human H-RAS gene in vivo, 41 samples of different normal tissues and 33 tumors of various histotypes were analysed for DNA methylation. In a subset of normal tissues the RNA expression was also examined. The promoter region of the gene showed the features of a CpG island being CpG rich and unmethylated in all the normal tissues and tumors. The coding region displayed an intermediate level of methylation in the majority of normal and tumor tissues. Among the normal tissues only thymus DNA was found to be hypermethylated, while testes and sperm cells DNAs were hypomethylated. The 3' region was found to he completely methylated only in sperm cells and was never completely demethylated. The majority of the tissues showed an intermediate level of methylation, and a certain tissue specificity emerged by comparing tissues of the same and different histotypes. However, the overall methylation of both coding and 3' regions did not correlate with the levels of tissue-specific RNA expression. In heterozygous individuals, allelic methylation of the 3' region showed either perfectly balanced or slightly unbalanced methylation of the two alleles in normal tissues, while an allele-specific methylation was found in 5 out of 12 fresh tumor samples.	IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY; IST NAZL TUMORI,DIV ANAT PATOL & CITOL,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan			Tamborini, Elena/C-3307-2017; Borrello, Maria Grazia/C-3161-2017	Tamborini, Elena/0000-0002-3819-8687; Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332				BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BORRELLO MG, 1988, ONCOGENE RES, V2, P197; BORRELLO MG, 1987, CANCER RES, V47, P75; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHANDLER LA, 1987, CELL, V50, P711, DOI 10.1016/0092-8674(87)90329-1; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; EDWARDS YN, 1985, MOL CELL BIOL, V5, P2147, DOI 10.1128/MCB.5.8.2147; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GROUDINE M, 1985, SCIENCE, V228, P1061, DOI 10.1126/science.2986289; HELLER DL, 1988, MOL CELL BIOL, V8, P2797, DOI 10.1128/MCB.8.7.2797; JONES PA, 1986, CANCER RES, V46, P461; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; METTER J, 1989, NUCLEIC ACIDS RES, V17, P7089, DOI 10.1093/nar/17.17.7089; MONK M, 1987, NATURE, V328, P203, DOI 10.1038/328203a0; MULLINS LJ, 1987, MOL CELL BIOL, V7, P3916, DOI 10.1128/MCB.7.11.3916; PERFETTI V, 1991, IN PRESS LEUKEMIA; PIEROTTI MA, 1986, CYTOGENET CELL GENET, V43, P174, DOI 10.1159/000132317; SALUZ HP, 1988, P NATL ACAD SCI USA, V85, P6697, DOI 10.1073/pnas.85.18.6697; SILVA AJ, 1988, TRENDS GENET, V4, P59; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; WOLF SF, 1985, NATURE, V314, P467, DOI 10.1038/314467a0	30	24	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					269	275						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549348				2022-12-28	WOS:A1992HG98200010
J	DEVOUGE, MW; MUKHERJEE, BB				DEVOUGE, MW; MUKHERJEE, BB			TRANSFORMATION OF NORMAL RAT-KIDNEY CELLS BY V-K-RAS ENHANCES EXPRESSION OF TRANSIN-2 AND AN S-100-RELATED CALCIUM-BINDING PROTEIN	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; EPIDERMAL GROWTH-FACTOR; COMPARATIVE BIOCHEMICAL-PROPERTIES; GUANINE NUCLEOTIDE-BINDING; MESSENGER-RNA; SIGNAL TRANSDUCTION; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; GENE-PRODUCT; 3T3 CELLS	v-K-ras transformants of normal rat kidney cells (KNRK) exhibit cell surface-related, transformation-specific properties, including cell-surface fibronectin depletion, induction of anchorage- and density-independent growth, and increased synthesis of transforming growth factors-alpha and beta. To search for potential distal effectors of v-K-ras-mediated transformation, we prepared a rabbit antiserum directed against intact KNRK cells to immunoprecipitate and compare proteins from detergent lysates and conditioned media of labeled NRK, KNRK, B77-NRK (a v-src transformant) and ts-371-NRK cells (a Ki-MSV encoding a temperature-sensitive p21v-K-ras). Proteins with enhanced expression in both wild-type v-K-ras and v-src transformants included a cell-surface phosphoglycoprotein with apparent M(r) of 79 000 (79K) modified from an 85K protein observed in NRK cell lysates, a cytoplasmic 47K and a 10K protein, and a 57K secreted glycoprotein. A KNRK-specific 21K membrane-associated protein and secreted 59K and 36K secreted glycoproteins were also detected. The expression of the 36K and 59K proteins best correlated with temperature-dependent activation of the ts-371-NRK p21v-K-ras. Immunoselection of recombinant clones from a KNRK-specific lambda-gt11 cDNA library allowed identification of the 59K and 10K proteins as transin 2 and an S-100-related calcium-binding protein identified as p9Ka/42A but not previously associated with oncogenic transformation of rat cells. Transin 2 detection by a cell-derived antiserum may also suggest the presence of specific cell-surface binding sites for this enzyme.	MCGILL UNIV,CTR HUMAN GENET,MONTREAL H3A 1B1,QUEBEC,CANADA	McGill University	DEVOUGE, MW (corresponding author), MCGILL UNIV,DEPT BIOL,1205 AV DOCTEUR PENFIELD,MONTREAL H3A 1B1,QUEBEC,CANADA.							ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ANZANO MA, 1982, CANCER RES, V42, P4776; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACK FM, 1990, BIOCHEM J, V267, P809, DOI 10.1042/bj2670809; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHARDIN P, 1988, BIOCHIMIE, V70, P865, DOI 10.1016/0300-9084(88)90226-X; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENHARDT DT, 1987, ONCOGENE, V2, P55; DER CJ, 1981, CELL, V26, P429, DOI 10.1016/0092-8674(81)90212-9; DEVOUGE MW, 1982, VIROLOGY, V121, P327, DOI 10.1016/0042-6822(82)90172-6; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; DURKIN JP, 1983, CANCER RES, V43, P5390; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GAL S, 1986, J BIOL CHEM, V261, P1760; GILLEN MF, 1987, J BIOL CHEM, V262, P5308; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDBERG AR, 1979, COLD SPRING HARB SYM, V44, P991; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GOTTESMAN MM, 1980, CELL, V19, P449, DOI 10.1016/0092-8674(80)90519-X; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; Marston F. A. O., 1987, DNA CLONING, P59; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MORRIS JDH, 1989, ONCOGENE, V4, P27; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAPAGEORGE A, 1982, J VIROL, V44, P509, DOI 10.1128/JVI.44.2.509-519.1982; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRICE BD, 1989, J BIOL CHEM, V264, P16638; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1987, J BIOL CHEM, V262, P10663; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHIH TY, 1979, J VIROL, V31, P546, DOI 10.1128/JVI.31.2.546-546.1979; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; STEIN RB, 1986, J VIROL, V60, P782, DOI 10.1128/JVI.60.2.782-786.1986; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TODARO GJ, 1980, CONTROL MECHANISMS A, V1, P223; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	76	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					109	119						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741158				2022-12-28	WOS:A1992HC22700015
J	JANSSEN, JWG; SCHULZ, AS; STEENVOORDEN, ACM; SCHMIDBERGER, M; STREHL, S; AMBROS, PF; BARTRAM, CR				JANSSEN, JWG; SCHULZ, AS; STEENVOORDEN, ACM; SCHMIDBERGER, M; STREHL, S; AMBROS, PF; BARTRAM, CR			A NOVEL PUTATIVE TYROSINE KINASE RECEPTOR WITH ONCOGENIC POTENTIAL	ONCOGENE			English	Article							GEL-ELECTROPHORESIS; SEQUENCES; DNA; PROTEIN; CELLS; FRAGMENTS; LEUKEMIA; HYBRIDIZATION; CLEAVAGE; DOMAINS	We have detected transforming activity by a tumorigenicity assay using NIH3T3 cells transfected with DNA from a chronic myeloproliferative disorder patient. Here, we report the cDNA cloning of the corresponding oncogene, designated UFO, in allusion to the as yet unidentified function of its protein. Nucleotide sequence analysis of a 3116 bp cDNA clone revealed a 2682-bp-long open reading frame capable of directing the synthesis of a 894 amino acid polypeptide. The predicted UFO protein exhibits characteristic features of a transmembrane receptor with associated tyrosine kinase activity. The UFO proto-oncogene maps to human chromosome 19q13.1 and is transcribed into two 5.0 kb and 3.2 kb mRNAs in human bone marrow and human tumor cell lines. The UFO locus is evolutionarily conserved between vertebrate species. A 4.0 kb mRNA of the murine UFO homolog is expressed in a variety of different mouse tissues. We thus have identified a novel element of the complex signaling network involved in the control of cell proliferation and differentiation.	UNIV ULM,DEPT PEDIAT 2,INTERNAL DIS PROPEDEUT SECT,PRITTWITZSTR 43,W-7900 ULM,GERMANY; DEPT TRANSFUS MED,W-7900 ULM,GERMANY; CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA	Ulm University; Saint Anna Children's Hospital			Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Strehl, Sabine/0000-0002-0179-0628				AFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AMBROS PF, 1987, HUM GENET, V77, P251, DOI 10.1007/BF00284479; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BIGNER SH, 1988, CANCER RES, V48, P405; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JANSSEN JWG, 1987, ONCOGENE, V1, P175; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LYON MF, 1987, MOUSE NEWS LETT, V787, P12; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROPERS HH, 1990, CYTOGENET CELL GENET, V55, P218, DOI 10.1159/000133015; RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; UESHIMA Y, 1985, INT J CANCER, V36, P287, DOI 10.1002/ijc.1985.36.3.287; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGELSTEIN B, 1987, ANAL BIOCHEM, V160, P115, DOI 10.1016/0003-2697(87)90620-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITTAKER PA, 1988, NUCLEIC ACIDS RES, V16, P6725, DOI 10.1093/nar/16.14.6725; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	42	226	255	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2113	2120						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1834974				2022-12-28	WOS:A1991GX11900023
J	MATSUZAWA, Y; SEMBA, K; KAWAMURATSUZUKU, J; SUDO, T; ISHII, S; TOYOSHIMA, K; YAMAMOTO, T				MATSUZAWA, Y; SEMBA, K; KAWAMURATSUZUKU, J; SUDO, T; ISHII, S; TOYOSHIMA, K; YAMAMOTO, T			CHARACTERIZATION OF THE PROMOTER REGION OF THE C-YES PROTOONCOGENE - THE IMPORTANCE OF THE GC BOXES ON ITS PROMOTER ACTIVITY	ONCOGENE			English	Article							TYROSINE KINASE; TRANSCRIPTION FACTOR; START SITES; GENE; EXPRESSION; SEQUENCE; RECEPTOR; CELLS; PURIFICATION; BINDING	In this study we cloned the 5' flanking sequence of the human c-yes gene and identified its promoter region. A 0.53 kilobase pair (kbp) fragment containing the 5' terminus of the c-yes gene showed strong promoter activity when placed upstream of the bacterial chloramphenicol acetyltransferase (CAT) gene and transfected into monkey CV-1 cells. By nuclease S1 mapping multiple transcriptional start sites were detected within the promoter region. Nucleotide sequence analysis revealed that the c-yes promoter region had high G + C contents (64%) and contained six GC box-like sequences (one at the 5' distal region and five in a cluster at the 5' proximal region), but not a TATA box. These features of the c-yes promoter region are similar to those of other protooncogenes, ras-family genes and c-raf-1, and some housekeeping genes. Deletion analysis suggested that the most downstream 0.21 kbp region is primarily important for the promoter activity. This 0.21 kbp region contains one major and another minor transcriptional start site. Five GC box-like sequences were located within this region, and four of them were shown to bind with purified Sp1 transcription factor. Furthermore, using the base-substituted mutants of the Sp1-binding sites, each GC box in the cluster (GC1 to GC4) was shown to affect the c-yes gene expression.	UNIV TOKYO, INST MED SCI,DEPT ONCOL,4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC GENET LAB, TSUKUBA, IBARAKI 305, JAPAN; OSAKA UNIV, MICROBIAL DIS RES INST, DEPT ONCOGENE RES, SUITA, OSAKA 565, JAPAN	University of Tokyo; RIKEN; Osaka University			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1990, SRC FAMILY PROTEIN T, P85; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE JM, 1987, CURRENT PROTOCOLS MO, V1; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MANIATIS T, 1982, NUCLEASE SI MAPPING, P207; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; PATEL M, 1990, ONCOGENE, V5, P201; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1985, SCIENCE, V227, P1038, DOI 10.1126/science.2983418; SEMBA K, 1990, STRUCTURE FUNCTION S, P74; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUKEGAWA J, 1990, ONCOGENE, V5, P611; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TSUKITA S, 1991, IN PRESS J CELL BIOL; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	47	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1561	1567						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923523				2022-12-28	WOS:A1991GX27400010
J	WAGNER, P; SIMANIS, V; MAIMETS, T; KEENAN, E; ADDISON, C; BRAIN, R; GRIMALDI, M; STURZBECHER, HW; JENKINS, J				WAGNER, P; SIMANIS, V; MAIMETS, T; KEENAN, E; ADDISON, C; BRAIN, R; GRIMALDI, M; STURZBECHER, HW; JENKINS, J			A HUMAN TUMOR-DERIVED MUTANT P53-PROTEIN INDUCES A P34CDC2 REVERSIBLE GROWTH ARREST IN FISSION YEAST	ONCOGENE			English	Article							SMALL-CELL CARCINOMA; P53 GENE; T-ANTIGEN; SCHIZOSACCHAROMYCES-POMBE; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; DNA-REPLICATION; CYCLE CONTROL; SHORT ARM; PROTEIN	We have expressed wild-type and human tumour-derived mutant p53 cDNA genes in the fission yeast Schizosaccharomyces pombe. In the case of one mutant this resulted in a growth arrest of recipient yeast cells. In contrast, wild-type p53 and three other mutant proteins tested did not block outgrowth of colonies. Human and yeast cdc2 acted as functionally equivalent extragenic suppressors of the mutant-induced growth arrest allowing the establishment of viable p53 expressor strains. In cotransformation assays the mutant allele was found to be dominant over wt p53. Our results provide the first evidence of a functional relationship between p53 and p34cdc2 in an in-vivo system and suggest that the wide variety of mutant proteins present in human tumours may fall into functionally distinct subclasses.	ESTONIAN BIOCENTER,TARTU 202400,ESTONIA,USSR; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research	WAGNER, P (corresponding author), MARIE CURIE CANC RES INST,CELL PROLIFERAT LAB,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.		Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365				BENCHIMOL S, 1985, SOMAT CELL MOLEC GEN, V11, P505, DOI 10.1007/BF01534845; BENDAVID Y, 1988, ONCOGENE, V3, P179; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BROEKER M, 1987, Biotechniques, V5, P518; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FANTES PA, 1989, MOL BIOL FISSION YEA; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; GOULD K, 1990, NATURE, V342, P39; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LATHE RA, 1988, CYTOGENET CELL GENET, V41, P404; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T., 1982, MOL CLONING; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; Mitchison J. M., 1988, YEAST PRACTICAL APPR, P51; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MULERIS M, 1985, Annales de Genetique, V28, P206; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STREIBLOVA E, 1988, YEAST PRACTICAL APPR, P9; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471	53	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1539	1547						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923520				2022-12-28	WOS:A1991GX27400007
J	HOFFMANLIEBERMANN, B; LIEBERMANN, DA				HOFFMANLIEBERMANN, B; LIEBERMANN, DA			SUPPRESSION OF C-MYC AND C-MYB IS TIGHTLY LINKED TO TERMINAL DIFFERENTIATION INDUCED BY IL6 OR LIF AND NOT GROWTH-INHIBITION IN MYELOID-LEUKEMIA CELLS	ONCOGENE			English	Article							MESSENGER-RNA; ERYTHROLEUKEMIA-CELLS; ONCOGENE EXPRESSION; GENE-EXPRESSION; PROTO-ONCOGENE; PROTEINS; ARREST; MOUSE; PROLIFERATION; TRANSCRIPTION	Cell proliferation and differentiation are intimately related processes where the proto-oncogenes c-myc and c-myb have been implicated to play a role. Previously, we have shown that both c-myc and c-myb were induced in normal myeloid precursors when the cells were stimulated for growth, were expressed in the autonomously proliferating myeloid leukemic M1 cell line and were rapidly suppressed in both normal and M1 cells following induction of terminal differentiation associated with growth arrest. In order to distinguish molecular events associated with terminal differentiation versus those due to growth inhibition, as well as to increase our understanding of the role of the proto-oncogenes c-myc and c-myb in both of these cellular processes, in this work we have studied the expression of c-myc and c-myb in M1 cells induced for growth inhibition associated with terminal differentiation (via treatment with the physiological inducers IL6 or leukemia inhibitory factor <LIF>), partial differentiation (using IL1 or LPS) or no detectable differentiation properties (using IFN-beta or IFN-gamma). We show that, for all the treatments used in this study, down regulation of the proto-oncogenes c-myc and c-myb occurred only when M1 cells were stimulated to undergo terminal differentiation. In addition, we transfected the M1 cell line with a vector containing the c-myc gene under control of the beta-actin promoter, so that c-myc was no longer down regulated by IL6 or LIF. Previously, we have shown that in the presence of the myeloid differentiation inducers IL6 or LIF, these M1myc cells were blocked at an intermediate stage of myeloid differentiation and continued to proliferate. In sharp contrast to their altered response to IL6 or LIF, M1myc cells were as responsive as the parental M1 cells to growth suppression by the different antiproliferative compounds which do not induce terminal differentiation. Thus, continued expression of c-myc had no effect on growth suppression induced by IL1, IFN-beta, IFN-gamma and LPS. Taken together, these results indicate that c-myc and c-myb down regulation is not necessary for growth suppression, but down regulation of c-myc is, and c-myb may be, essential for terminal differentiation.			HOFFMANLIEBERMANN, B (corresponding author), UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA43618-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOFFMANLIEBERMA.B, 1991, IN PRESS MOL CELL; HOFFMANLIEBERMANN B, 1978, CELL, V14, P825, DOI 10.1016/0092-8674(78)90338-0; HOFFMANLIEBERMANN B, 1981, DEV BIOL, V81, P255, DOI 10.1016/0012-1606(81)90289-X; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; IKEGAKI N, 1990, ONCOGENE, V5, P397; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KUEHL WM, 1988, CURR TOP MICROBIOL, V141, P318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMANN D, 1978, CELL, V15, P823, DOI 10.1016/0092-8674(78)90267-2; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LODMICO P, 1984, NATURE, V312, P458; LORD KA, 1990, ONCOGENE, V5, P387; LOTEM J, 1978, INT J CANCER, V22, P214, DOI 10.1002/ijc.2910220216; LOTEM J, 1989, LEUKEMIA RES, V13, P13, DOI 10.1016/0145-2126(89)90026-X; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; ONOZAKI K, 1987, CANCER RES, V47, P2397; ONOZAKI K, 1989, CANCER RES, V49, P3602; ONOZAKI K, 1988, J IMMUNOL, V140, P112; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; SHABO Y, 1988, BLOOD, V72, P2070; SHENONG GLC, 1987, P NATL ACAD SCI USA, V84, P199, DOI 10.1073/pnas.84.1.199; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIESE B, 1978, P NATL ACAD SCI USA, V75, P1374	45	62	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					903	909						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906157				2022-12-28	WOS:A1991GU62200003
J	RAZ, V; KELMAN, Z; AVIVI, A; NEUFELD, G; GIVOL, D; YARDEN, Y				RAZ, V; KELMAN, Z; AVIVI, A; NEUFELD, G; GIVOL, D; YARDEN, Y			PCR-BASED IDENTIFICATION OF NEW RECEPTORS - MOLECULAR-CLONING OF A RECEPTOR FOR FIBROBLAST GROWTH-FACTORS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CDNA LIBRARIES; EXPRESSION; FAMILY; GENE; DNA; CELLS; HOMOLOGY; AMPLIFICATION; POLYMERASE	Transmembrane tyrosine kinases are involved in the control of cell growth and differentiation by extracellular signals. To enable identification of new receptor tyrosine kinases we developed a method that selectively amplifies segments of receptor genes. The method is based on a combination of polymerase chain reaction (PCR) and hybridization screening and it employs three oligonucleotide primers derived from conserved domains of receptor tyrosine' kinases. It yields amplification of receptors' genes and appears to ignore cytoplasmic tyrosine kinases. When applied to RNA from 12.5 days post coitum mouse placenta, this methodology resulted in the detection of several putative or established receptors. Molecular cloning of one of these genes, which is identical to the partially characterized bek gene, identified a transmembrane tyrosine kinase with three immunoglobulin-like domains in the extracellular portion, and a cytoplasmic tyrosine kinase sequence. The isolated cDNA shows remarkable homology to the murine flg gene that encodes a receptor for fibroblast growth factors. Indeed, an antibody directed to the carboxy terminus of the deduced bek protein specifically recognized a receptor for acidic and basic fibroblast growth factors in murine hepatoma cells. We therefore expect that the methodology we developed will enable the study of new receptors in hardly accessible biological systems such as early mammalian embryos or stem cells.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	Weizmann Institute of Science; Technion Israel Institute of Technology	YARDEN, Y (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.		YARDEN, YOSEF/K-1467-2012; Neufeld, Gera/F-1524-2019					BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FOSTER DA, 1986, MOL CELL BIOL, V6, P325, DOI 10.1128/MCB.6.1.325; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HOGAN B, 1986, MANIPULATING MOUSE E; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARUYAMA T, 1986, NUCLEIC ACIDS RES, V14, pR151, DOI 10.1093/nar/14.suppl.r151; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHIBUYA M, 1990, ONCOGENE, V5, P519; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	43	60	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1991	6	5					753	760						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1711190				2022-12-28	WOS:A1991GT82500010
J	SIMON, D; KNOWLES, BB; WEITH, A				SIMON, D; KNOWLES, BB; WEITH, A			ABNORMALITIES OF CHROMOSOME-1 AND LOSS OF HETEROZYGOSITY ON 1P IN PRIMARY HEPATOMAS	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; HEPATITIS-B VIRUS; CELL-LINE; HUMAN NEUROBLASTOMAS; C-MYC; GENE; INTEGRATION; LIVER; HETEROCHROMATIN; EXPRESSION	Cytogenetic analysis of eight human hepatoma-derived cell lines and one primary hepatocellular carcinoma biopsy revealed multiple chromosome abnormalities; however, only chromosome 1 was consistently affected by rearrangements. Pseudopolysomy 1 as well as chromosome 1 deletions and/or translocations that resulted in loss of the distal 1p region from at least one copy of chromosome 1 were observed in all but one of the cell lines analysed. Molecular analyses of tumor-derived and normal genomic DNA from six cases of hepatocellular carcinoma and from two of hepatoblastoma, using a panel of chromosome 1p-specific DNA probes indicated allelic loss in the distal 1p region in five of the six hepatocellular carcinomas but not in either hepatoblastoma. These results suggest the location of a gene in the distal 1p region whose functional loss may be involved in hepatocellular carcinogenesis.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	The Wistar Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	KNOWLES, BB (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.			Knowles, Barbara B./0000-0002-2597-5619	NCI NIH HHS [CA10815, CA37725] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; ATKIN NB, 1986, CANCER GENET CYTOGEN, V21, P279, DOI 10.1016/0165-4608(86)90206-2; BEASLEY RP, 1981, LANCET, V2, P1129; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHATTERJEE B, 1989, MUTAT RES, V210, P49, DOI 10.1016/0027-5107(89)90043-2; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; HUH N, 1981, GANN, V72, P178; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; KEICHLESCHWARTZ M, 1990, GENE CHROMOSOME CANC, V1, P312; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OBRIEN SJ, 1990, GENETIC MAPS; PINTO MR, 1985, CANCER GENET CYTOGEN, V18, P11, DOI 10.1016/0165-4608(85)90033-0; ROBINSON WS, 1989, CANCER DETECT PREV, V14, P245; ROGLER CE, 1985, SCIENCE, V230, P219; ROONEY DE, 1971, HUMAN CYTOGENETICS P, V2, P971; SEABRIGH.M, 1971, LANCET, V2, P971; SIMON D, 1986, LAB INVEST, V55, P657; SIMON D, 1982, INT J CANCER, V30, P27, DOI 10.1002/ijc.2910300106; SIMON D, 1985, CYTOGENET CELL GENET, V39, P116, DOI 10.1159/000132118; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; Simon D.R., UNPUB; SMUZNESS W, 1978, PROG MED VIROL, V24, P40; STEVENSON D, 1987, HEPATOLOGY, V7, P1291, DOI 10.1002/hep.1840070619; SUMNER AT, 1972, EXP CELL RES, V75, P304, DOI 10.1016/0014-4827(72)90558-7; TADA M, 1990, CANCER RES, V40, P1122; TAKADA S, 1989, ONCOGENE, V4, P189; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TWIST EM, 1981, J VIROL, V37, P239, DOI 10.1128/JVI.37.1.239-243.1981; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WUU KD, 1987, CANCER GENET CYTOGEN, V26, P279, DOI 10.1016/0165-4608(87)90062-8; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	42	153	156	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					765	770						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646986				2022-12-28	WOS:A1991GT82500012
J	HANNIG, G; OTTILIE, S; SCHARTL, M				HANNIG, G; OTTILIE, S; SCHARTL, M			CONSERVATION OF STRUCTURE AND EXPRESSION OF THE C-YES AND FYN GENES IN LOWER-VERTEBRATES	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CELLULAR SRC GENE; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; TRANSFORMED-CELLS; SEQUENCE; XIPHOPHORUS; ONCOGENE; PRODUCT; ADULT	The src-gene family in mammals and birds consists of 9 closely related protein tyrosine kinases. We have cloned the c-yes and fyn homologues of the src-family from the teleost fish Xiphophorus helleri. Both genes show a high degree of sequence conservation and exhibit all structural motifs diagnostic for functional src-like protein tyrosine kinases. Sequence comparisons revealed three domains (exon 2, exons 3-6, exons 7-12) which evolve at different rates. Both genes exhibit an identical expression pattern, with preferential expression in neural tissues. No transcripts of c-yes were found in liver which is contrary to the situation in higher vertebrates. In malignant melanoma, elevated levels of c-yes and fyn were detected indicating a possible function during secondary steps of tumor progression for src-related tyrosine kinases.	MAX PLANCK INST BIOCHEM,CTR GENE,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY	Max Planck Society				Schartl, Manfred/0000-0001-9882-5948				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IOTHARA S, 1978, JAPANESE J CANCER RE, V69, P825; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P105; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAUELER W, 1988, ONCOGENE, V3, P113; MAUELER W, 1988, ONCOGENE, V2, P421; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MONTELL C, 1983, NATURE, V305, P600, DOI 10.1038/305600a0; OHNO S, 1968, HEREDITAS-GENETISK A, V59, P169; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAULF F, 1989, ONCOGENE RES, V5, P39; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARTL M, 1982, DIFFERENTIATION, V23, P109, DOI 10.1111/j.1432-0436.1982.tb01273.x; SCHARTL M, 1989, ONCOGENE, V4, P1185; SCHARTL M, 1985, INT J CANCER, V36, P199, DOI 10.1002/ijc.2910360212; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SEKI T, 1985, JPN J CANCER RES, V76, P907; SEMBA K, 1985, SCIENCE, V227, P1038, DOI 10.1126/science.2983418; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; STEELE RE, 1989, ONCOGENE RES, V4, P223; STEELE RE, 1990, ONCOGENE, V5, P369; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; Tavolga W. N., 1949, Bulletin of the American Museum of Natural History, V94, P163; WALLBANK AM, 1966, NATURE, V209, P1265, DOI 10.1038/2091265a0; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHENG XF, 1989, ONCOGENE, V4, P99	50	24	29	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					361	369						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1707152				2022-12-28	WOS:A1991FT34400003
J	SORRENTINO, V; GIORGI, M; GEREMIA, R; BESMER, P; ROSSI, P				SORRENTINO, V; GIORGI, M; GEREMIA, R; BESMER, P; ROSSI, P			EXPRESSION OF THE C-KIT PROTOONCOGENE IN THE MURINE MALE GERM-CELLS	ONCOGENE			English	Note							SPOTTING W LOCUS; SPERMATOGENIC CELLS; TYROSINE KINASE; V-KIT; MOUSE; PURIFICATION; TISSUES; PRODUCT; FAMILY; ACID	The proto-oncogene c-kit encodes a transmembrane protein tyrosine kinase receptor. The c-kit gene has recently been shown to be allelic with the W locus. Mutations at the white spotting locus (W) affect various aspects of hematopoiesis, melanogenesis and gametogenesis during development and in the adult animal. We have investigated the expression of the proto-oncogene c-kit in mouse testicular cell populations. The c-kit mRNA was found to be expressed at high levels in spermatogonia, and at lower levels in meiotic pachytene spermatocytes. Moreover, two novel testis-specific c-kit transcripts of 3.5 and 2.3 kb are present in postmeiotic haploid germ cells. These results suggest a role of c-kit not only during testis development in the embryo, but also throughout all stages of male germ cell development after birth.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; UNIV ROMA TOR VERGATA 2,DIPARTIMENTO SAN PUBBL & BIOL CELLULARE,ROME,ITALY	Memorial Sloan Kettering Cancer Center; University of Rome Tor Vergata	SORRENTINO, V (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY.		Sorrentino, Vincenzo/A-4793-2014; Rossi, Pellegrino/AAA-7072-2019	Sorrentino, Vincenzo/0000-0002-8573-8631; GEREMIA, Raffaele/0000-0001-9056-6603; GIORGI, Mauro/0000-0002-2923-4893; ROSSI, PELLEGRINO/0000-0003-4796-327X				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BESMER P, 1983, J VIROL, V46, P606, DOI 10.1128/JVI.46.2.606-613.1983; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BUCCI LR, 1986, BIOL REPROD, V34, P195, DOI 10.1095/biolreprod34.1.195; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOUMBRE JL, 1954, J EXP ZOOL, V126, P277; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GEREMIA R, 1976, Bollettino di Zoologia, V43, P139; GRIPPO P, 1978, CELL DIFFER DEV, V7, P237, DOI 10.1016/0045-6039(78)90025-8; HARRISON DE, 1976, TRANSPLANTATION, V22, P42, DOI 10.1097/00007890-197607000-00007; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; McLaren A, 1980, GERM CELLS SOMA NEW; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; MEISTRICH ML, 1986, BIOL REPROD, V34, P17, DOI 10.1095/biolreprod34.1.17; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PONZETT C, 1987, MOL CELL BIOL, V5, P5301; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1970, REGULATION HEMATOPOI, P649; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; Silvers W.K., 1979, COAT COLORS MICE, P206; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; STEFANINI M, 1984, BIOL FERTILIZATION, V2, P3; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; [No title captured]	41	174	179	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					149	151						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1704118				2022-12-28	WOS:A1991EY03900021
J	SANTORO, M; ROSATI, R; GRIECO, M; BERLINGIERI, MT; DAMATO, GL; DEFRANCISCIS, V; FUSCO, A				SANTORO, M; ROSATI, R; GRIECO, M; BERLINGIERI, MT; DAMATO, GL; DEFRANCISCIS, V; FUSCO, A			THE RET PROTOONCOGENE IS CONSISTENTLY EXPRESSED IN HUMAN PHEOCHROMOCYTOMAS AND THYROID MEDULLARY CARCINOMAS	ONCOGENE			English	Note									NAPLES UNIV, FAC MED & CHIRURG 2, DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC, I-80131 NAPLES, ITALY; UNIV REGGIO CALABRIA, FAC MED & CHIRURG CATANZARO, IST ONCOL CLIN & SPERIMENTALE, I-88100 CATANZARO, ITALY	University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	SANTORO, M (corresponding author), NAPLES UNIV, CNR, CTR ENDOCRINOL & ONCOL SPERIMENTALE, VIA PANSINI 5, I-80131 NAPLES, ITALY.			Fusco, Alfredo/0000-0003-3332-5197; Grieco, Michele/0000-0002-4212-7814				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BONGARZONE I, 1989, ONCOGENE, V4, P1457; DEBUSTROS A, 1985, J BIOL CHEM, V260, P98; DEBUSTROS A, 1986, J BIOL CHEM, V261, P8036; DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; Leong S, 1981, ADV THYROID NEOPLASI, P95; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; NAKAMURA Y, 1989, GENOMICS, V5, P199, DOI 10.1016/0888-7543(89)90046-3; NELKIN BD, 1984, BIOCHEM BIOPH RES CO, V123, P648, DOI 10.1016/0006-291X(84)90278-X; Sambrook J, 1989, MOL CLONING LABORATO; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VECCHIO G, 1989, ONCOGENE, V4, P897	25	250	268	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1595	1598						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	1701232				2022-12-28	WOS:A1990EK50200022
J	MELLERICK, DM; OSBORN, M; WEBER, K				MELLERICK, DM; OSBORN, M; WEBER, K			ON THE NATURE OF SEROLOGICAL TISSUE POLYPEPTIDE ANTIGEN (TPA) - MONOCLONAL KERATIN-8, KERATIN-18, AND KERATIN-19 ANTIBODIES REACT DIFFERENTLY WITH TPA PREPARED FROM HUMAN CULTURED CARCINOMA-CELLS AND TPA IN HUMAN SERUM	ONCOGENE			English	Article									MAX PLANCK INST BIOPHYS CHEM, W-3400 GOTTINGEN, GERMANY	Max Planck Society								BAKER WC, 1988, J UROLOGY, V140, P436, DOI 10.1016/S0022-5347(17)41652-1; BEHAM A, 1986, VIRCHOWS ARCH A, V409, P641, DOI 10.1007/BF00713430; BJORKLUND B, 1957, INT ARCH ALLER A IMM, V10, P153, DOI 10.1159/000228374; BJORKLUND B, 1980, TUMORDIAGNOSTIK, P9; BJORKLUND B, 1980, TUMORDIAGNOSTIK, P78; BJORKLUND B, 1983, CANCER DETECT PREV, V6, P41; BJORKLUND B, 1973, IMMUNOLOGICAL TECHNI, P133; BJORKLUND V, 1982, ACTA PATH MICRO IM A, V90, P471; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASELITZ J, 1983, Applied Pathology, V1, P115; CHAN R, 1986, CANCER RES, V46, P6353; CLAUDI S, 1983, PROTIDES BIOL FLUIDS, V31, P457; DEBUS E, 1982, EMBO J, V1, P1641, DOI 10.1002/j.1460-2075.1982.tb01367.x; DEBUS E, 1984, AM J PATHOL, V114, P121; DOMAGALA W, 1986, ACTA CYTOL, V30, P225; DRAHOVSKY D, 1984, PROTIDES BIOL FLUIDS, V32, P719; FRANKE WW, 1981, J MOL BIOL, V153, P933, DOI 10.1016/0022-2836(81)90460-5; FRANKE WW, 1981, COLD SPRING HARB SYM, V46, P431, DOI 10.1101/SQB.1982.046.01.041; FRANKE WW, 1979, EXP CELL RES, V118, P95, DOI 10.1016/0014-4827(79)90587-1; FUCHS E, 1985, ANN NY ACAD SCI, V455, P436, DOI 10.1111/j.1749-6632.1985.tb50427.x; GEISLER N, 1986, J ULTRA MOL STRUCT R, V94, P239, DOI 10.1016/0889-1605(86)90070-4; GEISLER N, 1982, EMBO J, V1, P1649, DOI 10.1002/j.1460-2075.1982.tb01368.x; GEISLER N, 1982, NATURE, V296, P448, DOI 10.1038/296448a0; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; Geisler N., 1986, P41; GEISLER N, 1983, EMBO J, V2, P2059, DOI 10.1002/j.1460-2075.1983.tb01700.x; GEISLER N, 1985, J MOL BIOL, V182, P173, DOI 10.1016/0022-2836(85)90035-X; HANUKOGLU I, 1982, CELL, V31, P243, DOI 10.1016/0092-8674(82)90424-X; HANUKOGLU I, 1983, CELL, V33, P915, DOI 10.1016/0092-8674(83)90034-X; HATZFELD M, 1987, J MOL BIOL, V197, P237, DOI 10.1016/0022-2836(87)90122-7; HATZFELD M, 1987, THESIS U HEIDELBERG; HOLLMANN M, 1985, BIOCHEM BIOPH RES CO, V128, P34, DOI 10.1016/0006-291X(85)91640-7; INOUE M, 1985, CANCER, V55, P2618, DOI 10.1002/1097-0142(19850601)55:11<2618::AID-CNCR2820551114>3.0.CO;2-S; KIRSCH J, 1983, TUMORDIAGN THER, V4, P222; KREIENBERG R, 1985, ONKOLOGIE, V8, P253, DOI 10.1159/000215669; KUMAR S, 1981, BRIT J UROL, V53, P578, DOI 10.1111/j.1464-410X.1981.tb03264.x; KURKI P, 1983, J RHEUMATOL, V10, P558; KURKI P, 1984, ALCOHOL CLIN EXP RES, V8, P212, DOI 10.1111/j.1530-0277.1984.tb05841.x; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LEUBE RE, 1986, DIFFERENTIATION, V33, P69, DOI 10.1111/j.1432-0436.1986.tb00412.x; LONING T, 1983, INT J GYNECOL PATHOL, V2, P105; LUNING B, 1980, BIOCHIM BIOPHYS ACTA, V624, P90, DOI 10.1016/0005-2795(80)90228-7; LUNING B, 1983, ACTA CHEM SCAND B, V37, P731, DOI 10.3891/acta.chem.scand.37b-0731; LUNING B, 1985, PROTIDES BIOL FLUIDS, V32, P717; LUTHGENS M, 1983, CANCER DETECT PREV, V6, P51; LUTHGENS M, 1985, TUMORDIAGN THER, V6, P1; LUTHGENS M, 1980, TUMOR DIAGNOSTIK, V2, P63; MADRI JA, 1983, LAB INVEST, V48, P98; MAGIN TM, 1986, DIFFERENTIATION, V30, P254, DOI 10.1111/j.1432-0436.1986.tb00788.x; MAGIN TM, 1987, EMBO J, V6, P2607, DOI 10.1002/j.1460-2075.1987.tb02551.x; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MENENDEZBOTET CJ, 1978, CLIN CHEM, V24, P868; MERRILL WW, 1984, AM REV RESPIR DIS, V130, P905; Moll R, 1987, Curr Top Pathol, V77, P71; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MROSS KB, 1985, ONCOLOGY, V42, P288, DOI 10.1159/000226048; NATHRATH WBJ, 1985, J HISTOCHEM CYTOCHEM, V33, P99, DOI 10.1177/33.2.3968422; NELSON WJ, 1981, EUR J BIOCHEM, V116, P51, DOI 10.1111/j.1432-1033.1981.tb05299.x; OCHI Y, 1985, CLIN CHIM ACTA, V151, P157, DOI 10.1016/0009-8981(85)90319-5; OEHR P, 1982, TUMORDIAGN THER, V3, P195; OEHR P, 1984, NUC COMPACT, V15, P152; OEHR P, 1981, TUMORDIAGNOSTIK, V2, P283; OSBORN M, 1986, LAB INVEST, V55, P497; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; OSBORN M, 1982, PATHOL RES PRACT, V175, P128; PANUCCI A, 1986, J CLIN PATHOL, V39, P75, DOI 10.1136/jcp.39.1.75; PANUCCI A, 1985, BRIT J CANCER, V52, P801, DOI 10.1038/bjc.1985.262; PAULICK R, 1985, CANCER DETECT PREV, V8, P115; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; RASMUSON T, 1983, RECENT RES CANCER, V84, P331; REDELIUS P, 1980, ACTA CHEM SCAND B, V34, P265, DOI 10.3891/acta.chem.scand.34b-0265; ROSSITTO PV, 1988, J UROLOGY, V140, P431, DOI 10.1016/S0022-5347(17)41651-X; SALVATI F, 1985, CANCER DETECT PREV, V8, P111; SCHILLER DL, 1983, CELL BIOL INT REP, V7, P3, DOI 10.1016/0309-1651(83)90098-X; SCHLEGEL G, 1981, TUMORDIAGNOSTIK, V2, P6; SKRYTEN A, 1981, TUMORDIAGNOSTIK, V2, P117; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1980, P NATL ACAD SCI-BIOL, V77, P4534, DOI 10.1073/pnas.77.8.4534; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; SUN TT, 1985, ANN NY ACAD SCI, V455, P307, DOI 10.1111/j.1749-6632.1985.tb50419.x; TOH BH, 1979, CLIN EXP IMMUNOL, V37, P76; TOLLE HG, 1985, EUR J CELL BIOL, V38, P234; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSENG SCG, 1982, CELL, V30, P361, DOI 10.1016/0092-8674(82)90234-3; WEBER K, 1984, EMBO J, V3, P2707, DOI 10.1002/j.1460-2075.1984.tb02198.x; WEBER K, 1982, EMBO J, V1, P1155, DOI 10.1002/j.1460-2075.1982.tb00006.x; WEBER K, 1984, CANCER CELL, V1, P153; WIKLUND B, 1981, ACTA CHEM SCAND B, V35, P325, DOI 10.3891/acta.chem.scand.35b-0325	93	62	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1990	5	7					1007	1017						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695723				2022-12-28	WOS:A1990DP41500008
J	MONTENARH, M				MONTENARH, M			BIOCHEMICAL-PROPERTIES OF THE GROWTH SUPPRESSOR ONCOPROTEIN P53	ONCOGENE			English	Review							LARGE-T-ANTIGEN; CELLULAR TUMOR-ANTIGEN; TRANSFORMATION-RELATED PROTEIN; HEAT-SHOCK PROTEINS; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; VIRUS 40-TRANSFORMED CELLS; AMINO-ACID-SEQUENCE; SIMIAN VIRUS-40; MUTANT P53	The cellular p53 protein is so called because of its molecular weight as determined by SDS-polyacrylamide gel electrophoresis. It was originally classified as a nuclear oncogene product when it was shown by DNA transfection experiments that p53 is able to extend the lifespan of primary rodent cell cultures and to cooperate with an activated ras oncogene to achieve complete transformation of primary cells. However, there is now conclusive evidence that loss of normal p53 expression may be an important step in cell transformation and tumorigenesis. Furthermore, it has been shown that mutant p53 was used for the experiments demonstrating the immortalizing and transforming capacity of p53. Wild-type p53 seems to negatively regulate cell growth and division. So far, the basic function of p53 is not known. Biochemical variability seems to be a key feature of p53 and an understanding of biochemical variations in the p53 protein may contribute to an understanding of how p53 is regulated or how p53 may regulate cell proliferation. Thus, the present review will focus on the biochemical properties of p53.			MONTENARH, M (corresponding author), UNIV SAARLAND,BLDG 44,W-6650 HOMBURG,GERMANY.							ADDISON C, 1990, ONCOGENE, V5, P423; Anderson CW., 1986, CANC CELLS, V4, P395; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BENCHIMOL S, 1985, SOMAT CELL MOLEC GEN, V11, P505, DOI 10.1007/BF01534845; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BENDORI R, 1983, FEBS LETT, V162, P384; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLAIR ZM, 1988, ONCOGENE, V2, P579; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; CARROLL RB, 1982, J VIROL, V44, P565, DOI 10.1128/JVI.44.2.565-573.1982; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; COULIER F, 1985, EMBO J, V4, P3413, DOI 10.1002/j.1460-2075.1985.tb04098.x; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; CROOK T, 1991, ONCOGENE, V6, P1251; CZOSNEK HH, 1984, MOL CELL BIOL, V4, P1638, DOI 10.1128/MCB.4.8.1638; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFROMENTEL CC, 1992, GENE, V112, P241, DOI 10.1016/0378-1119(92)90383-Z; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FANNING E, 1981, J GEN VIROL, V55, P367, DOI 10.1099/0022-1317-55-2-367; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREED MI, 1983, J VIROL, V46, P1061, DOI 10.1128/JVI.46.3.1061-1065.1983; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IGUCHIARIGA SMM, 1988, ONCOGENE, V3, P509; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1992, BIOCHIM BIOPHYS ACTA, V1119, P11, DOI 10.1016/0167-4838(92)90227-5; KRAISS S, 1990, ONCOGENE, V5, P845; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KRAISS S, 1990, LEUKEMIA RES, V14, P1041, DOI 10.1016/0145-2126(90)90118-S; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEPPARD K, 1983, EMBO J, V2, P1457, DOI 10.1002/j.1460-2075.1983.tb01608.x; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1990, VIROLOGY, V176, P302, DOI 10.1016/0042-6822(90)90258-S; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MILNER J, 1989, ONCOGENE, V4, P665; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1985, VIROLOGY, V147, P206, DOI 10.1016/0042-6822(85)90240-5; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONTENARH M, 1987, J VIROL, V61, P940, DOI 10.1128/JVI.61.3.940-944.1987; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; MONTENARH M, 1986, J VIROL, V60, P761, DOI 10.1128/JVI.60.2.761-764.1986; MONTENARH M, 1989, ONCOGENE, V4, P379; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OREN M, 1983, P NATL ACAD SCI-BIOL, V80, P56, DOI 10.1073/pnas.80.1.56; OREN M, 1992, MOL CELL BIOL, V7, P661; ORTTER V, 1991, ADV CANCER RES, V57, P257; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PUVION E, 1988, EXP CELL RES, V177, P73, DOI 10.1016/0014-4827(88)90026-2; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIGAUDY P, 1989, NUCLEIC ACIDS RES, V17, P8375, DOI 10.1093/nar/17.20.8375; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROTTER V, 1984, MOL CELL BIOL, V4, P383, DOI 10.1128/MCB.4.2.383; ROTTER V, 1983, J IMMUNOL, V131, P329; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SANTOS M, 1984, J VIROL, V49, P50, DOI 10.1128/JVI.49.1.50-56.1984; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHMIEG FI, 1984, J VIROL, V52, P350, DOI 10.1128/JVI.52.2.350-355.1984; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1987, VIROLOGY, V160, P445; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; SYMONDS H, 1991, J VIROL, V65, P5417, DOI 10.1128/JVI.65.10.5417-5424.1991; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; VANROY F, 1984, MOL CELL BIOL, V4, P232, DOI 10.1128/MCB.4.2.232; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS NW, 1989, EXP CELL RES, V184, P316, DOI 10.1016/0014-4827(89)90331-5; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	156	97	100	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1673	1680						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501881				2022-12-28	WOS:A1992JJ37600001
J	KUSSICK, SJ; COOPER, JA				KUSSICK, SJ; COOPER, JA			PHOSPHORYLATION AND REGULATORY EFFECTS OF THE CARBOXY TERMINUS OF A DROSOPHILA-SRC HOMOLOG	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; C-SRC; TRANSFORMING PROTEIN; CELL-TRANSFORMATION; NUCLEOTIDE-SEQUENCE; RETROVIRUS VECTORS; GENE-PRODUCT; PP60C-SRC; ACTIVATION	The kinase activities of the vertebrate src family members are repressed by phosphorylation of a tyrosine residue in the carboxy-terminal `tail' of these molecules. To explore whether the tail of an invertebrate src homolog might also serve a regulatory function, we examined the ability of the carboxy terminus of a Drosophila src homolog (p62D), which contains a tyrosine homologous to those in the vertebrate src family members, to regulate the following molecules in mammalian fibroblasts: (1) a chimeric protein, p60CD, containing the amino terminus and catalytic domains of chicken p60c-src joined to the C-terminus of p62D; and (2) full-length p62D itself. By a variety of criteria p60CD appears to be a partially, rather than fully, repressed form of p60c-src. Phosphopeptide mapping indicates that partial repression correlates with partial phosphorylation of the tyrosine in the p62D tail of the chimera. Phosphorylation of the tail may also regulate full-length p62D. Expression of p62D in fibroblasts does not affect cell morphology or the overall abundance of tyrosine-phosphorylated proteins. The molecule is phosphorylated at its C-terminal tyrosine (Tyr-547), but not at its in vitro autophosphorylation sites, suggesting that it is catalytically repressed in fibroblasts. Expression of a truncated p62D mutant lacking Tyr-547 is associated with a clear alteration in cellular morphology and a two- to threefold increase in cellular phosphotyrosine levels. These results suggest that phosphorylation of the C-terminal tyrosine of the tail of an invertebrate src-like kinase can repress the activity of adjacent catalytic domains.	UNIV WASHINGTON,SCH MED,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	KUSSICK, SJ (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PATHOL,1124 COLUMBIA ST,SEATTLE,WA 98195, USA.				NCI NIH HHS [CA-41072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUSICK SJ, 1991, NATO ASI SERIES H, V56, P295; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1988, MOL CELL BIOL, V8, P3560, DOI 10.1128/MCB.8.8.3560; MACAULEY A, 1990, New Biologist, V2, P828; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807	38	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1577	1586						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630818				2022-12-28	WOS:A1992JE81300014
J	EYCHENE, A; BARNIER, JV; DEZELEE, P; MARX, M; LAUGIER, D; CALOGERAKI, I; CALOTHY, G				EYCHENE, A; BARNIER, JV; DEZELEE, P; MARX, M; LAUGIER, D; CALOGERAKI, I; CALOTHY, G			QUAIL NEURORETINA C-RMIL(B-RAF) PROTOONCOGENE CDNAS ENCODE 2 PROTEINS OF 93.5-KDA AND 95-KDA RESULTING FROM ALTERNATIVE SPLICING	ONCOGENE			English	Article							AVIAN LYMPHOMATOSIS VIRUS; COMPLETE CODING SEQUENCE; ROUS-SARCOMA VIRUS; C-MIL; KINASE-ACTIVITY; RAF ONCOGENE; TRANSFORMING ACTIVITY; CELL-PROLIFERATION; DNA FRAGMENTS; V-MIL	c-Rmil is the cellular allele of the v-Rmil oncogene transduced during in vitro passaging of Rous-associated virus type 1 in chicken embryonic neuroretina (NR) cells. The c-Rmil proto-oncogene is the avian homolog of the mammalian B-raf gene and belongs to the mil/raf oncogene family of serine/threonine protein kinases. The c-Rmil/B-raf gene is preferentially expressed in avian and mammalian neural tissues. Two c-Rmil cDNA species, resulting from an alternative splicing mechanism, were isolated from quail embryonic NR cDNA libraries. They encode two proteins of 767 and 807 amino acids that differ by the presence of an alternative exon, located upstream of the kinase domain. Expression of these cDNAs in COS-1 cells leads to the synthesis of two proteins with apparent molecular weights of 93.5 and 95 kDa, recognized by an Rmil-specific antiserum. Both proteins are phosphorylated in an immune complex kinase assay. A protein of 94 kDa is also immunoprecipitated in avian NR cells and is identical to the 93.5-kDa protein expressed in COS-1 cells, as shown by Staphylococcus aureus V8 protease mapping. The c-Rmil proteins contain the three conserved regions previously identified in mil/raf protein kinases. In addition, they contain amino-terminal sequences that are not present in the other mil/raf proteins identified to date. These additional sequences may define a novel functional domain for c-Rmil/B-raf and could play a role in signal transduction in neural cells.	CTR UNIV ORSAY,INST CURIE,CNRS,UNITE RECH 1443,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P1213; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; DOZIER C, 1991, ONCOGENE, V6, P1307; EYCHENE A, 1989, NUCLEIC ACIDS RES, V17, P1250, DOI 10.1093/nar/17.3.1250; EYCHENE A, 1990, J VIROL, V64, P231; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ISHIKAWA F, 1988, ONCOGENE, V3, P653; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KOENEN M, 1988, ONCOGENE, V2, P179; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Maniatis T., 1982, MOL CLONING; MARK GE, 1986, P NATL ACAD SCI USA, V83, P6312, DOI 10.1073/pnas.83.17.6312; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PATCHINSKY T, 1986, MOL CELL BIOL, V6, P739; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STORM SM, 1990, ONCOGENE, V5, P345; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	56	33	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1315	1323						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620546				2022-12-28	WOS:A1992HZ97100009
J	CESANO, A; HOXIE, JA; LANGE, B; NOWELL, PC; BISHOP, J; SANTOLI, D				CESANO, A; HOXIE, JA; LANGE, B; NOWELL, PC; BISHOP, J; SANTOLI, D			THE SEVERE COMBINED IMMUNODEFICIENT (SCID) MOUSE AS A MODEL FOR HUMAN MYELOID LEUKEMIAS	ONCOGENE			English	Article							NUDE-MICE; HU MOUSE; HIV-INFECTION; CELL-LINES; T LEUKEMIA; DIFFERENTIATION; GROWTH; TRANSPLANTATION; LYMPHOCYTES; SEQUENCES	Recent work has demonstrated the ability of lymphoblastic leukemias of pre-B- and T-cell origin to grow in severe combined immunodeficient (SCID) mice with a pattern reminiscent of the human clinical disease. Here, we investigated the possibility of engrafting human myeloid leukemias using both established cell lines and primary patient material. Whereas the two growth factor-independent cell lines K562 and U937 grew aggressively and induced leukemia in these animals, three other myeloid cell lines which require interleukin 3 or granulocyte-macrophage colony-stimulating factor for continuous growth in vitro failed to induce disease. Primary bone marrow and peripheral blood cells from five out of seven patients with different types of myeloid leukemias (undifferentiated, megakaryoblastic, monoblastic and chronic myelogenous leukemia in blast crisis) induced patterns of leukemic infiltration that were distinct for each leukemia subtype. The diagnosis of leukemia in SCID mice was established by microscopic detection of myeloblasts in the bone marrow, peripheral blood and, in some instances, in extramedullary sites, including the central nervous system and gonads. The karyotype and phenotype of the blasts recovered from mouse tissues were identical to those of the original patient cells. Moreover, human specific ALU sequences were amplified from the bone marrow DNA by polymerase chain reaction. Despite their ability to grow in vivo by serial transfers in SCID mice, the leukemic cells recovered from mouse tissues could not be maintained in vitro, even in the presence of recombinant cytokines. Overall, these data indicate that the SCID mouse may represent a useful animal model for human myeloid leukemias and for the development of new pharmacological and molecular approaches to therapy.	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA; HOSP UNIV PENN, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA047589, R35CA042232] Funding Source: NIH RePORTER; NCI NIH HHS [CA42232, CA47589] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BANKERT RB, 1989, CURR TOP MICROBIOL, V152, P201; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CANNON MJ, 1990, J CLIN INVEST, V85, P1333, DOI 10.1172/JCI114573; CESANO A, 1991, BLOOD, V77, P2463; CHARLEY MR, 1990, J INVEST DERMATOL, V94, P381, DOI 10.1111/1523-1747.ep12874500; CLUTTERBUCK RD, 1985, LEUKEMIA RES, V9, P1511, DOI 10.1016/0145-2126(85)90044-X; DICK JE, 1991, CANCER CELL-MON REV, V3, P39; DORSHKIND K, 1989, CURR TOP MICROBIOL, V152, P169; DORSHKIND K, 1984, J IMMUNOL, V132, P1804; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; DUCHOSAL MA, 1990, J EXP MED, V172, P985, DOI 10.1084/jem.172.3.985; FRANKS CR, 1977, BRIT J CANCER, V35, P697, DOI 10.1038/bjc.1977.107; GHOSE T, 1988, AM J HEMATOL, V28, P146, DOI 10.1002/ajh.2830280304; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; LANGE B, 1987, BLOOD, V70, P192; LOZZIO BB, 1976, J EXP MED, V143, P225, DOI 10.1084/jem.143.1.225; MACHADO EA, 1984, BLOOD, V63, P1015; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1989, CURR TOP MICROBIOL, V152, P183; MOSIER DE, 1990, J CLIN IMMUNOL, V10, P185, DOI 10.1007/BF00918650; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; OCONNOR R, 1990, J IMMUNOL, V145, P3779; OCONNOR R, 1991, BLOOD, V77, P1534; SANTOLI D, 1990, J IMMUNOL, V144, P4703; SILVER SM, 1987, BLOOD, V69, P1031; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TIGHE H, 1990, EUR J IMMUNOL, V20, P1843, DOI 10.1002/eji.1830200832; WATANABE S, 1980, CANCER RES, V40, P2588	38	82	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					827	836						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570153				2022-12-28	WOS:A1992HP64200001
J	BURNS, PA; JACK, A; NEILSON, F; HADDOW, S; BALMAIN, A				BURNS, PA; JACK, A; NEILSON, F; HADDOW, S; BALMAIN, A			TRANSFORMATION OF MOUSE SKIN ENDOTHELIAL-CELLS INVIVO BY DIRECT APPLICATION OF PLASMID DNA ENCODING THE HUMAN T24 H-RAS ONCOGENE	ONCOGENE			English	Article							BLADDER-CARCINOMA ONCOGENE; MURINE SARCOMA-VIRUS; EMBRYO FIBROBLASTS; TRANSGENIC MICE; TUMOR PROMOTERS; POINT MUTATION; HARVEY; GENE; CARCINOGENESIS; ACTIVATION	Plasmid DNA containing the human T24 H-ras oncogene, with or without viral transcriptional enhancer sequences, was applied to scarified mouse skin, followed by multiple treatments with the tumour promoter 12-O-tetradecanoyl-phorbol-13-acetate. This resulted in the formation of vasoformative tumours histologically characterized as lymphangiosarcomas. All of the animals treated developed cystic fluid-filled swellings. Polymerase chain reaction analysis revealed the presence of human H-ras sequences within the cystic fluid from 3 out of 4 swellings. An endothelial cell line established from the cystic fluid removed from one of these swellings was found to contain human H-ras sequences and to express the mutant human p21ras. Injection of the cell line into nude mice, or adult syngeneic mice, resulted in the formation of aggressive angiosarcomas. Further experiments showed that 12-O-tetradecanol-phorbol-13-acetate promotion is not required for tumour formation and would appear to reduce the yield of tumours. These results indicate that a single application of the human H-ras oncogene is sufficient to induce endothelial cell transformation in vivo, even in the absence of any further promotional stimulus.	UNIV LEEDS, DEPT PATHOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds	BURNS, PA (corresponding author), BEATSON INST CANC RES, CRC BEATSON LABS, GARSCUBE ESTATE, GLASGOW G61 1BD, SCOTLAND.							ARMES J, 1989, ADV CANCER RES, V53, P73; ASSELIN C, 1984, MOL CELL BIOL, V4, P755, DOI 10.1128/MCB.4.4.755; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DONOGHUE DJ, 1984, NATURE, V308, P748, DOI 10.1038/308748a0; DOTTO GP, 1985, NATURE, V318, P472; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FUNG YKT, 1983, P NATL ACAD SCI-BIOL, V80, P353, DOI 10.1073/pnas.80.2.353; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; KATZ L, 1973, J BACTERIOL, V114, P577, DOI 10.1128/JB.114.2.577-591.1973; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAITOH A, 1990, ONCOGENE, V5, P1195; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WILLIAMS RL, 1988, CELL, V52, P121; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614	29	22	23	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					1973	1978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945407				2022-12-28	WOS:A1991GX11900005
J	JEYAPAUL, J; SESHAMMA, T; KHAN, SA				JEYAPAUL, J; SESHAMMA, T; KHAN, SA			SYNTHETIC HIV-1 TAT CAN DISSOCIATE HELA NUCLEAR-PROTEIN TAR RNA COMPLEXES INVITRO - A NOVEL TAT-NUCLEAR PROTEIN-INTERACTION	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; MUTATIONAL ANALYSIS; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE SEQUENCE; FUNCTIONAL DOMAINS; LOOP SEQUENCE; NASCENT RNA; TYPE-1	Multiple binding of Tat and nuclear protein(s) to HIV-1 TAR RNA appears to be essential for the Tat-mediated trans-activation. As synthetic Tat-(1-47), which lacks the basic domain and does not bind TAR RNA in vitro, efficiently transactivated HIV-1 LTR in HeLa nuclear extracts, we hypothesized that Tat might trans-activate by interaction with TAR RNA via a host nuclear protein. The role of nuclear proteins in Tat-TAR interaction was examined through evaluation of several synthetic Tat peptides for ability to bind TAR RNA in vitro both in the presence and in the absence of HeLa nuclear proteins. Our data show that both Tat-(1-47) and Tat-(1-86) interact with TAR RNA-bound nuclear proteins, leading to dissociation of the nuclear protein-TAR RNA complexes; the N-terminal sequence of Tat appears to be involved in this interaction. Thus, after binding to TAR RNA, Tat can interact with a proximal TAR-bound nuclear protein and the resulting Tat-nuclear protein complex, now displaced from TAR, may initiate a facile and rapid assembly of the RNA polymerase II transcription complex. This study thus recognizes a novel interaction between Tat and a nuclear protein(s). Here we propose that the interaction of Tat with a nuclear protein(s) occurring on TAR RNA may be one of several steps in the mechanism of Tat-mediated trans-activation of the HIV-1 LTR.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NIAID NIH HHS [AI27422, AI25380] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027422, P01AI025380] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DINGWALL C, 1989, CELL, V57, P1155; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPPAPORT J, 1989, New Biologist, V1, P101; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; RUBEN S, 1989, J VIROL, V63, P1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002	48	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1507	1513						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923518				2022-12-28	WOS:A1991GX27400003
J	WIMAN, KG; MAGNUSSON, KP; RAMQVIST, T; KLEIN, G				WIMAN, KG; MAGNUSSON, KP; RAMQVIST, T; KLEIN, G			MUTANT P53 DETECTED IN A MAJORITY OF BURKITT-LYMPHOMA CELL-LINES BY MONOCLONAL-ANTIBODY PAB240	ONCOGENE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; INCREASED EXPRESSION; TRANSFORMED-CELLS; FRIEND-VIRUS; LUNG-CANCER; NUDE-MICE; GENE; ONCOGENE	The status of the p53 gene in lymphoblastoid cell lines (LCLs) and Burkitt lymphoma cell lines (BLs) was investigated. Southern blot analysis demonstrated that no major deletions or rearrangements had occurred in the p53 gene in any of the cell lines. The p53 protein was examined by immunoprecipitation using two monoclonal anti-p53 antibodies. PAb1801 recognizes both wild-type and mutant p53. PAb240 reacts exclusively with mutant p53. Fourteen LCLs reacted with PAb1801, but not with PAb240, suggesting that none of them expressed mutant p53. However, one LCL had mutant p53. This LCL differs from other LCLs in that it grows to higher cell densities and has a higher agarose clonability. All BLs expressed p53. Out of 15 BLs, nine (60%) carried mutant p53, as indicated by their reactivity with PAb240. Among the nine BLs with mutant p53, eight were Epstein-Barr virus (EBV)-positive. Three out of the six BLs with wild-type p53 were EBV-positive. Multiple EBV-converted sublines all exhibited the same p53 status as the parental line. Our results indicate that the p53 gene is mutated in a majority of Burkitt lymphoma cell lines (BLs), and suggest that p53 mutation contributes to the malignant phenotype of these cell lines.			WIMAN, KG (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011; Wiman, Klas/AAB-8399-2021	Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826; Wiman, Klas/0000-0002-7113-524X	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2 R01 CA 30264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DILLNER J, 1988, ADV CANCER RES, V50, P95, DOI 10.1016/S0065-230X(08)60436-4; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EPSTEIN MA, 1966, J NATL CANCER I, V37, P547; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRESEN KO, 1976, INT J CANCER, V17, P161, DOI 10.1002/ijc.2910170203; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GIOVANELLA B, 1979, INT J CANCER, V24, P103, DOI 10.1002/ijc.2910240118; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINUMA Y, 1967, P SOC EXP BIOL MED, V124, P107; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LENOIR GM, 1985, BURKITTS LYMPHOMA HU, P309; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUCCI MG, 1987, P NATL ACAD SCI USA, V84, P4567, DOI 10.1073/pnas.84.13.4567; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MENEZES J, 1975, BIOMEDICINE, V22, P276; MILLER CW, 1990, CANCER RES, V50, P7950; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROONEY CM, 1984, INT J CANCER, V34, P339, DOI 10.1002/ijc.2910340310; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; Sambrook J, 1989, MOL CLONING LABORATO; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VENTURELLI D, 1988, HAEMATOLOGICA, V73, P259; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	65	90	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1633	1639						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923530				2022-12-28	WOS:A1991GX27400019
J	NEUBERG, M; SCHUERMANN, M; MULLER, R				NEUBERG, M; SCHUERMANN, M; MULLER, R			MUTAGENESIS OF THE DNA CONTACT SITE IN FOS PROTEIN - COMPATIBILITY WITH THE SCISSORS GRIP MODEL AND REQUIREMENT FOR TRANSFORMATION	ONCOGENE			English	Article							HYPOTHETICAL STRUCTURE COMMON; TRANSCRIPTION FACTOR AP-1; LEUCINE ZIPPER MOTIF; ONCOGENE V-JUN; C-FOS; BINDING PROTEINS; GENE-EXPRESSION; AUTO-REGULATION; CELLULAR GENES; NUCLEAR FACTOR	To elucidate the mechanisms involved in the transformation by fos we have initiated a study pertaining to the identification of molecular functions of Fos protein that are crucial for transformation. We have previously reported that the presence of an intact leucine zipper in Fos is an absolute requirement for the induction of transformation, but that the autorepression function of Fos is dispensable. We now show that Fos protein also needs an intact DNA (TRE)-binding site to be able to transform. Amino acid substitutions in this domain of Fos which impair DNA binding also destroy the transforming potential of Fos, suggesting that the interaction of Fos-Jun complexes with TREs may be a crucial part of Fos-induced transformation. This hypothesis is further strengthened by our observation that Fos and Jun can cooperate in the induction of transformation. We show that a Fos protein which contains a Jun leucine zipper and is thus capable of dimerization is still dependent on the presence of exogenous Jun to induce transformation. The critical positions in the Fos DNA-binding site include those which the 'scissors grip' model predicts to be crucial, although the DNA-binding site in Fos seems to extend beyond the basic region into an adjacent cluster of acidic amino acids.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FU TH, 1989, MOL CELL BIOL, V9, P1120; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALAZONETIS TD, 1988, CELL, V55, P916; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATSUI M, 1990, ONCOGENE, V5, P249; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MULLER R, 1984, EMBO J, V3, P1121, DOI 10.1002/j.1460-2075.1984.tb01939.x; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NEUBERG M, 1989, NATURE, V341, P2243; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHEURMANN M, 1989, CELL, V56, P507; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	60	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1325	1333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1909428				2022-12-28	WOS:A1991GX27200005
J	NIMMO, ER; SANDERS, PG; PADUA, RA; HUGHES, D; WILLIAMSON, R; JOHNSON, KJ				NIMMO, ER; SANDERS, PG; PADUA, RA; HUGHES, D; WILLIAMSON, R; JOHNSON, KJ			THE MEL GENE - A NEW MEMBER OF THE RAB/YPT CLASS OF RAS-RELATED GENES	ONCOGENE			English	Article							GTP-BINDING-PROTEINS; HUMAN-MALIGNANT MELANOMA; CELL-LINE; MOLECULAR-CLONING; DNA-BINDING; YEAST YPT1; C-MEL; TRANSLOCATION; CHROMOSOME-19; FAMILY	The MEL gene was identified following transfection of NIH3T3 mouse fibroblasts with DNA from a human melanoma cell line. The human MEL gene has been localized to 19cen-p13.2, a region in which translocation breakpoints occur in a number of malignancies. We have identified and sequenced human and mouse MEL cDNA clones which show homology of 92% and 96% at the nucleotide and amino acid levels respectively. The predicted human MEL protein shows only six amino acid differences between it and the recently described dog RAB8 protein. All of these changes occur in the 30 amino acids at the C-terminal of these proteins. MEL is similar to the RAB/YPT proteins in the region corresponding to the putative effector domain, suggesting that they may interact with the same cellular substrates. However, MEL contains a C-terminal CAAX motif in common with the majority of the RAS superfamily, unlike YPT1 and the majority of the RAB proteins.	CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND; UNIV LONDON IMPERIAL COLL SCI & TECHNOL,ST MARYS HOSP,SCH MED,BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND; HEATH PK HOSP,DEPT HAEMATOL,LRF PRELEUKAEMIA UNIT,CARDIFF CF4 4XN,WALES; UNIV SURREY,DEPT MICROBIOL,GUILDFORD GU2 5XH,SURREY,ENGLAND	Imperial College London; Imperial College London; University of Surrey			Padua, Rose Ann/GVT-5961-2022; PADUA, Rose Ann/E-8621-2019	PADUA, Rose Ann/0000-0001-9964-7864; johnson, keith/0000-0002-8578-5921				BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CAVANNA JS, 1990, GENOMICS, V7, P12, DOI 10.1016/0888-7543(90)90513-T; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NIMMO E, 1989, HUM GENET, V81, P382, DOI 10.1007/BF00283697; PADUA RA, 1984, NATURE, V311, P671, DOI 10.1038/311671a0; PARMITER AH, 1986, CANCER RES, V46, P1526; ROUSSEAUMERCK MF, 1989, GENOMICS, V5, P694, DOI 10.1016/0888-7543(89)90110-9; SALTMAN DL, 1990, GENE CHROMOSOME CANC, V2, P259, DOI 10.1002/gcc.2870020402; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SPURR NK, 1986, SOMAT CELL MOLEC GEN, V12, P637, DOI 10.1007/BF01671949; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204	33	24	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1347	1351						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886711				2022-12-28	WOS:A1991GX27200009
J	MORISHITA, K; PARGANAS, E; PARHAM, DM; MATSUGI, T; IHLE, JN				MORISHITA, K; PARGANAS, E; PARHAM, DM; MATSUGI, T; IHLE, JN			THE EVI-1 ZINC FINGER MYELOID TRANSFORMING GENE IS NORMALLY EXPRESSED IN THE KIDNEY AND IN DEVELOPING OOCYTES	ONCOGENE			English	Note									ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT PATHOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center			Parham, David M./AAN-1059-2020	Parham, David M./0000-0002-6912-9748	NCI NIH HHS [CA51020, P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; HONDA BM, 1980, CELL, V22, P19203; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; IHLE JN, 1989, INT J CELL CLONING, V1, P1; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, ONCOGENE RES, V2, P219; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; RUIZ IAA, 1987, EMBO J, V6, P3065	15	64	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1419	1423						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699199				2022-12-28	WOS:A1990EC24100023
J	IWAMOTO, T; TAKAHASHI, M; ITO, M; HAMAGUCHI, M; ISOBE, K; MISAWA, N; ASAI, JP; YOSHIDA, T; NAKASHIMA, I				IWAMOTO, T; TAKAHASHI, M; ITO, M; HAMAGUCHI, M; ISOBE, K; MISAWA, N; ASAI, JP; YOSHIDA, T; NAKASHIMA, I			ONCOGENICITY OF THE RET TRANSFORMING GENE IN MMTV/RET TRANSGENIC MICE	ONCOGENE			English	Article									NAGOYA UNIV,SCH MED,DEPT PATHOL 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DIS MECHANISM & CONTROL RES INST,SHOWA KU,NAGOYA,AICHI 466,JAPAN; AICHI CANC CTR,RES CTR,EXPTL PATHOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Nagoya University; Nagoya University; Aichi Cancer Center	IWAMOTO, T (corresponding author), NAGOYA UNIV,SCH MED,DEPT IMMUNOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN.		TAKAHASHI, Masahide/I-7244-2014; isobe, ken-ichi/A-6685-2011; Takahashi, Masahide/AAN-4770-2020	isobe, ken-ichi/0000-0002-8150-2496; Takahashi, Masahide/0000-0002-2803-2683				ANDERSON MLM, 1985, NUCLEIC ACID HYBRIDI, P73; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; Davis LG, 1986, BASIC METHODS MOL BI, P42; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HOGAN B, 1986, MANIPULATING MOUSE E, P79; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; LAND H, 1986, ONCOGENES GROWTH CON, P304; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6	23	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					535	542						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1691479				2022-12-28	WOS:A1990DB85300012
J	CHEN, XR; AZIZKHAN, JC; LEE, DC				CHEN, XR; AZIZKHAN, JC; LEE, DC			THE BINDING OF TRANSCRIPTION FACTOR SP1 TO MULTIPLE SITES IS REQUIRED FOR MAXIMAL EXPRESSION FROM THE RAT TRANSFORMING GROWTH-FACTOR ALPHA-PROMOTER	ONCOGENE			English	Article							SPECIFICALLY STIMULATES TRANSCRIPTION; REDUCTASE GENE PROMOTER; EPITHELIAL-CELL LINE; FACTOR RECEPTOR GENE; RNA POLYMERASE-II; C-FOS GENE; TGF-ALPHA; TRANSGENIC MICE; MESSENGER-RNA; HEPATOCELLULAR-CARCINOMA	Transcription from the rat transforming growth factor-alpha (TGF-alpha) promoter initiates at multiple sites within a 200-bp G+C-rich region that lacks TATA and CAAT motifs but contains multiple potential binding sites for the transcription factor Sp1. In the present study, we used deletion analysis to establish the 5' boundary of sequences required for efficient transcription from the predominant - 58 start site. We then examined the functional activity of several putative Spl binding sites that occur within the transcriptionally important region downstream from - 155. In the presence of either crude HeLa cell extract or purified Sp1 protein, two double-stranded oligonucleotides from this region, each of which contains three Spl elements, both displayed gel mobility shifts that were specifically inhibited in the presence of excess bona fide Spl-binding sequence from the hamster dihydrofolate reductase (DHFR) gene. Methylation interference analysis of the major gel-shift complex produced with one of these oligonucleotides revealed a series of critical guanine residues located in, or adjacent to, one of the putative Sp1 recognition elements. rhe functional importance of Sp1 binding was confirmed by these findings that transcription in vitro from the - 58 start site was inhibited in the presence of excess consensus Sp1-binding sequence and that coexpression of Spl dramatically induced TGF-alpha promoter-directed chloramphenicol acetyl transferase (CAT) expression in transfected Drostophila Schneider cells that otherwise lack functional Sp1. Additionally, the introduction of mutations into any of several putative Spl elements inhibited transcription in vitro from the - 58 site, with the most proximal element tested having the largest effect. Sequential mutation of more distal elements produced a synergistic inhibition of transcription, suggesting that cooperative interactions between Spl sites are necessary for full expression from the TGF-alpha promoter.	UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA-43793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1988, CANCER RES, V48, P5023; AZIZKHAN JC, 1986, BIOCHEMISTRY-US, V25, P6228, DOI 10.1021/bi00368a059; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1987, CANCER RES, V47, P707; DERYNCK R, 1986, J CELL BIOCHEM, V32, P293, DOI 10.1002/jcb.240320406; DICKSON RB, 1986, CANCER RES, V46, P1707; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GODWIN AK, 1990, ONCOGENE, V5, P1231; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENNINGHAUSEN L, 1987, METHOD ENZYMOL, V152, P725; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, NEW FRONTIERS STUDY, P87; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1989, CURRENT PROTOCOLS MO, P481; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LIU C, 1988, CANCER RES, V48, P850; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; LOBB DK, 1989, BIOL REPROD, V40, P1087, DOI 10.1095/biolreprod40.5.1087; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARCO ED, 1989, ONCOGENE, V4, P831; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RAJA RH, 1991, MOL ENDOCRINOL, V5, P514, DOI 10.1210/mend-5-4-514; RAYMOND VW, 1989, CANCER RES, V49, P3608; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SAMSOONDAR J, 1986, J BIOL CHEM, V261, P4408; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SKINNER MK, 1989, ENDOCRINOLOGY, V124, P845, DOI 10.1210/endo-124-2-845; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YEH YC, 1987, CANCER RES, V47, P896; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	79	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1805	1815						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501890				2022-12-28	WOS:A1992JJ37600017
J	GODBOUT, R; MIYAKOSHI, J; DOBLER, KD; ANDISON, R; MATSUO, K; ALLALUNISTURNER, MJ; TAKEBE, H; DAY, RS				GODBOUT, R; MIYAKOSHI, J; DOBLER, KD; ANDISON, R; MATSUO, K; ALLALUNISTURNER, MJ; TAKEBE, H; DAY, RS			LACK OF EXPRESSION OF TUMOR-SUPPRESSOR GENES IN HUMAN-MALIGNANT GLIOMA CELL-LINES	ONCOGENE			English	Article							RETINOBLASTOMA-SUSCEPTIBILITY GENE; HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; SV40 LARGE-T; SV40-TRANSFORMED CELLS; HUMAN FIBROBLASTS; ESCHERICHIA-COLI; CARCINOMA-CELLS; MESSENGER-RNA; P53 MUTATIONS; RB1 GENE	Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon-alpha and beta (IFNA, IFNB) genes and lack of O6-methylguanine-DNA methyltransferase (MGMT) expression. Yet, in the studies performed to date, the relationship between these alterations has not been addressed. In this report, we have studied gene expression in 29 malignant glioma cell lines and have determined that, although loss of the interferon genes and loss of RB, p53 and MGMT mRNAs are frequent events, combinations of genetic alterations involving these four proven or putative tumor-suppressor genes are relatively infrequent. The exception was loss of RB mRNA, which may be associated with lack of MGMT mRNA.	CROSS CANC INST,DEPT MED,MOLEC GENET & CARCINOGENESIS LAB,11560 UNIV AVE,EDMONTON T6G 1Z2,ALBERTA,CANADA; CROSS CANC INST,DEPT RADIAT ONCOL,RADIOBIOL LAB,EDMONTON T6G 1Z2,ALBERTA,CANADA; KYOTO UNIV,FAC MED,DEPT ANGEW PHYS,KYOTO 606,JAPAN	University of Alberta; University of Alberta; Kyoto University			Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIGNER SH, 1988, CANCER RES, V48, P405; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DAY RS, 1979, NATURE, V279, P797, DOI 10.1038/279797a0; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DAY RS, 1974, CANCER RES, V34, P1965; DAY RS, 1991, MUTAT RES, V254, P153, DOI 10.1016/0921-8777(91)90006-B; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORNACE AJ, 1990, CANCER RES, V50, P7908; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FULTS D, 1989, CANCER RES, V49, P6572; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARDNER E, 1991, GENOMICS, V11, P475, DOI 10.1016/0888-7543(91)90162-8; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; GOEDDEL DV, 1980, NATURE, V287, P411, DOI 10.1038/287411a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JAMES CD, 1988, CANCER RES, V48, P5546; JAMES CD, 1991, CANCER RES, V51, P1684; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KOIKE G, 1990, J BIOL CHEM, V265, P14754; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MIYAKOSHI J, 1991, MUTAT RES, V254, P55, DOI 10.1016/0921-8777(91)90040-V; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIEPER RO, 1991, CANCER COMMUN, V3, P241, DOI 10.3727/095535491820873092; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; Ponten J, 1975, HUMAN TUMOR CELLS IN, P175, DOI [10.1007/9781-47571647-4_7, DOI 10.1007/9781-47571647-4_7]; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SARIBAN E, 1987, CANCER RES, V47, P3988; SCUDIERO DA, 1984, CANCER RES, V44, P961; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SHRIVASTAVA S, 1990, NATURE, V348, P747; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VENTER DJ, 1991, ONCOGENE, V6, P445; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3863; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; YOKOTA J, 1988, ONCOGENE, V3, P471; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	57	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1879	1884						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501894				2022-12-28	WOS:A1992JJ37600026
J	MORGAN, IM; RANSONE, LJ; BOS, TJ; VERMA, IM; VOGT, PK				MORGAN, IM; RANSONE, LJ; BOS, TJ; VERMA, IM; VOGT, PK			TRANSFORMATION BY JUN - REQUIREMENT FOR LEUCINE ZIPPER, BASIC REGION AND TRANSACTIVATION DOMAIN AND ENHANCEMENT BY FOS	ONCOGENE			English	Article							C-JUN; DNA-BINDING; GLUCOCORTICOID RECEPTOR; ONCOGENE JUN; FACTOR AP-1; V-JUN; PROTEINS; ACTIVATION; HETERODIMER; EXPRESSION	Mutants in the leucine zipper and basic regions of mouse c-jun were tested for transformation in chicken embryo fibroblast cultures. Reduction or elimination of the ability of Jun to dimerize or to bind to DNA severely decreased transformation. A chicken v-jun gene from which the major transactivation domain was deleted also failed to transform. We conclude that an intact leucine zipper, basic region and transactivation domain are required for Jun-induced oncogenic transformation. Coexpression of chicken c-Fos increased formation of transformed foci by Jun proteins of moderate to low oncogenic potency but had no effect on highly transforming Jun. Chicken c-Fos could also transform chicken embryo fibroblasts on its own, albeit after prolonged culture and at a low efficiency.	NORRIS CANC CTR, LOS ANGELES, CA 90033 USA; SALK INST BIOL STUDIES, MOLEC BIOL & VIRUS LAB, LA JOLLA, CA 92186 USA; EASTERN VIRGINIA MED SCH, DEPT MICROBIOL & IMMUNOL, NORFOLK, VA 23501 USA	Salk Institute; Eastern Virginia Medical School	MORGAN, IM (corresponding author), UNIV SO CALIF, SCH MED, DEPT MICROBIOL, LOS ANGELES, CA 90033 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ANGEL P, 1989, New Biologist, V1, P35; BENBROOK DM, 1990, ONCOGENE, V5, P295; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NISHIMURA T, 1988, ONCOGENE, V3, P659; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAKAI M, 1989, CANCER RES, V49, P5633; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	42	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1119	1125						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594243				2022-12-28	WOS:A1992HU64200009
J	GALLAND, F; KATZAV, S; BIRNBAUM, D				GALLAND, F; KATZAV, S; BIRNBAUM, D			THE PRODUCTS OF THE MCF-2 AND VAV PROTOONCOGENES AND OF THE YEAST GENE CDC-24 SHARE SEQUENCE SIMILARITIES	ONCOGENE			English	Note							SACCHAROMYCES-CEREVISIAE; DBL-ONCOGENE; CDC24 GENE; OVEREXPRESSION; CELLS	Comparison of MCF-2, VAV and CDC-24 amino acids sequences shows similarities in a near central portion of the molecules, constituting a domain of around 250 residues, the role of which remains undefined.	INSERM, U119, DEPT MOLEC ONCOL, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); St Jude Children's Research Hospital				Birnbaum, Daniel/0000-0001-7920-9883	NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EVA A, 1991, NEW BIOL, V3, P158; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GALLAND F, 1991, ONCOGENE, V6, P833; GRAZIANI G, 1989, ONCOGENE, V4, P823; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH A, 1991, SCIENCE, V252, P68; MARGOLIS B, 1992, IN PRESS NATURE; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; NOGUCHI T, 1988, ONCOGENE, V3, P709; Pringle JR, 1991, CURR OPIN CELL BIOL, V3, P235, DOI 10.1016/0955-0674(91)90145-O; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113	20	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					585	587						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549372				2022-12-28	WOS:A1992HK00500028
J	GIVOL, I; GREENHOUSE, JJ; HUGHES, SH; EWERT, DL				GIVOL, I; GREENHOUSE, JJ; HUGHES, SH; EWERT, DL			RETROVIRUSES THAT EXPRESS DIFFERENT RAS MUTANTS CAUSE DIFFERENT TYPES OF TUMORS IN CHICKENS	ONCOGENE			English	Article								We have used replication-competent retroviral vectors to express avian and murine ras genes in cultured chick embryo fibroblasts (CEF) and in chickens. Since the viral vectors are identical, it is possible to compare the oncogenic potential of the ras genes directly. The normal (12 gly) form of chicken c-Ha-ras is not oncogenic in vivo, nor does high-level expression transform CEF. Expression of murine v-ras or modified forms of chicken c-Ha-ras with either lysine or glutamine at position 12 transforms CEF and causes tumors in birds. However, the oncogenic potential of the transforming ras genes is different, the viruses that express the genes with lysine and glutamine at position 12 cause a distinct spectrum of tumors.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, POB B, FREDERICK, MD 21702 USA; NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); The Wistar Institute					NCI NIH HHS [N01-CO-74101, CA39000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039000] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	16	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					141	146						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1632878				2022-12-28	WOS:A1992HC22700019
J	AGHIB, DF; BISHOP, JM				AGHIB, DF; BISHOP, JM			A 3' TRUNCATION OF MYC CAUSED BY CHROMOSOMAL TRANSLOCATION IN A HUMAN T-CELL LEUKEMIA IS TUMORIGENIC WHEN TESTED IN ESTABLISHED RAT FIBROBLASTS	ONCOGENE			English	Note							HUMAN C-MYC; MESSENGER-RNA; GENE; TRANSFORMATION; EXPRESSION; ONCOGENE; ACTIVATION; ADJACENT; SEQUENCE; REGION	We have previously identified in human T-leukemia cells a myc gene with an unusual 3' rearrangement, and we have shown that expression of the gene is deregulated by stabilization of mRNA. Here we report that the rearranged gene transforms established rat fibroblasts to a tumorigenic phenotype. In hybrid genes, the transforming capability segregates with the 3' rearrangement. Transformation is apparently due to a more than fivefold enhancement in myc expression, attributable to stabilization of mRNA. The rearranged allele of myc also contains a point mutation in a region upstream of the gene, identified previously as a potential negative regulator of myc expression. The mutation may increase expression of myc, but not sufficiently to cause cellular transformation. Our findings enlarge the variety of genetic lesions that may activate myc to an oncogene and sustain the view that augmented expression of an otherwise normal allele of myc can be pathogenic.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GW HOOPER RES FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA 44338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGHIB D, 1987, GENETIC VARIATION VI, V354, P338; AGHIB DF, 1990, ONCOGENE, V5, P707; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BIGNAMI M, 1988, ONCOGENE, V2, P509; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; SAGLIO G, 1986, CANCER RES, V46, P1413; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SYMONDS G, 1989, ONCOGENE, V4, P285; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	24	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2371	2375						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766681				2022-12-28	WOS:A1991GX73500029
J	ASKEW, DS; BARTHOLOMEW, C; BUCHBERG, AM; VALENTINE, MB; JENKINS, NA; COPELAND, NG; IHLE, JN				ASKEW, DS; BARTHOLOMEW, C; BUCHBERG, AM; VALENTINE, MB; JENKINS, NA; COPELAND, NG; IHLE, JN			HIS-1 AND HIS-2 - IDENTIFICATION AND CHROMOSOMAL MAPPING OF 2 COMMONLY REARRANGED SITES OF VIRAL INTEGRATION IN A MYELOID-LEUKEMIA	ONCOGENE			English	Article							T-CELL LYMPHOMAS; C-MYB LOCUS; PROVIRAL INSERTION; PROMOTER INSERTION; RETROVIRAL INSERTION; TRANSCRIPTIONAL ACTIVATION; HOMEOBOX GENE; N-MYC; VIRUS; LINE	To identify genes that contribute to myeloid leukemogenesis we have cloned viral integration sites from a CasBrM-MuLV-induced interleukin 3-independent myeloid leukemia cell line. Genomic probes derived from cellular sequences flanking two integrated proviruses were used to screen restriction digests of DNAs from a panel of 52 hematopoietic cell lines, 30 of which were established from CasBrM-MuLV- or MoMuLV-induced mouse leukemias. Probes from one integration site (His-1) defined a region that was rearranged in 3/52 cell lines, and probes from a second integration site (His-2) identified a rearrangement in 2/52 cell lines. Both cases of His-2 rearrangements occurred in concert with viral insertions in the His-1 locus. Genetic mapping of these loci using interspecific backcross analysis assigned the His-1 locus to mouse chromosome 2 and the His-2 locus to mouse chromosome 19. In situ hybridization with a probe from the human homologous region mapped the His-1 locus to human chromosome 2q14-q21. No recombinants were observed between His-2 and Gin-1, a common site of provirus integration in Gross passage A MuLV-induced T-cell leukemias, in 131 backcross animals, suggesting that these loci are tightly linked. The His-1 locus maps to mouse chromosome 2 distinct from any known oncogene or common site of integration but near the proximal breakpoint for a deletion that is observed in over 90% of radiation-induced leukemias.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; NCI, FREDERICK CANC RES & DEV CTR, MAMMALIAN GENET LAB, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; St Jude Children's Research Hospital				Buchberg, Arthur/0000-0002-0543-5631; Askew, David/0000-0002-6477-2515	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765, N01-CO-74101, CA 51020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BAUMBACH WR, 1988, J VIROL, V62, P3151, DOI 10.1128/JVI.62.9.3151-3155.1988; BERNS A, 1988, ARCH VIROL, V102, P1, DOI 10.1007/BF01315558; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BRECKON G, 1988, KEY CHROMOSOME C, V3; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; CANAANI E, 1983, P NATL ACAD SCI USA, V80, P7110; CHEN SJ, 1985, P NATL ACAD SCI USA, V82, P7284, DOI 10.1073/pnas.82.21.7284; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CUYPERS HT, 1984, CELL, V37, P141; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DOLCETTI R, 1989, ONCOGENE, V4, P1009; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; Green EL, 1981, GENETICS PROBABILITY, P77; HAYATA I, 1983, CANCER RES, V43, P367; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; IHLE JN, 1982, J IMMUNOL, V129, P2431; IHLE JN, 1989, J VIROL, V63, P2959, DOI 10.1128/JVI.63.7.2959-2966.1989; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LEBEAU MM, 1984, NATURE, V312, P70, DOI 10.1038/312070a0; LI Y, 1984, P NATL ACAD SCI-BIOL, V81, P6808, DOI 10.1073/pnas.81.21.6808; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; PALMER CG, 1990, AM J MED GENET, V36, P214, DOI 10.1002/ajmg.1320360215; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; ROCCHI M, 1986, HUM GENET, V74, P30; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; Sambrook J, 1989, MOL CLONING LABORATO; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SIRACUSA LD, 1990, GENOMICS, V6, P491, DOI 10.1016/0888-7543(90)90479-E; SIRACUSA LD, 1991, IN PRESS GENETICS; TRAKHTENBROT L, 1988, LEUKEMIA, V2, P545; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VILLEMUR R, 1987, MOL CELL BIOL, V7, P512, DOI 10.1128/MCB.7.1.512; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WEISS R, 1985, RNA TUMOR VIRUSES, V2; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	59	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2041	2047						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1682866				2022-12-28	WOS:A1991GX11900015
J	DEVILEE, P; VANVLIET, M; VANSLOUN, P; DIJKSHOORN, NK; HERMANS, J; PEARSON, PL; CORNELISSE, CJ				DEVILEE, P; VANVLIET, M; VANSLOUN, P; DIJKSHOORN, NK; HERMANS, J; PEARSON, PL; CORNELISSE, CJ			ALLELOTYPE OF HUMAN BREAST-CARCINOMA - A 2ND MAJOR SITE FOR LOSS OF HETEROZYGOSITY IS ON CHROMOSOME-6Q	ONCOGENE			English	Article							RECESSIVE MUTATION; CANCER; GENE; TUMORS; RETINOBLASTOMA; EXPRESSION; HOMOZYGOSITY; DELETION; REGIONS	Loss of heterozygosity (LOH), which is detected with polymorphic DNA markers by comparing constitutional and tumor genotypes, has been observed at a number of different chromosome arms in primary breast tumors. These include 1p, 1q, 3p, 11p, 13q, 17p and 18q. We present here the results of a screening of all nonacrocentric chromosome arms, including those of the X chromosome, with at least one polymorphic marker per arm, in a total of 86 breast carcinomas. This dataset, termed an allelotype, indicates that in addition to the chromosome regions listed above, allelic loss may be observed in more than 30% of informative cases on 6q, 8q, 9q, 15q, and 16q. Multiple LOH involving at least two different chromosomes in a single tumor was observed in approximately 75% of the investigated tumors, and revealed complex chromosome involvement. Six different combinations of concurrent LOH at two different chromosome arms were found to be significantly correlated (r > 0.45; P < 0.01). Tumors showing LOH at 3p or 17p were preferentially aneuploid, while LOH at 6q and 17q was inversely correlated with the number of positive lymph nodes and age respectively.	LEIDEN UNIV,FAC MED,DEPT PATHOL,2333 AL LEIDEN,NETHERLANDS; LEIDEN UNIV,FAC MED,DEPT MED STAT,2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	DEVILEE, P (corresponding author), LEIDEN UNIV,FAC MED,DEPT HUMAN GENET,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.		DEVILEE, PETER/ABR-2140-2022					ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BEERMAN H, 1990, INT J CANCER, V45, P34, DOI 10.1002/ijc.2910450108; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, CANCER RES, V51, P1020; DEVILEE P, 1991, ONCOGENE, V6, P311; DEVILEE P, 1991, CANCER SURV, V9, P605; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EHLEN T, 1990, ONCOGENE, V5, P219; FULTS D, 1990, CANCER RES, V50, P5784; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GERBAULTSEUREAU M, 1987, ANN GENET-PARIS, V30, P138; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KIDD KJ, 1989, CYTOGENET CELL GENET, V51; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MARS WM, 1990, CANCER METAST REV, V9, P35, DOI 10.1007/BF00047587; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MITCHELL ELD, 1990, GENE CHROMOSOME CANC, V2, P278, DOI 10.1002/gcc.2870020405; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1990, ONCOGENE, V5, P1573; RODGERS CS, 1984, CANCER GENET CYTOGEN, V13, P95, DOI 10.1016/0165-4608(84)90052-9; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SATO T, 1990, CANCER RES, V50, P7184; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SUZUKI T, 1989, CANCER RES, V49, P1095; THOMAS GA, 1991, CANCER RES, V51, P639; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TRENT JM, 1987, ONCOGENES HORMONES B, P142; VANDERVIJER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P35; VARLEY JM, 1989, ONCOGENE, V4, P725; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; YAMADA H, 1990, ONCOGENE, V5, P1141; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	42	246	246	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1705	1711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1681492				2022-12-28	WOS:A1991GX27400030
J	RAMEH, LE; ARMELIN, MCS				RAMEH, LE; ARMELIN, MCS			T-ANTIGENS ROLE IN POLYOMAVIRUS TRANSFORMATION - C-MYC BUT NOT C-FOS OR C-JUN EXPRESSION IS A TARGET FOR MIDDLE-T	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; EARLY-RESPONSE GENES; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; ONCOGENIC TRANSFORMATION; MOLECULAR-CLONING; PP60C-SRC KINASE; TRANSGENIC MICE; PHOSPHOLIPASE-C; EARLY PROTEINS	Polyoma virus (Py) causes neoplastic transformation in vitro and multiple tumors in vivo. The role played by large and middle T antigens (LT, MT) and their mechanisms of action are focused here. Py-transformed Balb-3T3 cells become independent of platelet-derived growth factor (PDGF) for growth. JE, c-fos, c-jun and c-myc are 'immediate early' genes induced in response to PDGF. To test whether these cellular genes play a role in malignant transformation by Py, we generated a number of transfectant cell lines overexpressing LT, MT or both. Characterization of these cell lines revealed that: (a) MT but not LT causes morphological transformation, ability to grow in PDGF-free plasma medium and ability to grow in agarose suspension; (b) cooperation between LT and MT is evident in vitro, however, high and simultaneous LT and MT expression does not warrant tumorigenic potential; (c) MT expression does not correlate with tumorigenic potential but alters the probability of eliciting tumors; (d) JE and c-myc (but not c-fos or c-jun) are constitutively expressed in MT transfectants. MT induction is followed by c-myc induction 1.5 h later. We conclude that some of the 'immediate-early' genes may play pivotal roles in Py transformation.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498 SAO PAULO,BRAZIL	Universidade de Sao Paulo	ARMELIN, MCS (corresponding author), UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,CP 20780,BR-01498 SAO PAULO,BRAZIL.							ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARMELIN HA, 1973, P NATL ACAD SCI USA, V70, P2702, DOI 10.1073/pnas.70.9.2702; ARMELIN MCS, 1985, COLD SPRING HARBOR C, V3, P195; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BENJAMIN T, 1990, VIROLOGY, P317; BOUCHARD L, 1984, VIROLOGY, V135, P53, DOI 10.1016/0042-6822(84)90116-8; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GELINAS C, 1989, VIROLOGY, V170, P193, DOI 10.1016/0042-6822(89)90366-8; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; ITO Y, 1977, P NATL ACAD SCI USA, V74, P4666, DOI 10.1073/pnas.74.10.4666; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAPLAN DR, 1985, MOL CELL BIOL, V5, P1795, DOI 10.1128/MCB.5.7.1795; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUSER J, 1989, ONCOGENE, V4, P1433; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SONOBE MH, 1991, IN PRESS ONCOGENE; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	55	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1049	1056						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648700				2022-12-28	WOS:A1991GU62200022
J	HORI, Y; KIKUCHI, A; ISOMURA, M; KATAYAMA, M; MIURA, Y; FUJIOKA, H; KAIBUCHI, K; TAKAI, Y				HORI, Y; KIKUCHI, A; ISOMURA, M; KATAYAMA, M; MIURA, Y; FUJIOKA, H; KAIBUCHI, K; TAKAI, Y			POSTTRANSLATIONAL MODIFICATIONS OF THE C-TERMINAL REGION OF THE RHO-PROTEIN ARE IMPORTANT FOR ITS INTERACTION WITH MEMBRANES AND THE STIMULATORY AND INHIBITORY GDP/GTP EXCHANGE PROTEINS	ONCOGENE			English	Article							GTP-BINDING PROTEIN; BOVINE BRAIN MEMBRANES; BOTULINUM ADP-RIBOSYLTRANSFERASE; GENE-PRODUCT; MOLECULAR-CLONING; CLOSTRIDIUM-BOTULINUM; PARTIAL-PURIFICATION; SUBSEQUENT BINDING; EFFECTOR DOMAIN; TOXIN TYPE-C1	We have recently found, by use of the rhoA p21 purified from bovine aortic smooth muscle, that it is similarly post-translationally processed as described for ras p21s: it is first geranylgeranylated at the cysteine residue in the C-terminal region followed by removal of the three C-terminal amino acids and the subsequent carboxyl methylation of the revealed C-terminal cysteine residue. In the present study, we investigated the function(s) of these post-translational modifications of the C-terminal region of rhoA p21 by use of the rhoA p21s purified from bovine aortic smooth muscle and rhoA p21-overexpressing Escherichia coli since the bacterial protein was not modified with a geranylgeranyl moiety. Bovine rhoA p21 bound to plasma membranes and phosphatidylserine-linked Affigel, but bacterial rhoA p21 did not bind to them. The inhibitory GDP/GTP exchange protein for rhoA p21, named GDP dissociation inhibitor (GDI), made a complex with the GDP-bound form of bovine rhoA p21 and thereby inhibited the dissociation of GDP from and the subsequent binding of GTP to it. However, rho GDI neither made a complex with the GDP-bound form of bacterial rhoA p21 nor affected these reactions of the bacterial protein. The stimulatory GDP/GTP exchange protein for rhoA p21, named GDP dissociation stimulator (GDS), stimulated the dissociation of GDP from bovine rhoA p21, but was inactive for the bacterial protein. In contrast, the GTPase activating protein for rhoA p21 is active not only for bovine rhoA p21 but also for the bacterial protein. These results suggest that the post-translational modifications of the C-terminal region of bovine rhoA p21, most presumably the geranylgeranylation, which are absent in bacterial rhoA p21, play important roles in its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins but not with the GAP.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ADAMVIZI V, 1988, FEBS LETT, V238, P277, DOI 10.1016/0014-5793(88)80496-4; ARAKI S, 1991, IN PRESS MOL CELL BI; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HIROYOSHI M, 1991, IN PRESS J BIOL CHEM; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; ISOMURA M, 1990, IN PRESS ONCOGENE; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, IN PRESS P NATL ACAD; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KIM S, 1989, MOL BRAIN RES, V6, P167, DOI 10.1016/0169-328X(89)90051-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OHGA N, 1989, BIOCHEM BIOPH RES CO, V163, P1523, DOI 10.1016/0006-291X(89)91153-4; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SSAKI T, 1990, J BIOL CHEM, V263, P2333; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; UEDA T, 1990, J BIOL CHEM, V265, P9373; Weber K, 1972, Methods Enzymol, V26, P3; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	44	202	205	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					515	522						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903193				2022-12-28	WOS:A1991FR93900004
J	NARANJO, JR; MELLSTROM, B; ACHAVAL, M; LUCAS, JJ; DELRIO, J; SASSONECORSI, P				NARANJO, JR; MELLSTROM, B; ACHAVAL, M; LUCAS, JJ; DELRIO, J; SASSONECORSI, P			COINDUCTION OF JUN B AND C-FOS IN A SUBSET OF NEURONS IN THE SPINAL-CORD	ONCOGENE			English	Article							DNA-BINDING DOMAINS; GENE-EXPRESSION; PROTO-ONCOGENE; GROWTH-FACTORS; LEUCINE ZIPPERS; RAT; STIMULATION; TRANSCRIPTION; HYBRIDIZATION; HYPERALGESIA	Noxious stimulation in vivo provokes the transcriptional activation of several genes which are though to play an important role in the phenomena of stress and pain. In the rat, the expression of the c-fos proto-oncogene is rapidly induced upon noxious stimulation in defined neurons in the dorsal horn of the spinal cord. Interestingly, expression of the prodynorphin gene, which is thought to be involved in the endogenous mechanisms for pain/stress control, also localizes in the same anatomical area. Fos proteins are known to associate in transcriptional complexes with the products of the jun family constituting nuclear factor AP-1. These considerations prompted us to analyse the expression of the jun gene family members c-jun, jun B and jun D in rats subjected to noxious stimulation. We present data indicating that in unstimulated animals the transcripts of the three genes are differentially expressed and abundant within the various laminas of the lumbar spinal cord. Surprisingly, upon stimulation only the jun B transcript is augmented, being co-localized with Fos in a subset of neurons of the medial dorsal horn.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE; CSIC,INST CAJAL NEUROCIENCIA,E-28002 MADRID,SPAIN	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Consejo Superior de Investigaciones Cientificas (CSIC)			NARANJO, Jose R/K-1950-2014; Lucas, Jose J./U-6543-2019; Sassone-Corsi, Paolo/H-6182-2011	NARANJO, Jose R/0000-0002-0270-3469; Lucas, Jose J./0000-0003-1597-3916				ALHO H, 1988, P NATL ACAD SCI USA, V85, P7018, DOI 10.1073/pnas.85.18.7018; ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BULLITT E, 1989, BRAIN RES, V493, P391, DOI 10.1016/0006-8993(89)91177-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CECCATELLI S, 1989, P NATL ACAD SCI USA, V86, P9569, DOI 10.1073/pnas.86.23.9569; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COMB M, 1988, EUR MOL BIOL ORG J, V7, P3795; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DRAISCI G, 1989, MOL BRAIN RES, V6, P31, DOI 10.1016/0169-328X(89)90025-9; DUBNER R, 1984, ADV PAIN RES THER, V6, P151; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GOELET P, 1986, NATURE, V311, P433; HALEZONETIS TD, 1988, CELL, V55, P917; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HERDEGEN T, 1990, 6TH P WORLD C PAIN; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; IADAROLA MJ, 1988, BRAIN RES, V455, P205, DOI 10.1016/0006-8993(88)90078-9; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MENETREY D, 1989, J COMP NEUROL, V285, P177, DOI 10.1002/cne.902850203; MINAMI M, 1989, NEUROSCI LETT, V98, P105, DOI 10.1016/0304-3940(89)90382-0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NOGUCHI K, 1989, MOL BRAIN RES, V5, P227, DOI 10.1016/0169-328X(89)90039-9; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RUDA MA, 1988, P NATL ACAD SCI USA, V85, P622, DOI 10.1073/pnas.85.2.622; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y	44	66	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					223	227						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900356				2022-12-28	WOS:A1991FZ13400007
J	RE, GG; ANTOUN, GR; ZIPF, TF				RE, GG; ANTOUN, GR; ZIPF, TF			MODULATION OF A CONSTITUTIVE TRANSCRIPTIONAL BLOCK AT EXON-1 CONTROLS HUMAN C-MYC ONCOGENE EXPRESSION	ONCOGENE			English	Note									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DIV LAB MED,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	RE, GG (corresponding author), UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DIV PEDIAT,PEDIAT LEUKEMIA RES PROGRAM,HOUSTON,TX 77030, USA.							ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BUTTURINI A, 1988, INT J CELL CLONING, V6, P2, DOI 10.1002/stem.5530060103; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DOEFLER W, 1981, J GEN VIROL, V47, P1; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURNEY RM, 1987, FOCUS, V10, P5; HUEBNER K, 1989, CANCER RES, V49, P4071; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KELLY K, 1988, J BIOL CHEM, V263, P4828; LEE WMF, 1989, ONCOGENES, P37; LIEBERMANN DA, 1989, ONCOGENE, V4, P589; RE GG, 1985, VIROLOGY, V146, P27, DOI 10.1016/0042-6822(85)90050-9; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0	21	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1247	1250						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	1697411				2022-12-28	WOS:A1990DX36100019
J	LITTLEWOOD, TD; AMATI, B; LAND, H; EVAN, GI				LITTLEWOOD, TD; AMATI, B; LAND, H; EVAN, GI			MAX AND C-MYC MAX DNA-BINDING ACTIVITIES IN CELL-EXTRACTS	ONCOGENE			English	Article							LEUCINE ZIPPER; MONOCLONAL-ANTIBODIES; PROTEIN; DIMERIZATION; OLIGOMERIZATION; TRANSFORMATION; TRANSCRIPTION; LOCALIZATION; REGIONS; DOMAINS	We have examined the interactions and DNA-binding activities of the c-Myc oncoprotein and its partner Max. In cell extracts virtually all c-Mvc molecules are associated with Max in heterodimeric complexes. Moreover, DNA-binding studies with in vitro-translated protein and cell extracts show that both Max alone and c-Myc/Max bind the same DNA sequence. Conversely, c-Myc is unable to bind this sequence in the absence of Max. These findings suggest that c-Myc may function via obligate complex formation with Max.	IMPERIAL CANC RES FUND,GROWTH CONTROL & DEV LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	LITTLEWOOD, TD (corresponding author), IMPERIAL CANC RES FUND,BIOCHEM CELL NUCLEUS LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BADER JP, 1985, J VIROL, V53, P509, DOI 10.1128/JVI.53.2.509-514.1985; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVAN GI, 1984, J IMMUNOL METHODS, V73, P427, DOI 10.1016/0022-1759(84)90417-4; EVAN GI, 1986, CURR TOP MICROBIOL, V132, P362; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, ONCOGENE, V6, P93; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WATERS C, 1991, ONCOGENE, V6, P101; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	27	102	102	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1783	1792						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501888				2022-12-28	WOS:A1992JJ37600015
J	JHIANG, SM; CARUSO, DR; GILMORE, E; ISHIZAKA, Y; TAHIRA, T; NAGAO, M; CHIU, IM; MAZZAFERRI, EL				JHIANG, SM; CARUSO, DR; GILMORE, E; ISHIZAKA, Y; TAHIRA, T; NAGAO, M; CHIU, IM; MAZZAFERRI, EL			DETECTION OF THE PTC RETTPC ONCOGENE IN HUMAN THYROID CANCERS	ONCOGENE			English	Article								We have investigated the PTC/ret(TPC) oncogene, an activated form of ret proto-oncogene with a specific rearrangement, in thyroid malignancies. Southern analysis was used to screen 36 thyroid papillary carcinomas (PC), 22 normal thyroid tissues from glands with PC elsewhere, three follicular carcinomas, eight follicular adenomas and 30 other non-malignant thyroids. Rearrangements were detected in four PCs (11%) using probes derived from the ret proto-oncogene. Genomic breakpoints from a PC and a PC cell line (TPC-1) were cloned and sequenced. The rearrangement points of ret proto-oncogene were found in the intron between the exon for the transmembrane domain and the first exon for the tyrosine kinase domain. Furthermore, the PTC/ret(TPC) chimeric transcripts were detected in two PCs with the rearrangement by reverse transcription polymerase chain reaction. Distant metastases were present in 50% (2/4) of PCs with the rearrangement, but in only two out of 32 PCs without a detectable rearrangement (P = 0.05, Fisher exact test). Our study suggests that the rearrangement of the ret proto-oncogene may be involved in the development of distant metastases in patients with papillary thyroid carcinomas. However, a larger clinical study will be required to verify this observation.	OHIO STATE UNIV, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; NATL CANC CTR, RES INST, DIV CARCINOGENESIS, CHUO KU, TOKYO 104, JAPAN; NATL CANC CTR, CTR COMPREHENS CANC, TOKYO 104, JAPAN	University System of Ohio; Ohio State University; National Cancer Center - Japan; National Cancer Center - Japan			Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [CA01369, CA45611] Funding Source: Medline; NCRR NIH HHS [GCRC-RR-34] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BONGARZONE I, 1989, ONCOGENE, V4, P1457; Cox D. R., 1984, ANAL SURVIVAL DATA; DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEITZ P, 1976, CANCER, V37, P2329, DOI 10.1002/1097-0142(197605)37:5<2329::AID-CNCR2820370523>3.0.CO;2-7; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; MAZZAFERRI EL, 1991, MAYO CLIN PROC, V66, P105, DOI 10.1016/S0025-6196(12)61179-3; MAZZAFERRI EL, 1987, SEMIN ONCOL, V14, P315; MAZZAFERRI EL, 1983, CLIN SURGERY INT, V6, P18; MAZZAFERRI EL, 1992, WERNER INGBARS THYRO, P1138; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SOZZI G, 1991, ONCOGENE, V6, P339; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; VENKATESH YSS, 1990, CANCER-AM CANCER SOC, V66, P321, DOI 10.1002/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A	25	148	152	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1331	1337						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620547				2022-12-28	WOS:A1992HZ97100011
J	NICOLSON, GL; GALLICK, GE; SPOHN, WH; LEMBO, TM; TAINSKY, MA				NICOLSON, GL; GALLICK, GE; SPOHN, WH; LEMBO, TM; TAINSKY, MA			TRANSFECTION OF ACTIVATED C-H-RASEJ/PSV2NEO OR PSV2NEO GENES INTO RAT MAMMARY CELLS - RAPID STIMULATION OF CLONAL DIVERSIFICATION OF SPONTANEOUS METASTATIC AND CELL-SURFACE PROPERTIES	ONCOGENE			English	Article							NIH 3T3 CELLS; C-HA-RAS; DIFFERENTIAL EXPRESSION; ADENOCARCINOMA CELLS; MONOCLONAL-ANTIBODY; MOLECULAR-WEIGHT; DNA TRANSFECTION; BREAST-CANCER; NIH/3T3 CELLS; FRESH PRIMARY	We examined whether the conversion of benign rat mammary cells to metastatic cells by transfection of c-H-ras(EJ)/pSV2neo or control pSV2neo genes results in rapid stimulation of diversification of cellular phenotypes. Transfection of c-H-ras(EJ) into twice-cloned, stable (> 1 year) rat mammary MTC.4 cells, followed quickly by cell cloning, revealed differences in transfected oncogene copy numbers and expression of p21-(rasEJ) . No correlation between c-H-ras(EJ) copy numbers or the cellular amounts of p21(rasEJ) or total p21ras and spontaneous metastatic potentials was found. By subcloning transfected cells as soon as possible after gene transfer, we found some rearrangements and amplifications of c-H-ras(EJ) and heterogeneous spontaneous metastatic potentials. In addition, the expression of the mammary tumor metastasis-associated cell-surface glycoprotein gp580 on untransfected and transfected MTC.4 cells indicated that the cell populations of higher metastatic potential were also more diverse in their cell-to-cell antigen expression than untransfected or non-metastatic, transfected MTC.4 cells. In contrast, the expression of a putative metastasis-suppressor gene, nm23, was unchanged after transfection and subcloning. Control pSV2neo transfections or calcium phosphate treatment alone also resulted in the generation of cellular heterogeneity, although at an apparently lower frequency than c-H-ras(EJ) transfections, suggesting that transfection of activated, dominantly acting oncogenes, or in some cases control genes, can result in destabilization of transfected cells, rapid diversification and generation of heterogeneity in growth rate, spontaneous metastatic potential and antigen expression.			NICOLSON, GL (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 108,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [R23-CA39803, P30-CA16672, R35-CA44352] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA039803, P30CA016672, R35CA044352] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERG P, 1982, MOL APPL GENET, P327; BERNSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P1726, DOI 10.1073/pnas.82.6.1726; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOLSCHER JGM, 1988, EMBO J, V7, P3361, DOI 10.1002/j.1460-2075.1988.tb03208.x; BONDY GP, 1985, CANCER RES, V45, P6005; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; CARNEY WP, 1986, J CELL BIOCHEM, V32, P207, DOI 10.1002/jcb.240320307; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; CLAIR T, 1987, CANCER RES, V47, P5290; COLLARD JG, 1987, CANCER RES, V47, P754; DEAR TN, 1988, CANCER RES, V48, P5203; DEBORTOLI ME, 1985, BIOCHEM BIOPH RES CO, V127, P699, DOI 10.1016/S0006-291X(85)80218-7; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1989, INT J CANCER, V43, P443, DOI 10.1002/ijc.2910430317; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FRAZIER ML, 1983, MOL CELL BIOCHEM, V56, P113; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GARBISA S, 1987, CANCER RES, V47, P1523; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; HAND PH, 1987, J NATL CANCER I, V79, P59; HILL SA, 1988, J NATL CANCER I, V80, P484, DOI 10.1093/jnci/80.7.484; ICHIKAWA T, 1990, CANCER RES, V50, P6349; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; KURZROCK R, 1986, CANCER RES, V46, P1530; KUZEK T, 1987, P NATL ACAD SCI USA, V84, P4490; KYPRIANOU N, 1990, CANCER RES, V50, P1499; LIOTTA LA, 1988, J NATL CANCER I, V80, P468, DOI 10.1093/jnci/80.7.468; LUNDY J, 1986, J CLIN ONCOL, V4, P1321, DOI 10.1200/JCO.1986.4.9.1321; MAREEL MM, 1986, ANTICANCER RES, V6, P419; MARSHALL CJ, 1988, J CELL SCI S, V10, P157; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NERI A, 1982, J NATL CANCER I, V68, P508; NICOLSON GL, 1984, CANCER METAST REV, V3, P25, DOI 10.1007/BF00047691; NICOLSON GL, 1987, CANCER RES, V47, P1473; NICOLSON GL, 1991, J CELL BIOCHEM, V46, P277, DOI 10.1002/jcb.240460402; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; NICOLSON GL, 1990, ONCOGENE, V5, P747; NORTH SM, 1988, INT J CANCER, V42, P607, DOI 10.1002/ijc.2910420423; OHUCHI N, 1986, CANCER RES, V46, P2511; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PRICE JE, 1989, CANCER RES, V49, P4274; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANROY FM, 1986, CANCER RES, V46, P4787; VERRELLE P, 1987, ANTICANCER RES, V7, P181; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149	51	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1127	1135						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594244				2022-12-28	WOS:A1992HU64200010
J	WADA, RK; SEEGER, RC; REYNOLDS, CP; ALLOGGIAMENTO, T; YAMASHIRO, JM; RULAND, C; BLACK, AC; ROSENBLATT, JD				WADA, RK; SEEGER, RC; REYNOLDS, CP; ALLOGGIAMENTO, T; YAMASHIRO, JM; RULAND, C; BLACK, AC; ROSENBLATT, JD			CELL TYPE-SPECIFIC EXPRESSION AND NEGATIVE REGULATION BY RETINOIC ACID OF THE HUMAN N-MYC PROMOTER IN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; DIHYDROFOLATE-REDUCTASE PROMOTER; SV40 EARLY PROMOTER; C-MYC; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; GENE; TRANSCRIPTION; UPSTREAM; ELEMENTS	Expression of the N-myc oncogene is an important determinant of tumor behavior in human neuroblastoma. To study the regulation of N-myc, we have subcloned fragments of the 5' flanking region of the human N-myc gene upstream of the chloramphenicol acetyl transferase (CAT) reporter gene, and assayed for promoter activity in transient transfections into neuroblastoma and other cell lines. Upstream sequences were found to possess promoter activity to within 121 bp of the major cap site (-121). Negative regulatory elements were identified in regions approximately 2 kb and 500 bp upstream from the major cap site, as well as 150-1000 bp downstream. promoter constructs containing downstream elements from bp +150 to +1000 were active in N-myc-expressing neuroblastoma cell lines, but not in non-expressing Epstein-Barr virus (EBV)-transformed 729-6 B-cell or HeLa cell lines, while those lacking this element were active in all cell types tested. All tested constructs retaining promoter activity showed decreased activity in parallel with the down-regulation of endogenous N-myc in response to treatment of transfected cells with retinoic acid. These studies suggest that N-myc regulation may be controlled at different levels, and provide a basis for further characterization of N-myc regulation in neuroblastoma.	UNIV CALIF LOS ANGELES,SCH MED,GWYNNE HAZEN CHERRY MEM LAB,LOS ANGELES,CA 90024; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Children's Hospital Los Angeles; University of Southern California; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	WADA, RK (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.			Reynolds, C. Patrick/0000-0002-2827-8536	NATIONAL CANCER INSTITUTE [R55CA044904, R01CA044904, R01CA022794] Funding Source: NIH RePORTER; NCI NIH HHS [CA 22794, CA44904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABISS LE, 1990, MOL CELL BIOL, V10, P6700, DOI 10.1128/MCB.10.12.6700; BATY D, 1984, NUCLEIC ACIDS RES, V12, P915, DOI 10.1093/nar/12.2.915; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; COHN SL, 1990, ONCOGENE, V5, P1821; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EVERETT RD, 1983, NUCLEIC ACIDS RES, V11, P2447, DOI 10.1093/nar/11.8.2447; EVERSON TC, 1964, ANN NY ACAD SCI, V114, P721; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; GHOSH PK, 1981, J VIROL, V40, P224, DOI 10.1128/JVI.40.1.224-240.1981; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRADY EF, 1987, CANCER RES, V47, P2931; HILLER S, 1991, ONCOGENE, V6, P969; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MCWILLIAMS NB, 1986, MED PEDIATR ONCOL, V14, P41, DOI 10.1002/mpo.2950140110; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; ROSEN N, 1986, CANCER RES, V46, P4139; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIDELL N, 1984, EXP CELL RES, V155, P305, DOI 10.1016/0014-4827(84)90795-X; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPINELLI W, 1982, CANCER RES, V42, P5067; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VIGNERON M, 1984, EMBO J, V3, P2373, DOI 10.1002/j.1460-2075.1984.tb02142.x; Wada R K, 1988, Prog Clin Biol Res, V271, P57; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WHARIN L, 1991, INT J CANCER, V48, P136; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	47	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					711	717						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565467				2022-12-28	WOS:A1992HQ68200013
J	TASHIRO, S; TAKECHI, M; ASOU, H; TAKAUCHI, K; KYO, T; DOHY, H; KIKUCHI, M; KAMADA, N; TSUJIMOTO, Y				TASHIRO, S; TAKECHI, M; ASOU, H; TAKAUCHI, K; KYO, T; DOHY, H; KIKUCHI, M; KAMADA, N; TSUJIMOTO, Y			CYTOGENETIC 2-18 AND 18-22 TRANSLOCATION IN CHRONIC LYMPHOCYTIC-LEUKEMIA WITH JUXTAPOSITION OF BCL-2 AND IMMUNOGLOBULIN LIGHT CHAIN GENES	ONCOGENE			English	Note							VARIANT T(2-18) TRANSLOCATION; FOLLICULAR LYMPHOMA; B-CELLS; CHROMOSOME-TRANSLOCATION; BREAKPOINT; SURVIVAL; RECOMBINATION; EXPRESSION; CLONING; CLUSTER	The majority of follicular lymphoma cells carry the typical chromosome translocation 14;18, which juxtaposes the bcl-2 gene to the immunoglobulin heavy-chain (IgH) gene. Variant translocations of the bcl-2 gene to the Ig-lambda, or Ig-kappa gene have been found by molecular biological techniques in a significant fraction (approximately 10%) of chronic lymphocytic leukemia (CLL). However, there have been no reports describing the presence of cytogenetic 18;22 and 2;18 translocations in CLL, in spite of extensive karyotypic studies. We present here two cases of CLL, one with cytogenetically detected t(2;18)(p11;q21) and the other with the t(18;22)(q2l;q11). The molecular analysis revealed that these translocations juxtaposed the bcl-2 and immunoglobulin light-chain (IgL) genes. The t(18;22) broke the 5' flanking region of the bcl-2 gene and juxtaposed to the immunoglobulin-lambda light-chain (Ig-lambda) gene in a head-to-head configuration, as in the cases previously described. In the case of the t(2;18), the bcl-2 gene and immunoglobulin-kappa light-Chain (Ig-kappa) gene were juxtaposed in a head-to-tail configuration, which is opposite to that expected from the orientation of the genes on chromosomes. The breakpoint was located within the 5' untranslated region of the bcl-2 gene. The results presented here indicate that the bcl-2/immunoglobulin light-chain (IgL) gene juxtaposition seen in a fraction of CLL is the result of cytogenetically detectable reciprocal chromosome translocations 2;18 and 18;22.	WISTAR INST,36TH ST & SPRUCE,PHILADELPHIA,PA 19104; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT HEMATOL,HIROSHIMA 730,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT PEDIAT,HIROSHIMA 730,JAPAN; FUKUOKA UNIV,FAC MED,DEPT PATHOL,FUKUOKA 81401,JAPAN; HIROSHIMA RED CROSS HOSP & ATOM BOMB SURVIVORS HOSP,DEPT MED,HIROSHIMA 734,JAPAN	The Wistar Institute; Hiroshima University; Hiroshima University; Fukuoka University					NCI NIH HHS [CA51864] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051864] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1989, ONCOGENE, V4, P1073; AVENTIN A, 1990, BRIT J HAEMATOL, V74, P367, DOI 10.1111/j.1365-2141.1990.tb02599.x; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CROCE CM, 1985, BLOOD, V65, P1; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HIETER PA, 1981, NATURE, V294, P536, DOI 10.1038/294536a0; HILLION J, 1991, ONCOGENE, V6, P169; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAMADA N, 1981, BLOOD, V58, P1213; LEROUX D, 1990, BRIT J HAEMATOL, V75, P290, DOI 10.1111/j.1365-2141.1990.tb02669.x; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MITELMAN F, 1988, CATALOG CHROMOSOME A; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OSADA H, 1989, JPN J CANCER RES, V80, P711, DOI 10.1111/j.1349-7006.1989.tb01702.x; PECH M, 1984, J MOL BIOL, V176, P189, DOI 10.1016/0022-2836(84)90420-0; POTTER H, 1984, P NATL ACAD SCI USA, V81, P7176; ROWLEY JD, 1982, SCIENCE, V216, P749, DOI 10.1126/science.7079737; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MA, 1987, J IMMUNOL, V139, P3834; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VASICEK TJ, 1990, J EXP MED, V172, P609, DOI 10.1084/jem.172.2.609; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	29	40	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					573	577						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549371				2022-12-28	WOS:A1992HK00500026
J	SCHNEIKERT, J; LUTZ, Y; WASYLYK, B				SCHNEIKERT, J; LUTZ, Y; WASYLYK, B			2 INDEPENDENT ACTIVATION DOMAINS IN C-ETS-1 AND C-ETS-2 LOCATED IN NONCONSERVED SEQUENCES OF THE ETS GENE FAMILY	ONCOGENE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; TAT PROTEIN; ONCOGENE; IDENTIFICATION; EXPRESSION; CELLS; ERYTHROBLASTOSIS; RETROVIRUS-E26	The c-Ets-1 oncoprotein is a transcription activator that specifically binds to DNA. We show, using fusion proteins with heterologous DNA-binding domains, that chicken c-Ets-1 (p68) contains two independent activation domains. The N-terminal activation domain is absent in c-Ets-1 (p54) that is generated from an alternatively spliced mRNA. A closely related member of the ets gene family, c-Ets-2, also contains two separate activation domains. They lie in the regions of the protein that are least conserved with c-Ets-1, suggesting that the activating function will determine the different physiological roles of these two proteins. The activation domains of c-Ets-1 (p68) and -2 are separated by a moderately conserved region that does not activate on its own. These sequences appear to affect stimulation by the domains, suggesting that they regulate transcription activation. Competition experiments show that c-Ets-1 and -2 interact with a common limiting coactivator. These studies provide important clues about the physiological roles of closely related members of the ets gene family.	CNRS, LGME,INSERM,U184,FAC MED,INST CHIM BIOL, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; POGNONEC P, 1990, ONCOGENE, V5, P603; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUBEN S, 1989, J VIROL, V63, P1; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	38	81	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					249	256						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549346				2022-12-28	WOS:A1992HG98200007
J	TAKAHASHI, T; TAKAHASHI, T; SUZUKI, H; HIDA, T; SEKIDO, Y; ARIYOSHI, Y; UEDA, R				TAKAHASHI, T; TAKAHASHI, T; SUZUKI, H; HIDA, T; SEKIDO, Y; ARIYOSHI, Y; UEDA, R			THE P53 GENE IS VERY FREQUENTLY MUTATED IN SMALL-CELL LUNG-CANCER WITH A DISTINCT NUCLEOTIDE SUBSTITUTION PATTERN	ONCOGENE			English	Article							MUTATIONS; EXPRESSION	The p53 gene has been implicated as a tumor-suppressor gene whose disruption is involved in the pathogenesis of common human cancers. The results of extensive analysis of p53 mutations in non-small cell lung cancers (NSCLCs) have revealed that p53 is mutated in 45% of NSCLC with base changes different from those of colon cancer. In this study, we examined 17 SCLC tumor samples taken directly from 15 patients as well as the corresponding nine tumor cell lines. Mutations changing the p53 coding sequence were found in 11 of 15 patients (73.3%) and showed a similar but distinct nucleotide substitution pattern compared with NSCLC, suggesting that a different mutagenic process is involved. In addition, a strong correlation was seen between the presence of p53 mutations in tumors and the successful establishment of the corresponding cell lines, suggesting that p53 mutations can confer a selective growth advantage in vitro (and probably also in vivo).	AICHI CANC CTR,DEPT INTERNAL MED,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LAB,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University	TAKAHASHI, T (corresponding author), AICHI CANC CTR,CHEMOTHERAPY LAB,NAGOYA,AICHI 464,JAPAN.		Sekido, Yoshitaka/P-9756-2015; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Sekido, Yoshitaka/0000-0002-2428-3848				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKER SJ, 1990, SCIENCE, V249, P1912; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LAWLEY P, 1990, N NITROSO COMPOUNDS, V1, P409; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Minna JD, 1989, CANCER PRINCIPLES PR, P591; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SINGER B, 1982, ANNU REV BIOCHEM, V52, P655; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; WATANABE S, 1987, JPN J CANCER RES, V78, P460; 1990, VITAL STATISTICS 198, V1, P252	23	215	216	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1775	1778						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656362				2022-12-28	WOS:A1991GX11800008
J	WHEELER, TT; XIAO, JP; DOWDY, SF; STANBRIDGE, EJ; YOUNG, DA				WHEELER, TT; XIAO, JP; DOWDY, SF; STANBRIDGE, EJ; YOUNG, DA			SUPPRESSION OF TUMORIGENICITY OF A WILMS-TUMOR CELL-LINE IS ASSOCIATED WITH A DECREASE IN SYNTHESIS OF 2 PROTEINS	ONCOGENE			English	Note							FAMILIAL PREDISPOSITION; HUMAN CHROMOSOME-11; SHORT ARM; GENE; 11P13; MAP; EXPRESSION; DELETION; LOCUS; ACID	Wilms' tumor has been associated with deletions in two loci on chromosome 11, and the introduction of a translocated human chromosome [t(X;11)] into a Wilms' tumor cell line (G401.6TG.6) by microcell hybridization suppresses tumor formation in nude mice. The tumorigenic phenotype is restored in segregants of these microcell hybrids, in which the introduced chromosome is lost. We have used ultrahigh-resolution 'giant' two-dimensional gel electrophoresis of metabolically labeled cellular proteins and in vitro translation products of isolated mRNA to identify changes in cellular gene expression that occur in these cell lines. The changes in gene expression associated with these chromosomal manipulations per se are quite minimal. However, we have identified two proteins (p16 and p28) whose synthesis is consistently decreased in three non-tumorigenic (suppressed) microcell hybrid clones relative to parental and segregant tumorigenic lines. They are also decreased at the level of mRNA in at least two of the non-tumorigenic clones. The decrease of these proteins represents markers of the suppressed phenotype, and their down-regulation may conceivably mediate the suppression of tumorigenicity.	E HENRY KEUTMANN LAB,DEPT MED,ENDOCRINE METAB UNIT,ROCHESTER,NY 14642; E HENRY KEUTMANN LAB,DEPT RADIAT BIOL & BIOPHYS,ENDOCRINE METAB UNIT,ROCHESTER,NY 14642; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL CANCER INSTITUTE [R01CA047650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016177] Funding Source: NIH RePORTER; NCI NIH HHS [CA194104, CA47650] Funding Source: Medline; NIDDK NIH HHS [DK16177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLBERT RA, 1989, J BIOL CHEM, V261, P14733; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVENSON RM, 1989, VIROLOGY, V172, P170, DOI 10.1016/0042-6822(89)90118-9; LEVENSON RM, 1987, CANCER CELLS, V5, P137; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; VANKEUREN ML, 1982, ANN NY ACAD SCI, V396, P55; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190; YOUNG DA, 1984, CLIN CHEM, V30, P2104	17	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1903	1907						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656366				2022-12-28	WOS:A1991GX11800026
J	HARTL, M; HUTCHINS, JT; VOGT, PK				HARTL, M; HUTCHINS, JT; VOGT, PK			THE CHICKEN JUND GENE AND ITS PRODUCT	ONCOGENE			English	Article							C-JUN; PROTO-ONCOGENE; SEQUENCES; FOS; REGULATOR; FRAGMENTS; PROTEINS; MEMBER; FAMILY	We have isolated and characterized the chicken junD gene. It does not contain an intron; its upstream regulatory sequences lack the AP-1-binding site seen in c-jun but include two CRE elements. Downstream untranslated sequences do not show the destabilizing signal ATTTA. The amino acid sequence of the chicken JunD protein is closely related to that of mouse JunD in the dimerization and DNA contact surfaces of the carboxy-terminal region; additional homologies to mouse JunD are seen in acidic and amphipathic amino-terminal domains. Chicken JunD contains stretches of oligoglycines, alanines and prolines, possibly acting as hinges that connect functionally distinct domains of the protein. Chicken junD is broadly expressed at low basal levels in differentiated tissues and at somewhat higher levels in cultured fibroblasts. The cDNA clone of junD was transcribed and translated in vitro. The resulting JunD protein migrates in between 40 and 50 kDa in an SDS gel and can be precipitated with an antibody prepared against a polypeptide consisting of the carboxy-terminal 100 amino acids of mouse c-Jun.	UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; NORRIS CANC CTR,LOS ANGELES,CA 90033	University of Southern California			Hartl, Markus/O-4655-2014; Vogt, Peter K./R-7547-2019	Hartl, Markus/0000-0001-7447-5920; Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1987, ONCOGENE, V2, P79; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KIMMEL SL, 1987, METHODS ENZYMOLOGY, V152; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1989, DECONTAMINATION DILU; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGH H, 1986, NATURE, V319, P144; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0	24	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1623	1631						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923529				2022-12-28	WOS:A1991GX27400018
J	ANESKIEVICH, BJ; HAIMOVICH, B; BOETTIGER, D				ANESKIEVICH, BJ; HAIMOVICH, B; BOETTIGER, D			PHOSPHORYLATION OF INTEGRIN IN DIFFERENTIATING TS-ROUS SARCOMA VIRUS-INFECTED MYOGENIC CELLS	ONCOGENE			English	Article							FIBRONECTIN-RECEPTOR COMPLEX; MONOCLONAL-ANTIBODIES; TYROSINE PHOSPHORYLATION; EXOGENOUS FIBRONECTIN; MUSCLE MORPHOGENESIS; SKELETAL-MUSCLE; CSAT ANTIGEN; CHICK-EMBRYO; MYOBLASTS; PROTEIN	The differentiation of primary myogenic cultures requires the attachment of the cells to an extracellular matrix substrate using an integrin family receptor. These integrin receptors can be phosphorylated on both their alpha and beta chains, and it has been postulated that phosphorylation regulates the receptor function. Quail myogenic clones transformed with ts-LA24A differentiated into mature myotubes following a temperature shift to non-permissive temperature which inactivates the viral src kinas. Phosphorylation of integrin beta-1 chain and of at least one alpha chain was detected on both serine and tyrosine. An additional alpha chain(s) with a mobility similar to alpha 5 was not phosphorylated at either temperature. Following the induction of differentiation by a temperature shift, there was a marked decrease in integrin phosphorylation of both alpha and beta integrin chains. This decrease was more prominent for serine than for tyrosine, suggesting that src could not be the only kinase involved. The drop in integrin phosphorylation correlated with the initiation of differentiation, suggesting that integrin phosphorylation could be at least part of the mechanism by which myogenic differentiation is blocked by v-src.	UNIV PENN,SCH MED,DEPT MICROBIOL,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA049866, R01CA030383] Funding Source: NIH RePORTER; NCI NIH HHS [CA 30383, CA 49866, CA 16503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; BISCHOFF R, 1967, J CELL BIOL, V36, P111; BOETTIGER D, 1989, UCLA S MOL CELLULAR, P57; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; CARLEY WW, 1981, J CELL BIOL, V97, P797; CHEN LB, 1977, CELL, V37, P357; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CHI JC, 1975, P NATL ACAD SCI USA, V72, P4999, DOI 10.1073/pnas.72.12.4999; CHI JCH, 1975, J CELL BIOL, V67, P523, DOI 10.1083/jcb.67.3.523; CHIQUET M, 1979, J BIOL CHEM, V254, P5475; CHIQUET M, 1981, DEV BIOL, V88, P220, DOI 10.1016/0012-1606(81)90166-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; DUBAND JL, 1988, FEBS LETT, V230, P181, DOI 10.1016/0014-5793(88)80667-7; FALCONE G, 1984, EMBO J, V3, P1327, DOI 10.1002/j.1460-2075.1984.tb01971.x; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; FOSTER RF, 1987, DEV BIOL, V122, P11, DOI 10.1016/0012-1606(87)90327-7; FURCHT LT, 1978, CELL, V13, P263, DOI 10.1016/0092-8674(78)90195-2; GEORGEWEINSTEIN M, 1988, DEV BIOL, V125, P34, DOI 10.1016/0012-1606(88)90056-5; HAIMOVICH B, 1991, CELL REGUL, V2, P271, DOI 10.1091/mbc.2.4.271; HAUSCHKA SD, 1966, P NATL ACAD SCI USA, V55, P119, DOI 10.1073/pnas.55.1.119; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; KAUSHAL V, 1986, ANAL BIOCHEM, V157, P291, DOI 10.1016/0003-2697(86)90629-9; KELLIE S, 1987, BIOCHEM SOC T, V15, P791, DOI 10.1042/bst0150791; KIENY M, 1984, J EXP ZOOL, V232, P327, DOI 10.1002/jez.1402320220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAPLEY P, 1989, ONCOGENE, V4, P325; WEBER K, 1974, COLD SPRING HARB SYM, V39, P363, DOI 10.1101/SQB.1974.039.01.047; WYKE JA, 1973, VIROLOGY, V54, P152	44	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1381	1390						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1653410				2022-12-28	WOS:A1991GX27200014
J	HADDOW, S; FOWLIS, DJ; PARKINSON, K; AKHURST, RJ; BALMAIN, A				HADDOW, S; FOWLIS, DJ; PARKINSON, K; AKHURST, RJ; BALMAIN, A			LOSS OF GROWTH-CONTROL BY TGF-BETA OCCURS AT A LATE STAGE OF MOUSE SKIN CARCINOGENESIS AND IS INDEPENDENT OF RAS GENE ACTIVATION	ONCOGENE			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; LIVER EPITHELIAL-CELLS; HA-RAS; TERMINAL DIFFERENTIATION; INHIBITION; PROLIFERATION; ONCOGENE; PROGRESSION; HEPATOCYTES; EXPRESSION	The relationship between the expression of a mutant ras gene in epithelial cells and loss of responsiveness to the negative effects of transforming growth factor-beta (TGF-beta) is presently unclear. We have investigated this question using a series of cell lines derived from benign and malignant mouse skin tumours which express mutant forms of the H-ras gene. Immortalised, non-tumorigenic mouse epidermal cells respond to TGF-beta by cessation of growth, whereas in a series of malignant carcinoma lines the response was substantially reduced. Introduction of a mutant H-ras gene into the immortalised cells did not lead to any appreciable change in TGF-beta responsiveness, suggesting that initiation of carcinogenesis by ras mutation does not directly alter growth control by this pathway. Of two non-tumorigenic papilloma lines tested which had mutant H-ras genes, one retained complete sensitivity to TGF-beta, whereas the other showed a similar response to carcinomas. We conclude that growth control by TGF-beta is lost at a relatively late stage of carinogenesis in this system, and is independent of ras gene activation.	BEATSON INST CANC RES,CRC,BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,BEARSDEN,GLASGOW G61 1BD,SCOTLAND; YORKHILL HOSP,DUNCAN GUTHRIE INST MED GENET,GLASGOW,SCOTLAND	Beatson Institute				AKHURST, ROSEMARY/0000-0002-4474-9668				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BOYD JA, 1990, CANCER RES, V50, P3394; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; FUSENIG N E, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V19, P219; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HOUCK KA, 1989, ONCOGENE, V4, P19; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; KULESZMARTIN M, 1990, CANCER RES, V50, P686; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN P, 1987, BIOCHEM BIOPH RES CO, V143, P26, DOI 10.1016/0006-291X(87)90624-3; MADHUKAR BV, 1989, CARCINOGENESIS, V10, P13, DOI 10.1093/carcin/10.1.13; MANNING A, 1991, IN PRESS ONCOGENE; MANSBRIDGE JN, 1988, J INVEST DERMATOL, V90, P336, DOI 10.1111/1523-1747.ep12456286; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCMAHON JB, 1986, CANCER RES, V46, P4665; NAGY P, 1989, MOL CARCINOGEN, V2, P345, DOI 10.1002/mc.2940020609; PARKINSON EK, 1990, CARCINOGENESIS, V11, P195; PERA MF, 1984, CARCINOGENESIS, V5, P671, DOI 10.1093/carcin/5.5.671; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Reddel R R, 1988, Oncogene Res, V3, P401; REISS M, 1987, CANCER RES, V47, P6705; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROLLINS BJ, 1989, J CELL PHYSIOL, V139, P455, DOI 10.1002/jcp.1041390302; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TERZAGHIHOWE M, 1989, CARCINOGENESIS, V10, P973, DOI 10.1093/carcin/10.6.973; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WOLLENBERG GK, 1987, CANCER RES, V47, P6595; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0	39	74	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1465	1470						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886717				2022-12-28	WOS:A1991GX27200025
J	BERGER, I; SHAUL, Y				BERGER, I; SHAUL, Y			STRUCTURE AND FUNCTION OF HUMAN JUN-D	ONCOGENE			English	Article							B VIRUS ENHANCER; C-JUN; TRANSCRIPTIONAL ACTIVATION; TRANS-ACTIVATOR; V-JUN; GENE; BINDING; AP-1; FOS; EXPRESSION	A jun related cDNA and its corresponding genomic fragment were cloned from human cells and sequenced. Polymerase chain reaction analysis showed that this gene is the human homologue of the mouse jun-D gene despite the fact that the degree of amino acid sequence conservation between the two is much poorer (77.3%) than that found between the homologues of c-jun and jun-B (95-98%). The product of this gene binds an AP-1 site and upon cotransfection stimulates the activity of a promoter that bears an AP-1 site. The level of activation is comparable to that of v-jun and the activity of both is further stimulated by v-fos. Deletion mutants of the gene that lack the best conserved region in the activating domain are poorly active. However, our data suggest that the activating domain is not confined exclusively to the conserved regions. Interestingly, at high concentrations human jun-D displays decreased activity which cannot be explained by a simple self squelching model.			BERGER, I (corresponding author), WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL.							ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; FAKTOR O, 1990, ONCOGENE, V5, P867; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHAUL Y, 1984, J VIROL, V51, P776, DOI 10.1128/JVI.51.3.776-787.1984; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YANG-YEN H-F, 1990, New Biologist, V2, P351	31	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					561	566						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903194				2022-12-28	WOS:A1991FR93900009
J	KRUGER, A; ANDERSON, SM				KRUGER, A; ANDERSON, SM			THE V-SRC ONCOGENE BLOCKS THE DIFFERENTIATION OF A MURINE MYELOID PROGENITOR-CELL LINE AND INDUCES A TUMORIGENIC PHENOTYPE	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; HEMATOPOIETIC-CELLS; LEUKEMIA-VIRUS; GRANULOCYTIC DIFFERENTIATION; INTERLEUKIN-3 DEPENDENCE; MYELOGENOUS LEUKEMIA; FACTOR INDEPENDENCE; MOLECULAR CONTROL; TRANSGENIC MICE; IL-3 DEPENDENCE	We have investigated the ability of the v-src oncogene to block the differentiation of the murine myeloid progenitor cell line 32D cl3. In response to granulocyte-colony stimulating factor (G-CSF), 32D cl3 cells are induced to differentiate into mature granulocytes (Valtieri et al., 1987). In contrast, no differentiation was observed following G-CSF treatment of 32D cl3 cells infected with a murine retrovirus carrying the wild-type v-src oncogene. Furthermore, cells infected with a v-src temperature-sensitive (ts) mutant did not differentiate at the permissive temperature, however, at the nonpermissive temperature G-CSF induced granulocytic differentiation. Differentiation of 32D cl3 cells infected with ts WP31A (ts LA31A src gene inserted into amphotropic murine leukemia virus 4070A; Anderson et al., 1987) occurred with the same kinetics as uninfected 32D cl3 cells. Temperature-shift experiments indicate that after 72 hours of treatment with G-CSF at the nonpermissive temperature, approximately half of the 32D cl3 cells infected with ts WP31A virus become committed to differentiation. Prior to that time, activation of v-src by shifting the cells to the permissive temperature resulted in the presence of only undifferentiated blast cells after six days in culture. In contrast to normal 32D cl3 cells, cells infected with the wild-type v-src were tumorigenic when injected into nu/nu Swiss mice. Lesions appeared in the spleen, liver, kidney, lungs and lymph nodes following subcutaneous injection. Growth factor-independent cells were recovered from the tumor, spleen, bone marrow and a lymph node of tumor-bearing nude mouse. Analysis of the proviral integration sites by inverse polymerase chain reaction (PCR) demonstrated that the tumor cells were of donor cell origin.	SUNY STONY BROOK,DEPT PATHOL,BHS-9,ROOM 153,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R29CA045241, R01CA045241] Funding Source: NIH RePORTER; NCI NIH HHS [CA45241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALEXANDER WS, 1989, ONCOGENE, V4, P575; ANDERSON SM, 1987, VIROLOGY, V160, P263, DOI 10.1016/0042-6822(87)90070-5; ANDERSON SM, 1990, ONCOGENE, V5, P317; ANDERSON SM, 1984, J VIROL, V46, P594; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; CHATTOPADHYAY SK, 1981, VIROLOGY, V113, P465, DOI 10.1016/0042-6822(81)90175-6; CHIRGWIN JJ, 1979, BIOCHEMISTRY-US, V13, P5294; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CRAMER E, 1985, BLOOD, V65, P423; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; GAMBKE C, 1985, P NATL ACAD SCI USA, V82, P879, DOI 10.1073/pnas.82.3.879; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MAVILIO F, 1989, ONCOGENE, V4, P301; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1985, BLOOD, V65, P357; NEEDLEMAN SW, 1986, BLOOD, V67, P753; OLIFF A, 1985, P NATL ACAD SCI USA, V82, P3306, DOI 10.1073/pnas.82.10.3306; OTT D, 1990, J VIROL, V64, P757, DOI 10.1128/JVI.64.2.757-766.1990; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROVERA G, 1987, ONCOGENE, V1, P29; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SACHS L, 1985, ANNU REV MED, V36, P177; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STOCKING C, 1989, CURR TOP MICROBIOL, V149, P117; TAKEYA T, 1982, J VIROL, V44, P1; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; WATSON JD, 1987, J IMMUNOL, V139, P123	50	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					245	256						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1705687				2022-12-28	WOS:A1991FZ13400010
J	DUMONT, DJ; YAMAGUCHI, TP; CONLON, RA; ROSSANT, J; BREITMAN, ML				DUMONT, DJ; YAMAGUCHI, TP; CONLON, RA; ROSSANT, J; BREITMAN, ML			TEK, A NOVEL TYROSINE KINASE GENE LOCATED ON MOUSE CHROMOSOME-4, IS EXPRESSED IN ENDOTHELIAL-CELLS AND THEIR PRESUMPTIVE PRECURSORS	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTO-ONCOGENE; MESSENGER-RNAS; EMBRYONIC-DEVELOPMENT; INSITU HYBRIDIZATION; TRANSFORMING GENE; 2 ISOFORMS; W-LOCUS; RECEPTOR; LOCALIZATION	A search for protein tyrosine kinases expressed during murine cardiogenesis resulted in the isolation of a novel tyrosine kinase, designated tek, which maps to mouse chromosome 4 between the brown and pmv-23 loci. The deduced amino acid sequence of tek predicts that it encodes a putative receptor tyrosine kinase that contains a 21 amino acid kinase insert and which is most closely related in its catalytic domains to FGFR1 and the product of the ret proto-oncogene. In situ hybridization analysis of adult tissues, as well as sectioned and whole-mount embryos, showed that tek is specifically expressed in the endocardium, the leptomeninges and the endothelial lining of the vasculature from the earliest stages of their development. Moreover, examination of the morphology of tek-expressing cells, and staging of tek expression relative to that of the endothelial cell marker von Willebrand factor, revealed that tek is expressed prior to von Willebrand factor and appears to mark the embryonic progenitors of mature endothelial cells. tek encodes a novel putative receptor tyrosine kinase that may be critically involved in the determination and/or maintenance of cells of the endothelial lineage.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								BEDDINGTON RSP, 1989, MOL BIOL MED, V6, P263; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COFFIN JD, 1988, DEVELOPMENT, V102, P735; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58, DOI 10.1111/j.1749-6632.1990.tb42364.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; FUJITA H, 1991, BIOCHEM BIOPH RES CO, V174, P946, DOI 10.1016/0006-291X(91)91510-J; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HORMIA M, 1984, EUR J CELL BIOL, V33, P217; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; KAUFMAN MH, 1981, J ANAT, V133, P235; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Lyon M., 1989, GENETIC VARIANTS STR; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MANASEK FJ, 1976, CELL SURFACE ANIMAL, P545; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MUSLIN AJ, 1991, DEVELOPMENT, V112, P1095; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; NODEN DM, 1988, DEVELOPMENT, V103, P121; NODEN DM, 1990, ANN NY ACAD SCI, V588, P236, DOI 10.1111/j.1749-6632.1990.tb13214.x; OBRIEN SJ, 1990, GENETIC MAPS; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAFRAN A, 1990, ONCOGENE, V5, P635; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMASI V, 1990, Biofactors, V2, P213; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R	54	341	351	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1471	1480						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630810				2022-12-28	WOS:A1992JE81300002
J	LALLEMAND, C; KAHAN, A; TELVI, L; JORET, AM; GERFAUX, J				LALLEMAND, C; KAHAN, A; TELVI, L; JORET, AM; GERFAUX, J			AN ANTISENSE INTERFERON-BETA RNA ABOLISHES REPRESSION OF C-FOS GENE-EXPRESSION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; PROTO-ONCOGENE FOS; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; RAT FIBROBLASTS; PHORBOL ESTER; 3T3 CELLS; KINASE-C	To determine the cellular functions which are modified when interferon-beta (IFN-beta) gene expression is inhibited, a plasmid allowing the constitutive expression of RNA complementary to IFN-beta mRNA was constructed and stably introduced into L929 cells. Some of the selected clones expressing this antisense IFN-beta mRNA, named L-ASI, were unable to produce IFN-beta and lost the ability to arrest in the G0 phase of the cell cycle. Indeed, the usual transrepression of the c-fos gene observed in quiescent cells was blocked in IFN-beta antisense L-ASI clones and the c-fos gene was permanently stimulated. This overexpression of c-fos was not modified in response to protein kinase C agonists such as phorbol esters, but increased in response to the adenylate cyclase activator forskolin. In addition, the ability to induce major histocompatibility class I genes following recombinant IFN-beta treatment was impaired in antisense IFN-beta L-ASI clones, suggesting an important alteration of this cell with regard to the interferon system. Unexpectedly, the tumorigenicity of the clones was significantly diminished. We postulate that IFN-beta antisense RNA blocks the repression of the c-fos gene and thus prevents the arrest of cells in the G0 phase of the cycle.	INSERM, U153, 17 RUE FER MOULIN, F-75005 PARIS, FRANCE; HOP COCHIN, INSERM, U283, F-75674 PARIS 14, FRANCE; HOP ST VINCENT DE PAUL, SERV HISTOL EMBRYOL CYTOGENET & ANAT PATHOL, F-75674 PARIS 14, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite				lallemand, christophe/0000-0001-5965-2482				BARBER JR, 1987, ANN NY ACAD SCI, V511, P117, DOI 10.1111/j.1749-6632.1987.tb36242.x; BARLOW DP, 1984, DIFFERENTIATION, V27, P229, DOI 10.1111/j.1432-0436.1984.tb01433.x; BRANCA AA, 1988, IN VITRO CELL DEV B, V24, P155; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUSCHER M, 1988, ONCOGENE, V3, P301; CHRISTOFINIS GJ, 1981, J GEN VIROL, V52, P169, DOI 10.1099/0022-1317-52-1-169; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COSMAN D, 1982, NATURE, V295, P73, DOI 10.1038/295073a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOHERTY PJ, 1989, ANAL BIOCHEM, V177, P7, DOI 10.1016/0003-2697(89)90003-1; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FISHER PB, 1983, P NATL ACAD SCI-BIOL, V80, P2961, DOI 10.1073/pnas.80.10.2961; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; FRANCIS MK, 1989, MOL CELL BIOL, V9, P3553, DOI 10.1128/MCB.9.8.3553; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GERFAUX J, 1989, CANCER RES, V49, P1241; GEWERT DR, 1984, EUR J BIOCHEM, V139, P619, DOI 10.1111/j.1432-1033.1984.tb08049.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREEN DA, 1984, MON NOT R ASTRON SOC, V211, P433, DOI 10.1093/mnras/211.2.433; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENE JJ, 1984, J INTERFERON RES, V4, P517, DOI 10.1089/jir.1984.4.517; GROSSBERG SE, 1989, EXPERIENTIA, V45, P508, DOI 10.1007/BF01990499; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIGASHI Y, 1983, J BIOL CHEM, V258, P9522; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JOKLIK WK, 1990, INTERFERONS VIROLOGY, P383; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KEAY S, 1980, P NATL ACAD SCI-BIOL, V77, P4099, DOI 10.1073/pnas.77.7.4099; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OLDBERG A, 1983, J BIOL CHEM, V258, P193; OLESZAK E, 1980, J INTERFERON RES, V1, P37, DOI 10.1089/jir.1980.1.37; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SERGIESCU D, 1986, P NATL ACAD SCI USA, V83, P5764, DOI 10.1073/pnas.83.16.5764; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; TOMINAGA S, 1985, J BIOL CHEM, V260, P1975; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WAN YJY, 1988, J INTERFERON RES, V8, P105, DOI 10.1089/jir.1988.8.105; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	69	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1109	1118						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594242				2022-12-28	WOS:A1992HU64200008
J	MISAWA, Y; SHIBUYA, M				MISAWA, Y; SHIBUYA, M			AMPLIFICATION AND REARRANGEMENT OF MELF/MOUSE CD43 (LEUKOSIALIN) GENE ENCODING A HIGHLY GLYCOSYLATED MEMBRANE-PROTEIN GP120 IN FRIEND-ERYTHROLEUKEMIA CELLS	ONCOGENE			English	Article							LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; WISKOTT-ALDRICH SYNDROME; MURINE LEUKEMIA-VIRUS; ELECTROPHORETIC TRANSFER; TRANSCRIPTION FACTOR; POLYACRYLAMIDE GELS; PUTATIVE ONCOGENE; RIBONUCLEIC-ACID; DIFFERENTIATION; SIALOPHORIN	Using a differential hybridization method, we isolated a cDNA (melF) overexpressed in a murine Friend erythroleukemia cell line, F5-5. Southern blotting and sequence analysis revealed that the melF cDNA encodes a membrane protein of 395 amino acids that is the counterpart to human CD43 (leukosialin) surface antigen of lymphocytes in mice. The melF/mouse CD43 (mCD43) gene was found to be amplified eight- to 10-fold not only in F5-5 cells, but also in their sib cell lines, including the earliest clone established. This indicates that the amplification of melF/mCD43 gene occurred at an early stage of malignant transformation of the F5-5 family. Furthermore, the same gene was rearranged in another Friend erythroleukemia cell line TSA8. In both cell lines, F5-5 and TSA8, the levels of melF/mCD43 mRNA were 30- to 50-fold higher than that in uninfected spleen cells. Among normal tissues examined, the expression of melF/mCD43 gene was restricted to hematopoietic tissues. These results suggest that melF/mCD43 gene has an important role in progression of leukemic cells in the erythroid lineage and also has a physiological function in normal hematopoiesis.	UNIV TOKYO,INST MED SCI,DEPT GENET,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								AXELSSON B, 1988, J IMMUNOL, V141, P2912; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BOYD AW, 1981, J IMMUNOL, V126, P2466; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P183; FEINBERG A, 1982, ANAL BIOCHEM, V132, P6; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HINIKOFF S, 1984, GENE, V28, P351; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; IKAWA Y, 1966, GANN, V57, P641; IKAWA Y, 1976, GANN, V67, P767; IKAWA Y, 1975, BIBL HAEMATOL, V43, P37; KILEEN N, 1987, EMBO J, V6, P4029; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; Maniatis T., 1982, MOL CLONING; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; MISAWA Y, 1990, BIOCHEM BIOPH RES CO, V170, P39, DOI 10.1016/0006-291X(90)91237-M; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OLIFF A, 1980, J VIROL, V35, P924, DOI 10.1128/JVI.35.3.924-936.1980; OSTERTAG W, 1973, NATURE-NEW BIOL, V243, P203, DOI 10.1038/newbio243203a0; OSTERTAG W, 1987, ADV CANCER RES, V48, P193, DOI 10.1016/S0065-230X(08)60693-4; PARK SH, 1990, PCR PROTOCOLS GUIDE, P407; PARKMAN R, 1981, LANCET, V2, P1387; RALPH P, 1973, J NATL CANCER I, V51, P883, DOI 10.1093/jnci/51.3.883; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SASAKI H, 1987, JPN J CANCER RES, V78, P776; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WONG RCK, 1990, J IMMUNOL, V144, P1455; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	47	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					919	926						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1533277				2022-12-28	WOS:A1992HP64200011
J	ARII, M; TAKADA, S; KOIKE, K				ARII, M; TAKADA, S; KOIKE, K			IDENTIFICATION OF 3 ESSENTIAL REGIONS OF HEPATITIS-B VIRUS X-PROTEIN FOR TRANSACTIVATION FUNCTION	ONCOGENE			English	Article							LONG TERMINAL REPEAT; HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; CELL-LINES; DNA; POLYMERASE; EXPRESSION	The X protein of hepatitis B virus (HBV) consists of 154 amino acids and trans-activates various cellular and viral promoters and enhancers. To investigate the essential amino acid sequences of X protein for trans-activation function, various mutations were introduced into the X open reading frame and analysed for trans-activation activity by chloramphenicol acetyltransferase assay. The amino acid sequences 46-52 (especially Pro-46, His-49 and His-52), 61-69 (especially Cys-61, Gly-67 to Pro-68 and Cys-69) and 132-139 (especially Phe-132, Cys-137 and His-139) of HBV X protein were found to be essential for the trans-activation function. These three sequences are included in the conserved amino acid sequences among hepadna virus X proteins. The first one could form a domain-like structure characteristic of histidine/aspartic acid requirement. The second and the third are homologous to the Kunitz domain of Kunitz-type serine protease inhibitors. The amino acids 5-27 region was found to make no positive contribution to the transactivation function like the last 12 amino acids in the carboxy-terminal region [Takada, S. & Koike, K. (1990). Proc. Natl. Acad. Sci. USA, 87, 5628-5632]. From these findings, the trans-activation function of X protein appears to be dependent on at least two types of domain-like structures.	JAPANESE FDN CANC RES,INST CANC,DEPT GENE RES,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BEASLEY RP, 1981, LANCET, V2, P1129; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FAKTOR O, 1990, ONCOGENE, V5, P867; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1986, ENZYMES, V17, P191; KAY A, 1985, EMBO J, V4, P1287, DOI 10.1002/j.1460-2075.1985.tb03774.x; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOBAYASHI M, 1984, GENE, V30, P227; KOIKE K, 1989, MOL BIOL MED, V6, P151; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MEYERS ML, 1986, J VIROL, V57, P101, DOI 10.1128/JVI.57.1.101-109.1986; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SEEGER C, 1984, J VIROL, V51, P367, DOI 10.1128/JVI.51.2.367-375.1984; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YAGINUMA K, 1989, J VIROL, V63, P2914, DOI 10.1128/JVI.63.7.2914-2920.1989; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990	46	99	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					397	403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549357				2022-12-28	WOS:A1992HK00500001
J	MCGREW, BR; NICHOLS, DW; STANTON, VP; CAI, H; WHORF, RC; PATEL, V; COOPER, GM; LAUDANO, AP				MCGREW, BR; NICHOLS, DW; STANTON, VP; CAI, H; WHORF, RC; PATEL, V; COOPER, GM; LAUDANO, AP			PHOSPHORYLATION OCCURS IN THE AMINO TERMINUS OF THE RAF-1 PROTEIN	ONCOGENE			English	Article								The ability of the Raf-1 protein to morphologically transform murine fibroblasts can be activated by amino-terminal deletions or substitutions. We have compared the phosphorylation states of full-length and representative transforming and non-transforming amino-terminal deletion mutants of the Raf-1 protein using phosphoamino acid analysis and tryptic phosphopeptide mapping. Several [P-32]orthophosphate-labeled tryptic phosphopeptides that were present in the full-length Raf-1 protein were absent from the highly transforming 22W Raf-1 mutant (lacking 305 amino-terminal residues). Peptide-specific antisera localized Raf-1 phosphorylation sites to several amino-terminal cyanogen bromide and tryptic peptides that are deleted from the 22W protein. A major phosphorylated tryptic peptide of the Raf-1 protein was immunoprecipitated by antiserum directed against amino acid residues 257-275, a highly conserved region of the raf family. This tryptic peptide is entirely deleted from the highly transforming 22W protein. Subtractive Edman degradation and electrophoretic analysis of the immunoprecipitated tryptic peptide indicated that phosphorylation of the Raf-1 protein occurs at serine 259. Multiple phosphorylated tryptic peptide forms were immunoprecipitated by antiserum directed against Raf-1 residues 283-309. The majority of this tryptic peptide is also deleted from the highly transforming Raf-1 mutant 22W.	UNIV NEW HAMPSHIRE, DEPT BIOCHEM, SPAULDING LIFE SCI BLDG, DURHAM, NH 03824 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	University System Of New Hampshire; University of New Hampshire; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Stanton, Vincent/0000-0002-2205-6000	NCI NIH HHS [CA18689, K08 CA01052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018689, K08CA001052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GRAY WR, 1970, ANAL BIOCHEM, V33, P36, DOI 10.1016/0003-2697(70)90436-7; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; ISHIKAWA F, 1988, ONCOGENE, V3, P653; KAGAN A, 1979, METHOD HORM RADIOIMM, P328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MITSUNOBU F, 1989, ONCOGENE, V4, P437; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; PERCY ME, 1972, ANAL BIOCHEM, V45, P60, DOI 10.1016/0003-2697(72)90007-3; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stewart JM, 1984, SOLID PHASE PEPTIDE; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247	42	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					33	42						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741164				2022-12-28	WOS:A1992HC22700005
J	MEDCALF, EA; TAKAHASHI, T; CHIBA, I; MINNA, J; MILNER, J				MEDCALF, EA; TAKAHASHI, T; CHIBA, I; MINNA, J; MILNER, J			TEMPERATURE-SENSITIVE MUTANTS OF P53 ASSOCIATED WITH HUMAN CARCINOMA OF THE LUNG	ONCOGENE			English	Article							TUMOR SUPPRESSOR PROTEIN; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; IMMUNOLOGICAL VARIANTS; GENE; TRANSFORMATION; ANTIGEN; CANCER; EXPRESSION; ONCOGENE	We have compared the effects of specific point mutations on the tertiary and quaternary structure of the human p53 protein. Eight mutants, each derived from primary resected tissues of lung carcinomas, were expressed in vitro under strictly defined conditions, such that the only known variant was the point mutation present in each p53 mRNA. All the mutations were located in highly conserved domains. The tertiary structure of each mutant protein was investigated by reactivity with anti-p53 monoclonal antibodies directed against conformation-dependent epitopes. Quaternary structure was examined by gel filtration. Although all the mutant proteins exhibited abnormal tertiary structures, their quaternary structures appeared similar to wild type, the one exception being p53-tyr135, which contains tyrosine in place of cysteine at residue 135. The conformational phenotype of mutant human p53 was found to be dependent upon (i) the locus of the mutation and (ii) the nature of the amino acid substitution: two different substitutions at residue 273 yielded two mutants with differing structural properties. We have discovered three mutants of human p53 that are temperature sensitive for conformation; one is mutated at codon 273, a 'hotspot' for p53 mutation in human cancer.	UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; USN HOSP,NCI,MED ONCOL BRANCH,BETHESDA,MD 20814	University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy			Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1591; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1222; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1991, CELL, V65, P1; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6567; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	32	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					71	76						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741167				2022-12-28	WOS:A1992HC22700010
J	BURNS, PA; KEMP, CJ; GANNON, JV; LANE, DP; BREMNER, R; BALMAIN, A				BURNS, PA; KEMP, CJ; GANNON, JV; LANE, DP; BREMNER, R; BALMAIN, A			LOSS OF HETEROZYGOSITY AND MUTATIONAL ALTERATIONS OF THE P53-GENE IN SKIN TUMORS OF INTERSPECIFIC HYBRID MICE	ONCOGENE			English	Article							MOUSE SKIN; CHEMICAL CARCINOGENESIS; P53 PROTEIN; WILD-TYPE; GENE; DNA; ACTIVATION; ONCOGENE; MODEL; RAS	Functional alterations or loss of tumor-suppressor genes are an important feature of neoplastic progression in humans. The employment of suitable animal model systems would greatly facilitate the detection and manipulation of such genes. We describe here an experimental approach to this problem based on the analysis of skin tumors induced in F1 hybrids between Mus musculus and Mus spretus mice. The results show that loss of heterozygosity on chromosome 11 occurred in 4/13 mouse skin carcinomas, but not in premalignant papillomas. Since the murine p53 gene is located on this chromosome, immunoprecipitation and DNA-sequencing studies were carried out on tumorigenic cell lines and primary tumor DNA respectively to determine the status of p53 alleles. These studies revealed the presence of p53 mutations, both frameshifts and missense, some of which are identical to those found in human tumors. Loss of normal p53 function is found in well-differentiated squamous-cell carcinomas and thus does not appear to be directly responsible for further progression to an undifferentiated spindle cell phenotype.	BEATSON INST CANC RES,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND; IMPERIAL CANC RES FUND,CLARE HALL LABS,MOLEC IMMUNOCHEM LAB,POTTERS BAR EN6 3LD,HERTS,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND; HOSP SICK CHILDREN,DEPT IMMUNOL & CANC,TORONTO M5G 1X8,ONTARIO,CANADA	Beatson Institute; University of Dundee; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Lane, David P/C-4920-2008; Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212; Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BOYD P, 1986, HUM GENET, V73, P171, DOI 10.1007/BF00291609; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRASH DE, 1991, IN PRESS P NATL ACAD; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHMANN A, 1991, CANCER RES, V51, P4097; CHENG SC, 1988, CARCINOGENESIS, V9, P1721, DOI 10.1093/carcin/9.9.1721; CHIBA I, 1990, ONCOGENE, V5, P1603; DIPPLE A, 1983, CANCER RES, V43, P4132; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUSENIG N E, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V19, P219; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MUNKE M, 1987, J MOL EVOL, V25, P134, DOI 10.1007/BF02101755; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; QUINTANILLA M, 1991, IN PRESS CARCINOGENE; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERT B, 1985, NATURE, V314, P181, DOI 10.1038/314181a0; SOUSSI T, 1990, ONCOGENE, V5, P945; STONE JC, 1989, GENOMICS, V5, P70, DOI 10.1016/0888-7543(89)90088-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	43	176	182	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2363	2369						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766680				2022-12-28	WOS:A1991GX73500028
J	KEEGAN, K; MEYER, S; HAYMAN, MJ				KEEGAN, K; MEYER, S; HAYMAN, MJ			STRUCTURAL AND BIOSYNTHETIC CHARACTERIZATION OF THE FIBROBLAST GROWTH-FACTOR RECEPTOR-3 (FGFR-3) PROTEIN	ONCOGENE			English	Article							EARLY XENOPUS EMBRYOS; TYROSINE KINASE; MAMMALIAN-CELLS; MESSENGER-RNAS; EXPRESSION; GENE; PHOSPHOTYROSINE; DIFFERENTIATION; IDENTIFICATION; TRANSLOCATION	Recently an additional member of the fibroblast growth factor receptor family, FGFR-3, was isolated. In this report, the structure and biosynthesis of the FGFR-3 protein product are investigated. In vitro transcription and translation of the three immunoglobulin-like domain form of FGFR-3 demonstrated the primary translation product to be approximately 97 kDa. However when analysed in COS-1 cells, this form of the receptor directed the expression of three polypeptides with apparent molecular weights of 97 kDa, 125 kDa and 135 kDa. Pulse-chase analysis, treatment of the cells with N-linked glycosylation inhibitors and digestion of these proteins with endoglycosidases demonstrated that the difference in molecular weights was the result of varying degrees of glycosylation. The 97 kDa protein was determined to be a non-glycosylated, cytoplasmic protein, whereas the 125-kDa protein was found to be a membrane-associated glycoprotein that is the biosynthetic precursor of the mature 135 kDa glycoprotein.	SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [R01 CA-42573, P01 CA-28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HAYMAN MJ, 1978, VIROLOGY, V85, P241, DOI 10.1016/0042-6822(78)90428-2; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAMPS MP, 1988, ONCOGENE, V2, P305; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMMELMAN D, 1988, SCIENCE, V242, P1053; KNIGHT J, 1988, ONCOGENE, V2, P317; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINKHART TA, 1981, DEV BIOL, V86, P18; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TARENTINO A, 1985, BIOCHEMISTRY-US, V261, P4465; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TIARA M, 1987, P NATL ACAD SCI USA, V84, P2980; TOGARI A, 1985, J NEUROSCI, V5, P307; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012	45	28	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2229	2236						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662791				2022-12-28	WOS:A1991GX73500008
J	LAVIGUEUR, A; BERNSTEIN, A				LAVIGUEUR, A; BERNSTEIN, A			P53 TRANSGENIC MICE - ACCELERATED ERYTHROLEUKEMIA INDUCTION BY FRIEND-VIRUS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; 2 DISTINCT STRAINS; WILD-TYPE P53; PUTATIVE ONCOGENE; BLAST CRISIS; CELL-GROWTH; LUNG-CANCER; GENE; MUTATIONS; LINE	Mutations in the p53 tumor-suppressor gene have been implicated in the pathogenesis of a significant proportion of human cancers and in a dominantly inherited familial cancer syndrome (Li-Fraumeni syndrome). Frequent rearrangements and point mutations have also been detected in the p53 gene in the murine erythroleukemias induced by Friend leukemia virus. We have previously reported that transgenic mice overproducing a mutated p53 protein are predisposed to the development of lung carcinomas, bone and soft-tissue sarcomas, as well as lymphoid malignancies. Here we report that p53 transgenic mice infected with the polycythemia-inducing strain of Friend virus (FV-P) progress to the late stage of erythroleukemia more rapidly than do normal mice. In addition, Friend leukemic cell lines derived from p53 transgenic mice overproduce mutant p53 protein and show a high frequency of rearrangement of the ets-related Spi-1 oncogene, as previously reported in Friend cell lines derived from non-transgenic animals. These results suggest that the same genetic changes involved in the evolution of Friend leukemia in normal mice are also required in mice with an inherited predisposition to cancer. The data also indicate that p53 transgenic mice provide an animal model in which to analyse the role that genetic and environmental factors play in influencing cancer predisposition.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1989, ANN NY ACAD SCI, V567, P165, DOI 10.1111/j.1749-6632.1989.tb16468.x; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HABER DA, 1991, CELL, V64, P5, DOI 10.1016/0092-8674(91)90200-I; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNUDSON AG, 1985, CANCER RES, V45, P1437; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MAGER D, 1981, MOL CELL BIOL, V1, P721, DOI 10.1128/MCB.1.8.721; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASHAL R, 1990, BLOOD, V75, P180; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1990, CANCER RES, V50, P7950; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEINBERG RA, 1989, CANCER RES, V49, P3713; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	52	42	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2197	2201						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766668				2022-12-28	WOS:A1991GX73500004
J	TARAKHOVSKY, A; ZAICHUK, T; PRASSOLOV, V; BUTENKO, ZA				TARAKHOVSKY, A; ZAICHUK, T; PRASSOLOV, V; BUTENKO, ZA			A 25-KDA POLYPEPTIDE IS THE LIGAND FOR P185NEU AND IS SECRETED BY ACTIVATED MACROPHAGES	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE-ACTIVITY; NEU PROTO-ONCOGENE; POINT MUTATION; EGF RECEPTOR; HUMAN-BREAST; C-ERBB-2 ONCOGENE; TUMOR-ANTIGEN; GENE; EXPRESSION	Medium conditioned by mouse peritoneal macrophages, activated by muramyl dipeptide (MDP), was used as a possible source of p185neu-specific ligand. MDP-activated macrophage-conditioned medium (MDP-CM) was shown to induce p185neu down-regulation in NEU-expressing NIH3T3 cells in a dose-dependent and temperature-sensitive manner. To exclude the possibility of an indirect action of proteins/metabolites present in MDP-CM on p185neu turnover, a ligand-trapping approach was used. Secreted NEU protein possessing only the extracellular domain but lacking transmembrane and protein kinase domains was expressed in HeLa cells and then purified from conditioned medium, using affinity chromatography on WGA-Sepharose. Co-incubation of the truncated, soluble NEU protein preparation with MDP-CM abolished MDP-CM-induced p185neu down-regulation and reduced self-phosphorylation. It is concluded that a putative p185neu-specific ligand is produced by macrophages activated by MDP. Using MDP-CM, the presence of a 25 kDa polypeptide, distinct from EGF, PDGF, FGF, IGF, TGF-alpha and TGF-beta and TNF-alpha, could be demonstrated by decorating a Western blot with soluble NEU and anti-NEU antibodies. Thus, a 25kDa (non-reduced) p185neu ligand has been described.	ACAD SCI UKSSR,INST ONCOL PROBLEMS,DEPT LEUKEMIAGENESIS,KIEV,UKRAINE,USSR; ACAD SCI USSR,INST MOLEC BIOL,MOSCOW V-71,USSR	National Academy of Sciences Ukraine								AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ALAN A, 1981, MOL CELL BIOCHEM, V41, P27; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BAHR GM, 1986, FASEB J, V45, P2541; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BERGER MS, 1988, CANCER RES, V48, P1238; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JALANKO A, 1988, BIOCHIM BIOPHYS ACTA, V949, P206, DOI 10.1016/0167-4781(88)90084-X; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PRASSOLOV VS, 1988, P ACAD SCI USSR, V300, P1498; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TALBOT PJ, 1984, J IMMUNOL METHODS, V73, P177, DOI 10.1016/0022-1759(84)90043-7; TARAKHOVSKY AM, 1990, ONCOGENE, V5, P405; TARAKHOVSKYA, 1990, ONCOGENES GROWTH CON, P207; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WIEDERMANN CJ, 1988, J IMMUNOL, V137, P3928; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; ZHOU DJ, 1987, CANCER RES, V47, P6123	59	38	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2187	2196						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1685016				2022-12-28	WOS:A1991GX73500003
J	WEIRTHOMPSON, E; CONDIE, A; LEONARD, RCF; PROSSER, J				WEIRTHOMPSON, E; CONDIE, A; LEONARD, RCF; PROSSER, J			A FAMILIAL RB1 MUTATION DETECTED BY THE HOT TECHNIQUE IS HOMOZYGOUS IN A 2ND-PRIMARY NEOPLASM	ONCOGENE			English	Note							HUMAN RETINOBLASTOMA GENE; OSTEO-SARCOMA; BREAST-TUMORS; T-ANTIGEN; EXPRESSION; CARCINOMA; PROTEIN; BINDING; POLYMORPHISMS; INACTIVATION	Using the hydroxylamine-osmium tetroxide (HOT) technique, we have identified a constitutional point mutation in the retinoblastoma susceptibility gene (RB1) which segregates with the expression of retinoblastoma in five affected family members. One member developed a second primary tumour, a small-cell lung carcinoma (SCLC), which metastasized to the liver. Analysis of liver tumour DNA revealed homozygosity for the constitutional mutation, a G --> A transition at the fifth base of intron 21, resulting in the excision of exon 21 from the mRNA. This is the first demonstration of homozygotization of a constitutional RB mutation in a metastatic second primary tumour and underlines the usefulness of the HOT technique for identification of mutations of the RB1 gene.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,IMPERIAL CANC RES FUND,MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh								BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHENG J, 1990, BLOOD, V75, P730; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FRIEND S, 1989, MOL GENETICS CANCER, P19; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAY FG, 1991, BRIT J CANCER, V63, P43; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MORI N, 1990, ONCOGENE, V5, P1713; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PROSSER J, 1990, ONCOGENE, V5, P1573; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; REISSMANN PT, 1989, CANCER CEL, V7, P229; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; STANBRIDGE EJ, 1990, GENETIC BASIS FOR CARCINOGENESIS, P3; STEWART CC, 1989, ARCH PATHOL LAB MED, V113, P634; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; VARLEY JM, 1989, ONCOGENE, V4, P725; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YOKOTA J, 1988, ONCOGENE, V3, P471; 1988, CYTOGENET CELL GENET, V51, P762	34	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2353	2356						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662795				2022-12-28	WOS:A1991GX73500026
J	DESBOIS, C; PAIN, B; GUILHOT, C; BENCHAIBI, M; FFRENCH, M; GHYSDAEL, J; MADJAR, JJ; SAMARUT, J				DESBOIS, C; PAIN, B; GUILHOT, C; BENCHAIBI, M; FFRENCH, M; GHYSDAEL, J; MADJAR, JJ; SAMARUT, J			V-ERBA ONCOGENE ABROGATES GROWTH-INHIBITION OF CHICKEN-EMBRYO FIBROBLASTS INDUCED BY RETINOIC ACID	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; RESPONSIVE ELEMENT; GLUCOCORTICOID RECEPTOR; GENE-TRANSCRIPTION; BINDING DOMAIN; DNA-BINDING; VITAMIN-A; C-ERBA; JUN; CELLS	Retinoic acid inhibits chicken embryo fibroblast (CEF) proliferation by altering the G1 phase of the cell cycle with induction of a strong increase in the generation time. This growth-inhibitory response to retinoic acid is abrogated by expression of the v-erbA oncogene, suggesting an interference between retinoic acid receptors and the v-ErbA oncoprotein. Moreover, CEF expressing either the v-src, v-jun or v-fos oncogenes are also insensitive to retinoic acid treatment. In contrast, CEF expressing either the v-myc, v-myb-ets, v-mil, v-sea or v-erbB oncogenes are still sensitive to retinoic acid. These data strongly suggest functional interferences between the retinoic acid receptors and the AP-1 transcription factor complex in the control of expression of genes involved in CEF proliferation.	FAC MED GRANGE BLANCHE,CYTOL ANALYT LAB,F-69373 LYONS 08,FRANCE; CTR UNIV ORSAY,INST CURIE,BIOL SECT,LABS 110-111-112,F-91405 ORSAY,FRANCE; ECOLE NORMALE SUPER LYON,INRA,CNRS,BIOL MOLEC & CELLULAIRE LAB,UMR 49,F-69364 LYONS 07,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE	DESBOIS, C (corresponding author), UNIV CLAUDE BERNARD LYON 1,FAC MED ALEXIS CARREL,CNRS,UMR 30,RUE GUILLAUME PARADIN,F-69372 LYONS 08,FRANCE.		Samarut, Jacques/AAD-2587-2019; GHYSDAEL, Jacques/F-3377-2013; Morris, Christelle/M-8168-2014; Pain, Bertrand/A-7686-2015	Morris, Christelle/0000-0003-1575-4609; Pain, Bertrand/0000-0002-1210-8444				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; CORDELL J, 1984, J HISTOCHEM CYTOCHEM, V31, P219; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIAZ JJ, 1989, ONCOL RES, V1, P163; DION LD, 1980, P SOC EXP BIOL MED, V163, P510; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HADDOX MK, 1979, CANCER RES, V39, P2476; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JANSSON M, 1987, ONCOGENE, V1, P167; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KHAZAIE K, 1991, ONCOGENE, V6, P21; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; LI RP, 1989, ONCOGENE RES, V5, P137; MAGAUD JP, 1988, J IMMUNOL METHODS, V106, P95, DOI 10.1016/0022-1759(88)90276-1; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PAIN B, 1990, New Biologist, V2, P284; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHRODER EW, 1982, P NATL ACAD SCI-BIOL, V79, P1549, DOI 10.1073/pnas.79.5.1549; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	46	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2129	2135						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1682867				2022-12-28	WOS:A1991GX11900025
J	VERSNEL, MA; CLAESSONWELSH, L; HAMMACHER, A; BOUTS, MJ; VANDERKWAST, TH; ERIKSSON, A; WILLEMSEN, R; WEIMA, SM; HOOGSTEDEN, HC; HAGEMEIJER, A; HELDIN, CH				VERSNEL, MA; CLAESSONWELSH, L; HAMMACHER, A; BOUTS, MJ; VANDERKWAST, TH; ERIKSSON, A; WILLEMSEN, R; WEIMA, SM; HOOGSTEDEN, HC; HAGEMEIJER, A; HELDIN, CH			HUMAN-MALIGNANT MESOTHELIOMA CELL-LINES EXPRESS PDGF BETA-RECEPTORS WHEREAS CULTURED NORMAL MESOTHELIAL CELLS EXPRESS PREDOMINANTLY PDGF ALPHA-RECEPTORS	ONCOGENE			English	Article							GROWTH-FACTOR PDGF; SIMIAN SARCOMA-VIRUS; B-CHAIN; CDNA CLONING; A-CHAIN; GENES; IDENTIFICATION; SIS; DIMERIZATION; COEXPRESSION	In human malignant mesothelioma cell lines elevated expression of the platelet-derived growth factor (PDGF) beta-chain (c-sis) gene was previously reported, while normal mesothelial cells barely express this gene. Expression of the PDGF A-chain gene was only slightly elevated in these cell lines compared with normal mesothelial cells. For a putative autocrine function of the produced PDGF, in these cells expression of PDGF receptors is a prerequisite. In this paper we report on the expression of PDGF alpha- and beta-receptors in normal and malignant mesothelial cells. Cultured normal mesothelial cells expressed PDGF alpha-receptor mRNA and protein and had weak to undetectable levels of the PDGF beta-receptor mRNA and protein. In contrast, malignant mesothelioma cell lines were found to express PDGF beta-receptor mRNA and protein, while PDGF alpha-receptor expression was not detectable by Northern blotting and immunoprecipitation. Binding experiments with [I-125]-PDGF-AA and [I-125]PDGF-BB to normal and malignant mesothelial cell lines confirmed these observations. These results suggest that autocrine stimulation of growth may occur both in cultured normal mesothelial cells (PDGF-AA acting via the alpha-receptor) and in malignant mesothelioma cell lines (PDGF-BB acting via the beta-receptor).	ERASMUS UNIV,DEPT PATHOL,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT PULM MED,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS; ACAD HOSP ROTTERDAM DIJKZIGT,ROTTERDAM,NETHERLANDS; LUDWIG INST CANC RES,UPPSALA,SWEDEN; HUBRECHT LAB,UTRECHT,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Ludwig Institute for Cancer Research; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	VERSNEL, MA (corresponding author), ERASMUS UNIV,DEPT IMMUNOL,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.			Van der Kwast, Theodorus/0000-0001-8640-5786				BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOBEL G, 1975, J CELL BIOL, V67, P837; CLAESSONWELSH L, 1987, P NATL ACAD SCI USA, V84, P8796, DOI 10.1073/pnas.84.24.8796; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GERWIN BI, 1987, CANCER RES, V47, P6180; GRONWALD RGK, 1989, J BIOL CHEM, V264, P8120; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; TERRACIO L, 1988, J CELL BIOL, V107, P1947, DOI 10.1083/jcb.107.5.1947; VANDENOUWELAND AMW, 1985, BIOCHIM BIOPHYS ACTA, V825, P140, DOI 10.1016/0167-4781(85)90097-1; VERSNEL MA, 1989, INT J CANCER, V44, P256, DOI 10.1002/ijc.2910440212; VERSNEL MA, 1988, ONCOGENE, V2, P601; WAGNER J C, 1960, Br J Ind Med, V17, P260; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WILLEMSEN R, 1988, ULTRASTRUCT PATHOL, V12, P471, DOI 10.3109/01913128809032232; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	39	78	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2005	2011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658707				2022-12-28	WOS:A1991GX11900010
J	ALEXANDRE, C; CHARNAY, P; VERRIER, B				ALEXANDRE, C; CHARNAY, P; VERRIER, B			TRANSACTIVATION OF KROX-20 AND KROX-24 PROMOTERS BY THE HTLV-1 TAX PROTEIN THROUGH COMMON REGULATORY ELEMENTS	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; SERUM RESPONSE ELEMENT; ZINC-FINGER GENE; LONG TERMINAL REPEAT; RECEPTOR-ALPHA-GENE; NERVE GROWTH-FACTOR; C-FOS PROMOTER; TRANSCRIPTION FACTOR; CDNA CLONES; CYCLIC-AMP	The HTLV-1 Tax protein has been shown to induce the expression of host cellular genes, some of which play crucial roles in cell proliferation and differentiation. We have examined the effect of Tax on the expression of two immediate-early genes, Krox-20 and Krox-24, which encode transcription factors. Several HTLV-1-infected T-cell lines and a HeLa cell line that constitutively expresses the Tax protein have a high level of expression of the Krox-20 and Krox-24 genes. In addition, Tax transactivates the promoters of both Krox-20 and Krox-24 in a co-transfection assay. Tax-responsive elements in Krox-20 and Krox-24 include the serum response elements (SREs) and the putative cAMP-responsive element (CRE). A correlation exists between the ability of these elements to mediate Tax transactivation and their affinity for their cognate factors, the serum response factor (SRF) or the CRE-binding protein (CREB) respectively. Since Tax is also able to transactivate the human c-fos promoter through the SRE and the CRE-60, our findings support the idea that the HTLV-1 Tax protein uses common mechanisms for transactivation of these three immediate-early genes. Deregulation of their expression may contribute to malignant transformation associated with HTLV-1 infection.	ECOLE NORMALE SUPER LYON, CNRS, UNITE MIXTE 103, 46 ALLEE ITALIE, F-69364 Lyon 07, FRANCE; ECOLE NORM SUPER, GENET MOLEC LAB, CNRS D1302, F-75230 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)				Charnay, Patrick/0000-0002-3847-6042				ALEXANDRE C, 1991, ONCOGENE, V6, P543; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEIMLING P, 1990, ONCOGENE, V5, P361; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GILARDI P, 1991, BIOCHIMIE, V73, P85, DOI 10.1016/0300-9084(91)90079-G; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LIM RW, 1987, ONCOGENE, V1, P263; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RUBEN SM, 1989, NEW BIOL, V3, P275; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHROTER H, 1987, NUCLEIC ACIDS RES, V15, P10145, DOI 10.1093/nar/15.24.10145; SEIKI M, 1985, GANN, V76, P1127; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	61	64	64	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1851	1857						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1833716				2022-12-28	WOS:A1991GX11800018
J	FURUKAWA, Y; DECAPRIO, JA; BELVIN, M; GRIFFIN, JD				FURUKAWA, Y; DECAPRIO, JA; BELVIN, M; GRIFFIN, JD			HETEROGENEOUS EXPRESSION OF THE PRODUCT OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE IN PRIMARY HUMAN LEUKEMIA-CELLS	ONCOGENE			English	Article							SV40 LARGE-T; OSTEO-SARCOMA; RB GENE; CYCLE; PHOSPHORYLATION; PROTEIN; BINDING; ABNORMALITIES; INACTIVATION; ANTIONCOGENE	To investigate the possible role of the product of the retinoblastoma susceptibility gene, pRB, in leukemogenesis, we examined fresh leukemia cells from 56 cases of primary leukemia (AML, 32; ALL, 12; CML-BC, 9; CLL, 3) for expression of pRB by using an immunoblotting assay with anti-pRB monoclonal antibodies PMG 3-245 or 3-340. Expression of the 70 kDa heat shock protein (Hsp70) was examined simultaneously as an internal control. pRB was found to be absent or expressed at an abnormally low level in 13 of 56 cases. Abnormal expression of pRB was most common in AML (8/32) and CML-BC (4/9), and less common in ALL (1/12). Expression of pRB was not induced in two cases of pRB- AML cultured for 24 h with GM-CSF, indicating that pRB expression could not be induced by increasing the rate of proliferation. The eight cases of AML lacking pRB protein were examined for RB1 mRNA by Northern blot. Two lacked RBI mRNA and six had a normal-sized mRNA (approximately 4.7 kb), although the amount of RB mRNA was very low in some cases. RB1 gene structure was normal by Southern blot in all eight cases lacking pRB protein which were studied. These results show that lack of pRB expression is relatively common in human myeloid leukemias, and suggests that loss of pRB expression could contribute to the altered growth control of these cells.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dryja T P, 1986, Symp Fundam Cancer Res, V39, P115; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FITCHETT M, 1987, CANCER GENET CYTOGEN, V24, P143, DOI 10.1016/0165-4608(87)90091-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; NADLER LM, 1981, PROG HEMATOL, V12, P187; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	32	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1343	1346						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886710				2022-12-28	WOS:A1991GX27200008
J	EISEMANN, A; AHN, JA; GRAZIANI, G; TRONICK, SR; RON, D				EISEMANN, A; AHN, JA; GRAZIANI, G; TRONICK, SR; RON, D			ALTERNATIVE SPLICING GENERATES AT LEAST 5 DIFFERENT ISOFORMS OF THE HUMAN BASIC-FGF RECEPTOR	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; MESSENGER-RNA; ENZYMATIC AMPLIFICATION; MOUSE-BRAIN; GENE; DNA; EXPRESSION; CDNA; CELLS	Fibroblast growth factors (FGFs) are polypeptide mitogens that induce the proliferation of a wide variety of cell types. Of the seven family members, the best characterized are basic and acidic FGF. In addition to their mitogenic effects, they participate in angiogenesis, differentiation and maintenance of survival of neurons, cell migration and embryonal development. Of all family members, keratinocyte growth factor (KGF) is unique in that it is a specific mitogen for epithelial cells and does not interact with the FGF receptor of fibroblasts. To study the interactions between KGF and its receptor, we isolated KGF and FGF receptors from keratinocytes and fibroblasts, respectively. In the course of this study, we isolated five different variants of the FGF receptor from human fibroblasts and showed that all were derived from a single genetic locus. Four of these variants encode transmembrane receptors and can be divided into two subgroups that differ from one another with respect to the number (two or three) of immunoglobulin (Ig)-like domains. Within each subgroup, one receptor differed from the other by the presence of a two-codon insertion. Thus, all the variations among the four isoforms are localized to their ligand binding domains. The fifth isoform encodes a molecule truncated just 3' to the first Ig-like domain and thus could be secreted from the cell. The transcripts encoding the long and short isoforms were found to be expressed in many cell types, but their reltive levels of expression varied greatly depending on the cell type. These findings indicate that alternative splicing generates diverse FGF receptor isoforms in human cells.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; GEORGETOWN UNIV HOSP,DIV MED ONCOL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Technion Israel Institute of Technology; Georgetown University	RON, D (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Graziani, Grazia/G-5747-2012	Graziani, Grazia/0000-0002-0221-768X				ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG JH, 1988, J BIOL CHEM, V263, P12824; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPADAROWICZ D, 1990, J CLIN ORTHOPED RELA, V58, P231; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; Maniatis T., 1982, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SHAPIRO MB, 1986, NUCLEIC ACIDS RES, V14, P65, DOI 10.1093/nar/14.1.65; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOGARI A, 1985, J NEUROSCI, V5, P307; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; ZHAN X, 1988, MOL CELL BIOL, V8, P4387	45	117	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1195	1202						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650441				2022-12-28	WOS:A1991GV26000015
J	XU, HJ; HU, SX; BENEDICT, WF				XU, HJ; HU, SX; BENEDICT, WF			LACK OF NUCLEAR RB PROTEIN STAINING IN G0 MIDDLE G1 CELLS - CORRELATION TO CHANGES IN TOTAL RB PROTEIN LEVEL	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; SV40 LARGE-T; OSTEO-SARCOMA; HUMAN CANCER; PRODUCT; EXPRESSION; CYCLE; PHOSPHORYLATION; CARCINOMA; INACTIVATION	Functional loss of the retinoblastoma (RB) gene has been implicated in a diverse group of human malignancies. The potential clinical importance of such loss demands a reproducible RB cell staining method to distinguish RB+ from RB- tumors. We report that normal and known RB+ tumor cells either in culture or in vivo display a mosaic RB staining pattern with variable proportions of cells having unstained nuclei which are indistinguishable from truly RB- tumor cells. We also show that the apparent lack of nuclear staining corresponds to RB+ cells which are in the G0 or middle G1 phase, where as much as 10-fold decrease in total cellular RB protein occurs compared to their G2/M phase counterparts. These findings not only provide new clues to RB protein function in cell growth and differentiation, but also need to be considered when evaluating the RB status in primary malignancies for its role in tumor initiation/progression or as a prognostic parameter.			XU, HJ (corresponding author), BAYLOR COLL MED,CTR BIOTECHNOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381, USA.				NATIONAL EYE INSTITUTE [R01EY002715] Funding Source: NIH RePORTER; NEI NIH HHS [EYO 2715, EYO 6195] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GRAND RJA, 1989, ONCOGENE, V4, P1291; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1988, ANTIBODIES LABORATOR; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; KNUDSON AG, 1985, CANCER RES, V45, P1437; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1988, J CELL BIOCHEM, V38, P213, DOI 10.1002/jcb.240380309; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VARLEY JM, 1989, ONCOGENE, V4, P725; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YOKOTA J, 1988, ONCOGENE, V3, P471	35	114	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1139	1146						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861863				2022-12-28	WOS:A1991GV26000007
J	KACINSKI, BM; SCATA, KA; CARTER, D; YEE, LD; SAPI, E; KING, BL; CHAMBERS, SK; JONES, MA; PIRRO, MH; STANLEY, ER; ROHRSCHNEIDER, LR				KACINSKI, BM; SCATA, KA; CARTER, D; YEE, LD; SAPI, E; KING, BL; CHAMBERS, SK; JONES, MA; PIRRO, MH; STANLEY, ER; ROHRSCHNEIDER, LR			FMS (CSF-1 RECEPTOR) AND CSF-1 TRANSCRIPTS AND PROTEIN ARE EXPRESSED BY HUMAN BREAST CARCINOMAS INVIVO AND INVITRO	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; CHORIOCARCINOMA CELL-LINES; FACTOR-I RECEPTOR; GROWTH-FACTOR; MESSENGER-RNA; OVARIAN ADENOCARCINOMAS; PLACENTAL DEVELOPMENT; INSITU HYBRIDIZATION; GENE-EXPRESSION; MAMMARY-GLAND	The expression in vivo of FMS transcripts and antigen by neoplastic epithelial cells was demonstrated immunohistochemically or by in situ hybridization in sixteen of seventeen human breast carcinoma specimens and one case of sclerosing adenosis. Expression of CSF-1 receptor (FMS) transcripts and protein was also observed in vitro in two or three breast carcinoma-derived cell lines and was dramatically increased by dexamethasone, a potent glucocorticoid and inducer of mammary epithelial cell differentiation. Immunohistochemical staining with an anti-CSF-1 antibody identified neoplastic epithelial cell co-expression of fms and CSF-1 antigens in more than one-third of the fms-positive invasive carcinoma specimens. These results suggest that autocrine and paracrine interactions of the lymphohematopoietic cytokine CSF-1 and its receptor may participate in the biology of human mammary neoplasms.	YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,BRONX,NY 10461; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Yale University; Yale University; Yeshiva University; Albert Einstein College of Medicine; Fred Hutchinson Cancer Center	KACINSKI, BM (corresponding author), YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NCI NIH HHS [CA-26504, CA-47292, CA-08341] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA026504, R29CA047292, P01CA008341, R01CA047292, R01CA026504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; BOLIVAR F, 1977, GENE, V26, P197; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEDHAR S, 1988, P NATL ACAD SCI USA, V85, P9253, DOI 10.1073/pnas.85.23.9253; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DISORBO D, 1977, ANN NY ACAD SCI, V286, P355, DOI 10.1111/j.1749-6632.1977.tb29429.x; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; FELDMAN M, 1988, SCI AM           NOV, P60; GODARD CM, 1983, HISTOCHEMISTRY, V77, P123, DOI 10.1007/BF00496643; HORIGUCHI J, 1988, BIOCHEM BIOPH RES CO, V157, P395, DOI 10.1016/S0006-291X(88)80060-3; HORWITZ KB, 1978, CANCER RES, V38, P2434; HUHN RD, 1989, J CELL BIOCHEM, V39, P129, DOI 10.1002/jcb.240390205; KACINSKI B M, 1989, Cancer Bulletin (Houston), V41, P44; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1990, PROG LEUC B, V10, P393; KACINSKI BM, 1989, YALE J BIOL MED, V62, P379; KACINSKI BM, 1990, INT J RADIAT ONCOL, V19, P619, DOI 10.1016/0360-3016(90)90488-6; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1989, CANCER CEL, V7, P333; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KAMPS MP, 1988, ONCOGENE, V2, P305; KASID A, 1987, J STEROID BIOCHEM, V27, P465, DOI 10.1016/0022-4731(87)90341-4; KASUKABE T, 1977, GANN, V68, P765; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; MANIATIS T, 1982, MOL CLONING LABORATO, P75; MCDIVITT RW, 1968, ATLAS TUMOR PATHOLOG; MELAMED MR, 1961, CANCER, V14, P699, DOI 10.1002/1097-0142(199007/08)14:4<699::AID-CNCR2820140404>3.0.CO;2-3; MUELLER R, MOL CELL BIOL, V3, P1062; PATTILLO RA, 1968, CANCER RES, V28, P1231; PETERS GN, 1981, ANN SURG, V193, P138, DOI 10.1097/00000658-198102000-00003; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; QUIRK SJ, 1990, J STEROID BIOCHEM, V35, P623, DOI 10.1016/0022-4731(90)90208-A; QUIRK SJ, 1989, MOL CELL ENDOCRINOL, V66, P135, DOI 10.1016/0303-7207(89)90025-7; RAJAVASHISTH TB, 1987, P NATL ACAD SCI USA, V84, P1157, DOI 10.1073/pnas.84.5.1157; RAMAKRISHNAN S, 1989, J CLIN INVEST, V83, P921, DOI 10.1172/JCI113977; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SAITO M, 1989, AM J REPROD IMMUNOL, V19, P114, DOI 10.1111/j.1600-0897.1989.tb00558.x; SCHAISON G, 1989, ANN ENDOCRINOL-PARIS, V50, P200; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STANLEY ER, 1986, CIBA F SYMP, V118, P29, DOI 10.1002/9780470720998.ch3; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANG RP, 1990, J CELL BIOCHEM, V44, P189, DOI 10.1002/jcb.240440307; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TAYLOR HB, 1967, CANCER, V20, P2245, DOI 10.1002/1097-0142(196712)20:12<2245::AID-CNCR2820201227>3.0.CO;2-0; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WALKER C, 1987, P NATL ACAD SCI USA, V84, P1804, DOI 10.1073/pnas.84.7.1804; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; WOOLFORD J, 1985, MOL CELL BIOL, V5, P458; [No title captured]	67	138	140	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					941	952						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829808				2022-12-28	WOS:A1991GU62200008
J	TIEFENBRUN, N; KIMCHI, A				TIEFENBRUN, N; KIMCHI, A			THE INVOLVEMENT OF PROTEIN-KINASE-C IN MEDIATING GROWTH SUPPRESSIVE SIGNALS OF INTERFERONS IN HEMATOPOIETIC-CELLS	ONCOGENE			English	Article							MYC MESSENGER-RNA; DAUDI CELLS; ALPHA-INTERFERON; PHORBOL ESTERS; EXPRESSION; GAMMA; GENE; DIFFERENTIATION; TRANSCRIPTION; TRANSDUCTION	The possible involvement of protein kinase C in transducing the growth suppressive signals of interferons was studied in this work in two different hematopoietic cell lines. Chronic exposure of human Burkitt lymphoma and mouse M1 myeloblastic cell lines to phorbol myristate acetate (PMA), reduced by more than 90% the PKC protein levels and enzymatic activity in cell extracts. The depletion of PKC from cells abrogated the ability of IFN (alpha + beta) to arrest cell growth at the G0/G1 resting phase of the cell cycle. In contrast, other responses to IFN such as the induction of (2'-5') oligoadenylate synthetase gene, continued to take place at the same dose response pattern thus excluding the possibility that early targets in the pathway, such as the number or affinity of IFN cell surface receptors might be affected by PMA. The same prolonged treatment of M1 cells with PMA did not interfere with the ability of another cytokine, transforming growth factor beta (TGF-beta), to induce the normal type of G0/G1 arrest further supporting the specificity of the effect towards IFN responses. Unexpectedly, depletion of PKC from cells did not interfere with the negative effects of IFN on c-myc mRNA and protein expression in spite of the direct involvement of this molecular event in growth responses to IFN. The putative PKC dependent molecular event could therefore function either downstream to or in combination with the reduction in c-myc protein levels, providing a necessary but not a sufficient step to arrest cell cycle progression at the G0/G1 phase.	DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL		KIMCHI, A (corresponding author), DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL.							ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; CHEBATH J, 1986, TIBS, V11, P166; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DRON M, 1986, MOL CELL BIOL, V6, P1374, DOI 10.1128/MCB.6.5.1374; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EINAT M, 1988, ONCOGENE, V2, P485; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; GATYABLONSKI G, 1990, BIOCHEM J, V270, P679, DOI 10.1042/bj2700679; JEFFREY AM, 1986, P NATL ACAD SCI USA, V83, P241, DOI 10.1073/pnas.83.2.241; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; Kimchi A, 1987, Interferon, V8, P85; KIMCHI A, 1979, P NATL ACAD SCI USA, V76, P3208, DOI 10.1073/pnas.76.7.3208; KIMCHI A, 1981, J INTERFERON RES, V1, P559, DOI 10.1089/jir.1981.1.559; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KUO JF, 1980, P NATL ACAD SCI-BIOL, V77, P7039, DOI 10.1073/pnas.77.12.7039; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOVICK D, 1982, J IMMUNOL, V129, P2244; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFER LM, 1989, J INTERFERON RES S2, V9, P5156; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RUBINSTEIN M, 1986, CRIT REV BIOCHEM MOL, V21, P249, DOI 10.3109/10409238609113613; SAGIEISENBERG R, 1984, IMMUNOL LETT, V8, P237, DOI 10.1016/0165-2478(84)90002-6; SHANI M, 1981, NUCLEIC ACIDS RES, V9, P579, DOI 10.1093/nar/9.3.579; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; TAYLORPAPADIMITRIOU J, 1981, J INTERFERON RES, V1, P401, DOI 10.1089/jir.1981.1.401; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; VANDENBARK GR, 1984, J NATL CANCER I, V73, P1013; YAP WH, 1986, P NATL ACAD SCI USA, V83, P7765, DOI 10.1073/pnas.83.20.7765; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366; YARDEN A, 1984, EMBO J, V3, P969, DOI 10.1002/j.1460-2075.1984.tb01915.x; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823	39	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1001	1007						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1712443				2022-12-28	WOS:A1991GU62200015
J	HARADA, S; YANAGI, K				HARADA, S; YANAGI, K			AMINO-ACID-SEQUENCE HOMOLOGY OF EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN-2 TO ADENOVIRUS E1A, HUMAN PAPILLOMA VIRUS-16 E7 AND SV40 LARGE T-ANTIGEN IN THE FUNCTIONAL DOMAINS FOR GROWTH TRANSFORMATION	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; SEPARATE DOMAINS; PHOSPHORYLATION; ACTIVATION; PROTEINS; BINDING				HARADA, S (corresponding author), NATL INST HLTH,DEPT VIROL & RICKETTSIOL,2-10-35 KAMIOSAKI,SHINAGAWA KU,TOKYO 141,JAPAN.							BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; KIEFF E, 1990, VIROLOGY, P1889; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1989, EMBO J, V8, P111; MILLER G, 1990, VIROLOGY, P1921; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	14	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					461	462						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849247				2022-12-28	WOS:A1991FT34400017
